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“To alcohol! The cause of, and solution to, all of life’s problems.” 
- Homer Simpson 
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Abstract 
 
In 2011, it was estimated that over 5% of the burden of disease and injury in Australia was 
attributable to alcohol consumption. In 2013, 81% of Australian adults consumed alcohol at least 
occasionally, while 19% exceeded the Australian drinking guideline of no more than two standard 
drinks per day. There is a clear relationship between alcohol consumption and diseases such as 
cancer and liver disease, but whether there are beneficial effects afforded by moderate alcohol 
consumption on other health outcomes, such as all-cause and cardiovascular mortality, remains 
controversial. A systematic review of systematic reviews of the impact of alcohol on all-cause 
mortality was performed, which identified a number of methodological biases, such as the ‘sick-
quitter effect’, which may explain part or all of these associations. Whether patterns of drinking such 
as heavy episodic drinking alter risk of cancer beyond total alcohol consumption is also under-
researched. 
Data from the New South Wales 45 and Up Study (2006-2014) linked to cancer registry and death 
records were used to examine 1) the clustering of behavioural risk factors, including alcohol 
consumption, among participants by country of birth; 2) examination of the ‘sick quitter’ effect by 
quantifying the association of newly acquired health conditions with alcohol consumption cessation; 
3) the impact of alcohol consumption and drinking pattern on cancer incidence; 4) the impact of 
alcohol consumption and drinking pattern on all-cause mortality and cause-specific mortality.  
Alcohol consumption was associated with risk of a range of cancer and mortality outcomes, and 
drinking patterns were associated with risk independent of total alcohol consumption. It was shown 
that failure to account for the ‘sick-quitter effect’ may result in biased risk estimates, particularly 
underestimates of risk for cardiovascular disease and all-cause mortality. The finding that heavy 
episodic drinking independently increases cancer and mortality risk, and that mortality risk may be 
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underestimated due to ‘sick-quitter effect’, have implications for Australian drinking guidelines and 
strategies to reduce alcohol-related harm.  
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Chapter 1 – Alcohol and the Australian Context 
 
Chapter summary 
This chapter outlines the definition of alcohol, alcohol metabolism and the acute effects of alcohol 
on the body. It then presents an overview of alcohol in the Australian context: the history of alcohol 
in Australia and its current role in Australian society; efforts by government and public health 
organisations to reduce the harm caused by alcohol; Australian health guidelines; and the 
prevalence of alcohol consumption. Finally, methodological issues in observational studies of alcohol 
consumption are discussed. Together, these sections explore the complex relationship of alcohol 
with Australian society, and provide a local context to the subsequent chapters exploring the harms 
of alcohol consumption. Finally, the aims of this thesis are stated. 
 
1.1 – Overview of Alcohol 
 
Alcohol 
‘Alcohol’ is the colloquial name for ethanol, one of many alcoholic compounds[1]. Ethanol is a 
colourless and volatile liquid at room temperature, with a pleasant odour but a burning taste. It has 
the chemical formula CH3CH2O2 and a molecular mass of 46 g/mol. Ethanol is produced from the 
fermentation of carbohydrates and its primary culinary use is in alcoholic beverages. Small amounts 
of ethanol can also be found in some food products, including sauces, cakes and chocolates[2]. As 
well as being the active ingredient of alcoholic beverages, ethanol is also used industrially as a 
solvent, preservative, disinfectant and fuel[1]. 
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When ingested, alcohol acts as a central nervous system depressant and promotes feelings of 
relaxation, sociability and disinhibition[3]. It also inhibits the action of the pituitary gland resulting in 
reduced secretion of anti-diuretic hormone, causing reduced reabsorption of water in the kidneys 
and then dehydration. With increasing consumption, alcohol causes a range of negative acute 
effects including incoordination, drowsiness, interrupted sleep patterns, nausea and vomiting, and 
at very high levels unconsciousness and loss of breathing[3]. Alcohol consumption is associated with 
risk of injury and a number of diseases, including cancer, cardiovascular disease, liver disease, 
malnutrition and foetal alcohol spectrum disorder[3]. Alcohol consumption was responsible for 5.1% 
of the burden of disease and injury in Australia in 2011[4]. 
 
Metabolism of alcohol 
Alcohol is primarily metabolised in the liver, with the stomach playing a minor role. In the liver, 
ethanol is converted to acetaldehyde by the enzyme alcohol dehydrogenase, and this is then 
oxidised to acetate by the enzyme aldehyde dehydrogenase (ALDH2)[5]. The majority of ethanol is 
converted to acetaldehyde by alcohol dehydrogenase, however the enzymes catalase and 
cytochrome P450 2E1 also contribute to this process[6]. A small amount (< 10%) of ethanol is also 
excreted in sweat, urine and breath[5]. Acetate leaves the liver and travels to peripheral tissue 
where it is converted to acetyl CoA, which is then converted to carbon dioxide, water, fatty acids, 
ketone bodies and cholesterol. 
There is much variation in the rate at which alcohol is metabolised from person to person, with 
typical values of between 7 and 10 grams of ethanol per hour[5]. The rate of metabolism increases 
with higher blood concentrations of ethanol, and also varies based on factors including sex, age, 
race, food intake before drinking, time of day, physical activity, liver disease status and the use of 
some medications which inhibit alcohol dehydrogenase, inhibit the mitochondrial respiration chain 
or inhibit the elimination of acetaldehyde[5]. It is estimated that 15-40% of people of East Asian 
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ancestry have a less active form of aldehyde dehydrogenase, that causes increased acetaldehyde in 
the bloodstream. This causes vasodilation and nausea, and persons with this condition consume 
little alcohol[5]. 
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1.2 – Alcohol in Australia 
 
History of alcohol in Australian society 
Alcohol in Australia predates European colonisation, with evidence that Aboriginal Australians 
produced mild alcoholic beverages from the fermentation of native plants[7]. In addition, it is known 
that Indonesian fishermen traded in alcohol with Aboriginal communities in Northern Australia[7]. 
From European colonisation, mass production of alcohol began in breweries and distilleries, and 
throughout the 19th century consumption increased during periods of wealth such as the gold rush 
and declined during economic recessions[7]. The most common beverage during this time was spirits 
such as rum, until this was overtaken by beer in the 1890s[7, 8]. There was a decline in consumption 
during each World War and the Great Depression, followed by increased consumption in the post-
war era, reaching a peak in the 1970s[8]. There were significant changes in drinking culture during 
the 1960s and 1970s. Specifically, it became acceptable for women to consume alcohol with men at 
pubs, it was made legal for Aboriginal Australians to consume alcohol, and wine became popular as 
an alternative to beer[7, 8]. In the modern era alcohol is advertised across a broad spectrum of 
media, and is strongly associated with cultural and sporting events[7, 8]. The most common 
locations Australians consume alcohol are at home, a friend’s house, at private parties, at 
restaurants and cafes and at licensed premises[9]. 
 
Classification of alcoholic beverages in Australia 
The Australian Bureau of Statistics classifies alcoholic beverages into five categories – beer, wine, 
spirits, ‘Ready-To-Drink’ (RTD) pre-mixed beverages and cider[10]. The Australian Food Standards 
Code states that beer is produced through the yeast fermentation of cereal grains in the presence of 
hops[11], and depending on strength has a typical ethanol concentration of 2.7-4.9% 
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volume/volume (v/v)[3]. Wine is produced through the fermentation of grapes and has a typical 
ethanol concentration of 9.5-13% v/v[3, 11]. Spirits are produced through the distillation of 
fermented beverages to increase ethanol concentration to at least 37% v/v, and have a typical 
ethanol concentration of 37-40% v/v[3, 11]. RTDs, also known colloquially as ‘alcopops’, are a 
mixture of spirits and a non-alcoholic beverage such as soft drink, and have a typical ethanol 
concentration of 5-7% v/v[3]. Cider is produced through the fermentation of apples or a mixture of 
apples and pears, and has a typical ethanol concentration of 4-8% v/v[11, 12]. 
 
The alcohol industry in Australia 
The production of alcohol in Australia generates $10.5 billion in annual revenue as of 2015[13]. 
Production is dominated by the beer and wine industries, accounting for 41% and 50% respectively 
of annual revenue in Australia. Spirit and cider production occurs on a much smaller scale, at 6% and 
3% respectively. Two international companies together have an 84% market share of beer 
production in Australia: Lion Pty Ltd and SABMiller Beverages Investments Pty Ltd. These companies 
own some of Australia’s oldest breweries, such as those producing Carlton Draught, James Boag and 
Victoria Bitter[14]. The wine industry is much more fragmented with the two largest companies, 
Treasury Wine Estates Ltd and Pernod Richard Pacific Holding Pty Ltd, together holding a 22% 
market share[13]. The two largest companies which produce spirits in Australia are Diageo Australia 
Ltd and Asahi Holdings (Australia) Pty Ltd with a combined market share of 39%, while Lion Pty Ltd 
and SABMiller Beverages Investments Pty Ltd have a combined market share of 66% of cider 
production. 
The sale of alcohol in Australia generates $31.8 billion in annual revenue as of 2015[13]. The retail 
and wholesale sectors (consumption off-premises) and on-licence sector (consumption on-premises, 
which includes clubs, pubs, restaurants, nightclubs and casinos) each account for about half of the 
annual revenue in Australia from the sale of alcohol. Two Australian-owned companies, Woolworths 
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and Wesfarmers Ltd, together have a 64% market share of the retail sector. These companies own 
stores such as Dan Murphy’s, BWS, Liquorland and Vintage Cellars[15]. Approximately 4.8 million 
Australian adults purchased alcohol from a retailer each week in 2014-2015[16]. The on-license 
sector is very fragmented, with Woolworths holding the largest market share at only 9%[13]. A small 
proportion of alcohol produced and consumed in Australia is unrecorded, comprising alcohol 
purchased internationally and brought to Australia by individuals legally, homemade alcohol, alcohol 
meant for industrial or medical purposes, and illegal or smuggled alcohol[17]. 
The alcohol industry spent $12.3 billion on advertising in Australia in 2011[13]. This includes 
traditional print, billboard, radio, television and online advertising and marketing, and via other 
methods such as branded merchandise, promotion at events and sports sponsorship[18]. Alcohol 
product placement in movies doubled in frequency between 1996 and 2015, while since 2010 
alcohol has also increasingly been promoted on social media websites[19, 20]. There is a particularly 
strong association between alcohol advertising and sport in Australia, with some football codes 
receiving 25% of their income from alcohol sponsorship, and 95% of sponsored sportspeople 
receiving at least some sponsorship from the alcohol advertising[18]. These methods frequently 
reach persons under 18 years of age, with a 2017 survey finding that 77% of Australian parents 
report their children have been subjected to alcohol advertising. Advertising is self-regulated by the 
alcohol industry under the voluntary Australian Beverages Advertising Code, which has been 
criticised for its ineffectiveness[21]. For example, marketing is often misleading regarding the risks of 
alcohol such as increased cancer risk[22]. There is also an independent Alcohol Advertising Review 
Board which manages community complaints relating to alcohol advertising but it does not have 
legal power to enforce breaches of its code[23]. 
The alcohol industry is politically active and is organised into numerous associations and lobby 
groups, such as the Australian Hotels Association, the Australian Liquor Stores Association, the 
Brewers Association of Australia & New Zealand and Clubs Australia[24]. These groups often oppose 
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interventions aiming to reduce the burden of alcohol-related harm (that may reduce sales), such as 
mandatory health warning labels on alcoholic beverages, increasing alcohol taxation, restricting 
alcohol advertising and altering industry advertising self-regulation[24]. The alcohol industry is 
dependent on heavy drinkers for revenue, as the top decile of Australian drinkers, who consume six 
standard drinks per day on average, account for 53% of all alcohol consumed in Australia[13]. Since 
2005, the alcohol industry has funded DrinkWise, a non-profit organisation “focused on promoting 
change towards a healthier and safer drinking culture in Australia”[14, 15, 25]. DrinkWise has been 
criticised as being in reality a public relations organisation with vested interests, and a recent 
DrinkWise campaign was found to be ineffective in promoting behaviour change whilst 
simultaneously reinforcing positive aspects of alcohol consumption[25, 26]. 
 
Public health efforts to reduce alcohol-related harm in Australia 
Public health initiatives relating to alcohol consumption before the 1950s were focused on the 
impacts of public drunkenness[7]. There were numerous efforts to curtail the social harms caused by 
alcohol, such as attempted prohibition during the gold rush, middle-class Christian groups 
advocating for the moderation of supply to lower-class groups during the 19th and early 20th 
centuries, a poorly-enforced prohibition attempt in the Australian Capital Territory from 1911 to 
1928, and the legal requirement for all alcohol establishments to close at 6pm during the middle of 
the 20th century[7, 8, 27]. In recent years there has been an increasing policy response to alcohol-
related harm from federal, state and local governments to address the growing evidence of harm 
related to alcohol consumption. World Health Organisation (WHO) member states (including 
Australia) endorsed a global strategy to reduce the harmful use of alcohol in 2010, in which harmful 
use was defined as causing “detrimental health and social consequences for the drinker, the people 
around the drinker and society at large, as well as the patterns of drinking that are associated with 
increased risk of adverse health outcomes”[17]. In 2013 these member states endorsed a global 
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action plan for the prevention and control of non-communicable diseases which included a voluntary 
target of a 10% reduction in the harmful use of alcohol at the national level[17]. 
Initiatives in Australia are guided by the National Alcohol Strategy within the National Drug Strategy 
framework, which is a collaboration between federal and state governments and non-government 
organisations[28]. There are over 90 public health organisations working to reduce alcohol-related 
harm in Australia such as the Foundation for Alcohol Research & Education, the National Alliance for 
Action on Alcohol and the Public Health Association of Australia[29]. According to a review of alcohol 
policy in Australia from 2014, there are seven distinctive policy areas which can be used to reduce 
the burden of alcohol consumption: pricing and taxation, regulating physical availability, modifying 
the drinking environment, drink-driving countermeasures, education and persuasion, restrictions on 
marketing and treatment and early intervention[30]. Economic cost-effectiveness analyses have 
found that the optimum set of alcohol policies to reduce alcohol-related harm include, in order from 
most to least cost-effective: alcohol taxation, banning alcohol advertising, raising the legal drinking 
age from 18 to 21 years, primary care interventions, alcohol licensing controls, anti-drink-driving 
campaigns and roadside random breath testing[31]. Only some of these policies have been 
implemented in Australia, including taxation, policies relating to regulating the physical 
environment, and education. 
There are three national taxes related to alcoholic beverages – the alcohol excise tax, the wine 
equalisation tax and the goods and services tax[30]. There is an additional ‘alcopop tax’ on RTDs, and 
most states have passed legislation enabling the restriction of price discounting, although 
implementation varies from state to state[30]. 
There are many policies in Australia relating to regulating physical availability, such as a national 
legal alcohol purchase age of 18 years, the banning of alcohol sales in high-risk communities such as 
in individual towns in the Northern Territory, time of day sale restrictions in all states and territories, 
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outlet density restrictions in all states and territories and the prohibition of drinking in public places 
often enacted by local governments[30]. 
Policies relating to modifying the drinking environment implemented in Australia include the training 
of staff in the responsible service of alcohol in all states and territories, server liability for serving 
intoxicated persons in all states and territories, voluntary codes of bar practice in some local areas, 
late-night lockouts of pubs and clubs in New South Wales, Queensland and South Australia, and 
police enforcement of laws on-premises and special powers such as banned drinker registers and the 
emergency closure of premises, the extent of which varies by state and territory[30].  
Drink-driving countermeasures used in Australia include advertising campaigns, a national blood 
alcohol concentration of 0.05% for most drivers and 0.00% for novice drivers, roadside random 
breath testing and penalties including fines, license suspension and imprisonment depending on 
severity of offence[30]. For repeat offenders, all states mandate the installation of breath testing 
systems that can prevent their car from being started. 
Policies relating to education and persuasion in Australia include alcohol education as part of 
schooling in all states and territories, voluntary drink warning labels and government mass media 
campaigns[30]. Voluntary drink warning labels were introduced by the alcohol industry in Australia 
in 2011, however as of 2013 these warnings were only present on about one third of products[32]. 
Mass media campaigns are commonly funded by state and federal governments, and past themes 
have included the harms related to drink-driving, violence, heavy episodic drinking and underage 
drinking[30].  
There are few restrictions on alcohol marketing in Australia, and the impact of alcohol marketing far 
outweighs that of government mass media campaigns[30]. Television advertising is only allowed by 
the Commercial Television Industry Code of Practice 2015 after 8:30pm during programs rated M15+ 
or greater, however there is an exception for sporting events which do not have a time of day 
restriction[33]. The South and Western Australian governments have recently announced an ending 
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of alcohol advertising on public transport[34]. New South Wales has liquor promotion guidelines 
however these do not apply to packaged alcohol outlets and are not effectively enforced[30].  
Efforts relating to treatment and early intervention for persons with alcohol use disorders include 
workplace programs targeting at-risk drinkers with brief interventions, self-help programs such as 
Alcoholics Anonymous and ‘sobering-up centres’[30].  
 
Alcohol consumption health guidelines 
The ‘Australian Guidelines to Reduce Health Risks from Drinking Alcohol’ were published by the 
National Health and Medical Research Council (NHMRC) in 2009 and are currently under review[3]. 
There are four guidelines. The first two guidelines recommend that healthy men and women should 
consume a maximum of 2 standard drinks on any day to reduce “the lifetime risk of harm from 
alcohol-related disease or injury”, and a maximum of 4 standard drinks on any day to reduce “the 
risk of alcohol-related injury arising from that occasion”. The third guideline states that children 
under 18 years old should not drink alcohol, especially children under 15 years old, and that the age 
of initiation to alcohol should be as late as possible for those aged 15 to 17 years old. The final 
guideline states that women who are planning a pregnancy, pregnant or breastfeeding should not 
drink alcohol. Appendix A1 of the guidelines discusses specific situations where drinking increases 
risk of harm, such as when taking medications, driving a motor vehicle, operating machinery, 
engaging in high-risk recreational activities and supervising children. 
Despite the first guideline recommending a maximum of two standard drinks on any day, in the 
supporting documentation for the guidelines, it is reported that any amount of alcohol consumption 
carries a lifetime risk of harm from disease or injury[3]. The cut point was chosen arbitrarily so that 
the lifetime risk would remain below 1 in 100. This fact is poorly understood by the Australian public 
according to the National Drug Strategy Household Survey. In Australia in 2013, 9% of men correctly 
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answered that there was no level of alcohol consumption that did not increase one’s risk of lifetime 
harm, 56% thought there was a level of consumption above zero that did not increase risk, and 36% 
stated that they did not know[9]. For women, 13% answered correctly, 42% answered incorrectly 
and 45% did not know. 
There was formerly a guideline to have one or two alcohol-free days per week in 2001[35]. The 
rationale for this was that although the evidence for effect on health was limited, it may help people 
control their drinking habits and avoid alcohol dependency. This recommendation did not appear in 
the 2009 guidelines, although it is mentioned in the explanatory document that alcohol-free days 
can further reduce the lifetime risk of disease and injury[3]. 
Alcohol consumption also appears in the 2013 Australian Dietary Guidelines, which state that one 
should “limit intake”, and that “not drinking alcohol is the safest option” for pregnant or 
breastfeeding women and for women planning a pregnancy[36]. A companion poster, the Australian 
Guide to Healthy Eating, states that for the general population alcohol should be consumed “only 
sometimes and in small amounts”. 
Alcohol health guidelines vary from country to country. Table 1.1 shows a comparison in Australian 
standard drinks of the alcohol health guidelines of Australia[3], Canada[37], New Zealand[38], the 
United Kingdom[39, 40] and the United States[41]. The guidelines in all five countries are consistent 
regarding alcohol consumption during pregnancy, under the legal drinking age, and in situations 
such as when using certain medication and undertaking high-risk activities. In addition, all guidelines 
state that individuals who do not currently drink alcohol should not start. The differences are 
predominantly found in recommendations for reducing long-term risk to health, short-term risk of 
injury and for drinking when breastfeeding. In terms of maximum weekly alcohol consumption, the 
guidelines with the lowest cut-point to minimise long-term risk for men are the United Kingdom 
guidelines (11.2 Australian standard drinks/week) and for women the United States guidelines (9.8 
Australian standard drinks/week). The guidelines with the highest cut-point for men are the 
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Canadian guidelines (20.2 Australian standard drinks/week) and for women the Australian guidelines 
(14 standard drinks/week). The differences in guidelines by country may reflect different sources 
taken into consideration, different methods used to calculate risk, and also the arbitrary level of risk 
that is considered reasonable. In both the Australian and United Kingdom guidelines the accepted 
lifetime level of risk of mortality was up to 1%, while the Canadian guidelines instead selected the 
cut-point where the number of deaths caused and prevented by alcohol consumption were balanced 
(assuming that moderate drinking is causally associated with decreased risk of all-cause mortality). 
The New Zealand guidelines do not state a level of accepted risk but do state that the Australian and 
Canadian guidelines were used as the “primary resource material”[38]. Lastly, in the United States 
guidelines, neither the level of accepted risk nor the specific method used to calculate risk were 
stated. 
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Table 1.1. Alcohol consumption health guidelines in Australia and four other countries. 
Country Long-term risk Short-term risk Pregnancy and 
breastfeeding 
Under legal 
drinking agea 
High-risk 
situationsb 
Australia ≤ 2.0 ASD on any day ≤ 4.0 ASD on any day None during 
pregnancy, none 
during breastfeeding 
None; Delay 
initiation as long 
as possible 
None 
Canada ≤ 3 SD (4.0 ASD)/day 
and ≤ 15 SD (20.2 
ASD)/week for men; 
≤ 2 SD (2.8 ASD)/day 
and ≤ 10 SD (13.5 
ASD)/week for 
women; “Some” non-
drinking days per 
week 
≤ 4 SD (5.4 ASD)/day 
for men and ≤ 3 SD 
(4.0 ASD)/day for 
women aged ≥ 25 
years; ≤ 3 SD (4.0 
ASD)/day for men 
and ≤ 2 SD (2.8 
ASD)/day for women 
aged < 25 years 
None during 
pregnancy, none 
before breastfeeding 
None; Delay 
initiation as long 
as possible 
None 
New 
Zealand 
≤ 3 SD (3 ASD)/day 
and ≤ 15 SD (15 
ASD)/week for men; 
≤ 2 SD (2 ASD)/day 
and ≤ 10 SD (10 
ASD)/week for 
women; ≥ 2 non-
drinking days per 
week 
≤ 5 SD (5 ASD)/day 
for men and ≤ 4 SD (4 
ASD)/day for women 
None during 
pregnancy, 
breastfeeding not 
mentioned 
None; Delay 
initiation as long 
as possible 
None 
United 
Kingdom 
≤ 14 SD (11.2 
ASD)/week, over at 
least 3 days 
Limit total intake on 
any one occasion 
None during 
pregnancy, 
breastfeeding not 
mentioned 
None; If 15 to 17 
year-olds do drink 
alcohol then 
never more than 
one day per week  
None 
United 
States 
≤ 2 SD (2.8 ASD)/day 
for men; ≤ 1 SD (1.4 
ASD)/day for women 
< 5 SD (7.0 ASD) on 
any day and < 15 SD 
(21.0 ASD)/week for 
men; < 4 SD (5.6 ASD) 
on any day and < 8 
SD (11.2 ASD)/week 
for women; do not 
mix alcohol with 
caffeine 
None during 
pregnancy, 
breastfeeding not 
mentioned 
None None 
a18 years in Australia, New Zealand, the United Kingdom and some provinces of Canada (Alberta, 
Manitoba and Quebec), 19 years in all other provinces of Canada, 21 years in the United States. 
bSuch as using certain medications, operating motor vehicles and machinery, high-risk recreational 
activities and supervising children. ASD, Australian Standard Drink (10 g of ethanol). SD, Standard 
Drink (13.45 g in Canada, 10 g in New Zealand, 8 g in the United Kingdom and 14 g in the United 
States). 
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Alcohol consumption prevalence 
Australians aged ≥ 15 years consumed 12.2 L per capita in 2010 (17.3 L for men and 7.2 L for 
women), and this is projected to increase to 13.5 L in 2025[17]. The 2010 value is higher than in 
Canada, New Zealand, the United Kingdom and the United States (all between 9.2 and 11.6 L) and 
the global average (6.2 L). Of all alcohol consumed in Australia, 39.9% is consumed as beer, 37.5% as 
wine, 12.8% as spirits, 6.0% as RTDs and 3.8% as cider[10]. These proportions have changed over 
time. Compared to 2010-11, as a proportion of all alcoholic beverages consumed, beer and RTDs 
decreased, spirits did not change, and wine and cider increased[10]. Beer is the most common 
alcoholic beverage choice of men and wine the most common choice of women[9]. Spirits, RTDs and 
cider are consumed more frequently by younger people while wine is consumed more frequently by 
older people[42]. There is also evidence of seasonality in alcohol consumption, with beer consumed 
more frequently in summer months and wine in winter months[43]. 
The most recent drinking habits study in Australia is the National Drug Strategy Household Survey in 
2013[9]. 81% of adults in 2013 were current drinkers, 8% were former drinkers and 11% were 
lifetime abstainers, while of current drinkers, 9% consumed alcohol daily, 49% at least weekly, and 
43% less than weekly. There has been a slight decline in the proportion of persons aged ≥ 14 years 
who are current drinkers, falling from 82% in 2001 to 78% in 2013. In 2013, a higher proportion of 
male adults were current drinkers than females, at 84% and 78% respectively. For age groups 
between 18 and 59 years, the proportion of current drinkers was between 82 and 84%, declining to 
79% in those aged 60-69 and 68% in those aged ≥ 70 years. The ≥ 70 years age group had the highest 
proportion of both former drinkers and lifetime abstainers at 15% and 17% respectively. The average 
age of initiation to alcohol in Australia in 2013 was 15.7 years, increasing from 14.8 years in 1995[9]. 
Of persons aged 12-17 years in 2013, 29% were current drinkers. Of women who were pregnant or 
breastfeeding in 2013, 47% and 63% respectively consumed at least some alcohol. 
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In 2013, 19% of adults (28% of men and 10% of women) were at risk of long-term harm according to 
the 2009 NHMRC guidelines by consuming greater than two standard drinks per day on average[9]. 
For all age groups between 18 and 69 years, the proportion was between 19% and 23%, declining to 
10% in those aged ≥ 70 years at risk of long-term harm. In addition, 27% of adults (36% of men and 
17% of women) were at risk of short-term harm by consuming greater than four standard drinks on a 
single occasion at least monthly[9]. This figure was highest in persons aged 18-24 years at 47% and 
lowest in persons aged ≥ 70 years at 6%. Finally, 7% of Australians aged ≥ 12 years consume alcohol 
at ‘very high risk’ levels by consuming greater than 10 standard drinks on a single occasion at least 
monthly[9]. This figure was highest in persons aged 18-24 years at 18% and lowest in persons aged ≥ 
70 years at 1%. It was estimated that 3.5% of Australians aged ≥ 15 years had an alcohol use disorder 
in 2010[17]. Using a definition of ≥ 6 standard drinks per occasion at least monthly, 11% of 
Australians aged ≥ 15 years engaged in heavy episodic drinking in 2010, including 17% of males and 
5% of females[17]. In Australia there is evidence of an association between heavy episodic drinking 
and the consumption of regular strength beer and RTDs, and less of an association for wine and low 
alcohol beer consumption[44]. 
Higher than recommended levels of alcohol consumption are more common in certain socio-
demographic groups. Aboriginal and Torres Strait Islander Australians, persons living in regional and 
remote areas, persons with higher socio-economic status, persons currently employed rather than 
unemployed or unable to work and homosexual or bisexual persons have a higher prevalence of 
consuming alcohol at levels that put them at risk of long-term harm[9, 45]. There is only a slight 
association between having a mental health condition and risky alcohol consumption, however a 
stronger association for general psychological distress. There is also variation in alcohol consumption 
by country of origin for different immigrant groups in Australia[46, 47]. Persons born in non-English 
speaking countries have a lower prevalence of exceeding the long-term risk guideline than persons 
born in English-speaking countries and in Australia[45]. In 2013, the Northern Territory had the 
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highest proportion of persons exceeding the lifetime risk and single occasion risk guidelines, while 
New South Wales and Victoria had the lowest proportions[9]. 
Importantly, alcohol consumption is associated with other risk factors for chronic disease. For 
example, in the Australian population it has been reported that high risk drinkers have a higher 
prevalence of smoking, obesity (men only; inversely associated in women), large waist 
circumference, physical inactivity (men only; inversely associated in women), insufficient fruit intake 
and insufficient vegetable intake (men only; no difference in women)[48]. In a New South Wales 
study the consumption of alcohol was shown to co-occur with smoking but was also inversely 
associated with physical inactivity[49]. Thus, it was of interest to understand how alcohol 
consumption might co-occur with other lifestyle risk factors in the context of chronic disease risk. In 
some cases, the co-occurrence of two risk factors can cause a multiplicative increase in risk for an 
outcome, for example, drinking and smoking on cancer risk[50]. The quantification of the co-
occurrence of drinking with other lifestyle risk factors is also relevant for understanding the potential 
extent to which these factors may confound associations between alcohol consumption and health 
outcomes. 
It is important to note that there are methodological issues impacting the measurement of alcohol 
consumption that have implications for estimating the prevalence of drinking behaviours and the 
risk of harm associated with drinking. These include problems related to the measurement of alcohol 
itself such as measurement error and inconsistencies between countries in defining standard drink 
sizes and cut-points for harm, as well as other problems such as selection bias and choice of 
reference group. These issues are discussed in the next section. 
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1.3 – Methodological Issues in Observational Studies of Alcohol Consumption 
 
Measurement of Alcohol Consumption 
Measurement error in self-reported alcohol consumption 
When measuring alcoholic beverage consumption the goal is to quantify ethanol intake. Studies that 
simply require participants to state how many drinks they consume may introduce measurement 
error in the ascertainment of ethanol consumed. The majority of epidemiological studies ask 
participants in an interview or survey about their usual quantity or frequency of alcoholic beverages 
per day or week, and sometimes with a guide as to what constitutes a standard drink of beer, wine 
and spirits[51]. Another common method is to ask participants to report their actual daily 
consumption during a period of time either retrospectively or prospectively. These quantities are 
often converted to grams of ethanol per day or week. Thus, measurement error can occur in a 
number of ways. 
Study participants may have difficulty converting their intake into the units of alcohol required by 
the questionnaire, often resulting in an underestimation of alcohol consumption[51, 52]. As well as 
varying in ethanol concentration, alcoholic drinks can vary greatly in serving size. For instance, beer 
in Australia is commonly consumed as a 285 mL ‘middy’, a 330 mL bottle, a 375 mL can and a 425 mL 
‘schooner’[2], and a recent survey of Australians found participants had a mean of 1.58 standard 
drinks in their usual serving of wine purchased from off-license premises[53]. In the United States, 
beverages served at home were reported to contain an average of 1.28 Australian standard drinks 
for beer, 1.56 for wine, and 1.96 for spirits[54]. A review of studies conducted in Australia, the 
Netherlands, United States and United Kingdom also found that participants generally serve greater 
quantities than the standard drink in each country, and also underestimate the alcohol content of 
the drinks they serve[52]. The discrepancy was greatest for spirits and mixed-drinks, then wine, and 
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then beer, while knowledge of standard drink sizes was associated with more accurate beverage 
pouring. Therefore, even in studies providing guides as to what constitutes a serving size, asking 
participants to record alcoholic drinks will likely result in an underestimation of alcohol 
consumption, and may vary depending on the type of beverage. 
Participants may also under-report their alcohol consumption due to concern that their drinking 
does not match societal norms, especially in the presence of an interviewer or family member[51, 
55]. A related factor is whether the participant perceives that their responses will be 
confidential[56]. These issues can manifest through the mode of survey, as survey results have been 
found to vary depending on whether the study is conducted using a telephone or in-person 
interview, a paper questionnaire or a computer-assisted questionnaire[57-59]. Estimates of total 
alcohol consumption and the prevalence of heavy episodic drinking have been reported as higher 
when using mailed surveys in comparison to telephone surveys and computer-assisted 
interviews[57, 58], while web-based surveys result in a greater prevalence of heavy episodic drinking 
compared to both mailed and telephone surveys[59]. One advantage of the presence of an 
interviewer however is that data quality can be improved by easing participant burden when the 
survey design is complex[58]. In addition, it is important to consider cultural context when 
measuring alcohol consumption in specific populations[60]. For example, there has recently been a 
trial on the use of electronic aids such as digital ‘apps’ to assess alcohol consumption more 
accurately and in a culturally appropriate way for Aboriginal and Torres Strait Islanders[61]. This is 
important as it has been estimated that surveys of drinking in Aboriginal and Torres Strait Islanders 
can underestimate alcohol consumption by up to a factor of seven[61]. 
Responses also appear to be particularly sensitive to the style of questions asked. Harmful drinking 
was shown to be three times more prevalent with the use of ‘graduated frequency’ style questions 
(assessing how frequently in the past year participants consumed 1-2 drinks, 3-4 drinks, 5-7 drinks in 
a single day, etc.) compared to the more common method of ‘quantity frequency’ style questions 
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(assessing average quantity and frequency of alcohol consumption over a period of time – in this 
case, the past year)[62]. Harmful drinking was also five times more prevalent when using ‘graduated 
frequency’ style questions compared to the assessment of total consumption in the past week[62]. 
Further, participants using a prospective weekly drinking diary reported greater alcohol consumption 
and a higher prevalence of 6 or more drinks consumed on one occasion than participants using 
graduated frequency and quantity/frequency style questions[63]. A disadvantage of the usual 
quantity/frequency approach is that it can be difficult for participants to summarise their alcohol 
consumption into a single measure such as average drinks per week, given that patterns of drinking 
may not be consistent over time and can occur in a wide variety of settings[51].  
Other question factors that may influence participant responses include the length of the period that 
participants are asked to report their usual alcohol consumption (from as little as in the previous day 
to as much as the previous 12 months), the use of open-ended or multiple choice responses, the 
ordering of multiple choice responses from low to high or high to low consumption, and the 
succinctness of questions to minimise participant burden[56]. It has also been reported that 
recording daily alcohol consumption prospectively in a diary can be burdensome and may cause the 
participant to alter their intake over the study period[51]. 
Finally, to adequately capture lifetime alcohol consumption (for either the purpose of measuring 
mean lifetime alcohol consumption or for ascertaining changes in drinking status over time) it is 
necessary to query both present alcohol consumption as well as consumption at one or multiple 
time points either retrospectively or prospectively[64]. This also helps to prevent bias from 
regression dilution, where current drinking may not be representative of past and future drinking 
(e.g. the classification of prior long-term heavy drinkers as current moderate drinkers and vice 
versa), which causes effect estimates to be biased towards the null[65, 66]. The majority of studies 
investigate current alcohol consumption at baseline rather than lifetime alcohol consumption, and 
there is variation in the methods used to capture lifetime alcohol consumption[64]. 
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Variation in the definition of a standard drink 
Because different alcoholic beverage types contain different quantities of ethanol, beverage labels 
and alcohol health guidelines require a reference alcohol measure so that consumers are informed 
of the amount of alcohol in each drink. The usual terms for this reference quantity are the ‘standard 
drink’ or a ‘unit’ of alcohol, however there is no international agreement on what constitutes a 
standard drink and there is wide variation from country to country. 
The Australian standard drink is defined as an alcoholic beverage containing 10 g of ethanol, which is 
equal to 12.5 mL of ethanol[3]. A standard drink is 8 g of ethanol in the United Kingdom[39], 10 g in 
New Zealand[67], 13.45 g in Canada[37], 14 g in the United States[41] and 19.75 g in Japan[68]. 
Furthermore, the standard drink is frequently smaller than the typical beverage as served in a bar, 
restaurant or at home. According to Australian alcohol guidelines, a 425 mL glass of full strength 
beer contains 1.6 standard drinks, a 150 mL serving of wine contains 1.4-1.6 standard drinks, and a 
30 mL nip of spirits contains 1 standard drink[3]. 
Variation in the description of drinking patterns 
There are no consistent definitions for terms such as ‘occasional’, ‘light’, ‘moderate’ and ‘heavy’ 
drinking. A recent systematic review of alcohol consumption and cancer risk defined ‘very light’ 
drinking as ≤ 0.5 drinks per day, ‘light’ drinking as ≤ 1 drink per day and ‘moderate’ drinking as 1-2 
drinks per day[69]. Other definitions of ‘moderate’ drinking have included < 1 drink per day[70], < 3 
drinks per day[71], 2-3 drinks per day[72] and > 1 and < 4 drinks per day[73]. Sometimes definitions 
differ by sex, with a common definition of ‘low’ or ‘moderate’ drinking as ≤ 2 drinks per day for men 
and ≤ 1 drink per day for women[74-76]. The term ‘occasional’ drinking has been referred to as 1-11 
drinks per year[77], ≤ 1 drink per week[78], 0.033-0.363 grams per day[77] or < 1.3 grams per 
day[78], while former drinking has been defined in the Australian National Drug Strategy Household 
Survey as “consumed at least a full serve of alcohol, but not in the previous 12 months”[9]. 
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For heavy episodic drinking or ‘binge’ drinking there is also no consistent definition between 
studies[79]. The Australian alcohol guidelines do not have a classification for heavy episodic drinking, 
but do state that consuming ≤ 4 drinks per occasion lessens the short-term risk of injury on drinking 
occasions[3]. One of the more common definitions in studies of binge drinking, and the definition 
adopted by the USA’s National Institute on Alcohol Abuse and Alcoholism (NIAAA), is ≥ 5 drinks (i.e. 7 
Australian standard drinks) per occasion for men and ≥ 4 drinks (5.6 Australian standard drinks) for 
women on at least one day per month[75, 79]. These cut-points were chosen as they should induce a 
blood alcohol concentration (BAC) of 0.08 g/dL if consumed within two hours[75]. Other definitions 
have included ≥ 6 drinks per occasion for men and ≥ 4 drinks for women, ≥ 7 drinks per occasion for 
men and ≥ 6 for women for ‘heavy binge drinking’, ≥ 5 drinks per occasion for both sexes, ≥ 10 drinks 
and < 2 days per week, ≥ 100 drinks in < 21 days in a month for men and ≥ 80 for women, “being 
drunk or very high from alcohol in past 90 days”, a ‘binge drinking score’ (i.e. calculated from drinks 
per hour, number of times ‘drunk’ in past 6 months and percentage of time ‘intoxicated’ when 
drinking), and a breath-measured blood alcohol concentration of ≥ 0.08[79]. Furthermore, the 
prevalence of heavy episodic drinking can vary depending on the length of time inquired. For 
example, a study querying about the past week will not capture participants who engage in heavy 
episodic drinking once per month or less frequently. Previous studies have defined a time period of 
past week, past 30 days, past six months and past year[79]. A review examining definitions of heavy 
episodic drinking recommended the following operational definition be used, adapted from the 
NIAAA definition: “A pattern of drinking alcohol that brings BAC to 0.08 gram percent or above (≥5/4 
for men/women in 2 hr) on more than one occasion within the past 6 months”[79]. The period of six 
months was selected to ensure a window large enough to capture individual variation in frequency 
of heavy episodic drinking. 
  
22 
 
Selection bias in observational studies 
Non-response bias is an important issue to consider in observational studies of alcohol consumption 
as it is possible that participants who consent may have different patterns of drinking to the general 
population. For example, a South Australian cohort study found that participants consumed alcohol 
at intermediate to high risk levels more frequently than participants in a representative continuous 
health surveillance study[80]. Non-representative sampling may occur if a study is conducted only on 
people living in regular housing, which may result in an underestimate of population alcohol 
consumption due to the exclusion of groups in society that may consume alcohol in higher than 
average amounts, such as the homeless, institutionalised people, the military and students living in 
dormitories[56]. 
 
Choice of reference group for estimates of relative risk 
The magnitude and direction of relative risk estimates are dependent on the choice of reference 
group. In studies of alcohol exposure, the choice of reference group is often ‘non-drinkers’ however 
it is important to differentiate between lifetime abstainers and former drinkers. This is because 
former drinkers may have health conditions which caused them to quit drinking, and may predispose 
them to increased morbidity and mortality compared to lifetime abstainers[56, 77, 81]. A reference 
group of non-drinkers that combines former drinkers with lifetime abstainers will therefore result in 
an underestimate of the health risks for current drinkers. For example, an inverse association was 
reported between “light or moderate” drinking and risk of heart disease, stroke, colorectal cancer, 
liver cirrhosis, type 2 diabetes and Alzheimer’s[82], while the risk curve for drinking and all-cause 
mortality is commonly found to be J-shaped (where moderate drinkers have a lower risk and heavy 
drinkers a higher risk than non-drinkers)[77]. This has been described as former drinker 
misclassification or the ‘sick-quitter effect’. The sick-quitter effect is thought to be responsible for 
spurious protective associations where no plausible biological mechanisms exist. For example, 
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studies have reported associations between “moderate” alcohol consumption and reduced risk of 
hearing loss and hip fractures[82]. 
Aside from using lifetime abstainers as the reference group, one proposed solution to the sick-
quitter effect is to assign former drinkers to the level of drinking intensity they reported before they 
quit[83]. This also reduces confounding by health status between drinkers and lifetime abstainers, 
whereby drinkers appear healthier because ‘sick-quitters’ are excluded from this group[83]. This is 
analogous to the ‘intention to treat’ principle in randomised controlled trials, whereby participants 
choosing to cease a treatment are still grouped with their initial exposure category to prevent 
selection bias[83, 84]. An alternative method which attempts to reduce confounding due to illness at 
baseline is to exclude participants with a history of disease (such as cancer and cardiovascular 
disease) from analysis, however this has the potential to introduce selection bias and induce false J-
shaped associations[78, 85]. 
Few studies have examined the specific health reasons that drive people to quit drinking, especially 
in prospective studies[81]. This is an important gap in the research base, as in the 2013 National 
Drug Strategy Household Survey it was reported that 50% of Australians who reduced their alcohol 
consumption in the previous 12 months did so due to health reasons[9]. Two recent prospective 
studies examined health conditions associated with quitting or decreasing alcohol consumption[81, 
86]. One study found associations with self-rated health, liver disease, hypertension, gastric disease, 
incident cardiovascular disease and cluster A personality disorders, but not prevalent cardiovascular 
disease, mood disorders, anxiety disorders or cluster B and C personality disorders[81]. The other 
study found associations with self-rated health and depressive symptoms[86]. There is a need to 
determine which diseases are associated with drinking cessation and reduction, including their 
relative importance. Understanding the nature of the sick-quitter effect will help inform methods to 
address it, and in turn enable robust alcohol-disease risk estimates. 
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Biased risk estimates of alcohol consumption may also be due to ‘occasional drinker 
misclassification’, whereby occasional drinkers are combined in the reference group with lifetime 
abstainers[77]. Measuring drinks per day rather than drinks per week and the use of categories such 
as ‘almost never drink’, ‘rarely/never drink’ and ‘never or less than once a month’ can lead to 
misclassification for occasional and former drinkers[87]. Like former drinkers, occasional drinkers (at 
least one standard drink per year but less than one per week) may have decreased their alcohol 
consumption due to ill-health. However two systematic reviews reported that occasional drinkers 
have a lower risk or no difference in risk of all-cause mortality compared to lifetime abstainers, and 
their inclusion in the reference group would therefore bias estimates of effect for drinkers upwards 
or not at all[77, 78].  
Indeed, occasional drinkers may be a more appropriate reference group than lifetime abstainers. 
Similar to former drinkers, lifetime abstainers may not have begun drinking alcohol due to health 
reasons[78]. For example, it has been reported that having a long-standing illness throughout young 
adulthood is associated with lifetime abstention[88]. Thus, due to their comparatively poorer health 
status, using lifetime abstainers as the reference group may result in conservative estimates of the 
effects of drinking on health, and has been termed the ‘sick non-starter effect’[88, 89]. Furthermore, 
inaccuracies in self-report have been documented for lifetime abstention. Two prospective studies 
that assessed alcohol consumption at multiple points in time found that 53% and 67% of persons 
claiming to be lifetime abstainers in the latest follow-up survey were in fact ex-drinkers, as they had 
reported being drinkers in previous surveys[90, 91]. The majority of these participants were 
previously light or moderate drinkers, however modelling showed that this misclassification could 
result in alcohol-attributable mortality being underestimated by 2-15% in men and 2-22% in 
women[90]. That study also found that 38% of participants reporting lifetime abstention at baseline 
then went on to report drinking in later surveys[90]. Given the unreliability of self-reported lifetime 
abstention, it has been proposed that lifetime abstainers and ‘irregular lifetime light drinkers’ 
combined could be used as an alternative reference group[90]. 
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Gold standard methods for measuring alcohol consumption 
A 2016 systematic review found there to be four international guidelines for the measurement of 
alcohol consumption[92]. These guidelines were published by the WHO in 2000, the Kettil Bruun 
Society in 2000, the American National Institute on Alcohol Abuse and Alcoholism in 2003, and the 
European Commission in 2010. All contained at least six questions. Typically, the questions asked 
about frequency of alcoholic beverage consumption in the previous 12 months, usual number of 
drinks on days that drinking occurred, frequencies and quantities for specific types of beverage (both 
usual and maximum), graduated frequency questions about heavy episodic drinking, and lastly 
questions about settings in which alcohol is consumed such as with meals, weekdays and weekends, 
alone or with others, at home, restaurants and bars. It should be noted that even if all of these 
prompts are used in order to capture alcohol consumption as completely as possible, the problems 
of non-response bias, non-representative sampling and the inaccurate measurement of irregular 
alcohol consumption remain[56, 92]. 
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1.4 – Thesis Aims 
 
Alcohol consumption is commonplace in Australia and is associated with substantial social and 
economic harm, including 5.1% of the national burden of disease and injury, second only to tobacco 
and overweight and obesity[4]. These harms are not evenly distributed however, with variation in 
alcohol consumption by certain population subgroups such as different immigrant groups, and a 
need for further evidence regarding differences in the co-occurrence of alcohol consumption with 
other risk factors by population subgroup, and implications for potential chronic disease risk. One of 
the most significant diseases caused by alcohol consumption is cancer, which contributes more to 
the national burden of disease and injury than any other health condition. Despite this, there have 
been few large-scale studies investigating the relationship between alcohol consumption and cancer 
in Australia. Investigations of cancer and other outcomes attributable to alcohol consumption in 
Australia have instead relied on internationally derived relative risks for their calculations[93-95].  
The effects of alcohol on health are not straightforward, possibly because of the methodological 
complexities involved in observational studies of alcohol exposure. Specifically, ‘moderate’ alcohol 
consumption has been associated with a lower risk of disease and all-cause mortality compared to 
non-drinking, however there is a lack of consistency across studies around definitions of ‘moderate’ 
consumption, definitions of a ‘standard drink’, and definitions of harm. Furthermore, inverse 
associations may be partially or totally accounted for by methodological biases such as the ‘sick-
quitter effect’. The exact nature of the sick-quitter effect remains to be determined, with few 
prospective data on the specific illnesses that cause people to cease drinking[81]. A better 
understanding of these mechanisms will inform methods of investigating the impact of bias from the 
‘sick-quitter effect’. 
Therefore, the overall aim of this thesis was to quantify the association between alcohol 
consumption and risk of cancer and mortality in Australia, and to examine whether risk estimates 
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are robust when taking into account methodological biases such as the ‘sick-quitter effect'. This was 
achieved by addressing a number of objectives, using a large, Australian prospective study, the 45 
and Up Study[96]. These objectives were to: 
1. Review of the association between alcohol consumption and disease and injury, with a particular 
focus on cancer (Chapter 2). 
 
2. Systematically review previous systematic reviews and meta-analyses of the association 
between alcohol consumption and all-cause mortality (Chapter 3), and examine whether there is 
variation in review findings by: 
 Methodological quality and risk of bias. 
 Population sub-groups such as sex, age and smoking status. 
 Alcohol exposure measurement such as pattern of drinking and beverage type. 
 Primary study attributes such as level of adjustment and length of follow-up. 
 
3. Investigate the clustering of alcohol consumption with other behavioural risk factors and assess 
potential variation by country of birth (Chapter 6). 
 
4. Investigate the relationship between a variety of incident health conditions and drinking 
cessation (Chapter 7). 
 
5. Investigate the association between alcohol consumption and cancer risk, exploring differences 
by sex, smoking status and region of birth, and estimate the absolute risk and population 
attributable risk of alcohol exposure for a range of cancer types (Chapter 8). 
 
6. Investigate the association between alcohol consumption and risk of all-cause and cause-specific 
mortality, exploring differences by sex, smoking status and region of birth, and estimate the 
28 
 
absolute risk and population attributable risk of alcohol exposure for all-cause mortality 
(Chapter 9). 
 
The methods used to address these objectives are summarised in Chapters 4 and 5. These objectives 
allowed for a thorough investigation of alcohol consumption and its relation to disease and 
mortality, and whether important risk estimates for Australia such as population attributable 
fractions for cancer and all-cause mortality are likely to be biased by the ‘sick-quitter effect’. The 
findings of each chapter are considered together in the discussion and conclusions in Chapter 10. 
 
29 
 
1.5 – References 
1. PubChem. Ethanol. 2016  [cited 2016 Nov 2]; Available from: 
https://pubchem.ncbi.nlm.nih.gov/compound/702. 
2. Food Standards Australia New Zealand, AUSNUT 2011-2013. 2016, FSANZ: Canberra. 
3. National Health and Medical Research Council, Australian Guidelines To Reduce Health Risks 
From Drinking Alcohol. 2009, NHMRC: Canberra. 
4. Australian Institute of Health and Welfare, Australian Burden of Disease Study: Impact and 
causes of illness and death in Australia 2011. 2016, AIHW: Canberra. 
5. Cederbaum, A.I., Alcohol metabolism. Clin Liver Dis, 2012. 16(4): p. 667-85. 
6. Zakhari, S., Overview: how is alcohol metabolized by the body? Alcohol Res Health, 2006. 
29(4): p. 245-54. 
7. National Expert Advisory Committee on Alcohol, Alcohol in Australia: Issues and Strategies. 
2001, NEACA: Canberra. 
8. Moodie R. A brief history of alcohol consumption in Australia. 2013  [cited 2016 May 24]; 
Available from: http://theconversation.com/a-brief-history-of-alcohol-consumption-in-
australia-10580. 
9. Australian Institute of Health and Welfare, National Drug Strategy Household Survey detailed 
report: 2013, in Drug statistics series. 2014, Australian Institute of Health and Welfare: 
Canberra. 
10. Australian Bureau of Statistics. Apparent Consumption of Alcohol, Australia, 2015-16. 2017  
[cited 2017 Nov 25]; Available from: 
http://www.abs.gov.au/AUSSTATS/abs@.nsf/allprimarymainfeatures/48BD96605A358A0AC
A256F16007D736D?opendocument. 
11. Food Standards Australia New Zealand. Food Standards Code. 2016  [cited 2016 May 23]; 
Available from: http://www.foodstandards.gov.au/code/Pages/default.aspx. 
30 
 
12. VicHealth, Attitudes of Australian cider drinkers research summary. 2014, VicHealth: 
Melbourne. 
13. Foundation for Alcohol Research & Education, Risky business: The alcohol industry's 
dependence on Australia's heaviest drinkers. 2016, FARE: Canberra. 
14. McCusker Centre for Action on Alcohol and Youth, A Guide to the Alcohol Industry. 2014, 
McCusker Centre for Action on Alcohol and Youth: Perth. 
15. McCusker Centre for Action on Alcohol and Youth, Major Alcohol Sales Outlets. 2014, 
McCusker Centre for Action on Alcohol and Youth: Perth. 
16. Roy Morgan Research. Dan Murphy’s (and Woolworths) blitzing the Aussie liquor market. 
2015  [cited 2017 Jan 14]; Available from: http://www.roymorgan.com/findings/6552-dan-
murphys-woolworths-blitzing-aussie-liquor-market-201511152333. 
17. World Health Organisation, Global status report on alcohol and health 2014. 2014, WHO: 
Geneva. 
18. Australian National Preventive Health Agency, Alcohol Advertising: The Effectiveness of 
Current Regulatory Codes in Addressing Community Concern. 2014, ANPHA: Canberra. 
19. Cukier, S.N.G., J., et al. Trends in alcohol brand placements in top U.S. Movies, 1996-2015. in 
Pediatric Academic Societies 2017 Meeting. 2017. San Francisco. 
20. Carrotte, E.R., et al., Who 'likes' alcohol? Young Australians' engagement with alcohol 
marketing via social media and related alcohol consumption patterns. Aust N Z J Public 
Health, 2016. 40(5): p. 474-479. 
21. Carah, N., S. Brodmerkel, and M. Shaul, Breaching the code: Alcohol, Facebook and self-
regulation. 2015, Foundation for Alcohol Research & Education: Canberra. 
22. Petticrew, M., et al., How alcohol industry organisations mislead the public about alcohol 
and cancer. Drug Alcohol Rev, 2017. 
23. Alcohol Advertising Review Board. Alcohol Advertising Review Board: FAQ. 2017  [cited 2017 
May 25]; Available from: http://www.alcoholadreview.com.au/about/faq/. 
31 
 
24. McCusker Centre for Action on Alcohol and Youth, Alcohol Industry Peak Bodies and 
Representative Groups. 2014, McCusker Centre for Action on Alcohol and Youth: Perth. 
25. Miller, P.G., et al., Vested interests in addiction research and policy. Alcohol industry use of 
social aspect public relations organizations against preventative health measures. Addiction, 
2011. 106(9): p. 1560-7. 
26. Pettigrew, S., et al., Reverse engineering a 'responsible drinking' campaign to assess strategic 
intent. Addiction, 2016. 111(6): p. 1107-13. 
27. National Archives of Australia. Prohibition in Canberra: King O’Malley and the ‘dry’ capital. 
2013  [cited 2016 May 31]; Available from: 
http://yourmemento.naa.gov.au/2013/04/prohibition-in-canberra-king-omalley-and-the-
dry-capital/. 
28. National Drug Strategy. National Drug Strategy. 2015  [cited 2017 Jun 13]; Available from: 
http://www.nationaldrugstrategy.gov.au/. 
29. National Alliance for Action on Alcohol. NAAA Members. 2016  [cited 2016 Jun 7]; Available 
from: http://actiononalcohol.org.au/about/naaa-members/. 
30. Howard, S.J., R. Gordon, and S.C. Jones, Australian alcohol policy 2001-2013 and implications 
for public health. BMC Public Health, 2014. 14: p. 848. 
31. Doran, C.M., et al., Alcohol policy reform in Australia: what can we learn from the evidence? 
Med J Aust, 2010. 192(8): p. 468-70. 
32. Coomber, K., et al., Do consumers 'Get the facts'? A survey of alcohol warning label 
recognition in Australia. BMC Public Health, 2015. 15: p. 816. 
33. Free TV, Commercial Television Industry Code of Practice. 2015, Free TV: Sydney. 
34. Pierce, H.L., J.M. Stafford, and M. Daube, Developing an alternative alcohol advertising 
complaint review system: lessons from a world-first public health advocacy initiative. Public 
Health Res Pract, 2017. 27(3). 
32 
 
35. National Health and Medical Research Council, Australian Alcohol Guidelines: Health Risks 
and Benefits. 2001, NHMRC: Canberra. 
36. National Health and Medical Research Council, Eat For Health - Australian Dietary Guidelines 
Summary. 2013, National Health and Medical Research Council: Canberra. 
37. Butt, P., et al., Alcohol and Health in Canada: A Summary of Evidence and Guidelines for Low-
risk Drinking. 2011, Canadian Centre on Substance Abuse: Ottawa. 
38. Health Promotion Agency. Low-risk alcohol drinking advice. 2016  [cited 2016 May 11]; 
Available from: http://alcohol.org.nz/help-advice/advice-on-alcohol/low-risk-alcohol-
drinking-advice. 
39. United Kingdom Department of Health, Alcohol Guidelines Review - Report from the 
Guidelines development group to the UK Chief Medical Officers. 2016, UK Department of 
Health: London. 
40. Institute of Alcohol Studies. A good measure: Units and drinking guidelines. 2016  [cited 
2016 Aug 18]; Available from: http://www.ias.org.uk/Alcohol-knowledge-
centre/Consumption/Factsheets/A-good-measure-Units-and-drinking-guidelines.aspx. 
41. U.S. Department of Health and Human Services and U.S. Department of Agriculture. 2015-
2020 Dietary Guidelines for Americans. 2015  [cited 2016 May 10]; Available from: 
http://health.gov/dietaryguidelines/2015/. 
42. Research, R.M. Booze news: Australians’ alcohol habits by age. 2015  [cited 2017 May 26]; 
Available from: http://www.roymorgan.com.au/findings/6145-australians-alcohol-habits-by-
age-201503252208. 
43. Roy Morgan Research. Winter warmers and fair-weather friends: our seasonal drinking 
habits. 2015  [cited 2017 May 26]; Available from: 
http://www.roymorgan.com/findings/6422-our-seasonal-drinking-habits-201508272256. 
33 
 
44. Srivastava, P.Z., X., What Do the Bingers Drink? Micro-unit Evidence on Negative Externalities 
and Drinker Characteristics of Alcohol Consumption by Beverage Types. 2010, Wine 
Economics Research Centre, University of Adelaide: Adelaide. 
45. Centre for Epidemiology and Research. HealthStats NSW: Alcohol. 2017  [cited 2017 May 
26]; Available from: 
http://www.healthstats.nsw.gov.au/Indicatorgroup/indicatorViewList?code=beh_alc&topic=
topic_alcohol&name=AlcoholTopic. 
46. Dassanayake, J., et al., Are immigrants at risk of heart disease in Australia? A systematic 
review. Aust Health Rev, 2009. 33(3): p. 479-91. 
47. Feng, X., T. Astell-Burt, and G.S. Kolt, Is an index of co-occurring unhealthy lifestyles suitable 
for understanding migrant health? Prev Med, 2014. 69: p. 172-5. 
48. Australian Institute of Health and Welfare, Risk factors contributing to chronic disease. 2012, 
AIHW: Canberra. 
49. Griffin, B., et al., The clustering of health behaviours in older Australians and its association 
with physical and psychological status, and sociodemographic indicators. Ann Behav Med, 
2014. 48(2): p. 205-14. 
50. International Agency for Research on Cancer, Alcohol consumption and ethyl carbamate. 
IARC Monogr Eval Carcinog Risks Hum, 2010. 96: p. 3-1383. 
51. Del Boca, F.K. and J. Darkes, The validity of self-reports of alcohol consumption: state of the 
science and challenges for research. Addiction, 2003. 98 Suppl 2: p. 1-12. 
52. Devos-Comby, L. and J.E. Lange, "My drink is larger than yours"? A literature review of self-
defined drink sizes and standard drinks. Curr Drug Abuse Rev, 2008. 1(2): p. 162-76. 
53. Callinan, S., How big is a self-poured glass of wine for Australian drinkers? Drug Alcohol Rev, 
2015. 34(2): p. 207-10. 
54. Kerr, W.C. and T. Stockwell, Understanding standard drinks and drinking guidelines. Drug 
Alcohol Rev, 2012. 31(2): p. 200-5. 
34 
 
55. Davis, C.G., J. Thake, and N. Vilhena, Social desirability biases in self-reported alcohol 
consumption and harms. Addict Behav, 2010. 35(4): p. 302-11. 
56. Dawson, D.A., Methodological issues in measuring alcohol use. Alcohol Res Health, 2003. 
27(1): p. 18-29. 
57. Beebe, T.J., et al., Mail surveys resulted in more reports of substance use than telephone 
surveys. J Clin Epidemiol, 2005. 58(4): p. 421-4. 
58. Tipping, S., et al., The effect of mode and context on survey results: analysis of data from the 
Health Survey for England 2006 and the Boost Survey for London. BMC Med Res Methodol, 
2010. 10: p. 84. 
59. Link, M.W. and A.H. Mokdad, Effects of survey mode on self-reports of adult alcohol 
consumption: a comparison of mail, web and telephone approaches. J Stud Alcohol, 2005. 
66(2): p. 239-45. 
60. Lee, K.S., et al., Better methods to collect self-reported alcohol and other drug use data from 
Aboriginal and Torres Strait Islander Australians. Drug Alcohol Rev, 2014. 33(5): p. 466-72. 
61. Lee, K.S.P., J., et al., Developing An Ipad App to Help Aboriginal and Torres Strait Islander 
Australians to Describe Their Drinking. Drug and Alcohol Review, 2016. 35(S1): p. 49. 
62. Rehm, J., et al., Assessment methods for alcohol consumption, prevalence of high risk 
drinking and harm: a sensitivity analysis. Int J Epidemiol, 1999. 28(2): p. 219-24. 
63. Heeb, J.L. and G. Gmel, Measuring alcohol consumption: a comparison of graduated 
frequency, quantity frequency, and weekly recall diary methods in a general population 
survey. Addict Behav, 2005. 30(3): p. 403-13. 
64. Jayasekara, H., et al., Alcohol consumption over time and risk of death: a systematic review 
and meta-analysis. Am J Epidemiol, 2014. 179(9): p. 1049-59. 
65. O'Neill, D., et al., Twenty-Five-Year Alcohol Consumption Trajectories and Their Association 
With Arterial Aging: A Prospective Cohort Study. J Am Heart Assoc, 2017. 6(2). 
35 
 
66. Hutcheon, J.A., A. Chiolero, and J.A. Hanley, Random measurement error and regression 
dilution bias. BMJ, 2010. 340: p. c2289. 
67. Health Promotion Agency, The straight up guide to standard drinks. 2015, HPA: Wellington. 
68. World Health Organisation. Global Health Observatory data repository: Standard drink 
measures, in grams per unit. 2010  [cited 2016 May 10]; Available from: 
http://apps.who.int/gho/data/view.main.54180. 
69. Choi, Y.J., S.K. Myung, and J.H. Lee, Light Alcohol Drinking and Risk of Cancer: A Meta-
analysis of Cohort Studies. Cancer Res Treat, 2017. 
70. Zhou, Q., et al., Does alcohol consumption modify the risk of endometrial cancer? A dose-
response meta-analysis of prospective studies. Arch Gynecol Obstet, 2017. 295(2): p. 467-
479. 
71. Pelucchi, C., et al., Alcohol drinking and bladder cancer risk: a meta-analysis. Ann Oncol, 
2012. 23(6): p. 1586-93. 
72. Jin, M., et al., Alcohol drinking and all cancer mortality: a meta-analysis. Ann Oncol, 2013. 
24(3): p. 807-16. 
73. Rota, M., et al., Alcohol consumption and prostate cancer risk: a meta-analysis of the dose-
risk relation. Eur J Cancer Prev, 2012. 21(4): p. 350-9. 
74. Naimi, T.S., et al., Confounding and studies of 'moderate' alcohol consumption: the case of 
drinking frequency and implications for low-risk drinking guidelines. Addiction, 2013. 108(9): 
p. 1534-43. 
75. National Institute on Alcohol Abuse and Alcoholism. Drinking Levels Defined. 2017  [cited 
2017 May 24]; Available from: https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-
consumption/moderate-binge-drinking. 
76. Mukamal, K.J., et al., Moderate Alcohol Consumption and Chronic Disease: The Case for a 
Long-Term Trial. Alcohol Clin Exp Res, 2016. 40(11): p. 2283-2291. 
36 
 
77. Fillmore, K.M., et al., Moderate alcohol use and reduced mortality risk: Systematic error in 
prospective studies. Addict Res Theory, 2006. 14(2): p. 101-132. 
78. Stockwell, T., et al., Do "Moderate" Drinkers Have Reduced Mortality Risk? A Systematic 
Review and Meta-Analysis of Alcohol Consumption and All-Cause Mortality. J Stud Alcohol 
Drugs, 2016. 77(2): p. 185-98. 
79. Courtney, K.E. and J. Polich, Binge drinking in young adults: Data, definitions, and 
determinants. Psychol Bull, 2009. 135(1): p. 142-56. 
80. Taylor, A.W., et al., Do people with risky behaviours participate in biomedical cohort studies? 
BMC Public Health, 2006. 6: p. 11. 
81. Dawson, D.A., R.B. Goldstein, and B.F. Grant, Prospective correlates of drinking cessation: 
variation across the life-course. Addiction, 2013. 108(4): p. 712-22. 
82. Fekjaer, H.O., Alcohol-a universal preventive agent? A critical analysis. Addiction, 2013. 
108(12): p. 2051-7. 
83. Liang, W. and T. Chikritzhs, The association between alcohol exposure and self-reported 
health status: the effect of separating former and current drinkers. PLoS One, 2013. 8(2): p. 
e55881. 
84. Delgado-Rodriguez, M. and J. Llorca, Bias. J Epidemiol Community Health, 2004. 58(8): p. 
635-41. 
85. Marschner, I.C., R.J. Simes, and A. Keech, Biases in the identification of risk factor thresholds 
and J-curves. Am J Epidemiol, 2007. 166(7): p. 824-31. 
86. Holdsworth, C., et al., Is regular drinking in later life an indicator of good health? Evidence 
from the English Longitudinal Study of Ageing. J Epidemiol Community Health, 2016. 70(8): 
p. 764-70. 
87. Fillmore, K.M., et al., Moderate alcohol use and reduced mortality risk: systematic error in 
prospective studies and new hypotheses. Ann Epidemiol, 2007. 17(5 Suppl): p. S16-23. 
37 
 
88. Ng Fat, L., et al., Persistent long-standing illness and non-drinking over time, implications for 
the use of lifetime abstainers as a control group. J Epidemiol Community Health, 2014. 68(1): 
p. 71-7. 
89. Whitaker, L. and H. Ward, Alcohol consumption and risk of coronary heart disease. 
Association cannot be assumed to be causal. BMJ, 1996. 313(7053): p. 365-6. 
90. Rehm, J., et al., Are lifetime abstainers the best control group in alcohol epidemiology? On 
the stability and validity of reported lifetime abstention. Am J Epidemiol, 2008. 168(8): p. 
866-71. 
91. Caldwell, T.M., et al., Drinking histories of self-identified lifetime abstainers and occasional 
drinkers: findings from the 1958 British Birth Cohort Study. Alcohol Alcohol, 2006. 41(6): p. 
650-4. 
92. Nugawela, M.D., et al., Measuring Alcohol Consumption in Population Surveys: A Review of 
International Guidelines and Comparison with Surveys in England. Alcohol Alcohol, 2016. 
51(1): p. 84-92. 
93. Pandeya, N., et al., Cancers in Australia in 2010 attributable to the consumption of alcohol. 
Aust N Z J Public Health, 2015. 39(5): p. 408-13. 
94. Wilson, L.F., et al., How many cancer cases and deaths are potentially preventable? 
Estimates for Australia in 2013. Int J Cancer, 2017. 
95. Gao, C., R.P. Ogeil, and B. Lloyd, Alcohol’s burden of disease in Australia. 2014, FARE and 
VicHealth in collaboration with Turning Point: Canberra. 
96. Banks, E., et al., Cohort profile: the 45 and up study. Int J Epidemiol, 2008. 37(5): p. 941-7. 
 
38 
 
Chapter 2 – Narrative Review of Alcohol Consumption and Risk of Disease and Injury 
 
Chapter summary 
This chapter contains a narrative review of the relationship between alcohol consumption and risk of 
disease and injury, with a focus on cancer. The burden of disease and injury in Australia, estimates of 
the direction and magnitude of the association between drinking and disease, and hypothesised 
causal mechanisms were examined. Health conditions other than cancer, including infectious 
diseases, diabetes, nutritional deficiencies, overweight and obesity, dementia, neuropsychiatric 
conditions, cardiovascular disease, liver disease, pancreatitis, other digestive system diseases and 
external causes of morbidity and mortality are reviewed in detail in the Appendix A. The evidence is 
summarised and areas requiring further research are discussed. 
 
2.1 – Background 
 
Alcohol consumption impacts human health in a multitude of ways and is a major contributor to 
preventable morbidity and mortality. Globally, 5.9% of deaths and 5.1% of the burden of disease and 
injury in 2012 was attributable to alcohol[1]. Alcohol-related morbidity and mortality are higher in 
men and those living in higher income countries, and alcohol is the leading risk factor for morbidity 
and mortality in those aged between 15 and 49 years. 
The burden of disease and injury attributable to alcohol consumption in Australia in 2011 was 5.1%, 
including 12.2% of the burden for mental health, 8.2% for gastrointestinal diseases, 4.8% for 
cardiovascular disease, 3.3% for cancer, 2.7% for infectious diseases, 2.0% for endocrine diseases, 
and 1.9% for neurological diseases[2]. Of all risk factors, alcohol contributed third-most to the 
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burden of disease and injury in Australia in 2011, behind smoking (9.0%) and overweight and obesity 
(5.5%)[2]. It was estimated that 4.7% of deaths in men and 3.0% of deaths in women in Australia in 
2010 were attributable to alcohol consumption[3], and 3.2% of deaths for both sexes in 2012[1]. In 
New South Wales there were 13,517 presentations to emergency departments for alcohol-related 
problems in 2014, 53,933 alcohol-attributable hospitalisations in 2014-2015 and 1289 alcohol-
attributable deaths in 2013[4]. Persons with lower socio-economic status experience greater harm 
from alcohol consumption than other persons for the same level of drinking[5], while Indigenous 
Australians have a burden of disease due to alcohol consumption approximately twice that of the 
general population[6]. 
Also significant is the economic cost of alcohol consumption to Australian society, which in 2004-
2005 was estimated to be approximately $15 billion[7]. This figure takes into account government 
healthcare expenditure, premature death, welfare, work absenteeism and loss of productivity, 
premature retirement, crime and violence. Other effects on the community include offensive 
behaviour, noise, littering and vandalism[7]. The direct costs of alcohol consumption in Australia are 
comparable to those of other developed countries[8]. 
While there have been previous reviews examining the relationship between alcohol consumption 
and disease and injury, many gaps in the evidence base have been identified. For example, the 
relationship between drinking and risk of certain cancer types such as kidney and prostate cancer, 
whether low-volume alcohol consumption causally lowers cardiovascular disease risk, and whether 
patterns of drinking such as heavy episodic drinking modify risk of diseases such as type 2 diabetes 
and pancreatitis[9]. Causal mechanisms for the alcohol-disease relationship are uncertain or only 
hypothesised for many outcomes[9]. Therefore, there is need for a literature review to provide an 
up-to-date summary of the evidence regarding the relationship between alcohol consumption and 
risk of disease and injury including an overview of hypothesised causal mechanisms, along with 
recent estimates of alcohol-attributable burden in Australia to provide local context.  
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2.2 – Scope and Methods 
 
The aim of this chapter was to provide a narrative review of the current evidence of the relationship 
between alcohol consumption and disease and injury, with a focus on cancer. Cancer contributed 
19% to the national burden of disease and injury in 2011, the highest of any health condition[2]. 
Further, of all deaths attributable to alcohol in Australia in 2015, 36% were due to cancer, more than 
any other disease or injury[10]. For the sake of brevity, all other alcohol-related diseases are 
reviewed in Appendix A. 
For each alcohol-disease relationship, estimates for the burden of disease in Australia (alcohol-
attributable, where available), estimates of the direction and magnitude of association between 
alcohol consumption and risk of disease (using systematic reviews and meta-analyses, where 
available) and hypothesised causal mechanisms were reviewed. Gaps in the evidence base were also 
identified. The disease classification codes used in this chapter and Appendix A are from the 
International Classification of Diseases version 10 (ICD-10)[11]. 
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2.3 – Results 
 
Cancer (ICD-10: C00-97; D45-47) 
Burden in Australia 
Cancer was responsible for 19% of the total burden of disease in Australia in 2011[2]. The most 
recent year for which both cancer incidence and cancer death (underlying cause) data were available 
was 2013, shown in Table 2.1[12]. Alcohol consumption was estimated to be responsible for 2.8% of 
Australian cancer cases [13, 14]; including 31% of mouth and pharynx, 20% of larynx, 9% of 
oesophagus, 8% of colon, 12% of rectum, 13% of liver, and 6% of female breast cancer cases (Figure 
2.1). The incidence of two alcohol-related cancers, breast and liver, has been increasing over time in 
Australia[15], although how much of this increase is attributable to alcohol consumption is unclear. 
The proportion of cancer deaths caused by alcohol consumption has been estimated at 3.5% in 
2010[3, 16] and 2.4% in 2013[14]. 
 
Table 2.1. Cancer incidence and cancer deaths (underlying cause) in 
Australia in 2013[12, 17]. 
Cancer type (ICD-10 code) n cases (%) n deaths (%) 
Prostate (C61) 19,233 (15.5) 3,112 (7.1) 
Breast (C50) 16,045 (12.9) 2,892 (6.6) 
Colorectum (C18-20) 14,962 (12.0) 4,162 (9.4) 
Melanoma (C43) 12,744 (10.2) 1,617 (3.7) 
Lung (C33-34) 11,174 (9.0) 8,217 (18.6) 
Non-Hodgkin lymphoma (C82-85) 4,880 (3.9) 1,471 (3.3) 
Mouth and pharynx (C00-14) 3,645 (2.9) 817 (1.9) 
Leukaemia (C91-95) 3,359 (2.7) 1,645 (3.7) 
Kidney (C64) 3,059 (2.5) 962 (2.2) 
Pancreas (C25) 2,865 (2.3) 2,558 (5.8) 
Other (Other C00-97;D45-47a) 32,499 (26.1) 16,683 (37.8) 
All types (C00-97;D45-47a) 124,465 (100.0) 44,136 (100.0) 
aNon-melanoma skin cancer excluded for incident cases and included 
for deaths. ICD-10, International Classification of Diseases, version 10. 
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Figure 2.1. Cancer cases attributable to alcohol consumption in Australia in 2010 by sex[12, 13]. 
 
Epidemiology 
The International Agency for Research on Cancer (IARC) classifies ethanol and alcoholic beverages as 
a group 1 carcinogens, meaning there is “sufficient evidence” for their carcinogenicity in humans[18]. 
The IARC reports that alcohol consumption is causally related to seven types of cancer – mouth, 
pharynx, larynx, oesophagus (stronger for evidence for squamous cell carcinoma (SCC) than 
adenocarcinoma), liver, colorectum and female breast[18, 19]. The World Cancer Research Fund 
(WCRF), reached a similar conclusion, stating there is a convincing level of evidence that alcohol 
consumption is causally related to cancers of the mouth, pharynx, larynx, oesophageal SCC, liver, 
colorectum and female breast[20, 21]. 
In addition, these organisations make conclusions for several other cancer types where the evidence 
for causality is not as strong. The IARC states there is evidence for an association between alcohol 
consumption and pancreatic cancer when consumption is > 30 grams ethanol per day, however it is 
Key 
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not clear whether the relationship is causal or due to residual confounding by smoking[19]. The IARC 
also concluded that there is no association with kidney or bladder cancer. The WCRF states there is a 
probable increased risk of stomach cancer, a probable decreased risk for kidney cancer, and limited 
evidence suggestive of an increased risk for pancreatic cancer above approximately 3 drinks per day. 
For the remaining 16 cancer types assessed by the IARC the evidence was found to be inconsistent 
or lacking, with some studies reporting an increased risk with alcohol consumption and others a 
decreased risk. For cancer types with inconsistent evidence, it was stated that many studies lacked 
adjustment for important potential confounders, such as Helicobacter pylori infection status for 
stomach cancer. For all other cancer types analysed by the WCRF the evidence was limited and so no 
conclusion could be made. A summary of the IARC monographs and WCRF reports is shown in Table 
2.2. For some additional cancer types, meta-analyses have found evidence of increased risk of 
cancers of the gallbladder[22], lung[22] (but not in never-smokers[23]), melanoma[22] and 
prostate[22, 24] with increasing alcohol consumption, and inverse associations for thyroid 
cancer[22, 25], Hodgkin lymphoma[22, 26] and non-Hodgkin lymphoma (NHL)[22, 27]. 
The relationship between alcohol consumption and cancer risk appears to be linear on an 
exponentiated scale[9]. There is no evidence for a safe threshold of drinking for which risk of cancer 
is not elevated, nor for any differences in risk by type of alcoholic beverage[20, 21]. Light alcohol 
consumption (up to 1 drink per day) has been found in a meta-analysis to increase risk of 
oesophageal SCC, mouth, pharynx and breast cancer[28-30], but not of larynx, colorectal or liver 
cancer[29].  
Risk estimates for the majority of cancer types appear to be fairly robust. A systematic review and 
meta-analysis of alcohol consumption and risk of 23 cancer types reported that when the results 
were restricted to studies that adjusted for confounders, risk estimations were not materially 
changed (except for prostate cancer, where effect estimates became higher)[22]. Risks were also 
largely unaffected when examining alternative choices of reference group. For most cancer types 
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there was no evidence that risk estimates varied by study type, except for higher relative risks in 
case-control studies compared to cohort studies for mouth and pharynx cancer and in cohort studies 
compared to case-control studies for ovarian cancer. Risk estimates only differ by sex for colorectal 
cancer, with higher risk in men than women. There was also no variation in risk by the region the 
study was conducted in, with the exception of an increased risk of lung cancer in North American 
studies but not in European or Asian studies, and an association with decreased risk of NHL in 
European and Asian studies but not in North American studies. 
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Table 2.2. Relationship between alcohol consumption and cancer according to the IARC[18, 19] and the WCRF[20, 21]. 
Cancer type (ICD-10 code) IARC WCRF 
Mouth and pharynx (C00-14) Increased risk (RR 3 at 50 g/day); interaction with smoking Convincing increased risk 
Oesophagus (C15) Increased risk (RR 2 at 50 g/day); interaction with smokinga Convincing increased riska 
Stomach (C16) Inconsistent evidence (increased risk in some studies) Probable increased riskb 
Colorectum (C18-20) Increased risk (only at > 30 g/day; RR 1.4 at 50 g/day) Convincing increased riskc 
Liver (C22) Increased risk, interaction with smoking Convincing increased riskb 
Gallbladder (C23-24) - Limited - no conclusion 
Pancreas (C25) Association with small increased risk (only at ≥ 30 g/day) Suggestive increased riskd 
Larynx (C32) Increased risk (RR 2 at 50 g/day); interaction with smoking Convincing increased risk 
Lung (C33-34) Inconsistent evidence (increased risk in some studies) Limited - no conclusion 
Melanoma (C43) Inconsistent evidence Limited - no conclusione 
Female breast (C50) Increased risk (RR 1.5 at 50 g/day) Convincing increased risk 
Male breast (C50) Inconsistent evidence - 
Vulva and vagina (C51-52) Inconsistent evidence (increased risk in some studies) - 
Cervix (C53) Inconsistent evidence (increased risk in some studies) Limited - no conclusionf 
Endometrium (C54.1) Inconsistent evidence Limited - no conclusion 
Ovary (C56) Little evidence for association Limited - no conclusion 
Prostate (C61) Little evidence for association (increased risk in some studies) Limited - no conclusion 
Testis (C62) Inconsistent evidence - 
Kidney (C64) No association (decreased risk in some studies) Probable decreased riskg 
Bladder (C67) No association Limited - no conclusion 
Brain (C71) Inconsistent evidence - 
Thyroid (C73) Inconsistent evidence (decreased risk in some studies) - 
Hodgkin lymphoma (C81) Inconsistent evidence (decreased risk in some studies) - 
Non-Hodgkin lymphoma (C82-85) Inconsistent evidence (decreased risk in some studies) - 
Multiple myeloma (C90.0) Inconsistent evidence - 
Leukaemia (C91-95)  Inconsistent evidence - 
aSquamous cell carcinoma only; not enough evidence/no association for adenocarcinoma. bFor alcohol consumption > 45 g/day. 
cFor alcohol consumption > 30 g/day. dLimited-suggestive increased risk, for alcohol consumption > 3 drinks/day. eFor all skin 
cancer. fFor alcoholism. gFor alcohol consumption ≤ 30 g/day. Relative risks are compared to non-drinkers. IARC, International 
Agency for Cancer Research. WCRF, World Cancer Research Fund. ICD-10, International Classification of Diseases version 10. RR, 
Relative Risk. 
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Several aspects of the relationship between alcohol consumption and cancer have been studied. 
One of these is the lag time between exposure to alcohol and cancer incidence, which remains 
unclear. Estimates of lag time have been reported for cancer mortality ranging from 10 to 25 
years[31], while a recent multi-country ecological study estimated a lag time of approximately eight 
years for mortality from cancers of the mouth, pharynx, larynx and oesophagus[31]. Further, an 
Australian study examined mortality rates from all cancers combined and found the lag time with 
the strongest correlation with per capita alcohol consumption was ten years[32]. 
Another important aspect of the relationship between alcohol and cancer is the potential impact of 
change in alcohol consumption over time. For example, it has been reported that temporal variation 
in population-level alcohol consumption in Australia predicts changes in pharynx and oesophagus 
cancer mortality rates[33]. Whether or not, and by how much drinking cessation reduces the risk of 
cancer is also of interest. Regarding mouth, pharynx, larynx and oesophageal cancer, drinking 
cessation has been associated with decreased risk[18]. Further, a number of studies have 
investigated changes in alcohol consumption over the life course for breast cancer, and found that 
risk may be cumulative. For example, breast cancer risk due to alcohol consumption begins in young 
adulthood[34], and in the Nurses’ Health Study it was found that alcohol consumption in earlier and 
later life each independently increased risk[35]. A recent cohort study examined change in alcohol 
consumption over time and found that postmenopausal women who increased their alcohol 
consumption over a five year period increased their risk of breast cancer after adjusting for total 
alcohol consumption at baseline, while no benefit was observed among those who decreased their 
alcohol consumption[36].  
Potential interactions between alcohol consumption and other risk factors may also impact cancer 
risk. For example, alcohol and tobacco smoking have a multiplicative effect on the risk of cancers of 
the mouth, pharynx, larynx, oesophagus and liver[18, 19]. Interactions between alcohol and other 
known risk factors for cancer are an area for further research, including smoking for stomach and 
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lung cancer, weight status for colorectal and pancreatic cancer, folate status for colorectal cancer, 
hormone replacement therapy use for breast cancer, and hepatitis B and C viral infection for liver 
cancer[18, 19]. 
Evidence for an effect of pattern of drinking on cancer risk, such as heavy episodic drinking or 
drinking frequency, is scarce[9, 37]. Drinking patterns have been investigated in a number of 
different ways in relation to cancer risk. Specifically, risk has been quantified by drinking frequency 
(days per week of alcohol consumption), the highest number of drinks consumed in one day in a 
typical month, drinks per day of alcohol consumption (including “heavy episodic drinking”), daily 
moderate drinking, as well as daily heavy drinking. Further, there is great diversity in the methods 
that have been used to assess drinking patterns[38], which makes studies difficult to compare 
directly. An analysis of the Health Professionals Follow-up Study and Nurses’ Health Study found that 
after adjusting for total alcohol consumption, neither the frequency of drinking in days per week or 
the highest number of drinks consumed in one day in a typical month were associated with risk of all 
cancers combined[37]. When combining the seven alcohol-related cancers identified by IARC, 
frequency of drinking (days per week of alcohol consumption) was positively associated with 
increased risk for men but not women, while highest number of drinks consumed in one day was 
associated with increased risk for women but not men. In contrast, a twelve country cohort study 
found no association of heavy episodic drinking with alcohol-related cancers combined, although the 
authors stated that the study was underpowered[39]. 
Other studies have reported that greater drinking frequency (i.e. increased drinking occasions) 
increased risk of mouth cancer[40], mouth and pharynx cancer[41], oesophageal cancer (men 
only)[42], stomach cancer (those with negative H. pylori status only)[43], prostate cancer[44] and 
total cancer (men only)[42], and no effect on risk of breast cancer[45, 46] or 15 cancer types[42]. 
Increased risk with drinks per day of alcohol consumption or heavy episodic drinking has been 
reported for stomach cancer (those with negative H. pylori status only)[43], pancreatic cancer[47], 
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lung cancer (smokers only)[48], breast cancer[46, 49] and prostate cancer[50], and also for total 
cancer mortality[51]. One study also found no effect on breast cancer risk for “sporadic” drinking or 
daily moderate drinking but an increased risk with daily heavier drinking[52]. The majority of these 
studies however did not, or only partially, adjusted for total alcohol consumption[40-44, 48-52], 
meaning it was not possible to determine whether drinking pattern affected risk independent of the 
overall amount of alcohol consumed. Overall, very few large prospective studies have examined 
drinking pattern and cancer risk, and no studies have examined multiple cancer types using a 
consistent methodology that included an adjustment for total alcohol consumption. 
A final consideration in the alcohol-cancer relationship is that the impact on cancer incidence may 
differ to that for cancer mortality. This is because alcohol consumption may impact disease 
progression and survival among those already diagnosed with cancer, particularly for colorectal and 
breast cancer. Specifically, pre-diagnostic heavy alcohol consumption was reported to result in 
poorer survival for those diagnosed with colorectal cancer[53]. For breast cancer, the effects on 
recurrence and survival are somewhat inconsistent. For breast cancer recurrence, it has been 
reported that there is no association with pre-diagnosis drinking[54], no association with post-
diagnosis drinking[54], a positive association with post-diagnosis drinking only in post-menopausal 
women[55], a positive association with pre- or post-diagnosis drinking as low as 6 grams per day[56], 
and a positive association with pre- or post-diagnosis drinking only in pre-menopausal women[54]. 
For breast cancer survival, it has been reported that there is no association with pre-diagnosis 
drinking[54, 57], no association with post-diagnosis drinking[54, 55], “weak evidence” of a positive 
association with post-diagnosis drinking in estrogen receptor negative cases (the authors state that 
the effect may be attributable to reverse causation)[57], and a positive association with pre- or post-
diagnosis drinking > 20 grams per day[54]. The impact of pre- and post-diagnosis drinking on 
recurrence and survival for other cancer types has been less studied, and is an area for further 
investigation. 
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In conclusion, there are significant gaps in the research base for alcohol and cancer risk in several 
areas. These include the large number of cancer types for which a causal relationship with alcohol 
remains uncertain, the lag-time between alcohol exposure and occurrence of cancer, the possibility 
of interactions between alcohol and other risk factors, whether drinking patterns (particularly 
drinking frequency and heavy episodic drinking) modify cancer risk, and whether drinking influences 
cancer recurrence and survival. 
Causal mechanisms 
The causal mechanism of alcohol on cancers of the mouth, pharynx, larynx and oesophagus is 
thought to be the ethanol metabolite acetaldehyde, which has mutagenic effects on 
deoxyribonucleic acid (DNA) through the formation of DNA adducts[58]. This is most apparent in 
persons with a gene polymorphism associated with the inactive form of the enzyme aldehyde 
dehydrogenase (ALDH2), as this condition causes acetaldehyde to accumulate when alcohol is 
consumed[18, 58]. This genetic variant is common in East Asian populations[59]. Two other gene 
polymorphisms associated with alcohol dehydrogenase are ADH1B and ADH1C, which control the 
rate of acetaldehyde formation from ethanol. ADH1B has been shown to influence risk of these 
cancers[19, 58], however studies examining the effect of ADH1C polymorphism on cancer risk have 
been inconsistent. Oesophageal cancer can also be caused by alcohol relaxing oesophageal motility 
and increasing the propensity for reflux among heavy drinkers with gastro-oesophageal reflux 
disease[58]. 
The multiplicative effect of alcohol and smoking on risk of upper aerodigestive tract cancers (mouth, 
pharynx, larynx and oesophagus) has been hypothesised to be caused by ethanol-induced increases 
in the activity of cytochrome P450 2E1, which produces reactive oxygen species (highly reactive 
molecules that in turn form DNA adducts) and may also ‘activate’ the carcinogens present in tobacco 
smoke. Ethanol may act as a solvent for other carcinogens including tobacco smoke[18, 58]. 
Polymorphisms in cytochrome P450 2E1 may also result in increased production of reactive oxygen 
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species (and therefore DNA adducts) in the presence of alcohol consumption[58], but evidence 
supporting this hypothesis is weak[18]. 
For liver cancer, drinking causes liver inflammation, fibrosis and cirrhosis which in turn can develop 
into hepatocellular carcinoma. Drinking also contributes to liver cancer directly through 
acetaldehyde-induced DNA adduct formation, increased oxidative stress (higher than normal levels 
of reactive oxygen species) via glutathione depletion and iron accumulation, altered DNA 
methylation (which controls DNA transcription) via s-adenosylmethionine depletion, decreased 
tissue levels of retinoic acid which helps to regulate cell growth, increased permeability of the gut to 
endotoxins from microflora which cause liver injury, and through decreasing the number and activity 
of natural killer cells which have anti-tumour effects in the liver[18, 58, 60]. Alcohol consumption has 
a greater effect on risk in those with hepatitis B or C virus infection, haemochromatosis, non-
alcoholic steatohepatitis and diabetes[18, 58, 61]. There may also be an interaction effect with 
smoking[18, 60]. Further detail of the mechanisms by which alcohol causes liver fibrosis and cirrhosis 
is provided in the liver disease section in Appendix A. 
For colorectal cancer, it is hypothesised that acetaldehyde produced by the metabolism of ethanol 
by bacteria in the gut may have a genotoxic effect, and also that alcohol may disrupt the role of 
folate metabolism in DNA synthesis and methylation[9, 58]. Vitamin B6 and B12 are also related to 
folate metabolism, and deficiencies in these factors associated with alcohol consumption may 
therefore increase the risk of colorectal cancer[58]. 
Drinking may cause breast cancer by increasing levels of oestradiol, androgens and insulin-like 
growth factor[9, 19, 58]. The elevation of oestradiol and androgen levels has been suggested to 
occur by alcohol consumption inhibiting sex steroid catabolism in the liver[19]. 
Methylenetetrahydrofolate reductase gene polymorphism (C677T) in combination with low folate 
status or heavy alcohol consumption is associated with an increased risk of breast cancer, suggesting 
that the disruptive effect of alcohol consumption on folate metabolism may play a role[18]. 
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The possible mechanisms for carcinogenesis are less clear for other sites. For many cancer types the 
causative mechanism with alcohol consumption is not understood completely, and the relative 
importance of ethanol-induced redox effects, reactive oxygen species, metabolic changes and 
impact on other carcinogens remains unknown[19, 62]. The eight additional cancer types which have 
been associated with alcohol consumption are cancers of the pancreas, stomach, gallbladder, lung, 
skin (both melanoma and non-melanoma), prostate and myelodysplastic syndromes[22, 63, 64].  
If causal, alcohol is hypothesised to cause pancreatic cancer via the inducement of chronic 
pancreatitis, which is a risk factor for pancreatic cancer[18]. The details of this process are explained 
in the pancreatitis section in Appendix A. Similarly, it has been hypothesised that heavy alcohol 
consumption causes gastritis which in turn may be a risk factor for stomach cancer[65], or instead 
that the relationship is explained by residual confounding from smoking or poor diet[22]. For these 
two cancer types, folate metabolism may also be important, as the aforementioned C677T 
polymorphism in combination with low folate status or heavy alcohol consumption is also associated 
increased risk of stomach and pancreatic cancer[18].  
For gallbladder cancer, the stimulation of bile acid secretion by alcohol consumption is a 
hypothesised mechanism[66].  
As the association between drinking and lung cancer may be limited to ever-smokers, the 
mechanism for this site may be through alcohol increasing the activity of cytochrome P450 activity 
and acting to ‘enhance’ the carcinogens present in tobacco smoke[23], or alternatively the 
relationship could be explained by residual confounding from smoking[22].  
For melanoma, drinking may amplify skin damage during sun exposure, or could promote the 
development of melanoma directly via immunosuppression[22].  
52 
 
Possible mechanisms explaining the relationship between alcohol consumption and prostate cancer 
include the action of acetaldehyde and cytochrome P450 2E1, raised levels of estrogen and 
alterations to folate metabolism[24]. 
Finally, for myelodysplastic syndromes, alcohol may increase risk by decreasing immune system 
activity, by inducing bone marrow failure or through chromosomal changes in haematopoietic 
cells[63]. 
Although the evidence remains inconsistent, some studies find associations with drinking and 
decreased risk for kidney, thyroid, Hodgkin lymphoma and NHL cancers, as did a systematic review 
and meta-analysis for all four of these sites[22]. If the protective effect of alcohol consumption on 
kidney cancer exists, hypotheses to explain this relationship have included increased insulin 
sensitivity and protection against diabetes (a possible risk factor for kidney cancer), decreased risk of 
chronic renal failure (also a risk factor for kidney cancer), the diuretic effect of alcohol resulting in 
carcinogens coming into contact with renal cells for a shorter period and reducing hypertension 
(another kidney cancer risk factor), and finally the antioxidant effect of phenolic compounds in 
alcoholic drinks[67].  
A proposed mechanism for the inverse relationship between thyroid cancer and alcohol is by the 
prevention of thyroid stimulating hormone from causing follicular thyroid cell proliferation[68]. 
For both Hodgkin lymphoma and NHL, the hypothesised mechanisms of the inverse relationship are 
that moderate alcohol consumption enhances the cellular and humoral immune response and 
increases insulin sensitivity, and has also been attributed to the antioxidant compounds in beer and 
wine[26, 27]. Alternatively, it has been suggested that the protective association for lymphoma is 
spurious and could be due to confounding by unknown factors or a form of the ‘sick-quitter effect’, 
whereby participants may have quit or reduced drinking in response to early symptoms, prior to 
diagnosis[22, 27]. 
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Gene polymorphism is thought to play a role in risk for many cancer types[62]. Other than the 
aforementioned effects of polymorphisms in aldehyde dehydrogenase, alcohol dehydrogenase, 
cytochrome P450 2E1 and methylenetetrahydrofolate reductase, there are a number of gene 
polymorphisms which decrease the effectiveness of repair of oxidative DNA damage and may 
therefore increase susceptibility to the genotoxic effects of alcohol at many sites. These include 
polymorphisms of O6-methylguanine-DNA methyltransferase, x-ray repair cross complementing 1, 
oxoguanine glycosylase 1 and nucleotide excision-repair genes[18]. For aldehyde dehydrogenase, 
there is currently not enough evidence to determine whether the inactive ALDH2 variant can cause 
cancer types other than those of the upper aerodigestive tract[18]. The effects of ethanol on 
cytochrome P450 2E1 activity may also cause DNA damage at other sites, including liver, breast and 
pancreas, however evidence for this in humans is limited[18, 19]. As well as gene polymorphism, 
gene expression may play an important role in risk, as alcohol-induced alterations to DNA 
methylation (which is involved in the control of DNA transcription) are a possible causal mechanism 
for many types of cancer[69]. 
Another factor which may have a role in the carcinogenesis of a range of cancer types is the 
inhibitory effect of alcohol consumption on the immune system[70]. There is evidence that drinking 
supresses both the innate and adaptive immune systems, including the aforementioned suppressive 
effect on natural killer cells as well as other mechanisms such as the inhibition of dendritic cell 
function and anti-tumour cytokine production[70]. Chronic alcohol consumption also stimulates the 
production of pro-inflammatory cytokines, which in turn may cause chronic inflammation and 
increased risk of cancer at a number of sites including the oesophagus, stomach, intestines and 
pancreas[70]. 
Apart from ethanol and its metabolites, there are other substances in alcoholic beverages that may 
cause cancer. Ethyl carbamate is a chemical found in alcoholic drinks that is classified as “probably 
carcinogenic to humans” by the IARC[18]. Ethyl carbamate is found in beer, wine, spirits and in some 
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foods such as bread, cheese and soy sauce. The highest concentrations are found in spirits. The 
IARC’s conclusion is based exclusively on rodent studies, which found oral administration caused 
lymphoma, leukaemia, lung, mammary gland, stomach, heart and liver cancers[18]. Ethyl carbamate 
is metabolised by cytochrome P450 in the liver to form vinyl carbamate and then vinyl carbamate 
epoxide, which induce DNA damage. This has never been demonstrated in human studies, however 
the authors of the IARC monograph note that humans and rodents have very similar metabolic 
pathways for ethyl carbamate. Other than ethanol and ethyl carbamate, 16 further carcinogens and 
possible carcinogens can be found in alcoholic beverages, including acrylamide, arsenic, benzene, 
cadmium, formaldehyde and lead[71, 72]. Most of these substances are estimated to have a very 
low impact on cancer risk compared to ethanol however, with lead and arsenic being the two most 
important contributors[72]. 
 
Other alcohol-related disease and injury 
Appendix A provides details on the wide variety of diseases and injury that contribute to alcohol-
related mortality in Australia. These include certain infections, nutritional deficiencies, overweight 
and obesity, vascular dementia, alcohol-related dementia, Wernicke-Korsakoff syndrome, alcohol 
use disorder, epilepsy, neurodegeneration, liver disease, acute pancreatitis in men and chronic 
pancreatitis in both sexes, some other digestive system diseases such as alcoholic gastritis and 
intestinal malabsorption, and many types of external causes of morbidity and mortality such as 
injury, poisoning, drowning, self-harm and interpersonal violence including domestic violence. 
For several other diseases – type 2 diabetes, acute pancreatitis in women, and many types of 
cardiovascular disease including ischaemic heart disease and ischaemic stroke – studies have 
sometimes reported a J- or U-shaped risk curve, where low-volume drinking is associated with 
reduced risk and heavy drinking with increased or similar risk compared to non-drinking. 
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For overweight and obesity, alcohol-related dementia, Wernicke-Korsakoff syndrome, 
neurodegeneration and liver disease, increased risk is observed with heavy drinking however the 
level of risk associated with low-volume drinking and whether a risk threshold exists (and at what 
level) are inconsistent or unknown. For Alzheimer’s disease and depression, the evidence for a 
causal relationship with alcohol consumption is inconsistent. It is clear that for many health 
conditions a precise dose-response relationship with alcohol consumption has not yet been 
established from prospective studies, and there is a particular need to examine how biases, including 
selection bias due to the exclusion of participants with health conditions at baseline, residual 
confounding, the ‘sick-quitter effect’ and the misclassification of alcohol consumption affect those 
dose-response relationships. 
Pattern of drinking also appears to be an important, independent determinant of risk for some 
outcomes. Heavy episodic drinking has been reported to be associated with an increased risk of HIV 
infection, diabetes, weight gain, cardiovascular disease including ischaemic heart disease, 
myocardial infarction, ischaemic stroke and haemorrhagic stroke, and liver disease. Drinking 
frequency has been associated with decreased risk of cardiovascular disease (low-volume, regular 
intake) and increased risk of liver cirrhosis (heavy, regular intake). Overall, the impact of alcohol 
consumption on human health has been widely investigated, however many questions regarding the 
strength and direction of specific alcohol-disease relationships remain. 
Combined, the deaths caused by these diseases, including cancer, contribute substantially to the 
burden of disease and injury in Australia. As alcohol consumption is causally associated with such a 
diversity of health outcomes, it is also necessary to consider how the competing risks from these 
individual diseases come together to influence risk of all-cause mortality. Chapter 3 investigates the 
association between alcohol consumption and all-cause mortality in more detail, by performing a 
systematic review of previous systematic reviews and meta-analyses.
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2.4 – Discussion and Conclusions 
 
There is evidence that alcohol consumption is causally related with increased risk of at least seven 
types of cancer (mouth, pharynx, oesophagus, colorectum, liver, larynx and female breast) as well as 
a wide variety of diseases and injury that contribute to mortality in Australia. These include certain 
infections, nutritional deficiencies, overweight and obesity, vascular dementia, alcohol-related 
dementia, Wernicke-Korsakoff syndrome, alcohol use disorder, epilepsy, neurodegeneration, liver 
disease, acute pancreatitis in men and chronic pancreatitis in both sexes, some other digestive 
system diseases such as alcoholic gastritis and intestinal malabsorption, and many types of external 
causes of morbidity and mortality such as injury, poisoning, drowning, self-harm and interpersonal 
violence including domestic violence. 
For 23 other types of cancer, evidence for a causal relationship with alcohol consumption remains 
inconsistent or unclear. For cancers of the stomach, gallbladder, pancreas, lung (in ever-smokers), 
skin (both melanoma and non-melanoma skin cancer), prostate and myelodysplastic syndromes, 
there is evidence of an association with alcohol consumption, however the evidence is not yet 
sufficient for IARC to conclude that these associations are causal. For Hodgkin lymphoma, NHL, and 
cancers of the kidney and thyroid, there is limited evidence of an inverse association with drinking, 
however it is uncertain whether these relationships are causal. Thus, further research on the size 
and direction of alcohol-related cancer outcomes is needed, particularly in Australia since almost all 
evidence to date has originated in other populations, where the level of exposure and risk profiles 
may differ. Although cancer risk estimates in relation to alcohol consumption have been 
demonstrated to be reasonably robust, for some cancers, in particular, those for which there is 
evidence of an inverse relationship, there is a need to systematically investigate the potential impact 
of residual confounding and other methodological factors such as the ‘sick-quitter effect’ on risk 
estimates. 
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Methodological biases such as the ‘sick-quitter effect’ and residual confounding are also alternative 
explanations for other diseases which have been associated with alcohol consumption in a J- or U-
shaped risk curve, where low-volume drinking is associated with reduced risk and heavy drinking 
with increased or similar risk compared to non-drinking. Specifically, the ‘sick-quitter effect’ may bias 
associations due to individuals quitting drinking in response to ill-health. If non-drinkers are used as 
the reference group, the former drinkers within this group may have an elevated risk of the 
outcome, potentially causing the risk for drinkers to be underestimated or for inverse associations to 
be found. Therefore, there is also a need to investigate potential bias from residual confounding and 
the ‘sick-quitter effect’ on risk estimates for diseases other than cancer. 
Pattern of drinking appears to be an important, independent determinant of risk for some 
outcomes, although for many health conditions, including cancer, Alzheimer’s disease and 
pancreatitis, the influence of pattern of drinking on risk remains uncertain. In addition, many studies 
fail to adjust for total alcohol consumption, meaning that any independent effect of drinking pattern 
cannot be determined. Common drinking patterns investigated were heavy episodic drinking and 
drinking frequency, but for many health conditions, evidence is lacking. An issue unique to morbidity 
and mortality from external causes is that acute alcohol consumption is more important for risk of 
injury than usual alcohol consumption. This may have the implication that measures of drinking 
pattern (especially heavy episodic drinking) capture risk more accurately than total alcohol 
consumption. There is need for evidence on the impact of both drinking frequency and heavy 
episodic drinking on disease risk that incorporates proper adjustment for total alcohol consumption. 
While there is an interaction between drinking and smoking on risk of cancers of the mouth, 
pharynx, larynx, oesophagus and liver, more evidence is needed regarding potential interactions 
between alcohol and other factors on disease. These include possible interactions with smoking for 
stomach and lung cancer, with folate status for colorectal cancer, with weight status for colorectal 
and pancreatic cancer, with hormone replacement therapy use for breast cancer, with hepatitis B 
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and C virus infection for liver cancer. Further research is also required to examine possible 
interaction effects with smoking for liver disease and with choledocholithiasis for pancreatitis. 
In conclusion, the evidence is clear that alcohol consumption at even light to moderate doses is 
detrimental to health, however for many, indeed the majority, of examined health conditions, there 
is a need for prospective studies to establish precise dose-response relationships, and the influence 
of pattern of drinking (in particular, drinking frequency and heavy episodic drinking) and interactions 
with other risk factors on disease risk. The potential for methodological biases in prospective studies 
has made interpretation of the evidence difficult, and so there is a clear need for observational 
research that explores the impact of these biases on risk estimates, namely, residual confounding, 
the ‘sick-quitter effect’, misclassification of alcohol consumption, and selection bias. This thesis 
aimed to quantify the relationship of alcohol consumption and patterns of drinking on cancer 
incidence, and all-cause and cause-specific mortality using a large, population based cohort study, 
the 45 and Up Study. The impact of bias on risk estimates was systematically and comprehensively 
addressed for each disease outcome. 
The focus of the next chapter is risk of all-cause mortality in relation to alcohol consumption. 
Diseases do not occur in isolation, and some diseases are more important determinants of mortality 
than others. It is therefore necessary to consider that the competing risks from these individual 
diseases come together to influence risk of all-cause mortality. The next chapter presents a 
systematic review of systematic reviews of the all-cause mortality risk of alcohol consumption. 
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Chapter 3 – Systematic Review of Alcohol Consumption and All-Cause Mortality 
 
Chapter summary 
This chapter presents a systematic review of the literature for previous systematic reviews and 
meta-analyses of studies quantifying alcohol consumption in relation to all-cause mortality, with a 
particular focus on methodological quality and risk of bias. The influence of the following factors on 
the shape of the alcohol-mortality risk curve was examined: population sub-groups (sex, age, region 
or ethnicity, smoking status and cardiovascular disease status), the distribution of alcohol 
consumption in the cohort or population (average, standard deviation, proportion of non-drinkers 
and per capita alcohol consumption), alcohol exposure measurement (i.e., pattern of drinking 
including heavy episodic drinking and frequency of drinking, change in alcohol consumption over 
time, measurement of alcohol consumption at single or multiple time points, whether risk is 
cumulative over the lifetime or if exposure during certain periods of life are more critical for risk, and 
beverage type) and primary study attributes (length of follow-up, sample size, year of publication, 
level of adjustment, modelling method, methodological quality, choice of reference group, and 
evidence of industry funding). The results are summarised and discussed in light of research gaps. 
 
3.1 – Background 
 
As a risk of preventable disease and injury, alcohol consumption is a major contributor to mortality 
in Australia and the rest of the world. It is estimated that 4.7% and 3.0% of deaths in men and 
women in Australia respectively in 2010[1], and 3.2% and 5.9% of deaths in Australia and the world 
in 2012 were attributable to alcohol consumption[2]. However, concerns regarding the 
methodological rigor of prospective studies of alcohol and mortality have been noted in the 
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literature[3], which may impact relative risk estimates. Because systematic reviews and meta-
analyses of prospective studies underpin most burden of disease estimates, it is important for the 
results to be as accurate as possible[1, 2]. In particular, the use of a reference group that includes 
former drinkers may result in spurious inverse associations with moderate drinking, and an 
underestimate of the harms associated with heavy drinking[3, 4]. This is due to the ‘sick quitter 
effect’. Other concerns relate to the adequacy of the measure of alcohol consumption used, the 
length of follow-up time, the age of the cohort, the inclusion or exclusion of participants with prior 
illness and the level of adjustment for confounding[4]. The shape of the risk curve with increasing 
amounts of alcohol consumption has been reported to vary by population sub-groups, such as by 
sex, age and region[5, 6]. Risk has also reported to vary according to drinking pattern, such as heavy 
episodic drinking and drinking frequency[7, 8]. Systematic reviews and meta-analyses have reached 
different conclusions regarding the shape of the all-cause mortality risk curve in relation to 
increasing levels of alcohol, with reviews finding a J-shaped relationship[5], no significant 
association[3], and a more recent review finding increased risk[4]. 
The aims of this chapter were to systematically review the literature for previous reviews and meta-
analyses of alcohol consumption and all-cause mortality, to summarise review findings including the 
current state of the evidence regarding differences in risk relationship by population sub-groups, 
measures of alcohol exposure, primary study attributes, and to determine if differences in review 
findings can be accounted for by the choice of reference group used in meta-analyses and/or the 
quality of the systematic review methodology. 
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3.2 – Scope and Methods 
 
Scope and inclusion criteria 
Peer-reviewed journal articles were selected for inclusion if they were a systematic review (with or 
without a meta-analysis) of population cohort studies and/or case-control studies in persons aged 18 
years or older, where the exposure was alcohol consumption and at least one of the outcomes was 
all-cause mortality. Articles were excluded if they were a narrative review or pooled analysis rather 
than a systematic review, if the participants were patients with a specific health condition rather 
than from the general population, if the exposure was not a quantity (such as ‘alcohol use disorder’, 
‘alcohol dependence’ or ‘alcoholism’), or if the article was not written in English. If an article did not 
explicitly state that it was a systematic review, yet still reported a search of the literature using at 
least one electronic database and otherwise appeared to be a systematic review, it was included. 
 
Search strategy 
Articles were extracted by one reviewer (Peter Sarich) from four databases (PubMed, MedLine, 
Embase and the Cochrane Library) to 4/12/2017. The search terms and restrictions used in each 
database query are shown in Table 3.1. References lists of included articles were also searched for 
relevant articles. 
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Table 3.1. Search terms and restrictions in database queries. 
Database Search terms Additional restrictions 
PubMed (alcohol[TIAB] OR ethanol[TIAB]) AND (mortality[TIAB] 
OR death[TIAB]) AND (systematic review[TIAB] OR 
systematic literature review[TIAB] OR structured 
review[TIAB] OR structured literature review[TIAB] OR 
meta analys*[TIAB] OR pooled analys*[TIAB]) 
Language: English 
MedLine (alcohol OR ethanol) AND (mortality OR death) AND 
(systematic review OR systematic literature review OR 
structured review OR structured literature review OR 
meta analys* OR pooled analys*) 
Language: English 
Embase (alcohol OR ethanol) AND (mortality OR death) AND 
(systematic review OR systematic literature review OR 
structured review OR structured literature review OR 
meta analys* OR pooled analys*) 
Language: English 
Database: Not MedLine 
Cochrane 
Library 
(alcohol OR ethanol) AND (mortality OR death) None 
 
Risk of bias assessment 
Risk of bias was assessed in a number of ways. Firstly, the risk of bias in systematic reviews (ROBIS) 
tool, a recent instrument developed to assess risk of bias in systematic reviews (with or without 
quantitative meta-analyses) was used[9]. The ROBIS tool contains four domains: Study eligibility 
criteria (e.g. clear and appropriate inclusion criteria), identification and selection of studies (e.g. 
database search terms, searching multiple databases and non-database sources, using at least two 
reviewers), data collection and study appraisal (e.g. including a primary study summary table and 
assessing methodological quality) and synthesis and findings (e.g. assessing publication bias – except 
in reviews without a meta-analysis, appropriate synthesis of information). For each domain, five or 
six ‘signalling questions’ were answered, and if a ‘no’ was recorded for any of these questions then 
there was a ‘high’ level of concern for the domain. Otherwise there was a ‘low’ level of concern for 
the domain. An exception was when the review did not contain a meta-analysis, for which the 
absence of a test for publication bias did not automatically cause the ‘synthesis and findings’ domain 
to be considered high concern. If there was a ‘high’ level of concern for at least one domain and the 
review did not address in the discussion all of the concerns raised by the signalling questions, then 
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the review was considered at ‘high’ risk of bias. Otherwise the review was considered at ‘low’ risk of 
bias. 
Another method used to assess risk of bias, specific to studies of alcohol consumption, was whether 
the review/meta-analysis used in the main analysis was a reference group of lifetime abstainers, or if 
former and/or occasional drinkers were also included. If the reference group contained either of the 
latter two groups, it was noted if a sensitivity analysis was performed using a reference group of 
lifetime abstainers. If a review included former drinkers in the reference group, this would be 
expected to bias risk estimates for drinking downward, while if occasional or light drinkers were 
included, this would be expected to bias risk estimates for drinking upward[3] (the latter scenario 
could also theoretically bias risk estimates for drinking downward if a substantial portion of 
occasional or light drinkers were former heavy drinkers). If a review did not state which reference 
group was used, but included a mixture of primary studies with reference groups of non-drinkers 
and lifetime abstainers, the reference group of the review was considered to be non-drinkers. It 
should be noted that although the use of lifetime abstainers as a reference group has been 
recommended[3, 4], the results may still be biased because lifetime abstainers have been reported 
to have unfavourable socio-demographic, health status and behavioural risk factors compared to 
moderate drinkers[10]. Other suggestions for mitigating bias have included the use of light drinkers 
as the reference group[11], or lifetime abstainers and light drinkers combined[12]. It was noted if a 
review used an alternative reference group such as these. 
Finally, the author affiliations, sources of funding and conflict of interest statements of reviews were 
examined for any evidence of alcohol industry funding or any other potential conflicts of interest. 
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Review synthesis 
The results of all reviews that reported risk estimates for the general population (without any 
restrictions by sub-population, such as sex or region) were summarised and compared. To examine 
possible heterogeneity in results by sub-population (e.g. sex, age), measure of alcohol exposure (e.g. 
pattern of drinking, change in alcohol consumption over time, beverage type) or primary study 
methodology (e.g. length of follow-up, level of adjustment), reviews which reported sub-analyses 
(including any sensitivity analyses, result stratifications or restrictions) by these topics or any other 
topic were summarised and compared. For each topic, the proportion of reviews with a reference 
group containing only lifetime abstainers and at low risk of bias were examined. 
When assessing the level of evidence for the alcohol-mortality risk relationship overall and for each 
sub-analysis, the following categories were used: 
 Lack of evidence: The reviews did not address this outcome. 
 Inconsistent evidence: The reviews reported different findings for this outcome. 
 Limited evidence: The reviews reported consistent findings for this outcome, but all reviews 
were considered at high risk of bias and/or used a reference group containing former 
drinkers. 
 Good evidence: The reviews reported consistent findings for this outcome, and at least one 
review was considered at low risk of bias and used a reference group without former 
drinkers. 
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3.3 – Results 
 
Literature search 
The database queries returned a total of 1048 results, including 414 from PubMed, 391 from 
MedLine, 161 from Embase and 82 from the Cochrane Library. In addition, 12 potentially relevant 
articles were identified from the reference lists of included articles. In total, 1060 journal articles 
were considered for inclusion. 21 articles, representing 18 individual systematic reviews (3 reviews 
had two articles), were included in the analysis. A flow diagram of the article retrieval process is 
shown in Figure 3.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Flow diagram of the article retrieval and assessment process. 
 
698 articles assessed for inclusion 
1060 articles identified 
 1048 from electronic database searches 
(PubMed: 414, MedLine: 391, Embase: 
161, Cochrane Library: 82) 
 12 from article reference lists 
677 articles excluded: 
 625: topic not relevant 
 46: topic relevant, but not a 
systematic review 
 6: topic relevant and a systematic 
review, but participants only those 
with health conditions rather than 
the general population 
362 duplicate articles excluded 
21 articles (18 systematic reviews) 
included in analysis 
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Review characteristics and risk of bias assessment 
The characteristics of included reviews are shown in Table 3.2. The largest review in terms of 
number of included primary studies (87), number of participants (3,998,626) and number of deaths 
(367,103) was Stockwell et al., (2016)[4]. Some reviews did not report number of participants and/or 
deaths. Few reviews included case-control studies. 14 of 18 reviews performed a quantitative meta-
analysis. There were sub-analyses, sensitivity analyses or result stratifications or restrictions by 
sex[4, 5, 13-21], age[3, 4, 15, 16, 18, 22], population (region or ethnicity)[4, 5, 14, 15, 18, 20, 21, 23], 
smoking status[3], exclusion of participants with pre-existing cardiovascular disease[15, 24], 
distribution of alcohol consumption in the cohort or population[16, 20], measurement of alcohol 
consumption at multiple time points[19], beverage type[25], follow-up duration[5, 16, 20, 21], 
primary study sample size[5, 20, 21], primary study year of publication[5, 20], level of adjustment[4, 
5, 15, 20, 21], model[17, 19], primary study methodological quality[4, 21], choice of reference 
group[3-5, 15, 16, 20] and evidence of industry funding[26]. No review examined the effect of 
pattern of drinking (e.g. heavy episodic drinking, frequency of drinking), change in alcohol 
consumption over time or whether risk is cumulative over the lifetime or if exposure during certain 
periods of life are more critical for risk. 11 of 18 reviews aimed to answer specific questions, and 
were restricted to studies which reported risk estimates by sex[5, 15, 20, 21], studies of participants 
in older age[22], ‘primarily European-origin populations’[14], no ‘participants of African or Asian 
origin’[18], Korean subjects[23], participants without pre-existing cardiovascular disease[24], studies 
which measured alcohol consumption at multiple time points[19], studies of specific beverage 
types[25], and studies that also assessed cardiovascular outcomes[24]. 
The reference group used in the main analysis of each review/meta-analysis is shown in Table 3.3. 
Three of 18 reviews/meta-analyses used a reference group of lifetime abstainers in the main 
analysis, without former or occasional drinkers. In one case it appears that only primary studies with 
a lifetime abstainer category were included (with any former or occasional drinker categories 
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excluded from the analysis entirely)[17], and in two cases primary studies using a reference group 
including former and/or occasional drinkers were included in some analyses, but the restriction to 
primary studies with a reference group of lifetime abstainers was a key aim of the review[3, 4]. A 
further 4 reviews/meta-analyses examined the restriction to primary studies with a reference group 
of lifetime abstainers in at least one sensitivity or sub-analysis[5, 15, 16, 20]. The remaining 11 
reviews examined primary studies with a reference group containing former drinkers (± occasional 
drinkers). No review used a reference group containing occasional drinkers without former drinkers 
in the main anlaysis. In addition, no review used the alternative reference groups of light drinkers or 
light drinkers and lifetime abstainers combined in the main analysis, although one review used a 
reference group of occasional drinkers (≤ 1 drink/week or < 1.3 g/day) alone in one analysis[4]. 
The risk of bias assessment for each review is also shown in Table 3.3. Four of 18 reviews were 
considered to be at low risk of bias[4, 21, 23, 24]. The remaining 12 reviews were considered at high 
risk of bias. Reasons for the high risk of bias included the failure to specify eligibility criteria[27, 28], 
to search more than one electronic database[5, 13-15, 18, 22, 27, 28], to specify search terms[3, 13, 
14, 17, 27, 28], to specify more than one reviewer for study selection and/or quality assessment[3, 5, 
13, 15-19, 25, 27, 28], to provide a table summarising study characteristics[13, 18, 22, 28], to 
perform an assessment of primary study quality[3, 5, 13, 15-17, 19, 20, 27, 28] and to test for 
publication bias[3, 5, 13-18, 22, 27]. Two reviews were considered to have a high level of concern for 
only one of the four ROBIS domains. That is, Costanzo et al., (2011) would have been considered at 
low risk of bias if the article had specified that two reviewers were used for primary study quality 
assessment, while Wang et al., (2014) did not specify that the primary studies had been assessed for 
quality (and with at least two reviewers). Only one review was considered at high risk of bias in all 
four ROBIS domains[28]. Stockwell et al., (2016) was the only review to both use a reference group 
of lifetime abstainers and be considered at low risk of bias[4]. 
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There was no evidence of potential conflicts of interest in any of the reviews. Two of 18 reviews 
appeared to have at least partial industry funding. Costanzo et al., (2011) was partially funded by 
Cervisia Consulenze[25], which appeared to be a consultant to the alcohol industry[29] (although it is 
stated that the funders had “no role in the selection of articles or conduct of the analyses or drafting 
of the manuscript”[25]). Park et al., (2015) was funded by the Korea Institute of Oriental 
Medicine[23], which appeared to be an organisation that researches traditional/herbal medicine[30] 
(although it is stated that there were no competing interests[23]). 
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Table 3.2. Characteristics of included systematic reviews. 
Review 
Primary study number 
and typea n participants n deaths 
Sub-analysis, sensitivity analysis, stratification or 
restriction Notes 
Anderson et al., 
(1993)[13] 
12 prospective Not stated Not stated Sex No meta-analysis 
Bagnardi et al., (2004)[17] 29 cohort 1,731,466 171,869 Sex, model, ex-/occasional drinkers excluded Focus on modelling fractional 
polynomials vs. cubic splines 
Burger et al., (2004)[18] 27 prospective Not stated Not stated Sex, age, ethnicity (no ‘participants of African or Asian 
origin’) 
No meta-analysis. Focus on deriving 
alcohol guidelines for Germany 
Cleophas (1999)[28] 8 cohort 307,591 Not stated - Main focus on CVD and beverage type 
Costanzo et al., 
(2011)[25] 
5 prospective 56,696 11,905 Beverage type Wine consumption only. Main focus on 
CVD and beverage type 
Di Castelnuovo et al., 
(2006)[5] 
34 cohort 1,015,835 94,533 Sex, region, studies without ex-/occasional drinkers in 
reference group, follow-up duration, sample size, year 
of publication, level of adjustment 
Only studies that reported risk estimates 
by sex 
Fillmore et al., (2006)[3] 54 prospective 2,137,785 Not stated Age, smoking status, studies without ex-/occasional 
drinkers in reference group 
Focus on choice of reference group 
Gmel et al., (2003)[16, 31] 50 cohort Not stated Not stated Sex, age, follow-up duration, distribution of alcohol 
consumption in the cohort or population, separating 
ex-drinkers from non-drinkers 
Focus on study characteristics 
Holman et al., (1996)[14, 
32] 
16 cohort 1,084,733 122,381 Sex, region (‘primarily European-origin populations’ 
only) 
Focus on Australian alcohol guidelines 
Jayasekara et al., 
(2014)[19] 
9 cohort 62,950 10,490 Sex, model Studies measuring drinking at multiple 
time points only 
Park et al., (2015)[23] 8 cohort, 1 nested 
case-control 
1,432,387 46,053 Ethnicity (‘Korean subjects’ only) Focus on Korean subjects and ‘mild’b 
alcohol consumption 
Poikolainen (1995)[27] 29 prospective Not stated 136,665 - No meta-analysis 
Reid et al., (2002)[22] 20 cohort/case-control Not stated Not stated Age (‘older persons’ only) No meta-analysis. Focus on older persons 
Ronksley et al., (2011)[24, 
26] 
31 cohort 844,414 Not stated CVD status (no pre-existing CVD only), evidence of 
industry funding 
Only studies that reported CVD 
outcomes. Main focus on CVD/industry 
funding 
Stockwell et al., (2016)[4] 87 cohort 3,998,626 367,103 Sex, age, region, studies without ex-/occasional 
drinkers in reference group, occasional drinkers as 
reference group, level of adjustment, study quality 
Focus on choice of reference group and 
study characteristics/quality 
aNumber of primary studies included in analyses where all-cause mortality was the outcome. bLowest category of drinking in each primary study. CVD, Cardiovascular 
disease. RRR, Relative Risk Ratio. 
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Table 3.2. (Continued) 
Review 
Primary study number 
and typea n participants n deaths 
Sub-analysis, sensitivity analysis, stratification or 
restriction Notes 
Wang et al., (2014)[20] 24 cohort 2,424,964 123,878 Sex, region, studies with lifetime abstainers as 
reference group, follow-up duration, sample size, year 
of publication, distribution of alcohol consumption in 
the cohort or population, level of adjustment 
Only studies that reported risk estimates 
by sex. Focus on female-to-male RRR 
White (1999)[15] 20 cohort 1,210,545 135,048 Sex, age, region, studies without ex-drinkers in 
reference group and/or without participants with pre-
existing coronary heart disease, level of adjustment 
Only studies that reported risk estimates 
by sex. Focus on level of alcohol 
consumption at which risk of mortality is 
lowest 
Zheng et al., (2015)[21] 9 cohort, 1 case-cohort 191,099 Not stated Sex, region, follow-up duration, sample size, level of 
adjustment, study quality 
Only studies that reported risk estimates 
by sex. Focus on female-to-male RRR and 
CVD 
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Table 3.3. Reference group and risk of bias assessment in included systematic reviews. 
Review 
Reference group (in 
main analysis) 
Former/occasional 
drinkers included 
in reference group 
Risk of bias assessment (risk of 
bias in each ROBIS domaina) Notes 
Anderson et al., 
(1993)[13] 
Non-drinkers Yes/Unclear High (Low; High; High; Low) - 
Bagnardi et al., (2004)[17] Lifetime abstainers No/No High (Low; High; High; High) - 
Burger et al., (2004)[18] Non-drinkers Yes/Yes High (Low; High; High; Low;) An unspecified number of included primary studies separated 
ex-drinkers and/or occasional drinkers from lifetime abstainers 
Cleophas (1999)[28] Non-drinkers Yes/Unclear High (High; High; High; Low) - 
Costanzo et al., 
(2011)[25] 
Non-drinkers Yes/Yes High (Low; Low; High; Low) 3 of 5 primary studies had ex-drinkers in reference group, 1 of 
5 studies had light drinkers in reference group. 3 of 5 studies 
did not adjust for total alcohol consumption 
Di Castelnuovo et al., 
(2006)[5] 
Non-drinkersb Yes/Yes High (Low; High; High; High) 27 of 56 risk curves did not have ex- or light drinkers in 
reference group. Stratification by whether study included ex- 
or light drinkers in reference group 
Fillmore et al., (2006)[3] Lifetime abstainersc No/No High (Low; High; High; High) - 
Gmel et al., (2003)[16, 31] Non-drinkersb Yes/No High (Low; High; High; High) In continuous analysis, a majority of primary studies used a 
reference group of non-drinkers. Categorical analysis 
separated ex-drinkers from lifetime abstainers 
Holman et al., (1996)[14, 
32] 
Non-drinkers or ≤ 0.25 
drinks/day 
Yes/Yes High (Low; High; Low; High) - 
Jayasekara et al., 
(2014)[19] 
Non-drinkers Yes/No High (Low; High; High; Low) “Most” primary studies separated ex-drinkers from lifetime 
abstainers 
Park et al., (2015)[23] Non-drinkers Yes/Yes Low (Low; Low; Low; Low) 3 of 9 primary studies separated ex-drinkers from lifetime 
abstainers 
Poikolainen (1995)[27] Non-drinkers Yes/Unclear High (High; High; High; Low) Reference group was lifetime abstainers in 1 of 29 primary 
studies and < 3 drinks/day in 1 of 29 studies 
Reid et al., (2002)[22] Non-drinkers Yes/Unclear High (Low; High; High; Low) An unspecified number of included primary studies separated 
ex-drinkers from lifetime abstainers 
Ronksley et al., (2011)[24, 
26] 
Non-drinkers Yes/No Low (Low; Low; Low; Low) Used lifetime abstainers as reference group in sub-analyses for 
cardiovascular disease but not for all-cause mortality 
Stockwell et al., (2016)[4] Lifetime abstainersc,d No/No Low (Low; Low; Low; Low) - 
aThe four ROBIS domains are, respectively: Study eligibility criteria; Identification and selection of studies; Data collection and study appraisal; Synthesis and findings. 
bLifetime abstainers as reference group in at least one sensitivity or sub-analysis. cResults also reported using a reference group containing former and/or occasional 
drinkers. dResults also reported using a reference group of occasional drinkers (< 1.3 g/day). ROBIS, Risk of bias in systematic reviews[9]. 
79 
 
Table 3.3. (Continued) 
Review 
Reference group (in 
main analysis) 
Former/occasional 
drinkers included 
in reference group 
Risk of bias assessment (risk of 
bias in each ROBIS domaina) Notes 
Wang et al., (2014)[20] Non-drinkersb Yes/Yes High (Low; Low; High; Low) The dose-response meta-analysis excluded ex- and occasional 
drinkers, and a sensitivity analysis for the categorical model 
excluded ex-drinkers 
White (1999)[15] Non-drinkersb Yes/Unclear High (Low; High; High; High) Sensitivity analysis excluded primary studies with ex-drinkers 
in the reference group 
Zheng et al., (2015)[21] Non-drinkers or lowest 
drinking category 
Yes/Yes Low (Low; Low; Low; Low) - 
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The J-shaped risk curve 
Many reviews reported a J-shaped risk curve between alcohol consumption and all-cause mortality. 
There were a variety of features of the J-shaped risk curve discussed in the reviews, particularly 
when comparing subgroups and performing sensitivity analyses. An illustration of the reported 
features of the J-shaped risk curve is shown in Figure 3.2. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Illustration of the features of a J-shaped risk curve between alcohol consumption and 
all-cause mortality. RR, Relative Risk.  
Quantity of alcohol consumption 
drinks per week 
Range of drinking associated 
with significant protection 
Level of drinking 
at which RR 
crosses 1 
Level of drinking 
associated with 
maximum protection 
RR at point 
of maximum 
protection 
RR all-cause 
mortality 
1 
Level of drinking 
above which increased 
risk significant 
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Review findings for the shape of the risk curve by methodological quality 
The overall findings for each review on the shape of the alcohol consumption and all-cause mortality 
risk curve by ROBIS assessment and choice of reference group are summarised in Table 3.4. If a 
review reported results using multiple reference groups then the review was counted twice where 
applicable. Of the thirteen reviews considered at high risk of bias and used a reference group of non-
drinkers, almost all found a U- or J-shaped risk curve. Three of these reviews included a sensitivity- 
or sub-analysis using a reference group of lifetime abstainers, so were reported in the table twice. 
Specifically, White (1999), Gmel et al., (2003) and Di Castelnuovo et al., (2006) still found a U- or J-
shaped risk curve (although the inverse association was attenuated in two). Nine reviews were 
considered at low risk of bias or used a reference group of lifetime abstainers (but not both), with 
the majority finding a U- or J-shaped risk curve and the remainder no significant association (Zheng 
et al., (2015) found a U-shaped risk curve in men and no significant association in women, and did 
not report results for both sexes combined. Fillmore et al., (2006) found a J-shaped risk curve when 
including former and occasional drinkers in the reference group, and no significant association when 
using a reference group of lifetime abstainers. The one review which used a reference group of 
lifetime abstainers and was considered at low risk of bias, Stockwell et al., (2016), reported a 
positive association with risk. This review also performed an analysis that included former and 
occasional drinkers in the reference group, finding a J-shaped risk curve, and used a reference group 
of occasional drinkers alone, finding a positive association with risk. 
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Table 3.4. Summary of review findings in relation to the shape of risk curve of alcohol 
consumption and all-cause mortality by ROBIS assessment and choice of reference group. 
  Shape of risk curve  
Review attributes 
n review 
findingsa U- or J-shaped No association 
Positive 
association 
High risk of bias and reference 
group of non-drinkers 
13 [3, 5, 13-16, 18-
20, 25, 27, 28] 
[22] - 
High risk of bias and reference 
group of lifetime abstainers 
5 [5, 15-17] [3] - 
Low risk of bias and reference 
group of non-drinkers 
4 [4, 21, 24]  [21, 23] - 
Low risk of bias and reference 
group of lifetime abstainers 
1 - - [4] 
Low risk of bias and reference 
group of occasional drinkersb 
1 - - [4] 
aSome reviews[3-5, 15, 16, 21] are reported twice or three times because separate results were 
reported in sub-group analyses. b≤ 1 drink/week or < 1.3 g/day. ROBIS, Risk of bias in systematic 
reviews[9].
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Review findings – general population 
Six of 18 reviews reported effect estimates for the general population, without stratification by a 
particular factor (e.g. sex, beverage type) or selection for a particular population (e.g. older persons) 
(Table 3.5)[3-5, 17, 27, 28]. It should be noted that two reviews were assumed to report effect 
estimates for the general population as they did not state any eligibility criteria[27, 28]. Four reviews 
reported a U- or J-shaped association between alcohol consumption and all-cause mortality[5, 17, 
27, 28], with a level of drinking associated with maximum protection of 5 or 6 grams per day[17], 6 
grams per day[5] or approximately 1 drink per day[27], and with significant protection until 37 grams 
per day[5]. The remaining two reviews used lifetime abstainers as the reference group[3, 4]. One 
reported no significant association between alcohol consumption and all-cause mortality (although 
the effect estimate confidence intervals appeared to be consistent with a J-shape)[3] while the other 
reported an increased risk[4]. Both reviews also reported a J-shaped relationship when including 
former and occasional drinkers in the reference group, and in one of the reviews, increased risk was 
reported only when using a reference group of occasional drinkers (≤ 1 drink/week or < 1.3 g/day) 
alone[4]. 
Reviews reported a significant increased risk at levels of intake ≥ 5 “drinks daily”[28], > 44 or > 46 
grams per day[17], ≥ 45 grams per day[3] or > 4 drinks or ≥ 45 grams per day[4] when using a 
reference group of non-drinkers, and approximately > 38 grams per day[5] or > 6 drinks or ≥ 65 
grams per day[4] when using a reference group of lifetime abstainers. Finally, in two reviews, former 
drinkers had similar effect estimates to heavy drinkers[3, 4]. The effect estimates for occasional 
drinkers were also similar to low-volume drinkers in these reviews. 
Overall, the evidence for the association between moderate alcohol consumption and all-cause 
mortality is inconsistent. While all five of the reviews examining the relationship between alcohol 
consumption and all-cause mortality including former drinkers in the reference reported a U- or J-
shaped association[3-5, 27, 28], the four reviews examining the relationship using lifetime abstainers 
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as the reference group reported different findings: a J-shaped relationship (maximum protection at 5 
to 6 grams per day, relative risk at point of maximum protection 0.84 (99% confidence interval: 0.82-
0.86))[5, 17], no significant association[3] and increased risk[4]. It is possible that some reviews using 
lifetime abstainers as the reference group may have been underpowered, due to a smaller number 
of primary studies included for analysis and/or a smaller-sized reference group compared to reviews 
using non-drinkers as the reference group. 
There is good evidence that heavy drinking increases risk, with the level of risky drinking ranging 
from > 4 to > 6 drinks per day or approximately > 38 to ≥ 65 grams per day (one review reported no 
significant association, but was consistent with an elevated risk). There is good evidence for a 
positive association with risk when occasional drinkers are used as the reference group. There is also 
good evidence that former and heavy drinkers have a similar level of increased risk. The review 
which reported only an association with increased risk was the only one not considered at high risk 
of bias [4]. Therefore, the evidence is strongest for a positive association between alcohol 
consumption and all-cause mortality, rather than a J-shaped association.  
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Table 3.5. Review findings for the general population. 
Review Reference group Risk of bias Results (95% CIa) 
Bagnardi et al., 
(2004)[17] 
Lifetime abstainers High Maximum protection at 5 g ethanol/day (fractional 
polynomial model) or 6 g/day (restricted cubic spline 
model). Significant increased risk above 44 g/day 
(fractional polynomial model) or 46 g/day (restricted 
cubic spline model) 
Cleophas 
(1999)[28] 
Non-drinkers High Significantly lower RR for 1-4 drinks daily (p < 0.02) 
Significantly higher RR for ≥ 5 drinks daily (p < 0.01) 
Di Castelnuovo 
et al., (2006)[5] 
Non-drinkers High Among 48 adjusted risk curves: 
Maximum protection at 6 g ethanol/day (RR 0.83 
(0.82-0.85)). Protection significant until 37 g/day 
Among 27 risk curves using a reference group only of 
lifetime abstainers: 
Maximum protection at 5 g ethanol/day (RR 0.84 
(0.82-0.86)). Protection significant until 30 g/day. 
Significant increased risk above ≈ 38 g/day 
Fillmore et al., 
(2006)[3] 
Lifetime abstainers High OR 0.94 (0.77-1.00) for occasional drinkingc 
OR 0.95 (0.84-1.08) for light drinkingc 
OR 0.99 (0.83-1.19) for moderate drinkingc 
OR 1.24 (1.00-1.53) for heavy drinkingc 
OR 1.18 (1.03-1.36) for former drinking 
No significant association in continuous analysis 
Poikolainen 
(1995)[27] 
 
Non-drinkers High Most studies found a U- or J-shaped risk curve. Most 
studies found the level of alcohol consumption 
associated with maximum protection to be one drink 
per day 
Stockwell et al., 
(2016)[4] 
Lifetime abstainers Low RR 0.94 (0.71-1.25) for occasional drinkingd 
RR 0.90 (0.76-1.06) for low-volume drinkingd 
RR 0.95 (0.80-1.13) for medium-volume drinkingd 
RR 1.11 (0.93-1.32) for high-volume drinkingd 
RR 1.42 (1.15-1.75) for higher-volume drinkingd 
RR 1.31 (1.09-1.57) for former drinking 
a99% CI for Di Castelnuovo et al., (2006). bIn the meta-analysis of 48 adjusted curves. cOccasional drinking: ≥ 1 
and < 12 drinks/year or ≥ 0.033 and ≤ 0.363 g ethanol/day; Light drinking: ≥ 1 drink/month and ≤ 2 drinks/day 
or ≥ 0.39 and < 25 g/day; Moderate drinking: > 2 and ≤ 4 drinks/day or ≥ 25 and < 45 g/day; Heavy drinking: > 4 
drinks/day or ≥ 45 g/day. dOccasional drinking: Current drinker and ≤ 1 drink/week or < 1.3 g ethanol/day; 
Low-volume drinking: > 1 drink/week and ≤ 2 drinks/day or ≥ 1.3 and < 25 g/day; Medium-volume drinking: > 2 
and ≤ 4 drinks/day or ≥ 25 and < 45 g/day; High-volume drinking: > 4 and ≤ 6 drinks/day or ≥ 45 and < 65 
g/day; Higher-volume drinking: > 6 drinks per day or ≥ 65 g/day. CI, Confidence Interval. OR, Odds Ratio. RR, 
Relative Risk. 
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Review findings – by sex 
11 of 18 reviews examined differences in the relationship between alcohol consumption and all-
cause mortality by sex (Table 3.6)[4, 5, 13-21]. When restricted to men, 10 of 10 reviews reported a 
J- or U-shaped relationship[5, 13-21], while when restricted to women, 8 of 9 reviews reported a J- 
or U-shaped relationship[5, 13-18, 20] and 1 reported no significant association[21]. When men and 
women were compared directly, the results were mostly consistent for some outcomes and mostly 
inconsistent for others. One review tested for an interaction with sex and found no significant 
effect[4]. This was the only review that was both considered at low risk of bias and which used 
lifetime abstainers as the reference group. In other reviews, the level of drinking associated with 
maximum protection was consistently greater in men compared to women, with estimates for men 
varying between 6 and 19 grams per day or 7.7 to 12.9 units per week, and for women between 5 
and 10 grams per day or 2.9 units per week[5, 15, 17, 18]. The range of drinking associated with 
significant protection was also larger in men compared to women[5, 14, 16, 21], except in one 
review where it was similar for both sexes[20]. The evidence for whether one sex had a lower 
minimum relative risk was inconsistent between reviews, with some reviews reporting a lower value 
in men[14, 16, 21], others in women[5, 17], and another review finding no difference[20]. Finally, in 
most reviews it was reported that the relative risk associated with heavy drinking was higher (or the 
risk was higher at lower levels of drinking) in women compared to men[5, 14, 16, 17, 20, 21]. 
Significant increased risk in men was reported at intakes ≥ 4 drinks per day[14], > 40 grams per 
day[16], approximately > 45 grams per day[5], > 60 grams per day[17] or ≥ 90 grams per day[20], 
and in women at intakes ≥ 2 drinks per day[14], > 30 grams per day[16], approximately > 35 grams 
per day[5], > 47 or > 51 grams per day[17] or ≥ 75 grams per day[20]. Finally, one review reported 
that former drinking compared to lifetime abstention was associated with greater risk in women 
compared to men[16]. 
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It should be noted that two reviews had the explicit aim of comparing risk estimates in men and 
women, using what was termed the ‘female-to-male relative risk ratio (RRR)’ (the ratio of the 
relative risk in women compared to men, for a given level of alcohol consumption)[20, 21]. For 
example, if the relative risk for a given level of drinking was 1.5 in women and 1.2 in men, then the 
female-to-male RRR was 1.25. One review reported a significantly elevated female-to-male RRR at 
levels of intake greater than approximately 70 grams per day[20]. In sensitivity analyses, the female-
to-male RRR for all drinkers combined compared to non-drinkers was unaffected by primary study 
region (Asia vs. not), cardiovascular disease status adjustment, cohort average alcohol consumption, 
duration of follow-up, primary study sample size and primary study year of publication, nor when 
using a reference group of lifetime abstainers. The other review reported a significantly elevated 
female-to-male RRR for moderate drinking but not low or heavy drinking (although the confidence 
intervals for both of the latter were consistent with a similar effect size to moderate drinking)[21]. In 
sensitivity analyses, the female-to-male RRR for heavy drinkers was affected by primary study 
country (significantly elevated for studies performed in the United States only), physical activity 
adjustment (significantly elevated when unadjusted only) and Newcastle-Ottawa Scale[33] 
(significantly elevated in lower quality studies only), and unaffected by primary study duration of 
follow-up, sample size, serum cholesterol adjustment and hypertension adjustment. In both of these 
reviews, the sensitivity analyses were not performed on the simple relative risks, and so these 
sensitivity tests are not considered in subsequent sections. 
Overall, there is inconsistent evidence that the risk relationship between alcohol consumption and 
all-cause mortality differs by sex, with most reviews, but not all, finding that a greater range of 
moderate drinking is associated with protection for men than in women, that a significant increase 
in risk begins at a lower level of drinking in women than in men, and that heavy drinking is 
associated with a higher level of risk in women than in men. This may mean that men and women 
experience a different biological response to alcohol consumption. The majority of studies used non-
drinkers as the reference group, which is of particular concern as one review found that the 
88 
 
association between former drinking and all-cause mortality differed by sex, meaning that the use of 
non-drinkers as the reference group could induce bias when investigating sex differences in the risk 
curve. Furthermore, the majority of reviews were considered at high risk of bias, with the one review 
both considered at low risk of bias and which used lifetime abstainers as the reference group finding 
no differences in the risk relationship by sex. 
Table 3.6. Review findings by sex. 
Review 
Reference group 
(in analysis 
stratified by sex) 
Risk 
of 
bias Strata Results (95% CIa) 
Anderson et 
al., (1993)[13] 
Non-drinkers High Men 
 
 
Women 
Eight of 12 studies found a J-shaped risk curve, one study only a 
significant increased risk in heavy drinkers, and three studies found 
no association 
Results were “similar” in four studies 
Bagnardi et al., 
(2004)[17] 
Lifetime 
abstainers 
High Men 
 
 
 
 
Women 
Maximum protection at 6 g ethanol/day (RR 0.82 (0.74-0.90), 
fractional polynomial model) or 7 g/day (RR 0.83 (0.74-0.93), 
restricted cubic spline model). Protection was significant until 28 
g/day (both models). Significant increase in risk above 60 g/day 
(both models) 
Maximum protection at 5 g/day (RR 0.76 (0.68-0.85), fractional 
polynomial model) or 6 g/day (RR 0.77 (0.68-0.88), restricted cubic 
spline model). Protection was significant until 24 g/day (both 
models). Significant increase in risk above 47 g/day (fractional 
polynomial model) or 51 g/day (restricted cubic spline model) 
Burger et al., 
(2004)[18] 
Non-drinkers High Men 
Women 
Maximum protection at ≈ 19 g ethanol/day 
Maximum protection at ≈ 10 g/day 
Di Castelnuovo 
et al., 
(2006)[5] 
Non-drinkers High Men 
 
 
Women 
 
 
Maximum protection at 6 g ethanol/day (RR 0.83 (0.81-0.85)). 
Protection significant until 38 g/day. Significant increase in risk 
above ≈ 45 g/day 
Maximum protection at 5 g/day (RR 0.82 (0.78-0.87)). Protection 
significant until 18 g/day. Significant increase in risk above ≈ 35 
g/day 
Significant difference in risk curve between strata (p < 0.001) 
Gmel et al., 
(2003)[16, 31] 
Lifetime 
abstainersb 
High Men 
 
 
 
 
 
 
 
Women 
RR 0.85 (0.83-0.87) for > 0-10 g ethanol/day 
RR 0.80 (0.78-0.82) for > 10-20 g/day 
RR 0.91 (0.89-0.94) for > 20-30 g/day 
RR 0.96 (0.93-1.00) for > 30-40 g/day 
RR 1.04 (1.01-1.07) for > 40-70 g/day 
RR 1.27 (1.23-1.31) for > 70-110 g/day 
RR 1.46 (1.33-1.60) for > 110 g/day 
RR 1.21 (1.10-1.32) for ex-drinkers 
RR 0.87 (0.84-0.89) for > 0-10 g/day 
RR 1.01 (0.99-1.04) for > 10-30 g/day 
RR 1.40 (1.34-1.47) for > 30-50 g/day 
RR 1.43 (1.34-1.53) for > 50 g/day 
RR 1.44 (1.28-1.61) for ex-drinkers 
a99% CI for Di Castelnuovo et al., (2006). bIn categorical analysis. In main analysis (continuous model) a 
majority of included studies had a reference group of non-drinkers. c1 unit = 9 g ethanol. CI, Confidence 
Interval. RR, Relative Risk. RRR, Relative Risk Ratio for women vs. men. 
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Table 3.6. (Continued) 
Review 
Reference group 
(in analysis 
stratified by sex) 
Risk 
of 
bias Strata Results (95% CIa) 
Holman et al., 
(1996)[14, 32] 
Non-drinkers or 
≤ 0.25 drinks/day 
High Men 
 
 
 
 
 
 
Women 
RR 0.88 (0.86-0.90) for 0-0.9 drinks/day 
RR 0.84 (0.82-0.86) for 1-1.9 drinks/day 
RR 0.93 (0.91-0.95) for 2-2.9 drinks/day 
RR 1.01 (0.98-1.04) for 3-3.9 drinks/day 
RR 1.06 (1.03-1.10) for 4-4.9 drinks/day 
RR 1.20 (1.15-1.26) for 5-5.9 drinks/day 
RR 1.37 (1.33-1.40) for ≥ 6.0 drinks/day 
RR 0.88 (0.86-0.90) for 0-0.9 drinks/day 
RR 0.94 (0.93-0.96) for 1-1.9 drinks/day 
RR 1.13 (1.10-1.16) for 2-2.9 drinks/day 
RR 1.33 (1.27-1.39) for 3-3.9 drinks/day 
RR 1.47 (1.39-1.56) for 4-4.9 drinks/day 
RR 1.47 (1.33-1.62) for 5-5.9 drinks/day 
RR 1.58 (1.49-1.69) for ≥ 6.0 drinks/day 
Jayasekara et 
al., (2014)[19] 
Non-drinkers High Men 
 
 
 
 
 
Women 
RR 0.90 (0.81-0.99) for 1-29 g ethanol/day 
RR 1.19 (0.89-1.58) for 30-59 g/day 
RR 1.52 (0.78-2.98) for ≥ 60 g/day 
In cubic spline analysis, greater alcohol consumption not significantly 
associated with all-cause mortality at intakes ≤ 40 g ethanol/day, 
followed by an increase in risk at intakes > 40 g/day 
Meta-analysis not possible 
Stockwell et 
al., (2016)[4] 
Lifetime 
abstainers 
Low - Sex was tested as an effect modifier and was not significant 
Wang et al., 
(2014)[20] 
Non-drinkers High Men 
 
 
 
 
 
Women 
RR 0.95 (0.92-0.98) for 10 g ethanol/day 
RR 0.92 (0.85-0.99) for 25 g/day 
RR 0.96 (0.83-1.10) for 50 g/day 
RR 1.15 (0.92-1.43) for 75 g/day 
RR 1.36 (1.02-1.80) for 90 g/day 
RR 1.56 (1.12-2.19) for 100 g/day 
RR 0.93 (0.90-0.96) for 10 g/day (RRR 0.98 (0.94-1.02)) 
RR 0.91 (0.85-0.96) for 25 g/day (RRR 0.99 (0.90-1.09)) 
RR 1.09 (0.93-1.27) for 50 g/day (RRR 1.14 (0.92-1.40)) 
RR 1.74 (1.23-2.47) for 75 g/day (RRR 1.52 (1.01-2.29)) 
RR 2.65 (1.59-4.42) for 90 g/day (RRR 1.95 (1.08-3.49)) 
RR 3.70 (1.95-7.04) for 100 g/day (RRR 2.36 (1.15-4.88)) 
White 
(1999)[15] 
Non-drinkers High  
Men 
Women 
 
Men 
Women 
United States: 
Maximum protection at 7.7 (6.4-9.1) units/weekc 
Maximum protection at 2.9 (2.0-2.4) units/week 
United Kingdom: 
Maximum protection at 12.9 (10.8-15.1) units/week 
Meta-analysis not possible 
Zheng et al., 
(2015)[21] 
Non-drinkers or 
lowest drinking 
category 
Low  
Men 
Women 
 
 
Men 
Women 
 
 
Men 
Women 
Low alcohol intake (< 15 g ethanol/day): 
RR 0.74 (0.60-0.92) 
RR 0.87 (0.71-1.07) 
RRR 1.07 (0.98-1.17) 
Moderate alcohol intake (15-30 g/day): 
RR 0.80 (0.68-0.95) 
RR 0.95 (0.83-1.08) 
RRR 1.10 (1.00-1.21) 
Heavy alcohol intake (> 30 g/day): 
RR 1.00 (0.81-1.22) 
RR 1.20 (0.99-1.46) 
RRR 1.09 (0.99-1.21) 
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Review findings – by age 
Six of 18 reviews reported effect estimates by age (Table 3.7)[3, 4, 15, 16, 18, 22]. Three reviews 
restricted to younger participants (< 40 years[18], < 45 years[16] and “young men”[15]). In two 
reviews a linear increased risk was found with increasing alcohol consumption[16, 18]. In the third 
review, which investigated the level of drinking associated with maximum protection, the value was 
determined to be zero (i.e. no level of drinking was associated with protection)[15]. 
Two reviews restricted to older participants (≥ 35 years[3] and aged ≥ 60 years at baseline or mean 
age of cohort ≥ 65 years at baseline[22]), with one review finding no difference in results for older 
participants compared to all participants (i.e. a J-shaped relationship when using a reference group 
including former drinkers and occasional drinkers and no significant association when using a 
reference group of lifetime abstainers)[3], and the other finding no significant association in the 
majority of primary studies examined[22]. One review, which found a J-shaped relationship overall, 
reported that older age did not significantly alter the level of drinking associated with maximum 
protection, the RR at the point of maximum protection, or the range of drinking associated with 
significant protection[16]. Finally, one review which found an association with increased risk overall, 
tested for an interaction with median age at baseline, finding no significant effect[4]. 
Overall, there is inconsistent evidence for differences in mortality risk by age. Alcohol consumption 
at younger ages may be associated with a linear increased risk of all-cause mortality, and at older 
ages with either a J-shaped relationship, or with increased risk, or no significant association. Two 
reviews reported no significant effect of age on risk estimates[4, 16], including the only review which 
was considered at low risk of bias[4]. The majority of reviews also used non-drinkers as the 
reference group, and differences in findings by age may therefore be related to less time having 
elapsed for heavy drinkers to experience negative health events and become former drinkers. 
Therefore, non-drinkers may be a less biased reference group in younger participants compared to 
older participants, resulting in J-shaped associations with mortality only in older participants. 
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Table 3.7. Review findings by age. 
Review 
Reference 
group 
Risk 
of 
bias Strata Results 
Burger et al., 
(2004)[18] 
Non-
drinkers 
High < 40 years Linear relationship between increasing alcohol 
consumption and all-cause mortality 
Fillmore et al., 
(2006)[3] 
Lifetime 
abstainers 
High ≥ 35 years “Similar results to the entire sample” 
Gmel et al., 
(2003)[16, 31] 
Non-
drinkers 
High  
< 45 years 
 
 
Older age 
Men: 
Linear increase in risk with increasing alcohol 
consumption 
Men and women: 
No significant effect on level of alcohol consumption 
associated with maximum protection, the RR at the 
point of maximum protection, or the range of 
drinking associated with significant protection 
Reid et al., 
(2002)[22] 
Non-
drinkers 
High Older 
personsa 
4 of 20 primary studies reported an association with 
increased risk with increasing drinking, 4 studies 
reported an association with decreased risk, and 13 
studies reported no associationb 
Stockwell et 
al., (2016)[4] 
Lifetime 
abstainers 
Low - Median age at baseline was tested as an effect 
modifier and was not significant 
White 
(1999)[15] 
Non-
drinkers 
High Young men Maximum protection at 0 units/weekc (i.e. no level 
of drinking was associated with protection) 
aParticipants aged ≥ 60 years at baseline or mean age of cohort ≥ 65 years at baseline. bStudies do not add up 
to twenty because one study was an analysis of three cohorts which differed in findings. c1 unit = 9 g ethanol.
92 
 
Review findings – by population (region or ethnicity) 
Six of 18 reviews reported effect estimates by population (region or ethnicity) (Table 3.8)[4, 5, 14, 
15, 18, 23]. In 4 reviews[4, 5, 14, 15], this was by the country or region the primary study was 
conducted in (e.g. United States, populations primarily of European origin), and in 2 reviews[18, 23] 
this was by ethnicity (e.g. studies with Korean subjects). Regarding region, two reviews compared 
primary studies performed in the United States and Europe[5, 15]. One review found a higher level 
of drinking associated with maximum protection in studies performed in the United Kingdom 
compared to studies performed in the United States in men, while a comparison for women was not 
possible due to lack of data for the United Kingdom[15]. The other review found a higher level of 
drinking associated with maximum protection in studies performed in Europe compared to studies 
performed in the United States for men (along with a lower relative risk at the point of maximum 
protection, and a larger range of drinking associated with protection), but no significant difference in 
women[5]. The same review also reported results for studies performed in Australia, China and 
Japan combined, finding all three factors to be higher than the results for the United States but 
lower than Europe for men, and no significant difference in women. A further review, which 
reported only an association with increased risk overall, tested for an interaction with country 
(“Mainly Caucasian” population (North America, Europe, Australia) vs. not (Japan, China, India)), 
finding no significant effect[4]. Finally, a review with the inclusion criteria of “study populations 
primarily of European origin” reported a J-shaped relationship between alcohol consumption and all-
cause mortality[14]. Regarding ethnicity, one review which excluded “studies on participants of 
African or Asian origin” reported “generally a U- or J-shaped dose-response relationship”[18], while 
another review with the inclusion criteria of “studies with Korean subjects” examined only the 
association of ‘mild’ drinking compared to non-drinking, finding no significant effect (although the 
confidence intervals were consistent with a relative risk as low as 0.72)[23]. 
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Overall, there is limited evidence for differences in mortality risk by population, with each review 
assessing different regions or ethnicities. There is limited evidence that moderate drinking is 
associated with lesser protection in the United States compared to the United Kingdom and Europe 
in men, and with a level of protection that is intermediate for Australia, China and Japan combined. 
However this evidence was provided by reviews considered at high risk of bias and using a reference 
group of non-drinkers. There is also limited evidence that ‘mild’ drinking is not associated with 
protection in persons with Korean ethnicity, although the review used non-drinkers as the reference 
group, did not calculate a result for a specific quantity of alcohol consumption, and may have been 
underpowered. Further reviews with inclusion criteria aiming to maximise Caucasian participants 
reported U- or J-shaped associations, but were considered at high risk of bias and used a reference 
group of non-drinkers. No identified reviews examined the populations of Africa, the Middle East, 
Latin America, the Pacific or other populations. This may be due to a lack of primary data, as in the 
review with the most primary studies, Stockwell et al., (2016), it was found that only 10 of 87 
primary studies were based on populations that were not ‘mainly Caucasian’[4]. Finally, there is 
good evidence for no difference in the risk relationship when comparing two specific sets of 
countries (North America, Europe and Australia combined and vs. Japan, China and India combined). 
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Table 3.8. Review findings by population (region or ethnicity). 
Review 
Reference 
group 
Risk of 
bias Population Results (95% CIa) 
Burger et al., 
(2004)[18] 
Non-
drinkers 
High “Studies on 
participants of 
African or Asian 
origin” excluded 
U- or J-shaped risk curve. Maximum protection at ≈ 19 g 
ethanol/day in men and ≈ 10 g/day in women. Significant 
increased risk beyond 24 g/day in some studies 
Di Castelnuovo 
et al., (2006)[5] 
Non-
drinkers 
High United States;  
Europe;  
Australia/ 
Japan/China; 
United States men: 
Maximum protection at 4 g ethanol/day (RR 0.84 (0.81-0.86)). 
Protection significant until 27 g/day 
European men: 
Maximum protection at 9 g ethanol/day (RR 0.76 (0.72-0.80)). 
Protection significant until 58 g/day 
Australian/Chinese/Japanese men: 
Maximum protection at 6 g ethanol/day (RR 0.82 (0.77-0.87)). 
Protection significant until 33 g/day 
Significant difference in risk curve between strata (p = 0.003) 
United States women: 
Maximum protection at 5 g ethanol/day (RR 0.81 (0.76-0.87)). 
Protection significant until 22 g/day 
European women: 
Maximum protection at 4 g ethanol/day (RR 0.80 (0.66-0.97)). 
Protection significant until 8 g/day 
Australian/Chinese/Japanese women: 
Maximum protection at 5 g ethanol/day (RR 0.88 (0.77-1.00)). 
Protection significant until 27 g/day 
No significant difference in risk curve between strata (p > 0.54) 
Holman et al., 
(1996)[14, 32] 
Non-
drinkers or 
≤ 0.25 
drinks/day 
High “Study 
populations 
primarily of 
European origin” 
Men: 
RR 0.88 (0.86-0.90) for 0-0.9 drinks/day 
RR 0.84 (0.82-0.86) for 1-1.9 drinks/day 
RR 0.93 (0.91-0.95) for 2-2.9 drinks/day 
RR 1.01 (0.98-1.04) for 3-3.9 drinks/day 
RR 1.06 (1.03-1.10) for 4-4.9 drinks/day 
RR 1.20 (1.15-1.26) for 5-5.9 drinks/day 
RR 1.37 (1.33-1.40) for ≥ 6.0 drinks/day 
Women: 
RR 0.88 (0.86-0.90) for 0-0.9 drinks/day 
RR 0.94 (0.93-0.96) for 1-1.9 drinks/day 
RR 1.13 (1.10-1.16) for 2-2.9 drinks/day 
RR 1.33 (1.27-1.39) for 3-3.9 drinks/day 
RR 1.47 (1.39-1.56) for 4-4.9 drinks/day 
RR 1.47 (1.33-1.62) for 5-5.9 drinks/day 
RR 1.58 (1.49-1.69) for ≥ 6.0 drinks/day 
Park et al., 
(2015)[23] 
Non-
drinkers 
Low “Studies with 
Korean subjects” 
OR 0.85 (0.72-1.01) for ‘mild’ drinkingb 
Stockwell et al., 
(2016)[4] 
Lifetime 
abstainers 
Low “Mainly 
Caucasian” 
population 
Mainly Caucasian population (North America, Europe, 
Australia) vs. not (Japan, China, India) was tested as an effect 
modifier and was not significant 
White 
(1999)[15] 
Non-
drinkers 
High United Kingdom;  
United States 
 
United Kingdom men: 
Maximum protection at 12.9 (10.8-15.1) units/weekc 
United States men: 
Maximum protection at 7.7 (6.4-9.1) units/week 
United States women: 
Maximum protection at 2.9 (2.0-2.4) units/week 
a99% CI for Di Castelnuovo et al., (2006). bLowest category of alcohol consumption in each primary study. c1 
unit = 9 g ethanol. CI, Confidence Interval. RR, Relative Risk. OR, Odds Ratio.
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Review findings – by smoking status 
One of 18 reviews reported effect estimates by smoking status[3]. Fillmore et al., (2006) reported 
that when using a reference group including former and occasional drinkers, alcohol consumption 
was associated with all-cause mortality in a J-shaped relationship while there was no significant 
association when using lifetime abstainers as the reference group. Regarding smoking status, risk 
estimates were only altered for ‘heavier’ drinking (> 4 drinks/day or ≥ 45 g/day), with a stronger 
association with all-cause mortality in current smokers compared to non-smokers. It was stated that 
heavier drinking and current smoking was associated with twice the risk of all-cause mortality than 
heavier drinking and non-smoking, but quantitative information on the alcohol-mortality 
relationship itself by smoking status was not reported. Ex-smoking was not examined, and there 
were no further details reported. 
Overall, there is limited evidence the association of ‘heavier’ drinking with all-cause mortality is 
higher in current smokers than non-smokers, and that smoking status does not alter risk estimates 
for levels of drinking lower than ‘heavier’. The review was considered at high risk of bias, did not 
separate ex-smokers from never-smokers, and also did not report any quantitative information 
about the alcohol-mortality relationship in each strata. 
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Review findings – by exclusion of participants with pre-existing cardiovascular disease 
Two of 18 reviews reported effect estimates by the exclusion of studies containing participants with 
pre-existing coronary heart disease[15] or cardiovascular disease[24] (Table 3.9). In one review this 
was performed as a sensitivity test, with the rationale that subjects with coronary heart disease 
could potentially “exaggerate the protective effect of moderate drinking”[15]. The other review 
simply had the absence of pre-existing cardiovascular disease as an article inclusion criterion and did 
not state a rationale[24], but as the main outcomes were cardiovascular disease incidence and 
mortality, the exclusion of participants with pre-existing cardiovascular disease was presumably to 
prevent reverse causation. Both reviews reported that moderate drinking was associated with a 
decreased risk of all-cause mortality when participants with pre-existing cardiovascular disease were 
excluded. White (1999) examined the level of drinking associated with maximum protection for 
three strata separately (American men, American women and British men), finding that the 
exclusion of studies containing participants with pre-existing cardiovascular disease did not alter 
estimates for men, but in American women the estimate increased from 2.2 to 3.7 units per 
week[15]. A caveat was that this sensitivity test also excluded studies containing former drinkers, so 
it was not possible to tell which of these two factors (the exclusion of former drinkers or subjects 
with cardiovascular disease), or both, were responsible for the result. Ronksley et al., (2011) 
reported that among participants without pre-existing cardiovascular disease, drinkers had a lower 
relative risk of all-cause mortality compared to non-drinkers, while a J-shaped association was found 
when using multiple categories of drinking with significant increased risk (relative risk 1.30, 95% 
confidence interval: 1.22-1.38) at levels of intake > 60 grams per day[24]. These findings for 
increased risk are consistent with the results of the reviews examining the general population. The 
category of drinking with the lowest relative risk (0.83, 0.80-0.86) was 2.5 to 14.9 grams per day. 
Overall, there is limited evidence of an association of moderate drinking with lower risk of all-cause 
mortality when participants with pre-existing cardiovascular disease are excluded. It cannot be 
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determined whether the level of drinking associated with maximum protection is altered by 
cardiovascular disease status, due to one review using inconsistent reference groups between the 
main and sensitivity analyses. No review was both considered at low risk of bias and used a 
reference group free of former drinkers. 
 
Table 3.9. Review findings by exclusion of participants with pre-existing cardiovascular disease. 
Review 
Reference 
group (in no 
pre-existing 
CVD analysis) 
Risk of 
bias CVD Strata Results (95% CI) 
Ronksley et al., 
(2011)[24, 26] 
Non-drinkers Low Subjects 
without CVD 
RR 0.87 (0.83-0.92) for drinkers 
RR 0.83 (0.80-0.86) for 2.5-14.9 g ethanol/daya 
RR 1.30 (1.22-1.38) for > 60 g/day 
White 
(1999)[15] 
Inconsistentb High Subjects with 
CHD included;  
Subjects with 
CHD excluded 
 
British men 
CHD included: Maximum protection at 13.0 
units/weekc 
CHD excluded: Maximum protection at 9.3 
units/week 
No significant difference between strata (p = 0.43) 
American men 
CHD included: Maximum protection at 7.5 
units/week 
CHD excluded: Maximum protection at 8.3 
units/week 
No significant difference between strata (p = 0.59) 
American women 
CHD included: Maximum protection at 2.2 
units/week 
CHD excluded: Maximum protection at 3.7 
units/week 
Significant difference between strata (p = 0.005) 
aThe minimum relative risk. bNon-drinkers for the strata that included subjects with coronary heart disease and 
lifetime abstainers for the strata that excluded subjects with coronary heart disease. c1 unit = 9 g ethanol. CVD, 
Cardiovascular disease. CI, Confidence Interval. CHD, Coronary heart disease. RR, Relative Risk. 
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Review findings – by distribution of alcohol consumption in the cohort or population 
One of 18 reviews reported effect estimates by the distribution of alcohol consumption in the cohort 
or population (Table 3.10)[16]. Gmel et al., (2003) examined four factors: the cohort average alcohol 
consumption among drinkers, the cohort standard deviation of alcohol consumption among 
drinkers, the cohort proportion of abstainers, and the per capita alcohol consumption in the 
population[16]. The three outcomes examined were the level of alcohol consumption associated 
with maximum protection, the relative risk at the point of maximum protection and the range of 
drinking associated with significant protection. In men, it was found that the cohort average alcohol 
consumption, the cohort standard deviation of alcohol consumption and the per capita alcohol 
consumption in the population were all positively associated with a higher level of drinking for the 
point of maximum protection and a larger range of drinking associated with significant protection. 
The cohort proportion of abstainers was inversely associated with these factors. None of the factors 
were associated with a change in the relative risk at the point of maximum protection. In women, 
the only significant factor was cohort standard deviation of alcohol consumption, which was 
positively associated with a higher level of drinking for the point of maximum protection and a larger 
range of drinking associated with significant protection. 
Overall, there is limited evidence that the shape of the risk curve between alcohol consumption and 
all-cause mortality is influenced by the distribution of alcohol consumption in the cohort or 
population. The level of drinking for the point of maximum protection and the range of drinking 
associated with significant protection were positively associated with greater cohort average alcohol 
consumption (men only), greater cohort standard deviation of alcohol consumption (men and 
women), smaller cohort proportion of abstainers (men only) and with greater population per capita 
alcohol consumption (men only). There is also limited evidence that the relative risk at the point of 
maximum protection is not affected by these factors. The review was considered at high risk of bias 
and used non-drinkers as the reference group. 
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Table 3.10. Review findings by the distribution of alcohol consumption in the cohort or population. 
Review 
Reference 
group 
Risk of 
bias 
Strata of alcohol 
consumption Results (95% CI) 
Gmel et al., 
(2003)[16, 31] 
Non-
drinkers 
High Cohort average 
alcohol 
consumption;  
 
 
 
Cohort standard 
deviation of 
alcohol 
consumption;  
 
 
Cohort 
proportion of 
abstainers 
 
 
 
Per capita alcohol 
consumptiona;  
 
Men: Greater average alcohol consumption 
associated with higher level of alcohol 
consumption for point of maximum protection, 
and no change in the RR at this point. Larger range 
of drinking associated with significant protection 
Women: No significant effect 
Men and women: Greater standard deviation of 
alcohol consumption associated with higher level 
of alcohol consumption for point of maximum 
protection, and no change in the RR at this point. 
Larger range of drinking associated with significant 
protection 
Men: Greater proportion of abstainers associated 
with lower level of alcohol consumption for point 
of maximum protection, and no change in the RR 
at this point. Smaller range of drinking associated 
with significant protection 
Women: No significant effect 
Men: Greater per capita alcohol consumption 
associated with higher level of alcohol 
consumption for point of maximum protection, 
and no change in the RR at this point. Larger range 
of drinking associated with significant protection 
Women: No significant effect 
aFor the country the study was conducted in rather than for the cohort itself. CI, Confidence Interval. RR, 
Relative Risk. 
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Review findings – by measurement of alcohol consumption at single or multiple time points 
One of 18 reviews reported effect estimates only for primary studies which measured alcohol 
consumption at multiple time points (average consumption measured either retrospectively or 
prospectively from baseline)[19]. It was remarked that few primary studies have captured alcohol 
consumption at multiple time points. Due to lack of data, a meta-analysis was only possible for men. 
Decreased risk was found for moderate drinking and increased risk for heavy drinking. Specifically, a 
relative risk of 0.90 (95% confidence interval: 0.81-0.99) was reported for an average consumption 
of 1-29 grams/day, while an average consumption greater than 40 grams/day was associated with 
significant increased risk. Altogether, the results were consistent with a J-shaped association. The 
review did not examine if results differed when using only baseline alcohol consumption as the 
exposure. 
Overall, there is a lack of evidence for whether the association between alcohol consumption and 
all-cause mortality differs when measuring alcohol consumption at multiple time points compared to 
using only baseline alcohol consumption. The review was considered at high risk of bias and used a 
reference group of non-drinkers. 
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Review findings – by beverage type 
One of 18 reviews reported effect estimates by beverage type[25]. For wine consumption a J-shaped 
risk curve was found, with maximum protection at 10 grams of ethanol per day and a relative risk of 
0.75 (0.66-0.86) at this point. Protection was significant until 41 grams per day, and a significant 
increased risk was apparent at intakes greater than approximately 105 grams per day (with a relative 
risk of approximately 1.3 at this point). The review only retrieved two studies of beer and spirit 
consumption and therefore a meta-analysis was not performed for these beverage types. Three of 
the five primary studies did not adjust for total alcohol consumption, meaning that the results for 
wine consumption could be confounded by the consumption of beer and spirits. 
Overall, there is limited evidence that wine consumption has a J-shaped association with all-cause 
mortality, but confounding by the consumption of other alcoholic beverages cannot be ruled out. 
There is a lack of evidence for beer and spirit consumption. The review was considered at high risk of 
bias and used a reference group of non-drinkers. There is therefore not enough evidence to 
determine whether risk of all-cause mortality differs by beverage type. 
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Review findings – by follow-up duration 
Two of 18 reviews reported effect estimates by follow-up duration (Table 3.11)[5, 16]. Both reviews 
reported that a longer period of follow-up was associated with a higher relative risk at the point of 
maximum protection and a smaller range of drinking associated with significant protection. Gmel et 
al., (2003) reported that a longer period of follow-up was associated with a lower level of drinking 
for the point of maximum protection[16], while Di Castelnuovo et al., (2006) reported no 
difference[5]. Finally, Di Castelnuovo et al., (2006) reported that a longer period of follow-up was 
associated with a lower level of drinking associated with significant increased risk. It was not 
reported whether risk estimates for heavy drinking differed significantly by period of follow-up, and 
this was not clear from the graph provided in the article. 
Overall, there is limited evidence that a longer period of follow-up attenuates the association of 
moderate drinking with protection from all-cause mortality in two ways. Namely, through an 
increased relative risk at the point of maximum protection and a smaller range of drinking associated 
with significant protection. The evidence was inconsistent whether the duration of follow-up alters 
level of drinking associated with maximum protection. There is also limited evidence that a longer 
period of follow-up results in a lower level of drinking associated with significant increased risk. Both 
reviews were considered at high risk of bias and used a reference group of non-drinkers. 
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Table 3.11. Review findings by follow-up duration. 
Review Reference group Risk of bias 
Follow-up 
duration Results (95% CIa) 
Di Castelnuovo 
et al., (2006)[5] 
Non-drinkers High ≤ 10 years; 
> 10 years 
≤ 10 years: 
Maximum protection at 6 g 
ethanol/day (RR 0.79 (0.75-0.82)). 
Protection significant until 37 g/day. 
Significant increased risk above ≈ 52 
g/day 
> 10 years: 
Maximum protection at 6 g 
ethanol/day (RR 0.85 (0.73-0.87)). 
Protection significant until 34 g/day. 
Significant increased risk above ≈ 43 
g/day 
Significant difference in risk curve 
between strata (p < 0.001) 
Gmel et al., 
(2003)[16, 31] 
Non-drinkers High Greater follow-
up time 
Men: 
Associated with lower level of alcohol 
consumption for maximum protection, 
a higher RR at this point, and a smaller 
range of drinking associated with 
significant protection 
Women: 
No significant effect 
a99% CI for Di Castelnuovo et al., (2006). CI, Confidence Interval. RR, Relative Risk. 
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Review findings – by primary study sample size 
One of 18 reviews reported effect estimates by primary study sample size (Table 3.12)[5]. Di 
Castelnuovo et al., (2006) found no significant difference in the shape of the risk curve by study 
sample size[5]. The review was considered at high risk of bias and used non-drinkers as the 
reference group. The evidence for no difference by primary study sample size is therefore limited. 
 
Table 3.12. Review findings by primary study sample size. 
Review Reference group Risk of bias Sample 
size 
Results (99% CI) 
Di Castelnuovo 
et al., (2006)[5] 
Non-drinkers High n ≤ 6000; 
n > 6000 
n ≤ 6000: 
Maximum protection at 5 g ethanol/day 
(RR 0.83 (0.78-0.85)). Protection 
significant until 26 g/day. Significant 
increased risk above ≈ 55 g/day 
n > 6000: 
Maximum protection at 5 g ethanol/day 
(RR 0.85 (0.80-0.90)). Protection 
significant until 36 g/day. Significant 
increased risk above ≈ 45 g/day 
No significant difference in risk curve 
between strata (p = 0.61) 
CI, Confidence Interval. RR, Relative Risk. 
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Review findings – by primary study year of publication 
One of 18 reviews reported effect estimates by primary study year of publication (Table 3.13)[5]. Di 
Castelnuovo et al., (2006) found that earlier studies (1981-1998) reported a significantly lower risk 
associated with moderate drinking, maximum protection at a lower level of drinking, a smaller range 
of drinking associated with protection and a lower level of drinking associated with significant 
increased risk than studies published later (1999-2005)[5]. The relative risk associated with heavy 
drinking was also higher in earlier studies than in later studies. The review was considered at high 
risk of bias and used non-drinkers as the reference group. There is therefore not enough evidence to 
determine whether the risk relationship differs by primary study year of publication. 
 
Table 3.13. Review findings by primary study year of publication. 
Review Reference group Risk of bias 
Study 
period Results (99% CI) 
Di Castelnuovo 
et al., (2006)[5] 
Non-drinkers High 1981-1998 
 
 
 
1999-2005 
Maximum protection at 5 g ethanol/day 
(RR 0.85 (0.82-0.87)). Protection 
significant until 29 g/day. Significant 
increased risk above ≈ 36 g/day 
Maximum protection at 8 g ethanol/day 
(RR 0.79 (0.76-0.82)). Protection 
significant until 48 g/day. Significant 
increased risk above ≈ 62 g/day 
Significant difference in risk curve 
between strata (p < 0.001) 
CI, Confidence Interval. RR, Relative Risk. 
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Review findings – by level of adjustment 
Three of 18 reviews reported effect estimates by level of adjustment (Table 3.14)[4, 5, 15]. In two 
reviews this was by level of adjustment in the primary studies[5, 15] and in one review this was by 
adjustment for study characteristics at the meta-analysis stage[4]. White (1999) examined whether 
primary study adjustment for ‘smoking’ or blood pressure altered the level of drinking associated 
with maximum protection, finding no material difference[15]. Di Castelnuovo et al., (2006) 
investigated incrementally how primary study adjustment for age, ‘social status’ and ‘dietary factors’ 
affected the alcohol-mortality relationship[5]. It was found that incremental adjustment for each of 
these factors were each associated with a significant changes to the shape of the risk curve. 
Adjustment for age had the largest effect, approximately halving the level of drinking associated 
with maximum protection, the magnitude of the relative risk at the point of maximum protection, 
and the range of drinking associated with significant protection[5]. The inclusion of social status and 
dietary factors reduced the range of drinking associated with significant protection but did not alter 
the other two factors. Adjustment also increased the effect estimate for heavy drinking. Stockwell et 
al., (2016) found that when adjusting for an increasing number of ten study characteristics at the 
meta-analysis stage (such as adjustment for smoking, adequacy of drinking measure and follow-up 
time), the association with protection for occasional, low- and medium-volume drinking compared 
to non-drinking was eliminated, while risk estimates for high- and higher-volume drinking were 
increased[4]. The level of drinking associated with significant increased risk, > 4 drinks per day or ≥ 
45 grams per day, did not change. The selection of the ten study characteristics to include as 
covariates in the model was derived empirically. 
Overall, there is limited evidence that adjustment at the primary study level for age, social status 
and dietary factors increases effect estimates for heavy drinking and substantially attenuates the 
observed relationship between alcohol consumption and protection against all-cause mortality (but 
does not eliminate it entirely), and limited evidence that adjustment for smoking and blood pressure 
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does not materially alter one aspect of the relationship – the level of drinking associated with 
maximum protection. Both reviews however were considered at high risk of bias and used non-
drinkers as the reference group. As Stockwell et al., (2016) was considered at low risk of bias, there 
is also good evidence that the association of occasional, low- and medium-volume drinking with 
lowered risk of all-cause mortality can be accounted for by inter-study characteristics. Further, that 
when accounting for inter-study characteristics, effect estimates for heavy drinking are increased, 
and the level of drinking associated with significant increased risk does not change. While non-
drinkers were used as the reference group for the level of adjustment analysis, this was accounted 
for through adjustment for primary study inclusion of former and/or occasional drinkers in the 
reference group. 
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Table 3.14. Review findings by level of adjustment. 
Review Reference group Risk of bias Strata Results (95% CIa) 
Di Castelnuovo 
et al., (2006)[5] 
Non-drinkers High Unadjusted 
 
 
Adjusted at least for 
age 
 
Further adjusted for 
social status 
 
Further adjusted for 
dietary factors 
 
Maximum protection at 10 g 
ethanol/day (RR 0.64 (0.60-0.81)). 
Protection significant until 68 g/day 
Maximum protection at 6 g 
ethanol/day (RR 0.83 (0.82-0.85)). 
Protection significant until 37 g/day 
Maximum protection at 9 g 
ethanol/day (RR 0.82 (0.79-0.85)). 
Protection significant until 46 g/day 
Maximum protection at 6 g 
ethanol/day (RR 0.82 (0.76-0.88)). 
Protection significant until 30 g/day 
Significant difference in risk curve 
between strata (p < 0.04 in all 
tests) 
Stockwell et al., 
(2016)[4] 
Non-drinkers Low Adjustment for study 
characteristics: 
None 
6 characteristicsc 
10 characteristicsc,d 
 
None 
6 characteristicsc 
10 characteristicsc,d 
 
None 
6 characteristicsc 
10 characteristicsc,d 
 
None 
6 characteristicsc 
10 characteristicsc,d 
 
None 
6 characteristicsc 
10 characteristicsc,d 
 
RR occasional drinkingb: 
0.84 (0.79-0.89) 
0.86 (0.80-0.92) 
0.95 (0.85-1.05) 
RR low-volume drinkingb: 
0.86 (0.83-0.90) 
0.89 (0.84-0.94) 
0.97 (0.88-1.07) 
RR medium-volume drinkingb: 
0.95 (0.91-1.00) 
0.98 (0.92-1.04) 
1.07 (0.97-1.18) 
RR high-volume drinkingb: 
1.12 (1.07-1.17) 
1.13 (1.06-1.20) 
1.24 (1.12-1.37) 
RR higher-volume drinkingb: 
1.29 (1.22-1.36) 
1.32 (1.23-1.41) 
1.44 (1.30-1.60) 
White 
(1999)[15] 
Non-drinkers High Adjustment for 
smoking or blood 
pressure 
The level of alcohol consumption 
associated with maximum 
protection did not change by more 
than 3 units per weeke 
a99% CI for Di Castelnuovo et al., (2006). bOccasional drinking: Current drinker and ≤ 1 drink/week or < 1.3 g 
ethanol/day; Low-volume drinking: > 1 drink/week and ≤ 2 drinks/day or ≥ 1.3 and < 25 g/day; Medium-
volume drinking: > 2 and ≤ 4 drinks/day or ≥ 25 and < 45 g/day; High-volume drinking: > 4 and ≤ 6 drinks/day 
or ≥ 45 and < 65 g/day; Higher-volume drinking: > 6 drinks per day or ≥ 65 g/day. cAdjustment for sex, age, 
Caucasian or not, adequacy of drinking measure, former drinker bias and occasional drinker bias. dFollow-up 
years, inclusion or exclusion of participants with ill-health and adjustment for race and smoking. e1 unit = 9 g 
ethanol. CI, Confidence Interval. RR, Relative Risk. 
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Review findings – by model 
Two of 18 reviews reported continuous effect estimates using different models (Table 3.15)[17, 19]. 
As alcohol consumption may not be associated with all-cause mortality in a linear relationship, it is 
important to determine the non-linear model that provides the best fit. Bagnardi et al., (2004) 
compared both the shape and fit the fit of the risk curves derived from linear, quadratic, fractional 
polynomial (second order) and restricted cubic spline (1 knot at the 25th percentile of alcohol 
consumption) models[17]. The fractional polynomial and restricted cubic spline models produced 
similar J-shaped risk curves and had a better fit than the quadratic model, which in turn had a better 
fit than the linear model. The quadratic model estimated a higher level of drinking associated with 
maximum protection (20 grams per day) compared to the fractional polynomial (5 grams) or 
restricted cubic spline (6 grams) models, but also a higher relative risk at the point of maximum 
protection. The level of drinking associated with significant increased risk was slightly lower when 
using the latter two models. It was concluded that both fractional polynomials and restricted cubic 
splines were useful and complementary, and should be used in preference to other models. 
Jayasekara et al., (2014) compared risk curves using linear and restricted cubic spline (3 knots at the 
10th, 50th and 90th percentiles of alcohol consumption) models[19]. Using the linear model, a positive 
association between alcohol consumption and all-cause mortality was reported. In contrast to 
Bagnardi et al., (2004), the restricted cubic spline model did not produce a significant protective 
effect associated with moderate drinking, while still producing a significant increase in risk at intakes 
greater than 40 grams of ethanol per day. Significant non-linearity was detected (p = 0.02). 
Overall, there is limited evidence that fractional polynomial or restricted cubic spline models should 
be selected over quadratic and linear models when modelling the relationship between alcohol 
consumption and all-cause mortality. Both reviews were considered at high risk of bias. 
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Table 3.15. Review findings by model. 
Review Reference group Risk of bias Strata Results 
Bagnardi et 
al., (2004)[17] 
Lifetime 
abstainers 
High Linear 
Quadratic 
 
 
Fractional 
polynomial 
 
Restricted 
cubic spline 
The worst fit of all models 
Better fit than linear model. Maximum 
protection at 20 g ethanol/day, 
significant increased risk above 52 g/day 
Better fit than linear/quadratic models. 
Maximum protection at 5 g ethanol/day, 
significant increased risk above 44 g/day 
Better fit than linear/quadratic models. 
Maximum protection at 6 g ethanol/day, 
significant increased risk above 46 g/day 
Jayasekara et 
al., (2014)[19] 
Non-drinkers High Linear 
 
Restricted 
cubic spline 
In men, greater alcohol consumption 
associated with increased risk 
In men, greater alcohol consumption not 
significantly associated with all-cause 
mortality at intakes ≤ 40 g ethanol/day, 
followed by an increase in risk at intakes 
> 40 g/day 
(p non-linearity = 0.02) 
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Review findings – by primary study methodological quality 
One of 18 reviews reported effect estimates by primary study methodological quality (Table 3.16)[4]. 
Among 13 primary studies with lifetime abstainers as the reference group, Stockwell et al., (2016) 
assessed the change in alcohol-mortality outcomes when analysing all 13 studies compared to 
restricting to 6 studies rated as higher quality. The criteria were: ‘adequate’ measure of mean 
alcohol consumption, adjustment for smoking status, median age < 60 years at baseline and ≥ 55 
years at follow-up. One of the 13 primary studies was also excluded as it was determined to be an 
outlier (6 of 8 effect estimates in the study were ‘extreme outliers’)[4]. When restricted to the 6 high 
quality studies, the RR of all-cause mortality increased for medium- and higher-volume drinking, 
while there was no association for low- and high-volume drinking in either analysis. 
There is limited evidence that primary study methodological quality impacted risk estimates, with 
lower quality studies potentially causing the risk associated alcohol consumption to be 
underestimated. While the Stockwell et al., (2016) review examined primary study quality, it did not 
use a validated scale such as the Newcastle-Ottawa Scale[33]. Although an advantage of the scale 
used by Stockwell et al., (2016) may be that it was more specific to alcohol consumption than a 
generic quality scale, it was not clear how the various factors were selected, how the cut-points of 
55 and 60 years were selected, or whether other important factors may have been missed. 
Therefore, this analysis could be replicated using a validated quality assessment scale. Alternatively, 
the quality assessment scale that is specific to the biases accompanying studies of alcohol 
consumption used by Stockwell et al., (2016) could be externally validated. 
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Table 3.16. Review findings by primary study methodological quality. 
Review Reference group Risk of bias Strata Results (95% CI) 
Stockwell et 
al., (2016)[4] 
Lifetime abstainers Low  
13 studies 
6 higher quality studies 
 
13 studies 
6 higher quality studies 
 
13 studies 
6 higher quality studies 
 
13 studies 
6 higher quality studies 
RR low-volume drinkinga: 
0.90 (0.76-1.06) 
1.04 (0.95-1.15) 
RR medium-volume drinkinga: 
0.95 (0.80-1.13) 
1.29 (1.06-1.56) 
RR high-volume drinkinga: 
1.11 (0.93-1.32) 
1.07 (0.83-1.36) 
RR higher-volume drinkinga: 
1.42 (1.15-1.75) 
1.85 (1.51-2.27) 
aLow-volume drinking: > 1 drink/week and ≤ 2 drinks/day or ≥ 1.3 and < 25 g/day; Medium-volume drinking: > 
2 and ≤ 4 drinks/day or ≥ 25 and < 45 g/day; High-volume drinking: > 4 and ≤ 6 drinks/day or ≥ 45 and < 65 
g/day; Higher-volume drinking: > 6 drinks per day or ≥ 65 g/day. CI, Confidence Interval. RR, Relative Risk.  
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Review findings – by choice of reference group  
Five of 18 reviews examined the effect of reference group choice on effect estimates (Table 3.17)[3-
5, 15, 16]. All five reviews reported a J-shaped relationship when former drinkers (± occasional 
drinkers) were included in the reference group. The level of alcohol consumption associated with 
maximum protection was estimated to be 5 [3] or 8[5] grams per day for all participants, or in a 
review presenting results stratified by sex and region 2.2 units per week in American women, 7.5 
units per week in American men and 13.0 units per week in British men[15]. The relative risk at the 
point of maximum protection was estimated to be 0.77[5] or 0.81[3] and with significant protection 
until 40.5[3] or 52[5] grams per day. When using a reference group of lifetime abstainers, three 
reviews still reported a J-shaped association[5, 15, 16], one reported no significant association[3] 
and one reported an association only with increased risk[4]. The reviews consistently reported at 
least an attenuation of the relative risk at the point of maximum protection[3-5]. Of the three 
reviews to report a J-shaped association, one found no significant difference in the level of drinking 
associated with maximum protection in men but a higher level of drinking for this point in 
women[15], another reported an attenuation in the level of drinking associated with maximum 
protection, the relative risk at this point and the range of drinking associated with protection[5], 
while the findings of the third review were not directly comparable as the results using the reference 
group of lifetime abstainers were reported categorically and the results using non-drinkers as the 
reference group were reported continuously[16]. The review which found no significant association 
when using a reference group of lifetime abstainers reported that, among primary studies using a 
reference group of lifetime abstainers, a J-shaped relationship was produced when former and 
occasional drinkers were combined with lifetime abstainers[3]. Finally, one review also reported an 
association only with increased risk when using a reference group of occasional drinkers[4]. 
Reviews reported a significant increased risk at levels of intake > 40 grams per day in men[16], > 20 
grams per day in women[16], ≥ 45 grams per day (both sexes)[3], approximately > 70 grams per day 
(both sexes)[5] or > 4 drinks or ≥ 45 grams per day (both sexes)[4] when using a reference group of 
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non-drinkers, no increased risk with any level of drinking[3], approximately > 38 grams per day (both 
sexes)[5] or > 6 drinks or ≥ 65 grams per day (both sexes)[4] when using a reference group of lifetime 
abstainers and > 2 drinks or ≥ 25 grams per day when using a reference group of occasional drinkers 
(both sexes)[4]. Among the three reviews reporting the level of drinking associated with increased 
risk when using a reference group of both lifetime abstainers and of non-drinkers, the differences by 
choice of reference group were inconsistent. When using a reference group of lifetime abstainers, 
one reported a lower value[5], one a higher value[4] and one no increased risk with any level of 
drinking[3]. In these same three reviews, risk estimates for heavy drinking were higher when using a 
reference group of lifetime abstainers compared to non-drinkers in two reviews[4, 5], and 
unchanged in one review (although the confidence interval was still consistent with the magnitude 
of difference in the other two reviews)[3]. In the one review using all three reference groups, risk 
estimates for heavy drinking were highest when using a reference group of occasional drinkers[4]. 
Overall, using a reference group of non-drinkers consistently results in a J-shaped relationship 
between alcohol consumption and all-cause mortality, however the evidence for the shape of the 
risk relationship is inconsistent when using lifetime abstainers as the reference group. Each review 
reported a different result, including an unchanged level of drinking associated with maximum 
protection in men and a higher level in women, an attenuated J-shaped relationship, no significant 
association and an association only with increased risk. The latter result came from the only review 
which was considered at low risk of bias. There is however good evidence that using a reference 
group of lifetime abstainers at least attenuates the relative risk at the point of maximum protection 
and results in higher risk estimates associated with heavy drinking, but the evidence is inconsistent 
for whether the level of drinking associated with significant increased risk is altered. There is also 
good evidence that using a reference group of occasional drinkers results in an association only with 
increased risk, with the level of drinking associated with significant increased risk lower and risk 
estimates for heavy drinking higher than when using a reference group of lifetime abstainers or non-
drinkers. 
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Table 3.17. Review findings by choice of reference group. 
Review Risk of bias Reference group strata Results (95% CIa) 
Di Castelnuovo 
et al., (2006)[5] 
High Former and/or light 
drinkers included 
 
Former and/or light 
drinkers excluded 
Maximum protection at 8 g ethanol/day (RR 0.77 
(0.74-0.80)). Protection significant until 52 g/day. 
Significant increased risk above ≈ 70 g/day 
Maximum protection at 5 g ethanol/day (RR 0.84 
(0.82-0.86)). Protection significant until 30 g/day. 
Significant increased risk above ≈ 38 g/day 
Significant difference in risk curve between strata (p < 
0.001) 
Fillmore et al., 
(2006)[3] 
High  
All studies 
 
 
No former or occasional 
drinkers in reference 
group 
 
No former or occasional 
drinkers in reference 
group 
 
Combining former and 
occasional drinkers with 
lifetime abstainers 
Continuous analysis: 
Relationship is significant. Maximum protection (OR 
0.81) at 5 g ethanol/day, risk curve crosses OR 1.00 at 
40.5 g/day 
Relationship is not significant. (Maximum protection 
(OR 0.85) at 2 g ethanol/day, risk curve crosses OR 
1.00 at 25.6 g/day) 
Categorical analysis: 
OR 0.95 (0.84-1.08) for light drinkingb 
OR 0.99 (0.83-1.19) for moderate drinkingb 
OR 1.24 (1.00-1.53) for heavy drinkingb 
OR 1.18 (1.03-1.36) for former drinking 
OR 0.91 (0.84-0.99) for light drinking 
OR 0.95 (0.81-1.11) for moderate drinking 
OR 1.24 (1.02-1.51) for heavy drinking 
Gmel et al., 
(2003)[16, 31] 
High Continuous analysis 
with majority of studies 
including ex-drinkers 
Categorical analysis 
separating ex-drinkers 
from lifetime abstainers 
J-shaped risk curve for men and women 
 
 
J-shaped risk curve for men and women 
Men: 
RR 0.85 (0.83-0.87) for > 0-10 g ethanol/day 
RR 0.80 (0.78-0.82) for > 10-20 g/day 
RR 0.91 (0.89-0.94) for > 20-30 g/day 
RR 0.96 (0.93-1.00) for > 30-40 g/day 
RR 1.04 (1.01-1.07) for > 40-70 g/day 
RR 1.27 (1.23-1.31) for > 70-110 g/day 
RR 1.46 (1.33-1.60) for > 110 g/day 
RR 1.21 (1.10-1.32) for ex-drinkers 
Women: 
RR 0.87 (0.84-0.89) for > 0-10 g/day 
RR 1.01 (0.99-1.04) for > 10-30 g/day 
RR 1.40 (1.34-1.47) for > 30-50 g/day 
RR 1.43 (1.34-1.53) for > 50 g/day 
RR 1.44 (1.28-1.61) for ex-drinkers 
a99% CI for Di Castelnuovo et al., (2006). bLight drinking: ≥ 1 drink/month and ≤ 2 drinks/day or ≥ 0.39 and < 25 
g/day; Moderate drinking: > 2 and ≤ 4 drinks/day or ≥ 25 and < 45 g/day; Heavy drinking: > 4 drinks/day or ≥ 45 
g/day. cLow-volume drinking: > 1 drink/week and ≤ 2 drinks/day or ≥ 1.3 and < 25 g/day; Medium-volume 
drinking: > 2 and ≤ 4 drinks/day or ≥ 25 and < 45 g/day; High-volume drinking: > 4 and ≤ 6 drinks/day or ≥ 45 
and < 65 g/day; Higher-volume drinking: > 6 drinks per day or ≥ 65 g/day. d1 unit = 9 g ethanol. CI, Confidence 
Interval. RR, Relative Risk. OR, Odds Ratio. 
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Table 3.17. (Continued) 
Review Risk of bias Reference group strata Results (95% CIa) 
Stockwell et al., 
(2016)[4] 
Low Non-drinkers (former ± 
occasional drinkers in 
reference group) 
 
Lifetime abstainers (no 
former or occasional 
drinkers in reference 
group) 
 
Occasional drinkers (≤ 1 
drinks/week or < 1.3 
g/day) 
RR 0.91 (0.83-1.00) for low-volume drinkingc 
RR 1.00 (0.91-1.10) for medium-volume drinkingc 
RR 1.17 (1.06-1.29) for high-volume drinkingc 
RR 1.30 (1.17-1.45) for higher-volume drinkingc 
RR 0.90 (0.76-1.06) for low-volume drinking 
RR 0.95 (0.80-1.13) for medium-volume drinking 
RR 1.11 (0.93-1.32) for high-volume drinking 
RR 1.42 (1.15-1.75) for higher-volume drinking 
RR 1.31 (1.09-1.57) for former drinking 
RR 1.19 (1.12-1.27) for lifetime abstention 
RR 1.02 (0.95-1.10) for low-volume drinking 
RR 1.13 (1.05-1.22) for medium-volume drinking 
RR 1.33 (1.24-1.44) for high-volume drinking 
RR 1.52 (1.40-1.66) for higher-volume drinking 
RR 1.45 (1.33-1.59) for former drinking 
White 
(1999)[15] 
High  
Ex-drinkers included 
Ex-drinkers excluded 
 
 
Ex-drinkers included 
Ex-drinkers excluded 
 
 
Ex-drinkers included 
Ex-drinkers excluded 
 
British men: 
Maximum protection at 13.0 units/weekd 
Maximum protection at 9.3 units/week 
No significant difference between strata (p = 0.43) 
American men: 
Maximum protection at 7.5 units/week 
Maximum protection at 8.3 units/week 
No significant difference between strata (p = 0.59) 
American women: 
Maximum protection at 2.2 units/week 
Maximum protection at 3.7 units/week 
Significant difference between strata (p = 0.005) 
117 
 
Review findings – by evidence of industry funding 
One of 18 reviews reported effect estimates by evidence of industry funding[26]. No significant 
difference was found in effect estimate for drinkers vs. non-drinkers and all-cause mortality by level 
of concern about industry funding, with a risk ratio of 0.84 (0.78-0.91) in studies with some level of 
concern and 0.89 (0.83-0.96) in studies with no concern[26]. The limitations of the review include 
that it was considered at high risk of bias, used a reference group of non-drinkers and did not 
consider a dose-response relationship. It should also be noted the review excluded primary studies 
containing participants with pre-existing cardiovascular disease. The evidence for no difference by 
evidence of industry funding is therefore limited. 
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Review findings – by other factors 
None of the 18 reviews examined the influence of drinking pattern (e.g. drinking frequency, heavy 
episodic drinking) on risk estimates, nor did any review examine the effect of change in alcohol 
consumption over time, or whether risk is cumulative over the lifetime or if exposure during certain 
periods of life are more critical for risk. 
There is a lack of evidence for the effect of these factors on the relationship between alcohol 
consumption and all-cause mortality. 
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3.4 – Discussion and Conclusions 
 
In summary, the majority of reviews (13 of 18) reported a U- or J-shaped relationship between 
alcohol consumption and all-cause mortality in the main analysis, with three reviews finding no 
significant association with alcohol consumption[3, 22, 23], one review finding a U-shaped 
relationship in men and no significant association in women[21], and another review finding only an 
association with increased risk[4] (Table 3.4). 
 
Findings for alcohol consumption and increased risk of all-cause mortality 
In the majority of reviews, heavy drinking was associated with increased risk of all-cause mortality. 
Among meta-analyses of the general population, there is good evidence that the level of drinking 
associated with significant increased risk ranges from intakes > 4 to > 6 drinks per day or 
approximately > 38 to ≥ 65 grams per day[3-5, 17, 28]. A relative risk of 1.42 (95% confidence 
interval: 1.15-1.75) was associated with higher-volume drinking (> 6 drinks per day or ≥ 65 g/day), 
the highest level of drinking examined in a review considered at low risk of bias and using a 
reference group of lifetime abstainers[4]. One review reporting no significant association when using 
a reference group of lifetime abstainers, however the confidence intervals for the heavy drinking 
effect estimate were consistent with an elevated risk[3]. There is also good evidence that former 
drinkers have a similar risk of all-cause mortality to heavy drinkers, and that the level of drinking 
associated with increased risk is lower and the level of risk associated with heavy drinking is higher 
when using a reference group of occasional drinkers. 
It should be noted that these results are similar to findings based on alternative methods of 
calculating all-cause burden of disease. For example, rather than measuring the association between 
alcohol consumption and all-cause mortality directly, the Global Burden of Disease Study summed 
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cause-specific incidence risk curves weighted by disability-adjusted life years to obtain an estimate 
of all-cause burden of disease[34]. The association was found to be monotonically increasing, with a 
relative risk of 1.5 at approximately 6 standard drinks (60 grams) per day. This is comparable to the 
findings of Stockwell et al., (2016) that consumption of > 6 drinks per day (≥ 65 g/day) was 
associated with an all-cause mortality relative risk of 1.42 (1.15-1.75)[4]. 
A summary of findings regarding the association between alcohol consumption and increased risk of 
all-cause mortality is shown in Table 3.18. Overall, there is good evidence that the relationship with 
increased risk differs by adjustment for primary study characteristics at the review level and by 
choice of reference group. There is limited evidence that the relationship with increased risk (for at 
least one of the two outcomes in the table) may differ by population (region or ethnicity), smoking 
status, follow-up duration, primary study publication date, adjustment at the primary study level, 
modelling method and primary study methodological quality, and limited evidence that it does not 
differ when excluding participants with pre-existing cardiovascular disease and by primary study 
sample size. The evidence is inconsistent regarding sex and age. There is a lack of evidence for 
differences by the distribution of alcohol consumption in the cohort or population, drinking pattern, 
change in alcohol consumption over time, measurement of alcohol consumption at single or 
multiple time points, beverage type and evidence of industry funding. The majority of reviews were 
considered at high risk of bias and used non-drinkers as the reference group, and the reviews 
examining subgroups were often inconsistent. There is also a lack of evidence for whether increased 
risk is cumulative over the lifetime or if exposure during certain periods of life are more critical for 
risk. The lack of higher quality reviews may have biased the findings of this review, and therefore the 
comparisons (i.e. other than those from Stockwell et al., (2016)) should be heeded with caution. For 
almost all sub-analyses further evidence from high quality reviews and meta-analyses is required to 
clarify the level of drinking associated with significant increased risk, and the corresponding effect 
estimates.  
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Table 3.18. Synthesis of 18 systematic reviews and meta-analyses of the association between alcohol 
consumption and all-cause mortality: evidence for associations with increased risk in the general population 
and by sub-analysis. 
Sub-analysis n reviews 
Minimum level of drinking 
associated with significant 
increased risk 
Effect estimate (95% CI) in 
heavy drinkers 
General population 6[3-5, 17, 
27, 28] 
Ranged from > 4 to > 6 
drinks/day or approximately > 
38 to ≥ 65 g/day (good 
evidence) 
RR 1.42 (1.15-1.75) for 
higher-volume drinkinga 
(good evidence) 
Population subgroups    
Sex 11[4, 5, 
13-21] 
Evidence inconsistent Evidence inconsistent 
Age 6[3, 4, 
15, 16, 
18, 22] 
Evidence inconsistent  Lack of evidence 
Population (region or ethnicity) 6[4, 5, 
14, 15, 
18, 23] 
No difference for North 
America/Europe/Australia vs. 
Japan/China/India (good 
evidence). Lack of evidence for 
other population comparisons 
No difference for North 
America/Europe/Australia 
vs. Japan/China/India 
(good evidence). Lack of 
evidence for other 
population comparisons 
Smoking status 1[3] Lack of evidence Higher in current smokers 
than non-current smokers 
(limited evidence) 
No pre-existing cardiovascular 
disease 
2[15, 24] Similar to overall (limited 
evidence) 
Similar to overall (limited 
evidence) 
Distribution of alcohol consumption 
in cohort or population 
   
Cohort average alcohol consumption 1[16] Lack of evidence Lack of evidence 
Cohort SD of alcohol consumption 1[16] Lack of evidence Lack of evidence 
Cohort proportion of abstainers 1[16] Lack of evidence Lack of evidence 
Per capita alcohol consumption 1[16] Lack of evidence Lack of evidence 
Alcohol exposure measurement    
Pattern of drinking 0 Lack of evidence Lack of evidence 
Change in drinking over time 0 Lack of evidence Lack of evidence 
Measurement of alcohol 
consumption at single or multiple 
time points 
1[19] Lack of evidence Lack of evidence 
Whether risk is cumulative over the 
lifetime or if exposure during certain 
periods of life are more critical for 
risk 
0 Lack of evidence Lack of evidence 
a> 6 drinks per day or ≥ 65 g/day. Each review did not necessarily examine both outcomes. RR, Relative Risk. CI, 
Confidence Interval. SD, Standard Deviation. 
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Table 3.18. (Continued) 
Sub-analysis n reviews 
Minimum level of drinking 
associated with significant 
increased risk 
Effect estimate (95% CI) in 
heavy drinkers 
Beverage type 1[25] Approximately > 105 g/day for 
wine consumption (limited 
evidence), lack of evidence for 
beer and spirit consumption 
and for differences by beverage 
type 
RR approximately 1.3 at 
105 g/day, lack of evidence 
for beer and spirit 
consumption and for 
differences by beverage 
type 
Primary study attributes    
Follow-up duration 2[5, 16] Lower with longer follow-up 
duration (limited evidence) 
Lack of evidence 
Sample size 1[5] No difference (limited 
evidence) 
No difference (limited 
evidence) 
Year of publication 1[5] Higher with later publication 
date (limited evidence) 
Higher with earlier 
publication date (limited 
evidence) 
Level of adjustment (at primary 
study level) 
2[5, 15] Lack of evidence Higher with adjustment for 
age, social status and 
dietary factors compared 
to no adjustment (limited 
evidence) 
Level of adjustment (at review level) 1[4] No difference with adjustment 
for primary study 
characteristics (good evidence) 
Higher with adjustment for 
primary study 
characteristics (good 
evidence) 
Modelling method 2[17, 19] Lower when using fractional 
polynomial or restricted cubic 
spline models compared to 
quadratic model (limited 
evidence) 
Lower when using 
fractional polynomial or 
restricted cubic spline 
models compared to 
quadratic model (limited 
evidence) 
Primary study methodological 
quality 
1[4] Lower in higher quality studies 
(limited evidence) 
Higher in higher quality 
studies (limited evidence) 
Choice of reference group 5[3-5, 15, 
16] 
Lower when using reference 
group of occasional drinkers 
(good evidence). Evidence 
inconsistent for reference 
group of lifetime abstainers vs. 
non-drinkers 
Higher when using a 
reference group of lifetime 
abstainers vs. non-
drinkers, and higher still 
when using a reference 
group of occasional 
drinkers (good evidence) 
Evidence of industry funding 1[26] Lack of evidence Lack of evidence 
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Findings for alcohol consumption and decreased risk of all-cause mortality 
In reviews and meta-analyses of the general population, the evidence regarding a possible 
association of moderate drinking with reduced risk of all-cause mortality was inconsistent. Among 
the four reviews using a reference group of lifetime abstainers, two reported a J-shaped 
association[5, 17], one no significant association[3] and one only an association with increased 
risk[4]. The latter review was the only review considered at low risk of bias. Among these four 
reviews, the reported estimates for the range of drinking associated with decreased risk were either 
none[3, 4] or < 30 grams per day[5], for the level of drinking associated with maximum protection 
either none[3, 4] or 5 to 6 grams per day[5, 17], and for the relative risk at the point of maximum 
protection either 1.00 for lifetime abstention[3, 4] or 0.84 (99% confidence interval: 0.82-0.86) for 5 
grams per day[5]. 
A summary of findings regarding the association between alcohol consumption and decreased risk of 
all-cause mortality is shown in Table 3.19. There is good evidence that that the relationship with 
decreased risk is accounted for by adjustment for primary study characteristics at the review level 
and that the relative risk is at least attenuated when using a reference group of lifetime abstainers 
instead of non-drinkers and is eliminated when using a reference group of occasional drinkers. There 
is limited evidence that the relationship with decreased risk may differ (for at least one of the three 
outcomes in the table) by population (region or ethnicity), the distribution of alcohol consumption in 
the cohort or population, follow-up duration, primary study publication date, adjustment at the 
primary study level (age, social status and dietary factors), modelling method and primary study 
methodological quality, and limited evidence that it does not differ by primary study sample size and 
adjustment at the primary study level for some other factors (smoking and blood pressure). The 
evidence is inconsistent regarding sex, age and choice of reference group. There is a lack of evidence 
for differences by smoking status, the exclusion of participants with pre-existing cardiovascular 
disease, drinking pattern, change in alcohol consumption over time, measurement of alcohol 
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consumption at single or multiple time points, beverage type and evidence of industry funding. 
There is also a lack of evidence for whether decreased risk is cumulative over the lifetime or if 
exposure during certain periods of life are more critical for risk. The majority of reviews were 
considered at high risk of bias and used non-drinkers as the reference group, and the reviews 
examining subgroups were often inconsistent. For the general population and almost all sub-
analyses further evidence from high quality reviews and meta-analyses is required to clarify the level 
of drinking associated with significant decreased risk, and the corresponding effect estimates. 
 
Table 3.19. Synthesis of 18 systematic reviews and meta-analyses of the association between alcohol 
consumption and all-cause mortality: evidence for associations with decreased risk in the general 
population and by sub-analysis. 
Sub-analysis 
n 
reviews 
Range of drinking 
associated with 
significant decreased risk 
Level of drinking 
associated with 
maximum protection 
Effect estimate (95% CI) 
at point of maximum 
protection 
General population 6[3-5, 
17, 27, 
28] 
No level of drinking 
protective or < 30 g/day 
(evidence inconsistent) 
0 or 5 to 6 g/day 
(evidence inconsistent) 
1.00 for lifetime 
abstention or 0.84 (0.82-
0.86a) for 5 g/day 
(evidence inconsistent) 
Population subgroups     
Sex 11[4, 5, 
13-21] 
Evidence inconsistent Evidence inconsistent Evidence inconsistent 
Age 6[3, 4, 
15, 16, 
18, 22] 
Evidence inconsistent Evidence inconsistent Evidence inconsistent 
Population (region or ethnicity) 6[4, 5, 
14, 15, 
18, 23] 
No difference for North 
America/Europe/Australia 
vs. Japan/China/India 
(good evidence). Smaller 
in United States vs. 
Europe for men, with 
Australia/Japan/China in 
between; no difference 
for women (limited 
evidence). Limited 
evidence ‘mild’ drinking 
not associated with 
protection in Korean 
persons. Lack of evidence 
for other population 
comparisons 
No difference for North 
America/Europe/Australia 
vs. Japan/China/India 
(good evidence). Lower in 
United States vs. United 
Kingdom and Europe for 
men, with 
Australia/Japan/China in 
between; no difference 
for women (limited 
evidence). Lack of 
evidence for other 
population comparisons 
No difference for North 
America/Europe/Australia 
vs. Japan/China/India 
(good evidence). Higher in 
United States vs. Europe 
for men, with 
Australia/Japan/China in 
between; no difference 
for women (limited 
evidence). Lack of 
evidence for other 
population comparisons 
a99% confidence interval. Each review did not necessarily examine all three outcomes. RR, Relative Risk. CI, 
Confidence Interval. SD, Standard Deviation. 
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Table 3.19. (Continued) 
Sub-analysis 
n 
reviews 
Range of drinking 
associated with 
significant decreased risk 
Level of drinking 
associated with 
maximum protection 
Effect estimate (95% CI) 
at point of maximum 
protection 
Smoking status 1[3] Lack of evidence Lack of evidence Lack of evidence 
No pre-existing cardiovascular 
disease 
2[15, 
24] 
Lack of evidence Lack of evidence Lack of evidence 
Distribution of alcohol consumption 
in cohort or population 
    
Cohort average alcohol consumption 1[16] Larger with greater 
average alcohol 
consumption in men, no 
difference in women 
(limited evidence) 
Higher with greater 
average alcohol 
consumption in men, no 
difference in women 
(limited evidence) 
No difference (limited 
evidence) 
Cohort SD of alcohol consumption 1[16] Larger with greater SD of 
alcohol consumption 
(limited evidence) 
Higher with greater SD of 
alcohol consumption 
(limited evidence) 
No difference (limited 
evidence) 
Cohort proportion of abstainers 1[16] Smaller with greater 
proportion of abstainers 
in men, no difference in 
women (limited evidence) 
Lower with greater 
proportion of abstainers 
in men, no difference in 
women (limited evidence) 
No difference (limited 
evidence) 
Per capita alcohol consumption 1[16] Larger with greater per 
capita alcohol 
consumption in men, no 
difference in women 
(limited evidence) 
Higher with greater per 
capita alcohol 
consumption in men, no 
difference in women 
(limited evidence) 
No difference (limited 
evidence) 
Alcohol exposure measurement     
Pattern of drinking 0 Lack of evidence Lack of evidence Lack of evidence 
Change in drinking over time 0 Lack of evidence Lack of evidence Lack of evidence 
Measurement of alcohol 
consumption at single or multiple 
time points 
1[19] Lack of evidence Lack of evidence Lack of evidence 
Whether risk is cumulative over the 
lifetime or if exposure during certain 
periods of life are more critical for 
risk 
0 Lack of evidence Lack of evidence Lack of evidence 
Beverage type 1[25] < 41 g/day for wine 
consumption (limited 
evidence), lack of 
evidence for beer and 
spirit consumption and for 
differences by beverage 
type 
10 g/day for wine 
consumption (limited 
evidence), lack of 
evidence for beer and 
spirit consumption and for 
differences by beverage 
type 
RR 0.75 (0.66-0.86) for 
wine consumption 
(limited evidence), lack of 
evidence for beer and 
spirit consumption and for 
differences by beverage 
type 
Primary study attributes     
Follow-up duration 2[5, 16] Smaller with longer 
follow-up duration 
(limited evidence) 
Evidence inconsistent Higher with longer follow-
up duration (limited 
evidence) 
Sample size 1[5] No difference (limited 
evidence) 
No difference (limited 
evidence) 
No difference (limited 
evidence) 
126 
 
Table 3.19. (Continued) 
Sub-analysis 
n 
reviews 
Range of drinking 
associated with 
significant decreased risk 
Level of drinking 
associated with 
maximum protection 
Effect estimate (95% CI) 
at point of maximum 
protection 
Year of publication 1[5] Larger with later 
publication date (limited 
evidence) 
Higher with later 
publication date (limited 
evidence) 
Lower with later 
publication date (limited 
evidence) 
Level of adjustment (at primary 
study level) 
2[5, 15] Larger with adjustment 
for age, social status and 
dietary factors compared 
to no adjustment (limited 
evidence) 
Lower with adjustment for 
age, social status and 
dietary factors compared 
to no adjustment; no 
difference with 
adjustment for smoking or 
blood pressure (limited 
evidence) 
Higher with adjustment 
for age, social status and 
dietary factors compared 
to no adjustment (limited 
evidence) 
Level of adjustment (at review level) 1[4] No level of drinking 
protective with 
adjustment for primary 
study characteristics 
(good evidence) 
0 g/day with adjustment 
for primary study 
characteristics (good 
evidence) 
1.00 for non-drinking with 
adjustment for primary 
study characteristics 
(good evidence) 
Modelling method 2[17, 
19] 
Lack of evidence Lower when using 
fractional polynomial or 
restricted cubic spline 
models compared to 
quadratic model (limited 
evidence) 
Lower when using 
fractional polynomial or 
restricted cubic spline 
models compared to 
quadratic model (limited 
evidence) 
Primary study methodological 
quality 
1[4] No level of drinking 
protective among higher 
quality studies (limited 
evidence)  
0 g/day among higher 
quality studies (limited 
evidence) 
1.00 for lifetime 
abstention among higher 
quality studies (limited 
evidence) 
Choice of reference group 5[3-5, 
15, 16] 
Evidence inconsistent for 
reference group of 
lifetime abstainers vs. 
non-drinkers. No level of 
drinking protective when 
using reference group of 
occasional drinkers 
Evidence inconsistent for 
reference group of 
lifetime abstainers vs. 
non-drinkers. Drinker and 
≤ 1 drink/week or > 0 and 
< 1.3 g/day when using 
reference group of 
occasional drinkers 
Attenuation of association 
with protection for 
reference group of 
lifetime abstainers vs. 
non-drinkers (good 
evidence), evidence 
inconsistent for whether 
protection is eliminated. 
1.00 for occasional 
drinking when using 
reference group of 
occasional drinkers 
Evidence of industry funding 1[26] Lack of evidence Lack of evidence Lack of evidence 
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Limitations of the systematic reviews and meta-analyses 
Review findings overall and by subgroup were often not directly comparable due to differing aims, 
scope, inclusion criteria, methodological quality, meta-analysis methods and presentation of results. 
The heterogeneity in aims, scope and inclusion criteria is important, as it has previously been shown 
that differences in review search strategy and inclusion criteria can lead to differing conclusions[35]. 
For example, some reviews only included primary studies which also assessed the relationship 
between alcohol consumption and cardiovascular disease, or which reported risk estimates for both 
men and women, which may have caused biased and account for some of the differences in review 
findings. Many reviews also had methodological problems causing them to be considered at high risk 
of bias, including searching only one electronic database, not specifying search terms, not using at 
least two reviewers for study selection and/or quality assessment, not performing an assessment of 
primary study quality and not performing a test of publication bias. Only one of 18 reviews was both 
considered at low risk of bias and used a reference group of lifetime abstainers, and the results of 
that review materially differed from other reviews, reporting only a positive association of increased 
risk with increasing alcohol consumption[4]. The results of the other reviews should therefore be 
interpreted with caution. Finally, the use of different meta-analysis methods (such as continuous vs. 
categorical analysis), the use of different cut-points for categorical analyses and the presentation of 
different result outcomes (e.g. the level of drinking associated with maximum protection vs. the 
range of drinking associated with significant protection) meant the results of reviews were not 
directly comparable. This often necessitated the use of more simple comparisons in sub-analyses 
such as whether the level of risk is higher in one subgroup over another, although an attempt was 
made to compare more specific outcomes wherever possible. 
Aside from the methodological differences and problems of the reviews themselves, each meta-
analysis would be expected contain a mixture of studies of high and low quality, with different 
exclusion criteria and differing methods of measuring alcohol consumption and adjustment for 
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confounding. For example, in the review with the largest number of primary studies and 
participants, Stockwell et al., (2016), it was found that of 87 primary studies, 34 made exclusions for 
baseline disease or poor health while 53 did not, and 65 used a reference group containing former 
drinkers while 22 did not[4]. Most reviews did not examine primary study methodological quality or 
these other factors, and this may be another source of bias. Of all reviews, Stockwell et al., (2016) 
undertook the most comprehensive approach to examining the impact of primary study 
methodological quality and ten differences in inter-study characteristics (such as adjustment for 
confounding and inclusion criteria based on disease status), finding that these materially changed 
risk estimates. When taking these factors into account, the protective association of moderate 
drinking was eliminated and risk estimates for higher levels of drinking were increased. Primary 
study methodological heterogeneity therefore biases risk estimates for the general population, and 
so sub-analysis findings could potentially be biased as well. There is a need however for the quality 
assessment scale used by Stockwell et al., (2016) to be externally validated, or alternatively, the 
analysis could be replicated using a validated quality assessment scale. 
 
Strengths and limitations 
This systematic review has several strengths, including the use of multiple databases for article 
extraction to decrease the likelihood that relevant articles would be missed, the use of broad 
inclusion criteria enabling the examination of as many sub-analysis outcomes as possible and the use 
of the ROBIS tool and the consideration of reference group to examine results in light of risk of bias. 
This review also has a number of limitations. Firstly, only one reviewer performed the article 
extraction, data extraction and review quality appraisal. A second reviewer is required to ensure 
inter-rater reliability, which would lower the risk of error and potential bias that could result from 
one reviewer. Secondly, non-English journal articles were excluded, potentially limiting 
generalizability if there is heterogeneity in the alcohol-risk relationship across population groups. 
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Finally, as these reviews and meta-analyses are mostly based on cohort studies, the results are 
vulnerable to selection bias and the possibility of residual confounding by known and unknown 
factors. To be absolutely certain of the relationship between alcohol consumption and all-cause 
mortality (or for that matter, any disease) it may be necessary to perform a long-term randomised 
controlled trial, which has recently been proposed[36, 37]. However ethical and practical concerns 
have so far precluded the conduct of such a trial[38]. 
 
Conclusions 
This review has identified 18 systematic reviews and meta-analyses of alcohol consumption and all-
cause mortality, most of which were considered at high risk of bias. Almost all reviews considered at 
high risk of bias and using a reference group including former drinkers reported a J- or U-shaped risk 
curve, but reviews considered at low risk of bias or using a reference group of lifetime abstainers or 
occasional drinkers more frequently found no significant relationship or only an association with 
increased risk. There was no evidence of potential conflicts of interest in any of the reviews. Factors 
which may influence the alcohol-mortality association include sex, age, population (region or 
ethnicity), current smoking, the exclusion of participants with pre-existing cardiovascular disease, 
average cohort alcohol consumption, variability in cohort alcohol consumption, the proportion of 
non-drinkers in the cohort, per capita alcohol consumption in the population, length of follow-up, 
primary study year of publication, level of adjustment for confounders, modelling method, primary 
study methodological quality and choice of reference group. No evidence was found that the risk 
relationship is influenced by primary study sample size or by evidence of industry funding, however 
the evidence base for these factors was limited. Evidence was lacking for whether certain 
populations (e.g. Africa, the Middle East, Latin America), ex-smoking, pattern of drinking (including 
drinking frequency and heavy episodic drinking, independent of total alcohol consumption), change 
in alcohol consumption over time, measurement of alcohol consumption at single or multiple time 
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points, and beverage type influenced the risk relationship. Evidence was also lacking regarding 
whether risk is cumulative over the lifetime or if exposure during certain periods of life are more 
critical for risk. For many of the other sub-analyses examined, the evidence was lacking for specific 
outcomes of the alcohol-mortality relationship. Unfortunately, for few sub-analyses and outcomes 
was the level of evidence considered to be ‘good’, owing to inconsistencies between reviews and the 
large proportion of reviews considered at high risk of bias or using a reference group including 
former drinkers. 
In conclusion, the evidence base is largely limited, inconsistent or lacking. There is evidence however 
that the apparent protective effect of moderate drinking is questionable, and may be partly or 
wholly attributable to biases in primary study design including choice of reference group, inadequate 
measures of alcohol consumption and differences in adjustment for confounding and inclusion 
criteria. These same factors may also be responsible for underestimating the harms of higher levels 
of drinking. There is a need for further well-designed reviews and meta-analyses to confirm the 
influence of population subgroups, the distribution of alcohol consumption in the cohort or 
population, measures of alcohol exposure and primary study methodology on the shape of the 
alcohol-mortality risk curve, with a particular focus on associations between moderate drinking and 
decreased risk and heavier drinking and increased risk. In the absence of randomised controlled 
trials, cohort study analyses and meta-analyses must take the identified factors into account when 
interpreting the effects of alcohol consumption on all-cause mortality. Further, given that the risk 
relationship may vary by population around the world, there is a need for local Australian data. 
The next chapter will outline the 45 and Up Study, a large, Australian prospective study, which was 
used to investigate the relationship between alcohol consumption and drinking pattern for a number 
of outcomes including cancer incidence and all-cause and cause-specific mortality. The important 
methodological factors identified in this and previous chapters were taken into consideration when 
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planning the analyses, particularly choice of reference group and other cohort study characteristics 
responsible for inter-study heterogeneity in results. 
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Chapter 4 – Methods: The 45 and Up Study 
 
Chapter summary 
This chapter outlines the methods for the remaining chapters and introduces the 45 and Up Study. 
The questionnaire items available and coding for important variables in the analyses are explained 
and the distribution of alcohol consumption by each variable is examined. 
 
4.1 – The 45 and Up Study 
 
Study population 
The 45 and Up Study is a prospective cohort study of 266,794 people randomly sampled from the 
general population of New South Wales (NSW) between 2006 and 2009[1]. The majority of 
participants were sampled in 2008 and the median baseline questionnaire date is February 2008. 
Participants were randomly sampled from the Medicare Australia database and received a mailed 
invitation, consent form and self-administered questionnaire. The database contains records for all 
Australian citizens and permanent residents, along with some temporary residents and refugees. An 
additional 1.3% of participants joined the cohort without receiving an invitation by voluntarily 
contacting the study. Persons aged 80 years and over and those living in rural and remote areas 
were oversampled by a factor of two. The response rate to mailed invitations was estimated to be 
18%, representing around 10% of the NSW population in this age group[1]. These proportions imply 
that over half of the NSW population aged at least 45 years was invited to participate in the study. 
All participants were aged at least 45 years at completion of the baseline questionnaire. Due to the 
relatively low response rate and the oversampling of key demographic groups, the study is not 
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necessarily representative of the population, however a comparison of the 45 and Up Study with the 
NSW Population Health Survey found consistent exposure-outcome relationships between the two 
studies[2]. 
Baseline questionnaire 
The baseline questionnaire focused on socio-demographic information, health behaviours, health 
status, medical history and usage of medical services. Copies of the male and female baseline and 
follow-up questionnaires are available on the study’s website[3]. There were three versions of the 
questionnaire, with changes to some variables[3]. Questionnaire version 1 was answered by 13.9% 
of participants, version 2 by 1.0% of participants and version 3 by 85.1% of participants. Questions 
with significant changes that were relevant to this project were those ascertaining daily 
consumption of red meat and processed meat, bowel screening history, breast screening history, 
depression, anxiety, asthma and hayfever (version 2 onwards) and physical activity (version 3). How 
these changes affected coding is explained for each variable in Section 4.2. 
Follow-up questionnaire 
Participants completed a 5-year follow-up questionnaire that was similar to the baseline 
questionnaire and was mailed from 2012 to 2016[4]. The first follow-up questionnaire data were 
available for 142,492 participants (53%). These data were used in Chapter 7, where factors related to 
quitting alcohol consumption between baseline and follow-up were characterised. 
Data linkage and external data sources 
The cancer and mortality outcomes quantified in chapters 8 and 9 were captured through record 
linkage of the 45 and Up Study to population-wide health datasets by the NSW Ministry of Health’s 
Centre for Health Record Linkage (CHeReL). The CHeReL used a best practice approach in privacy 
preserving record linkage[5] and the open source probabilistic record linkage software Choice 
Maker[6]. The probabilistic matching process is known to be highly accurate (false-positive and false-
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negative rates < 0.4%) and a more detailed description of the linkage process has been described 
elsewhere[7]. 
Linkage to the NSW Central Cancer Registry was used for cancer incidence outcome data in Chapter 
8. The registry is administered by the NSW Cancer Institute (an agency of the NSW Government) and 
captures all primary cancers diagnosed in residents of NSW with the exception of non-melanoma 
skin cancer. Cancer incidence data was available from January 1994 to December 2010. Cancer 
diagnoses were coded according to the World Health Organisation International Classification of 
Diseases, version 10[8].  
Mortality outcomes used in Chapter 9 were obtained via linkage to the NSW Registry of Births, 
Deaths and Marriages (RBDM) and the Australian Bureau of Statistics (ABS). Fact of death was 
captured to December 2014 from the RBDM and cause of death was captured to December 2012 
from the ABS. Cause-specific mortality was coded according to the World Health Organisation 
International Classification of Diseases, version 10.  
Ethics and study management 
The 45 and Up Study was approved by the University of NSW Human Research Ethics Committee, 
while ethics approval for this specific project was granted by NSW Population Health Services 
Research Ethics Committee. The Sax Institute manages the study in partnership with Cancer Council 
NSW (the major partner), the National Heart Foundation of Australia (NSW Division), NSW Ministry 
of Health, beyondblue, NSW Government Family & Community Services – Carers, Ageing and 
Disability Inclusion and the Australian Red Cross Blood Service. 
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4.2 – Ascertainment of Baseline Covariates 
 
This section outlines the baseline questionnaire items used for analysis. The variables listed are 
those which are common to several chapters, such as alcohol consumption and factors used for 
adjustment. All analyses were adjusted for socio-demographic characteristics (sex, age, remoteness, 
household income, highest level of education, health insurance status, partner status and country of 
birth). Additional behavioural and health-related factors were used to adjust for disease-specific 
models where specified. All variables included a missing indicator value for participants with missing 
data. 
 
Socio-demographic characteristics 
Alcohol consumption, cancer incidence, and mortality are known to vary by socio-demographic 
characteristics. For alcohol consumption in Australia, there is a higher prevalence of drinking at 
levels associated with risk of long-term harm among men, younger persons, persons living in 
regional and remote areas, persons with higher socio-economic status, persons who have never 
married, persons born in Australia and English-speaking countries[9, 10]. For cancer in Australia, 
there is a higher incidence among men, older persons, persons living in regional and remote areas 
(but not very remote areas) and persons with lower socio-economic status[11]. Cancer incidence 
varies by country of birth, with the many immigrant groups having a lower incidence of melanoma, 
colorectal, lung, breast and prostate cancer and a greater incidence of stomach and liver cancer 
compared to the Australian-born population[12]. Finally, mortality rates in NSW are higher in men, 
older persons, persons in living in regional and remote areas, persons with lower socio-economic 
status, persons born outside of Australia (especially in East, Southeast and South Asia) and 
Indigenous Australians[13]. Household income, highest level of education and health insurance 
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status were used as indicators of socio-economic status. It was not possible to access Indigenous 
status data in the 45 and Up Study. 
Sex 
The sex variable was provided by the study, and was obtained from Medicare. Sex was coded as a 
categorical variable with two values: Male; Female. There were no participants with missing data for 
sex. 
Age 
Age in years was calculated from two questions: “What is your date of birth?” and “What is today’s 
date?”. Ages ranged from 45.0 to 106.2 years, and the median age was 61.1 years. Age was used 
either as a continuous variable measured in years, or a categorical variable with five values: ≥ 45 and 
< 55 years; ≥ 55 and < 65 years; ≥ 65 and < 75 years; ≥ 75 and < 85 years; ≥ 85 years. There were no 
participants with missing data for age. 
Remoteness 
Remoteness was calculated from exact residential address and classified using the 2006 
Accessibility/Remoteness Index of Australia (ARIA+), which is based on road distances to the nearest 
service centre[14]. Five categories are derived: Major city; Inner regional; Outer regional; Remote; 
Very Remote. For the purposes of analysis, participants in ‘Remote’ and ‘Very Remote’ areas were 
pooled to reduce variability. The areas of NSW classified by ARIA+ as major city are Sydney, 
Newcastle, Wollongong, the Central Coast, Tweed Heads and areas bordering the Australian Capital 
Territory[15]. 
Household income 
Annual household income was obtained from the question: “What is your usual yearly HOUSEHOLD 
income before tax, from all sources? (please include benefits, pensions, superannuation, etc)”. The 
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nine possible responses were “less than $5,000 per year”, “$5,000-$9,999 per year”, “$10,000-
$19,999 per year”, “$20,000-$29,999 per year”, “$30,000-$39,999 per year”, “$40,000-$49,999 per 
year”, “$50,000-$69,999 per year”, “$70,000 or more per year” and “I would rather not answer this 
question”. These responses were collapsed into: < $30,000 per year; ≥ $30,000 and < $ 70,000 per 
year; ≥ $70,000 per year; “I would rather not answer this question” (which also included those with 
missing/invalid responses). “I would rather not answer this question” has been used as a category in 
previous analyses of the 45 and Up Study[16]. 
Highest level of education 
The question used ascertain educational attainment was: “What is the highest qualification you have 
completed?”. The six possible responses were “No school certificate or other qualifications”, “School 
or intermediate certificate (or equivalent)”, “Higher school or leaving certificate (or equivalent)”, 
“Trade/apprenticeship (e.g. hairdresser, chef)”, “Certificate/diploma (e.g. childcare, technician)” and 
“University degree or higher”. 
Health insurance status 
Health insurance status was ascertained by: “Which of the following do you have? (excluding 
Medicare)”. The five possible responses were “Private health insurance – with extras”, “Private 
health insurance – without extras”, “Department of Veterans’ Affairs white or gold card”, “Health 
care concession card” and “None of these”. 
Partner status 
Partner status was defined by two values. That is, participants who responded, “Single”, “Widowed”, 
“Divorced” or “Separated” to the question, “What best describes your current situation?” were 
classified as, 1) Not married or living with a partner. Those who responded, “Married” or “De 
facto/living with a partner were classified as, 2) Married or living with a partner. Participants were 
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able to select multiple responses to this question. Therefore, this grouping was chosen due to the 
potential for living with a partner to influence health behaviours including alcohol consumption. 
Country of birth 
The questionnaire item, “In which country were you born?” had tick boxes for Australia, UK, Ireland, 
Italy, China, Greece, New Zealand, Germany, Lebanon, Philippines, Netherlands, Vietnam, Malta, 
Poland and “other (please specify)” with a free text space. This variable was coded and cleaned by 
the study coordinating centre. In analyses where country of birth was used for adjustment, it was 
collapsed into three values: Australia; Majority English-speaking countries (Canada, Ireland, New 
Zealand, the United Kingdom (UK) and the United States of America); Majority other language 
countries (all other countries). This grouping was chosen to divide participants born outside of 
Australia into two equal groups.  
In Chapter 6, where country of birth was a key exposure of interest, country of birth was grouped 
into 13 regions: Australia; New Zealand; Oceania; East Asia; Southeast Asia; Central and South Asia; 
UK and Ireland; Western Europe; Eastern and Central Europe; Middle East and North Africa; Sub-
Saharan Africa; North America; Central and South America. These regions were based on groupings 
used in the Global Burden of Disease Study and have been used previously in analyses of 45 and Up 
Study data[17, 18]. The countries included in each region are listed in Table 4.1. There were no 
participants born in countries that do not appear on this list. Further detail of participant numbers 
by country of birth is shown in Table B.1 in Appendix B. 
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Table 4.1. Region of birth classification. 
Region of birth Country of birth 
Australia Australia, Norfolk Island 
New Zealand New Zealand 
Oceania Cook Islands, Fiji, French Polynesia, Kiribati, Nauru, New Caledonia, Niue, 
Papua New Guinea, Samoa, Solomon Islands, Tonga, Vanuatu, Wallis and 
Fortuna 
East Asia China, Hong Kong, Japan, Macau, South Korea, Taiwan 
Southeast Asia Brunei Darussalam, Burma (Myanmar), Cambodia, East Timor, Indonesia, Laos, 
Malaysia, Philippines, Singapore, Sri Lanka, Thailand, Viet Nam 
Central & South 
Asia 
Afghanistan, Armenia, Bangladesh, Georgia, India, Kyrgyz Republic, Mongolia, 
Nepal, Pakistan 
UK & Ireland Channel Islands, Ireland, Isle of Man, Northern Ireland, Scotland, UK, Wales 
Western Europe Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Gibraltar, 
Greece, Iceland, Israel, Italy, Luxembourg, Malta, Netherlands, Norway, 
Portugal, Spain, Sweden, Switzerland 
Eastern & 
Central Europe 
Albania, Belarus, Bosnia Herzegovina, Bulgaria, Croatia, Czech Republic, 
Estonia, Hungary, Latvia, Lithuania, Moldova, Montenegro, Poland, Republic of 
Macedonia, Romania, Russian Federation, Serbia, Slovakia, Slovenia, Ukraine, 
Union of Soviet Socialist Republics, Yugoslavia 
Middle East & 
North Africa 
Algeria, Bahrain, Egypt, Gaza Strip & West Bank, Iran, Iraq, Jordan, Lebanon, 
Libya, Morocco, Syria, Tunisia, Turkey, Yemen 
Sub-Saharan 
Africa 
Africa Unspecified, Botswana, Congo, East Africa, Ethiopia, Ghana, Kenya, 
Lesotho, Madagascar, Malawi, Mauritius, Mozambique, Namibia, Nigeria, 
Senegal, Seychelles, South Africa, St Helena, Sudan, Tanzania, Uganda, Zambia 
North America Bermuda, Canada, United States 
Central & South 
America 
Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican 
Republic, Dutch West Indies, Ecuador, El Salvador, Falkland Islands, Guatemala, 
Guyana, Jamaica, Mexico, Netherlands Antilles, Nicaragua, Panama, Paraguay, 
Peru, South America Unspecified, St Vincent and the Grenadines, Suriname, 
Trinidad and Tobago, Uruguay, Venezuela 
UK, United Kingdom. 
 
Length of time lived in Australia 
The question used to derive length of time lived in Australia was “What year did you first come to 
live in Australia for one year or more? (e.g. 1970)”. The questionnaire year was then used to 
calculate the number of years lived in Australia. Among participants not born in Australia, the 
median length of time lived in Australia was 39 years. Length of time lived in Australia was coded as 
a categorical variable with seven values: < 10 years; ≥ 10 and < 20 years; ≥ 20 and < 30 years; ≥ 30 
and < 40 years; ≥ 40 years; Born in Australia. 
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Language spoken at home 
The question used for language spoken at home was “Do you speak a language other than English at 
home?” with responses categorised as “Yes” or “No”. 
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Key behavioural and physical characteristics 
Alcohol consumption, cancer incidence, and mortality are known to vary by other lifestyle and 
health related factors. These factors, and how they are ascertained in the 45 and Up Study baseline 
questionnaire are detailed here. 
Smoking, body mass and physical inactivity are risk factors for cancer[19] and mortality[20], while 
height has been adjusted for in previous cohort studies examining alcohol consumption and 
mortality[21-24]. Above-guideline drinking has been associated with a higher prevalence of smoking, 
obesity and physical inactivity compared to within-guideline drinking[25]. Drinking has been 
associated with greater height compared to non-drinking[21]. 
Smoking status and smoking intensity 
Smoking status and intensity was included as a covariate in all cancer and mortality analyses, and 
was ascertained from the questions, “Have you ever been a regular smoker?” (Yes/No), “How old 
were you when you started smoking regularly?”, “Are you a regular smoker now?” (Yes/No), “If No – 
how old were you when you stopped smoking regularly?” and “About how much do you/did you 
smoke on average each day? (If you are an ex-smoker, how much did you smoke on average when 
you smoked?)” with separate responses for ‘cigarettes per day’ and ‘pipes and cigars per day’. Pipes 
or cigars were counted as one cigarette. The variable provided by the study classified > 200 
cigarettes per day and > 100 pipes or cigars per day as invalid. Smoking status and intensity were 
combined into a single variable with seven values: Never smoker; Ex-smoker (≤ 15 cigarettes/day); 
Ex-smoker (> 15 cigarettes/day); Ex-smoker (missing cigarettes/day); Current smoker (≤ 15 
cigarettes/day); Current smoker (> 15 cigarettes/day); Current smoker (missing cigarettes/day). The 
cut-point of 15 cigarettes was chosen as this was the median number of cigarettes/day among all 
ever-smokers. Some analyses used smoking status alone with three values (Never; Ex-smoker; 
Current) and some used two values (Never; Ever-smoker). Smoking duration was not considered as 
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this has been shown in the 45 and Up Study to be highly correlated with age, due to little variation in 
age commenced smoking[26]. When performing interaction tests and stratifications by smoking 
status, never-smoking vs. ever-smoking was used due to the small proportion of current smokers. 
Height 
Height was included as a covariate in the mortality analyses and was ascertained by the question, 
“How tall are you without shoes (please give to the nearest cm or inch)” with possible responses in 
cm or feet and inches. A variable provided by the study already had all heights converted to cm. 
Height was coded as a categorical variable with six values: Male, < 175 cm; Male, ≥ 175, < 180 cm; 
Male, ≥ 180 cm; Female, < 160 cm; Female, ≥ 160, < 165 cm; Female, ≥ 165 cm. These cut-points 
were chosen to divide each sex into approximate tertiles of height.  
Body mass index 
Body mass index (BMI) was included as a covariate in all cancer and mortality analyses. BMI was 
provided by the study, and the two questions used for its calculation were, “How tall are you 
without shoes? (please give to the nearest cm or inch)” with possible responses in cm or feet and 
inches and, “About how much do you weigh?” with possible responses in kg or stone and pounds. 
BMI ranged from 9.1 to 50.0 kg/m2, and the median BMI was 26.3 kg/m2. The variable provided by 
the study classified a height < 55 cm or > 240 cm as invalid, a weight < 35 kg or > 270 kg as invalid, 
and a BMI < 9 or > 50 kg/m2 as invalid. BMI was coded according to the classifications used by the 
World Health Organisation: Underweight (BMI < 18.5 kg/m2); Normal range (BMI ≥ 18.5 and < 25 
kg/m2); Overweight (BMI ≥ 25 and < 30 kg/m2); Obese (BMI ≥ 30 kg/m2). These cut-points were 
chosen to correspond with the World Health Organisation international BMI classification[27]. When 
performing interaction tests and stratifications by BMI, normal range vs. overweight or obese was 
used. 
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Physical activity 
Physical activity was included as a covariate in all cancer and mortality analyses. The two questions 
used to ascertain physical activity were, “How many TIMES did you do each of these activities LAST 
WEEK? (put “0” if you did not do this activity) …Walking continuously, for at least 10 minutes (for 
recreation or exercise or to get to or from places) …Vigorous physical activity (that made you breathe 
harder or puff and pant, like jogging, cycling, aerobics, competitive tennis, but not household chores 
or gardening) …Moderate physical activity (like gentle swimming, social tennis, vigorous gardening 
or work around the house)” and “If you add up all the time you spent doing each activity LAST WEEK, 
how much time did you spend ALTOGETHER doing each type of activity?” for the same three sets of 
activities as the first question. Time spent in vigorous physical activity was given twice the weighting 
of lower intensity physical activity, as per the Active Australia survey[28]. Earlier versions of the 
questionnaire (versions 1 and 2) used different descriptions for each type of physical activity. For 
walking, “Walking continuously, for at least 10 minutes” was instead “Walking briskly”. For 
moderate physical activity, the examples were instead “like social tennis, golf, gentle swimming, 
vigorous gardening or work around the house”. For vigorous physical activity, the description was 
instead “Vigorous leisure activities (that made you breathe harder or puff and pant, like aerobics, 
vigorous sport, cycling, swimming, running)”. Met-adjusted physical activity time ranged from 0 to 
21,600 minutes per week, and the median was 420 minutes per week. Met-adjusted physical activity 
time > 21,600 minutes per week was classified as invalid. Physical activity time was categorised in 
line with the Australian physical activity guidelines[29]: Inactive (0 minutes/week); Insufficient (< 150 
minutes/week); Sufficient (≥ 150 and < 300 minutes/week); High (≥ 300 minutes/week).  
Weekly number of sessions of physical activity ranged from 0 to 1300, and the median was 8 
sessions. Weekly number of sessions > 700 for any of the three types of physical activity was 
classified as invalid. Number of sessions of physical activity was used to calculate the Chronic Disease 
Risk Index examined in Chapter 6.
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Sun exposure 
Sun exposure is a risk factor for melanoma, while darker skin tone is associated with lower risk[30]. 
Alcohol consumption has been associated with outdoor leisure activities in Western countries[31]. 
Time spent outdoors was used as an indicator of sun exposure and skin tone as an indicator of 
susceptibility to harm from sun exposure. Time spent outdoors and skin tone were included as 
covariates in models where melanoma, non-alcohol-related cancer and total cancer were the 
outcomes. 
Time spent outdoors 
The questionnaire item was, “About how many hours a DAY would you usually spend outdoors on a 
weekday and on the weekend?” with separate responses for ‘weekday’ and ‘weekend’. A weighted 
average (a weighting of 5 for weekday and 2 for weekend) was calculated to determine the average 
hours spent outdoors per day. Time spent outdoors ranged from 0 to 24 hours per day with a 
median of 2.86 hours per day. Time spent outdoors > 24 hours per day was classified as invalid. Time 
spent outdoors was coded as a categorical variable with four values: < 2 hours per day; ≥ 2 and < 4 
hours per day; ≥ 4 and < 6 hours per day; ≥ 6 hours per day. The cut-points were chosen to dive the 
cohort into approximate quartiles. 
Skin tone 
The question used for skin tone was, “What best describes the colour of the skin on the inside of your 
upper arm, that is your skin colour without any tanning?” with the possible responses of “Very fair”, 
“Fair”, “Light olive”, “Dark olive”, “Brown”, “Black”. Skin tone was coded as a categorical variable 
with three values: Fair; Olive; Brown or black. 
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Dietary intake 
Low fruit, vegetable, fibre consumption and greater red and processed meat consumption are risk 
factors for cancer[19, 32], and these variables have been adjusted for in a previous cohort study 
examining alcohol consumption and mortality[22]. Compared to never-drinking, drinking has been 
associated with lower fruit and vegetable consumption and with greater fibre, red meat and 
processed meat consumption[22]. In men, heavy drinking has also been associated with greater 
fruit, vegetable, red meat and processed meat consumption compared to light to moderate drinking, 
while in women an inverse association has been reported[22]. All dietary variables were adjusted for 
in the mortality analyses. The selection of dietary factors for adjustment for each cancer type in the 
cancer analysis was based on the World Cancer Research Fund Continuous Update Project[32]. 
Fruit consumption 
The question used to ascertain fruit consumption was, “About how many serves of fruit or glasses of 
fruit juice do you usually have each day? A serve is 1 medium piece or 2 small pieces or 1 cup of diced 
or canned fruit pieces (put “0” if you eat less than one serve a day)” with responses for ‘fruit’ and 
‘fruit juice’. There was also a checkbox for “I don’t eat fruit”. In most analyses, fruit juice was 
excluded from the number of serves of fruit per day (fruit juice was only included in Chapter 6 for 
consistency with the Chronic Disease Risk Index). This is because the Australian dietary guidelines 
recommend against consuming fruit juice[33]. Serves of fruit per day ranged from 0 to 16, with a 
median of 2. Serves of fruit > 16 per day were classified as invalid. Fruit consumption was coded as a 
categorical variable with three values: < 1 serve per day; ≥ 1 and < 2 serves per day; ≥ 2 serves per 
day. The cut-point of 2 serves per day was chosen to correspond with the Australian dietary 
guideline for fruit consumption[33]. 
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Vegetable consumption 
Daily vegetable consumption was ascertained by the question, “About how many serves of 
vegetables do you usually eat each day? A serve is half a cup of cooked vegetables or one cup of 
salad (please include potatoes and put “0” if less than one a day)” with responses for ‘cooked’ and 
‘raw’/‘salad’ vegetables. There was also a checkbox for “I don’t eat vegetables”. Serves of vegetables 
per day ranged from 0 to 32, with a median of 3. Serves of raw or cooked vegetables > 16 per day 
were classified as invalid. Vegetable consumption was coded as a categorical variable with three 
values: < 3 serves per day; ≥ 3 and < 5 serves per day; ≥ 5 serves per day. The cut-point of 5 serves 
per day was chosen to correspond with the Australian dietary guideline for vegetable 
consumption[33]. The cut-point of 3 serves per day was chosen to divide the remaining vegetable 
consumers into two equal groups. 
Fibre intake 
The question used for fibre intake was, “About how many of the following do you usually eat: slices 
or pieces of brown/wholemeal bread each week (also include multigrain, rye bread, etc.) … bowls of 
breakfast cereal each week” with separate responses for ‘bread’ and ‘breakfast cereal’. These two 
responses were summed to create a proxy for fibre intake. Serves of fibre per week ranged from 0 to 
152, with a median of 14. Serves of breakfast cereal and bread > 45 and > 140 per week respectively 
were classified as invalid. Fibre intake was coded as a categorical variable with four values: < 7 serves 
per week; ≥ 7 and < 14 serves per week; ≥ 14 and < 21 serves per week; ≥ 21 serves per week. The 
cut-points were chosen to correspond with serves per day. 
Red meat consumption 
The question used for red meat consumption was “About how many times each week do you eat: 
(please count all meals and snacks, put ‘0’ if never eaten or eaten less than once a week) … beef, 
lamb or pork”. An earlier version of the questionnaire (version 1) asked “… red meat” rather than “… 
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beef, lamb or pork”. There was also the question “Please put a cross in the box if you NEVER eat: red 
meat … pork ham … any meat”. Number of times eating red meat per week ranged from 0 to 50, 
with a median of 3. Times eating red meat > 50 per week was classified as invalid. Red meat 
consumption was coded as a categorical variable with four values: 0 times per week; > 0 and ≤ 2 
times per week; > 2 and ≤ 5 times per week; > 5 times per week. Although the Australian dietary 
guidelines recommend a maximum of 7 serves of red meat per week[34], only a small number of 
participants (3%) exceeded this. Therefore a cut-point of 5 serves per week was used so that the 
highest level of consumption group had a larger number of participants (11%). The cut-point of 2 
was chosen to divide the remaining red meat consumers as close as possible into two equal-sized 
groups. It should be noted that the question referred to times consumed rather than number of 
serves, and no guide to serving size was provided. 
Processed meat consumption 
Weekly consumption of processed meat was ascertained by the question, “About how many times 
each week do you eat: (please count all meals and snacks. put ‘0’ if never eaten or eaten less than 
once a week) … processed meat (include bacon, sausages, salami, devon, burgers, etc)”. An earlier 
version of the questionnaire (version 1) did not include “bacon” as an example. There was also the 
question “Please put a cross in the box if you NEVER eat: any meat”. Number of times eating 
processed meat per week ranged from 0 to 50, with a median of 1. Times eating processed meat > 
50 per week was classified as invalid. Processed meat consumption was coded as a categorical 
variable with four values: 0 times per week; > 0 and ≤ 1 times per week; > 1 and ≤ 2 times per week; 
> 2 times per week. The cut-points were chosen to divide the cohort into approximate quartiles. It 
should be noted that the question referred to times consumed rather than number of serves, and no 
guide to serving size was provided. 
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Female reproductive characteristics 
For women, low parity, first pregnancy at a later age, not breastfeeding, menopausal status, 
hormone replacement therapy (HRT) use and hormonal contraceptive use are risk factors for 
cancer[19, 32, 35]. Parity, menopausal status and HRT use have been adjusted for in previous cohort 
studies examining alcohol consumption and mortality[21, 22]. Drinking has been associated with a 
lower prevalence of ever breastfeeding and a greater prevalence of nulliparity, HRT use and 
hormonal contraceptive use[21, 22, 36, 37]. In different analyses of the European Prospective 
Investigation into Cancer and Nutrition study, drinking has been associated with a greater 
prevalence of pre-menopausal status[22] and a lower prevalence of post-menopausal status[21], but 
in one analysis had a U-shaped associated with post-menopausal status[37]. All female reproductive 
characteristics were adjusted for in the cancer analyses where cancers of the breast, endometrium 
and ovary, alcohol-related cancer, non-alcohol-related cancer and total cancer were the outcomes. 
In addition, hormonal contraceptive use and HRT use were included in the model for cancers of the 
liver and colorectum respectively. Parity, menopausal status and HRT use were adjusted for in the 
mortality analyses. 
Parity and age at first birth 
The two questions used to ascertain parity and age at first birth were, “How many children have you 
given birth to? (please include stillbirths but do not include miscarriages, please write “0” if you have 
not had any children)” and “How old were you when you gave birth to your FIRST child?”. Number of 
children ranged from 0 to 20, with a median of 2. Number of children > 20 was classified as invalid. 
Parity and age at first birth was combined into a categorical variable with eight values: No children; 1 
child, < 25 years; 1 child, ≥ 25 years; 2 children, < 25 years; 2 children, ≥ 25 years; ≥ 3 children, < 25 
years; ≥ 3 children, ≥ 25 years; Male indicator. The cut-point of 25 years was chosen as this was the 
median age at first birth. In some analyses only parity was used. Parity was categorised with five 
levels: No children; 1 child; 2 children; ≥ 3 children; Male indicator. 
153 
 
Breastfeeding time 
Breastfeeding was ascertained by the question, “For how many months, in total, have you breastfed? 
(please add together all the time you spent breastfeeding all of your children; put “0” if you never 
breastfed)”. Months breastfed ranged from 0 to 400, with a median of 8. Months breastfed > 400 
was classified as invalid. Breastfeeding time was coded as a categorical variable with five values: 
Never breastfed; > 0 and ≤ 12 months; > 12 and ≤ 24 months; > 24 months; Male indicator. The cut-
points were chosen to divide the cohort into approximate quartiles. 
Menopausal status 
The question used for menopausal status was, “Have you been through menopause?” with the 
possible responses of “No”, “Not sure (because hysterectomy, taking HRT, etc.)”, “My periods have 
become irregular” and “Yes”. Menopausal status was coded as a categorical variable with four 
values: Pre-menopausal; Irregular periods; Post-menopausal; Male indicator. 
Hormonal contraceptive use 
The question used for hormonal contraceptive use was, “Have you ever used the pill or other 
hormonal contraceptives? (e.g. the combined pill, mini pill, contraceptive implant or injections)” 
(Yes/No). Hormonal contraceptive use was coded as a categorical variable with three values: Never 
used; Ever used; Male indicator. 
Hormone replacement therapy use 
The two questions used for hormone replacement therapy use were, “Have you ever used hormone 
replacement therapy (HRT)?” and “Are you currently taking HRT?”, (Yes/No). Hormone replacement 
therapy use was coded as a categorical variable with four values: Never used; Formerly used; 
Current user; Male indicator. When performing interaction tests by HRT use, never-used HRT vs. 
ever-used HRT was used. 
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Medical and health-related factors 
Cancer screening history was adjusted for in the cancer analysis as it has the potential to bias 
estimates of effect for alcohol consumption and cancer risk[38]. Moderate drinking has been 
associated with increased cancer screening compared to non-drinking[38]. Aspirin use is associated 
with lower risk of oesophageal and colorectal cancer[39]. Drinking has a U-shaped relationship with 
aspirin use[40]. 
Self-rated overall health and physical functioning score were not adjusted for in the analyses, but 
were important exposure variables in the drinking cessation analysis and their restriction was 
considered as a sensitivity test to examine possible bias from the ‘sick-quitter effect’.  
Bowel screening history 
Bowel screening history was included as a covariate in models where colorectum cancer, alcohol-
related cancer and total cancer were the outcomes. The two questions used for bowel screening 
history were, “Have you ever been screened for colorectal (bowel) cancer?” (Yes/No) and, “What 
year did you have the most recent one of these tests? (e.g. 2005)”. The questionnaire year was then 
used to calculate the number of years since last bowel screen. An earlier version of the 
questionnaire (version 1) asked “about how many years ago was the most recent of these tests?” 
rather than the year of most recent test. Bowel screening history categorised into three values: Not 
in the last 10 years; Yes, ≥ 2 and ≤ 10 years ago; Yes, < 2 years ago. The cut-point of 2 years was 
chosen to divide screened participants into two equal groups. 
Breast screening history 
Breast screening history was included as a covariate in models where breast cancer, alcohol-related 
cancer and total cancer were the outcomes. The two questions used for breast screening history 
were, “Have you ever been for a breast screening mammogram?” (Yes/No) and, “If Yes, what year 
did you have your last mammogram? (e.g. 2005)”. The questionnaire year was then used to calculate 
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the number of years since last breast screen. An earlier version of the questionnaire (version 1) 
asked “about how many years ago was your last mammogram?” rather than the year of last 
mammogram. Breast screening history was categorised into four values: Not in the last 10 years; 
Yes, ≥ 2 and ≤ 10 years ago; Yes, < 2 years ago; Male indicator. The cut-point of 2 years was chosen 
to divide screened participants into two equal groups. 
Prostate specific antigen (PSA) test use 
PSA test use was included as a covariate in models where prostate cancer, non-alcohol-related 
cancer and total cancer were the outcomes. PSA test use was captured by the questions, “Have you 
ever had a blood test ordered by your doctor to check for prostate disease? (PSA test)” (Yes/No) and, 
“How many times have you had a PSA test altogether?”. PSA test use was categorised into five 
values: Never; Yes, 1-3 times; Yes, > 3 times; Yes, times missing; Female indicator. The cut-point of 3 
times was chosen to divide the tested participants into two equal groups. 
Aspirin use 
Aspirin use was included as a covariate in models where cancers of the oesophagus and colorectum, 
alcohol-related cancer and total cancer were the outcomes. Aspirin use was ascertained by the 
question, “Have you taken any medications, vitamins or supplements for most of the last 4 weeks, 
including HRT and the pill?” with checkboxes for “aspirin for the heart” and “aspirin for other 
reasons”. If a participant checked either box they were classified as an aspirin user (No; Yes). 
Self-rated overall health 
Self-rated overall health was used as an exposure in the drinking cessation analysis and was 
ascertained by the question, “In general, how would you rate your overall health?” with the possible 
responses of “Excellent”, “Very good”, “Good”, “Fair”, “Poor”. It has been reported that self-rated 
overall health is a valid and reliable measure of health status and is independently associated with 
mortality[41]. Self-rated overall health was coded as a categorical variable with two values: 
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Excellent, very good, good or fair; Poor. A restriction to fair or better health was considered as a 
sensitivity to test examine possible bias from the ‘sick-quitter effect’.  
Physical functioning score 
Physical functioning score was used as an exposure in the drinking cessation analysis, and restriction 
to a score of ≥ 50% as a sensitivity test in the cancer and mortality analyses, and was ascertained by 
the Medical Outcomes Study Physical Functioning scale (MOS-PF) was used[42, 43]. Studies of the 
validity and reliability of the MOS-PF have found mixed results[44]. The question used was “Does 
your health now LIMIT YOU in any of the following activities?” with the possible responses of “Yes, 
limited a lot”, “Yes, limited a little” and “No, not limited at all”. The ten activities were: 
 “VIGOROUS activities (e.g. running, strenuous sports) 
 MODERATE activities (e.g. pushing a vacuum cleaner, playing golf) 
 Lifting or carrying shopping 
 Climbing several flights of stairs 
 Climbing one flight of stairs 
 Walking one kilometre 
 Walking half a kilometre 
 Walking 100 metres 
 Bending, kneeling or stooping 
 Bathing or dressing yourself” 
Participants were assigned a physical functioning score between 0 and 100%, with 10 percentage 
points given for each response of “No, not limited at all”, 5 points for each response of “Yes, limited 
a little” and 0 points for each response of “Yes, limited a lot”. Physical functioning score was coded 
as a categorical variable with two values: ≥ 50%; < 50%. 17,714 participants (6.6%) were missing a 
response for one or more activities, but could still be allocated to one of the two groups with 
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certainty. The cut-point of < 50% was chosen to represent low physical functioning score, as this 
corresponded to an average response of greater than “a little” limitation.  
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4.3 – Ascertainment of Alcohol Consumption and Distribution by Covariates at Baseline in the 45 
and Up Study 
 
Ascertainment of alcohol consumption 
Total alcohol consumption 
The question used for total alcohol consumption was “About how many alcoholic drinks do you have 
each week? One drink = a glass of wine, middy of beer or nip of spirits (put “0” if you do not drink, or 
have less than one drink each week)”. Total alcohol consumption ranged from 0 to 140 drinks/week, 
and the median was 4 drinks/week. The variable provided by the study classified > 140 drinks/week 
as invalid. In analyses were alcohol consumption was the key exposure, participants with missing 
alcohol consumption data were excluded. 
It should be noted that the 45 and Up Study did not include a category for former drinking, as the 
question grouped all participants consuming less than one drink per week together without 
distinction. This was unfortunate as only very light drinkers could be used as a reference group 
rather than lifetime abstainers, and the effects of lifetime abstention, former drinking and 
occasional drinking (less than one drink per week) could not be estimated. The questions available in 
the 45 and Up Study were also much less comprehensive than the questions used in the ‘gold 
standard’ methods for measuring alcohol consumption described in Chapter 1. Therefore alcohol 
consumption in the 45 and Up Study was likely to have been underreported due to a lack of prompts 
regarding frequency of various quantities of intake, beverage types and the settings in which alcohol 
is consumed. 
Drinks per week was analysed as both a categorical variable and a continuous variable. For analyses 
where alcohol consumption was reported as a categorical variable, there were six levels:  
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1. Non-drinker (< 1 drink/week) 
2. ≥ 1 and ≤ 3.5 drinks/week (The cut-point of 3.5 drinks/week was chosen as it corresponds to 
0.5 drinks/day which has been described as the upper limit of ‘very light drinking’[45]) 
3. > 3.5 and ≤ 7 drinks/week 
4. > 7 and ≤ 14 drinks/week 
5. > 14 and ≤ 28 drinks/week (The cut-points of 14 and 28 drinks/week were chosen because 
they correspond with the Australian alcohol guidelines to minimise risk of long-term harm (≤ 
2 drinks/day) and short-term harm (≤ 4 drinks/day) from drinking respectively[46]) 
6. > 28 drinks/week 
Very light drinkers (≥ 1 and ≤ 3.5 drinks/week) were used as the reference group. The median 
quantity of alcohol consumption in this group was 2 drinks/week. A test for trend (ptrend) was also 
calculated for these categories excluding non-drinkers, using the median alcohol consumption in 
each group.  
The non-drinking group used in analyses is a mix of three distinct drinking status groups: lifetime 
abstainers, former drinkers, and occasional drinkers (who consume less than one alcoholic drink per 
week). The questionnaire item did not allow these three groups to be distinguished, so the group is 
referred to as ‘non-drinkers (< 1 drink/week)’ in the analyses. The proportion of each, however, may 
be similar to the background population. That is, a 2007 representative survey of alcohol 
consumption estimated that of Australians aged 50-59 years consuming alcohol ‘less than weekly’, 
68% were occasional drinkers, 16% former drinkers and 16% lifetime abstainers for persons, while 
for those aged ≥ 60 years, 50% were occasional drinkers, 25% former drinkers and 25% lifetime 
abstainers for persons [47]. These proportions for occasional and former drinkers were slightly 
higher in men than in women, while the lifetime abstainer proportion was lower in men. It should be 
noted that the relative proportions of each of these groups comprising ‘non-drinkers’ in the 45 and 
Up Study may differ from the background population due to the 18% response rate. 
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Total alcohol consumption in the cohort by sex is shown in Figure 4.1. Overall, 81,187 (32.7%) were 
non-drinkers at baseline, and 10,215 (3.8%) reported consuming more than 28 drinks per week. A 
higher proportion of women than men were non-drinkers, while a higher proportion of men were 
heavier drinkers. 
 
 
Figure 4.1. Total alcohol consumption at baseline by sex in the 45 and Up Study (2006-2009), New 
South Wales, Australia. Non-drinker: < 1 alcoholic drink per week. 
 
Frequency of alcohol consumption 
The drinking pattern variables were based on the methods used in recent analyses of the Nurses’ 
Health Study and the Health Professionals Follow-up Study[48, 49]. These analyses both examined, 
separately, the influence of frequency of alcohol consumption and highest number of drinks 
consumed in a typical month on cancer risk, before and after adjusting for total alcohol consumption 
as a categorical variable. 
The question used for frequency of alcohol consumption (drinking-days per week) was, “On how 
many days each week do you usually drink alcohol?”. Among drinkers, the median was five drinking-
days per week. Drinking frequency was coded as a categorical variable with four values: 1-2 
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days/week; 3-5 days/week; 6-7 days/week; Non-drinker. Analyses of drinking frequency used ‘1-2 
days/week’ as the reference group and non-drinkers were excluded. The median total alcohol 
consumption in the reference group was 2 drinks/week. A ptrend for these categorical variables was 
also calculated, excluding non-drinkers. The effects of drinking frequency on risk were reported both 
with and without an adjustment for total alcohol consumption as a log-linear continuous variable. 
Adjusting for total alcohol consumption provided an estimate of the independent effect of drinking 
frequency on risk. Specifically, whether daily or near-daily drinking is associated with a lower risk of 
harm than consuming the same total quantity of alcohol but over fewer occasions. 
Frequency of alcohol consumption by sex is shown in Figure 4.2. A higher proportion of men than 
women consumed alcohol 6 or 7 days per week. 
 
 
Figure 4.2. Frequency of alcohol consumption at baseline by sex in the 45 and Up Study (2006-
2009), New South Wales, Australia. Non-drinker: < 1 alcoholic drink per week. 
 
Drinks per drinking-day 
The drinks per drinking-day variable was used rather than highest number of drinks consumed in a 
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calculated as the average number of drinks consumed per day by dividing the number of drinks 
consumed per week by the number of drinking-days per week. This variable was used to examine 
whether there is an independent effect of drinks per drinking-day on harm beyond the effect of total 
alcohol consumption. The median was 2 drinks per day (Q1-Q3; 1-3). Drinks per drinking-day was 
coded as a categorical variable with four levels: ≤ 2 drinks per day; > 2 and ≤ 4 drinks per day; > 4 
drinks per day; Non-drinker. The cut-points of 2 and 4 drinks per day were chosen because they 
correspond with the Australian alcohol guidelines to minimise risk of long-term harm and short-term 
harm from drinking respectively[46]. The cut-point of 4 is similar to the United States definition of 
heavy episodic drinking of, ≥ 5 drinks per occasion in men and ≥ 4 drinks in women (at least one day 
per month)[50]. For the purpose of analysis, ‘≤ 2 drinks per drinking-day’ was assigned as the 
reference group and non-drinkers were excluded. The median total alcohol consumption in the 
reference group was 5 drinks/week. A ptrend was also calculated excluding non-drinkers. The analysis 
was performed both unadjusted and adjusted for total alcohol consumption as a log-linear 
continuous variable. 
It should be noted that it was not possible to replicate the exact definition of the alcohol guidelines 
(≤ 2 and ≤ 4 drinks on any day of drinking) as only mean drinks per drinking-day could be calculated. 
In addition, due to the use of mean drinks per drinking-day, some participants who were in fact 
heavy episodic drinkers will have been grouped with less intense drinkers, potentially biasing results 
towards the null. For example, a participant consuming alcohol 2 days per week, with 5 drinks on 
one day and 1 on the other, would have been grouped with a participant consuming alcohol 2 days 
per week, with 3 drinks on both days. It is possible that the risk profile of these two participants 
differs but it was not possible to differentiate between them. If heavy episodic drinking was 
independently associated with increased risk of an outcome, averaging the total number of drinks 
across days of drinking may therefore result in risk estimates for the drinks per drinking-day variable 
to be underestimated. Finally, this variable only accounts for participants who usually consume at 
least one alcoholic drink per week, meaning that participants who engage in heavy episodic drinking 
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less frequently than once per week may have been excluded (e.g. once per month, as has been 
captured previously[49]). However, a possible advantage of the use of mean drinks per drinking-day 
may be that it is more representative of a participant’s usual exposure to alcohol than highest 
number of drinks consumed in one day over a period of time. 
Drinks per drinking-day by sex is shown in Figure 4.3. Men consumed more alcohol per drinking-day 
than women. 
 
 
Figure 4.3. Drinks per drinking-day at baseline by sex in the 45 and Up Study (2006-2009), New 
South Wales, Australia. Non-drinker: < 1 alcoholic drink per week. 
 
Drinking pattern 
The three categories of frequency of alcohol consumption and three categories of drinks per 
drinking-day were combined to create a novel nine-category drinking pattern variable (see Table 
4.2). The purpose of this variable was to examine the risks associated with more specific drinking 
patterns than those estimated by drinking frequency and drinks per drinking-day alone. This is 
necessary as there may be an interaction between drinking frequency and drinks per drinking-day. 
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Further, greater drinking frequency has been reported to be inversely related to both drinks per 
drinking-day and the proportion of days with heavy episodic drinking [51], and therefore drinking 
frequency and drinks per drinking-day could potentially confound the effect of each other. It should 
also be noted that the drinks per drinking-day variable includes regular heavy drinkers as well as 
heavy episodic drinkers – combining the drinking frequency and heavy episodic drinking variables 
enables these groups to be examined separately. The three by three table generated four categories 
of particular interest, specifically: “low-volume episodic drinkers”, “low-volume frequent drinkers”, 
“heavy episodic drinkers”, “heavy frequent drinkers”. The model was fitted with “low-volume 
episodic drinkers” (1-2 drinking-days per week, ≤ 2 drinks per drinking-day) as the reference group 
and non-drinkers were excluded. The median total alcohol consumption in the reference group was 
2 drinks/week. Of particular interest are the comparisons between ‘low-volume frequent drinkers’ 
and ‘low-volume episodic drinkers’, and between ‘heavy episodic drinkers’ to ‘low-volume episodic 
drinkers’, to examine the effects of drinking frequency and heavy episodic drinking respectively. 
Drinking pattern by sex among drinkers is shown in Table 4.3. Men consumed alcohol more 
frequently and consumed more alcohol per drinking-day than women. 
 
Table 4.2. Drinking pattern variable. 
 Drinks per drinking-day 
Drinking-days per week ≤ 2 > 2 and ≤ 4 > 4 
1-2 Low-volume episodic drinkera … Heavy episodic drinker 
3-5 … … … 
6-7 Low-volume frequent drinker … Heavy frequent drinker 
aReference group. Non-drinkers excluded. 
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Table 4.3. Drinking pattern at baseline by sex among drinkers in the 
45 and Up Study (2006-2009), New South Wales, Australia. 
 Drinks per drinking-day (n participants) 
Drinking-days per week ≤ 2 > 2 and ≤ 4 > 4 
Men    
1-2 14,925 5,151 3,012 
3-5 15,656 10,311 4,041 
6-7 16,723 13,754 8,281 
Women    
1-2 21,050 3,595 1,078 
3-5 22,552 6,295 697 
6-7 18,214 6,124 995 
Non-drinkers excluded (28,879 men and 58,308 women). 
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Distribution of total alcohol consumption by each drinking variable 
The distribution of total alcohol consumption by each drinking variable is shown in Table 4.4. As 
expected, mean number of drinks per week was higher among participants who consumed alcohol 
on more days of the week and who consume greater drinks per drinking-day. 
 
 
Table 4.4. Distribution of total alcohol consumption by drinking variables 
in the 45 and Up Study (2006-2009), New South Wales, Australia. 
  Alcoholic drinks per week 
Variable  n Mean (SD) Median (Q1-Q3) 
Total alcohol consumption    
Non-drinkera 87,187 0.0 (0.0) 0 (0-0) 
≥ 1, ≤ 3.5 drinks/week 40,491 2.0 (0.8) 2 (1-3) 
> 3.5, ≤ 7 drinks/week 50,494 5.6 (1.1) 6 (5-7) 
> 7, ≤ 14 drinks/week 46,117 11.0 (2.1) 10 (10-13) 
> 14, ≤ 28 drinks/week 27,249 20.1 (3.7) 20 (17-21) 
> 28 drinks/week 10,215 40.0 (13.6) 35 (30-42) 
Missing 5,041 -b -b 
Drinking-days per week    
1-2 days/week 48,811 3.3 (3.1) 2 (1-4) 
3-5 days/week 59,552 9.1 (6.5) 7 (5-10) 
6-7 days/week 64,091 17.2 (12.1) 14 (9-21) 
Missing 7,153 9.5 (11.5) 6 (3-12) 
Drinks per drinking-day    
≤ 2 drinks/drinking-day 109,120 5.8 (3.8) 5 (2-8) 
> 2, ≤ 4 drinks/drinking-day 45,230 14.3 (6.7) 15 (9-20) 
> 4 drinks/drinking-day 18,104 29.2 (16.4) 30 (18-36) 
Missing 7,153 9.5 (11.5) 6 (3-12) 
Drinking pattern (drinking-days 
per week; drinks/drinking-day) 
  
 
1-2 days; ≤ 2 drinks/day 35,975 2.0 (1.0) 2 (1-2) 
1-2 days; > 2, ≤ 4 drinks/day 8,746 5.0 (1.5) 5 (4-6) 
1-2 days; > 4 drinks/day 4,090 10.3 (5.3) 10 (7-12) 
3-5 days; ≤ 2 drinks/day 38,208 5.8 (2.3) 5 (4-7) 
3-5 days; > 2, ≤ 4 drinks/day 16,606 12.3 (3.6) 12 (10-15) 
3-5 days; > 4 drinks/day 4,738 24.6 (9.2) 22 (20-30) 
6-7 days; ≤ 2 drinks/day 34,937 9.6 (3.2) 10 (7-12) 
6-7 days; > 2, ≤ 4 drinks/day 19,878 20.0 (3.9) 20 (16-21) 
6-7 days; > 4 drinks/day 9,276 39.8 (13.9) 35 (30-42) 
Missing 7,153 9.5 (11.5) 6 (3-12) 
Total 266,794 7.0 (9.7) 4 (0-10) 
a< 1 alcoholic drink per week. bNot possible to calculate. SD, Standard 
Deviation. Q1, 25th percentile. Q3, 75th percentile. 
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Distribution of alcohol consumption by covariates 
Socio-demographic characteristics 
The association between alcohol consumption and socio-demographic characteristics in the 45 and 
Up Study has been examined previously[16]. It was reported that consuming any alcohol without 
current smoking was associated with being male, aged < 85 years, greater highest level of education 
and greater household income, while risky alcohol consumption (> 2 drinks per day) with current 
smoking was associated with being male, aged 45-64 years, lesser highest level of education and 
lower household income. 
There was variation in alcohol consumption by every socio-demographic characteristic examined. 
Specifically, mean weekly alcoholic drinks was higher among men, participants aged less than 75 
years, those living in regional and remote areas, those with higher annual household income, those 
with a trade or apprenticeship as their highest level of education, those without a healthcare 
concession card, those who were married or living with a partner, those born in Australia or other 
English-speaking countries, those who have lived in Australia longer, and those with English as the 
only language spoken at home (Table B.1, Appendix B). A high proportion of non-drinkers (> 40%) 
was found among women, those aged greater than 85 years, those with an annual household 
income less than $30,000, those with no school certificate, those holding a health care concession 
card, those not married or living with a partner, immigrants not born in majority English-speaking 
countries, immigrants living in Australia less than 20 years and those speaking a language other than 
English at home. A high proportion of participants consuming greater than 14 drinks per week (> 
20%) was found in men and those with a trade or apprenticeship as their highest level of education. 
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Distribution of alcohol consumption by key behavioural and physical covariates 
The association between alcohol consumption and key behavioural covariates in the 45 and Up Study 
has been examined previously[52]. A higher mean alcohol consumption was reported in participants 
who were ever-smokers compared to never-smokers, and those who were physically active rather 
than sedentary. 
The distribution of alcohol consumption by key behavioural and physical covariates is shown in Table 
B.2 in Appendix B. Mean alcohol consumption was higher for participants who were ex- or current 
smokers, taller, overweight and had a high level of physical activity than in participants without these 
factors. Current smokers consuming greater than 15 cigarettes per day had the highest level of mean 
alcohol consumption and the highest proportion of participants consuming greater than 14 drinks 
per week out of all variables. Half of all participants who were physically inactive were non-drinkers. 
Men with a height greater than or equal to 180 cm had the lowest proportion of non-drinkers out of 
all variables. 
 
Distribution of alcohol consumption by sun exposure covariates 
The distribution of alcohol consumption by sun exposure covariates is shown in Table B.3 in 
Appendix B. Mean alcohol consumption was higher for participants who spent greater periods of 
time outdoors and who had a fair or olive skin tone than in participants without these factors.  
 
Distribution of alcohol consumption by dietary factors 
The distribution of alcohol consumption by dietary factors is shown in Table B.4 in Appendix B. Mean 
number of drinks per week was high among participants consuming low amounts of fruit, vegetables, 
fibre, and those consuming high amounts of red and processed meat. Over half of those who 
consumed no red meat were non-drinkers, and over 20% of those who consumed red meat more 
than 5 times per week were heavy drinkers. 
169 
 
 
Distribution of alcohol consumption by female reproductive characteristics 
Alcohol consumption distributed by female reproductive characteristics is shown in Table B.5 in 
Appendix B. Mean weekly alcohol consumption was higher for participants with fewer children, with 
less breastfeeding time, who were pre-menopausal or had irregular periods, had ever used hormonal 
contraceptives and who were current users of hormone replacement therapy. Never users of 
hormonal contraceptives had the lowest mean weekly alcohol consumption, the highest proportion 
of non-drinkers, and the lowest proportion of participants consuming greater than 14 drinks per 
week. 
 
Distribution of alcohol consumption by medical and health-related factors 
The distribution of alcohol consumption by medical and health-related factors is shown in Table B.6 
in Appendix B. Participants who recently had bowel and breast screening, in better self-rated overall 
health and with a greater physical functioning score had a higher level of mean alcohol consumption 
than participants without these characteristics. There were no clear differences in alcohol 
consumption by number of times prostate screened or by aspirin use. Participants with a physical 
functioning score < 25% and with missing aspirin use status had the highest proportion of non-
drinkers out of all variables. 
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Conclusion 
It has been shown that the distribution of alcohol consumption appears to vary by numerous key 
covariates that impact health. Therefore, these were accounted for by adjustment (and by 
stratification for sex and smoking status) in the cancer and mortality analyses. It is not appropriate 
to control for self-rated overall health, physical functioning score or other health-related factors 
such as disease status, as these are likely to be on the causal pathway between alcohol consumption 
and cancer and mortality. Adjusting for (or stratifying by, restricting by) a variable on the causal 
pathway between an exposure and outcome can cause overadjustment bias, likely biasing estimates 
of effect towards the null[53]. Confounding by illness at baseline was considered further in Chapter 
7, and as a solution it was decided to perform a sensitivity test excluding participants with a low 
physical functioning score in the cancer and mortality analyses. 
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4.4 – Summary and Conclusions 
 
Alcohol consumption is known to vary by key socio-demographic, lifestyle, and other health-related 
factors[9, 10, 25, 51]. This chapter described the covariates required for analysis including socio-
demographic characteristics (sex, age, remoteness, household income, highest level of education, 
health insurance status, partner status, country of birth, length of time lived in Australia, language 
spoken at home), behavioural and physical factors (smoking status and intensity, height, BMI, 
physical activity, time spent outdoors, skin tone, fruit consumption, vegetable consumption, fibre 
intake, red meat consumption, processed meat consumption), female reproductive characteristics 
(parity and age at first birth, breastfeeding time, menopausal status, HRT use, hormonal 
contraceptive use) and medical and health-related factors (bowel, breast and prostate cancer 
screening history, aspirin use, self-rated overall health and physical functioning score). Alcohol 
consumption was shown to vary by almost every one of these covariates. Accounting for these 
factors in analyses of alcohol consumption and health outcomes will minimise the potential for 
confounding. The next chapter compares the 45 and Up Study to other contemporaneous 
population based surveys.  
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Chapter 5 – Comparison of the 45 and Up Study to Representative Health Surveys 
 
Chapter summary 
In this chapter, the distribution of variables in the 45 and Up Study are compared to population-
based estimates using the 2008 New South Wales Population Health Survey, the Australian Bureau 
of Statistics New South Wales population estimates for June 2008, the 2007 National Drug Strategy 
Household Survey and the 2007-2008 National Health Survey. 
 
5.1 – Comparison to Representative Health Surveys 
 
This section compares how closely responses to the baseline survey of the 45 and Up Study match 
those of contemporaneous surveys of the NSW and Australian populations. Because the response 
rate of the 45 and Up Study is only around 18%, it is not likely to be representative of the general 
population. By comparing the prevalence of responses and outcomes of the 45 and Up Study cohort 
to other population based surveys of the same time period, the representativeness of socio-
demographic, behavioural and health-related factors in the 45 and Up Study can be investigated. 
Surveys conducted as close as possible to the 45 and Up Study median baseline questionnaire date 
of February 2008 were examined. 
 
New South Wales Population Health Survey (2008) 
The 2008 NSW Population Health Survey (PHS) is one of the annual health surveys conducted by the 
NSW Department of Health[1]. Computer assisted telephone interviews of 12,485 residents of NSW 
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were conducted, of which 7,416 were aged ≥ 45 years. Participants were sampled via random digit 
dialling and the overall response rate was 63%. Participants of all ages including children were 
sampled, and the results were weighted to the Australian Bureau of Statistics (ABS) NSW population 
estimates for June 2008. Results for persons aged over 45 years were compared to the 45 and Up 
Study baseline responses. Although alcohol consumption was not reported in a way that could be 
compared to the 45 and Up Study (risky alcohol consumption based on the 2001 Australian alcohol 
guidelines, defined partially by highest number of drinks consumed in one day in the previous four 
weeks), comparable data were available online at NSW HealthStats[2]. 
The age and sex structure of the two surveys are compared in Table 5.1. Additional columns are 
included showing the sex and age distribution of the whole NSW population aged ≥ 45 years 
according to the ABS NSW population estimates for June 2008, and sex, age, partner status and 
country of birth data for the NSW population aged ≥ 45 years according to the 2006 census[3]. The 
45 and Up Study had a higher proportion of men than the NSW PHS but a lower proportion of men 
compared to the NSW population estimates and the census. There was a higher proportion of 
participants aged < 65 years in the 45 and Up Study compared to the NSW PHS, a higher proportion 
of participants aged ≥ 55 years compared to the NSW population estimates, and a higher proportion 
of participants aged ≥ 55 and < 75 years compared to the census. There was also a higher proportion 
of participants married or living with a partner and born in Australia compared to the census. 
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Table 5.1. Distribution of socio-demographic characteristics in the baseline survey of the 45 and Up Study 
(2006-2009), New South Wales (NSW), the NSW Population Health Survey (2008), the Australian Bureau 
of Statistics NSW population estimates for June 2008 and the 2006 Census in NSW. 
Characteristic  
45 and Up Study 
(%) (95% CI) 
NSW PHS 
2008 (%) 
ABS NSW population 
estimates for June 2008a (%) 
2006 Census 
in NSW (%) 
n participants 266,794 7,416 2,532,017 2,529,657 
Sex     
Male 46.4 (46.2-46.6) 40.0 48.3 47.8 
Female 53.6 (53.4-53.8) 60.0 51.7 52.2 
Age (years)     
45-54 29.2 (29.0-29.4) 24.2 36.7 35.7 
55-64 32.2 (32.0-32.4) 31.0 29.0 28.4 
65-74 21.7 (21.6-21.9) 24.6 18.5 18.4 
≥ 75 16.9 (16.8-17.1) 20.3 15.8 17.4 
Married or living with partner     
No 25.1 (24.9-25.3) - - 31.0 
Yes 74.9 (74.7-75.1) - - 69.0 
Country of birth     
Australia 75.6 (75.4-75.7) - - 65.9 
Other 24.4 (24.3-24.6) - - 34.1 
Proportions exclude missing data. aExcludes residents of institutions. NSW, New South Wales. CI, 
Confidence Interval. PHS, Population Health Survey. ABS, Australian Bureau of Statistics. 
 
The distribution of socio-demographic characteristics and lifestyle risk factors at baseline in the 45 
and Up Study are compared to the NSW PHS in Table 5.2. Across all sex and age groups, a higher 
proportion of participants in the 45 and Up Study had private health insurance, had adequate 
physical activity, consumed ≥ 5 serves of vegetables per day, rated their health as good, very good or 
excellent and had breast screening within the past 2 years, while a lower proportion were current 
smokers. On the other hand, across all sex and age groups a higher proportion of participants in the 
45 and Up Study consumed alcohol at least weekly and were overweight or obese (except men aged 
≥ 75 years), while a lower proportion consumed ≥ 2 serves of fruit per day and consumed red meat < 
3 times per week. Consumption of processed meat per week was similar between the two surveys 
for women, but a lower proportion of men in the 45 and Up Study consumed processed meat < 3 
times per week in all age groups except 45-54 years. 
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Table 5.2. Distribution of socio-demographic characteristics and lifestyle risk factors in the baseline survey of the 45 and Up Study (2006-2009), New South Wales (NSW) 
and the NSW Population Health Survey (2008). 
  Men (95% CI)  Women (95% CI) 
Study and characteristic 45-54 years 55-64 years 65-74 years ≥ 75 years  45-54 years 55-64 years 65-74 years ≥ 75 years 
45 and Up Study          
n participants 31,435 39,073 29,507 23,754  46,417 46,749 28,511 21,348 
Private health insurance (%) 68.2 (67.6-68.7) 70.0 (69.5-70.5) 63.0 (62.5-63.6) 53.1 (52.5-53.7)  67.8 (67.3-68.2) 69.4 (69.0-69.8) 60.2 (59.6-60.8) 52.2 (51.6-52.9) 
Drink alcohol at least weekly (%) 78.7 (78.3-79.2) 79.5 (79.1-79.9) 75.6 (75.1-76.1) 68.7 (68.1-69.3)  64.4 (63.9-64.8) 61.4 (60.9-61.8) 53.8 (53.2-54.4) 43.9 (43.2-44.6) 
Current smoker (%) 12.1 (11.7-12.4) 8.7 (8.5-9.0) 5.6 (5.3-5.8) 2.6 (2.4-2.8)  10.6 (10.3-10.9) 7.1 (6.9-7.4) 4.2 (4.0-4.4) 2.1 (1.9-2.3) 
Overweight or obeseb (%) 71.1 (70.6-71.7) 72.8 (72.4-73.3) 70.5 (69.9-71.0) 54.9 (54.3-55.6)  52.8 (52.3-53.2) 59.4 (58.9-59.8) 60.4 (59.8-61.0) 48.8 (48.1-49.5) 
Adequate physical activityc (%) 68.8 (68.3-69.4) 70.7 (70.2-71.2) 72.5 (72.0-73.0) 61.2 (60.5-61.8)  71.6 (71.2-72.0) 74.0 (73.6-74.4) 71.1 (70.6-71.7) 53.3 (52.6-54.0) 
≥ 2 serves of fruit per day (%) 46.2 (45.7-46.8) 48.9 (48.4-49.4) 51.3 (50.8-51.9) 53.9 (53.3-54.6)  58.0 (57.5-58.4) 65.7 (65.3-66.2) 69.1 (68.6-69.7) 67.3 (66.7-68.0) 
≥ 5 serves of vegetables per day (%) 19.0 (18.6-19.5) 23.4 (23.0-23.8) 27.9 (27.4-28.4) 26.9 (26.3-27.5)  34.2 (33.8-34.6) 41.2 (40.7-41.6) 45.1 (44.5-45.7) 39.1 (38.4-39.7) 
Consume red meat < 3 times per week (%) 35.3 (34.8-35.9) 32.3 (31.9-32.8) 31.2 (30.7-31.7) 33.5 (32.9-34.1)  42.3 (41.9-42.8) 38.4 (37.9-38.8) 35.9 (35.3-36.5) 37.7 (37.1-38.4) 
Consume processed meat < 3 times per week (%) 76.0 (75.6-76.5) 78.3 (77.8-78.7) 80.1 (79.6-80.5) 80.4 (79.9-80.9)  88.5 (88.2-88.8) 89.4 (89.1-89.7) 89.5 (89.1-89.8) 88.7 (88.3-89.2) 
Good/very good/excellent self-rated health (%) 88.0 (87.7-88.4) 86.4 (86.1-86.7) 85.1 (84.7-85.5) 76.8 (76.3-77.4)  90.0 (89.7-90.3) 89.0 (88.7-89.3) 86.5 (86.1-86.9) 74.4 (73.8-75.0) 
Breast screening within past 2 years (%) - - - -  - 84.1 (83.8-84.5)d - - 
NSW Population Health Survey 2008a          
n participants 729 914 709 588  1,065 1,382 1,115 914 
Private health insurance (%) 67.1 65.6 57.6 48.4  66.0 66.5 56.1 49.1 
Drink alcohol at least weekly (%) 61.5 65.7 60.3 54.8  45.0 43.7 36.4 30.5 
Current smoker (%) 17.6 15.6 8.1 4.5  17.6 13.0 7.8 3.7 
Overweight or obeseb (%) 67.1 70.3 69.0 56.0  52.1 57.8 59.3 45.2 
Adequate physical activityc (%) 59.9 57.1 52.4 43.5  50.1 50.9 39.9 26.4 
≥ 2 serves of fruit per day (%) 51.7 51.5 56.8 59.9  61.7 67.5 72.8 72.8 
≥ 5 serves of vegetables per day (%) 6.3 7.4 10.7 9.6  15.7 18.3 18.9 14.3 
Consume red meat < 3 times per week (%) 38.9 42.3 44.8 43.7  43.7 44.9 47.3 49.1 
Consume processed meat < 3 times per week (%) 74.7 80.4 82.9 85.5  88.3 91.7 89.5 88.6 
Good/very good/excellent self-rated health (%) 82.4 76.2 77.3 71.5  79.1 76.5 71.4 68.1 
Breast screening within past 2 years (%) - - - -  - 76.2d - - 
Proportions exclude missing data. aResults weighted by age, sex, health area and probability of selection in household to match Australian Bureau of Statistics estimates for 
June 2008, excluding residents of institutions. bBody mass index ≥ 25 kgm-2. c150 minutes of physical activity per week on at least 5 separate occasions, with time spent in 
vigorous physical activity was given twice the weighting of lower intensity physical activity. dParticipants aged 50-69 years. NSW, New South Wales. CI, Confidence Interval. 
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National Drug Strategy Household Survey (2007) 
The 2007 National Drug Strategy Household Survey (NDSHS), conducted by the Australian Institute of 
Health and Welfare, had a focus on alcohol, tobacco and illicit drug use[4]. Drop and collect surveys 
and computer assisted telephone interviews were conducted for 23,356 randomly sampled residents 
of Australia aged ≥ 12 years, with a response rate of 49%. The results were weighted to population 
estimates for 2007. Information on weekly alcohol consumption was available for NSW by 10 year 
age strata (thus it was only possible to make comparisons for participants aged ≥ 50 years). 
The age and sex distribution of alcohol consumption and smoking status in the NDSHS and the 45 
and Up Study are shown in Table 5.3. Compared to the 2007 NDSHS, a higher proportion of 
participants in the 45 and Up Study consumed alcohol at least weekly and were never smokers. The 
45 and Up Study had fewer current smokers however the proportion of ex-smokers was similar 
across the two surveys. 
 
National Health Survey (2007-2008) 
The National Health Survey (NHS), was a random sample of 20,788 Australian residents aged ≥ 15 
years, with a response rate of 91%[5]. Participants were interviewed in their homes by the Australian 
Bureau of Statistics and the results were weighted to population estimates for December 2007. The 
NHS had information on the consumption of alcohol ‘at least weekly’. It should be noted that unlike 
the previous two surveys, the NHS captured alcohol consumption in the last week rather than usual 
alcohol consumption. 
The distribution of alcohol consumption and other lifestyle risk factors at baseline the 45 and Up 
Study and in the 2007-2008 NHS are shown in Table 5.4. Compared to the NHS, a higher proportion 
of participants in the 45 and Up Study consumed alcohol at least weekly (except women aged ≥ 75 
years) and consumed ≥ 5 serves of vegetables per day. Overall, a lower proportion of participants in 
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the 45 and Up Study were current smokers, overweight or obese and physically inactive. The 
proportion of participants consuming ≥ 2 serves of fruit per day varied by age group. Specifically, 
men aged < 55 years and women aged ≥ 55 and < 75 years in the 45 and Up Study consumed more 
fruit than those in the NHS, men aged ≥ 55 years and women aged < 55 years consumed less, and 
women aged ≥ 75 years consumed a similar amount. The proportion of participants with private 
health insurance was reported in the NHS by age but not by sex. For participants aged 45-54, 55-64, 
65-74 and ≥ 75 years in the NHS, 59.0%, 62.0%, 55.4% and 44.5% had private health insurance, 
respectively. The corresponding proportions for the 45 and Up Study were all higher, at 67.9%, 
69.7%, 61.7% and 52.7% respectively. 
It should be noted that the surveys of the Australian population will not be as comparable to the 45 
and Up Study as surveys of the NSW population. Other limitations of these comparisons include the 
45 and Up Study oversampling participants aged ≥ 80 years and living in remote areas, different 
timings of sampling, different wording of questions, different methods of data collection such as via 
telephone interview rather than paper questionnaire, different response rates, the exclusion of 
persons in institutions such as nursing homes (nursing home residents were included in the 45 and 
Up Study) and the use of population weightings. Furthermore, the 2008 NSW PHS and the 2007-
2008 NHS reported conducted surveys in languages other than English when required, while the 
2007 NDSHS and the 45 and Up Study did not, potentially causing bias by English language ability. 
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Table 5.3. Comparison of alcohol consumption and smoking status by sex and age between the baseline survey of the 45 and Up Study (2006-2009), New South Wales 
and the Australian National Drug Strategy Household Survey (2007). 
  45 and Up Study (%) (95% CI)  NDSHS 2007a (%) 
Characteristic 
Men, 
50-59 years 
Men, 
≥ 60 years 
Women, 
50-59 years 
Women, 
≥ 60 years 
 Men, 
50-59 years 
Men, 
≥ 60 years 
Women, 
50-59 years 
Women, 
≥ 60 years 
n participants 37,872 72,236 50,578 71,228  ≈ 1,800b ≈ 3,100b ≈ 2,200b ≈ 3,700b 
Alcohol consumption          
Non-drinker or drink less than weekly 20.8 (20.4-21.2) 25.7 (25.4-26.0) 36.9 (36.5-37.4) 47.1 (46.8-47.5)  34.5 39.4 54.2 58.9 
Drink alcohol at least weekly 79.2 (78.8-79.6) 74.3 (74.0-74.6) 63.1 (62.6-63.5) 52.9 (52.5-53.2)  65.5 60.6 45.8 41.1 
Smoking status          
Never smoker 52.2 (51.7-52.7) 45.2 (44.8-45.5) 62.2 (61.8-62.6) 68.7 (68.4-69.0)  40.0 39.8 56.6 63.1 
Ex-smoker 37.3 (36.8-37.8) 49.7 (49.3-50.0) 29.1 (28.7-29.5) 27.1 (26.8-27.4)  38.3 48.3 27.4 27.4 
Current smoker 10.5 (10.2-10.8) 5.2 (5.0-5.3) 8.7 (8.4-8.9) 4.2 (4.1-4.4)  21.8 11.9 16.1 10.6 
Proportions exclude missing data. aResults weighted by age, sex and state to match Australian Bureau of Statistics estimates for June 2007. bExact numbers by sex and age 
not reported; 23,356 participants (10,231 men and 13,125 women) in total aged ≥ 12 years. CI, Confidence Interval. NDSHS, National Drug Strategy Household Survey.  
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Table 5.4. Comparison of behavioural risk factors between the baseline survey of the 45 and Up Study (2006-2009), New South Wales and the Australian National Health 
Survey (2007-2008). 
  Men (95% CI)  Women (95% CI) 
Study and characteristic 45-54 years 55-64 years 65-74 years ≥ 75 years  45-54 years 55-64 years 65-74 years ≥ 75 years 
45 and Up Study          
n participants 31,435 39,073 29,507 23,754  46,417 46,749 28,511 21,348 
Drink alcohol at least weekly (%) 78.7 (78.3-79.2) 79.5 (79.1-79.9) 75.6 (75.1-76.1) 68.7 (68.1-69.3)  64.4 (63.9-64.8) 61.4 (60.9-61.8) 53.8 (53.2-54.4) 43.9 (43.2-44.6) 
Current smoker (%) 12.1 (11.7-12.4) 8.7 (8.5-9.0) 5.6 (5.3-5.8) 2.6 (2.4-2.8)  10.6 (10.3-10.9) 7.1 (6.9-7.4) 4.2 (4.0-4.4) 2.1 (1.9-2.3) 
Overweight or obesec (%) 71.1 (70.6-71.7) 72.8 (72.4-73.3) 70.5 (69.9-71.0) 54.9 (54.3-55.6)  52.8 (52.3-53.2) 59.4 (58.9-59.8) 60.4 (59.8-61.0) 48.8 (48.1-49.5) 
Inactived (%) 4.6 (4.4-4.8) 4.9 (4.7-5.2) 4.9 (4.7-5.2) 9.0 (8.7-9.4)  4.5 (4.3-4.7) 4.4 (4.2-4.6) 5.5 (5.2-5.7) 14.4 (13.9-14.8) 
≥ 2 serves of fruit per day (%) 46.2 (45.7-46.8) 48.9 (48.4-49.4) 51.3 (50.8-51.9) 53.9 (53.3-54.6)  58.0 (57.5-58.4) 65.7 (65.3-66.2) 69.1 (68.6-69.7) 67.3 (66.7-68.0) 
≥ 5 serves of vegetables per day (%) 19.0 (18.6-19.5) 23.4 (23.0-23.8) 27.9 (27.4-28.4) 26.9 (26.3-27.5)  34.2 (33.8-34.6) 41.2 (40.7-41.6) 45.1 (44.5-45.7) 39.1 (38.4-39.7) 
Australian NHS 2007-2008a          
Drink alcohol at least weekly (%) 76.0 72.5 68.2 60.2  61.9 60.6 52.8 45.4 
Current smoker (%) 24.3 16.2 10.5 5.3  21.7 17.3 9.1 4.7 
Overweight or obesec (%) 76.7 74.9 78.9 74.3  58.8 67.9 71.4 56.9 
Inactived (%) 38.4 35.0 37.1 51.5  33.3 37.3 41.2 58.9 
≥ 2 serves of fruit per day (%) 43.3 53.5 62.5 63.6  58.8 64.8 67.5 66.8 
≥ 5 serves of vegetables per day (%) 5.8 6.7-10.1e 14.0 10.0-12.6e  12.7 9.7-14.9e 13.3 9.0-13.7e 
Proportions exclude missing data. aResults weighted by age, sex, area of usual residence and probability of selection in household to match Australian Bureau of Statistics 
estimates for December 2007, excluding persons living in very remote areas and residents of hotels, motels, caravan parks and institutions; n participants by sex and age 
not available; n participants for all ages ≥ 15 years = 20,788. cBody mass index ≥ 25 kgm-2. d0 minutes of physical activity per week. eExact proportion cannot be calculated 
due to supressed cells with small numbers. CI, Confidence Interval. NHS, National Health Survey. 
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Conclusion 
In summary, it appears that participants in the 45 and Up Study have healthier lifestyle behaviours, 
better self-rated overall health and a higher prevalence of private health insurance than participants 
in contemporaneous, representative population-based health surveys. Although there were some 
exceptions such as a higher prevalence of drinking alcohol at least weekly and lower fruit 
consumption. Thus, the 45 and Up Study is possibly healthier than the overall NSW population. It 
should be noted that other factors may contribute to the differences in findings, such as differences 
in sampling method (e.g. the Medicare Australia database vs. random digit dialling) and data 
collection (e.g. the use of paper questionnaires vs. home interviews). 
As the majority of participants in the 45 and Up Study were moderate drinkers (≤ 14 drinks/week), 
and as moderate drinking has previously been associated with good general health status and a 
range of healthy lifestyle behaviours such as physical activity and lower BMI compared to non-
drinking[6], perhaps the higher prevalence of persons consuming alcohol at least weekly is to be 
expected in a healthier cohort. Unfortunately, the 45 and Up Study’s measure of alcohol 
consumption was not comparable to the measures used in other surveys, meaning that the 
prevalence of within- and above-guideline drinking could not be compared. Specifically, it was not 
possible to determine if participants in the 45 and Up Study consumed > 2 or > 4 standard drinks on 
any day of alcohol consumption. Different measures of risky alcohol consumption were also reported 
in the three comparison surveys. The 2008 NSW PHS used a definition of “1 or more of the following: 
consuming alcohol every day, consuming on average more than [4 if male/2 if female] standard 
drinks, consuming more than [6 if male/4 if female] on any 1 occasion or day.”[1], the 2007 NDSHS 
used a similar definition but without the item of consuming alcohol every day[4], while the 2007-
2008 NHS used a definition of “average daily consumption of alcohol by persons aged 15 years and 
over for 3 days of the week prior to interview” > 50 mL in men and > 25 mL in women[5]. Further, the 
use of differently worded questions to capture alcohol consumption between the surveys reduces 
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comparability, even when using a similar measure of alcohol consumption such as whether a 
participant consumed alcohol at least weekly. As was reported in Chapter 1, prevalence estimates for 
alcohol consumption are particularly sensitive to the style of question asked[7]. Another limitation 
was that the 2008 NHS captured alcohol consumption in the past week rather than usual alcohol 
consumption, which could potentially alter prevalence estimates as well. Overall, it appears possible 
but not certain that a higher proportion of participants in the 45 and Up Study consume alcohol at 
least weekly compared to the general population. 
The selection of healthy participants into cohort studies and randomised controlled trials is known as 
the ‘healthy volunteer effect’, and when compared to the general population may lead to a lower 
observed incidence of cancer, cardiovascular disease and mortality[8, 9]. The possibility of a healthier 
cohort means that interpretations of prevalence estimates should be made with caution, as they may 
not be representative of the overall NSW population. 
A detailed comparison of the 45 and Up Study with the NSW PHS found consistent exposure-
outcome relationships between the two studies, meaning that the study will most likely provide 
generalisable results when analyses are based on internal comparisons within the cohort[10]. For 
example, consistent exposure-outcome relationships were found for BMI and odds of having 
diabetes, BMI and odds of having hypertension, remoteness and odds of having ≥ 2 serves of fruit per 
day, educational attainment and odds of obesity, and smoking status and odds of bowel screening in 
the past five years. However, this means that null results should be interpreted with caution. 
188 
 
5.2 – Summary and Conclusions 
 
Comparing the 45 and Up Study to other population based surveys with a higher response rate was 
important to determine the representativeness of the cohort. The distribution of exposures in the 45 
and Up Study were compared with similar measures of exposure in the NSW Population Health 
Survey (2008), the NSW data from the National Drug Strategy Household Survey (2007) and National 
Health Survey (2007-2008). Overall, 45 and Up Study participants were potentially healthier than the 
general population, similar to the ‘healthy volunteer effect’ described in other cohort studies[8, 9]. 
Specifically, a higher proportion of participants in the 45 and Up Study had private health insurance, 
had adequate physical activity or were physically active, consumed ≥ 5 serves of vegetables per day, 
and rated their health as good, very good or excellent, while a lower proportion were current 
smokers compared to the general population. On the other hand, a higher proportion of participants 
consumed alcohol at least weekly (except compared to women aged ≥ 75 years in the NHS) and a 
lower proportion consumed red meat < 3 times per week. The proportion overweight or obese was 
higher than the NSW PHS and lower than the NHS, while the proportion consuming ≥ 2 serves of 
fruit per day was lower than the NSW PHS and varied compared to the NHS depending on sex and 
age group. Finally, regarding alcohol consumption, the 45 and Up Study used measures mostly not 
comparable to the measures used in other surveys, and so the prevalence of within- and above-
guideline drinking could not be compared. 
The possibility of a healthier cohort means that lower rates of cancer and mortality may be observed 
than in the New South Wales general population. It also means that null associations should be 
interpreted with caution, although a previous analysis showed that majority of observed 
associations were consistent with observations from the more representative NSW PHS[10]. Overall, 
the large number of participants in the 45 and Up Study, the use of multiple measures of total 
alcohol consumption and drinking pattern and the consideration of a large number of important 
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covariates are strengths, and should enable the influence of alcohol consumption on risk of cancer 
and mortality to be examined thoroughly while ensuring that bias from confounding is minimised. 
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Chapter 6 – Co-occurrence of Chronic Disease Lifestyle Risk Factors in Middle-aged and Older 
Immigrants 
 
Chapter summary 
This chapter contains a published article, which investigated the co-occurrence of five chronic 
disease lifestyle risk factors among immigrant groups in New South Wales (NSW) compared to the 
Australian-born population. This was achieved using the Chronic Disease Risk Index (CDRI) – a tool 
developed using the NSW population with risk factors weighted according to their contribution to 
burden of disease in Australia. The rationale for this work was that lifestyle risk factors for cancer 
and chronic disease do not often occur in isolation. Alcohol consumption was examined along with 
smoking, body mass index, physical inactivity, and insufficient fruit and vegetable consumption. 
Differences in CDRI score by both region of birth and number of years lived in Australia were 
examined. Immigrant groups at lower and higher potential risk of chronic disease than the 
Australian-born population were identified. The findings of the article were presented at the 
Population Health Congress 2015 (Hobart). 
An additional set of analyses were performed that examined the distribution of drinking patterns by 
country of birth and years since migration. The CDRI incorporated a now outdated definition of 
harmful alcohol consumption and therefore the measure of alcohol consumption used in the 
published article for the CDRI was not comparable to the rest of this thesis. Differences in total 
alcohol consumption and drinking pattern and implications for the remaining chapters are discussed. 
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6.1 – Publication 
 
The following article was published in the December 2015 issue of Preventive Medicine[1]. See 
Appendix C for a breakdown of participants by country and region of birth (Table C.1), and of decade 
first migrated to Australia for at least one year by region of birth (Table C.2). 
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bining common lifestyle risk factors into aweighted chronic disease risk index (CDRI). Among64,194 immigrants
and 199,908 Australian-born participants in the 45 and Up Study (2006–2009), Poisson regression was used to
derive relative risks (RR) and 95% conﬁdence intervals (CI) for ﬁve risk factors (smoking, alcohol use, over-
weight/obesity, physical activity, diet) by place of birth adjusting for socio-demographic characteristics. Multiple
linear regression was used to determine adjusted mean differences (AMDs) in CDRI score by place of birth and
years lived in Australia.
Results. Immigrants had higher RRs of smoking than Australian-born participants, lower RRs of excessive al-
cohol consumption and overweight/obesity, and no difference in RR for physical inactivity and insufﬁcient fruit/
vegetable intake. Participants born in the Middle East/North Africa (AMD 3.5, 95% CI 2.7, 4.3), Eastern/Central
Europe (1.3, 0.8, 1.9), andWestern Europe (0.5, 0.1, 0.8) had higher mean CDRI scores than Australian-born par-
ticipants, while participants born in East Asia (−7.2,−7.8,−6.6), Southeast Asia (−6.6,−7.2,−6.1), Central/
South Asia (−3.1,−4.0,−2.1), Sub-Saharan Africa (−1.9,−2.6,−1.2) and the United Kingdom/Ireland (−0.2,
−0.5, 0.0) had lower scores. CDRI score among immigrants generally approximated that of Australian-born par-
ticipants with greater years lived in Australia.
Conclusions. This study reveals differences in potential risk of chronic disease among different immigrant
groups in Australia.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Non-communicable diseases have a major impact on premature
morbidity and mortality, comprising around 55% of the burden of
disease globally, and 85% in Australia (2010) (Murray et al., 2012a). A
large proportion of the burden comes from chronic diseases that share
many lifestyle risk factors including smoking, alcohol intake, physical
inactivity and poor diet (Australian Institute of Health and Welfare,
2014).
While the population prevalence of individual lifestyle risk factors is
routinely ascertained through national health surveys, it is important to
consider that these risk factors do not often occur in isolation. Indeed,
risk factors often cluster and can interact, where the risk of chronicW 1340, Australia.
rich),
l.com (F. Sitas),
. This is an open access article underdiseasemay be elevated above that of the sumof each risk factor consid-
ered individually (Australian Institute of Health and Welfare, 2005,
2012). Lifestyle risk factor co-occurrence has also been shown to inﬂu-
ence mortality, whereby mortality risk is proportionate to the number
of healthy lifestyle behaviours adhered to (Loef and Walach, 2012). To
better estimate chronic disease risk it is therefore necessary to study
lifestyle risk factors in combination.
Risk factor prevalence and the burden of chronic disease vary greatly
across different regions of the world (Murray et al., 2012a; World
Health Organisation, 2014). For example, in 2007–2010, 36% of the Chi-
nese population aged ≥50 years were found to have three or more
chronic disease risk factors, compared to 45% for India, 56% for Russia
and 69% for South Africa (Wu et al., 2015). In Australia (2007–2008),
itwas found that 64%of adults had at least three chronic disease risk fac-
tors, with males, those aged ≥75 years, those with disadvantaged socio-
economic status, and those living in rural areas having the greatest
proportion (Australian Institute of Health andWelfare, 2012). However,
the way in which chronic disease risk factors co-occur among peoplethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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twelve studies included in a systematic review of cardiovascular disease
risk factors among immigrant groups in Australia, only one considered
multiple risk factors together (Dassanayake et al., 2009). The
Australian population has a relatively high proportion of immigrants
(27% in 2011) and ethnic diversity (60% of immigrants originate from
non-European countries and 53% speak a language other than English
at home) (Australian Bureau of Statistics, 2012). Further, chronic dis-
ease incidence (Dassanayake et al., 2009; Hodge et al., 2004;
Supramaniam et al., 2006) and mortality (Anikeeva et al., 2011, 2015),
as well as individual risk factors (Centre for Epidemiology and
Research, 2010; Singh and de Looper, 2002; Bennett, 1993) have been
found to vary substantially in Australia by place of birth. For example,
from 1981–2007, death from lung, stomach, and bladder cancer was
more common among immigrants than the Australian-born population,
whereas immigrants were less likely to die from colorectal cancer
(Anikeeva et al., 2011). Death from cardiovascular disease was higher
among immigrants from Eastern Europe (1997–2007), but lower for
other parts of Europe, and lowest among Chinese Asians (Anikeeva
et al., 2015). In the same period, the immigrant groups with the highest
number of deaths from diabetes mellitus were those from Southern
Europe, Eastern Europe, and Southern Asia (Anikeeva et al., 2015). Un-
derstanding howmodiﬁable health behavioursmay contribute to varia-
tions in health outcomes can potentially be achieved by exploring
multiple risk factors.
There are various methods for quantifying multiple risk factors
(McAloney et al., 2013), but it is important to account for the fact that
some risk factors have stronger associations with chronic diseases
than others. The Chronic Disease Risk Index (CDRI) developed by
Miller and Bauman (2005) accounts for the proportional impact of
each risk factor on disease using a population health survey in New
South Wales (NSW), Australia (Miller and Bauman, 2005). This index
takes into account the impact of each factor on loss of disability-
adjusted life years in Australia (Miller and Bauman, 2005; Miller, 2003).
We applied this CDRI to self-reported health and lifestyle data from
the baseline questionnaire of a large cohort study inNSW, the 45 andUp
Study. We aimed to identify immigrant groups with higher or lower
CDRI than Australian-born participants, and determine how this rela-
tionship varies by number of years lived in Australia.Methods
Study sample
Baseline data from the Sax Institute's 45 and Up Study (2006–2009), a co-
hort study of 266,848 participants was used. The study is described elsewhere
(Banks et al., 2008), but brieﬂy, residents of NSW aged at least 45 years were
randomly sampled from the general population using the Medicare Australia
database. This database includes records for all citizens and permanent resi-
dents of Australia, and also some temporary residents and refugees. Persons
aged 80 and over and those living in rural and remote areas were oversampled
by a factor of two. The response rate to mailed invitations was estimated to be
18% (Banks et al., 2008). Ethics approval for the study was provided by the Uni-
versity of NSWHuman Research Ethics Committee and the Cancer Council NSW
Ethics Committee.Place of birth and years lived in Australia
Immigrants were deﬁned as persons who reported a country of birth other
than Australia. To ensure adequate sample sizes for comparison, countries of
birth were grouped into thirteen regions (see Table A.1 supplementary con-
tent). These are modiﬁed groups from the Global Burden of Disease Study and
have been used previously to analyse 45 and Up Study data (Murray et al.,
2012b; Weber et al., 2011). The regions were generated to maximise inter-
region variation and minimise intra-region variation in infant mortality and
adult morbidity and mortality (Murray et al., 2012b). Participants with missing
or invalid places of birth were excluded from the analyses. Number of yearslived in Australia was calculated using the survey date and year ﬁrst lived in
Australia for one year or more.
Chronic disease risk index (CDRI) and lifestyle risk factors
A CDRI scorewas calculated for each participant using themethods ofMiller
and Bauman (Miller and Bauman, 2005; Miller, 2003). Speciﬁcally, ﬁve self-
reported risk factors (smoking, alcohol, BMI, physical activity and fruit and
vegetable intake) were assigned values between 0 and 1 to capture the magni-
tude of associations with disability adjusted life years in Australia. These were
then summed to create a CDRI score for each participant, with higher scores
indicating greater chronic disease risk. Scores ranged from 0 to 3.8, and were
re-scaled into a 100-point scale.
BMI (calculated from self-reported height and weight (Ng et al., 2011)) and
physical activity (weekly number of sessions and time in minutes, with time
spent in vigorous activity doubled as itwas assumed to have twice themetabol-
ic equivalent value of low and moderate activity (Australian Institute of Health
andWelfare, 2003; Australian Government Department of Health, 2014)) were
assigned risk values as per the original methodology (Miller and Bauman, 2005;
Miller, 2003). Smoking status, alcohol and fruit and vegetable intake weremod-
iﬁed as described below.
Current smoking was assigned a risk value of 1, former smoking 0.5 and
never-smoking 0. We were not able to include a category for occasional
smoking (assigned a value of 0.8).
Alcohol consumption was divided into ‘low risk’ (assigned a value of 0),
‘hazardous’ (assigned 0.3), and ‘harmful’ (assigned 0.4) levels. For men this
equated to ≤4, N4 and ≤6, and N6 standard drinks per occasion respectively,
and for women, ≤2, N2 and ≤4, and N4.We used days of drinking as a substitute
for occasions of drinking.
Participants in the low tertile of fruit and vegetable intake (b3 serves of total
fruit/vegetables per day) were assigned a value of 0.4, those in the moderate
tertile (≥3 and b5 serves/day) a value of 0.2, and those in the high tertile (≥5
serves/day) a value of 0. Tertile cut-off values were based on the 2010 NSW
Population Health Survey (Centre for Epidemiology and Research, 2011).
Participants with incomplete data for any of the ﬁve lifestyle risk factors
were excluded from CDRI analyses.
Socio-demographic covariates
All socio-demographic covariates analysed are listed in Table 1. Remoteness
was derived from postcode using the Accessibility/Remoteness Index for
Australia (ARIA+ 2006) (Glover and Tennant, 2003). A missing indicator vari-
able was included for each factor.
Statistical analyses
Weexamined the distribution of socio-demographic characteristics by place
of birth. All subsequent analyses were adjusted for sex, age, remoteness, educa-
tion level, marital status, household income and health insurance status.
It has been shown that for binary outcomes, exponentiated linear coefﬁ-
cients estimated from Poisson regression provide valid estimates of adjusted
relative risk, and robust standard errors produce conﬁdence intervals that
achieve nominal coverage (Zou, 2004; Greenland, 2004; Spiegelman and
Hertzmark, 2005). Thismethod has been referred to asmodiﬁed Poisson regres-
sion, and was used to calculate the adjusted relative risk (RR) and 95% conﬁ-
dence interval (CI) of being in the highest risk category for each individual
risk factor by place of birth. That is, being a current smoker, drinking a harmful
level of alcohol, being obese, being physically inactive and being in the lowest
tertile of fruit and vegetable intake.
Multiple linear regressionwas used to determine adjustedmean differences
(AMDs) in CDRI score by place of birth and years lived in Australia. In each
regression model, place of birth and socio-demographic covariates were the
independent variables and CDRI score was the dependent variable. A test for
trend between years lived in Australia and CDRI score (using the median
value for each category of years lived in Australia: b10; 10–19; 20–29; 30–39;
≥40 years) was used for each region of birth.
Analyses were performed using SAS 9.3.
Results
266,848 participants completed the baseline questionnaire. 22
(0.008%) of these were excluded for being b45 years old. A further
Table 1
Socio-demographic characteristics by place of birth in the 45 and Up Study (2006–2009), New South Wales, Australia.
Place of birth n [%] Male
(%)
Age (mean
[SD]) (years)
Major city
resident (%)
University
degree (%)
Married or
living with
partner (%)
Household
incomea
≥$70 000
(%)
Private health
insuranceb (%)
Speak
non-English
at home (%)
Year arrived
in Australiac
(median
[IQR])
Years lived
in Australia
(median
[IQR])
Australia 199,908 [75.7] 45.4 62.5 [11.1] 39.9 21.6 74.6 24.0 67.4 2.3 – –
New Zealand 5069 [1.9] 45.5 60.5 [10.4] 51.6 26.7 72.9 32.9 59.6 3.5 1977
[1968–1985]
31.1
[22.6–39.7]
Oceania 887 [0.3] 47.0 59.3 [10.2] 72.2 22.0 74.9 22.4 55.4 55.2 1979
[1964–1988]
29.1
[19.3–44.1]
East Asia 3231 [1.2] 45.2 59.7 [11.2] 91.3 42.1 80.4 17.8 64.8 85.4 1988
[1979–1994]
19.5
[14.1–28.7]
Southeast Asia 4487 [1.7] 42.3 59.3 [10.5] 83.4 40.9 76.6 20.8 55.9 74.9 1984
[1977–1990]
24.1
[18.1–31.1]
Central &
South Asia
1357 [0.5] 60.2 61.3 [11.4] 79.7 58.0 81.1 30.1 62.6 53.4 1982
[1969–1992]
25.1
[15.4–38.3]
UK & Ireland 26,282 [10.0] 49.5 64.7 [11.3] 49.4 24.7 74.6 24.4 61.0 2.2 1966
[1958–1974]
41.3
[33.7–49.3]
Western
Europe
11,534 [4.4] 52.9 66.1 [11.1] 58.2 16.7 73.0 15.4 55.2 53.9 1959
[1953–1969]
48.3
[38.6–54.3]
Eastern &
Central
Europe
3940 [1.5] 53.1 67.4 [11.8] 73.8 21.1 67.7 12.7 49.7 66.9 1961
[1951–1971]
46.4
[36.1–56.2]
Middle East &
North Africa
2125 [0.8] 58.8 61.7 [11.0] 90.3 28.1 76.1 13.2 45.6 81.1 1973
[1966–1986]
35.1
[21.6–42.2]
Sub-Saharan
Africa
2247 [0.9] 49.0 60.1 [10.6] 68.1 44.5 80.4 39.3 72.0 23.8 1982
[1971–1994]
25.2
[13.2–36.4]
North America 1768 [0.7] 44.4 60.2 [10.2] 51.6 64.0 74.3 40.4 74.4 4.5 1975
[1969–1986]
33.1
[21.3–39.1]
Central &
South
America
1267 [0.5] 43.6 60.2 [9.5] 84.0 25.3 71.6 15.2 47.1 83.4 1975
[1971–1986]
32.1
[21.4–36.3]
Total
immigrants
64,194 [24.3] 49.5 63.5 [11.4] 60.9 27.8 74.5 22.7 58.9 31.7 1969
[1959–1982]
38.6
[25.8–48.7]
Total 264,102 [100.0] 46.4 62.7 [11.2] 45.0 23.1 74.5 23.6 65.3 9.4 – –
Percentages include participants with missing or invalid responses. SD, standard deviation. IQR, interquartile range.
a Pre-tax annual household income from all sources in Australian dollars.
b Including Department of Veterans' Affairs white or gold card.
c Year ﬁrst migrated to Australia for at least one year.
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sponses for country of birth, leaving 264,102 participants.
The socio-demographic characteristics of participants by place of
birth are shown in Table 1. Compared to Australian-born participants,
a higher proportion of immigrants were male, lived in major cities,
had university degrees and spoke a non-English language at home,
while a lower proportion of immigrants were married or living with a
partner, had an annual household income of at least $70,000
(Australian dollars), and had private health insurance. On average, im-
migrants were older than Australian-born participants. Of all regions
of birth, participants born in Western Europe immigrated the earliest,
with a median year of arrival of 1959, while participants born in East
Asia immigrated most recently, with a median year of 1988.
The proportion of participants with each individual lifestyle risk
factor is shown in Table 2. After adjusting for covariates, immigrants
overall had a signiﬁcantly higher RR of current smoking and a lower
RR of harmful alcohol consumption and obesity than Australian-born
participants.
Analyses from this point excluded 43,731 participants (16.4%) with
missing or invalid responses for at least one of the ﬁve risk factors, leav-
ing 220,371 participants. 17,273 (10.3%) Australian-born and 5659
(10.6%) immigrant participants had the lowest possible CDRI score of
0, while 32 (0.019%) Australian-born and 6 (0.011%) immigrant partic-
ipants had scores ≥90.
For each region of birth, themean CDRI score and adjustedmean dif-
ference (AMD) in CDRI score from Australian-born participants are
shown in Table 3. The contribution of each risk factor to the adjusted
mean CDRI score is shown in the supplementary content (Figure A.1).
Mean CDRI scores ranged from 14.9 for participants from East Asia to
27.7 for participants from the Middle East and North Africa. There wassigniﬁcant variation in CDRI by place of birth (p b 0.0001). Participants
born in all Asian regions, the United Kingdom (UK) and Ireland and
Sub-Saharan Africa had lower CDRI scores than Australian-born partic-
ipants. Signiﬁcantly higher CDRI scores were observed for Western
Europe, Eastern and Central Europe and the Middle East and North
Africa.
The AMD in CDRI score by 10-year strata of years lived in Australia
for each region of birth is shown in Fig. 1. 1949 (0.7%) participants
with missing or invalid responses for age of migration were excluded,
leaving 218,422 participants for these analyses. For immigrants overall,
there was a signiﬁcant increasing trend in AMD in CDRI score with
increasing years lived in Australia (p b 0.001), with those living in
Australia b10 years having an AMD of −3.4 and those living in
Australia ≥40 years having an AMD of 0.6.
A signiﬁcant increasing trend in AMD was found for participants
born in Oceania, all Asian regions, the UK and Ireland and Western
Europe, with those living in Australia b10 years having an AMD ranging
between−9.5 and−1.9, and those living in Australia ≥40 years having
an AMD ranging between−1.3 and 1.1. No signiﬁcant trends in AMD
were found for the remaining regions of birth.
Discussion
We found diversity in the co-occurrence of chronic disease lifestyle
risk factors across different immigrant groups in the 45 and Up Study
in NSW, Australia. Using the CDRI developed by Miller and Bauman,
we found that only about 10% of both Australian-born and immigrant
participants overall had the lowest possible risk of chronic disease. Par-
ticipants born in Western Europe, Eastern and Central Europe, and the
Middle East and North Africa had a mean CDRI score that potentially
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212 P.E.A. Sarich et al. / Preventive Medicine 81 (2015) 209–215puts them at greater risk of chronic disease than Australian-born par-
ticipants. We also found that participants born in all Asian regions,
the UK and Ireland, and Sub-Saharan Africa have a potentially lower
risk of chronic disease than Australian-born participants. Further, par-
ticipants born in Oceania and all Asian regions had mean CDRI scores
that converged on that of Australian-born participants with increasing
years lived in Australia. The samewas true for immigrants from the UK
and Ireland and Western Europe except for those living in Australia
≥40 years who had an estimated level of risk that slightly surpassed
that of Australian-born participants.
The distribution of individual risk factors among immigrants in our
study was similar to that reported in the NSW Population Health Sur-
vey (2006–2009) (Centre for Epidemiology and Research, 2010). For
example, people born in China had lower rates of harmful alcohol con-
sumption, smoking and obesity than the population average, but
higher rates of physical inactivity and inadequate vegetable intake.
The same pattern was observed for participants from East Asia in our
study, more than half of whomwere born in China. To our knowledge,
only one other study has examined combinations of risk factors be-
tween immigrant groups in Australia. Feng et al. (2014) derived a risk
index using unweighted, dichotomous variables in the 45 and Up
Study (Feng et al., 2014). Their index, although primarily focused on di-
etary factors, identiﬁed differences between countries within a region.
For example, of the three Eastern and Central European countries
analysed, Russia had a signiﬁcantly higher unhealthy lifestyle index
than Australian-born participants, while Croatia and Poland were not
signiﬁcantly different (Feng et al., 2014). Together with our report,
these studies highlight groups of immigrants with risky lifestyle
behaviours.
It is unclear how the health proﬁle of participants in this study may
compare to that of their country of origin. Studies comparing multiple
risk factors across countries are few. One study that directly compared
data from six countries found that multiple risk factors occurred much
more frequently in upper-middle income countries than in low-middle
income countries (Wu et al., 2015). The authors suggested that lower-
middle income countries are less likely to be exposed to risk factors as-
sociated with urban living (such as sedentary lifestyles and processed
foods). However, immigrants are often a speciﬁc sub-group of their
country of origin and are not necessarily representative of the popula-
tion they left behind. Migration policies to Australia are complex,
change over time and vary from a selection of skilled migrants using
a points system to small groups of refugees accepted on humanitarian
grounds (Statistics Section Department of Immigration and
Multicultural Affairs, 2001). As such, socioeconomic factors among im-
migrant groups, such as educational attainment, can be higher than
that of their home country (and Australian-born for that matter)
(Australian Bureau of Statistics, 2007). Nevertheless, the immigrant
groups with the lowest health risks in our study were also from low-
middle income countries (e.g., those included in East and Southeast
Asia), which suggests that some of the lifestyle patterns prior tomigra-
tion may have been maintained.
A pattern of increasing CDRI score with increasing strata of years
lived in Australia suggests that lifestyle behaviours may ‘acculturate’
for some immigrant groups, whereby immigrants tend to adopt the
health behaviours of the host population over time (Bennett, 1993;
Delavari et al., 2013). However, this was not observed for all regions
of birth, and speciﬁcally, thosewithmean CDRI scores that were higher
than Australian-born participants (i.e. immigrants from Eastern/Cen-
tral Europe and theMiddle East/North Africa). These immigrant groups
tended to have higher CDRI scores regardless of the number of years
lived in Australia. This may indicate that acculturation of health behav-
iours primarily occurs when immigrants adopt poorer health behav-
iours over time, but not the opposite. A review of acculturation and
obesity appears to support this hypothesis, ﬁnding that seven of nine
studies reported a positive association between higher acculturation
and body weight variables, while three studies reported a negative
Table 3
Chronic disease risk index (CDRI) by place of birth in the 45 and Up Study (2006–2009), New South Wales, Australia.
Place of birth Mean CDRI score (SD) Adjusteda mean difference in CDRI
score from Australian-born participants
Lower 95% CI Upper 95% CI p
Australia 23.0 (16.7) – – – –
New Zealand 22.6 (16.4) −0.5 −0.9 0.0 0.06
Oceania 22.5 (16.9) −0.9 −2.1 0.3 0.1
East Asia 14.9 (12.9) −7.2 −7.8 −6.6 b0.0001
Southeast Asia 16.0 (13.8) −6.6 −7.2 −6.1 b0.0001
Central & South Asia 18.6 (14.8) −3.1 −4.0 −2.1 b0.0001
UK & Ireland 22.5 (16.0) −0.2 −0.5 0.0 0.03
Western Europe 23.9 (16.1) 0.5 0.1 0.8 0.007
Eastern & Central Europe 24.6 (16.0) 1.3 0.8 1.9 b0.0001
Middle East & North Africa 27.7 (17.3) 3.5 2.7 4.3 b0.0001
Sub-Saharan Africa 19.6 (14.9) −1.9 −2.6 −1.2 b0.0001
North America 20.1 (15.2) −0.7 −1.5 0.1 0.08
Central & South America 23.0 (16.2) −0.3 −1.3 0.6 0.5
Total immigrants 22.0 (16.0) −0.8 −1.0 −0.6 b0.0001
Total 22.7 (16.5) – – – –
SD, Standard Deviation. CI, Conﬁdence Interval.
a Adjusted for sex, age, remoteness, education level, marital status, household income and health insurance status.
213P.E.A. Sarich et al. / Preventive Medicine 81 (2015) 209–215association in females only (Delavari et al., 2013). As well as obesity, ac-
culturation has been observed with physical activity and diet (Huang
et al., 1996; Shah et al., 2015). For example, in a study of Japanese–
American men in Hawaii it was found that those who retained a tradi-
tional Japanese diet and had spent more time living in Japan had a
lower BMI, higher physical activity levels and a healthier diet, and a re-
duced prevalence of type 2 diabetes than those who adopted a
‘Westernised’ lifestyle (Huang et al., 1996).
Possible explanations for the differences in risk factor co-occurrence
between immigrant groups are the diversity in levels of urbanisation
and socioeconomic development in low-, middle- and high-income
countries, and the rate of ‘risk transition’ from infectious disease burden
to non-communicable diseases burden over time (Wu et al., 2015;
World Health Organisation, 2009). Overweight and obesity, physical in-
activity and dietary risk factors are all associated with increased urban-
isation (Wu et al., 2015), and as low-income countries become
wealthier there tends to be an increased burden of disease attributable
to these three risk factors along with alcohol and tobacco use (World
Health Organisation, 2009). In our study, this may partially explain
why participants born in Sub-Saharan Africa and Asian regions had
lower mean CDRI scores than Australian-born participants while partic-
ipants born in American and European regions and theMiddle East and
North Africa had equal or higher CDRI scores, and the trend of increasing
CDRI score with increasing years lived in Australia.
While individual risk factor analysis is informative, it cannot be used
to estimate the overall level of chronic disease risk. For example, partic-
ipants born in the three Asian regions had relatively high RRs of physical
inactivity and inadequate fruit and vegetable intake, however they had
the lowest mean CDRI scores. Conversely, participants born in Western
Europe, Eastern and Central Europe and the Middle East and North
Africa had relatively low RRs of harmful alcohol consumption and inad-
equate fruit and vegetable intake, yet had the highestmean CDRI scores.
A cohort study in Hawaii found a dose response relationship between a
similar version of a CDRI and a number of chronic disease outcomes
(Meng et al., 1999). Although smoking accounted for over 50% of the
CDRI's impact on mortality, and BMI 25%, the effects of negative health
practises were cumulative. Therefore both individual and multiple risk
factor analyses are necessary to obtain a complete picture of chronic dis-
ease risk.
This study has several limitations. Firstly, being a cross-sectional
study, participants were not tracked over time, so it is possible that
changing health behaviours in migrants' country of origin over time
could partially explain the apparent trends, rather than acculturation.
A limitation of the 45 and Up Study is the potential for selection bias
due to the relatively low response rate (18%), where participants in cer-
tain population sub-groups, such as the highly economicallydisadvantaged, may be under-represented. Therefore caution is needed
when generalising prevalence data to the NSW population. However, a
direct comparison of the 45 and Up Study with the NSW Population
Health Survey found consistent exposure-outcome relationships be-
tween the two studies, including variables related to lifestyle behav-
iours (Mealing et al., 2010). Another limitation is that some immigrant
groups may be under-represented because the questionnaire was only
available in English. The proportion of immigrants who spoke a non-
English language at home in this study was 32%, lower than the 53% re-
ported for ﬁrst generation immigrants in the 2011 census (Australian
Bureau of Statistics, 2012). This may suggest that immigrant partici-
pants selected in this study have a higher degree of acculturation than
those in the general population of NSW, and so the AMDs in CDRI
score may be biased towards the null. Caution must therefore be
exercised when interpreting null results.
The CDRI is likely to have greater validity than most other ap-
proaches to co-occurrence analysis due to the use of multiple risk levels
and assigningweights based on impact on loss of disability-adjusted life
years, however it is not without limitations. Firstly, an assumption un-
derlying the CDRI is that multiple risk factors have an additive effect
on chronic disease, and therefore any potential multiplicative effects
are not captured. Secondly, the multiple risk levels deﬁned for alcohol
consumption and inadequate physical activity are based on nowoutdat-
ed versions of national health guidelines (Australian Government De-
partment of Health, 2014). Furthermore, the fruit and vegetable intake
risk levels are based on tertiles of intake in NSW rather than health
guidelines as for the other four risk factors. Updating the CDRI to ac-
count for current alcohol, physical activity and fruit and vegetable in-
take guidelines would conﬁrm that the risk levels used reﬂect current
evidence. Finally, a disadvantage common to all methods of co-
occurrence analysis/combining risk factors, including the CDRI, is that
they do not provide information about statistical associations between
each of the individual risk factors (McAloney et al., 2013). An alternative
method would be cluster analysis, where ascertaining the strength of
relationships between risk factorsmeans that risk factors that common-
ly occur together can be grouped and used to identify sub-populations
with qualitatively different risk proﬁles (e.g. (Grifﬁn et al., 2014)).
Conclusion
This study reveals differences in potential risk of chronic disease
across immigrant groups in Australia. These results will assist policy
makers in targeting culturally appropriate chronic disease prevention
programmes to the groups with the highest need, and the speciﬁc be-
havioural risk factors to target for maximum impact on burden of dis-
ease in different immigrant groups. Future work in this area will focus
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215P.E.A. Sarich et al. / Preventive Medicine 81 (2015) 209–215on quantifying health outcomes in relation to the CRDI over time. It will
be of interest whether the regions of birth identiﬁed in our study will
have higher than average rates of chronic disease in the future.
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Table A.1: Countries of birth in each region used in the analyses. 
Place of birth Countries 
Australia Australia 
New Zealand New Zealand 
Oceania 
 
 
Cook Islands, Fiji, French Polynesia, Kiribati, Nauru, New 
Caledonia, Niue, Papua New Guinea, Samoa, Solomon Islands, 
Tonga, Vanuatu, Wallis and Futuna 
East Asia China, Hong Kong, Japan, Macau, South Korea, Taiwan 
Southeast Asia 
 
 
Brunei Darussalam, Burma (Myanmar), Cambodia, East Timor, 
Indonesia, Laos, Malaysia, Philippines, Singapore, Sri Lanka, 
Thailand, Vietnam 
Central & South Asia 
 
Afghanistan, Armenia, Bangladesh, Georgia, India, Kyrgyz 
Republic, Mongolia, Nepal, Pakistan 
UK & Ireland Ireland, United Kingdom 
Western Europe 
 
 
Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, 
Gibraltar, Greece, Iceland, Israel, Italy, Luxembourg, Malta, 
Netherlands, Norway, Portugal, Spain, Sweden, Switzerland 
Eastern & Central Europe 
 
 
 
Albania, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, 
Czech Republic, Estonia, Hungary, Latvia, Lithuania, Moldova, 
Montenegro, Poland, Republic of Macedonia, Romania, Russia, 
Serbia, Slovakia, Slovenia, Ukraine 
Middle East & North Africa 
 
Algeria, Bahrain, Egypt, Gaza Strip and West Bank, Iran, Iraq, 
Jordan, Lebanon, Libya, Morocco, Syria, Tunisia, Turkey, Yemen 
Sub-Saharan Africa 
 
 
 
Botswana, Congo, Ethiopia, Ghana, Kenya, Lesotho, Madagascar, 
Malawi, Mauritius, Mozambique, Namibia, Nigeria, Senegal, 
Seychelles, South Africa, St Helena, Sudan, Tanzania, Uganda, 
Zambia, Zimbabwe 
North America Bermuda, Canada, United States of America 
Central & South America 
 
 
 
 
 
Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, 
Dominican Republic, Dutch West Indies, Ecuador, El Salvador, 
Falkland Islands, Guatemala, Guyana, Jamaica, Mexico, 
Netherlands Antilles, Nicaragua, Panama, Paraguay, Peru, Saint 
Vincent and the Grenadines, Suriname, Trinidad and Tobago, 
Uruguay, Venezuela 
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Figure A.1: Contribution of each risk factor to adjusted mean chronic disease risk index (CDRI) score and 95% confidence intervals (CI) by 
place of birth in the 45 and Up Study (2006-2009), New South Wales, Australia. Adjusted for sex, age, remoteness, education level, marital 
status, household income and health insurance status. aBody mass index ≥ 25 kgm-2. bCurrent and former smoking. cWeekly physical activity 
time < 150 minutes or < 5 activity sessions per week. d< 3 serves of total fruit and vegetables per day. e> 4 standard drinks per occasion if male; 
> 2 if female. 
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6.2 – Additional Analyses 
 
Additional analyses were conducted to investigate two further questions with regards to alcohol 
consumption and region of birth: 
1. How does the prevalence of alcohol consumption vary by region of birth? 
2. Do differences in alcohol consumption behaviours by region of birth acculturate with greater 
time since migration? 
Rationale and Methods. The main analysis showed that the prevalence of harmful drinking, and the 
contribution of harmful drinking to the CDRI, varied by region of birth. Additional analyses were 
conducted to investigate whether the odds of consuming > 14 alcoholic drinks per week, daily or 
near-daily drinking (consuming alcohol 6-7 days per week) and mean > 4 drinks per drinking-day 
differed by region of birth, compared to Australian-born participants. These were calculated using 
logistic regression models adjusted for all the covariates used in the main analysis, both for all 
participants and after restriction to participants classified as current drinkers (≥ 1 drink per week). 
The main analysis also suggested that health behaviours acculturate to those of the host country 
with greater time since migration. Thus, additional analyses investigated whether the odds of 
consuming > 14 alcoholic drinks per week by region of birth approximated that of Australian born 
participants with longer time since migration. These were calculated using logistic regression, 
including a test for linear trend using the median number of years lived in Australia in each category. 
Results. Immigrants from most regions of birth had lower odds of consuming > 14 drinks per week, 
having 6-7 drinking-days per week and consuming > 4 drinks per drinking-day compared to 
Australian-born participants (Table 6.1). Participants born in English-speaking countries generally 
had higher odds for all three outcomes compared to participants born in non-English speaking 
countries. Participants born in the three Asian regions, the Middle East and North Africa and Central 
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and South America generally had lower odds ratios across the three outcomes compared to other 
regions of birth. The only region of birth with higher odds for any outcome compared to Australian-
born participants was the United Kingdom and Ireland, with higher odds of both consuming > 14 
drinks per week and having 6-7 drinking-days per week (among all participants). 
When examining the odds of consuming > 14 drinks per week by time lived in Australia, there was a 
trend of increasing odds with greater number of years lived in Australia for most region of birth 
groups (Table 6.2). For participants born in the United Kingdom and Ireland there was a trend of 
decreasing odds. Only for Western Europe and English-speaking countries combined were there no 
significant trends. 
Conclusions. Immigrants in the 45 and Up Study cohort appear to have lower levels of drinking that 
Australian born participants. Additionally, drinking pattern differed by region of birth, with higher 
odds of having 6-7 drinking-days per week and consuming > 4 drinks per drinking-day for 
participants born in English-speaking countries and Australia compared to participants born in non-
English speaking countries. Further, although this is a cross-sectional study, the results suggest that 
alcohol consumption patterns among migrants may acculturate to that of Australian born 
participants. 
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Table 6.1. Odds of consuming greater than 14 drinks per week, consuming alcohol 6-7 days per 
week and consuming mean > 4 drinks per day of drinking by region of birth in the 45 and Up Study 
(2006-2009), New South Wales, Australia. 
  OR (95% CI) 
Region of birth n 
> 14 
drinks/week 
Consumed 
alcohol 6-7 
days/week 
Mean > 4 
drinks/drinking-day 
Among all participants     
Australia 196,874 1.00 1.00 1.00 
New Zealand 5,002 0.99 (0.91-1.07) 1.12 (1.05-1.20) 0.88 (0.78-0.98) 
Oceania 868 0.70 (0.56-0.87) 0.64 (0.54-0.77) 0.95 (0.74-1.23) 
East Asia 3,129 0.15 (0.12-0.19) 0.25 (0.22-0.29) 0.16 (0.12-0.23) 
Southeast Asia 4,234 0.18 (0.15-0.22) 0.26 (0.23-0.29) 0.24 (0.19-0.30) 
Central & South Asia 1,311 0.31 (0.25-0.39) 0.40 (0.34-0.48) 0.26 (0.18-0.37) 
UK & Ireland 25,914 1.07 (1.03-1.11) 1.16 (1.13-1.20) 1.00 (0.95-1.05) 
Western Europe 11,439 0.60 (0.56-0.64) 0.96 (0.92-1.01) 0.55 (0.50-0.60) 
Eastern & Central Europe 3,537 0.45 (0.40-0.52) 0.62 (0.56-0.67) 0.45 (0.37-0.55) 
Middle East & North Africa 2,041 0.16 (0.12-0.20) 0.29 (0.25-0.34) 0.16 (0.11-0.23) 
Sub-Saharan Africa 2,237 0.49 (0.42-0.57) 0.79 (0.71-0.87) 0.48 (0.39-0.61) 
North America 1,783 0.97 (0.85-1.11) 1.02 (0.92-1.14) 0.79 (0.64-0.98) 
Central & South America 1,221 0.26 (0.20-0.35) 0.64 (0.55-0.75) 0.34 (0.24-0.47) 
Majority ESCa 32,699 1.06 (1.02-1.09) 1.15 (1.12-1.18) 0.97 (0.92-1.02) 
Majority Non-ESCb 30,054 0.41 (0.39-0.43) 0.63 (0.61-0.65) 0.42 (0.39-0.44) 
Total Immigrants 62,753 0.74 (0.72-0.76) 0.90 (0.88-0.92) 0.70 (0.67-0.73) 
Among drinkers only     
Australia 133,169 1.00 1.00 1.00 
New Zealand 3,677 0.94 (0.86-1.02) 1.03 (0.96-1.11) 0.84 (0.75-0.94) 
Oceania 462 0.94 (0.74-1.18) 0.83 (0.68-1.02) 1.32 (1.01-1.74) 
East Asia 957 0.29 (0.23-0.37) 0.56 (0.48-0.65) 0.31 (0.22-0.43) 
Southeast Asia 1,341 0.33 (0.27-0.39) 0.53 (0.46-0.60) 0.43 (0.34-0.55) 
Central & South Asia 628 0.45 (0.36-0.57) 0.60 (0.50-0.71) 0.37 (0.26-0.55) 
UK & Ireland 19,016 0.99 (0.95-1.02) 1.03 (0.99-1.06) 0.93 (0.88-0.98) 
Western Europe 7,578 0.57 (0.53-0.60) 0.92 (0.88-0.97) 0.53 (0.48-0.58) 
Eastern & Central Europe 2,045 0.46 (0.40-0.52) 0.64 (0.58-0.71) 0.46 (0.38-0.56) 
Middle East & North Africa 871 0.21 (0.17-0.28) 0.41 (0.35-0.49) 0.23 (0.16-0.33) 
Sub-Saharan Africa 1,485 0.52 (0.45-0.61) 0.87 (0.78-0.98) 0.52 (0.42-0.66) 
North America 1,309 0.99 (0.86-1.14) 1.02 (0.91-1.15) 0.81 (0.65-1.01) 
Central & South America 701 0.28 (0.21-0.37) 0.72 (0.61-0.86) 0.36 (0.25-0.52) 
Majority ESCa 24,002 0.98 (0.95-1.01) 1.03 (1.00-1.06) 0.91 (0.86-0.95) 
Majority Non-ESCb 16,086 0.48 (0.46-0.50) 0.77 (0.74-0.79) 0.49 (0.45-0.52) 
Total Immigrants 40,088 0.76 (0.74-0.78) 0.92 (0.90-0.94) 0.73 (0.70-0.76) 
aCanada, Ireland, New Zealand, the United Kingdom and the United States of America. bAll other 
countries. Adjusted for sex, age, remoteness, education, household income, health insurance status 
and partner status. OR, Odds Ratio. CI, Confidence Interval. UK, United Kingdom. ESC, English-
Speaking Countries. 
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Table 6.2. Odds of consuming greater than 14 drinks per week by region of birth and time lived in Australia in the 45 and Up Study (2006-
2009), New South Wales, Australia. 
  Years lived in Australia: OR consume > 14 drinks/weeka (95% CI) 
Region of birth n < 10 years 10-19 years 20-29 years 30-39 years ≥ 40 years ptrend 
New Zealand 4,798 0.49 (0.34-0.71) 0.64 (0.49-0.84) 0.93 (0.79-1.09) 1.20 (1.04-1.39) 1.12 (0.96-1.32) < 0.001 
Oceania 837 0.33 (0.13-0.84) 0.34 (0.18-0.66) 0.70 (0.44-1.09) 0.64 (0.37-1.09) 1.07 (0.76-1.50) 0.04 
East Asia 3,045 0.13 (0.06-0.27) 0.06 (0.03-0.10) 0.09 (0.05-0.16) 0.13 (0.06-0.28) 0.55 (0.39-0.78) < 0.001 
Southeast Asia 4,089 0.02 (0.00-0.14) 0.08 (0.05-0.14) 0.12 (0.08-0.16) 0.27 (0.19-0.38) 0.54 (0.40-0.74) < 0.001 
Central & South Asia 1,273 0.08 (0.03-0.26) 0.09 (0.04-0.19) 0.32 (0.19-0.54) 0.42 (0.27-0.64) 0.73 (0.50-1.06) < 0.001 
UK & Ireland 24,844 1.18 (0.98-1.43) 1.27 (1.10-1.47) 1.17 (1.06-1.29) 1.16 (1.08-1.25) 0.99 (0.94-1.04) < 0.001 
Western Europe 10,742 1.07 (0.70-1.63) 0.57 (0.39-0.82) 0.65 (0.52-0.80) 0.58 (0.49-0.69) 0.60 (0.55-0.65) 0.68 
Eastern & Central Europe 3,277 0.27 (0.10-0.75) 0.17 (0.09-0.33) 0.22 (0.14-0.37) 0.38 (0.27-0.53) 0.57 (0.48-0.67) < 0.001 
Middle East & North Africa 1,904 0.04 (0.01-0.27) 0.10 (0.04-0.23) 0.03 (0.01-0.13) 0.12 (0.08-0.20) 0.30 (0.21-0.43) < 0.001 
Sub-Saharan Africa 2,174 0.32 (0.21-0.48) 0.22 (0.13-0.37) 0.50 (0.38-0.67) 0.58 (0.42-0.80) 0.79 (0.58-1.07) < 0.001 
North America 1,738 0.65 (0.37-1.15) 0.93 (0.65-1.33) 0.79 (0.57-1.08) 1.03 (0.82-1.30) 1.32 (1.01-1.73) 0.04 
Central & South America 1,143 0.13 (0.02-0.96) 0.13 (0.05-0.35) 0.26 (0.14-0.47) 0.24 (0.16-0.36) 0.95 (0.47-1.92) 0.001 
Majority ESCb 31,380 0.91 (0.78-1.07) 1.05 (0.93-1.19) 1.07 (0.98-1.16) 1.16 (1.09-1.23) 1.01 (0.96-1.06) 0.56 
Majority Non-ESCc 28,520 0.24 (0.19-0.31) 0.15 (0.12-0.18) 0.28 (0.25-0.32) 0.39 (0.35-0.43) 0.60 (0.56-0.64) < 0.001 
Total Immigrants 59,900 0.53 (0.46-0.60) 0.45 (0.41-0.49) 0.63 (0.59-0.68) 0.83 (0.79-0.88) 0.82 (0.79-0.86) < 0.001 
aCompared to Australian-born participants. bCanada, Ireland, New Zealand, the United Kingdom and the United States of America. cAll other 
countries. Adjusted for sex, age, remoteness, education, household income, health insurance status and partner status. OR, Odds Ratio. CI, 
Confidence Interval. UK, United Kingdom. ESC, English-Speaking Countries. 
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6.3 – Discussion and Conclusions 
 
Overall, immigrants in the 45 and Up Study had a higher odds of smoking, a lower odds of harmful 
alcohol consumption and overweight and obesity, and no difference in odds of physical inactivity 
and insufficient fruit and vegetable consumption compared to Australian-born participants. Using 
the CDRI, the regions of birth with the highest potential risk of chronic disease due the combination 
of these risk factors were the Middle East and North Africa, and Eastern and Central Europe, while 
the regions of birth with the lowest risk were East Asia, Southeast Asia and Central and South Asia. 
Further, differences in CDRI score between Australian-born participants and immigrants were largely 
attenuated with greater number of years since migration. Specifically, the risk profile of immigrants 
approximated that of the Australian-born participants the longer they had lived in Australia. 
The risk factor contributing the most to CDRI score varied by region of birth, with the largest 
contributor being either smoking, overweight and obesity or physical inactivity depending on the 
region of birth group. Interestingly, across all regions of birth, harmful alcohol consumption 
contributed the least to CDRI scores. Alcohol contributed the most to CDRI scores among Australian-
born participants and participants born in English-speaking countries. 
Several additional analyses were performed. These showed that participants born in Australia and 
English-speaking countries had higher odds of the three different measures of alcohol consumption. 
That is, consuming > 14 drinks per week, having 6-7 drinking-days per week and consuming > 4 
drinks per drinking-day compared to participants born elsewhere, even when restricted to drinkers. 
For almost all regions of birth the odds of consuming > 14 drinks per week increased with greater 
years lived in Australia. 
The identified differences in chronic disease risk factors for key immigrant groups observed here can 
be used by policy makers and health workers to monitor chronic disease outcomes for these groups 
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and potentially plan targeted chronic disease prevention and/or education programmes to achieve 
maximal public health gain. The results also suggest that lifestyle behaviours ‘acculturate’ to the host 
population for certain groups over time, but possibly in the direction of worsening health behaviours 
only. Thus, interventions could target both the groups with the highest CDRI scores overall, as well 
as the groups with low CDRI scores that may be at risk of worsening over time. For alcohol 
consumption in particular, the increasing odds of consuming > 14 drinks per week with greater years 
lived in Australia was apparent for almost every region of birth group, particularly for participants 
born in non-English speaking countries. Future studies will determine whether the observed 
differences in CDRI scores and alcohol consumption by region of birth will result in overall 
differences in mortality and other health outcomes. 
The next chapter investigated the relationship between incident health conditions and drinking 
cessation, to examine the nature of the ‘sick-quitter effect’ and potential strategies of addressing it. 
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Chapter 7 – The Association between Illness and Change in Alcohol Consumption 
 
Chapter summary 
This chapter contains an article prepared for publication, which investigated the association 
between incident disease and drinking cessation, with the aim of understanding the relative 
contributions of a variety of health conditions to the ‘sick-quitter effect’. This was examined by 
comparing the odds of quitting drinking between baseline and the 5-year follow-up questionnaire, in 
relation to the occurrence of 28 health conditions and four general indicators of health. Sensitivity 
tests were performed to determine whether associations varied by sex, age and smoking status, 
whether associations remained unchanged with mutual adjustment for other health conditions, and 
whether associations between general indicators of health and drinking cessation were accounted 
for by the occurrence of specific health conditions and vice versa. The health conditions and general 
indicators of health with the greatest impact on drinking cessation were identified, and implications 
for further research and methods of addressing the ‘sick-quitter effect’ in prospective studies were 
discussed. The findings of the article were presented at the Australasian Epidemiological Association 
Annual Scientific Meeting 2017 (Sydney) and the 45 and Up Study Annual Forum 2017 (Sydney). 
Additional analyses examined the association between incident health conditions and changes in 
drinking behaviour other than quitting (e.g. becoming a very light drinker), and a comparison of the 
effectiveness of different methods of addressing the ‘sick-quitter effect’ in reducing confounding by 
baseline health status. Implications of these results for the remaining chapters were discussed. 
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7.1 – Journal Article (Prepared for Publication) 
 
The following article is prepared for publication. The results of the main analysis are additionally 
graphed in Figure D.1 in Appendix D (this graph did not appear in the article). 
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Abstract 
Background: Prior studies have suggested that people who develop serious health conditions are 
more likely to cease drinking alcohol (the ‘sick-quitter effect’); the magnitude of this effect across a 
large range of diseases is uncertain. We quantified the ‘sick-quitter effect’ after diagnosis of a variety 
of health conditions. 
Methods: We investigated the relationship of 28 health conditions and four general indicators of 
health to ceasing alcohol consumption among 97,852 drinkers aged ≥45 years between baseline 
(2006-2009) and median 5.3 years follow-up in the New South Wales (NSW) 45 and Up Study. 
Incident health conditions at follow-up were self-reported. Logistic regression quantified odds ratios 
(OR) and 95% confidence intervals (CI) of ceasing alcohol consumption at follow-up (vs continuing), 
in relation to illness, adjusted for socio-demographic characteristics. 
Results: At follow-up, 9.6% (n=9438) of drinkers had ceased drinking. Drinking cessation was 
significantly associated with 24 of 32 health variables examined: 15.4% of participants with incident 
diabetes quit drinking (OR for quitting vs continuing 1.77, 95% CI 1.60-1.96), 16.4% with Parkinson’s 
disease (1.71, 1.35-2.17), 17.8% with poor memory (1.68, 1.43-1.97), 19.2% with hip fracture (1.64, 
1.30-2.06), 14.7% with stroke (1.45, 1.27-1.66), 12.5% with depression (1.40, 1.26-1.55), 15.0% with 
breast cancer (1.38, 1.18-1.61), 12.3% with heart disease (1.34, 1.25-1.44), and 13.3% with 
osteoarthritis (1.22, 1.12-1.33). Strong associations with quitting were observed in those with a 
decline in self-rated overall health (2.93, 2.53-3.40) and quality of life (2.68, 2.24-3.21). Findings 
were generally consistent for men and women, by age-group and by smoking status. 
Conclusions: Diagnosis with a variety of health conditions appears to prompt drinking cessation in 
older adults. Reduced general health doubles or triples the odds of quitting, and odds of cessation 
are increased by 22-77% in those who reported diabetes, Parkinson’s disease, poor memory, hip 
fracture, stroke, depression, breast cancer, heart disease and osteoarthritis. 
Word count: 300  
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Introduction 
Alcohol consumption is causally related to many health conditions, including various cancers, 
cardiovascular disease, liver disease and injury[1]. However the relationship of all-cause mortality 
and other health outcomes with alcohol is routinely reported to have a J-shaped risk curve, where 
light or moderate drinking is associated with lower risk than non-drinking and heavy drinking[2]. The 
J-shaped risk curve is often explained by the ‘sick-quitter effect’, whereby the “non-drinking” group 
appear to have a higher risk of negative health outcomes than light or moderate drinkers because it 
includes a large number of ex-drinkers, who have health conditions which both caused them to quit 
drinking and increase their risk of morbidity and mortality[2-5]. Using non-drinkers as a reference 
group in regression analyses will therefore lower the relative risk observed in drinkers. Furthermore, 
if the ‘sick-quitter effect’ is strong enough, it can produce spurious protective effect estimates 
among light and moderate drinkers, even for implausible outcomes such as hearing loss and hip 
fracture[5]. 
One method to overcome the ‘sick-quitter effect’ involves making a distinction between lifetime 
abstainers and ex-drinkers and using lifetime abstainers as the reference group; however lifetime 
abstainers also have a higher prevalence of ill-health than light and moderate drinkers which may 
also bias estimates of association[5]. Another practice in cohort studies is to exclude from the 
analysis persons who at baseline have one or more serious diseases, which may have caused them 
to quit or limit their alcohol intake. A recent meta-analysis of alcohol consumption and all-cause 
mortality found that 34 of 87 studies made exclusions for known prior disease[2]. Commonly, people 
with cancer, ischemic heart disease and stroke are excluded, although the selection of health 
conditions is inconsistent between studies, with other diseases such as thrombosis, type 2 diabetes, 
chronic obstructive pulmonary disease and liver disease also excluded[6-10]. Further, individuals 
often change their behaviour in response to feeling unwell, prior to the overt diagnosis of disease, so 
the practice of exclusion is unlikely to fully account for this issue[11, 12]. 
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There are few large prospective studies that have quantified the relative relation of health 
conditions to drinking cessation. Health conditions previously reported to be associated with 
drinking cessation (or reduction) in prospective studies included poor/declining self-rated overall 
health[13-16], cancer[15], ischaemic heart disease[17], cardiovascular disease[16], liver disease[16], 
incident hospitalisation[18], depression[13], poor psychological health[16, 19], “longstanding 
illness”[19] and beginning prescription medications including anti-neoplastic agents, anti-
thrombolytic agents and antidepressants[14]. Conversely, some studies did not find an association 
between negative health events[20], cancer[21], hypertension[16], cardiovascular disease[15], 
gastric disease[16], hospitalisation[21] and psychiatric diagnosis[21] with drinking cessation or 
reduction. One study reported differential effects by age, where younger drinkers were more likely 
to quit in relation to liver disease and older drinkers were more likely to quit in relation to 
cardiovascular disease[16]. Studies have also examined differential effects by sex[18] and smoking 
status[20]. Overall, these studies have differed in methodology and in number of participants 
(ranging from 1291 to 14,885; some were possible underpowered), and have mostly examined a 
small number of illnesses. 
The aim of this study was to use data from a large cohort study to examine how newly-acquired 
health conditions are associated with alcohol drinking cessation, while testing for interactions with 
sex, age and smoking status. 
 
Methods 
Study sample 
The Sax Institute’s 45 and Up Study, a cohort study of New South Wales (NSW) residents, was used 
for the analysis. Detailed study methods have previously been described[22]. In summary, from 2006 
to 2009 persons aged at least 45 years were randomly sampled from the Department of Human 
Services enrolment database and completed a baseline health and lifestyle questionnaire. The 
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database includes all citizens and permanent residents of Australia as well as some temporary 
residents and refugees. Persons residing in rural and remote areas and those aged 80 years and over 
were oversampled by a factor of two. Participants completed a follow-up questionnaire between 
2012 and 2016, with a response rate of 53%. The study questionnaires are available at 
https://www.saxinstitute.org.au/our-work/45-up-study/questionnaires. 
Ethics approval for the 45 and Up Study was granted by the University of NSW Human Research 
Ethics Committee and for this specific analysis by the NSW Population Health Services Research 
Ethics Committee. 
 
Ascertainment of alcohol consumption patterns 
Alcohol consumption was self-reported at baseline and follow-up with the question, “About how 
many alcoholic drinks do you have each week?”. Those who reported 0 drinks at baseline were 
excluded from the main analysis. Those who reported ≥ 1 drink per week at baseline and 0 
(indicating either no alcohol consumption or < 1 drink per week) at follow-up were considered 
quitters. Those who reported ≥ 1 drink per week at follow-up were considered continuing drinkers. 
 
Ascertainment of health conditions 
Health conditions were self-reported and included 28 health conditions and four indicators of 
general health. Participants who did not report the health condition at baseline and reported having 
the health condition at follow-up were considered a new case.  
The 28 health conditions were captured by the following questionnaire items:  
1) “Has a doctor EVER told you that you have…” female breast cancer, prostate cancer, melanoma, 
non-melanoma skin cancer, “other” cancer, heart disease, stroke, blood clot, high blood pressure 
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(except if only during pregnancy), diabetes (any type), Parkinson’s disease, enlarged prostate, 
asthma, hayfever, depression and anxiety. At follow-up the checkbox for heart disease in the 
baseline questionnaire was replaced with three checkboxes: “heart failure (cardiac failure, weak 
heart, enlarged heart)”, “atrial fibrillation” and “other heart disease”. Ticking any of these three 
checkboxes at follow-up and not baseline was counted as a new case of heart disease. 12.6% of 
participants received an early version of the questionnaire which did not include an item for 
depression or anxiety, and only one item which combined “asthma or hayfever”. These participants 
were set to missing for analyses of depression and anxiety. 2.3% of participants answered “yes” to 
“asthma or hayfever” and were set to missing for the separate analyses of asthma and hayfever.  
2) “In the last month have you been treated for…” thyroid “problems”, osteoarthritis and 
osteoporosis or low bone density.  
3) “In general, how would you rate your…” eyesight, memory, and teeth and gums (excellent/very 
good/good/fair/poor. ‘Poor’ was defined as the condition being present and all other options taken 
as the condition being absent).  
4) “Have you had a broken/fractured bone in the last 5 years?” (yes/no) for hip, and all other bones.  
5) “Do you feel you have a hearing loss?” (yes/no).  
6) “How many of your own teeth do you have left?” (0/1-9/10-19/≥ 20, with ‘0’ defined as having the 
condition of having no teeth left). 
7) “About how many times a week are you usually troubled by leaking urine?” (never/once a week or 
less/2-3 times/4-6 times/every day, with ‘2-3 times’ or more defined as the condition being present 
and once a week or less as the condition being absent). 
8) “How often are you able to get and keep an erection that is firm enough for satisfactory sexual 
activity?” (always/usually/sometimes/never/I would rather not answer the question, where ‘never’ 
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was defined as the condition being present and ‘always’, ‘usually’ or ‘sometimes’ taken as the 
condition being absent). 
The four general health indicators were poor overall health, poor quality of life, needing help with 
daily tasks, and low physical functioning, captured respectively by the following questions: 1) “In 
general, how would you rate your overall health?” (excellent/very good/good/fair/poor), with ‘poor’ 
defined as the condition being present; 1) “In general, how would you rate your quality of life?” 
(excellent/very good/good/fair/poor), with ‘poor’ defined as the condition being present; 3) “Do you 
regularly need help with daily tasks because of long-term illness or disability?” (yes/no); 4) the 
Medical Outcomes Study scale for Physical Functioning (MOS-PF) was used[23, 24] where a score of 
100 reflects good physical functioning and 0 as completely limited. A score of 50 was considered the 
critical cut-point. Participants whose score changed from ≥ 50 at baseline to below 50 at follow-up 
were defined as a new case of physical limitation. 
 
Statistical analyses 
Participants were included in the study if they were alcohol drinkers at baseline, completed both the 
baseline and follow-up questionnaire and did not have missing alcohol consumption data at baseline 
or follow-up. We first examined the distribution of socio-demographic and behavioural factors 
between those included and not included in the study. 
Descriptive statistics were then used to report the proportion of those who quit drinking in relation 
to each newly acquired health condition. For each health variable, a logistic regression model was 
used to estimate adjusted odd ratios (OR) and 95% confidence intervals (CI) of quitting drinking at 
follow-up vs. continued drinking (dependent variable) for those who developed the condition 
compared to those who did not (independent variable). Participants who already had the condition 
at baseline, or who had missing data for the condition at baseline or follow-up, were excluded from 
the analysis of that health variable. 
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All analyses were adjusted for socio-demographic characteristics; missing indicators were included 
for incomplete data. Baseline socio-demographic covariates included for analysis were sex, age (45-
54, 55-64, 65-74, 75-84, ≥ 85 years), highest level of education attained (no school certificate or 
other qualifications/school or intermediate certificate/higher school or leaving certificate/trade or 
apprenticeship/certificate or diploma/university degree or higher), annual pre-tax household income 
from all sources (< $30,000/$30,000 to $69,999/≥ $70,000 Australian dollars), health insurance 
status (none/health care concession card/Department of Veterans’ Affairs white or gold card/private 
health insurance without extras/private health insurance with extras), partner status (married or 
living with partner/not), country of birth (Australia/Canada, Ireland, New Zealand, United Kingdom 
or United States/other) and remoteness of residence. Remoteness was derived from postcode using 
the Accessibility/Remoteness Index for Australia (ARIA+ 2006)[25]. 
To investigate whether the associations between each of the general health indicators (i.e., poor 
overall health, poor quality of life, needing help with daily tasks and low physical functioning score) 
with drinking cessation could be wholly accounted for by the selected 28 health conditions, we 
assessed how much the odds ratios were attenuated (towards the null) by incremental, additional 
adjustment for each of the 28 conditions (condition present at baseline/no condition at baseline or 
follow-up/condition at follow-up but not baseline/missing indicator). We also examined whether 
associations between quitting and each of the health conditions persisted when analyses were 
restricted to participants with good self-rated overall health and good general health indicators at 
follow-up. In sensitivity analyses, we investigated the effect of restricting the analysis to participants 
who had good, very good or excellent self-rated health at baseline and the extent to which 
relationships between quitting and health could be accounted for by poor self-rated health, by 
adjusting for poor overall health (poor health present at baseline/no poor health at baseline or 
follow-up/poor health at follow-up but not baseline/missing indicator). 
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Further sensitivity analyses addressed a number of possible interpretations of the data. 1) To assess 
the extent to which associations between illness and quitting drinking were explained by the 
presence/occurrence of other health conditions, we adjusted for all other health conditions 
concurrently. This analysis included participants who had health conditions at baseline, resulting in 
four categories for each health condition covariate (i.e., health condition present at baseline/no 
condition at baseline or follow-up/condition at follow-up but not baseline/missing indicator). The 
four general health indicators, as well as depression and anxiety were not included in this analysis. 2) 
To assess whether relationships between quitting and illness were affected by drinking intensity, we 
included number of drinks per week reported at baseline as a covariate. 3) To assess the extent to 
which associations could be explained by other lifestyle risk factors, we adjusted for a number of key 
risk factors at baseline. These were smoking status (never-smoker/ex-smoker/current smoker), body 
mass index (BMI; underweight, < 18.5 kgm-2/normal range, ≥ 18.5 and < 25 kgm-2/overweight, ≥ 25 
and < 30 kgm-2/obese, ≥ 30 kgm-2), fruit consumption (< 1 serve/≥ 1 and < 2 serves/≥ 2 serves per 
day), vegetable consumption(< 3 serves/≥ 3 and < 5 serves/≥ 5 serves per day), and physical activity 
(0 min/> 0 and < 150 min/≥ 150 and < 300 min/≥ 300 min per week). Physical activity time was 
weighted according to the Active Australia Survey, with each minute of walking or moderate 
intensity physical activity counted as one minute and each minute of vigorous intensity physical 
activity counted as two minutes[26]. 
We tested for 2-way statistical interactions (p < 0.05) between each health variable and sex, age (45-
64 or ≥ 65 years) and smoking status (ever/never smoked), and then examined potential differences 
in stratified analyses where appropriate. 
A significance level of 5% was used in all analyses. Analyses were performed using SAS 9.4. 
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Results 
266,878 participants completed the baseline questionnaire (Table 1), of whom 142,492 (53%) 
completed the follow-up questionnaire. Of participants with complete follow-up, those with missing 
information on alcohol consumption were excluded (4535, 3.2%) and a further 40,105 (28.1%) were 
non-drinkers at baseline and therefore excluded, leaving 97,852 (49,699 men and 48,153 women, 
median baseline age 59 years) participants in the study. Of the included participants, the median 
follow-up time was 5.3 years (Q1-Q3, 5.1-7.9 years; range: 1.6 to 10.7 years). 
Overall, 9.6% of drinkers had ceased alcohol consumption at follow-up. Compared to participants 
who continued drinking, participants who quit drinking were slightly older on average and a higher 
proportion were women. At baseline, a lower proportion of quitters held a university degree, had an 
annual household income ≥ $70,000, held private health insurance and consumed > 14 alcoholic 
drinks per week compared to those who continued drinking. All health variables had < 5% missing 
data at baseline and/or follow-up, except for poor quality of life (5.3%), physical functioning score 
(11.1%), depression (12.6%), anxiety (12.6%), and erectile dysfunction (16.6%). 
The proportion of new cases of the 28 health conditions who quit drinking varied from 8.4% of men 
with newly acquired erectile dysfunction to 19.2% of men and women who broke or fractured their 
hip (Table 2). Three of the four general health indicators had the highest proportions of new cases 
quitting drinking, with 27.3% of those reporting a decline in their overall health to poor ceasing 
alcohol consumption, as well as 26.6% of those reporting a decline in their quality of life to poor, and 
20.3% of those reporting a change to needing regular help with daily tasks. Of those who quit 
drinking, 73% reported at least one new health condition, compared to 67% of those who continued 
drinking. 
Of the 32 health variables examined, 24 were significantly associated with cessation (Table 3). Strong 
associations with quitting were found for all four of the general health indicators and for specific 
health conditions including diabetes, Parkinson’s disease, poor memory and a broken/fractured hip. 
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Some common conditions that were also positively associated with quitting included breast cancer, 
other cancer, heart disease, stroke, osteoarthritis and depression, while for others such as prostate 
cancer, melanoma, non-melanoma skin cancer, asthma and hearing loss there was no significant 
association. No conditions were inversely associated with cessation. For all four general health 
indicators, the odds ratios of quitting were attenuated by the inclusion of all other health conditions 
in the models but remained significant (Table 4). Restriction to participants with good overall health 
at follow-up tended to attenuate all point estimates (Table 3). Restriction of analyses to participants 
with good general health indicators at follow-up further attenuated most associations. 
The relationship of drinking cessation according to each of the health variables was broadly similar 
for men and women, across different age groups and among ever- and never-smokers (see 
Supplementary material), with a small number of exceptions. Of 92 tests for statistical interaction, 
10 yielded statistically significant results. Bearing the number of statistical tests conducted in mind, 
significant statistical interactions were found for three health conditions by sex, where the 
relationship between diagnosis and quitting differed significantly between men and women: high 
blood pressure, urine leakage, and osteoporosis/osteopenia (Supplementary Table 1). For two 
conditions, the odds of quitting in relation to health variables were significantly higher among older 
versus younger participants: heart disease and erectile dysfunction (Supplementary Table 2). For 
four conditions, odds ratios were significantly attenuated in older versus younger participants: 
asthma, poor teeth and gums, needing help with daily tasks, and low physical functioning score. 
Differences by smoking status were only observed for broken/fractured other bone (Supplementary 
Table 3). 
Adjusting for baseline drinking intensity and other lifestyle risk factors, and restricting analyses to 
persons with excellent/very good/good self-rated health at baseline did not materially alter OR 
estimates. Additionally, adjusting for the occurrence of the other specific health conditions 
ascertained in our study tended to attenuate OR point estimates slightly, however all remained 
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significant independent predictors of quitting except osteoporosis/osteopenia and poor teeth and 
gums. Adjusting for poor overall health tended to attenuate OR point estimates but all effects 
remained statistically significant (Supplementary Table 4). 
 
Discussion 
In this study, individuals diagnosed with a wide range of illnesses and/or having indicators of 
declining health were consistently more likely to quit drinking alcohol than those remaining in good 
health. Most of the 32 health variables were associated with quitting, and a decline in self-rated 
health to ‘poor’ was associated with almost triple the odds of drinking cessation. The health 
conditions associated with cessation were diverse and included diabetes, Parkinson’s disease, poor 
memory, hip fracture, stroke, depression, breast cancer, heart disease and osteoarthritis. 
The relationship of drinking cessation with the occurrence of new health conditions was broadly 
similar for men and women, and by smoking status at baseline, however a few differences by age 
were detected. Relationships between the 28 health conditions and quitting persisted even when 
analyses were restricted to participants with good overall health and/or good general health 
indicators at follow-up. Similarly, adjusting for all 28 health conditions attenuated but did not 
eliminate the association of each general health indicator to drinking cessation completely. 
While previous research has demonstrated that socio-demographic factors, such as older age, low 
levels of education, lower income and retirement are associated with drinking cessation[16], the 
relative impact of specific health conditions is far less clear. Our results are consistent with 
prospective studies showing that drinking cessation (or reduction) is associated with cardiovascular 
disease[16] and ischaemic heart disease[17], and also with one study that reported increased odds 
of drinking cessation in relation to commencing certain medications to treat disease[14]. There are 
however inconsistencies between some of our results and prior research, as not all studies have 
reported significant decreased drinking for the health conditions we examined, including for 
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cardiovascular disease[15]. Our effect estimates for cancer (the highest of which was an odds ratio 
of 1.51) were also lower than one study examining all cancers combined, which found an odds ratio 
of almost four[15]. Differences in findings between studies could be explained by the diversity in 
study populations (including by health behaviours and health status), sample sizes, length of follow-
up, use of prevalent vs. incident disease as the exposure, use of drinking reduction vs. cessation as 
the outcome, use of abstention as the base outcome group rather than continued drinking (e.g.[21]), 
and the covariates included for adjustment (e.g., adjusting for self-rated overall health[16]). 
Indicators of general health such as self-rated overall health are often included in epidemiological 
questionnaires, and are useful because they are simple measures of health status that can be 
applied across different populations. We chose to examine a decline in overall health to poor, 
finding a strong association with drinking cessation. A number of previous studies have also reported 
associations with drinking cessation or reduction for various measures of overall health, including for 
less than very good health at baseline[16], fair or poor health at baseline[14], continuing fair or poor 
health[13] and a decline in health to fair or poor[13]. Not all studies reported a positive association 
however. One study examining worsened perceived health reported an inverse association with 
drinking cessation (0.77, 0.63-0.93)[15], while another examining and an index of 27 negative health 
events at baseline reported no significant association (however with only 1291 participants this was 
the smallest study, and may have been underpowered)[20]. Differences in findings between studies 
could reflect the use of differing general health indicator measures as the exposure, as well as the 
same factors responsible for differences in results for specific health conditions. 
We have shown that a large number of health conditions may lead to the ‘sick-quitter effect’ for 
alcohol consumption, however there may be others which also contribute. We were not able to 
examine all possible health conditions, and the persistence of associations between the general 
health indicator variables and drinking cessation after adjustment for all other health conditions 
confirms that there are other health conditions not diagnosed or not examined here that also lead to 
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quitting. Some notable omissions from our study were chronic obstructive pulmonary disease, liver 
disease and kidney disease, which have been considered possible sources of bias in studies of 
alcohol consumption and mortality[6, 9]. Therefore there are likely several other health conditions 
not examined here that should be taken into account when addressing the ‘sick-quitter effect’. 
The exclusion of participants with health conditions or poor indicators of general health at baseline 
in studies of alcohol and health has both advantages and disadvantages. The quantity and breadth of 
health conditions related to drinking cessation found here and elsewhere suggests that the exclusion 
of participants with specific diseases at baseline in observational studies where alcohol is the 
exposure of interest is not practical and may only be partially effective in mitigating the ‘sick-quitter 
effect’. For example, restricting an analysis to participants without any of the 24 significant health 
conditions reported here at baseline in the 45 and Up Study would mean excluding 76% of 
participants. The use of general health indicator variables such as self-rated overall health status is 
likely to be a better strategy to capture a person’s total disease experience rather than focusing on 
specific health conditions; in our study this was also a better predictor of drinking cessation. For 
example, 14.2% of participants reported fair or poor self-rated health at baseline in the 45 and Up 
Study. It should be noted however, that when we restricted our analyses to participants with good 
overall health or good general health indicators at follow-up, although the associations between 
quitting and health conditions were attenuated, many of the health conditions remained significant 
predictors of quitting. Thus, accounting for general health indicators may not be a completely 
adequate method of addressing the ‘sick-quitter effect’. 
Another disadvantage of excluding participants with a health condition or poor health status at 
baseline is the potential for selection bias and the inducement of false J-shaped associations[27]. 
This is because the exclusion could create confounding between alcohol consumption and other risk 
factors for the outcome (e.g. cardiovascular disease risk factors if the outcome is cardiovascular 
disease). Alternative methods of addressing the ‘sick-quitter effect’ have been considered, including 
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using lifetime abstainers or light drinkers (or both) as the reference group[3, 28], calculating a log-
linear trend in risk for drinkers only[29], assigning ex-drinkers to their former levels of drinking at 
analysis[30], ascertaining alcohol consumption at multiple time points (either retrospectively or 
prospectively from baseline)[10, 31] and excluding outcomes that occur early in the period of follow-
up[9]. As the prevalence of fair or poor health increases with age[30], another option may be to 
restrict the study to younger participants who have had fewer health events causing them to reduce 
or quit drinking. For instance, 63% of participants aged 45-54 years in the 45 and Up Study reported 
any one of the 24 health conditions related to quitting at baseline compared to 95% of participants 
aged ≥ 75 years. These alternative methods of addressing the ‘sick-quitter effect’ could be used to 
avoid the potential for selection bias arising from exclusion. 
Strengths of this study include the prospective design, large sample size, the consideration of a large 
number of health conditions and the use of incident rather than prevalent illness, allowing for 
appraisal of the relative relation of many health conditions and general health indicators to drinking 
cessation. A limitation is that 53% of participants had completed follow-up, which has potential to 
bias the results. Specifically, participants who developed more severe disease may have been less 
likely to complete the follow-up questionnaire, and more likely to quit drinking, which may mean our 
estimates are conservative. Further, persons who participate in cohort studies may be more health 
conscious than the general population, and so might reduce their drinking to a greater degree in 
response to incident health conditions. This may also mean that heavy drinkers are 
underrepresented in our analysis, however we found that adjusting for baseline levels of alcohol 
consumption did not materially alter our results. It has also been shown that participants tend to 
underreport alcohol consumption[32], meaning that the proportion of participants who quit drinking 
may be overestimated for both participants with and without incident health conditions, possibly 
biasing the odds ratios towards the null hypothesis if the error was non-differential. On the other 
hand, as participants were instructed to write ‘0’ for alcohol consumption if they consumed less than 
one alcoholic drink per week, the proportion of participants who ceased drinking is likely to be 
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overestimated as some participants who became occasional drinkers will be misclassified as quitters. 
Again, if this misclassification was non-differential then it would be expected to bias the results 
towards the null hypothesis. Our results are also based on self-reported health outcomes, and 
therefore there may have been misclassification for some health conditions. This is especially true 
for conditions such as melanoma and non-melanoma skin cancer which are known to be reported 
inaccurately[33, 34]. 
The median follow-up period of participants included in our analysis was 5.3 years, however both 
the onset of illness and the decision to quit drinking could have occurred at any time between 
baseline and follow-up, and in any order. Our results suggest that the onset of disease could 
motivate an individual to improve their lifestyle behaviours[35], however we could not determine 
whether the decision to cease drinking was due to the onset of symptoms or the fact of diagnosis, or 
both. Finally, we were not able to capture those who may have quit in relation to a diagnosis early 
on in the study period but then restarted drinking by the point of follow-up. It would be of interest 
for future studies to examine follow-up at multiple time periods to investigate changes in 
consumption patterns in relation to the time of diagnosis, and the extent to which participants 
maintain their drinking cessation over longer time periods. 
In conclusion, we provide evidence that the onset of a range of health conditions is associated with 
drinking cessation and therefore provide evidence for a widespread ‘sick-quitter effect’. Alcohol 
consumption patterns are closely related to illness in a way that is likely to affect risk estimates for 
associations between alcohol and disease. Importantly, many health conditions were moderately or 
strongly associated with cessation, and not just health conditions commonly accounted for in studies 
of alcohol consumption such as cancer, ischaemic heart disease and stroke. Adjusting for the 
occurrence of specific health conditions did not completely remove associations between indicators 
of general health and drinking cessation, nor did adjusting for poor overall health. The breadth of 
health conditions related to drinking cessation is large enough that observational studies with 
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alcohol consumption as the exposure should use means other than the exclusion of specific health 
conditions to mitigate the ‘sick-quitter effect’. There is a need for further large prospective cohort 
studies of incident health conditions and changes in drinking to replicate these findings in different 
populations, and to examine drinking trajectory across multiple time points, and during the course of 
a lifetime. 
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Tables 
 
Table 1. Distribution of socio-demographic and behavioural characteristics in the 45 and Up Study (2006-2016), New 
South Wales, Australia for those who did and did not complete the follow-up questionnaire and those who did and did 
not quit alcohol consumption at follow-up. 
Characteristic at baseline 
Completed baseline 
questionnaire 
(n=266,878) 
Completed follow-
up questionnaire  
(n=142,492) 
Included in 
analysisa 
(n=97,852) 
Continued 
drinking 
(n=88,414) 
Quit 
drinking 
(n=9438) 
Male (%) 46.4 44.8 50.8 51.9 40.8 
Mean age (SD) 62.7 (11.2) 60.8 (9.7) 60.2 (9.4) 60.0 (9.2) 62.0 (10.2) 
Major city resident (%) 52.2 50.3 50.5 50.8 47.8 
University degree (%) 23.1 28.5 31.9 32.6 24.5 
Household income ≥ $70,000b (%) 23.5 29.5 34.7 36.1 21.5 
Private health insurancec (%) 65.2 71.0 75.3 76.4 65.1 
Married or living with partner (%) 74.4 78.3 81.0 81.8 74.1 
Born in Australia (%) 74.9 77.9 78.2 78.2 77.8 
Ever-smoker (%) 43.0 40.6 45.0 45.3 42.5 
Overweight or obesed (%) 57.1 57.6 57.4 57.2 59.9 
Inadequate physical activitye (%) 21.6 17.3 15.4 14.9 19.2 
< 2 fruit serves per dayf (%) 41.5 39.9 41.8 42.3 37.6 
< 5 vegetable serves per day (%) 66.0 65.9 67.1 67.5 63.9 
> 14 alcoholic drinks per week (%) 14.0 14.9 21.5 23.1 6.0 
Percentages include participants with missing or invalid responses. aCompleted follow-up questionnaire, alcohol 
consumption data not missing and consumed ≥ 1 alcoholic drink per week at baseline. bPre-tax annual household 
income from all sources in Australian dollars. cIncluding Department of Veterans’ Affairs white or gold card. dBody mass 
index ≥ 25 kgm-2. eWeekly physical activity time < 150 weighted minutes, with each minute of walking or moderate 
intensity physical activity counted as one minute and each minute of vigorous intensity physical activity counted as two 
minutes. fExcludes fruit juice. SD, Standard Deviation. 
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Table 2. Proportion of participants in the 45 and Up Study (2006-2016), New South 
Wales, Australia who reported quitting alcohol consumption at follow-up by 
selected health variables. 
 
 
 
 
Condition not 
present at baseline 
or follow-up 
 Condition not present 
at baseline but 
present at follow-up 
 n n quit (%)  n n quit (%) 
Health conditions      
Cancer      
  Breast cancer (women) 44,524 5100 (11.5)  1307 196 (15.0) 
  Prostate cancer (men) 44,606 3368 (7.6)  2667 229 (8.6) 
  Melanoma 89,064 8569 (9.6)  3511 334 (9.5) 
  Non-melanoma skin cancer 60,673 5978 (9.9)  10,343 969 (9.4) 
  Other cancer 88,542 8217 (9.3)  4327 630 (14.6) 
Cardiovascular disease      
  Heart disease 79,323 7178 (9.0)  9383 1153 (12.3) 
  Stroke 94,362 8909 (9.4)  1840 271 (14.7) 
  Blood clot 92,507 8723 (9.4)  1893 255 (13.5) 
  High blood pressure 56,459 5071 (9.0)  9861 908 (9.2) 
Endocrine conditions      
  Diabetes  89,177 8097 (9.1)  3269 502 (15.4) 
  Thyroid problems 90,932 8501 (9.3)  2416 333 (13.8) 
Genitourinary conditions      
  Leaking urine > 1 time per week 73,946 6526 (8.8)  7577 913 (12.0) 
  Enlarged prostate (men) 37,619 2678 (7.1)  4598 415 (9.0) 
  Erectile dysfunction (men) 28,895 1747 (6.0)  6600 556 (8.4) 
Conditions affecting mobility      
  Parkinson’s disease 97,059 9302 (9.6)  517 85 (16.4) 
  Osteoarthritis 86,553 7962 (9.2)  5240 699 (13.3) 
  Osteoporosis/osteopenia 90,489 8450 (9.3)  3319 439 (13.2) 
  Broken/fractured hip 97,156 9319 (9.6)  495 95 (19.2) 
  Broken/fractured other bone 81,061 7743 (9.6)  7546 738 (9.8) 
Mental health conditions      
  Depression 69,921 6163 (8.8)  3775 472 (12.5) 
  Anxiety 73,693 6630 (9.0)  4296 549 (12.8) 
  Poor memory 92,165 8681 (9.4)  1126 200 (17.8) 
Other conditions      
  Asthma 83,055 7833 (9.4)  2782 301 (10.8) 
  Hayfever 76,499 7321 (9.6)  5219 508 (9.7) 
  Hearing loss 44,416 4166 (9.4)  10,216 997 (9.8) 
  Poor eyesight 92,380 8711 (9.4)  869 148 (17.0) 
  Poor teeth and gums 88,238 8092 (9.2)  1548 228 (14.7) 
  No teeth left 89,342 8295 (9.3)  852 144 (16.9) 
General health indicators      
  Poor overall health 92,368 8594 (9.3)  971 265 (27.3) 
  Poor quality of life 91,433 8588 (9.4)  655 174 (26.6) 
  Need regular help with daily tasks 87,366 7740 (8.9)  4146 841 (20.3) 
  Physical functioning score < 50% 78,984 6542 (8.3)  4332 816 (18.8) 
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Table 3. Odds ratios (OR) and 95% confidence intervals (CI) of quitting drinking by newly acquired 
health conditions among participants with good general health indicators at follow-up in the 45 
and Up Study (2006-2016), New South Wales, Australia. 
aExcellent, very good or good overall health at follow-up. bExcellent, very good or good overall health 
and quality of life, do not need regular help with daily tasks and physical functioning score ≥ 50% at 
follow-up. Adjusted for sex, age, remoteness, education, household income, health insurance status, 
partner status and country of birth. 
Health conditions 
OR quit drinking (95% CI) 
Main analysis 
Restricted to good 
overall health at 
follow-upa 
Restricted to good 
general health 
indicators at follow-upb 
Cancer    
  Breast cancer (women) 1.38 (1.18-1.61) 1.35 (1.13-1.62) 1.38 (1.13-1.68) 
  Prostate cancer (men) 1.05 (0.91-1.21) 0.96 (0.81-1.14) 0.91 (0.75-1.11) 
  Melanoma 1.00 (0.89-1.12) 0.95 (0.83-1.09) 0.84 (0.71-0.99) 
  Non-melanoma skin cancer 0.94 (0.88-1.01) 0.93 (0.86-1.01) 0.93 (0.85-1.02) 
  Other cancer 1.51 (1.38-1.65) 1.39 (1.24-1.55) 1.32 (1.16-1.49) 
Cardiovascular disease    
  Heart disease 1.34 (1.25-1.44) 1.23 (1.13-1.34) 1.16 (1.06-1.28) 
  Stroke 1.45 (1.27-1.66) 1.34 (1.13-1.60) 1.10 (0.88-1.38) 
  Blood clot 1.39 (1.22-1.60) 1.26 (1.06-1.49) 1.16 (0.95-1.42) 
  High blood pressure 0.98 (0.91-1.05) 0.97 (0.89-1.06) 0.99 (0.90-1.08) 
Endocrine conditions    
  Diabetes  1.77 (1.60-1.96) 1.61 (1.42-1.82) 1.52 (1.32-1.76) 
  Thyroid problems 1.32 (1.17-1.49) 1.29 (1.12-1.48) 1.29 (1.11-1.51) 
Genitourinary conditions    
  Leaking urine > 1 time per week 1.20 (1.11-1.29) 1.13 (1.03-1.23) 1.07 (0.97-1.19) 
  Enlarged prostate (men) 1.22 (1.09-1.37) 1.16 (1.02-1.32) 1.17 (1.01-1.36) 
  Erectile dysfunction (men) 1.29 (1.16-1.43) 1.20 (1.06-1.35) 1.18 (1.03-1.34) 
Conditions affecting mobility    
  Parkinson’s disease 1.71 (1.35-2.17) 1.45 (1.05-2.00) 1.26 (0.84-1.91) 
  Osteoarthritis 1.22 (1.12-1.33) 1.17 (1.05-1.29) 1.10 (0.97-1.25) 
  Osteoporosis/osteopenia 1.16 (1.05-1.29) 1.08 (0.95-1.22) 1.00 (0.86-1.16) 
  Broken/fractured hip 1.64 (1.30-2.06) 1.51 (1.11-2.04) 1.29 (0.82-2.02) 
  Broken/fractured other bone 0.95 (0.88-1.03) 0.89 (0.81-0.98) 0.85 (0.76-0.94) 
Mental health conditions    
  Depression 1.40 (1.26-1.55) 1.32 (1.17-1.49) 1.28 (1.11-1.48) 
  Anxiety 1.38 (1.26-1.52) 1.40 (1.25-1.56) 1.32 (1.16-1.50) 
  Poor memory 1.68 (1.43-1.97) 1.53 (1.21-1.92) 1.73 (1.30-2.32) 
Other conditions    
  Asthma 1.07 (0.94-1.21) 1.10 (0.95-1.27) 1.14 (0.97-1.34) 
  Hayfever 0.99 (0.90-1.09) 0.99 (0.89-1.11) 0.99 (0.88-1.12) 
  Hearing loss 1.05 (0.97-1.13) 1.05 (0.97-1.14) 1.02 (0.93-1.12) 
  Poor eyesight 1.50 (1.25-1.79) 1.33 (1.03-1.73) 1.35 (0.98-1.87) 
  Poor teeth and gums 1.35 (1.17-1.57) 1.21 (0.99-1.47) 1.41 (1.13-1.76) 
  No teeth left 1.51 (1.26-1.82) 1.57 (1.26-1.97) 1.55 (1.18-2.02) 
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Table 4. Odds ratios (OR) and 95% confidence intervals (CI) of quitting drinking among participants whose general health indicators declined to 
poor at follow-up, with adjustment for selected health conditions in the 45 and Up Study (2006-2016), New South Wales, Australia. 
aBreast cancer, prostate cancer, melanoma and other cancer, except not non-melanoma skin cancer. bBreast cancer, other cancer (except 
prostate cancer, melanoma and non-melanoma skin cancer), heart disease, stroke, blood clot, diabetes, thyroid problems, leaking urine > 1 time 
per week, enlarged prostate, erectile dysfunction, Parkinson’s disease, osteoarthritis, osteoporosis/osteopenia, broken/fractured hip, poor 
memory, poor eyesight, poor teeth and gums and having no teeth left. All models adjusted for sex, age, remoteness, education, household 
income, health insurance status, partner status and country of birth. 
 
 
 
 
 OR quit drinking (95% CI) 
Adjustment factors 
Poor overall 
health 
Poor quality of 
life 
Need regular help 
with daily tasks 
Physical functioning 
score < 50% 
Sociodemographic variables only (main analysis) 2.93 (2.53-3.40) 2.68 (2.24-3.21) 1.96 (1.81-2.13) 2.00 (1.84-2.18) 
Cancera, heart disease and stroke 2.64 (2.27-3.06) 2.50 (2.08-2.99) 1.84 (1.70-2.01) 1.91 (1.75-2.08) 
All significant health conditions except depression and anxietyb 2.13 (1.83-2.49) 2.03 (1.69-2.44) 1.63 (1.49-1.78) 1.71 (1.57-1.87) 
All health conditions except depression and anxiety 2.12 (1.82-2.47) 2.04 (1.69-2.45) 1.63 (1.49-1.78) 1.71 (1.56-1.87) 
All health conditions including depression and anxiety 2.09 (1.79-2.44) 1.96 (1.63-2.36) 1.60 (1.47-1.75) 1.68 (1.54-1.84) 
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Supplementary data 
 
Supplementary Table 1. Odds ratios (OR) and 95% confidence intervals (CI) of quitting drinking at 
follow-up by health conditions newly acquired between baseline and follow-up by sex in the 45 
and Up Study (2006-2016), New South Wales, Australia. 
Adjusted for age, remoteness, education, household income, health insurance status, partner status 
and country of birth. 
 
 
 
OR quit drinking (95% CI) 
Main analysis Men Women pinteraction 
Health conditions     
Cancer     
  Melanoma 1.00 (0.89-1.12) 1.02 (0.87-1.19) 0.97 (0.82-1.16) 0.62 
  Non-melanoma skin cancer 0.94 (0.88-1.01) 0.87 (0.78-0.98) 1.00 (0.90-1.10) 0.17 
  Other cancer 1.51 (1.38-1.65) 1.59 (1.40-1.82) 1.44 (1.27-1.62) 0.18 
Cardiovascular disease     
  Heart disease 1.34 (1.25-1.44) 1.40 (1.27-1.55) 1.28 (1.16-1.42) 0.07 
  Stroke 1.45 (1.27-1.66) 1.40 (1.17-1.66) 1.50 (1.22-1.85) 0.91 
  Blood clot 1.39 (1.22-1.60) 1.58 (1.30-1.91) 1.24 (1.02-1.50) 0.06 
  High blood pressure 0.98 (0.91-1.05) 0.84 (0.75-0.95) 1.08 (0.98-1.20) 0.002 
Endocrine conditions     
  Diabetes 1.77 (1.60-1.96) 1.67 (1.45-1.91) 1.90 (1.64-2.20) 0.20 
  Thyroid problems 1.32 (1.17-1.49) 1.33 (1.01-1.75) 1.32 (1.15-1.51) 0.90 
Genitourinary conditions     
  Leaking urine > 1 time per week 1.20 (1.11-1.29) 1.42 (1.27-1.59) 1.06 (0.96-1.18) < 0.001 
Conditions affecting mobility     
  Parkinson’s disease 1.71 (1.35-2.17) 1.84 (1.35-2.50) 1.55 (1.06-2.25) 0.42 
  Osteoarthritis 1.22 (1.12-1.33) 1.22 (1.06-1.42) 1.23 (1.11-1.37) 0.72 
  Osteoporosis/osteopenia 1.16 (1.05-1.29) 1.48 (1.20-1.83) 1.09 (0.96-1.23) 0.005 
  Broken/fractured hip 1.64 (1.30-2.06) 1.57 (1.07-2.31) 1.71 (1.28-2.29) 0.97 
  Broken/fractured other bone 0.95 (0.88-1.03) 1.03 (0.89-1.18) 0.92 (0.83-1.01) 0.16 
Mental health conditions     
  Depression 1.40 (1.26-1.55) 1.55 (1.33-1.82) 1.30 (1.14-1.49) 0.09 
  Anxiety 1.38 (1.26-1.52) 1.49 (1.27-1.76) 1.33 (1.18-1.49) 0.27 
  Poor memory 1.68 (1.43-1.97) 1.69 (1.38-2.08) 1.64 (1.28-2.11) 0.63 
Other conditions     
  Asthma 1.07 (0.94-1.21) 1.09 (0.89-1.33) 1.05 (0.90-1.23) 0.77 
  Hayfever 0.99 (0.90-1.09) 0.99 (0.84-1.17) 0.99 (0.88-1.12) 0.99 
  Hearing loss 1.05 (0.97-1.13) 1.02 (0.90-1.15) 1.07 (0.97-1.18) 0.56 
  Poor eyesight 1.50 (1.25-1.79) 1.74 (1.35-2.26) 1.32 (1.02-1.71) 0.07 
  Poor teeth and gums 1.35 (1.17-1.57) 1.33 (1.09-1.62) 1.37 (1.11-1.70) 0.99 
  No teeth left 1.51 (1.26-1.82) 1.59 (1.24-2.02) 1.41 (1.06-1.87) 0.40 
General health indicators     
  Poor overall health 2.93 (2.53-3.40) 2.85 (2.34-3.47) 2.98 (2.39-3.72) 0.98 
  Poor quality of life 2.68 (2.24-3.21) 2.67 (2.11-3.38) 2.68 (2.03-3.54) 0.82 
  Need regular help with daily tasks 1.96 (1.81-2.13) 2.05 (1.81-2.33) 1.92 (1.72-2.15) 0.08 
  Physical functioning score < 50% 2.00 (1.84-2.18) 2.00 (1.67-2.28) 2.00 (1.79-2.24) 0.36 
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Supplementary Table 2. Odds ratios (OR) and 95% confidence intervals (CI) of quitting drinking at 
follow-up by health conditions newly acquired between baseline and follow-up by age in the 45 
and Up Study (2006-2016), New South Wales, Australia. 
Adjusted for sex, age, remoteness, education, household income, health insurance status, partner 
status and country of birth. 
 
 
OR quit drinking (95% CI) 
Main analysis 
Age 45-64 years 
at baseline 
Age ≥ 65 years 
at baseline pinteraction 
Health conditions     
Cancer     
  Breast cancer (women) 1.38 (1.18-1.61) 1.41 (1.17-1.70) 1.01 (0.86-1.20) 0.65 
  Prostate cancer (men) 1.05 (0.91-1.21) 0.91 (0.72-1.15) 0.96 (0.86-1.08) 0.12 
  Melanoma 1.00 (0.89-1.12) 0.98 (0.83-1.15) 1.48 (1.30-1.67) 0.60 
  Non-melanoma skin cancer 0.94 (0.88-1.01) 0.92 (0.84-1.01) 1.46 (1.33-1.61) 0.27 
  Other cancer 1.51 (1.38-1.65) 1.54 (1.35-1.74) 1.37 (1.15-1.62) 0.66 
Cardiovascular disease     
  Heart disease 1.34 (1.25-1.44) 1.22 (1.10-1.35) 1.46 (1.33-1.61) 0.006 
  Stroke 1.45 (1.27-1.66) 1.57 (1.26-1.95) 1.37 (1.15-1.62) 0.34 
  Blood clot 1.39 (1.22-1.60) 1.45 (1.21-1.75) 1.33 (1.09-1.62) 0.53 
  High blood pressure 0.98 (0.91-1.05) 1.02 (0.93-1.12) 0.90 (0.79-1.03) 0.09 
Endocrine conditions     
  Diabetes  1.77 (1.60-1.96) 1.89 (1.66-2.15) 1.61 (1.37-1.88) 0.11 
  Thyroid problems 1.32 (1.17-1.49) 1.28 (1.10-1.48) 1.41 (1.15-1.73) 0.63 
Genitourinary conditions     
  Leaking urine > 1 time per week 1.20 (1.11-1.29) 1.18 (1.07-1.31) 1.22 (1.09-1.36) 0.80 
  Enlarged prostate (men) 1.22 (1.09-1.37) 1.35 (1.16-1.57) 1.09 (0.93-1.28) 0.07 
  Erectile dysfunction (men) 1.29 (1.16-1.43) 1.15 (1.00-1.32) 1.51 (1.29-1.77) 0.008 
Conditions affecting mobility     
  Parkinson’s disease 1.71 (1.35-2.17) 1.82 (1.26-2.62) 1.61 (1.18-2.21) 0.65 
  Osteoarthritis 1.22 (1.12-1.33) 1.20 (1.07-1.35) 1.26 (1.12-1.42) 0.94 
  Osteoporosis/osteopenia 1.16 (1.05-1.29) 1.12 (0.97-1.31) 1.21 (1.04-1.40) 0.77 
  Broken/fractured hip 1.64 (1.30-2.06) 1.30 (0.81-2.09) 1.79 (1.37-2.33) 0.28 
  Broken/fractured other bone 0.95 (0.88-1.03) 0.92 (0.83-1.02) 1.00 (0.88-1.15) 0.47 
Mental health conditions     
  Depression 1.40 (1.26-1.55) 1.35 (1.19-1.52) 1.50 (1.26-1.79) 0.43 
  Anxiety 1.38 (1.26-1.52) 1.36 (1.21-1.52) 1.42 (1.20-1.69) 0.97 
  Poor memory 1.68 (1.43-1.97) 1.95 (1.54-2.48) 1.48 (1.20-1.82) 0.07 
Other conditions     
  Asthma 1.07 (0.94-1.21) 1.19 (1.03-1.38) 0.85 (0.68-1.06) 0.01 
  Hayfever 0.99 (0.90-1.09) 0.95 (0.85-1.07) 1.07 (0.91-1.26) 0.27 
  Hearing loss 1.05 (0.97-1.13) 1.02 (0.93-1.12) 1.10 (0.97-1.25) 0.31 
  Poor eyesight 1.50 (1.25-1.79) 1.43 (1.09-1.89) 1.53 (1.20-1.96) 0.88 
  Poor teeth and gums 1.35 (1.17-1.57) 1.54 (1.27-1.85) 1.13 (0.80-1.42) 0.02 
  No teeth left 1.51 (1.26-1.82) 1.54 (1.17-2.02) 1.51 (1.18-1.95) 0.68 
General health indicators     
  Poor overall health 2.93 (2.53-3.40) 3.02 (2.46-3.72) 2.81 (2.28-3.45) 0.52 
  Poor quality of life 2.68 (2.24-3.21) 2.72 (2.12-3.50) 2.62 (2.03-3.39) 0.65 
  Need regular help with daily tasks 1.96 (1.81-2.13) 2.19 (1.92-2.49) 1.83 (1.64-2.04) 0.02 
  Physical functioning score < 50% 2.00 (1.84-2.18) 2.28 (2.02-2.57) 1.79 (1.59-2.01) 0.001 
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Supplementary Table 3. Odds ratios (OR) and 95% confidence intervals (CI) of quitting drinking at 
follow-up by health conditions newly acquired between baseline and follow-up by smoking status 
in the 45 and Up Study (2006-2016), New South Wales, Australia. 
Adjusted for sex, age, remoteness, education, household income, health insurance status, partner 
status and country of birth. 
 
 
 
OR quit drinking (95% CI) 
Main analysis Never-smokers Ever-smokers pinteraction 
Health conditions     
Cancer     
  Breast cancer (women) 1.38 (1.18-1.61) 1.54 (1.27-1.87) 1.13 (0.86-1.49) 0.08 
  Prostate cancer (men) 1.05 (0.91-1.21) 1.13 (0.92-1.37) 0.97 (0.79-1.19) 0.19 
  Melanoma 1.00 (0.89-1.12) 0.98 (0.84-1.15) 1.02 (0.85-1.21) 0.80 
  Non-melanoma skin cancer 0.94 (0.88-1.01) 0.97 (0.88-1.07) 0.90 (0.81-1.01) 0.26 
  Other cancer 1.51 (1.38-1.65) 1.53 (1.35-1.73) 1.53 (1.34-1.74) 0.81 
Cardiovascular disease     
  Heart disease 1.34 (1.25-1.44) 1.31 (1.19-1.44) 1.41 (1.27-1.56) 0.64 
  Stroke 1.45 (1.27-1.66) 1.58 (1.31-1.90) 1.35 (1.11-1.64) 0.17 
  Blood clot 1.39 (1.22-1.60) 1.38 (1.15-1.66) 1.41 (1.15-1.73) 0.94 
  High blood pressure 0.98 (0.91-1.05) 0.98 (0.89-1.09) 0.98 (0.88-1.10) 0.99 
Endocrine conditions     
  Diabetes  1.77 (1.60-1.96) 1.76 (1.52-2.03) 1.81 (1.57-2.08) 0.72 
  Thyroid problems 1.32 (1.17-1.49) 1.26 (1.07-1.48) 1.42 (1.19-1.70) 0.38 
Genitourinary conditions     
  Leaking urine > 1 time per week 1.20 (1.11-1.29) 1.20 (1.09-1.33) 1.20 (1.07-1.34) 0.66 
  Enlarged prostate (men) 1.22 (1.09-1.37) 1.18 (1.01-1.39) 1.26 (1.08-1.47) 0.87 
  Erectile dysfunction (men) 1.29 (1.16-1.43) 1.22 (1.05-1.42) 1.36 (1.18-1.57) 0.63 
Conditions affecting mobility     
  Parkinson’s disease 1.71 (1.35-2.17) 1.94 (1.44-2.63) 1.41 (0.95-2.08) 0.18 
  Osteoarthritis 1.22 (1.12-1.33) 1.14 (1.02-1.29) 1.34 (1.19-1.52) 0.14 
  Osteoporosis/osteopenia 1.16 (1.05-1.29) 1.14 (1.00-1.31) 1.18 (1.00-1.40) 0.92 
  Broken/fractured hip 1.64 (1.30-2.06) 1.77 (1.30-2.43) 1.54 (1.09-2.17) 0.42 
  Broken/fractured other bone 0.95 (0.88-1.03) 0.88 (0.79-0.99) 1.04 (0.92-1.17) 0.04 
Mental health conditions     
  Depression 1.40 (1.26-1.55) 1.32 (1.14-1.52) 1.52 (1.31-1.75) 0.09 
  Anxiety 1.38 (1.26-1.52) 1.40 (1.23-1.60) 1.37 (1.19-1.58) 0.98 
  Poor memory 1.68 (1.43-1.97) 1.74 (1.38-2.19) 1.65 (1.33-2.06) 0.73 
Other conditions     
  Asthma 1.07 (0.94-1.21) 1.17 (0.99-1.38) 0.98 (0.82-1.18) 0.21 
  Hayfever 0.99 (0.90-1.09) 0.95 (0.84-1.08) 1.06 (0.91-1.22) 0.26 
  Hearing loss 1.05 (0.97-1.13) 1.01 (0.92-1.12) 1.11 (0.99-1.25) 0.24 
  Poor eyesight 1.50 (1.25-1.79) 1.68 (1.30-2.16) 1.35 (1.03-1.76) 0.25 
  Poor teeth and gums 1.35 (1.17-1.57) 1.15 (0.90-1.48) 1.54 (1.29-1.85) 0.0503 
  No teeth left 1.51 (1.26-1.82) 1.52 (1.13-2.06) 1.57 (1.24-1.99) 0.90 
General health indicators     
  Poor overall health 2.93 (2.53-3.40) 3.21 (2.57-4.00) 2.76 (2.26-3.37) 0.42 
  Poor quality of life 2.68 (2.24-3.21) 3.04 (2.32-3.99) 2.47 (1.94-3.14) 0.36 
  Need regular help with daily tasks 1.96 (1.81-2.13) 1.92 (1.71-2.16) 2.05 (1.82-2.31) 0.79 
  Physical functioning score < 50% 2.00 (1.84-2.18) 1.92 (1.70-2.16) 2.16 (1.91-2.43) 0.41 
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Supplementary Table 4. Sensitivity analyses for odds ratios (OR) and 95% confidence intervals (CI) of quitting drinking at 
follow-up by health conditions newly acquired between baseline and follow-up in the 45 and Up Study (2006-2016), New 
South Wales, Australia. 
aAdjusted for sex, age, remoteness, education, household income, health insurance status, partner status and country of 
birth. bAlso adjusted for the all other health conditions listed except depression, anxiety and general health indicators 
(categories: have had health condition at baseline; have not had at baseline or follow-up; have not had at baseline and have 
had at follow-up; missing indicator). cAlso adjusted for baseline alcohol consumption. dAlso adjusted for baseline smoking 
status, body mass index, physical activity time, fruit consumption and vegetable consumption. eGood/very good/excellent 
self-rated health at baseline. fAlso adjusted for poor overall health (categories: poor health at baseline; no poor health at 
baseline or follow-up; poor health at follow-up but not at baseline; missing indicator). 
 
OR quit drinking (95% CI) 
Main analysisa 
Adjusted for 
other health 
conditionsa,b 
Adjusted for 
baseline 
drinking 
intensitya,c 
Adjusted for 
lifestyle risk 
factorsa,d 
Participants 
with good 
health at 
baseline onlya,e 
Adjusted for poor 
overall health at 
baseline and/or 
follow-upa,f 
Health conditions       
Cancer       
  Breast cancer (women) 1.38 (1.18-1.61) 1.29 (1.10-1.51) 1.43 (1.21-1.69) 1.37 (1.17-1.60) 1.48 (1.25-1.74) 1.36 (1.16-1.59) 
  Prostate cancer (men) 1.05 (0.91-1.21) 0.91 (0.78-1.05) 1.08 (0.93-1.25) 1.05 (0.91-1.22) 1.06 (0.90-1.23) 1.05 (0.91-1.21) 
  Melanoma 1.00 (0.89-1.12) 0.96 (0.85-1.08) 1.04 (0.92-1.17) 1.01 (0.90-1.14) 0.97 (0.86-1.11) 1.00 (0.89-1.12) 
  Non-melanoma skin cancer 0.94 (0.88-1.01) 0.92 (0.85-0.99) 0.97 (0.90-1.04) 0.95 (0.89-1.03) 0.93 (0.86-1.01) 0.94 (0.87-1.01) 
  Other cancer 1.51 (1.38-1.65) 1.42 (1.30-1.56) 1.59 (1.44-1.75) 1.50 (1.37-1.64) 1.54 (1.39-1.69) 1.46 (1.33-1.60) 
Cardiovascular disease       
  Heart disease 1.34 (1.25-1.44) 1.24 (1.15-1.33) 1.37 (1.27-1.47) 1.32 (1.23-1.41) 1.33 (1.23-1.43) 1.31 (1.22-1.40) 
  Stroke 1.45 (1.27-1.66) 1.19 (1.04-1.37) 1.49 (1.29-1.72) 1.44 (1.26-1.65) 1.38 (1.18-1.61) 1.40 (1.23-1.61) 
  Blood clot 1.39 (1.22-1.60) 1.20 (1.04-1.38) 1.34 (1.16-1.54) 1.35 (1.18-1.54) 1.38 (1.19-1.61) 1.35 (1.18-1.55) 
  High blood pressure 0.98 (0.91-1.05) 0.93 (0.86-1.00) 1.03 (0.95-1.11) 0.95 (0.88-1.02) 0.98 (0.90-1.06) 0.97 (0.90-1.05) 
Endocrine conditions       
  Diabetes 1.77 (1.60-1.96) 1.62 (1.46-1.80) 1.68 (1.51-1.87) 1.59 (1.44-1.77) 1.69 (1.50-1.89) 1.72 (1.55-1.90) 
  Thyroid problems 1.32 (1.17-1.49) 1.21 (1.07-1.37) 1.24 (1.09-1.41) 1.29 (1.14-1.46) 1.33 (1.17-1.52) 1.29 (1.14-1.45) 
Genitourinary conditions       
  Leaking urine > 1 time per week 1.20 (1.11-1.29) 1.11 (1.03-1.20) 1.18 (1.09-1.28) 1.15 (1.07-1.25) 1.15 (1.06-1.25) 1.17 (1.08-1.26) 
  Enlarged prostate (men) 1.22 (1.09-1.37) 1.18 (1.05-1.32) 1.18 (1.05-1.32) 1.23 (1.10-1.37) 1.17 (1.03-1.32) 1.21 (1.09-1.35) 
  Erectile dysfunction (men) 1.29 (1.16-1.43) 1.24 (1.11-1.37) 1.29 (1.16-1.44) 1.28 (1.16-1.42) 1.28 (1.14-1.43) 1.27 (1.14-1.40) 
Conditions affecting mobility       
  Parkinson’s disease 1.71 (1.35-2.17) 1.36 (1.06-1.75) 1.78 (1.38-2.30) 1.71 (1.35-2.17) 1.73 (1.33-2.25) 1.61 (1.27-2.05) 
  Osteoarthritis 1.22 (1.12-1.33) 1.13 (1.04-1.24) 1.28 (1.17-1.40) 1.18 (1.08-1.28) 1.20 (1.09-1.32) 1.19 (1.09-1.29) 
  Osteoporosis/osteopenia 1.16 (1.05-1.29) 1.09 (0.98-1.22) 1.19 (1.06-1.33) 1.19 (1.07-1.33) 1.16 (1.04-1.31) 1.14 (1.03-1.27) 
  Broken/fractured hip 1.64 (1.30-2.06) 1.56 (1.24-1.97) 1.82 (1.42-2.34) 1.64 (1.30-2.06) 1.81 (1.40-2.32) 1.57 (1.25-1.98) 
  Broken/fractured other bone 0.95 (0.88-1.03) 0.90 (0.83-0.98) 0.98 (0.90-1.07) 0.95 (0.88-1.04) 0.93 (0.86-1.02) 0.93 (0.86-1.01) 
Mental health conditions       
  Depression 1.40 (1.26-1.55) 1.25 (1.12-1.38) 1.42 (1.27-1.58) 1.38 (1.25-1.53) 1.34 (1.20-1.51) 1.35 (1.22-1.49) 
  Anxiety 1.38 (1.26-1.52) 1.26 (1.15-1.39) 1.37 (1.24-1.52) 1.37 (1.25-1.51) 1.41 (1.27-1.57) 1.35 (1.22-1.48) 
  Poor memory 1.68 (1.43-1.97) 1.46 (1.24-1.71) 1.75 (1.48-2.08) 1.68 (1.43-1.97) 1.69 (1.40-2.03) 1.50 (1.27-1.76) 
Other conditions       
  Asthma 1.07 (0.94-1.21) 0.96 (0.84-1.09) 1.05 (0.92-1.20) 1.04 (0.92-1.18) 1.11 (0.97-1.27) 1.04 (0.92-1.18) 
  Hayfever 0.99 (0.90-1.09) 0.95 (0.86-1.05) 0.98 (0.88-1.08) 0.99 (0.90-1.09) 1.01 (0.91-1.12) 0.98 (0.89-1.08) 
  Hearing loss 1.05 (0.97-1.13) 1.02 (0.94-1.10) 1.03 (0.95-1.11) 1.04 (0.97-1.12) 1.04 (0.97-1.13) 1.04 (0.97-1.12) 
  Poor eyesight 1.50 (1.25-1.79) 1.26 (1.05-1.52) 1.56 (1.29-1.90) 1.46 (1.22-1.76) 1.43 (1.15-1.78) 1.34 (1.11-1.61) 
  Poor teeth and gums 1.35 (1.17-1.57) 1.16 (1.00-1.34) 1.42 (1.21-1.66) 1.33 (1.15-1.54) 1.45 (1.23-1.71) 1.26 (1.09-1.46) 
  No teeth left 1.51 (1.26-1.82) 1.33 (1.10-1.61) 1.46 (1.20-1.78) 1.51 (1.26-1.82) 1.56 (1.27-1.93) 1.45 (1.20-1.75) 
General health indicators       
  Poor overall health 2.93 (2.53-3.40) 2.12 (1.82-2.47) 3.24 (2.76-3.81) 2.68 (2.31-3.11) 3.76 (3.06-4.62) - 
  Poor quality of life 2.68 (2.24-3.21) 2.04 (1.69-2.45) 3.00 (2.46-3.65) 2.48 (2.07-2.97) 3.32 (2.64-4.18) 1.82 (1.49-2.21) 
  Need regular help with daily tasks 1.96 (1.81-2.13) 1.63 (1.49-1.78) 2.05 (1.88-2.25) 1.86 (1.71-2.02) 1.97 (1.78-2.16) 1.76 (1.61-1.92) 
  Physical functioning score < 50% 2.00 (1.84-2.18) 1.71 (1.56-1.87) 2.14 (1.96-2.35) 1.87 (1.72-2.04) 2.07 (1.89-2.27) 1.83 (1.68-2.00) 
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7.2 – Additional Analyses 
 
A number of additional analyses addressed important questions in relation to the ‘sick-quitter 
effect'. 
1. Which health conditions are likely to contribute most to the ‘sick-quitter effect’? 
Rationale and Method. As well as the odds of drinking cessation in relation to incident disease, the 
prevalence of disease is also important in terms of assessing which diseases are likely to contribute 
greatest to the ‘sick-quitter effect’. For example, if a disease is strongly associated with drinking 
cessation but has a very low prevalence, it may contribute less to the ‘sick-quitter effect’ than a 
disease which is more modestly associated with drinking cessation but has a high prevalence. 
Therefore, the odds of each disease and general health indicator that was significantly associated 
with quitting drinking were plotted against its prevalence in the cohort to assess the relative 
importance of each (Figure 7.1). 
Results. Poor health and quality of life at baseline had the highest odds ratios for quitting, but were 
among the least prevalent. Genitourinary conditions were the most prevalent at baseline, but were 
among the conditions with the lowest odds ratios. Low physical functioning score and diabetes 
appeared to be health variables with both a relatively high prevalence and high odds ratio. 
Conclusions. For any health condition potentially related to the ‘sick-quitter effect’, when 
determining exclusion criteria to reduce bias, it is important to consider both its association with 
drinking cessation and its prevalence in the cohort.
243 
 
 
 
Figure 7.1. Prevalence of illnesses at baseline and odds of quitting drinking at five-year follow-up by illnesses newly acquired between baseline and follow-up in 
the 45 and Up Study (2006-2016), New South Wales, Australia. Only significant illnesses shown. OR, Odds Ratio. CI, Confidence Interval. 
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2. Whether newly acquired health conditions are associated with reduction in overall intake 
(rather than complete cessation), a reduction in drinking frequency (i.e. number of drinking-
days in the week), or an increase in drinks per drinking-day. 
Rationale and Method. Illness may be associated with a decrease in alcohol consumption rather 
than complete cessation[1]. Further, it has been reported that infrequent and heavy episodic 
drinkers have a higher prevalence of poor health compared to frequent and non-heavy episodic 
drinkers respectively[2]. Thus, persons may change their pattern of drinking in response to the 
occurrence of illness, as well as the total amount consumed. If for example, it is found that the 
occurrence of disease is associated with decreased drinking frequency, this would imply that 
apparent association of frequent drinking with better health outcomes may be overestimated and at 
least partially attributable to bias. In the same way, it may also be possible that the harms of heavy 
episodic drinking could be overestimated, if (although unlikely) the occurrence of disease is 
associated with an increase in mean drinks per drinking-day for the days on which participants 
remain drinking. 
Logistic regression models were used to estimate the odds of 1) decreasing to low-volume drinking 
(≥ 1 and ≤ 3.5 drinks per week); 2) decreasing drinking frequency to 1-2 drinking-days per week; 3) 
increasing mean drinks per drinking-day to > 4. The models were adjusted for sex, age (categorical), 
remoteness, education, household income, health insurance status, partner status, country of birth, 
smoking status and intensity, body mass index, physical activity, fruit consumption, vegetable 
consumption, fibre intake, red meat consumption, processed meat consumption, parity (women), 
menopausal status (women), hormone replacement therapy use (women) and height. 
Results. At follow-up, 7748 participants had decreased to very light drinking, 7825 had decreased to 
infrequent drinking, and 3386 had increased to > 4 drinks per drinking-day. Eleven of 28 incident 
health conditions were associated with increased odds of reducing intake to very light levels and one 
(high blood pressure) with decreased odds (Table 7.1). The highest odds ratios were observed for 
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diabetes, breast cancer and stroke. However, the odds of quitting completely were higher than the 
odds of reducing intake across all diseases. All four indicators of general health were associated with 
increased odds of reducing intake, with the highest odds ratio observed for poor health. 
Nine of 28 health conditions were associated with increased odds of becoming an infrequent 
drinker, with the highest odds found for diabetes, breast cancer and poor memory. All four 
indicators of general health were associated with increased odds, with the highest odds ratio 
observed for poor quality of life.  
Seven of 28 health conditions were associated with increased odds of an increase in drinks 
consumed per drinking-day to > 4 and one (thyroid problems) with decreased odds. The highest 
odds were found for poor memory, poor teeth and gums and osteoarthritis. Only one of the four 
indicators of general health, low physical functioning score, was associated with increased odds. 
Conclusions. The occurrence of disease and a decline in indicators of general health were associated 
with a reduction in alcohol consumption to the level of very light drinking (1-3.5 drinks/week), a 
decrease in drinking frequency to 1-2 drinking-days per week, and an increase in number of drinks 
consumed per drinking-day to > 4. An implication of these results is that just as the non-drinking 
group in a cohort study is likely to contain former drinkers who ceased drinking in association with 
the occurrence of ill-health, the very light drinking group is also likely to contain participants who 
have decreased their drinking in association with ill-health. Fewer health conditions were 
significantly associated with a decline to very light drinking compared to those associated with 
drinking cessation, and the odds ratios were generally smaller. This means that while the use of very 
light drinkers as a reference group may be vulnerable to bias from decreased drinking in response to 
ill-health (whereby risk estimates for moderate and heavy drinking may be underestimated), the 
effect is likely to be smaller than the ‘sick-quitter effect’.  
Similarly, the findings for illness and drinking pattern suggest that inverse associations between 
drinking frequency and negative health outcomes and positive associations between greater drinks 
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per drinking-day (or heavy episodic drinking) and negative health outcomes may be at least partially 
attributable to bias from changes in drinking patterns in response to ill-health. Compared to drinking 
cessation and decreased drinking, fewer diseases were significantly associated with changes in 
drinking pattern and the odds ratios were generally smaller. This indicates that bias from changes in 
drinking pattern in response to ill-health may have a smaller impact on risk estimates compared to 
the ‘sick-quitter effect’ and decreased drinking in response to ill-health. 
The only indicator of general health significantly associated with all four changes in drinking pattern 
was low physical functioning score, indicating that the exclusion of participants with a low physical 
functioning score may allow for the most reliable risk estimates for the impact of alcohol-related 
harms. 
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Table 7.1. Odds of quitting drinking, decreasing to very light drinking, decreasing to infrequent drinking and increasing 
number of drinks per drinking-day at five-year follow-up by illnesses newly acquired between baseline and follow-up in 
the 45 and Up Study (2006-2016), New South Wales, Australia. 
Models adjusted for sex, age, remoteness, education, household income, health insurance status, partner status and 
country of birth. aAmong drinkers at baseline. b≥ 1 and ≤ 3.5 drinks per week, among drinkers consuming > 3.5 drinks per 
week at baseline. cConsume alcohol 1-2 days per week, among drinkers consuming alcohol 3-7 days per week at baseline. 
dConsume mean > 4 drinks per drinking-day, among drinkers consuming mean ≤ 4 drinks per drinking-day at baseline. 
New illness 
OR quit drinkinga 
(95% CI) 
OR decrease to 
very light 
drinkingb (95% CI) 
OR decrease to 
infrequent 
drinkingc (95% CI) 
OR increase to > 4 
drinks per drinking-
dayd (95% CI) 
Health conditions     
Cancer     
  Breast cancer (women) 1.38 (1.18-1.61) 1.33 (1.11-1.59) 1.38 (1.15-1.66) 1.19 (0.80-1.77) 
  Prostate cancer (men) 1.05 (0.91-1.21) 1.18 (1.02-1.36) 1.22 (1.05-1.40) 1.02 (0.84-1.23) 
  Melanoma 1.00 (0.89-1.12) 0.95 (0.84-1.09) 0.99 (0.87-1.13) 1.12 (0.94-1.34) 
  Non-melanoma skin cancer 0.94 (0.88-1.01) 0.99 (0.92-1.08) 0.96 (0.89-1.04) 0.98 (0.87-1.10) 
  Other cancer 1.51 (1.38-1.65) 1.29 (1.16-1.44) 1.22 (1.09-1.36) 0.96 (0.80-1.16) 
Cardiovascular disease     
  Heart disease 1.34 (1.25-1.44) 1.12 (1.03-1.21) 1.06 (0.97-1.15) 1.04 (0.92-1.18) 
  Stroke 1.45 (1.27-1.66) 1.32 (1.12-1.55) 1.26 (1.06-1.49) 1.00 (0.77-1.30) 
  Blood clot 1.39 (1.22-1.60) 1.06 (0.90-1.26) 1.20 (1.02-1.42) 1.10 (0.85-1.41) 
  High blood pressure 0.98 (0.91-1.05) 0.92 (0.84-1.00) 0.96 (0.88-1.04) 1.20 (1.07-1.35) 
Endocrine conditions     
  Diabetes  1.77 (1.60-1.96) 1.39 (1.23-1.58) 1.51 (1.33-1.72) 0.83 (0.67-1.03) 
  Thyroid problems 1.32 (1.17-1.49) 1.31 (1.14-1.51) 1.14 (0.98-1.33) 0.71 (0.53-0.97) 
Genitourinary conditions     
  Leaking urine > 1 time per week 1.20 (1.11-1.29) 1.10 (1.01-1.21) 1.11 (1.01-1.21) 1.20 (1.05-1.37) 
  Enlarged prostate (men) 1.22 (1.09-1.37) 1.17 (1.04-1.32) 1.11 (0.98-1.25) 0.89 (0.76-1.03) 
  Erectile dysfunction (men) 1.29 (1.16-1.43) 1.07 (0.96-1.19) 1.13 (1.02-1.25) 1.02 (0.90-1.16) 
Conditions affecting mobility     
  Parkinson’s disease 1.71 (1.35-2.17) 1.31 (0.97-1.78) 1.18 (0.86-1.64) 0.92 (0.55-1.53) 
  Osteoarthritis 1.22 (1.12-1.33) 1.13 (1.02-1.25) 1.07 (0.96-1.19) 1.22 (1.04-1.44) 
  Osteoporosis/osteopenia 1.16 (1.05-1.29) 1.13 (1.00-1.27) 1.07 (0.95-1.22) 0.91 (0.71-1.16) 
  Broken/fractured hip 1.64 (1.30-2.06) 1.15 (0.84-1.57) 0.92 (0.65-1.31) 1.10 (0.63-1.94) 
  Broken/fractured other bone 0.95 (0.88-1.03) 0.97 (0.89-1.06) 0.97 (0.89-1.06) 1.21 (1.07-1.38) 
Mental health conditions     
  Depression 1.40 (1.26-1.55) 1.11 (0.98-1.25) 1.11 (0.98-1.25) 1.16 (0.97-1.38) 
  Anxiety 1.38 (1.26-1.52) 1.14 (1.02-1.28) 1.04 (0.92-1.17) 0.98 (0.81-1.17) 
  Poor memory 1.68 (1.43-1.97) 1.15 (0.92-1.42) 1.27 (1.02-1.57) 1.51 (1.13-2.03) 
Other conditions     
  Asthma 1.07 (0.94-1.21) 1.01 (0.88-1.17) 0.98 (0.85-1.13) 0.90 (0.72-1.12) 
  Hayfever 0.99 (0.90-1.09) 0.95 (0.85-1.06) 0.94 (0.84-1.05) 0.97 (0.83-1.13) 
  Hearing loss 1.05 (0.97-1.13) 1.02 (0.94-1.11) 0.99 (0.91-1.08) 1.01 (0.89-1.14) 
  Poor eyesight 1.50 (1.25-1.79) 1.10 (0.87-1.41) 1.12 (0.88-1.44) 1.33 (0.93-1.91) 
  Poor teeth and gums 1.35 (1.17-1.57) 0.90 (0.74-1.10) 1.18 (0.98-1.42) 1.42 (1.10-1.82) 
  No teeth left 1.51 (1.26-1.82) 1.24 (0.97-1.58) 1.16 (0.89-1.49) 1.06 (0.72-1.55) 
General health indicators     
  Poor overall health 2.93 (2.53-3.40) 1.54 (1.23-1.92) 1.47 (1.17-1.85) 1.22 (0.85-1.74) 
  Poor quality of life 2.68 (2.24-3.21) 1.51 (1.15-1.98) 1.56 (1.19-2.05) 1.46 (0.98-2.17) 
  Need regular help with daily tasks 1.96 (1.81-2.13) 1.45 (1.30-1.62) 1.31 (1.17-1.48) 1.20 (0.99-1.45) 
  Physical functioning score < 50% 2.00 (1.84-2.18) 1.48 (1.33-1.65) 1.32 (1.18-1.48) 1.29 (1.07-1.55) 
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3. Whether the prevalence of ill-health at baseline differs by total alcohol intake, drinking 
frequency and drinks per drinking-day. 
Rationale and Method. For risk estimates in the 45 and Up Study to be biased by the ‘sick-quitter 
effect’ and other changes in drinking behaviour in response to illness, the prevalence of poor health 
status must differ by levels of alcohol consumption and/or by drinking patterns. 
Logistic regression was used to calculate odds ratios and 95% confidence intervals of having “poor” 
general health indicators at baseline across categories of total intake, drinking frequency and drinks 
per drinking-day. All models were adjusted for all covariates listed above. For drinking frequency and 
drinks per drinking-day, total alcohol consumption was included for adjustment and non-drinkers 
were excluded. For total alcohol consumption, significance was additionally calculated for drinkers 
alone. 
Results. The odds of having poor indicators of general health at baseline by level of alcohol 
consumption is shown in Table 7.2. Compared to participants consuming ≥ 1 and ≤ 3.5 drinks per 
week, for all four indicators higher odds were found in non-drinkers, and lower odds in participants 
consuming > 3.5 and ≤ 28 drinks per week. 
The odds of having poor indicators of general health at baseline by drinking pattern is shown in 
Table 7.3. Compared to participants consuming alcohol 1-2 days per week, for all four indicators 
lower odds were found in participants consuming alcohol more frequently. There were no significant 
differences in odds of poor quality of life by mean drinks per drinking-day. For the other three 
indicators, compared to participants consuming ≤ 2 drinks per drinking-day, lower odds were found 
in participants consuming > 2 and ≤ 4 drinks per drinking-day. For participants consuming > 4 drinks 
per drinking-day, higher odds of a physical functioning score < 50% were found, and no significant 
difference for the other general health indicators. 
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Conclusions. There were differences in the prevalence of general health indicators by total alcohol 
consumption, drinking frequency and drinks per drinking-day, even when adjusting for a variety of 
socio-demographic and health-related covariates. There was a U-shaped association for the 
prevalence of poor health status by total alcohol consumption, and an inverse association with 
drinking frequency. Therefore, risk estimates for the association between health outcomes and 
alcohol consumption and drinking patterns may be biased due to differences in health status 
between categories of drinking groups. For total alcohol consumption, even when using a reference 
group of very light drinkers, bias may not be completely removed. 
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Table 7.2. Odds of having poor general health indicators by alcohol consumption at baseline in the 45 and Up Study (2006-2009), New South Wales, Australia. 
 OR of having illness by drinks/week (95% CI)   
Illness Non-drinkera ≥ 1, ≤ 3.5 > 3.5, ≤ 7 > 7, ≤ 14 > 14, ≤ 28 > 28 pall pdrinkers 
Poor overall health 1.45 (1.32-1.58) 1.00 0.77 (0.69-0.87) 0.69 (0.61-0.78) 0.69 (0.60-0.80) 0.88 (0.75-1.03) < 0.001 < 0.001 
Poor quality of life 1.29 (1.17-1.42) 1.00 0.75 (0.66-0.85) 0.73 (0.63-0.83) 0.72 (0.62-0.84) 0.96 (0.81-1.14) < 0.001 < 0.001 
Need regular help with daily tasks 1.27 (1.20-1.34) 1.00 0.81 (0.75-0.86) 0.74 (0.69-0.80) 0.72 (0.66-0.78) 0.79 (0.70-0.89) < 0.001 < 0.001 
Physical functioning score < 50% 1.37 (1.30-1.43) 1.00 0.85 (0.80-0.90) 0.78 (0.73-0.83) 0.83 (0.78-0.89) 0.96 (0.87-1.05) < 0.001 < 0.001 
Models adjusted for sex, age, remoteness, education, household income, health insurance status, partner status, country of birth, smoking status and dose, body 
mass index, physical activity, fruit consumption, vegetable consumption, fibre intake, red meat consumption, processed meat consumption, parity (women), 
menopausal status (women), hormone replacement therapy use (women) and height. a< 1 drink per week. OR, Odds Ratio. CI, Confidence Interval. 
 
 
Table 7.3. Odds of having poor general health indicators by drinking pattern among drinkers at baseline in the 45 and Up Study (2006-2009), New South 
Wales, Australia. 
 OR of having illness by drinking-days per week - 
adjusted for total alcohol consumption (95% CI) 
  OR of having illness by drinks per drinking-day - 
adjusted for total alcohol consumption (95% CI) 
 
Illness 1-2 3-5 6-7 p  ≤ 2 > 2, ≤ 4 > 4 p 
Poor overall health 1.00 0.80 (0.71-0.90) 0.75 (0.66-0.85) < 0.001  1.00 0.84 (0.75-0.95) 1.04 (0.87-1.24) 0.002 
Poor quality of life 1.00 0.70 (0.61-0.79) 0.73 (0.64-0.84) < 0.001  1.00 0.88 (0.78-1.00) 0.97 (0.81-1.18) 0.13 
Need regular help with daily tasks 1.00 0.83 (0.77-0.90) 0.81 (0.75-0.88) < 0.001  1.00 0.87 (0.80-0.93) 1.12 (0.99-1.26) < 0.001 
Physical functioning score < 50% 1.00 0.83 (0.78-0.88) 0.85 (0.79-0.90) < 0.001  1.00 0.90 (0.85-0.96) 1.13 (1.02-1.24) < 0.001 
Models adjusted for total alcohol consumption, sex, age, remoteness, education, household income, health insurance status, partner status, country of birth, 
smoking status and dose, body mass index, physical activity, fruit consumption, vegetable consumption, fibre intake, red meat consumption, processed meat 
consumption, parity (women), menopausal status (women), hormone replacement therapy use (women) and height. OR, Odds Ratio. CI, Confidence Interval. 
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4. Whether the exclusion of participants with different types of health characteristics at 
baseline reduces the prevalence of disease in the cohort and decreases differences in health 
status between drinking group categories. 
Rationale and background. One method of mitigating potential bias from the ‘sick-quitter effect’ 
and other changes in drinking behaviour in response to illness is to exclude participants with certain 
indicators of pre-existing ill-health at baseline. Seven potential indicators of ill-health were examined 
here, and the impact of their exclusion on the prevalence of disease at baseline in the cohort and the 
odds of six selected health conditions across categories of total alcohol consumption and drinking 
pattern.  
The seven indicators used for exclusion were participants with 1) poor overall health, 2) poor quality 
of life, 3) needing regular help with daily tasks, 4) a physical functioning score < 50%, 5) a pre-
existing cancer diagnosis (excluding non-melanoma skin cancer) and/or cardiovascular disease 
diagnosis (heart disease or stroke), 6) those who died within the first three years of follow-up, and 7) 
those aged 65 years or older. The six conditions examined were cancer and cardiovascular disease 
combined (due to prior cohort studies of alcohol consumption and mortality commonly accounting 
for these diseases when considering the ‘sick-quitter effect’), and diabetes, Parkinson’s disease, hip 
fracture and poor memory (due to these diseases having the strongest association with drinking 
cessation in the main analyses). 
The effect of the seven exclusion scenarios on the six health conditions was examined for 1) the 
unadjusted prevalence of disease at baseline in the cohort, and 2) the odds of the six diseases across 
categories of alcohol consumption. Logistic regression was used to calculate the odds and 95% 
confidence intervals of having each of the six diseases at baseline across categories of total alcohol 
consumption, drinking frequency and drinks per drinking-day, after adjustment for all covariates. 
Each disease was modelled separately for all seven exclusion scenarios and compared to the model 
with no exclusions. 
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Results. The number of participants and proportion with each of the six baseline health conditions 
by exclusion scenario are shown in Table 7.4. The exclusion of participants with poor physical 
functioning and participants aged 65 years or older reduced the prevalence of all six diseases to a 
greater degree than other exclusion scenarios, with the latter exclusion scenario appearing to be 
most effective. The exclusion of participants with poor quality of life appeared to reduce the 
prevalence of disease the least of any exclusion scenario. 
The odds of having six specific diseases at baseline by level of alcohol consumption and method of 
exclusion is shown in Table 7.5. In the models with no exclusions, non-drinkers had higher odds of 
cardiovascular disease, diabetes, Parkinson’s disease and poor memory compared to participants 
consuming ≥ 1 and ≤ 3.5 drinks per week, and for all six diseases, the odds ratio was significantly 
lower in at least one category of drinking with levels above 3.5 drinks/week. The exclusion of 
participants with poor physical functioning appeared to attenuate the odds ratios of non-drinkers to 
a greater degree than the other exclusion scenarios. For most scenarios, the variation in 
cardiovascular disease, diabetes, Parkinson’s disease and poor memory remained significant across 
levels of alcohol consumption. Exceptions were the scenarios excluding participants aged ≥ 65 years 
and those needing help with daily tasks (when restricting to drinkers only), where Parkinson’s 
disease was not significant. 
The odds of having six specific diseases at baseline by drinking pattern and exclusion scenario is 
shown in Table 7.6. In the models with no exclusions, only diabetes and poor memory varied 
significantly by drinking frequency, with lower odds found in participants consuming alcohol > 2 days 
per week compared to 1-2 days per week. No exclusion scenario appeared to make a material 
difference to the odds for diabetes. The exclusion of participants with pre-existing cancer or 
cardiovascular disease eliminated the variation in poor memory across levels of drinking frequency. 
The exclusion of participants with poor overall health or those aged 65 years or older resulted in 
significant increased odds of Parkinson’s disease for more frequent drinkers. 
253 
 
In the models with no exclusions, all diseases except cancer differed in the number of drinks per 
drinking-day, with lower odds of cardiovascular disease, Parkinson’s disease and poor memory for 
participants consuming > 2 and ≤ 4 drinks per drinking-day, and with higher odds of diabetes and hip 
fracture and lower odds of cardiovascular disease for participants consuming > 4 drinks per drinking-
day. The exclusion of participants with poor physical functioning appeared to attenuate the variation 
across drinking categories for most diseases to a greater degree than the other exclusion scenarios, 
with an overall effect only for diabetes and poor memory remaining significant. However, the 
exclusion of participants aged < 65 years attenuated the differences in diabetes to a greater degree 
than the exclusion of participants with poor physical functioning. 
Conclusions. Overall, the exclusion of participants with a low physical functioning score appeared to 
be the most effective method examined here to test for bias from the ‘sick-quitter effect’ and other 
changes in drinking behaviours in response to ill-health. It appeared to be useful when examining 
total alcohol consumption and drinks per drinking-day, while no method appeared to be effective 
when examining drinking frequency. The exclusion of participants aged ≥ 65 years appeared to be 
most effective in reducing the prevalence of disease in the cohort. 
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Table 7.4. Prevalence of illnesses at baseline by exclusion scenario in the 45 and Up Study (2006-2009), New South Wales, Australia. 
  Prevalence at baseline (%) 
Exclusion scenario n participants (%) 
Ever had 
cancer 
Ever had 
CVD 
Ever had 
diabetes 
Ever had 
Parkinson’s disease 
Hip fracture in 
past 5 years 
Poor 
memory 
No exclusion 261,740 (100.0) 16.9 13.9 8.9 0.6 0.5 2.5 
Poor overall health 247,580 (94.6) 16.7 13.4 8.5 0.6 0.5 2.1 
Poor quality of life 244,474 (93.4) 16.8 13.7 8.6 0.6 0.5 2.1 
Need help with daily tasks 235,527 (90.0) 16.3 12.7 8.1 0.4 0.3 1.8 
Physical functioning score < 50% 207,003 (79.1) 15.7 11.5 7.4 0.4 0.2 1.6 
Ever had cancer or CVD 190,272 (72.7) 0.0 0.0 7.1 0.4 0.4 2.0 
Death within 3 years of baseline 253,935 (97.0) 16.1 13.2 8.6 0.6 0.4 2.3 
Age ≥ 65 years 161,527 (71.7) 11.7 7.1 6.4 0.3 0.2 2.0 
CVD, Cardiovascular Disease. 
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Table 7.5. Odds of having illness by alcohol consumption at baseline by exclusion scenario in the 45 and Up Study (2006-2009), New South Wales, Australia. 
 OR of having illness by drinks/week (95% CI)   
Exclusion scenario Non-drinkera ≥ 1, ≤ 3.5 > 3.5, ≤ 7 > 7, ≤ 14 > 14, ≤ 28 > 28 pall pdrinkers 
No exclusion         
   Ever had cancer 1.00 (0.97-1.03) 1.00 0.99 (0.95-1.03) 1.02 (0.99-1.06) 0.99 (0.95-1.03) 0.93 (0.88-0.99) 0.07 0.07 
   Ever had cardiovascular disease 1.13 (1.09-1.18) 1.00 0.93 (0.89-0.97) 0.94 (0.90-0.98) 0.85 (0.81-0.90) 0.78 (0.81-0.90) < 0.001 < 0.001 
   Ever had diabetes 1.40 (1.34-1.46) 1.00 0.78 (0.74-0.82) 0.68 (0.65-0.72) 0.67 (0.63-0.71) 0.62 (0.57-0.68) < 0.001 < 0.001 
   Ever had Parkinson’s disease 1.22 (1.04-1.42) 1.00 1.07 (0.90-1.27) 0.81 (0.67-0.99) 0.73 (0.58-0.92) 0.50 (0.34-0.74) < 0.001 < 0.001 
   Hip fracture in past 5 years 1.06 (0.89-1.25) 1.00 0.96 (0.79-1.17) 0.79 (0.63-0.99) 0.84 (0.64-1.10) 1.04 (0.72-1.51) 0.06 0.21 
   Poor memory 1.10 (1.02-1.18) 1.00 0.91 (0.83-1.00) 0.79 (0.71-0.87) 0.84 (0.75-0.94) 0.90 (0.78-1.03) < 0.001 < 0.001 
Poor overall health excluded         
   Ever had cancer 0.99 (0.96-1.02) 1.00 0.99 (0.95-1.03) 1.02 (0.98-1.06) 1.00 (0.95-1.04) 0.94 (0.89-1.01) 0.17 0.12 
   Ever had cardiovascular disease 1.14 (1.09-1.18) 1.00 0.94 (0.90-0.98) 0.96 (0.92-1.00) 0.87 (0.83-0.92) 0.80 (0.75-0.86) < 0.001 < 0.001 
   Ever had diabetes 1.38 (1.32-1.44) 1.00 0.77 (0.73-0.82) 0.67 (0.64-0.71) 0.66 (0.62-0.71) 0.61 (0.56-0.67) < 0.001 < 0.001 
   Ever had Parkinson’s disease 1.19 (1.01-1.40) 1.00 1.06 (0.88-1.28) 0.84 (0.68-1.03) 0.75 (0.58-0.96) 0.50 (0.33-0.76) < 0.001 0.001 
   Hip fracture in past 5 years 1.11 (0.92-1.33) 1.00 1.04 (0.84-1.28) 0.86 (0.68-1.09) 0.89 (0.67-1.19) 0.98 (0.65-1.47) 0.21 0.52 
   Poor memory 1.04 (0.96-1.14) 1.00 0.89 (0.81-0.99) 0.79 (0.71-0.88) 0.85 (0.75-0.96) 0.92 (0.79-1.07) < 0.001 < 0.001 
Poor quality of life excluded         
   Ever had cancer 1.00 (0.97-1.04) 1.00 0.98 (0.95-1.02) 1.01 (0.98-1.05) 0.99 (0.94-1.03) 0.93 (0.88-1.00) 0.11 0.12 
   Ever had cardiovascular disease 1.13 (1.09-1.17) 1.00 0.93 (0.89-0.97) 0.95 (0.90-0.99) 0.87 (0.82-0.91) 0.79 (0.74-0.85) < 0.001 < 0.001 
   Ever had diabetes 1.39 (1.33-1.45) 1.00 0.78 (0.74-0.82) 0.68 (0.64-0.72) 0.67 (0.62-0.71) 0.62 (0.57-0.68) < 0.001 < 0.001 
   Ever had Parkinson’s disease 1.17 (1.00-1.38) 1.00 0.99 (0.83-1.19) 0.78 (0.64-0.96) 0.73 (0.57-0.93) 0.50 (0.33-0.75) < 0.001 0.002 
   Hip fracture in past 5 years 1.08 (0.90-1.30) 1.00 1.02 (0.82-1.26) 0.80 (0.63-1.01) 0.85 (0.63-1.13) 1.00 (0.67-1.51) 0.08 0.23 
   Poor memory 1.10 (1.01-1.20) 1.00 0.94 (0.85-1.04) 0.78 (0.70-0.87) 0.88 (0.78-0.99) 0.92 (0.79-1.07) < 0.001 < 0.001 
Need help with daily tasks excluded         
   Ever had cancer 0.99 (0.96-1.03) 1.00 1.00 (0.96-1.04) 1.03 (0.99-1.07) 0.99 (0.94-1.03) 0.96 (0.90-1.03) 0.19 0.18 
   Ever had cardiovascular disease 1.11 (1.07-1.16) 1.00 0.95 (0.91-0.99) 0.96 (0.91-1.00) 0.88 (0.83-0.93) 0.80 (0.75-0.87) < 0.001 < 0.001 
   Ever had diabetes 1.36 (1.30-1.42) 1.00 0.76 (0.72-1.81) 0.67 (0.63-0.71) 0.66 (0.62-0.70) 0.60 (0.55-0.66) < 0.001 < 0.001 
   Ever had Parkinson’s disease 1.21 (1.00-1.47) 1.00 1.09 (0.88-1.35) 0.88 (0.70-1.11) 0.86 (0.66-1.13) 0.60 (0.38-0.93) < 0.001 0.08 
   Hip fracture in past 5 years 1.15 (0.92-1.44) 1.00 1.15 (0.90-1.48) 0.90 (0.68-1.18) 0.97 (0.69-1.35) 1.04 (0.65-1.68) 0.28 0.31 
   Poor memory 1.09 (0.99-1.19) 1.00 0.92 (0.82-1.03) 0.82 (0.73-0.92) 0.85 (0.75-0.97) 0.93 (0.80-1.10) < 0.001 0.15 
Models adjusted for sex, age, remoteness, education, household income, health insurance status, partner status, country of birth, smoking status and dose, body 
mass index, physical activity, fruit consumption, vegetable consumption, fibre intake, red meat consumption, processed meat consumption, parity (women), 
menopausal status (women), hormone replacement therapy use (women) and height. a< 1 drink per week. OR, Odds Ratio. CI, Confidence Interval. CVD, 
Cardiovascular Disease. 
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Table 7.5. (Continued) 
 OR of having illness by drinks/week (95% CI)   
Exclusion scenario Non-drinkera ≥ 1, ≤ 3.5 > 3.5, ≤ 7 > 7, ≤ 14 > 14, ≤ 28 > 28 pall pdrinkers 
Physical functioning score < 50% 
excluded 
        
   Ever had cancer 1.00 (0.96-1.04) 1.00 0.99 (0.95-1.04) 1.04 (1.00-1.09) 1.00 (0.95-1.05) 0.97 (0.91-1.04) 0.13 0.07 
   Ever had cardiovascular disease 1.10 (1.05-1.15) 1.00 0.95 (0.91-1.00) 0.96 (0.91-1.01) 0.88 (0.83-0.93) 0.80 (0.74-0.87) < 0.001 < 0.001 
   Ever had diabetes 1.32 (1.26-1.39) 1.00 0.78 (0.74-0.83) 0.66 (0.62-0.71) 0.65 (0.61-0.70) 0.60 (0.54-0.66) < 0.001 < 0.001 
   Ever had Parkinson’s disease 1.09 (0.89-1.34) 1.00 1.00 (0.80-1.25) 0.74 (0.58-0.95) 0.77 (0.58-1.03) 0.44 (0.26-0.74) < 0.001 0.005 
   Hip fracture in past 5 years 1.18 (0.89-1.55) 1.00 1.17 (0.86-1.58) 0.96 (0.69-1.34) 0.98 (0.66-1.46) 0.94 (0.52-1.69) 0.60 0.64 
   Poor memory 1.06 (0.95-1.18) 1.00 0.90 (0.79-1.01) 0.79 (0.69-0.89) 0.83 (0.72-0.96) 0.94 (0.78-1.12) < 0.001 0.003 
Ever had cancer or CVD excluded         
   Ever had cancer - - - - - - - - 
   Ever had cardiovascular disease - - - - - - - - 
   Ever had diabetes 1.41 (1.33-1.49) 1.00 0.77 (0.72-0.82) 0.67 (0.63-0.72) 0.69 (0.63-0.74) 0.65 (0.58-0.72) < 0.001 < 0.001 
   Ever had Parkinson’s disease 1.23 (0.98-1.54) 1.00 1.18 (0.92-1.52) 0.79 (0.59-1.05) 0.64 (0.45-0.92) 0.41 (0.22-0.79) < 0.001 < 0.001 
   Hip fracture in past 5 years 1.12 (0.89-1.41) 1.00 1.08 (0.83-1.40) 0.90 (0.67-1.20) 0.96 (0.67-1.36) 1.10 (0.69-1.78) 0.57 0.76 
   Poor memory 1.18 (1.07-1.31) 1.00 0.89 (0.78-1.00) 0.86 (0.76-0.98) 0.88 (0.76-1.02) 0.98 (0.82-1.17) < 0.001 0.07 
Death within 3 years of baseline 
excluded 
        
   Ever had cancer 1.00 (0.96-1.03) 1.00 0.99 (0.95-1.03) 1.03 (0.99-1.07) 0.99 (0.94-1.03) 0.94 (0.88-1.00) 0.07 0.07 
   Ever had cardiovascular disease 1.13 (1.08-1.17) 1.00 0.93 (0.89-0.97) 0.94 (0.90-0.98) 0.86 (0.92-0.90) 0.78 (0.73-0.84) < 0.001 < 0.001 
   Ever had diabetes 1.40 (1.34-1.46) 1.00 0.78 (0.74-0.82) 0.68 (0.65-0.72) 0.66 (0.62-0.71) 0.62 (0.57-0.68) < 0.001 < 0.001 
   Ever had Parkinson’s disease 1.20 (1.02-1.42) 1.00 1.06 (0.88-1.27) 0.79 (0.65-0.97) 0.76 (0.59-0.96) 0.44 (0.29-0.68) < 0.001 < 0.001 
   Hip fracture in past 5 years 1.12 (0.93-1.35) 1.00 1.07 (0.86-1.32) 0.87 (0.69-1.11) 0.89 (0.67-1.20) 0.94 (0.61-1.44) 0.21 0.43 
   Poor memory 1.09 (1.00-1.18) 1.00 0.90 (0.82-0.99) 0.78 (0.70-0.86) 0.82 (0.73-0.92) 0.90 (0.78-1.04) < 0.001 < 0.001 
Age ≥ 65 years excluded         
   Ever had cancer 1.00 (0.96-1.05) 1.00 0.97 (0.92-1.02) 1.02 (0.97-1.07) 0.99 (0.93-1.05) 0.99 (0.91-1.08) 0.60 0.45 
   Ever had cardiovascular disease 1.15 (1.08-1.22) 1.00 0.92 (0.86-0.99) 0.95 (0.89-1.02) 0.91 (0.85-0.99) 0.79 (0.72-0.88) < 0.001 < 0.001 
   Ever had diabetes 1.41 (1.32-1.49) 1.00 0.73 (0.68-0.79) 0.63 (0.58-0.68) 0.65 (0.59-0.71) 0.59 (0.52-0.66) < 0.001 < 0.001 
   Ever had Parkinson’s disease 1.34 (0.99-1.82) 1.00 1.12 (0.79-1.57) 1.21 (0.86-1.71) 1.11 (0.74-1.66) 0.74 (0.40-1.35) 0.21 0.55 
   Hip fracture in past 5 years 1.25 (0.88-1.77) 1.00 0.91 (0.60-1.38) 0.97 (0.64-1.46) 0.85 (0.52-1.39) 0.72 (0.38-1.37) 0.23 0.94 
   Poor memory 1.17 (1.05-1.30) 1.00 0.89 (0.78-1.02) 0.75 (0.65-0.86) 0.84 (0.73-0.98) 0.96 (0.80-1.14) < 0.001 < 0.001 
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Table 7.6. Odds of having illness by drinking pattern among drinkers at baseline by exclusion scenario in the 45 and Up Study (2006-2009), New South 
Wales, Australia. 
 OR of having illness by drinking-days per week - 
adjusted for total alcohol consumption (95% CI) 
  OR of having illness by drinks per drinking-day - 
adjusted for total alcohol consumption (95% CI) 
 
Exclusion scenario 1-2 3-5 6-7 p  ≤ 2 > 2, ≤ 4 > 4 p 
No exclusion          
   Ever had cancer 1.00 0.99 (0.96-1.03) 1.01 (0.97-1.05) 0.52  1.00 1.03 (1.00-1.07) 0.99 (0.93-1.06) 0.10 
   Ever had cardiovascular disease 1.00 0.98 (0.94-1.02) 0.99 (0.94-1.03) 0.70  1.00 0.93 (0.90-0.97) 0.93 (0.87-1.01) 0.004 
   Ever had diabetes 1.00 0.77 (0.74-0.81) 0.63 (0.59-0.67) < 0.001  1.00 1.03 (0.98-1.09) 1.34 (1.23-1.46) < 0.001 
   Ever had Parkinson’s disease 1.00 1.19 (0.99-1.45) 1.26 (1.03-1.56) 0.07  1.00 0.78 (0.64-0.96) 0.71 (0.49-1.03) 0.04 
   Hip fracture in past 5 years 1.00 1.05 (0.85-1.30) 0.95 (0.75-1.19) 0.62  1.00 1.09 (0.87-1.37) 1.59 (1.10-2.30) 0.04 
   Poor memory 1.00 0.85 (0.77-0.93) 0.88 (0.80-0.98) 0.002  1.00 0.90 (0.82-0.99) 1.09 (0.94-1.26) 0.006 
Poor overall health excluded          
   Ever had cancer 1.00 1.00 (0.96-1.03) 1.01 (0.97-1.06) 0.59  1.00 1.03 (1.00-1.07) 0.99 (0.93-1.06) 0.08 
   Ever had cardiovascular disease 1.00 0.99 (0.95-1.03) 1.00 (0.95-1.05) 0.87  1.00 0.94 (0.90-0.98) 0.94 (0.87-1.02) 0.01 
   Ever had diabetes 1.00 0.77 (0.73-0.81) 0.63 (0.59-0.67) < 0.001  1.00 1.03 (0.98-1.09) 1.31 (1.20-1.43) < 0.001 
   Ever had Parkinson’s disease 1.00 1.23 (1.01-1.51) 1.31 (1.04-1.63) 0.048  1.00 0.81 (0.66-1.01) 0.70 (0.47-1.04) 0.09 
   Hip fracture in past 5 years 1.00 1.04 (0.83-1.31) 1.00 (0.78-1.27) 0.90  1.00 1.02 (0.80-1.30) 1.48 (1.00-2.19) 0.10 
   Poor memory 1.00 0.84 (0.76-0.93) 0.90 (0.80-1.00) 0.004  1.00 0.90 (0.81-0.99) 1.08 (0.92-1.26) 0.01 
Poor quality of life excluded          
   Ever had cancer 1.00 1.00 (0.96-1.04) 1.02 (0.97-1.06) 0.60  1.00 1.04 (1.00-1.08) 1.01 (0.95-1.08) 0.07 
   Ever had cardiovascular disease 1.00 0.99 (0.94-1.03) 1.00 (0.95-1.05) 0.82  1.00 0.94 (0.90-0.98) 0.93 (0.87-1.01) 0.01 
   Ever had diabetes 1.00 0.79 (0.74-0.83) 0.64 (0.60-0.69) < 0.001  1.00 1.04 (0.98-1.10) 1.34 (1.23-1.47) < 0.001 
   Ever had Parkinson’s disease 1.00 1.19 (0.95-1.50) 1.37 (1.06-1.77) 0.06  1.00 0.81 (0.66-1.01) 0.70 (0.47-1.04) 0.09 
   Hip fracture in past 5 years 1.00 1.05 (0.81-1.37) 1.00 (0.75-1.34) 0.91  1.00 1.10 (0.86-1.41) 1.77 (1.20-2.61) 0.01 
   Poor memory 1.00 0.84 (0.74-0.95) 0.91 (0.79-1.04) 0.02  1.00 0.92 (0.83-1.02) 1.17 (1.00-1.37) 0.003 
Need help with daily tasks excluded          
   Ever had cancer 1.00 0.99 (0.96-1.03) 1.01 (0.97-1.06) 0.58  1.00 1.03 (0.99-1.07) 1.00 (0.94-1.08) 0.32 
   Ever had cardiovascular disease 1.00 0.99 (0.95-1.04) 1.00 (0.95-1.05) 0.97  1.00 0.93 (0.89-0.98) 0.92 (0.85-0.99) 0.007 
   Ever had diabetes 1.00 0.76 (0.72-0.80) 0.62 (0.58-0.66) < 0.001  1.00 1.05 (1.00-1.11) 1.34 (1.22-1.47) < 0.001 
   Ever had Parkinson’s disease 1.00 1.27 (1.01-1.58) 1.21 (0.94-1.56) 0.12  1.00 0.93 (0.74-1.17) 0.77 (0.49-1.19) 0.49 
   Hip fracture in past 5 years 1.00 1.03 (0.80-1.34) 0.94 (0.70-1.25) 0.74  1.00 1.08 (0.82-1.43) 1.63 (1.04-2.55) 0.09 
   Poor memory 1.00 0.85 (0.76-0.94) 0.88 (0.78-0.99) 0.008  1.00 0.92 (0.83-1.02) 1.11 (0.94-1.31) 0.03 
Models adjusted for total alcohol consumption, sex, age, remoteness, education, household income, health insurance status, partner status, country of birth, 
smoking status and dose, body mass index, physical activity, fruit consumption, vegetable consumption, fibre intake, red meat consumption, processed meat 
consumption, parity (women), menopausal status (women), hormone replacement therapy use (women) and height. OR, Odds Ratio. CI, Confidence Interval. 
CVD, Cardiovascular Disease. 
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Table 7.6. (Continued) 
 OR of having illness by drinking-days per week - 
adjusted for total alcohol consumption (95% CI) 
  OR of having illness by drinks per drinking-day - 
adjusted for total alcohol consumption (95% CI) 
 
Exclusion scenario 1-2 3-5 6-7 p  ≤ 2 > 2, ≤ 4 > 4 p 
Physical functioning score < 50% 
excluded 
         
   Ever had cancer 1.00 0.99 (0.95-1.03) 1.01 (0.97-1.06) 0.55  1.00 1.03 (0.99-1.07) 1.00 (0.93-1.07) 0.26 
   Ever had cardiovascular disease 1.00 0.99 (0.94-1.03) 0.99 (0.93-1.04) 0.82  1.00 0.95 (0.90-0.99) 0.97 (0.89-1.05) 0.08 
   Ever had diabetes 1.00 0.76 (0.72-0.81) 0.60 (0.56-0.64) < 0.001  1.00 1.06 (1.00-1.13) 1.38 (1.25-1.53) < 0.001 
   Ever had Parkinson’s disease 1.00 1.21 (0.96-1.53) 1.15 (0.88-1.51) 0.28  1.00 0.91 (0.71-1.16) 0.74 (0.46-1.20) 0.46 
   Hip fracture in past 5 years 1.00 1.03 (0.75-1.40) 0.94 (0.67-1.33) 0.84  1.00 1.00 (0.72-1.39) 1.34 (0.76-2.35) 0.53 
   Poor memory 1.00 0.85 (0.76-0.96) 0.90 (0.78-1.02) 0.03  1.00 0.84 (0.74-0.94) 1.06 (0.88-1.28) < 0.001 
Ever had cancer or CVD excluded          
   Ever had cancer - - - -  - - - - 
   Ever had cardiovascular disease - - - -  - - - - 
   Ever had diabetes 1.00 0.76 (0.71-0.81) 0.60 (0.55-0.65) < 0.001  1.00 1.07 (1.00-1.14) 1.44 (1.29-1.60) < 0.001 
   Ever had Parkinson’s disease 1.00 1.30 (0.98-1.72) 1.67 (1.23-2.28) 0.005  1.00 0.56 (0.41-0.76) 0.29 (0.14-0.57) < 0.001 
   Hip fracture in past 5 years 1.00 1.13 (0.86-1.50) 1.06 (0.78-1.44) 0.67  1.00 1.07 (0.80-1.43) 1.20 (0.73-1.97) 0.77 
   Poor memory 1.00 0.88 (0.78-0.99) 0.94 (0.82-1.07) 0.09  1.00 0.88 (0.78-0.99) 1.05 (0.87-1.26) 0.03 
Death within 3 years of baseline 
excluded 
         
   Ever had cancer 1.00 0.99 (0.96-1.03) 1.01 (0.97-1.06) 0.49  1.00 1.03 (0.99-1.07) 1.00 (0.93-1.06) 0.16 
   Ever had cardiovascular disease 1.00 0.99 (0.94-1.03) 0.98 (0.94-1.03) 0.68  1.00 0.94 (0.90-0.98) 0.94 (0.88-1.02) 0.01 
   Ever had diabetes 1.00 0.78 (0.74-0.82) 0.62 (0.59-0.66) < 0.001  1.00 1.04 (0.98-1.10) 1.35 (1.24-1.47) < 0.001 
   Ever had Parkinson’s disease 1.00 1.18 (0.97-1.43) 1.21 (0.97-1.51) 0.17  1.00 0.84 (0.68-1.04) 0.73 (0.49-1.08) 0.17 
   Hip fracture in past 5 years 1.00 1.06 (0.84-1.33) 1.05 (0.81-1.35) 0.90  1.00 1.10 (0.86-1.40) 1.42 (0.94-2.13) 0.24 
   Poor memory 1.00 0.85 (0.78-0.94) 0.87 (0.78-0.96) 0.003  1.00 0.88 (0.80-0.97) 1.12 (0.96-1.30) < 0.001 
Age ≥ 65 years excluded          
   Ever had cancer 1.00 0.99 (0.94-1.03) 1.00 (0.94-1.06) 0.76  1.00 1.03 (0.98-1.08) 1.00 (0.92-1.09) 0.46 
   Ever had cardiovascular disease 1.00 0.99 (0.93-1.05) 1.01 (0.93-1.09) 0.81  1.00 0.96 (0.91-1.02) 0.96 (0.87-1.07) 0.48 
   Ever had diabetes 1.00 0.73 (0.68-0.78) 0.60 (0.55-0.66) < 0.001  1.00 1.01 (0.94-1.09) 1.29 (1.15-1.45) < 0.001 
   Ever had Parkinson’s disease 1.00 1.45 (1.05-2.01) 1.74 (1.19-2.56) 0.02  1.00 0.68 (0.49-0.94) 0.58 (0.32-1.03) 0.045 
   Hip fracture in past 5 years 1.00 1.18 (0.81-1.74) 1.16 (0.73-1.85) 0.68  1.00 1.01 (0.70-1.48) 0.83 (0.43-1.63) 0.81 
   Poor memory 1.00 0.83 (0.73-0.94) 0.83 (0.72-0.96) 0.007  1.00 0.85 (0.75-0.97) 1.13 (0.94-1.35) 0.001 
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7.3 – Discussion and Conclusions 
 
Chapter 7 demonstrated that the occurrence of a large number of health conditions were associated 
with drinking cessation, and that indicators of general health were associated with higher odds of 
quitting than specific diseases. The highest odds were found for the general health indicators of poor 
overall health and poor quality of life, and the specific diseases of diabetes, Parkinson’s disease, 
poor memory and hip fracture. It was shown that accounting for cancer and cardiovascular disease 
alone will only address a small portion of the ‘sick-quitter effect’, while accounting for all associated 
diseases using a method such as exclusion is impractical due to a substantial decrease in sample size. 
Further, accounting for general indicators of health is likely to be a more effective approach than 
accounting for specific diseases, yet it was also shown that this is unlikely to address the ‘sick-quitter 
effect’ entirely. Further, limitation of excluding participants based on health status is the potential 
for selection bias. There were few differences in quitting by sex, age or smoking status, and the 
results appeared to be robust to sensitivity analyses. 
A key implication of the results is that the exclusion of participants with specific diseases or poor 
indicators of general health is likely to only partially address the ‘sick-quitter effect’, and other 
methods (preferably those without the potential for selection bias) may also need to be considered. 
Alternative methods of addressing the ‘sick-quitter effect’ include the use of lifetime abstainers or 
light drinkers (or both) as the reference group, calculating a log-linear trend in risk for drinkers only, 
assigning ex-drinkers to their former levels of drinking at analysis, ascertaining alcohol consumption 
at multiple time points (either retrospectively or prospectively from baseline), excluding outcomes 
that occur early in the period of follow-up and restricting the study to younger participants who 
have had fewer health events causing them to reduce or quit drinking. It is possible to perform most 
of these methods using the 45 and Up Study, with the exception of the use of lifetime abstainers as 
the reference group and assigning ex-drinkers to their former levels of drinking. The first wave of 
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follow-up was completed in 2016, which is after the date of the cancer (2010) and mortality (2014) 
ascertainment. Thus, while it was not possible to ascertain alcohol consumption at multiple time 
points for these analyses this could be conducted in the future. Therefore, to examine associations 
between alcohol consumption and cancer and mortality in Chapters 8 and 9 with reduced risk of bias 
from the ‘sick-quitter effect’, risks were estimated where possible using very light drinkers as the 
reference group, calculating a log-linear trend in risk for drinkers only, excluding outcomes that 
occur early in the period of follow-up and restricting the study to younger participants. 
The additional results showed that the odds of a disease in relation to quitting is not necessarily a 
good indicator of the potential for that disease to induce bias from the sick-quitter effect on its own. 
Accounting for the prevalence of each health variable is also important. For example, diseases that 
are highly related to quitting but are very uncommon would have a relatively small impact on the 
sick-quitter effect. Low physical functioning score and diabetes appeared to be health variables with 
both a relatively high prevalence and odds ratio. Thus, for any health condition potentially related to 
the ‘sick-quitter effect’, when determining exclusion criteria to reduce bias, it is important to 
consider both its association with drinking cessation and its prevalence in the cohort. 
It was then shown that illness is also related to reductions in alcohol consumption and changes in 
drinking pattern, however fewer health conditions were significantly associated with a decline to 
very light drinking compared to those associated with drinking cessation, and the odds ratios were 
generally smaller. There were associations with a decline in drinking frequency in relation to some 
diseases (e.g. diabetes, breast cancer and poor memory). Overall, participants with low physical 
functioning score were significantly more likely to quit or reduce intake, reduce their number of 
drinking-days, and increase the number of drinks per drinking-day. 
The odds of having poor indicators of general health also varied by total alcohol consumption, with 
higher odds of poor health outcomes observed among non-drinkers. There was generally a U-shaped 
association for the prevalence of poor health status by total alcohol consumption, and an inverse 
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association with drinking frequency. The odds of having selected diseases also varied by total alcohol 
consumption and drinking pattern, except for cancer. This means that despite the finding that cancer 
is associated with drinking behaviour change, potential confounding by prior cancer status may not 
bias risk estimates in the 45 and Up Study, unless there remain important differences in the 
distribution of cancer type or stage not examined here. 
The results suggest that when examining alcohol consumption as a log-linear variable, a sensitivity 
test restricting the calculation to participants consuming ≥ 7 drinks per week may be effective in 
reducing bias caused by participants decreasing their alcohol consumption to light drinking in 
response to ill-health. This is because light drinkers had poorer health status compared to moderate 
drinkers, with the odds of having poor general health indicators appearing to reach a minimum after 
approximately 7 drinks per week. This sensitivity test should therefore provide an estimate of the 
log-linear association between alcohol consumption and outcomes less biased by ill-health, under 
the assumption that any association between moderate drinking and better health status compared 
to light and non-drinking is not causal and is instead entirely attributable to confounding. 
Consistent with the analysis examining changes in drinking frequency in association with the 
occurrence of disease, frequent drinkers generally had lower odds of poor general health indicators 
at baseline, as well as diabetes and poor memory compared to infrequent drinkers. Persons 
consuming > 4 drinks per drinking-day were found to have higher odds of a low physical functioning 
score, diabetes and hip fracture, but no difference in odds for the other health variables. There were 
also lower odds of a number of health variables in participants consuming > 2 and ≤ 4 drinks per day 
compared to those consuming ≤ 2 drinks per day. It was found that the exclusion of participants with 
low physical functioning score performed best at reducing the uneven distribution of disease 
between categories of total alcohol consumption and drinks per drinking-day, however the 
improvements were only modest. For example, the odds of having cardiovascular disease and 
diabetes associated with non-drinking compared to very light drinking were only attenuated by 20 to 
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25%. No method of exclusion appeared to make a material difference to the uneven distribution of 
disease between categories of drinking frequency. The implication of these results is again that the 
exclusion of participants with low a physical functioning score may be an effective method to test for 
bias from the ‘sick-quitter effect’ when examining total alcohol consumption and drinks per drinking-
day (but cannot be expected to remove the bias entirely), while it may not be effective when 
examining drinking frequency. 
Taken together, these additional results suggest the exclusion of participants with a low physical 
functioning score is likely to be the most effective method examined here to assess bias from the 
‘sick-quitter effect’ when using an exposure of total alcohol consumption or drinks per drinking-day, 
while no method appeared to be effective when using drinking frequency. The potential for 
selection bias however is a disadvantage of exclusion by physical functioning score. Another method 
identified as likely to reduce bias when analysing alcohol consumption as a log-linear variable was 
restriction to participants consuming ≥ 7 drinks per week, as this removes the potential for bias from 
any participants who may have decreased their alcohol consumption to light drinking in response to 
poor health status. Further, restriction to participants aged less than 65 years is also likely to be 
effective due to the resulting decrease in overall prevalence of disease, limiting the potential for 
confounding by health status. One disadvantage of using this method in the 45 and Up Study is that 
it results in the exclusion of the majority of outcomes (cancer and mortality) as these are associated 
with greater age, thereby greatly reducing statistical power. The exclusion of participants who died 
within three years of baseline was generally not as effective in reducing the uneven distribution of 
baseline disease by measures of drinking at baseline, but has the advantages of excluding the least 
participants and a low likelihood of introducing selection bias. Therefore, in Chapters 8 and 9 all four 
methods were examined where possible to test for the possibility of bias due to the ‘sick-quitter 
effect’ and other changes in drinking amount and pattern in relation to ill-health. This enabled the 
investigation of the robustness of associations between moderate and frequent alcohol 
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consumption and decreased risk of health outcomes, and between non-drinking, heavy drinking and 
drinks per drinking-day and increased risk of health outcomes. 
The next chapter investigated the association between alcohol consumption, drinking pattern and 
cancer risk, with an examination of the likelihood that effect estimates may be over or 
underestimated due to bias from changes in drinking behaviours in response to ill-health. 
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Chapter 8 – Alcohol Consumption and Cancer Risk 
 
Chapter summary 
This chapter contains an article prepared for publication, which investigated the association 
between alcohol consumption and risk of various cancer types, with a focus on the effect of pattern 
of drinking. This was achieved by using baseline data from the 45 and Up Study linked to the NSW 
Central Cancer Registry to December 2010. The hazard of a cancer diagnosis was calculated for 
overall weekly alcohol intake assessed in three ways: as a categorical variable, a continuous log-
linear variable and a continuous restricted cubic spline variable. After adjusting for total alcohol 
consumption, the independent effect on cancer risk of two measures of drinking pattern, drinking-
days per week and mean drinks per drinking-day, was examined, along with an analysis accounting 
for both measures simultaneously. Interaction tests were performed to test for effect modification 
by sex and smoking status. Cancer types for which there was evidence of an independent effect of 
drinking pattern were identified. The findings of the article were presented at the University of 
Sydney Public Health Research Showcase 2017 (Sydney), the Australasian Epidemiological 
Association Annual Scientific Meeting 2017 (Sydney), the 45 and Up Study Annual Forum 2017 
(Sydney) and the Dietitians Association of Australia National Conference 2018 (Sydney). 
In additional analyses, sensitivity analyses examined possible bias in risk estimates due to the sick-
quitter effect. Risk estimates were then used to calculate population attributable fractions, 
estimates of absolute risk and number of persons needed to quit or reduce drinking to prevent one 
cancer case. 
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8.1 – Journal Article (Prepared for Publication) 
 
The following article is prepared for publication. The results of the proportional hazards assumption 
tests (Table E.1), the p-values for the interaction tests (Table E.2), and the Akaike information 
criterion results (Table E.3) are shown in Appendix E.1. The results of additional interaction tests for 
body mass index and hormone replacement therapy status are shown in Table E.2 in Appendix E.1 
and Table E.4 in Appendix E.2. 
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Abstract 
Background: Although alcohol has been associated with increased risk of incidence of a number of 
cancers, the particular role of patterns of drinking, has not been quantified in detail. We quantified 
these associations in the 45 and Up Study, a prospective cohort study in New South Wales (NSW). 
Methods: Cox proportional hazards were used to calculate hazard ratios (HR) and 95% confidence 
intervals (CI) of cancer risk associated with alcohol consumption (drinks/week) and pattern of 
drinking among 217,568 participants aged ≥ 45 years (2006-2009). Incident cancer cases were 
ascertained by linkage to the NSW Cancer Registry to December 2010. 
Results: In a median follow-up of 2.4 years, 7733 cancers occurred. Increasing total alcohol 
consumption was associated with increased risk of any cancer (HR/one drink increase in mean daily 
alcohol consumption: 1.02; 95% CI: 1.00-1.04), and cancers of the colorectum (1.07; 1.02-1.12), 
colon (1.10; 1.04-1.17), larynx (1.18; 1.02-1.36) and female breast (1.09; 1.01-1.18); inverse 
associations were observed for non-Hodgkin lymphoma, bladder and thyroid cancer. People 
consuming > 28 drinks per week had over 5 times the risk of liver cancer. After adjusting for overall 
weekly alcohol intake, the average number of drinks consumed on drinking-days was independently 
associated with risk of any cancer (1.17; 1.04-1.33 for > 4 drinks per drinking-day), mouth and 
pharynx cancer (2.45; 1.22-4.92), oesophageal squamous cell carcinoma (9.04; 1.71-47.7) and kidney 
cancer (2.61; 1.24-5.47). Risk of kidney cancer and all cancers combined was increased when more 
than 4 drinks were consumed per drinking-day on only one or two days in a week (i.e. heavy episodic 
drinking), while risk of colorectal and colon cancer was increased with heavy frequent drinking. 
Conclusions: Higher numbers of drinks per drinking-day, including both heavy episodic drinking and 
heavy frequent drinking, increased cancer risk independent of the risk associated with total alcohol 
consumption. 
Word count: 300  
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Introduction 
Alcohol consumption is an important risk factor for cancer, and has been estimated to account for 
2.8% of cancer incidence in Australia and 5.5% of cancer incidence globally[1, 2]. The International 
Agency for Research on Cancer (IARC) has determined that seven types of cancer are causally related 
to alcohol consumption: mouth, pharynx, oesophagus, colorectal, liver, larynx and female breast[3, 
4]. In addition, the World Cancer Research Fund (WCRF) concluded it is probable that heavy drinking 
increases risk of stomach cancer and low-volume drinking decreases risk of kidney cancer[5]. Both 
organisations conclude that evidence is suggestive of an association of heavy drinking with 
pancreatic cancer, with recent meta-analyses supporting this conclusion [6-9]. The evidence for 
other cancer types is less clear, although meta-analyses have found a positive association with 
gallbladder[6], lung[6] (but not in never-smokers[10]), melanoma[6] and prostate cancer[6, 11], and 
an inverse association with thyroid cancer[6, 12], Hodgkin lymphoma[6, 13] and non-Hodgkin 
lymphoma (NHL)[6, 14].  
One aspect of the alcohol-cancer risk relationship that is unclear is the influence of pattern of 
drinking[15, 16]. In general, there have been two patterns of interest in relation to disease 
outcomes: 1) low-volume frequent intake and 2) heavy infrequent intake, which is commonly 
referred to as either ‘binge drinking’ or ‘heavy episodic drinking’. Prospective studies have found 
that compared to non-drinking, daily low-volume drinking has been associated with lower risk of 
cardiovascular disease while heavy episodic drinking has been associated with higher risk[17, 18]. 
The many different ways in which drinking patterns are defined, the strong relationship between 
patterns and overall consumption levels and the diversity in the methods used to assess drinking 
patterns[19, 20] makes comparisons between studies difficult. Some studies report frequency of 
drinking occasions, for example, daily vs. weekly[15]. Other studies have reported the average 
number of drinks consumed per day that drinking occurs (i.e., mean drinks per drinking-day)[21]; 
and others, the highest number of drinks consumed in one day in a typical month[15, 22]. Higher 
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drinking frequency has also been reported to be inversely related to both drinks per drinking-day 
and the proportion of days with heavy episodic drinking[23]. Consequently, failure to account for 
drinks per drinking-day when examining the effect of drinking frequency (and vice versa) could 
potentially result in confounding of effect estimates for either of the two individual measures of 
drinking pattern alone. 
A recent analysis of two prospective, United States cohorts examined the influence of two measures 
of drinking pattern on cancer risk and found that risk of alcohol-related cancers was increased for 
men who consumed alcohol on more days of the week compared to those who consumed alcohol 
less frequently, even when accounting for total intake. For women, risk of alcohol-related cancer 
was increased among those who reported higher number of drinks consumed in one day in a typical 
month, a finding that was also reported in the same cohort study for breast cancer[22]. Other 
studies of drinking pattern and cancer risk have used differing measures of drinking pattern, levels of 
adjustment for confounding factors, study populations, sample sizes and cancer types under 
examination[21, 24-36]. Most of these studies did not, or only partially, adjusted the effects of 
drinking patterns for total alcohol consumption[21, 24-32]. That is, it was not possible to determine 
whether drinking pattern had an independent effect on risk or whether the effect was primarily 
mediated through total alcohol consumption. Furthermore, large prospective studies of drinking 
pattern and cancer risk are few, especially those which have examined multiple cancer types and 
have included adjustment for total alcohol consumption. 
The aim of our investigation was to use a large prospective Australian cohort study to quantify the 
risk of cancer in relation to total alcohol consumption and the independent effects of drinking 
frequency (number of alcohol drinking-days per week) and drinks per drinking-day. We directly 
compared the effects of low-volume infrequent drinking with low-volume daily drinking and heavy 
infrequent (episodic) drinking. 
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Methods 
Study sample 
The Sax Institute’s 45 and Up Study is a prospective cohort study of 266,794 participants, with 
methods previously described[37]. In summary, men and women aged ≥ 45 years were randomly 
sampled from the general population of New South Wales (NSW) between 2006 and 2009 using the 
Department of Human Services enrolment database. The database has records for all Australian 
citizens and permanents residents, as well as some temporary residents and refugees. Oversampling 
by a factor of two was performed for persons aged ≥ 80 years and persons living in rural and remote 
areas. Participants completed a health and lifestyle questionnaire, with an estimated response rate 
of 18%. Ethics approval for the 45 and Up Study was provided by the University of NSW Human 
Research Ethics Committee and the NSW Population Health Services Research Ethics Committee. 
Data linkage 
The 45 and Up Study questionnaire data were probabilistically linked to the NSW Cancer Registry 
(NSWCR) and the NSW Registry of Births Deaths and Marriages by the NSW Ministry of Health’s 
Centre for Health Record Linkage (CHeReL). The CHeReL used a best practice approach in privacy 
preserving record linkage[38] along with the open source probabilistic record linkage software 
Choice Maker[39]. The probabilistic matching process is highly accurate (false-positive and false-
negative rates < 0.4%) and a detailed explanation of the linkage process has been published 
elsewhere[40]. 
Cancer and mortality data 
Cancer incidence was ascertained from the NSWCR, which captures all primary cancers diagnosed in 
all NSW residents apart from non-melanoma skin cancer. Cancer diagnoses were available from 
January 1994 to December 2010 and were classified according to the International Classification of 
Diseases, version 10[41]. All cancers stated by IARC to be causally related to alcohol consumption 
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were examined separately, along with any cancer type examined in the IARC alcohol monographs or 
the WCRF reports[3-5] that had least 50 cases in the current study. Female breast cancer was 
examined separately from male breast cancer. All other cancer types were combined into an ‘other’ 
cancer group. All cancers combined, IARC-determined alcohol-related cancers combined (mouth and 
pharynx, oesophagus, colorectum, liver, larynx and female breast), and non-alcohol related cancers 
combined (all other cancer types) were also examined. Where subtype data was available, cancer of 
the oesophagus was subdivided by the histological subtypes adenocarcinoma (AC) and squamous 
cell carcinoma (SCC), due to evidence of a stronger association of alcohol with risk for SCC compared 
to AC[3, 4]. Cancer of the colorectum was subdivided into colon and rectum, due to evidence that 
the risk relationship may differ between these two sites[4]. Date of diagnosis was only available to 
the month, so all diagnosis dates were set to the 15th day of the month. The source of death data for 
censoring was via linkage to the NSW Registry of Births, Deaths and Marriages to December 2010. 
Alcohol consumption 
The question used to determine total alcohol consumption was “About how many alcoholic drinks do 
you have each week? One drink = a glass of wine, middy of beer or nip of spirits (put “0” if you do not 
drink, or have less than one drink each week)”. Responses were categorised into six values: ‘Non-
drinker (< 1 drink/week)’, ‘≥ 1 and ≤ 3.5 drinks/week’, ‘> 3.5 and ≤ 7 drinks/week’, ‘> 7 and ≤ 14 
drinks/week’, ‘> 14 and ≤ 28 drinks/week’ and ‘> 28 drinks/week’. The cut-points of 14 and 28 
drinks/week were chosen because they correspond with the Australian alcohol guidelines to 
minimise risk of long-term harm (≤ 2 drinks/day) and short-term harm (≤ 4 drinks/day)[42]. 
An additional question, “On how many days each week do you usually drink alcohol?”, was used to 
make three categorical drinking pattern variables which applied to drinkers only. Firstly, drinking-
days per week (drinking frequency) was coded with three values: ‘1-2 days per week’, ‘3-5 days per 
week’ and ‘6-7 days per week’. Secondly, mean drinks per drinking-day (with drinking-day being any 
day in a week where at least one alcoholic drink was consumed) was calculated by dividing the 
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number of drinks consumed per week by the number of days of alcohol consumption per week, 
giving the mean number of drinks per drinking-day. This variable was coded with three values: ‘≤ 2 
drinks per drinking-day’, ‘> 2 and ≤ 4 drinks per drinking-day’ and ‘> 4 drinks per drinking-day’. 
Finally, an ‘overall drinking pattern’ variable with nine categories was constructed by combining the 
drinking-days per week and drinks per drinking-day variables. This variable allowed for more specific 
drinking patterns to be examined, such as daily low-volume intake and heavy episodic drinking. 
Statistical analyses 
Participants with missing alcohol consumption data, a prior diagnosis of cancer (either self-reported 
or in the cancer registry dataset from January 1994) or had a date of death earlier than their 
questionnaire completion date were excluded from analysis. 
Hazard ratios (HR) and 95% confidence intervals (CI) of being diagnosed with cancer were calculated 
using Cox proportional hazards regression models using age as the underlying time variable[43]. 
Censoring occurred if a participant died, was diagnosed with a cancer type different to the type 
being analysed, or was not diagnosed with a cancer by the end of study period (December 2010). If a 
participant was diagnosed with more than one primary cancers in the same month, they were 
counted as a case in the analysis of each cancer type. If a participant reported a hysterectomy, 
bilateral oophorectomy or radical prostatectomy at baseline, they were excluded respectively from 
the analysis for endometrium, ovary and prostate cancer, but still included in the analysis of all 
cancers combined. 
For each cancer type, three analyses of total weekly alcohol consumption were performed. 1) 
Categorical levels of alcohol consumption were estimated. Light drinkers (≥ 1 and ≤ 3.5 drinks/week) 
were used as the reference group rather than non-drinkers to minimise bias from the ‘sick-quitter 
effect’, whereby ‘non-drinkers’ may have quit drinking due to cancer-related symptoms[44]. Tests 
for linear trend excluding non-drinkers were conducted by replacing the categorical alcohol 
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consumption variable with a continuous variable where the median level of alcohol consumption 
was assigned to participants within each category (to limit the impact of outliers). Two-way 
statistical interaction tests between alcohol consumption categories and sex, and between alcohol 
consumption categories and smoking status (never-smoking vs. ever-smoking) were conducted and 
the results stratified where relevant. This is because sex differences have been reported for alcohol 
and colorectal cancer risk, and differences between never- and ever-smokers for alcohol and cancers 
of the mouth, pharynx, oesophagus, liver and larynx[3, 4, 6]. 2) Total number of drinks/week was 
analysed as a continuous variable in log-linear Cox models with hazard ratios representing the 
change in risk per one drink increase in mean daily alcohol consumption, excluding non-drinkers. 3) 
To assess non-linearity, a restricted cubic spline was fitted with three knots at the 25th, 50th and 75th 
percentiles of alcohol consumption (excluding non-drinkers). The reference quantity of alcohol 
consumption was 1 drink per week. When graphed, the x-axis was truncated at 56 drinks per week 
for presentation purposes, but the model included participants up to the maximum quantity of 
drinking: 140 drinks per week. The Akaike Information Criterion (AIC) was used to compare the log-
linear and cubic spline models for best fit. 
Three drinking patterns were assessed in separate models. To prevent bias from the ‘sick-quitter 
effect’ these analyses were restricted to drinkers. All three drinking patterns were analysed 
separately using categorical and continuous covariate counterparts (the continuous version was 
coded as the median number of drinks in each category): 1) Drinking frequency with 3 levels: those 
who reported consuming alcohol on ‘1-2 days per week’ (reference), ‘3-5 days’, ‘6-7 days’ per week. 
2) Mean drinks per drinking-day, where ‘≤ 2 drinks per drinking-day’ was the reference category, 
compared to ‘> 2 and ≤ 4 drinks per drinking-day’, and ‘> 4 drinks per drinking-day’. These models 
were calculated both without adjustment for total alcohol consumption and adjusted for total 
alcohol consumption (as a continuous log-linear variable). Statistical interaction tests for drinking 
pattern as a categorical variable (after adjusting for total alcohol consumption) and sex and smoking 
status were performed for each of the first two drinking patterns and the results stratified where 
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appropriate. 3) An interaction test between the drinking frequency and drinks per drinking-day 
variables was performed for all cancer types. Where significant, drinking frequency stratified by 
levels of drinks per drinking-day and vice versa was examined, along with an overall drinking pattern. 
The overall drinking pattern combined drinking frequency and mean drinks per drinking-day into a 
3x3 matrix resulting in 9 categories (‘overall drinking pattern’). The reference group was the 
category with the lowest total alcohol consumption: ‘≤ 2 drinks per drinking-day’ consumed on ‘1-2 
days per week’. The matrix captured low-volume episodic drinking, heavy episodic ‘binge’ drinking 
(defined here as > 4 drinks per drinking-day on 1-2 days per week), low-volume daily drinking and 
heavy daily drinking. Overall drinking pattern was also examined for all cancers combined. 
All analyses were adjusted for a range of potential confounders as self-reported in the baseline 
questionnaire, including sex, age, remoteness, education, household income, health insurance 
status, partner status, country of birth, smoking status and intensity, body mass index and physical 
activity (see Supplementary Table 1). Remoteness categories were based on the 2006 ARIA 
(Accessibility/Remoteness Index of Australia) index[45]. Melanoma risk was additionally adjusted for 
time spent outdoors and skin tone. Dietary related variables (fruit, vegetable, fibre, red meat and 
processed meat consumption) were included as potential confounders in regression models for 
cancer types where the WCRF has found convincing or probable evidence of a causal relationship[5]. 
Analyses of colorectal cancer were additionally adjusted for fruit and vegetable consumption 
because these foods contain dietary fibre. Parity and age of first birth, breastfeeding time, 
menopausal status, hormonal contraceptive use, hormone replacement therapy (HRT) use were 
included as potential confounders in Cox models analysing cancers of the breast, endometrium and 
ovary. Hormonal contraceptive use was also included in regression models for liver cancer[46], and 
HRT use for colorectal cancer models[47]. Adjustment for aspirin use was made for oesophageal and 
colorectal cancer[48]. Finally, adjustment for history of bowel, breast and prostate screening was 
made for colorectum, breast and prostate cancer regression models. 
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A test of the proportional hazards assumption was performed for all Cox models. If significant 
violations were detected then log-log survival curves stratified by the variables in violation were 
plotted. If the lines were considerably non-parallel upon visual inspection, the model was stratified 
by the variable in violation. 
Analyses were performed using SAS 9.4. 
 
Results 
217,568 of 266,794 participants (81.5%) were included for analysis after excluding 5,041 (1.9%) 
participants with missing information on total alcohol consumption, a further 13 (0.005%) who died 
before the questionnaire date and 44,172 (16.6%) participants who had previously been diagnosed 
with cancer. Of included participants, 7,733 (3.6%) had at least one incident diagnosis of cancer by 
December 2010 in a median follow-up of 2.4 years. 
Overall, 145,605 (66.9%) participants consumed at least one alcoholic drink per week, including 
31,148 (14.3%) who consumed > 14 drinks per week. Of drinkers, 1,711 (1.2%) were excluded from 
the drinking pattern analyses due to missing information on number of drinking-days per week. Of 
the 143,894 drinkers included in the drinking pattern analyses, 51,957 (36.1%) consumed alcohol 6 
or 7 days per week and 15,286 (10.6%) reported an average of > 4 drinks per drinking-day. Very few 
women drinkers in the cohort (1.2%) were frequent heavy drinkers. Overall, 28,035 (19.5%) were 
low-volume daily drinkers, and 3452 (2.4%) reported infrequent (1-2 days) heavy (> 4 drinks) 
consumption and could be considered binge drinkers. 
Participants consuming higher numbers of drinks per week were, on average, more likely to be men, 
Australian-born, consumed processed meat > 1 time per week and spent ≥ 2 hours outdoors per day 
(Table 1). Drinkers tended to be younger than non-drinkers. Among women, participants consuming 
higher numbers of drinks per week were more likely to be nulliparous, had never breastfed and had 
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ever used hormonal contraceptives. Non-drinkers were more likely to be current smokers, physically 
inactive and aspirin users compared to light drinkers, and less likely to have had a university degree, 
a household income ≥ $70,000 per year, private health insurance or be married or living with a 
partner. Among women, a greater proportion of non-drinkers had never breastfed compared to 
those who consumed up to 14 drink per week. For most baseline characteristics, there was greater 
variation by drinks per drinking-day than by drinking frequency. Participants consuming more than 4 
drinks per drinking-day were more likely to be in lower socio-demographic categories and have 
unhealthy behavioural risk factors than those who consumed less than 4. Participants with higher 
drinking frequency were more likely to have private health insurance and a history of cancer 
screening, and less likely to be overweight or obese, while the reverse was true for participants with 
higher drinks per drinking-day. 
Among drinkers, a greater number of drinks per week was significantly associated with increased risk 
of cancers of the colorectum, colon alone, larynx and breast, alcohol-related cancer and all cancer, 
and decreased risk of NHL (Table 2). For liver cancer, there was evidence of greater risk in non-
drinkers and in those consuming > 28 drinks per week compared to those consuming ≥ 1 and ≤ 3.5 
drinks per week. Significant interactions between total alcohol consumption and sex were detected 
for alcohol-related cancers (p = 0.01) and all cancers combined (p = 0.04) and between total alcohol 
consumption and smoking status for cancers of the pancreas (p = 0.04) and kidney (p = 0.02), non-
alcohol-related cancer (p = 0.005) and all cancers combined (p = 0.004). When stratified by sex, risk 
of both alcohol-related cancer and all cancers combined was elevated in women compared to men 
for > 14 and ≤ 28 drinks per week, and in men compared to women for > 28 drinks per week 
(Supplementary Tables 2 and 3). When stratified by smoking status, risk of pancreatic cancer was 
most elevated in never-smokers compared to ever-smokers for > 7 and ≤ 14 drinks per week. For 
kidney cancer, risk was elevated in heavy drinking (> 28 drinks per day) never-smokers but not heavy 
drinking ever-smokers (Supplementary Tables 4 and 5). For both non-alcohol-related and all cancer 
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there were no large differences in hazard ratios by smoking status, except perhaps elevated risk in 
the non-drinking category among ever-smokers. 
Figure 1 shows the results of the log-linear models in which the risk associated with each additional 
drink per day was plotted for each cancer type. The direction and statistical significance of effect 
estimates were similar to the corresponding categorical models, but with an additional inverse 
association for thyroid cancer. 
Figure 2 shows the results of the restricted cubic spline models in which the risk associated with 
each additional drink per week was plotted by cancer type, accounting for a non-linear relationship 
with intake. The AIC was lower in the cubic spline model compared to the log-linear model for 
cancers of the colorectum, colon, breast, ovary and bladder (results not shown), suggesting non-
linear relationships between these cancer types and overall alcohol consumption among drinkers. 
After adjusting for total alcohol consumption, drinking frequency (drinking-days per week) was not 
significantly associated with any one cancer type, but more drinking-days per week was inversely 
associated with risk of any cancer (ptrend = 0.03; Table 3). A statistical interaction with sex was 
detected for alcohol-related cancers (p = 0.004) and with smoking status for breast cancer (p = 0.04). 
For alcohol-related cancer, the HR for 3-5 drinking-days per week was higher in women (HR: 1.10; 
95% CI: 0.92-1.31) than men (0.80; 0.63-1.01) (Supplementary Table 6). For breast cancer, the HRs 
for 3-5 and 6-7 drinking-days per week were higher for non-smokers ((1.26; 0.97-1.65) and (1.14; 
0.82-1.59) respectively) than for smokers ((0.97; 0.70-1.34) and (0.71; 0.47-1.08) respectively) 
(Supplementary Table 7). 
Table 4 shows the risk of cancer by mean drinks per drinking-day. After adjustment for total alcohol 
consumption, drinks per drinking-day was positively associated with risk of mouth and pharynx (ptrend 
= 0.01), oesophagus (SCC) (ptrend = 0.009), kidney (ptrend = 0.02), alcohol-related (ptrend = 0.04), non-
alcohol-related (ptrend = 0.04) and all cancer (ptrend = 0.007). For persons consuming > 2 and ≤ 4 drinks 
per drinking-day, there was evidence of decreased risk of colon cancer (HR: 0.75; 95% CI: 0.57-0.99) 
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and increased risk of ovarian cancer (3.54; 1.51-8.32). There was also evidence that risk differed by 
drinking category for colorectal cancer, which appeared to be due to elevated risk in persons 
consuming > 4 drinks per drinking-day compared to those consuming > 2 and ≤ 4 drinks. Statistical 
interactions with sex were detected for alcohol-related cancer (p = 0.02), and with smoking status 
for kidney cancer (p = 0.02) and multiple myeloma (p = 0.03). For alcohol-related cancer, the HR for > 
4 drinks per drinking-day was higher in men (1.42; 1.05-1.92) than women (1.08; 0.70-1.66) 
(Supplementary Table 8). For kidney cancer, the HR for > 2 and ≤ 4 drinks per drinking-day was 
higher in ever-smokers (1.87; 1.01-3.46) than never-smokers (0.20; 0.05-0.89) (Supplementary Table 
9). For multiple myeloma, the HR for ≥ 2 and < 4 drinks per drinking-day was higher in ever-smokers 
(3.07; 1.02-9.29) than never-smokers (0.45; 0.12-1.70). 
A significant interaction was found between drinking-days per week and drinks per drinking-day for 
cancers of the colorectum (p = 0.04), colon (p = 0.03) and kidney (p = 0.02). Stratified results are 
presented in Supplementary Tables 10 and 11. For colorectal and colon cancer, more drinking-days 
per week was positively associated with risk (ptrend = 0.04 and 0.03 respectively) in persons 
consuming > 4 drinks per drinking-day, while drinks per drinking-day was positively associated with 
risk (ptrend = 0.006 and < 0.001 respectively) in persons with 6-7 drinking-days per week. For kidney 
cancer, more drinking-days per week was inversely associated with risk (ptrend = 0.003) in persons 
consuming > 4 drinks per drinking-day, while drinks per drinking-day was positively associated with 
risk (ptrend = 0.009) in persons with 1-2 drinking-days per week. 
Table 5 shows the results of the overall drinking pattern analysis. For all cancers combined, there 
was a significantly elevated HR in those consuming > 4 drinks on 1-2 days per week (i.e. heavy 
episodic ‘binge’ drinkers) compared to those in the lowest consumption group (≤ 2 drinks on 1-2 
days/week). For colorectal and colon cancer there was a significantly elevated HR in those 
consuming > 4 drinks on 6-7 days per week, with a significantly lowered HR in those consuming > 2 
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and ≤ 4 drinks on 1-2 days per week for colorectal cancer only. For kidney cancer, there was a 
significantly elevated HR in those consuming > 4 drinks on 1-2 and 3-5 days per week. 
There were no violations of the proportional hazards assumption detected for the main exposure in 
any model. Violations were detected for some covariates in the total alcohol consumption models 
for colorectal cancer (partner status, fruit consumption, p = 0.02), thyroid cancer (health insurance 
status, p = 0.03), multiple myeloma (household income, health insurance status, p = 0.01) and 
alcohol-related cancers combined (partner status, physical activity, fruit consumption, p = 0.04). In 
each of the drinking pattern models violations were detected for colorectal cancer (p = 0.02 in 
drinking frequency and drinks per drinking-day models and 0.01 in overall drinking pattern model; 
partner status, BMI group). A violation was also detected for thyroid cancer in the mean drinks/day 
model (health insurance status, p = 0.048). Plotting the log-log graphs revealed non-parallel partner 
status strata for colorectal cancer (in both the total alcohol and drinking pattern models), but not for 
the other cancer types and variable strata (results not shown). A stratified Cox model was therefore 
used for colorectal cancer.  
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Discussion 
Consistent with the IARC monographs, we found that increasing numbers of alcoholic drinks per 
week was associated with increased risk of cancers of the colorectum, colon, larynx and female 
breast, alcohol-related cancers combined and all cancers combined. Consuming > 28 drinks per week 
was also associated with increased risk of liver cancer. The HR point estimates for > 28 drinks per 
week were elevated (> 1) for cancers of the mouth and pharynx, oesophagus and rectum but not to 
the point of statistical significance. For other cancers not considered to be alcohol-related by IARC 
but reported to be positively associated with alcohol intake in meta-analyses (stomach, pancreas, 
lung, melanoma and prostate) we found no significant effects. For cancers where alcohol is reported 
to be associated with decreased risk, such as thyroid cancer and NHL, we also found an inverse 
association, but not kidney cancer. A U-shaped association with alcohol among drinkers was found 
for bladder cancer, where low to medium volume drinking (between 1 and 29 drinks per week) was 
associated with lower risk and heavier drinking with no difference in risk compared to those 
consuming 1 drink per week. Our results also suggest that cancers of the colorectum, colon, breast 
and bladder have a non-linear relationship with alcohol consumption, meaning that the relationship 
with alcohol may be more complex than a simple dose-response relationship. Regarding drinking 
patterns, drinking frequency was positively associated with risk of colorectal and colon cancer in 
persons consuming > 4 drinks per drinking-day, inversely associated with risk of kidney cancer in 
persons consuming > 4 drinks per drinking-day, and inversely associated with risk of all cancers 
combined. Mean number of drinks per drinking-day was positively associated with risk of mouth and 
pharynx, oesophageal (SCC), colorectal (in those with 6-7 drinking-days per week), colon (in those 
with 6-7 drinking-days per week), kidney (in those with 1-2 drinking-days per week), alcohol-related, 
non-alcohol-related and all cancer. 
Our results for total weekly alcohol consumption and cancer risk are broadly consistent with 
previous research. Specifically, the positive associations with cancers of the colorectum, colon, liver, 
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larynx and breast, alcohol-related cancer combined and all cancer, and inverse associations for 
thyroid cancer and NHL. Alcohol is considered to be causally related to cancers of the mouth and 
pharynx, oesophagus and rectum. These cancers were not significantly associated with alcohol in our 
study, although the HR point estimates for consuming > 28 drinks per week were all above 1. Owing 
to the short follow-up period, it is possible that our analysis was underpowered for cancer types 
with fewer cases. The confidence intervals for consuming > 28 drinks per week were consistent with 
increased risk, particularly for mouth and pharynx and oesophageal cancer, which were consistent 
with a 3-fold increase in risk. Our confidence intervals are also consistent for some other cancer 
types which are possibly related to alcohol consumption, particularly for increased risk with stomach 
cancer and with decreased risk for kidney cancer. 
The functional form of the relationship between total alcohol consumption and cancer risk has been 
reported as largely log-linear[16], apart from colorectal cancer[5]. In addition to colorectal cancer, 
we found non-linear relationships for cancers of the colon, breast, ovary and bladder. According to 
the WCRF, there is evidence of a non-linear relationship for colorectal cancer with increased risk at 
high levels of alcohol intake (i.e. > 30 g ethanol per day, i.e. 3 Australian standard drinks per day). 
The shape of the risk curve for colorectal and colon cancer in our study was consistent with the 
WCRF conclusion. Our finding of a non-linear relationship for breast cancer is inconsistent with the 
WCRF report. The WCRF systematic literature review and meta-analyses for cancers of the breast 
and bladder found no evidence for a non-linear relationship, while for ovarian cancer a test of non-
linearity was not reported[5]. 
For bladder cancer, while there was no linear relationship with total alcohol intake, we observed a 
notable U-shaped association, whereby decreased risk was associated with moderate levels of 
weekly alcohol consumption in comparison to light drinking. This U-shaped relationship appears to 
be a novel finding, as both IARC and a recent meta-analysis reported no association[4, 6]. It is 
possible that the diuretic effect of alcohol could cause the bladder epithelium to be less subjected to 
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carcinogens[49]. Alternatively, there may be a role of the ‘sick-quitter effect’[44, 50], although our 
analysis accounted for this by excluding non-drinkers. Perhaps a similar effect applies to decreasing 
alcohol consumption as well as quitting[51], in which light drinkers may have previously reduced 
their drinking in response to early symptoms of bladder cancer. 
The ‘sick-quitter effect’ has also been suggested as an explanation for the protective associations 
seen for other cancer types[6, 12, 14]. For example, it has been reported that subtypes of NHL which 
characteristically produce symptoms before diagnosis (and may therefore cause a decrease in 
alcohol consumption prior to diagnosis) have an inverse association with alcohol consumption, while 
other subtypes without early symptoms do not[14]. If causal however, some of the proposed 
mechanisms for the association between alcohol and reduced risk for NHL are improved insulin 
sensitivity or an immunomodulatory effect[14], for thyroid cancer improved insulin sensitivity or 
altered thyroid or sex steroid hormone levels[12, 52], and for kidney cancer the antioxidant content 
of alcoholic beverages, the diuretic effect of alcohol reducing carcinogen exposure time or again 
improved insulin sensitivity[8]. The ‘sick-quitter effect’ may also explain our finding of elevated risk 
of liver cancer for non-drinkers in comparison to light drinkers. 
Our results for the independent effect of drinking pattern on risk of cancer are only partially 
consistent with previous research. This is not surprising given that we assessed drinking patterns in 
three different ways and observed different outcomes for each. Almost every study to date has used 
a unique method to assess the impact of drinking pattern on cancer outcomes. This demonstrates 
the difficulty of comparing outcomes for patterns of interest including ‘binge drinking’ and 
‘moderate drinking’ both within and across studies. Variation in study outcomes likely reflect the 
diversity of methods that have been used to assess drinking pattern. The patterns we compared 
directly to the literature were drinking frequency and drinks per drinking-day (including heavy 
episodic drinking). 
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For drinking frequency, more drinking-days per week was not independently associated with risk of 
any individual cancer type after accounting for total weekly consumption, consistent with a number 
of prior studies (i.e. breast cancer[22, 25, 33], stomach cancer (positive H. pylori status)[21], and 
mortality from 14 cancer types[31]). However, there are reports of increased risks of a number of 
cancer types associated with greater drinking frequency (i.e. mouth and pharynx cancer[29], mouth 
cancer[30], stomach cancer (negative H. pylori status)[21], prostate cancer[26], and mortality from 
oesophageal cancer in men[31]). Of the six studies which found a positive association between 
drinking frequency and risk of cancer[15, 21, 26, 29-31] where we did not, all except one ([15]) did 
not, or only partially, adjusted for total alcohol consumption. It is therefore not clear whether the 
observed associations between drinking frequency and increased risk were due to the impact of 
drinking frequency per se, or whether the results can simply be explained by more frequent drinkers 
consuming greater quantities of alcohol overall. 
More drinks per drinking-day was independently associated with increased risk of cancers of the 
mouth and pharynx, oesophagus (SCC) and kidney after adjusting for total alcohol consumption, 
with between 2.5 to 9 times increased risk observed among those reporting > 4 drinks per day. As far 
as we are aware, this is the first study to report an increased risk of these cancer types with pattern 
of drinking. Previous studies have found increased risks with increasing drinks per drinking-day or 
heavy episodic drinking for breast cancer[22, 24], stomach cancer (negative H. pylori status)[21], 
lung cancer (in smokers)[28], pancreatic cancer[34] and prostate cancer[26, 27], however we did 
not. However, our estimates may be underpowered for some of these cancer types (e.g. stomach 
and pancreatic cancer), and the confidence intervals for > 4 drinks per drinking-day in our analyses 
are consistent with a hazard ratio of 2 or more for many cancer types including stomach, liver, larynx 
and breast. Nevertheless, our results are consistent with studies reporting no association with 
stomach cancer (positive H. pylori status)[21] or lung cancer (non-smokers)[28]. Of the seven studies 
which found an association between greater drinks per drinking-day and risk of cancer where we did 
not[21, 22, 24, 26-28, 34], six did not, or only partially, adjusted for total alcohol consumption[21, 
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24, 26-28, 32]. Similar to drinking frequency, it therefore cannot be determined from these studies 
whether there was an independent effect of drinks per drinking-day. Previous studies found 
increased risk of both breast[24] and prostate cancer[26, 27] without adjusting for total alcohol 
intake, similar to our estimates unadjusted for total alcohol intake. 
For colorectal, colon and kidney cancer there was an interaction between drinking frequency and 
drinks per drinking-day. More drinking-days per week was positively associated with risk of 
colorectal and colon cancer and inversely associated with risk of kidney cancer in persons consuming 
> 4 drinks per drinking-day. Drinks per drinking-day was positively associated with risk in persons 
with 1-2 drinking-days per week for kidney cancer and in only in persons with 6-7 drinking-days per 
week for colorectal and colon cancer. When we analysed drinking frequency and drinks per drinking-
day simultaneously, we were able to compare patterns such as heavy episodic, or ‘binge’, drinking 
and low-volume ‘moderate’ daily drinking. In this analysis we found a significant independent effect 
for drinking pattern on all three cancers. Specifically, kidney cancer risk was 3.5 times higher among 
those consuming > 4 drinks per drinking-day within 1-2 days per week compared to low-volume 
‘moderate’ episodic drinkers (i.e. those averaging no more than 2 drinks on only 1-2 days in a week). 
This finding indicates an increased risk of kidney cancer in relation to heavy episodic binge drinking, 
which has not been reported previously. IARC concluded there is no causal association between 
alcohol consumption and kidney cancer[4], but reviews have found an inverse association with 
moderate drinking but not heavy drinking for kidney cancer[5, 6]. Thus, our findings could be 
interpreted as consistent with a slight decrease in risk associated with greater total alcohol 
consumption, except where heavy episodic drinking causes increased risk in heavy drinkers. 
Compared to light drinkers, the risk of colorectal and colon cancer was significantly higher among 
regular heavy drinkers, and for colorectal cancer only, lower risk among intermediate drinkers (those 
averaging > 2 and ≤ 4 drinks on 1-2 days). This is consistent with the WCRF report, which found 
evidence of increased risk only at high levels of alcohol intake. 
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For all cancers combined, we observed an independent inverse association with drinking frequency 
and an independent positive association with more drinks per drinking-day. Our results differ from 
studies which found positive associations between drinking frequency and all cancer mortality[31, 
36], and another study which reported no association after adjusting for total alcohol 
consumption[15]. Our findings for drinks per drinking-day are consistent with the confidence 
intervals of one study, which reported a positive association between drinks per drinking-day and all 
cancer mortality in men but not women[36], but differ from a second study, which found no 
association with highest number of drinks consumed in one day in a typical month and risk of all 
cancer[15]. When analysing drinking frequency and drinks per drinking-day simultaneously, the only 
individual drinking category associated with significant elevated risk was consuming alcohol 1-2 days 
per week and with > 4 drinks per drinking-day (i.e. heavy episodic drinking), however the interaction 
was not significant. An association of increased risk with heavy episodic drinking has also been 
reported in a previous study examining all cancer mortality[32]. While combining all cancers 
together has the advantage of providing more cancer cases, the overall hazard ratio understates the 
role of alcohol in many individual cancers. Overall, these results suggest there is an independent 
effect of drinks per drinking-day including heavy episodic drinking on all cancer risk. 
For alcohol-related cancers combined, we observed increased risk with more drinks per drinking-
day, and no association with drinking frequency. An interaction with sex was detected for drinks per 
drinking-day, which when stratified appeared to show the association with increased risk was limited 
to men who drink > 4 drinks per drinking-day. The results for drinks per drinking-day are inconsistent 
with one report which showed no association for heavy episodic drinking and alcohol-related cancer, 
although the authors state the analysis was underpowered for this outcome[35]. They are also 
inconsistent with a previous study finding no association with highest number of drinks consumed in 
one day in a typical month for alcohol-related cancer in men but an association with increased risk in 
women[15]. This study also examined drinking frequency, and our results are consistent with the 
finding of no association in women, but differed from the finding of an association with increased 
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risk in men[15]. Therefore, we have found new evidence of an independent effect of drinks per 
drinking-day for risk of alcohol-related cancer. 
One issue which may also explain the differences in results across studies is the inconsistent choice 
of potential confounders included. In an analysis of an American population survey, it was reported 
that infrequent drinkers had a higher prevalence of 13 of 15 measured risk factors compared to 
more frequent drinkers, including health insurance status, being physically inactive and having fair or 
poor overall health[23]. To a lesser extent these factors were also associated with heavy episodic 
drinking. Therefore, there is the potential for bias from confounding between studies due to 
unmeasured, or poorly measured, covariates that influence cancer risk. 
Our study has several strengths. It is a prospective cohort study with a large number of participants, 
and examined multiple cancer types using a consistent methodology. We directly compared drinking 
pattern measured in three different ways and adjusted for a large number of potential confounders. 
We used age as the underlying time variable to minimise potential confounding by age. We used a 
reference group of very light drinkers as opposed to ‘non-drinkers’ to mitigate bias from the ‘sick-
quitter effect’ and to ensure that any effect of drinking pattern is relative to other drinkers. The 
adjustment for total alcohol consumption enabled the independent effect of drinking pattern on 
cancer risk to be examined as separate from overall consumption. Adjusting for total alcohol 
consumption as a continuous (rather than a categorical variable, as in previous studies) should also 
have minimised bias from residual confounding by total alcohol consumption between drinking 
pattern groups. 
The limitations of our study include the possibility of being underpowered for cancer types with a 
low number of cases, which can be addressed by a longer period of follow-up. For breast cancer in 
particular, the drinking pattern analysis may be underpowered due to the small number of women 
with a high number of drinks per drinking-day. Due to the use of very light drinkers as the reference 
group instead of lifetime abstainers, the risk associated with total alcohol consumption may be 
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slightly underestimated (or overestimated, where hazard ratios were less than 1). For example, even 
very light drinking (≤ 0.5 drinks per day) has been associated with elevated risk for breast cancer[53]. 
Also, due to the questionnaire design our drinks per drinking-day variable was based on the mean 
level of alcohol consumption. Some participants who were in fact heavy episodic drinkers will 
therefore have been grouped with less intense drinkers. For example, a participant who consumes 
alcohol 2 days per week, with 5 drinks on one day and 1 on the other, would have been grouped 
with a participant who consumed alcohol 2 days per week, with 3 drinks on both days. It is possible 
that the risk profile of these two participants is different but we were unable to differentiate 
between them. Further, because heavy episodic drinking was found to be independently associated 
with increased cancer risk, averaging the total number of drinks across days of drinking may have 
resulted in risk estimates for the drinks per drinking-day variable to be underestimated. In addition, 
our drinking pattern analysis only included participants who usually consume at least one alcoholic 
drink per week, meaning that participants who engage in heavy episodic drinking less frequently 
than once per week were excluded (such as once a month, as has been captured previously[15]). 
However, a possible advantage of using mean drinks per drinking-day may be that it is more 
representative of a person’s usual exposure to alcohol than highest number of drinks consumed in 
one day over a period of time. 
A potential problem common to all observational studies measuring alcohol consumption is the 
tendency for participants to underreport intake[54]. This could bias findings if underreporting differs 
by drinking patterns and consumption levels. In both Australian and a Canadian studies, low-risk and 
non-heavy episodic drinkers were found to underreport their drinking to a greater extent than 
higher-risk and heavy episodic drinkers[55, 56]. On the other hand, an English study found 
underreporting to be disproportionately associated with heavy drinking, frequent drinking and non-
routine drinking compared to participants without these drinking behaviours[57]. If for example 
participants consuming alcohol 1-2 days per week underreported their total alcohol consumption to 
a greater extent than daily drinkers, this could result in conservative estimates of risk for total 
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alcohol consumption. Finally, despite our best efforts to control for covariates, confounding by 
unmeasured factors associated with drinking pattern and cancer risk could be responsible for at 
least part of our associations. For example, it was shown in a prospective study that declining health 
results in a reduction in drinking frequency[58], meaning that poorer health at baseline could bias 
estimates. 
 
Conclusion 
In conclusion, we used a large prospective study to examine the influence of total alcohol 
consumption on cancer risk, finding results largely consistent with those of prior research. Our 
robust investigation of the influence of drinking pattern on cancer risk suggests that number of 
drinks per drinking-day is independently associated with risk of cancers of the mouth, pharynx, 
oesophagus (SCC), colorectum, colon and kidney, as well as alcohol-related cancers combined and all 
cancer. More drinking-days per week was positively associated with risk of colorectal and colon 
cancer and inversely associated with risk of kidney cancer among persons consuming > 4 drinks per 
drinking-day. Heavy episodic ‘binge’ drinking was significantly related to kidney cancer and all 
cancer, while frequent heavy drinking was related to colorectal and colon cancer risk. These results 
have implications for burden of disease calculations, alcohol guidelines and government policies and 
programs aimed at reducing alcohol-related disease. Further, well-designed studies using a similar 
methodology to assess drinking pattern are needed to examine the effect of drinks per drinking-day, 
including heavy episodic drinking, on risk of cancer types for which our study may have been 
underpowered, such as cancers of the liver, stomach and pancreas. We provide evidence that 
limiting drinks per drinking-day, including both heavy episodic drinking and heavy frequent drinking, 
should be regarded as an approach to reduce cancer risk independent of and in addition to limiting 
total alcohol consumption. 
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Tables and figures 
Table 1. Socio-demographic and other characteristics by alcohol consumption in the 45 and Up Study (2006-2010), New South Wales, Australia. 
Characteristic at baseline 
Alcoholic drinks per week  Drinking frequency (days per week)  Drinks per drinking-day 
Non-drinkera ≥ 1 and ≤ 3.5 > 3.5 and ≤ 7 > 7 and ≤ 14 > 14 and ≤ 28 > 28  1-2 3-5 6-7  ≤ 2 > 2, ≤ 4 > 4 
n 71,963 34,093 42,083 38,281 22,598 8550  41,371 50,566 51,957  90,730 37,878 15,286 
Male (%) 32.1 41.0 43.4 52.8 71.8 89.5  46.8 49.9 59.3  42.2 63.8 84.7 
Mean age in years (SD) 63.2 (11.6) 60.5 (10.6) 61.6 (10.9) 60.8 (10.2) 60.6 (9.7) 59.8 (9.0)  59.3 (10.1) 59.2 (9.6) 63.7 (10.6)  61.8 (10.8) 59.4 (9.5) 58.7 (9.1) 
Major city resident (%) 53.3 54.2 52.2 51.3 48.8 45.2  53.8 52.2 49.0  52.5 50.9 46.7 
University degree (%) 18.0 26.7 27.3 28.7 27.2 19.4  25.1 29.6 26.4  28.2 28.0 18.5 
Household income ≥ $70,000b (%) 14.5 27.0 28.9 33.7 35.2 29.2  29.1 35.3 27.8  28.5 36.4 30.6 
Private health insurancec (%) 55.3 69.2 72.2 73.2 70.6 59.4  67.9 73.2 71.0  72.5 71.5 59.6 
Married or living with partner (%) 68.7 76.3 78.8 80.6 80.5 73.7  75.7 80.2 79.7  78.9 80.2 73.8 
Born in Australia (%) 71.9 72.0 75.1 76.8 78.2 81.3  74.3 76.7 76.0  73.9 78.1 80.5 
Current smoker (%) 7.7 5.7 5.3 6.9 10.1 18.8  7.7 6.1 8.3  5.0 8.6 17.9 
Overweight or obesed (%) 56.5 58.0 53.7 56.4 62.9 68.6  61.5 57.7 54.7  53.6 62.8 69.8 
Physically inactivee (%) 8.3 4.3 3.7 3.4 3.9 6.1  4.2 3.2 4.3  3.6 3.8 5.3 
< 2 fruit serves per dayf (%) 37.8 37.2 38.7 44.4 52.9 63.5  39.7 41.1 49.0  39.0 48.5 58.4 
< 5 vegetable serves per day (%) 64.6 66.4 65.3 67.1 70.0 73.1  67.4 66.6 67.8  65.6 69.4 72.0 
< 7 fibre serves per weekg (%) 15.2 13.6 11.2 13.6 17.1 27.4  14.9 13.2 14.8  11.9 16.0 24.3 
Red meat > 5 times per week (%) 9.7 8.4 9.0 10.6 14.2 21.5  8.8 9.3 13.9  9.3 11.8 17.9 
Processed meat > 1 time per week (%) 27.2 29.5 30.3 34.0 41.7 51.3  31.9 33.7 36.3  30.0 38.1 48.6 
≥ 2 hours spent outdoors per day (%) 63.9 67.1 70.3 72.8 76.9 80.6  68.9 71.5 74.7  69.5 74.8 79.1 
Fair skin tone (%) 68.9 68.1 69.6 69.8 70.1 70.1  67.5 69.7 70.8  69.6 69.4 69.1 
Nulliparous (women) (%) 10.0 9.7 10.5 12.3 16.5 22.1  10.0 11.4 13.1  10.6 14.0 16.8 
Never breastfed (women) (%) 24.2 18.8 19.6 21.0 26.2 33.4  19.6 19.6 22.6  19.4 23.5 28.9 
Post-menopausal (women) (%) 65.4 61.9 64.0 62.2 60.6 52.5  59.2 59.9 68.9  64.5 56.6 51.2 
Ever used HC (women) (%) 70.3 81.9 83.4 87.1 89.0 88.7  84.2 86.9 82.3  83.2 89.7 87.8 
Ever used HRT (women) (%) 34.3 36.0 38.6 38.4 38.8 35.8  34.3 36.9 42.4  38.7 35.4 31.6 
Current aspirin use (%) 22.0 19.0 19.9 19.8 21.0 20.9  18.1 18.0 23.0  20.2 19.1 19.8 
Ever had bowel screening (%) 43.9 46.2 49.2 50.3 50.8 46.8  44.7 48.6 52.6  49.5 49.3 44.8 
Ever had breast screening (women) (%) 85.2 87.2 89.2 88.9 87.4 82.1  86.5 88.7 89.7  89.0 86.7 82.1 
Ever had PSA test (men) (%) 65.3 67.7 69.9 70.6 69.7 64.5  66.3 68.8 71.2  70.8 69.4 63.9 
Percentages include participants with missing or invalid responses. a< 1 alcoholic drink per week. bPre-tax annual household income from all sources in Australian dollars. cIncluding 
Department of Veterans’ Affairs white or gold card. dBody mass index ≥ 25 kgm-2. eWeekly physical activity time = 0 minutes. fExcludes fruit juice. gServes of breakfast cereal and brown or 
wholemeal bread. SD, Standard Deviation. HC, Hormonal Contraceptives. HRT, Hormone Replacement Therapy. PSA, Prostate Specific Antigen. 
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Table 2. Hazard ratios and 95% confidence intervals of cancer risk by alcohol consumption in the 45 and Up Study (2006-2010), New South Wales, Australia. 
  Drinks/week   
Cancer type (ICD-10 code) n cases Non-drinkera ≥ 1 and ≤ 3.5 > 3.5 and ≤ 7 > 7 and ≤ 14 > 14 and ≤ 28 > 28 pb ptrendc 
Mouth and pharynx (C00-14) 150 0.63 (0.37-1.08) 1.00 0.92 (0.53-1.61) 1.08 (0.62-1.88) 1.09 (0.59-2.03) 1.65 (0.83-3.30) 0.10 0.24 
Oesophagus (C15) 76 1.00 (0.48-2.09) 1.00 0.91 (0.40-2.09) 0.68 (0.27-1.69) 1.01 (0.41-2.47) 1.68 (0.64-4.44) 0.64 0.21 
- Adenocarcinoma (C15) 49 1.03 (0.42-2.53) 1.00 0.90 (0.33-2.43) 0.50 (0.16-1.60) 0.88 (0.30-2.56) 1.29 (0.39-4.21) 0.76 0.60 
- Squamous cell carcinoma (C15) 24 1.40 (0.30-6.58) 1.00 1.49 (0.27-8.20) 1.40 (0.23-8.57) 2.32 (0.36-14.8) 5.40 (0.79-36.8) 0.53 0.08 
Colorectum (C18-20) 985 0.98 (0.80-1.20) 1.00 0.86 (0.68-1.07) 0.97 (0.77-1.21) 0.97 (0.75-1.26) 1.34 (0.98-1.84) 0.13 0.03 
- Colon (C18-19) 676 0.99 (0.78-1.26) 1.00 0.82 (0.62-1.08) 0.93 (0.71-1.23) 0.99 (0.72-1.36) 1.57 (1.07-2.29) 0.04 0.006 
- Rectum (C20) 315 0.92 (0.64-1.32) 1.00 0.90 (0.61-1.33) 1.00 (0.68-1.48) 0.90 (0.58-1.40) 1.09 (0.65-1.85) 0.96 0.73 
Liver (C22) 67 3.61 (1.27-10.2) 1.00 1.45 (0.42-4.98) 1.85 (0.55-6.20) 1.94 (0.54-6.97) 5.21 (1.51-17.9) 0.02 0.051 
Larynx (C32) 38 1.43 (0.38-5.33) 1.00 0.47 (0.08-2.80) 1.49 (0.38-5.81) 2.61 (0.70-9.70) 3.45 (0.85-13.9) 0.12 0.03 
Breast (C50d) 1012 0.96 (0.79-1.16) 1.00 1.13 (0.92-1.39) 1.25 (1.01-1.55) 1.60 (1.22-2.10) 0.71 (0.29-1.73) < 0.001 0.007 
Alcohol-related (C00-15;18-20;22;32;50d) 2325 0.97 (0.85-1.10) 1.00 0.98 (0.85-1.13) 1.09 (0.94-1.26) 1.17 (0.99-1.39) 1.49 (1.18-1.88) 0.002 < 0.001 
Stomach (C16) 112 1.52 (0.80-2.91) 1.00 1.45 (0.71-2.93) 1.21 (0.57-2.57) 1.26 (0.54-2.90) 1.59 (0.58-4.36) 0.83 0.38 
Pancreas (C25) 156 1.23 (0.73-2.08) 1.00 1.30 (0.74-2.28) 1.02 (0.55-1.90) 1.34 (0.70-2.57) 0.55 (0.16-1.87) 0.64 0.75 
Lung (C33-34) 546 0.98 (0.74-1.30) 1.00 0.93 (0.68-1.27) 0.90 (0.66-1.24) 1.06 (0.76-1.48) 0.91 (0.59-1.41) 0.92 0.92 
Melanoma (C43) 909 0.88 (0.71-1.09) 1.00 0.93 (0.74-1.17) 1.15 (0.92-1.43) 1.16 (0.90-1.49) 1.01 (0.70-1.45) 0.09 0.24 
Endometrium (C54.1) 132 1.59 (0.92-2.74) 1.00 0.68 (0.32-1.45) 1.23 (0.61-2.49) 1.68 (0.71-3.99) -e 0.11 0.40 
Ovary (C56) 67 0.55 (0.30-1.01) 1.00 0.24 (0.09-0.64) 0.73 (0.34-1.56) 0.95 (0.34-2.62) -e 0.08 0.82 
Prostate (C61) 1946 0.92 (0.78-1.07) 1.00 1.02 (0.87-1.20) 1.01 (0.86-1.18) 1.12 (0.95-1.32) 1.10 (0.90-1.36) 0.14 0.15 
Kidney (C64) 146 0.91 (0.53-1.58) 1.00 1.08 (0.61-1.92) 1.11 (0.62-1.97) 1.00 (0.53-1.89) 0.90 (0.39-2.08) 0.97 0.76 
Bladder (C67) 128 0.82 (0.50-1.34) 1.00 0.45 (0.24-0.84) 0.66 (0.37-1.17) 0.40 (0.19-0.84) 0.56 (0.22-1.36) 0.06 0.14 
Brain (C71) 91 0.91 (0.48-1.73) 1.00 0.96 (0.49-1.89) 0.79 (0.39-1.59) 0.51 (0.21-1.23) 0.76 (0.27-2.16) 0.73 0.39 
Thyroid (C73) 98 1.02 (0.58-1.79) 1.00 1.06 (0.57-1.99) 0.67 (0.32-1.41) 0.21 (0.05-0.93) 0.30 (0.04-2.34) 0.20 0.051 
Non-Hodgkin lymphoma (C82-85) 264 0.88 (0.61-1.27) 1.00 0.74 (0.49-1.12) 1.01 (0.68-1.51) 0.64 (0.38-1.08) 0.48 (0.20-1.14) 0.19 0.04 
Multiple myeloma (C90.0) 85 1.67 (0.79-3.52) 1.00 1.40 (0.62-3.14) 0.79 (0.31-2.01) 1.51 (0.61-3.72) 1.77 (0.58-5.45) 0.40 0.31 
Leukaemia (C91-95) 145 1.05 (0.63-1.75) 1.00 0.95 (0.54-1.66) 0.79 (0.44-1.43) 0.68 (0.34-1.35) 0.72 (0.29-1.81) 0.74 0.39 
Other (Other C;D45-47) 575 1.05 (0.82-1.36) 1.00 0.73 (0.54-1.00) 1.00 (0.75-1.35) 1.04 (0.74-1.45) 0.84 (0.52-1.37) 0.13 0.56 
Non-alcohol-related (Other C;D45-47) 5413 0.97 (0.89-1.06) 1.00 0.92 (0.84-1.01) 0.99 (0.90-1.09) 1.03 (0.93-1.14) 0.93 (0.81-1.07) 0.22 0.68 
All cancer (C00-97;D45-47) 7733 0.97 (0.90-1.04) 1.00 0.94 (0.87-1.01) 1.02 (0.94-1.10) 1.06 (0.97-1.16) 1.03 (0.92-1.17) 0.052 0.03 
Models were adjusted for covariates as shown in Supplementary Table 1. Cancer cases do not sum to totals as some participants were diagnosed with two primary cancers 
in the same month. a< 1 drink per week. bOverall. cLinear trend using median alcohol consumption of each category, excluding non-drinkers. dFemale breast cancer only. 
eZero cases in cell. ICD-10, International Classification of Diseases, version 10.  
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Figure 1. Hazard ratios (HR) and 95% confidence intervals (CI) of cancer risk per one drink increase in mean 
daily alcohol consumption among drinkers in the 45 and Up Study (2006-2010), New South Wales, Australia. 
Non-drinkers were excluded. Models were adjusted for cancer-specific covariates as listed in Supplementary 
Table 1. Cancer cases do not sum to totals as some participants were diagnosed with two primary cancers in 
the same month. Breast cancer in women only. SCC, Squamous Cell Carcinoma. AC, Adenocarcinoma. 
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Figure 2. Hazard ratios and 95% confidence intervals (CI) of cancer risk by alcohol consumption using restricted cubic splines among drinkers in the 45 and Up Study 
(2006-2010), New South Wales, Australia. Non-drinkers were excluded. Models were adjusted for cancer-specific covariates as listed in Supplementary Table 1. Cancer 
cases do not sum to totals as some participants were diagnosed with two primary cancers in the same month. Breast cancer in women only. AC, Adenocarcinoma. SCC, 
Squamous Cell Carcinoma. 
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Figure 2. (Continued) 
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Figure 2. (Continued) 
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Table 3. Hazard ratios (HR) and 95% confidence intervals (CI) of cancer risk by drinking-days per week among drinkers in the 45 and Up Study (2006-2010), New South Wales, Australia. 
  HR drinking-days per week - unadjusted for total alcohol 
consumption (95% CI) 
 HR drinking-days per week - adjusted for total alcohol 
consumption (95% CI) 
Cancer type (ICD-10 code) n cases 1-2 3-5 6-7 pa ptrendb  1-2 3-5 6-7 pa ptrendb 
Mouth and pharynx (C00-14) 114 1.00 0.87 (0.54-1.41) 0.80 (0.50-1.27) 0.64 0.35  1.00 0.81 (0.50-1.32) 0.66 (0.38-1.14) 0.34 0.14 
Oesophagus (C15) 50 1.00 0.84 (0.37-1.91) 1.17 (0.58-2.34) 0.66 0.57  1.00 0.81 (0.35-1.88) 1.07 (0.48-2.40) 0.77 0.81 
- Adenocarcinoma (C15) 33 1.00 0.77 (0.28-2.14) 1.09 (0.46-2.56) 0.75 0.74  1.00 0.77 (0.27-2.19) 1.09 (0.40-2.99) 0.76 0.80 
- Squamous cell carcinoma (C15) 15 1.00 1.47 (0.32-6.80) 1.92 (0.49-7.60) 0.64 0.34  1.00 1.36 (0.29-6.42) 1.49 (0.32-6.98) 0.87 0.62 
Colorectum (C18-20) 630 1.00 0.94 (0.76-1.16) 1.02 (0.83-1.24) 0.69 0.78  1.00 0.87 (0.70-1.08) 0.84 (0.67-1.06) 0.31 0.16 
- Colon (C18-19) 414 1.00 1.01 (0.77-1.31) 1.01 (0.79-1.30) 1.00 0.94  1.00 0.91 (0.69-1.19) 0.77 (0.58-1.03) 0.19 0.07 
- Rectum (C20) 220 1.00 0.78 (0.54-1.13) 1.02 (0.73-1.42) 0.25 0.72  1.00 0.76 (0.52-1.11) 0.95 (0.64-1.40) 0.28 0.90 
Liver (C22) 31 1.00 0.79 (0.27-2.37) 1.61 (0.66-3.95) 0.27 0.22  1.00 0.78 (0.26-2.38) 1.54 (0.54-4.33) 0.39 0.34 
Larynx (C32) 29 1.00 1.58 (0.39-6.34) 2.80 (0.82-9.62) 0.17 0.06  1.00 1.37 (0.34-5.62) 2.01 (0.52-7.76) 0.53 0.26 
Breast (C50c) 630 1.00 1.25 (1.02-1.52) 1.13 (0.92-1.40) 0.09 0.26  1.00 1.16 (0.94-1.42) 0.95 (0.74-1.23) 0.12 0.73 
Alcohol-related (C00-15;18-20;22;32;50c) 1483 1.00 1.06 (0.92-1.21) 1.06 (0.93-1.21) 0.65 0.43  1.00 0.99 (0.86-1.13) 0.89 (0.76-1.04) 0.25 0.14 
Stomach (C16) 66 1.00 0.87 (0.45-1.69) 0.90 (0.49-1.64) 0.91 0.75  1.00 0.80 (0.41-1.56) 0.71 (0.35-1.43) 0.62 0.34 
Pancreas (C25) 93 1.00 1.03 (0.60-1.75) 0.82 (0.49-1.39) 0.63 0.41  1.00 0.97 (0.56-1.68) 0.71 (0.38-1.32) 0.45 0.26 
Lung (C33-34) 348 1.00 0.78 (0.57-1.05) 0.91 (0.70-1.19) 0.26 0.69  1.00 0.78 (0.57-1.07) 0.94 (0.69-1.28) 0.27 0.82 
Melanoma (C43) 651 1.00 1.10 (0.89-1.35) 1.05 (0.86-1.29) 0.68 0.70  1.00 1.05 (0.85-1.31) 0.95 (0.75-1.21) 0.59 0.63 
Endometrium (C54.1) 52 1.00 0.93 (0.45-1.89) 1.36 (0.69-2.69) 0.49 0.36  1.00 0.91 (0.43-1.93) 1.30 (0.55-3.08) 0.64 0.55 
Ovary (C56) 39 1.00 0.81 (0.38-1.72) 0.66 (0.29-1.50) 0.61 0.32  1.00 0.75 (0.33-1.67) 0.55 (0.19-1.57) 0.53 0.26 
Prostate (C61) 1524 1.00 0.97 (0.84-1.12) 1.02 (0.90-1.17) 0.71 0.64  1.00 0.95 (0.82-1.09) 0.96 (0.82-1.12) 0.76 0.65 
Kidney (C64) 105 1.00 0.86 (0.53-1.40) 0.69 (0.42-1.12) 0.31 0.12  1.00 0.83 (0.50-1.38) 0.63 (0.35-1.13) 0.30 0.12 
Bladder (C67) 78 1.00 0.62 (0.34-1.15) 0.60 (0.36-1.02) 0.14 0.08  1.00 0.61 (0.33-1.15) 0.57 (0.30-1.08) 0.17 0.10 
Brain (C71) 65 1.00 0.76 (0.41-1.41) 0.66 (0.36-1.22) 0.40 0.19  1.00 0.75 (0.40-1.41) 0.62 (0.29-1.33) 0.46 0.22 
Thyroid (C73) 55 1.00 0.74 (0.41-1.34) 0.39 (0.18-0.84) 0.054 0.02  1.00 0.84 (0.43-1.62) 0.52 (0.20-1.37) 0.41 0.21 
Non-Hodgkin lymphoma (C82-85) 174 1.00 1.06 (0.72-1.55) 0.79 (0.54-1.16) 0.24 0.19  1.00 1.15 (0.77-1.72) 0.97 (0.61-1.56) 0.61 0.88 
Multiple myeloma (C90.0) 51 1.00 1.17 (0.54-2.54) 1.17 (0.56-2.45) 0.90 0.69  1.00 1.14 (0.52-2.52) 1.11 (0.47-2.61) 0.95 0.84 
Leukaemia (C91-95) 91 1.00 0.66 (0.39-1.13) 0.58 (0.35-0.97) 0.09 0.04  1.00 0.67 (0.39-1.17) 0.61 (0.33-1.14) 0.24 0.12 
Other (Other C;D45-47) 339 1.00 0.96 (0.72-1.29) 1.13 (0.86-1.48) 0.43 0.32  1.00 0.96 (0.71-1.30) 1.14 (0.83-1.57) 0.49 0.39 
Non-alcohol-related (Other C;D45-47) 3738 1.00 0.94 (0.86-1.02) 0.95 (0.87-1.03) 0.31 0.27  1.00 0.92 (0.85-1.01) 0.92 (0.83-1.01) 0.15 0.09 
All cancer (C00-97;D45-47) 5217 1.00 0.97 (0.90-1.04) 0.98 (0.91-1.05) 0.68 0.53  1.00 0.94 (0.87-1.02) 0.91 (0.84-0.99) 0.07 0.03 
Non-drinkers were excluded. Models were adjusted for cancer-specific covariates as listed in Supplementary Table 1. Cancer cases do not sum to totals as some participants were diagnosed 
with two primary cancers in the same month. aOverall. bLinear trend using median number of drinking-days per week of each category. cFemale breast cancer only. ICD-10, International 
Classification of Diseases, version 10. 
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Table 4. Hazard ratios (HR) and 95% confidence intervals (CI) of cancer risk by mean drinks per drinking-day among drinkers in the 45 and Up Study (2006-2010), New South Wales, 
Australia. 
  HR mean drinks per drinking-day - unadjusted for total 
alcohol consumption (95% CI) 
 HR mean drinks per drinking-day - adjusted for total alcohol 
consumption (95% CI) 
Cancer type (ICD-10 code) n cases ≤ 2 > 2 and ≤ 4 > 4 pa ptrendb  ≤ 2 > 2 and ≤ 4 > 4 pa ptrendb 
Mouth and pharynx (C00-14) 114 1.00 1.33 (0.84-2.09) 1.86 (1.09-3.19) 0.07 0.02  1.00 1.46 (0.90-2.37) 2.45 (1.22-4.92) 0.04 0.01 
Oesophagus (C15) 50 1.00 0.98 (0.47-2.04) 2.12 (1.00-4.50) 0.10 0.06  1.00 1.08 (0.50-2.35) 2.76 (1.01-7.53) 0.09 0.054 
- Adenocarcinoma (C15) 33 1.00 0.85 (0.36-2.01) 1.35 (0.52-3.52) 0.68 0.59  1.00 0.88 (0.35-2.23) 1.51 (0.40-5.71) 0.68 0.59 
- Squamous cell carcinoma (C15) 15 1.00 1.68 (0.39-7.25) 6.69 (1.67-26.8) 0.02 0.007  1.00 1.88 (0.42-8.53) 9.04 (1.71-47.7) 0.03 0.009 
Colorectum (C18-20) 630 1.00 0.87 (0.71-1.07) 1.42 (1.11-1.81) 0.002 0.02  1.00 0.81 (0.65-1.01) 1.15 (0.81-1.62) 0.03 0.74 
- Colon (C18-19) 414 1.00 0.83 (0.64-1.08) 1.67 (1.23-2.25) < 0.001 0.007  1.00 0.75 (0.57-0.99) 1.26 (0.83-1.94) 0.01 0.57 
- Rectum (C20) 220 1.00 0.93 (0.67-1.29) 1.14 (0.76-1.71) 0.65 0.62  1.00 0.88 (0.62-1.26) 0.99 (0.56-1.75) 0.75 0.88 
Liver (C22) 31 1.00 0.86 (0.34-2.18) 1.66 (0.67-4.11) 0.38 0.27  1.00 0.84 (0.32-2.21) 1.56 (0.47-5.14) 0.56 0.48 
Larynx (C32) 29 1.00 1.72 (0.73-4.08) 1.47 (0.52-4.17) 0.46 0.46  1.00 1.23 (0.50-3.05) 0.48 (0.10-2.20) 0.33 0.37 
Breast (C50c) 630 1.00 1.32 (1.09-1.60) 1.38 (0.91-2.08) 0.01 0.006  1.00 1.26 (1.01-1.58) 1.24 (0.76-2.03) 0.13 0.11 
Alcohol-related (C00-15;18-20;22;32;50c) 1483 1.00 1.07 (0.94-1.21) 1.50 (1.26-1.80) < 0.001 < 0.001  1.00 1.02 (0.89-1.17) 1.33 (1.04-1.69) 0.047 0.04 
Stomach (C16) 66 1.00 1.18 (0.65-2.14) 1.65 (0.77-3.50) 0.43 0.20  1.00 1.15 (0.60-2.22) 1.55 (0.54-4.43) 0.72 0.42 
Pancreas (C25) 93 1.00 1.14 (0.70-1.86) 0.78 (0.34-1.78) 0.67 0.74  1.00 1.03 (0.59-1.81) 0.60 (0.19-1.87) 0.56 0.48 
Lung (C33-34) 348 1.00 1.27 (0.99-1.63) 1.14 (0.81-1.59) 0.16 0.29  1.00 1.40 (1.06-1.84) 1.46 (0.93-2.30) 0.051 0.06 
Melanoma (C43) 651 1.00 1.14 (0.95-1.37) 1.16 (0.89-1.51) 0.30 0.19  1.00 1.10 (0.89-1.35) 1.05 (0.72-1.52) 0.65 0.68 
Endometrium (C54.1) 52 1.00 1.41 (0.73-2.71) -d 0.59 0.68  1.00 1.04 (0.45-2.39) -d 1.00 0.27 
Ovary (C56) 39 1.00 2.50 (1.24-5.04) -d 0.04 0.33  1.00 3.54 (1.51-8.32) -d 0.02 0.16 
Prostate (C61) 1524 1.00 1.15 (1.03-1.29) 1.14 (0.98-1.32) 0.04 0.0497  1.00 1.14 (1.00-1.30) 1.12 (0.90-1.39) 0.13 0.22 
Kidney (C64) 105 1.00 0.92 (0.57-1.48) 1.53 (0.88-2.67) 0.20 0.18  1.00 1.13 (0.67-1.90) 2.61 (1.24-5.47) 0.03 0.02 
Bladder (C67) 78 1.00 0.70 (0.40-1.23) 0.59 (0.26-1.35) 0.29 0.14  1.00 0.64 (0.34-1.21) 0.46 (0.14-1.51) 0.30 0.15 
Brain (C71) 65 1.00 0.73 (0.39-1.35) 0.88 (0.39-1.97) 0.60 0.59  1.00 0.75 (0.38-1.49) 0.97 (0.31-3.02) 0.67 0.82 
Thyroid (C73) 55 1.00 0.66 (0.32-1.40) 0.94 (0.32-2.82) 0.56 0.59  1.00 1.04 (0.46-2.34) 2.52 (0.73-8.75) 0.31 0.23 
Non-Hodgkin lymphoma (C82-85) 174 1.00 0.84 (0.58-1.22) 0.49 (0.25-0.95) 0.09 0.03  1.00 0.90 (0.59-1.38) 0.58 (0.24-1.38) 0.46 0.25 
Multiple myeloma (C90.0) 51 1.00 1.24 (0.65-2.38) 1.20 (0.47-3.05) 0.80 0.61  1.00 1.22 (0.59-2.53) 1.15 (0.31-4.22) 0.87 0.76 
Leukaemia (C91-95) 91 1.00 0.66 (0.38-1.14) 1.03 (0.53-2.00) 0.28 0.76  1.00 0.81 (0.44-1.47) 1.71 (0.70-4.15) 0.19 0.36 
Other (Other C;D45-47) 339 1.00 1.03 (0.79-1.35) 1.33 (0.94-1.88) 0.26 0.13  1.00 1.08 (0.80-1.45) 1.50 (0.93-2.40) 0.23 0.11 
Non-alcohol-related (Other C;D45-47) 3738 1.00 1.10 (1.02-1.19) 1.08 (0.97-1.20) 0.04 0.06  1.00 1.12 (1.03-1.22) 1.14 (0.98-1.32) 0.03 0.04 
All cancer (C00-97;D45-47) 5217 1.00 1.10 (1.03-1.17) 1.16 (1.06-1.28) 0.001 < 0.001  1.00 1.10 (1.02-1.18) 1.17 (1.04-1.33) 0.01 0.007 
Non-drinkers were excluded. Models were adjusted for cancer-specific covariates as listed in Supplementary Table 1. Cancer cases do not sum to totals as some participants were diagnosed 
with two primary cancers in the same month. aOverall. bLinear trend using median number of drinks per drinking-day of each category. cFemale breast cancer only. dZero cases in cell. ICD-10, 
International Classification of Diseases, version 10. 
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Table 5. Hazard ratios (HR) and 95% confidence intervals (CI) of cancer risk by drinking pattern 
among drinkers in the 45 and Up Study (2006-2010), New South Wales, Australia. 
  Drinking-days 
per week 
HR mean drinks per drinking-day (95% CI) 
Cancer type n cases ≤ 2 > 2 and ≤ 4 > 4 
Colorectum 630 1-2 1.00 0.54 (0.32-0.91) 0.99 (0.58-1.67) 
 3-5 0.91 (0.71-1.16) 0.69 (0.47-1.01) 1.04 (0.62-1.75) 
 6-7 0.81 (0.64-1.04) 0.92 (0.69-1.23) 1.47 (1.06-2.02) 
Colon 414 1-2 1.00 0.50 (0.25-1.00) 0.97 (0.48-1.94) 
  3-5 0.99 (0.74-1.34) 0.64 (0.39-1.05) 1.26 (0.66-2.40) 
  6-7 0.77 (0.57-1.04) 0.89 (0.62-1.29) 1.82 (1.23-2.69) 
Kidney 105 1-2 1.00 1.64 (0.67-4.03) 3.55 (1.49-8.48) 
 3-5 0.91 (0.45-1.83) 1.29 (0.59-2.83) 2.59 (1.03-6.49) 
 6-7 1.26 (0.67-2.38) 0.58 (0.24-1.38) 0.70 (0.25-1.95) 
All cancer 5217 1-2 1.00 1.01 (0.88-1.17) 1.27 (1.07-1.52) 
 3-5 0.96 (0.88-1.05) 1.08 (0.97-1.21) 1.02 (0.85-1.23) 
 6-7 0.95 (0.87-1.03) 1.06 (0.96-1.17) 1.11 (0.98-1.26) 
Non-drinkers were excluded. Models were adjusted for cancer-specific covariates as listed in 
Supplementary Table 1. 
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Supplementary data 
 
Supplementary Table 1. Covariates in models by cancer type in the 45 and Up Study (2006-2010), New South Wales, Australia. 
Cancer type (ICD-10 code) 
Age, remoteness, education, 
household income, health 
insurance status, partner 
status, country of birth, 
smoking status and dose, body 
mass index, physical activity Sex 
Fruit 
intake 
Vegetable 
intake 
Fibre and 
red meat 
intake 
Processed 
meat 
intake 
Time 
spent 
outdoors, 
skin tone 
Parity and age 
of first birth, 
breastfeeding 
time, 
menopausal 
status 
HC 
use 
HRT 
use 
Aspirin 
use 
Bowel, 
breast and 
prostate 
screening 
history 
Mouth and pharynx (C00-14) Yes Yes Yes Yes - - - - - - - - 
Oesophagus (C15) Yes Yes - - - - - - - - Yes - 
Colorectum (C18-20) Yes Yes Yes Yes Yes Yes - - - Yes Yes Bowel 
Liver (C22) Yes Yes - - - - - - Yes - - - 
Larynx (C32) Yes Yes Yes Yes - - - - - - - - 
Breast (C50a) Yes - - - - - - Yes Yes Yes - Breast 
Alcohol-related (C00-15;18-20;22;32;50a) Yes Yes Yes Yes Yes Yes - Yes Yes Yes Yes Bowel/Breast 
Stomach (C16) Yes Yes - - - Yes - - - - - - 
Pancreas (C25)  Yes Yes - - - - - - - - - - 
Lung (C33-34) Yes Yes Yes - - - - - - - - - 
Melanoma (C43) Yes Yes - - - - Yes - - - - - 
Endometrium (C54.1) Yes - - - - - - Yes Yes Yes - - 
Ovary (C56) Yes - - - - - - Yes Yes Yes - - 
Prostate (C61) Yes - - - - - - - - - - Prostate 
Kidney (C64) Yes Yes - - - - - - - - - - 
Bladder (C67) Yes Yes - - - - - - - - - - 
Brain (C71) Yes Yes - - - - - - - - - - 
Thyroid (C73) Yes Yes - - - - - - - - - - 
Non-Hodgkin lymphoma (C82-85) Yes Yes - - - - - - - - - - 
Multiple myeloma (C90.0) Yes Yes - - - - - - - - - - 
Leukaemia (C91-95) Yes Yes - - - - - - - - - - 
Other (Other C;D45-47) Yes Yes - - - - - - - - - - 
Non-alcohol-related (Other C;D45-47) Yes Yes Yes - - Yes Yes Yes Yes Yes - Prostate 
All cancer (C00-97;D45-47) Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes All three 
aFemale breast cancer only. ICD-10, International Classification of Diseases, version 10. HC, Hormonal Contraceptive. HRT, Hormone Replacement Therapy. 
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Supplementary Table 2. Hazard ratios and 95% confidence intervals of cancer risk by alcohol consumption in men in the 45 and Up Study (2006-2010), New South Wales, 
Australia. 
  Drinks/week   
Cancer type (ICD-10 code) n cases Non-drinkera ≥ 1 and ≤ 3.5 > 3.5 and ≤ 7 > 7 and ≤ 14 > 14 and ≤ 28 > 28 pb ptrendc 
Mouth and pharynx (C00-14) 96 0.45 (0.21-0.97) 1.00 0.85 (0.41-1.75) 0.96 (0.48-1.93) 1.18 (0.58-2.40) 1.58 (0.73-3.41) 0.053 0.17 
Oesophagus (C15) 53 0.85 (0.35-2.04) 1.00 0.76 (0.29-1.98) 0.48 (0.17-1.39) 0.79 (0.30-2.09) 1.13 (0.40-3.22) 0.73 0.43 
- Adenocarcinoma (C15) 41 1.17 (0.40-3.40) 1.00 1.11 (0.36-3.40) 0.66 (0.19-2.30) 1.04 (0.32-3.34) 1.43 (0.40-5.13) 0.89 0.51 
- Squamous cell carcinoma (C15) 9 0.36 (0.05-2.75) 1.00 0.36 (0.03-4.30) -d 0.61 (0.08-4.85) 0.82 (0.10-6.89) 0.93 0.34 
Colorectum (C18-20) 555 0.92 (0.70-1.22) 1.00 0.84 (0.62-1.13) 0.94 (0.70-1.26) 0.94 (0.69-1.29) 1.39 (0.98-1.97) 0.09 0.03 
- Colon (C18-19) 345 0.93 (0.65-1.32) 1.00 0.84 (0.57-1.23) 0.80 (0.54-1.18) 0.98 (0.65-1.46) 1.69 (1.10-2.61) 0.01 0.002 
- Rectum (C20) 215 0.94 (0.59-1.49) 1.00 0.83 (0.50-1.37) 1.17 (0.74-1.86) 0.87 (0.52-1.46) 1.14 (0.64-2.03) 0.64 0.81 
Liver (C22) 52 3.76 (1.12-12.7) 1.00 1.92 (0.49-7.46) 2.34 (0.62-8.92) 1.47 (0.32-6.66) 5.43 (1.39-21.2) 0.051 0.10 
Larynx (C32) -e 1.34 (0.35-5.09) 1.00 0.23 (0.02-2.21) 1.45 (0.37-5.68) 2.52 (0.68-9.39) 3.35 (0.83-13.6) 0.10 0.03 
Alcohol-related (C00-15;18-20;22;32) 789 0.93 (0.73-1.18) 1.00 0.85 (0.65-1.10) 0.96 (0.74-1.23) 1.01 (0.78-1.32) 1.54 (1.15-2.05) 0.001 < 0.001 
Stomach (C16) 76 1.57 (0.67-3.69) 1.00 1.84 (0.76-4.46) 1.53 (0.61-3.83) 1.40 (0.52-3.73) 1.74 (0.57-5.33) 0.84 0.44 
Pancreas (C25) 89 1.14 (0.54-2.42) 1.00 1.80 (0.86-3.78) 1.32 (0.60-2.88) 1.25 (0.54-2.89) 0.43 (0.09-2.01) 0.31 0.23 
Lung (C33-34) 308 1.08 (0.73-1.61) 1.00 0.97 (0.62-1.50) 1.08 (0.71-1.64) 1.16 (0.75-1.79) 1.05 (0.64-1.73) 0.96 0.70 
Melanoma (C43) 558 0.95 (0.70-1.28) 1.00 0.99 (0.73-1.35) 1.19 (0.89-1.60) 1.20 (0.88-1.64) 1.10 (0.74-1.65) 0.42 0.34 
Kidney (C64) 108 0.79 (0.41-1.50) 1.00 0.95 (0.49-1.83) 0.89 (0.47-1.72) 0.88 (0.44-1.75) 0.82 (0.35-1.97) 0.98 0.66 
Bladder (C67) 99 0.69 (0.39-1.23) 1.00 0.45 (0.23-0.89) 0.63 (0.34-1.16) 0.35 (0.16-0.77) 0.42 (0.16-1.13) 0.08 0.08 
Brain (C71) 60 1.71 (0.67-4.36) 1.00 1.31 (0.48-3.56) 1.41 (0.54-3.71) 0.80 (0.27-2.43) 1.18 (0.35-3.94) 0.65 0.72 
Thyroid (C73) 24 3.04 (0.67-13.8) 1.00 2.10 (0.41-10.9) 1.49 (0.27-8.22) 0.43 (0.04-4.84) 0.70 (0.06-7.94) 0.27 0.40 
Non-Hodgkin lymphoma (C82-85) 147 0.78 (0.47-1.28) 1.00 0.67 (0.39-1.16) 0.81 (0.48-1.36) 0.55 (0.30-1.02) 0.48 (0.20-1.19) 0.37 0.04 
Multiple myeloma (C90.0) 56 2.42 (0.81-7.22) 1.00 2.12 (0.68-6.60) 0.99 (0.28-3.52) 2.39 (0.75-7.60) 2.64 (0.59-10.0) 0.28 0.14 
Leukaemia (C91-95) 97 1.19 (0.62-2.26) 1.00 0.92 (0.46-1.86) 0.82 (0.41-1.66) 0.66 (0.30-1.45) 0.74 (0.28-1.96) 0.64 0.48 
Other (Other C;D45-47) 331 0.97 (0.69-1.37) 1.00 0.68 (0.45-1.01) 0.95 (0.65-1.39) 1.00 (0.69-1.49) 0.86 (0.51-1.46) 0.37 0.51 
Non-alcohol-related (Other C;D45-47f) 3910 0.97 (0.87-1.08) 1.00 0.97 (0.87-1.09) 1.02 (0.91-1.14) 1.05 (0.93-1.18) 0.99 (0.85-1.15) 0.71 0.46 
All cancer (C00-97;D45-47f) 4696 0.96 (0.87-1.06) 1.00 0.95 (0.86-1.06) 1.01 (0.91-1.12) 1.04 (0.94-1.16) 1.09 (0.95-1.24) 0.24 0.04 
Models were adjusted for cancer-specific covariates as listed in Supplementary Table 1. Cancer cases do not sum to totals as some participants were diagnosed with two 
primary cancers in the same month. a< 1 drink per week. bOverall. cLinear trend using median alcohol consumption of each category, excluding non-drinkers. dZero cases in 
cell. eCensored as this value would enable calculation of value for women (< 5 cases). fIncludes prostate cancer, which is not shown. ICD-10, International Classification of 
Diseases, version 10. 
 
 
 
308 
 
Supplementary Table 3. Hazard ratios and 95% confidence intervals of cancer risk by alcohol consumption in women the 45 and Up Study (2006-2010), New South Wales, 
Australia. 
  Drinks/week   
Cancer type (ICD-10 code) n cases Non-drinkera ≥ 1 and ≤ 3.5 > 3.5 and ≤ 7 > 7 and ≤ 14 > 14 and ≤ 28 > 28 pb ptrendc 
Mouth and pharynx (C00-14) 54 0.83 (0.38-1.84) 1.00 1.00 (0.42-2.38) 1.20 (0.49-2.95) 0.29 (0.04-2.32) -d 0.79 0.31 
Oesophagus (C15) 23 1.62 (0.36-7.37) 1.00 1.48 (0.27-8.14) 1.89 (0.21-11.7) 1.61 (0.14-19.0) 13.9 (1.13-172.2) 0.47 0.10 
- Adenocarcinoma (C15) 8 0.57 (0.11-3.07) 1.00 0.35 (0.03-3.93) -d -d -d 0.98 0.28 
- Squamous cell carcinoma (C15) 15 -e 1.00 -e -e -e -e 0.39 0.03 
Colorectum (C18-20) 430 1.05 (0.79-1.39) 1.00 0.88 (0.63-1.24) 1.01 (0.71-1.44) 1.14 (0.71-1.86) 0.74 (0.18-3.05) 0.84 0.58 
- Colon (C18-19) 331 1.07 (0.77-1.48) 1.00 0.80 (0.54-1.18) 1.12 (0.75-1.68) 1.05 (0.59-1.88) 0.50 (0.07-3.68) 0.50 0.81 
- Rectum (C20) 100 0.87 (0.49-1.54) 1.00 1.03 (0.54-1.95) 0.58 (0.26-1.32) 1.26 (0.51-3.11) 1.24 (0.16-9.55) 0.68 0.50 
Liver (C22) 15 2.86 (0.36-22.7) 1.00 -d -d 7.60 (0.65-89.3) -d 0.75 0.04 
Larynx (C32) < 5 -f 1.00 -f -f -f -f -f -f 
Alcohol-related (C00-15;18-20;22;32;50g) 1536 1.00 (0.86-1.17) 1.00 1.05 (0.89-1.25) 1.18 (0.99-1.41) 1.42 (1.13-1.80) 0.75 (0.37-1.52) 0.02 0.01 
Stomach (C16) 36 1.39 (0.52-3.74) 1.00 0.87 (0.25-3.03) 0.52 (0.10-2.72) 0.76 (0.09-6.68) -c 0.80 0.61 
Pancreas (C25) 67 1.28 (0.61-2.68) 1.00 0.75 (0.30-1.89) 0.60 (0.20-1.81) 2.01 (0.70-5.79) 2.74 (0.34-22.1) 0.23 0.049 
Lung (C33-34) 238 0.93 (0.63-1.37) 1.00 0.92 (0.59-1.43) 0.72 (0.44-1.18) 1.02 (0.58-1.78) 0.28 (0.04-2.03) 0.60 0.28 
Melanoma (C43) 351 0.84 (0.62-1.15) 1.00 0.87 (0.62-1.23) 1.11 (0.78-1.58) 1.25 (0.78-2.02) 0.88 (0.21-3.61) 0.38 0.38 
Kidney (C64) 38 1.41 (0.47-4.27) 1.00 1.76 (0.53-5.89) 2.46 (0.73-8.32) 1.81 (0.32-10.2) -d 0.78 0.42 
Bladder (C67) 29 1.26 (0.42-3.78) 1.00 0.39 (0.07-2.13) 0.60 (0.11-3.33) 0.90 (0.10-8.30) 6.82 (0.71-65.7) 0.28 0.27 
Brain (C71) 31 0.44 (0.17-1.14) 1.00 0.74 (0.29-1.87) 0.31 (0.08-1.18) 0.32 (0.04-2.62) -d 0.41 0.11 
Thyroid (C73) 74 0.79 (0.43-1.46) 1.00 0.93 (0.47-1.85) 0.56 (0.24-1.33) 0.20 (0.03-1.55) -d 0.55 0.04 
Non-Hodgkin lymphoma (C82-85) 117 1.02 (0.59-1.76) 1.00 0.84 (0.44-1.60) 1.42 (0.76-2.65) 0.85 (0.31-2.33) -d 0.66 0.84 
Multiple myeloma (C90.0) 29 1.10 (0.39-3.06) 1.00 0.77 (0.22-2.67) 0.71 (0.17-3.02) -d -d 0.98 0.16 
Leukaemia (C91-95) 48 0.85 (0.37-1.93) 1.00 1.01 (0.40-2.58) 0.73 (0.24-2.28) 0.87 (0.18-4.19) -d 0.99 0.73 
Other (Other C;D45-47) 244 1.20 (0.81-1.76) 1.00 0.81 (0.51-1.31) 1.10 (0.68-1.78) 1.26 (0.66-2.40) 0.71 (0.10-5.23) 0.47 0.54 
Non-alcohol-related (Other C;D45-47h) 1503 0.95 (0.82-1.11) 1.00 0.80 (0.67-0.96) 0.93 (0.77-1.12) 1.04 (0.81-1.33) 0.48 (0.21-1.09) 0.06 0.73 
All cancer (C00-97;D45-47g,h) 3037 0.98 (0.88-1.09) 1.00 0.92 (0.82-1.04) 1.04 (0.92-1.19) 1.22 (1.03-1.44) 0.61 (0.36-1.03) 0.009 0.14 
Models adjusted for covariates as shown in Supplementary Table 1. Cancer cases do not sum to totals as some participants were diagnosed with two primary cancers in the 
same month. a< 1 drink per week. bOverall. cLinear trend using median alcohol consumption of each category, excluding non-drinkers. dZero cases in cell. eNot possible to 
calculate due to zero deaths in reference group. fModel failed to converge. gIncludes breast cancer, which is not shown. hIncludes endometrium and ovary cancer, which are not 
shown. ICD-10, International Classification of Diseases, version 10. 
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Supplementary Table 4. Hazard ratios and 95% confidence intervals of cancer risk by alcohol consumption in never-smokers in the 45 and Up Study (2006-2010), New South 
Wales, Australia. 
  Drinks/week   
Cancer type (ICD-10 code) n cases Non-drinkera ≥ 1 and ≤ 3.5 > 3.5 and ≤ 7 > 7 and ≤ 14 > 14 and ≤ 28 > 28 pb ptrendc 
Mouth and pharynx (C00-14) 67 0.60 (0.30-1.17) 1.00 0.81 (0.39-1.67) 0.53 (0.21-1.31) 0.90 (0.32-2.52) 2.88 (0.91-9.08) 0.09 0.27 
Oesophagus (C15) 26 0.93 (0.29-2.95) 1.00 1.39 (0.40-4.78) 0.35 (0.04-3.20) 0.92 (0.10-8.49) 4.26 (0.44-41.4) 0.59 0.56 
- Adenocarcinoma (C15) 14 0.59 (0.14-2.53) 1.00 1.36 (0.32-5.73) -d 0.98 (0.10-9.96) -d 0.89 0.49 
- Squamous cell carcinoma (C15) 11 -e 1.00 -e -e -e -e 0.01 0.01 
Colorectum (C18-20) 484 0.96 (0.74-1.25) 1.00 0.92 (0.68-1.25) 0.78 (0.55-1.11) 0.96 (0.62-1.48) 1.52 (0.83-2.77) 0.40 0.24 
- Colon (C18-19) 357 0.99 (0.73-1.33) 1.00 0.84 (0.59-1.20) 0.81 (0.54-1.22) 0.75 (0.43-1.32) 1.42 (0.67-3.02) 0.52 0.75 
- Rectum (C20) 128 0.88 (0.52-1.49) 1.00 1.16 (0.66-2.04) 0.69 (0.34-1.40) 1.43 (0.70-2.90) 1.66 (0.61-4.53) 0.34 0.15 
Liver (C22) 28 7.25 (0.96-54.5) 1.00 1.77 (0.16-19.6) 4.03 (0.41-39.3) 2.70 (0.17-44.2) 8.90 (0.53-149.2) 0.18 0.27 
Larynx (C32) < 5 -f 1.00 -f -f -f -f 0.92 -f 
Breast (C50g) 632 0.85 (0.68-1.06) 1.00 1.11 (0.87-1.42) 1.25 (0.95-1.65) 1.52 (1.02-2.31) 1.64 (0.52-5.15) 0.005 0.01 
Alcohol-related (C00-15;18-20;22;32;50g) 1241 0.92 (0.78-1.08) 1.00 1.02 (0.85-1.22) 0.98 (0.80-1.21) 1.13 (0.85-1.50) 1.81 (1.16-2.81) 0.046 0.02 
Stomach (C16) 56 0.68 (0.31-1.47) 1.00 1.15 (0.51-2.60) 0.90 (0.34-2.41) 1.10 (0.34-3.61) -d 0.79 0.31 
Pancreas (C25) 70 0.96 (0.46-2.01) 1.00 0.96 (0.41-2.23) 1.44 (0.62-3.32) 1.78 (0.66-4.79) 0.99 (0.13-7.90) 0.71 0.41 
Lung (C33-34) 87 1.14 (0.61-2.12) 1.00 0.86 (0.40-1.83) 0.92 (0.39-2.18) 0.90 (0.25-3.21) -d 0.96 0.48 
Melanoma (C43) 521 0.78 (0.60-1.02) 1.00 0.87 (0.66-1.15) 1.12 (0.85-1.49) 1.09 (0.76-1.56) 0.99 (0.54-1.82) 0.09 0.53 
Endometrium (C54.1) 91 2.15 (1.06-4.37) 1.00 0.77 (0.28-2.06) 2.01 (0.83-4.87) 1.43 (0.31-6.67) -d 0.08 0.27 
Ovary (C56) 47 0.61 (0.29-1.27) 1.00 0.32 (0.10-0.99) 0.98 (0.38-2.52) 1.61 (0.45-5.78) -d 0.23 0.65 
Prostate (C61) 975 0.88 (0.72-1.07) 1.00 0.95 (0.77-1.17) 0.96 (0.77-1.18) 1.12 (0.89-1.41) 1.06 (0.75-1.50) 0.36 0.27 
Kidney (C64) 60 1.14 (0.50-2.61) 1.00 1.75 (0.75-4.10) 1.09 (0.41-2.94) 0.54 (0.11-2.56) 4.03 (1.28-12.7) 0.08 0.15 
Bladder (C67) 39 0.72 (0.31-1.68) 1.00 0.58 (0.20-1.69) 0.29 (0.06-1.39) 0.96 (0.25-3.73) 1.01 (0.12-8.32) 0.69 0.96 
Brain (C71) 39 0.56 (0.23-1.35) 1.00 0.89 (0.38-2.11) 0.58 (0.21-1.62) -d 0.68 (0.08-5.48) 0.79 0.15 
Thyroid (C73) 55 0.69 (0.36-1.32) 1.00 0.49 (0.21-1.17) 0.54 (0.21-1.42) -d -d 0.66 0.03 
Non-Hodgkin lymphoma (C82-85) 141 0.99 (0.60-1.61) 1.00 1.04 (0.60-1.79) 1.28 (0.73-2.26) 0.54 (0.20-1.44) -d 0.64 0.10 
Multiple myeloma (C90.0) 55 1.35 (0.60-3.03) 1.00 1.33 (0.55-3.22) 0.52 (0.16-1.74) 0.81 (0.21-3.10) 0.84 (0.10-6.86) 0.58 0.63 
Leukaemia (C91-95) 64 0.90 (0.43-1.85) 1.00 1.06 (0.48-2.35) 1.02 (0.43-2.43) 0.42 (0.09-1.93) 1.53 (0.33-7.10) 0.84 0.85 
Other (Other C;D45-47) 299 1.01 (0.72-1.41) 1.00 0.76 (0.50-1.15) 0.95 (0.62-1.45) 1.17 (0.70-1.96) 1.43 (0.67-3.06) 0.45 0.16 
Non-alcohol-related (Other C;D45-47) 2603 0.91 (0.81-1.03) 1.00 0.90 (0.79-1.02) 0.99 (0.87-1.13) 1.03 (0.88-1.21) 1.04 (0.80-1.33) 0.27 0.47 
All cancer (C00-97;D45-47) 3842 0.91 (0.83-1.01) 1.00 0.94 (0.84-1.04) 0.99 (0.88-1.11) 1.06 (0.92-1.11) 1.16 (0.93-1.21) 0.07 0.08 
Models were adjusted for cancer-specific covariates as listed in Supplementary Table 1. Cancer cases do not sum to totals as some participants were diagnosed with two 
primary cancers in the same month. a< 1 drink per week. bOverall. cLinear trend using median alcohol consumption of each category, excluding non-drinkers. dZero cases in cell. 
eNot possible to calculate due to zero deaths in reference group. fModel failed to converge. gFemale breast cancer only. ICD-10, International Classification of Diseases, version 
10. 
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Supplementary Table 5. Hazard ratios and 95% confidence intervals of cancer risk by alcohol consumption in ever-smokers in the 45 and Up Study (2006-2010), New 
South Wales, Australia. 
  Drinks/week   
Cancer type (ICD-10 code) n cases Non-drinkera ≥ 1 and ≤ 3.5 > 3.5 and ≤ 7 > 7 and ≤ 14 > 14 and ≤ 28 > 28 pb ptrendc 
Mouth and pharynx (C00-14) 83 0.69 (0.28-1.67) 1.00 1.12 (0.46-2.70) 1.77 (0.79-3.97) 1.39 (0.58-3.34) 1.60 (0.62-4.12) 0.15 0.56 
Oesophagus (C15) 50 1.03 (0.39-2.71) 1.00 0.67 (0.22-2.09) 0.77 (0.27-2.24) 0.95 (0.33-2.71) 1.31 (0.43-4.01) 0.87 0.35 
- Adenocarcinoma (C15) 35 1.35 (0.43-4.27) 1.00 0.65 (0.16-2.63) 0.69 (0.19-2.61) 0.90 (0.25-3.24) 1.40 (0.37-5.37) 0.73 0.55 
- Squamous cell carcinoma (C15) 13 0.35 (0.05-2.57) 1.00 0.73 (0.10-5.30) 0.64 (0.09-4.64) 1.18 (0.19-7.37) 1.05 (0.14-8.08) 0.85 0.51 
Colorectum (C18-20) 501 1.00 (0.73-1.35) 1.00 0.78 (0.56-1.10) 1.10 (0.81-1.51) 0.99 (0.71-1.40) 1.34 (0.90-1.97) 0.11 0.07 
- Colon (C18-19) 319 1.01 (0.68-1.49) 1.00 0.81 (0.52-1.24) 1.06 (0.70-1.58) 1.15 (0.75-1.76) 1.72 (1.06-2.79) 0.06 0.003 
- Rectum (C20) 187 0.94 (0.57-1.55) 1.00 0.71 (0.41-1.23) 1.12 (0.69-1.84) 0.73 (0.42-1.28) 0.98 (0.53-1.84) 0.39 0.72 
Liver (C22) 39 2.16 (0.62-7.57) 1.00 1.22 (0.29-5.12) 1.18 (0.28-4.96) 1.38 (0.33-5.88) 3.25 (0.81-13.1) 0.35 0.13 
Larynx (C32) -d 0.96 (0.24-3.89) 1.00 0.46 (0.08-2.75) 1.35 (0.35-5.27) 2.22 (0.60-8.24) 2.35 (0.57-9.80) 0.25 0.08 
Breast (C50e) 380 1.26 (0.89-1.78) 1.00 1.19 (0.82-1.72) 1.33 (0.92-1.91) 1.76 (1.18-2.64) 0.42 (0.10-1.74) 0.06 0.19 
Alcohol-related (C00-15;18-20;22;32;50e) 1084 1.07 (0.87-1.32) 1.00 0.94 (0.74-1.18) 1.21 (0.97-1.50) 1.23 (0.97-1.56) 1.44 (1.08-1.92) 0.02 0.003 
Stomach (C16) 56 5.60 (1.32-23.8) 1.00 2.80 (0.59-13.2) 2.92 (0.63-13.6) 2.72 (0.56-13.3) 4.54 (0.90-23.1) 0.11 0.13 
Pancreas (C25) 86 1.56 (0.74-3.29) 1.00 1.59 (0.73-3.49) 0.76 (0.31-1.87) 1.30 (0.54-3.14) 0.51 (0.11-2.42) 0.22 0.40 
Lung (C33-34) 459 0.94 (0.69-1.28) 1.00 0.95 (0.67-1.34) 0.91 (0.64-1.27) 1.07 (0.75-1.52) 0.90 (0.58-1.42) 0.93 0.95 
Melanoma (C43) 388 1.15 (0.79-1.68) 1.00 1.04 (0.70-1.54) 1.22 (0.84-1.77) 1.31 (0.89-1.93) 1.15 (0.71-1.88) 0.73 0.27 
Endometrium (C54.1) 41 0.92 (0.38-2.26) 1.00 0.60 (0.19-1.93) 0.59 (0.18-1.90) 1.43 (0.47-4.38) -f 0.70 0.97 
Ovary (C56) 20 0.43 (0.14-1.35) 1.00 0.11 (0.01-0.89) 0.38 (0.10-1.38) 0.34 (0.07-1.78) -f 0.32 0.31 
Prostate (C61) 971 0.98 (0.76-1.26) 1.00 1.14 (0.89-1.46) 1.09 (0.85-1.38) 1.17 (0.92-1.49) 1.17 (0.89-1.54) 0.50 0.34 
Kidney (C64) 86 0.78 (0.37-1.63) 1.00 0.72 (0.33-1.57) 1.01 (0.50-2.06) 0.97 (0.46-2.04) 0.35 (0.10-1.26) 0.54 0.24 
Bladder (C67) 89 0.86 (0.47-1.58) 1.00 0.39 (0.18-0.85) 0.72 (0.38-1.38) 0.31 (0.13-0.75) 0.49 (0.18-1.35) 0.04 0.09 
Brain (C71) 52 1.70 (0.61-4.70) 1.00 1.15 (0.38-3.45) 1.17 (0.40-3.40) 1.00 (0.32-3.11) 1.18 (0.31-4.51) 0.85 0.88 
Thyroid (C73) 43 2.73 (0.79-9.44) 1.00 3.91 (1.12-13.7) 1.56 (0.39-6.31) 0.81 (0.13-4.96) 1.01 (0.10-10.1) 0.08 0.43 
Non-Hodgkin lymphoma (C82-85) 123 0.75 (0.43-1.30) 1.00 0.46 (0.24-0.87) 0.77 (0.44-1.34) 0.58 (0.30-1.10) 0.51 (0.20-1.28) 0.21 0.15 
Multiple myeloma (C90.0) 30 4.08 (0.51-32.9) 1.00 2.37 (0.26-21.3) 2.41 (0.28-20.8) 4.35 (0.54-35.4) 4.96 (0.54-45.4) 0.58 0.10 
Leukaemia (C91-95) 81 1.22 (0.60-2.47) 1.00 0.87 (0.39-1.92) 0.69 (0.31-1.54) 0.76 (0.33-1.75) 0.56 (0.18-1.78) 0.52 0.36 
Other (Other C;D45-47) 276 1.17 (0.79-1.74) 1.00 0.71 (0.44-1.12) 1.07 (0.70-1.64) 1.03 (0.65-1.63) 0.74 (0.40-1.40) 0.15 0.85 
Non-alcohol-related (Other C;D45-47) 2810 1.07 (0.93-1.22) 1.00 0.94 (0.81-1.08) 1.00 (0.87-1.15) 1.07 (0.92-1.23) 0.96 (0.81-1.15) 0.27 0.80 
All cancer (C00-97;D45-47) 3891 1.06 (0.95-1.19) 1.00 0.94 (0.83-1.06) 1.05 (0.94-1.18) 1.10 (0.98-1.25) 1.06 (0.91-1.23) 0.07 0.10 
Models were adjusted for cancers-specific covariates as listed in Supplementary Table 1. Cancer cases do not sum to totals as some participants were diagnosed with two 
primary cancers in the same month. a< 1 drink per week. bOverall. cLinear trend using median alcohol consumption of each category, excluding non-drinkers. dCensored as 
this value would enable calculation of value for never-smokers (< 5 cases). eFemale breast cancer only. fZero cases in cell. ICD-10, International Classification of Diseases, 
version 10. 
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Supplementary Table 6. Hazard ratios (HR) and 95% confidence intervals (CI) of cancer risk by drinking-days per week among drinkers by sex in the 45 and Up Study 
(2006-2010), New South Wales, Australia. 
 
n cases 
HR drinking-days per week in men - adjusted for total alcohol 
consumption (95% CI) 
  HR drinking-days per week in women - adjusted for total 
alcohol consumption (95% CI) 
Cancer type (ICD-10 code) 1-2 3-5 6-7 pa ptrendb  n cases 1-2 3-5 6-7 pa ptrendb 
Mouth and pharynx (C00-14) 81 1.00 0.75 (0.42-1.35) 0.61 (0.32-1.18) 0.34 0.14  33 1.00 1.14 (0.45-2.88) 1.03 (0.33-3.17) 0.95 0.96 
Oesophagus (C15) 39 1.00 0.58 (0.22-1.57) 0.97 (0.39-2.39) 0.47 0.93  11 1.00 1.91 (0.33-11.3) 1.21 (0.19-7.91) 0.72 0.92 
- Adenocarcinoma (C15) -c 1.00 0.62 (0.19-2.01) 1.25 (0.44-3.60) 0.43 0.56  -c 1.00 29.9 (0.17-5237.5) -d 0.44 0.59 
- Squamous cell carcinoma (C15) -c 1.00 0.47 (0.05-4.61) 0.53 (0.06-5.00) 0.79 0.62  -c 1.00 1.83 (0.15-22.5) 2.30 (0.20-26.2) 0.80 0.51 
Colorectum (C18-20) 409 1.00 0.82 (0.62-1.09) 0.87 (0.65-1.17) 0.40 0.44  221 1.00 0.92 (0.65-1.31) 0.75 (0.49-1.15) 0.38 0.21 
- Colon (C18-19) 248 1.00 0.90 (0.63-1.30) 0.79 (0.54-1.15) 0.45 0.21  166 1.00 0.92 (0.61-1.39) 0.78 (0.48-1.28) 0.61 0.33 
- Rectum (C20) 164 1.00 0.68 (0.43-1.09) 1.00 (0.63-1.58) 0.14 0.79  56 1.00 0.91 (0.46-1.81) 0.68 (0.30-1.57) 0.64 0.37 
Liver (C22) -c 1.00 0.90 (0.28-2.87) 1.63 (0.55-4.87) 0.46 0.32  -c 1.00 -e -e -e -e 
Larynx (C32) -c 1.00 1.09 (0.25-4.67) 1.84 (0.47-7.12) 0.51 0.28  -c 1.00 -e -e -e -e 
Alcohol-related (C00-15;18-20;22;32;50f) 585 1.00 0.80 (0.63-1.01) 0.88 (0.69-1.13) 0.17 0.44  898 1.00 1.10 (0.92-1.31) 0.90 (0.73-1.12) 0.08 0.36 
Stomach (C16) 53 1.00 0.81 (0.37-1.77) 0.81 (0.36-1.78) 0.84 0.62  13 1.00 1.10 (0.24-5.06) 0.85 (0.12-6.23) 0.95 0.89 
Pancreas (C25) 64 1.00 1.05 (0.53-2.06) 0.92 (0.43-1.95) 0.92 0.80  29 1.00 0.84 (0.32-2.19) 0.44 (0.15-1.29) 0.27 0.12 
Lung (C33-34) 221 1.00 0.73 (0.48-1.10) 0.96 (0.65-1.42) 0.23 0.95  127 1.00 0.93 (0.57-1.51) 0.98 (0.57-1.70) 0.94 0.96 
Melanoma (C43) 430 1.00 1.15 (0.87-1.52) 1.00 (0.74-1.35) 0.42 0.85  221 1.00 0.92 (0.65-1.31) 0.89 (0.58-1.36) 0.85 0.58 
Kidney (C64) 83 1.00 0.75 (0.42-1.32) 0.48 (0.25-0.94) 0.10 0.03  22 1.00 1.29 (0.41-4.08) 1.55 (0.41-5.90) 0.81 0.52 
Bladder (C67) 69 1.00 0.57 (0.29-1.13) 0.56 (0.29-1.11) 0.17 0.11  9 1.00 1.09 (0.19-6.10) 0.64 (0.08-5.30) 0.85 0.69 
Brain (C71) 43 1.00 0.81 (0.36-1.82) 0.61 (0.24-1.56) 0.58 0.30  22 1.00 0.92 (0.30-2.86) 1.38 (0.30-6.47) 0.81 0.73 
Thyroid (C73) 13 1.00 1.05 (0.29-3.86) 0.27 (0.04-2.03) 0.31 0.25  42 1.00 0.92 (0.41-2.04) 0.90 (0.28-2.88) 0.98 0.84 
Non-Hodgkin lymphoma (C82-85) 109 1.00 1.05 (0.63-1.77) 1.01 (0.56-1.83) 0.98 0.97  65 1.00 1.26 (0.66-2.40) 0.83 (0.36-1.93) 0.41 0.68 
Multiple myeloma (C90.0) 38 1.00 1.90 (0.66-5.53) 1.91 (0.63-5.79) 0.46 0.31  13 1.00 0.54 (0.12-2.37) 0.49 (0.05-4.52) 0.70 0.47 
Leukaemia (C91-95) 66 1.00 0.63 (0.33-1.20) 0.51 (0.25-1.07) 0.18 0.08  25 1.00 0.78 (0.27-2.24) 0.89 (0.25-3.12) 0.90 0.84 
Other (Other C;D45-47) 225 1.00 0.90 (0.62-1.32) 1.04 (0.70-1.54) 0.71 0.79  114 1.00 1.06 (0.64-1.77) 1.28 (0.71-2.31) 0.67 0.41 
Non-alcohol-related (Other C;D45-47) 2941 1.00 0.94 (0.84-1.04) 0.93 (0.83-1.04) 0.35 0.20  797 1.00 0.91 (0.76-1.10) 0.88 (0.70-1.10) 0.48 0.25 
All cancer (C00-97;D45-47) 3523 1.00 0.91 (0.85-1.00) 0.91 (0.82-1.01) 0.11 0.10  1694 1.00 1.00 (0.88-1.14) 0.88 (0.76-1.03) 0.13 0.12 
Non-drinkers were excluded. Models were adjusted for cancers-specific covariates as listed in Supplementary Table 1. Cancer cases do not sum to totals as some 
participants were diagnosed with two primary cancers in the same month. aOverall. bLinear trend using median number of drinking-days per week of each category. 
cCensored due to < 5 cases in women, or if this value would enable calculation of value for another cell for which there is < 5 cases in women. dZero cases in cell. eModel 
failed to converge. fFemale breast cancer only. ICD-10, International Classification of Diseases, version 10. 
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Supplementary Table 7. Hazard ratios (HR) and 95% confidence intervals (CI) of cancer risk by drinking-days per week among drinkers by smoking status in the 45 and 
Up Study (2006-2010), New South Wales, Australia. 
 
n cases 
HR drinking-days per week in never-smokers - adjusted for 
total alcohol consumption (95% CI) 
  HR drinking-days per week in ever-smokers - adjusted for 
total alcohol consumption (95% CI) 
Cancer type (ICD-10 code) 1-2 3-5 6-7 pa ptrendb  n cases 1-2 3-5 6-7 pa ptrendb 
Mouth and pharynx (C00-14) 45 1.00 0.76 (0.37-1.57) 0.52 (0.21-1.28) 0.36 0.15  69 1.00 0.81 (0.42-1.58) 0.76 (0.37-1.55) 0.73 0.46 
Oesophagus (C15) 14 1.00 1.15 (0.27-4.93) 0.95 (0.20-4.45) 0.96 0.94  36 1.00 0.71 (0.25-2.02) 1.19 (0.45-3.18) 0.55 0.61 
- Adenocarcinoma (C15) -c 1.00 1.54 (0.27-8.82) 1.09 (0.13-8.93) 0.87 0.92  -c 1.00 0.64 (0.17-2.45) 1.36 (0.40-4.61) 0.46 0.50 
- Squamous cell carcinoma (C15) -c 1.00 -d -d 1.00 0.61  -c 1.00 0.79 (0.15-4.17) 0.80 (0.14-4.52) 0.96 0.81 
Colorectum (C18-20) 261 1.00 0.93 (0.68-1.27) 0.70 (0.48-1.01) 0.13 0.06  369 1.00 0.82 (0.60-1.12) 0.95 (0.70-1.30) 0.39 0.93 
- Colon (C18-19) 182 1.00 1.02 (0.71-1.48) 0.67 (0.43-1.05) 0.09 0.09  232 1.00 0.82 (0.55-1.22) 0.87 (0.59-1.29) 0.61 0.59 
- Rectum (C20) 79 1.00 0.73 (0.41-1.30) 0.77 (0.40-1.47) 0.54 0.42  141 1.00 0.78 (0.47-1.30) 1.06 (0.64-1.76) 0.37 0.66 
Liver (C22) 6 1.00 0.44 (0.04-5.42) 0.92 (0.09-9.57) 0.79 0.95  25 1.00 0.91 (0.25-3.24) 1.77 (0.54-5.79) 0.42 0.28 
Larynx (C32) -c 1.00 -e -e -e -e  -c 1.00 1.44 (0.35-5.91) 2.11 (0.54-8.24) 0.51 0.25 
Breast (C50f) 373 1.00 1.26 (0.97-1.65) 1.14 (0.82-1.59) 0.21 0.42  257 1.00 0.97 (0.70-1.34) 0.71 (0.47-1.08) 0.16 0.10 
Alcohol-related (C00-15;18-20;22;32;50f) 700 1.00 1.07 (0.88-1.30) 0.88 (0.69-1.11) 0.14 0.28  783 1.00 0.89 (0.73-1.09) 0.89 (0.72-1.11) 0.48 0.35 
Stomach (C16) 34 1.00 0.62 (0.24-1.57) 0.78 (0.28-2.15) 0.59 0.62  32 1.00 1.35 (0.45-4.05) 1.08 (0.35-3.32) 0.81 0.98 
Pancreas (C25) 42 1.00 1.33 (0.58-3.04) 1.08 (0.42-2.82) 0.75 0.90  51 1.00 0.71 (0.34-1.52) 0.50 (0.22-1.10) 0.23 0.08 
Lung (C33-34) 38 1.00 0.77 (0.31-1.91) 1.68 (0.62-4.55) 0.24 0.32  310 1.00 0.80 (0.57-1.12) 0.91 (0.65-1.26) 0.43 0.66 
Melanoma (C43) 351 1.00 1.02 (0.77-1.34) 0.83 (0.59-1.15) 0.32 0.25  300 1.00 1.09 (0.77-1.55) 1.09 (0.76-1.57) 0.87 0.69 
Endometrium (C54.1) 29 1.00 1.49 (0.56-3.93) 1.40 (0.40-4.87) 0.73 0.58  23 1.00 0.37 (0.09-1.54) 1.34 (0.36-4.91) 0.18 0.63 
Ovary (C56) 26 1.00 0.74 (0.29-1.90) 0.48 (0.13-1.76) 0.54 0.27  13 1.00 0.73 (0.16-3.44) 0.70 (0.11-4.34) 0.91 0.70 
Prostate (C61) 718 1.00 0.89 (0.73-1.09) 0.87 (0.69-1.08) 0.41 0.22  806 1.00 1.00 (0.81-1.24) 1.03 (0.83-1.29) 0.94 0.75 
Kidney (C64) 39 1.00 1.34 (0.60-3.03) 0.78 (0.29-2.12) 0.39 0.61  66 1.00 0.58 (0.30-1.13) 0.54 (0.26-1.11) 0.17 0.10 
Bladder (C67) 20 1.00 0.11 (0.01-0.87) 0.67 (0.22-2.00) 0.11 0.54  58 1.00 0.87 (0.43-1.76) 0.57 (0.26-1.24) 0.32 0.15 
Brain (C71) 28 1.00 1.14 (0.43-2.98) 1.48 (0.41-5.41) 0.83 0.57  37 1.00 0.65 (0.27-1.59) 0.47 (0.18-1.25) 0.32 0.13 
Thyroid (C73) 29 1.00 0.48 (0.19-1.22) 0.13 (0.02-0.81) 0.07 0.02  26 1.00 1.81 (0.64-5.10) 1.67 (0.45-6.18) 0.53 0.43 
Non-Hodgkin lymphoma (C82-85) 83 1.00 1.42 (0.82-2.48) 0.98 (0.47-2.02) 0.27 0.98  91 1.00 0.95 (0.53-1.71) 0.99 (0.52-1.88) 0.98 0.98 
Multiple myeloma (C90.0) 29 1.00 0.79 (0.29-2.15) 1.02 (0.34-3.11) 0.84 0.96  22 1.00 2.58 (0.53-12.5) 1.98 (0.38-10.3) 0.49 0.61 
Leukaemia (C91-95) 38 1.00 0.59 (0.25-1.42) 0.87 (0.34-2.22) 0.47 0.75  53 1.00 0.71 (0.34-1.45) 0.47 (0.20-1.08) 0.20 0.07 
Other (Other C;D45-47) 158 1.00 1.03 (0.68-1.56) 1.08 (0.67-1.73) 0.95 0.76  181 1.00 0.87 (0.56-1.36) 1.14 (0.73-1.77) 0.41 0.46 
Non-alcohol-related (Other C;D45-47) 1663 1.00 0.92 (0.81-1.04) 0.86 (0.74-0.99) 0.12 0.04  2075 1.00 0.91 (0.80-1.04) 0.93 (0.81-1.06) 0.35 0.38 
All cancer (C00-97;D45-47) 2362 1.00 0.96 (0.87-1.07) 0.87 (0.76-0.98) 0.054 0.02  2855 1.00 0.90 (0.81-1.01) 0.92 (0.82-1.03) 0.16 0.19 
Non-drinkers were excluded. Models were adjusted for cancer-specific covariates as listed in Supplementary Table 1. Cancer cases do not sum to totals as some participants 
were diagnosed with two primary cancers in the same month. aOverall. bLinear trend using median number of drinking-days per week of each category. cCensored due to < 5 
cases in never-smokers, or if this value would enable calculation of value for another cell for which there is < 5 cases in never-smokers. dNot possible to calculate due to zero 
deaths in reference group. eModel failed to converge. fFemale breast cancer only. ICD-10, International Classification of Diseases, version 10. 
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Supplementary Table 8. Hazard ratios (HR) and 95% confidence intervals (CI) of cancer risk by mean drinks per drinking-day among drinkers by sex in the 45 and Up 
Study (2006-2010), New South Wales, Australia. 
 
n cases 
HR mean drinks per drinking-day in men - adjusted for total 
alcohol consumption (95% CI) 
  HR mean drinks per drinking-day in women - adjusted for total 
alcohol consumption (95% CI) 
Cancer type (ICD-10 code) ≤ 2 > 2 and ≤ 4 > 4 pa ptrendb  n cases ≤ 2 > 2 and ≤ 4 > 4 pa ptrendb 
Mouth and pharynx (C00-14) 81 1.00 2.10 (1.19-3.71) 3.37 (1.57-7.21) 0.005 0.002  33 1.00 0.43 (0.11-1.77) -c 0.50 0.13 
Oesophagus (C15) 39 1.00 0.82 (0.34-2.00) 2.47 (0.84-7.23) 0.10 0.11  11 1.00 2.26 (0.44-11.8) 3.20 (0.21-49.3) 0.57 0.33 
- Adenocarcinoma (C15) -d 1.00 0.92 (0.36-2.38) 1.43 (0.37-5.56) 0.78 0.63  -d 1.00 -c -c 1.00 1.00 
- Squamous cell carcinoma (C15) -d 1.00 -c 26.0 (1.73-392.7) 0.06 0.01  -d 1.00 3.14 (0.48-20.7) 4.96 (0.19-127.1) 0.46 0.26 
Colorectum (C18-20) 409 1.00 0.78 (0.60-1.02) 1.19 (0.81-1.73) 0.02 0.52  221 1.00 0.98 (0.63-1.50) 0.82 (0.32-2.14) 0.92 0.73 
- Colon (C18-19) 248 1.00 0.67 (0.48-0.95) 1.27 (0.78-2.05) 0.007 0.51  166 1.00 1.05 (0.64-1.73) 1.06 (0.38-2.98) 0.98 0.86 
- Rectum (C20) 164 1.00 0.94 (0.63-1.40) 1.11 (0.61-2.03) 0.80 0.78  56 1.00 0.72 (0.30-1.70) 0.29 (0.03-3.22) 0.55 0.27 
Liver (C22) -d 1.00 0.75 (0.27-2.10) 1.61 (0.48-5.40) 0.44 0.45  -d 1.00 -e -e -e -e 
Larynx (C32) -d 1.00 1.31 (0.52-3.33) 0.50 (0.11-2.36) 0.30 0.41  -d 1.00 -e -e -e -e 
Alcohol-related (C00-15;18-20;22;32;50f) 585 1.00 0.92 (0.74-1.14) 1.42 (1.05-1.92) 0.007 0.04  898 1.00 1.16 (0.95-1.41) 1.08 (0.70-1.66) 0.33 0.34 
Stomach (C16) 53 1.00 1.05 (0.52-2.12) 1.42 (0.48-4.24) 0.80 0.55  13 1.00 2.14 (0.30-15.2) -c 0.75 0.77 
Pancreas (C25) 64 1.00 0.97 (0.50-1.89) 0.72 (0.21-2.44) 0.85 0.64  29 1.00 1.11 (0.40-3.05) 0.34 (0.02-7.74) 0.69 0.73 
Lung (C33-34) 221 1.00 1.35 (0.96-1.90) 1.76 (1.06-2.92) 0.08 0.03  127 1.00 1.73 (1.06-2.82) 0.22 (0.03-1.68) 0.01 0.97 
Melanoma (C43) 430 1.00 1.05 (0.82-1.33) 0.91 (0.59-1.39) 0.71 0.74  221 1.00 1.14 (0.77-1.69) 1.98 (0.94-4.18) 0.20 0.11 
Kidney (C64) 83 1.00 1.36 (0.77-2.40) 3.33 (1.52-7.26) 0.009 0.003  22 1.00 0.38 (0.08-1.82) 0.74 (0.05-10.3) 0.48 0.45 
Bladder (C67) 69 1.00 0.56 (0.29-1.09) 0.29 (0.08-1.09) 0.12 0.046  9 1.00 1.63 (0.16-17.0) 10.4 (0.98-111.1) 0.15 0.07 
Brain (C71) 43 1.00 0.53 (0.24-1.20) 0.68 (0.19-2.36) 0.31 0.44  22 1.00 2.78 (0.86-9.04) -c 0.24 0.26 
Thyroid (C73) 13 1.00 0.69 (0.17-2.76) 0.20 (0.01-4.13) 0.58 0.30  42 1.00 1.20 (0.43-3.37) 6.98 (1.85-26.3) 0.01 0.02 
Non-Hodgkin lymphoma (C82-85) 109 1.00 0.89 (0.54-1.47) 0.46 (0.16-1.28) 0.32 0.17  65 1.00 0.89 (0.39-2.04) 1.41 (0.28-7.18) 0.84 0.88 
Multiple myeloma (C90.0) 38 1.00 1.47 (0.66-3.29) 1.28 (0.32-5.06) 0.63 0.65  13 1.00 1.01 (0.11-9.49) -c 1.00 0.89 
Leukaemia (C91-95) 66 1.00 0.89 (0.46-1.74) 1.87 (0.71-4.93) 0.25 0.27  25 1.00 0.46 (0.09-2.29) 1.36 (0.13-14.8) 0.55 0.80 
Other (Other C;D45-47) 225 1.00 1.14 (0.80-1.61) 1.71 (1.02-2.87) 0.12 0.048  114 1.00 0.89 (0.50-1.58) 1.04 (0.33-3.32) 0.89 0.90 
Non-alcohol-related (Other C;D45-47) 2941 1.00 1.10 (1.02-1.21) 1.14 (0.97-1.33) 0.10 0.07  797 1.00 1.20 (0.97-1.48) 1.13 (0.72-1.79) 0.24 0.23 
All cancer (C00-97;D45-47) 3523 1.00 1.07 (0.98-1.16) 1.18 (1.03-1.36) 0.06 0.02  1694 1.00 1.18 (1.03-1.37) 1.11 (0.82-1.52) 0.07 0.11 
Non-drinkers were excluded. Models were adjusted for cancer-specific covariates as listed in Supplementary Table 1. Cancer cases do not sum to totals as some participants 
were diagnosed with two primary cancers in the same month. aOverall. bLinear trend using median number of drinks per drinking-day of each category. cZero cases in cell. 
dCensored due to < 5 cases in women, or if this value would enable calculation of value for another cell for which there is < 5 cases in women. eModel failed to converge. 
fFemale breast cancer only. ICD-10, International Classification of Diseases, version 10. 
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Supplementary Table 9. Hazard ratios (HR) and 95% confidence intervals (CI) of cancer risk by mean drinks per drinking-day among drinkers by smoking status in the 45 
and Up Study (2006-2010), New South Wales, Australia. 
 
n cases 
HR mean drinks per drinking-day in never-smokers - adjusted 
for total alcohol consumption (95% CI) 
  HR mean drinks per drinking-day in ever-smokers - adjusted 
for total alcohol consumption (95% CI) 
Cancer type (ICD-10 code) ≤ 2 > 2 and ≤ 4 > 4 pa ptrendb  n cases ≤ 2 > 2 and ≤ 4 > 4 pa ptrendb 
Mouth and pharynx (C00-14) 45 1.00 1.54 (0.67-3.53) 3.29 (0.92-11.8) 0.18 0.07  69 1.00 1.48 (0.80-2.73) 2.16 (0.93-5.03) 0.19 0.07 
Oesophagus (C15) 14 1.00 0.72 (0.08-6.56) 4.99 (0.70-35.3) 0.20 0.14  36 1.00 1.13 (0.47-2.69) 2.09 (0.66-6.61) 0.41 0.21 
- Adenocarcinoma (C15) -c 1.00 1.69 (0.16-18.0) 5.67 (0.47-67.8) 0.39 0.18  -c 1.00 0.82 (0.29-2.29) 0.88 (0.19-4.02) 0.93 0.85 
- Squamous cell carcinoma (C15) -c 1.00 -d 1.85 (0.01-478.1) 0.98 0.82  -c 1.00 2.50 (0.45-13.8) 8.97 (1.29-62.2) 0.08 0.02 
Colorectum (C18-20) 261 1.00 0.75 (0.51-1.10) 1.00 (0.52-1.91) 0.27 0.64  369 1.00 0.84 (0.64-1.10) 1.18 (0.78-1.78) 0.12 0.57 
- Colon (C18-19) 182 1.00 0.59 (0.36-0.98) 1.16 (0.54-2.52) 0.06 0.75  232 1.00 0.85 (0.60-1.20) 1.32 (0.79-2.21) 0.14 0.39 
- Rectum (C20) 79 1.00 1.08 (0.59-1.99) 0.71 (0.21-2.42) 0.74 0.71  141 1.00 0.78 (0.50-1.21) 1.01 (0.52-1.95) 0.43 0.93 
Liver (C22) 6 1.00 -d 0.31 (0.01-17.8) 0.85 0.42  25 1.00 1.20 (0.41-3.46) 1.91 (0.51-7.18) 0.61 0.33 
Larynx (C32) -c 1.00 -e -e -e -e  -c 1.00 1.22 (0.49-3.05) 0.41 (0.08-2.02) 0.26 0.31 
Breast (C50f) 373 1.00 0.88 (0.63-1.22) 0.51 (0.19-1.36) 0.38 0.19  257 1.00 1.74 (1.28-2.38) 2.21 (1.24-3.96) < 0.001 < 0.001 
Alcohol-related (C00-15;18-20;22;32;50f) 700 1.00 0.84 (0.66-1.07) 0.94 (0.59-1.50) 0.34 0.44  783 1.00 1.15 (0.96-1.37) 1.52 (1.14-2.02) 0.02 0.005 
Stomach (C16) 34 1.00 1.20 (0.42-3.45) 2.09 (0.37-11.7) 0.70 0.42  32 1.00 1.35 (0.55-3.28) 1.50 (0.40-5.71) 0.78 0.54 
Pancreas (C25) 42 1.00 1.25 (0.53-2.94) 0.64 (0.10-4.29) 0.65 0.85  51 1.00 0.91 (0.43-1.91) 0.61 (0.15-2.47) 0.78 0.51 
Lung (C33-34) 38 1.00 0.82 (0.27-2.50) 0.68 (0.07-6.92) 0.92 0.69  310 1.00 1.48 (1.11-1.97) 1.55 (0.98-2.47) 0.03 0.04 
Melanoma (C43) 351 1.00 1.13 (0.84-1.52) 1.15 (0.66-2.01) 0.72 0.51  300 1.00 1.06 (0.79-1.42) 0.98 (0.59-1.63) 0.87 0.99 
Endometrium (C54.1) 29 1.00 0.90 (0.26-3.13) -d 0.99 0.47  23 1.00 1.10 (0.33-3.66) -d 0.99 0.39 
Ovary (C56) 26 1.00 2.79 (0.92-8.40) -d 0.19 0.37  13 1.00 4.79 (1.08-21.2) -d 0.12 0.34 
Prostate (C61) 718 1.00 1.18 (0.98-1.43) 1.06 (0.74-1.50) 0.18 0.48  806 1.00 1.10 (0.92-1.31) 1.14 (0.86-1.52) 0.54 0.34 
Kidney (C64) 39 1.00 0.20 (0.05-0.89) 2.13 (0.63-7.21) 0.02 0.51  66 1.00 1.87 (1.01-3.46) 3.20 (1.28-7.99) 0.04 0.01 
Bladder (C67) 20 1.00 0.59 (0.16-2.21) 0.07 (0.00-3.70) 0.42 0.18  58 1.00 0.65 (0.31-1.36) 0.65 (0.18-2.33) 0.51 0.41 
Brain (C71) 28 1.00 1.37 (0.45-4.20) 3.73 (0.66-21.2) 0.33 0.16  37 1.00 0.58 (0.25-1.35) 0.52 (0.12-2.19) 0.43 0.31 
Thyroid (C73) 29 1.00 2.09 (0.69-6.31) 3.57 (0.41-31.2) 0.30 0.12  26 1.00 0.55 (0.17-1.80) 1.59 (0.31-8.11) 0.37 0.84 
Non-Hodgkin lymphoma (C82-85) 83 1.00 0.78 (0.38-1.59) 1.01 (0.29-3.50) 0.76 0.81  91 1.00 0.90 (0.52-1.56) 0.38 (0.11-1.23) 0.23 0.15 
Multiple myeloma (C90.0) 29 1.00 0.45 (0.12-1.70) 0.88 (0.11-7.14) 0.47 0.61  22 1.00 3.07 (1.02-9.29) 1.97 (0.33-11.8) 0.11 0.42 
Leukaemia (C91-95) 38 1.00 0.52 (0.18-1.51) 0.59 (0.08-4.31) 0.48 0.38  53 1.00 1.01 (0.48-2.10) 2.58 (0.93-7.15) 0.12 0.09 
Other (Other C;D45-47) 158 1.00 0.97 (0.61-1.55) 1.66 (0.80-3.43) 0.29 0.25  181 1.00 1.13 (0.77-1.66) 1.42 (0.77-2.62) 0.53 0.12 
Non-alcohol-related (Other C;D45-47)  1663 1.00 1.08 (0.94-1.23) 1.14 (0.89-1.45) 0.46 0.24  2075 1.00 1.14 (1.02-1.28) 1.17 (0.97-1.41) 0.06 0.06 
All cancer (C00-97;D45-47) 2362 1.00 1.02 (0.91-1.14) 1.08 (0.87-1.34) 0.79 0.51  2855 1.00 1.14 (1.04-1.26) 1.25 (1.07-1.46) 0.007 0.004 
Non-drinkers were excluded. Models were adjusted for cancer-specific covariates as listed in Supplementary Table 1. Cancer cases do not sum to totals as some participants 
were diagnosed with two primary cancers in the same month. aOverall. bLinear trend using median number of drinks per drinking-day of each category. cCensored due to < 5 
cases in never-smokers, or if this value would enable calculation of value for another cell for which there is < 5 cases in never-smokers. dZero cases in cell. eModel failed to 
converge. fFemale breast cancer only. ICD-10, International Classification of Diseases, version 10.
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Supplementary Table 10. Hazard ratios (HR) and 95% confidence intervals (CI) of cancer risk by drinking-days 
per week stratified by mean drinks per drinking-day among drinkers in the 45 and Up Study (2006-2010), 
New South Wales, Australia. 
 Mean drinks per 
drinking-day 
 HR drinking-days per week (95% CI) 
Cancer type n cases 1-2 3-5 6-7 pa ptrendb 
Colorectum ≤ 2 397 1.00 0.90 (0.70-1.15) 0.80 (0.63-1.03) 0.21 0.08 
 > 2 and ≤ 4 135 1.00 1.21 (0.67-2.19) 1.60 (0.92-2.78) 0.17 0.06 
 > 4 98 1.00 1.05 (0.52-2.13) 1.70 (0.95-3.03) 0.09 0.04 
Colon ≤ 2 270 1.00 1.00 (0.74-1.35) 0.78 (0.58-1.06) 0.19 0.11 
 > 2 and ≤ 4 79 1.00 1.19 (0.54-2.62) 1.42 (0.68-2.95) 0.59 0.31 
 > 4 65 1.00 1.20 (0.48-2.98) 2.13 (0.99-4.59) 0.07 0.03 
Kidney ≤ 2 59 1.00 0.92 (0.46-1.84) 1.34 (0.71-2.55) 0.44 0.32 
 > 2 and ≤ 4 26 1.00 0.70 (0.27-1.82) 0.30 (0.11-0.87) 0.07 0.82 
 > 4 20 1.00 0.84 (0.29-2.43) 0.19 (0.06-0.60) 0.01 0.003 
Non-drinkers were excluded. Models were adjusted for cancer-specific covariates as listed in Supplementary Table 1. 
Cancer cases do not sum to totals as some participants were diagnosed with two primary cancers in the same 
month. aOverall. bLinear trend using median number of drinking-days per week of each category.  
 
 
Supplementary Table 11. Hazard ratios (HR) and 95% confidence intervals (CI) of cancer risk by mean drinks 
per drinking-day stratified by drinking-days per week among drinkers in the 45 and Up Study (2006-2010), 
New South Wales, Australia. 
 Drinking-days 
per week 
 HR mean drinks per drinking-day (95% CI) 
Cancer type n cases ≤ 2 > 2 and ≤ 4 > 4 pa ptrendb 
Colorectum 1-2 161 1.00 0.52 (0.31-0.89) 1.02 (0.59-1.75) 0.053 0.50 
 3-5 177 1.00 0.80 (0.54-1.19) 1.40 (0.80-2.44) 0.17 0.56 
 6-7 292 1.00 1.09 (0.82-1.45) 1.64 (1.16-2.30) 0.01 0.006 
Colon 1-2 104 1.00 0.47 (0.23-0.94) 0.93 (0.46-1.91) 0.10 0.38 
 3-5 122 1.00 0.69 (0.41-1.15) 1.49 (0.75-2.96) 0.11 0.70 
 6-7 188 1.00 1.17 (0.81-1.68) 2.29 (1.51-3.49) < 0.001 < 0.001 
Kidney 1-2 31 1.00 1.62 (0.65-4.08) 3.36 (1.35-8.34) 0.03 0.009 
 3-5 34 1.00 1.38 (0.61-3.11) 2.36 (0.85-6.61) 0.26 0.10 
 6-7 40 1.00 0.48 (0.21-1.09) 0.63 (0.23-1.75) 0.20 0.23 
Non-drinkers were excluded. Models were adjusted for cancer-specific covariates as listed in Supplementary Table 1. 
Cancer cases do not sum to totals as some participants were diagnosed with two primary cancers in the same 
month. aOverall. bLinear trend using median number of drinks per drinking-day of each category.  
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8.2 – Additional Analyses 
 
Additional research questions regarding the relationship between cancer incidence and alcohol 
consumption reported in the main analysis are reported here. The first set of analyses addressed the 
potential impact of the ‘sick-quitter effect’ and other biases on the main results. The second set used 
the cancer-specific risk estimates to calculate the population attributable fraction (PAF) of alcohol 
for the Australia, cumulative absolute cancer risk, and the number of persons needed to quit or 
reduce drinking to prevent one cancer case. 
1. The impact of the ‘sick-quitter effect’ and other changes in drinking behaviours in response to 
ill-health on risk estimates. 
Rationale and methods. A number of promising methods for mitigating bias from the ‘sick-quitter 
effect’ (and other changes in drinking behaviour) were identified in Chapter 7. Based on these 
findings, there are several exclusion scenarios that would be expected to decrease bias from the 
‘sick-quitter effect’ in the cancer main analysis: exclusion of participants with a physical functioning 
score < 50%, exclusion of participants that consumed < 7 drinks per week, exclusion of cancer cases 
diagnosed within one year of baseline (analogous to the exclusion of deaths within three years of 
baseline when examining mortality as an outcome), and exclusion of participants aged ≥ 65 years at 
baseline. For analyses aimed at identifying a linear trend between alcohol and risk, a method that 
would be expected to increase bias from the ‘sick-quitter effect’ would be the inclusion of non-
drinkers in the calculation. As some of these exclusion scenarios include a large proportion of cases, 
these analyses were only investigated for all cancers combined. 
Fully adjusted HRs and 95% CIs for risk of all cancers combined were estimated from Cox 
Proportional Hazards models (as per the main results) under each ‘exclusion scenario’ noted above, 
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and directly compared with the main results. These models were conducted for total alcohol 
consumption as a log-linear variable. 
Cancer-specific HRs and 95% CIs were then calculated for total alcohol consumption, drinking 
frequency, and drinks per drinking-day after exclusion of participants with a physical functioning 
score < 50%. Overall drinking pattern, incorporating both number of drinking-days and number of 
drinks per drinking-day was assessed for all cancers combined, and colorectal, colon, and kidney 
cancer. The low physical functioning score exclusion scenario was selected for these more detailed 
analyses based on the conclusion in Chapter 7 that it was likely the most effective exclusion scenario 
examined to assess bias from the ‘sick-quitter effect’. 
For the continuous log-linear analysis estimating the increase in risk per additional drink/day, the 
sensitivity tests excluding participants with a physical functioning score < 50% and restricting the 
calculation to participants consuming ≥ 7 drinks per week were performed (as this exclusion was 
intended to be applied to the log-linear analysis specifically). 
Results. None of the sensitivity analyses materially altered the log-linear association between 
alcohol consumption and risk of all cancers combined (Figure 8.1).
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Figure 8.1. Hazard ratios (HR) and 95% confidence intervals (CI) of risk of all cancers combined per 
one drink increase in mean daily alcohol consumption among drinkers by different exclusion 
scenarios in the 45 and Up Study (2006-2010), New South Wales, Australia. Non-drinkers were 
excluded. Models were adjusted for sex, age, remoteness, education, household income, health 
insurance status, partner status, country of birth, smoking status and dose, body mass index, 
physical activity, fruit consumption, vegetable consumption, fibre intake, red meat consumption, 
processed meat consumption, hormone replacement therapy use (women), aspirin use and bowel 
screening history.   
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The sensitivity analyses excluding participants with a low physical functioning score resulted in 
several risk estimates that differed from the main results and are presented in Tables 8.1-8.4. For 
categorical total alcohol consumption, there were significant trends of increased risk for cancers of 
the mouth and pharynx, oesophagus (squamous cell carcinoma) and liver (Table 8.1). The trends for 
laryngeal cancer, non-Hodgkin lymphoma (NHL) and all cancers combined were non-significant, 
however the hazard ratios were not materially different compared to the main analysis. There was 
also evidence of lower risk in those consuming ‘> 3.5 and ≤ 7’ and ‘> 14 and ≤ 28’ drinks per week for 
bladder cancer, and that those consuming ‘> 7 and ≤ 14’ and ‘> 14 and ≤ 28’ drinks per week had 
higher risk of melanoma compared to non-drinkers. For drinking-days per week, the inverse 
association of drinking frequency with all cancer risk was non-significant however the hazard ratio 
was not materially different compared to the main analysis (Table 8.2). There were no other changes 
in results.  
For mean drinks per drinking-day, a significant trend of increased risk of cancer of the oesophagus 
was detected (Table 8.3). The associations for kidney cancer and non-alcohol-related cancer were 
non-significant, however the hazard ratios were not materially different compared to the main 
anlaysis. There was also evidence of higher risk in those consuming > 2 and ≤ 4 drinks per drinking-
day for lung cancer. For the overall drinking pattern sensitivity analysis, consuming > 2 and ≤ 4 drinks 
on 1-2 days per week was associated with significant decreased risk for colon cancer, while 
consuming > 4 drinks on 1-2 days per week was non-significant for all cancers combined, but the 
hazard ratios were not materially different compared to the main analysis (Table 8.4). There were no 
other notable differences in results. 
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Table 8.1. Hazard ratios and 95% confidence intervals of cancer risk by alcohol consumption after excluding participants with physical functioning score < 50% at baseline 
in the 45 and Up Study (2006-2010), New South Wales, Australia. 
  Drinks/week   
Cancer type (ICD-10 code) n cases Non-drinkera ≥ 1 and ≤ 3.5 > 3.5 and ≤ 7 > 7 and ≤ 14 > 14 and ≤ 28 > 28 pb ptrendc 
Mouth and pharynx (C00-14) 107 0.70 (0.39-1.27) 1.00 0.47 (0.23-0.97) 0.89 (0.47-1.67) 1.03 (0.51-2.07) 2.06 (0.97-4.41) 0.02 0.01 
Oesophagus (C15) 51 1.10 (0.45-2.67) 1.00 1.08 (0.42-2.79) 0.41 (0.12-1.41) 0.84 (0.27-2.55) 1.89 (0.61-5.92) 0.32 0.17 
- Adenocarcinoma (C15) 32 0.75 (0.26-2.15) 1.00 0.96 (0.33-2.78) 0.23 (0.05-1.15) 0.61 (0.17-2.20) 0.94 (0.22-3.98) 0.54 0.94 
- Squamous cell carcinoma (C15) 17 2.68 (0.33-22.1) 1.00 2.00 (0.21-19.3) 0.83 (0.05-13.4) 2.69 (0.23-31.5) 10.9 (1.01-117.9) 0.21 0.02 
Colorectum (C18-20) 722 1.08 (0.86-1.37) 1.00 0.82 (0.63-1.08) 1.04 (0.80-1.35) 1.04 (0.77-1.39) 1.42 (1.00-2.04) 0.052 0.03 
- Colon (C18-19) 476 1.14 (0.86-1.53) 1.00 0.83 (0.60-1.16) 0.99 (0.71-1.38) 1.10 (0.76-1.59) 1.67 (1.07-2.62) 0.04 0.01 
- Rectum (C20) 252 0.94 (0.63-1.41) 1.00 0.78 (0.49-1.22) 1.08 (0.70-1.65) 0.90 (0.55-1.46) 1.18 (0.67-2.07) 0.63 0.51 
Liver (C22) 42 1.96 (0.65-5.92) 1.00 0.97 (0.26-3.62) 0.80 (0.20-3.21) 1.65 (0.45-5.99) 3.76 (1.04-13.5) 0.11 0.03 
Larynx (C32) 25 1.32 (0.25-6.88) 1.00 0.32 (0.03-3.53) 1.05 (0.19-5.79) 2.43 (0.50-11.8) 2.48 (0.46-13.4) 0.32 0.08 
Breast (C50e) 816 1.02 (0.83-1.27) 1.00 1.17 (0.94-1.47) 1.23 (0.97-1.56) 1.63 (1.21-2.20) 0.52 (0.16-1.63) 0.008 0.04 
Alcohol-related (C00-15;18-20;22;32;50d) 1,761 1.03 (0.89-1.19) 1.00 0.96 (0.81-1.13) 1.07 (0.91-1.27) 1.22 (1.01-1.49) 1.60 (1.24-2.08) 0.002 < 0.001 
Stomach (C16) 77 1.51 (0.71-3.24) 1.00 1.19 (0.51-2.77) 1.22 (0.52-2.88) 1.28 (0.50-3.32) 1.69 (0.54-5.27) 0.89 0.30 
Pancreas (C25) 107 1.35 (0.69-2.62) 1.00 1.56 (0.79-3.11) 1.04 (0.49-2.22) 1.74 (0.81-3.71) 0.55 (0.12-2.48) 0.37 0.89 
Lung (C33-34) 339 0.88 (0.61-1.25) 1.00 1.00 (0.68-1.46) 0.91 (0.62-1.34) 1.18 (0.79-1.77) 0.80 (0.45-1.43) 0.58 0.69 
Melanoma (C43) 711 0.80 (0.62-1.02) 1.00 0.88 (0.68-1.13) 1.13 (0.88-1.44) 1.19 (0.90-1.56) 0.95 (0.63-1.43) 0.01 0.30 
Endometrium (C54.1) 95 1.51 (0.82-2.80) 1.00 0.69 (0.30-1.58) 1.32 (0.61-2.85) 1.37 (0.48-3.91) -e 0.32 0.54 
Ovary (C56) 52 0.67 (0.32-1.39) 1.00 0.33 (0.12-0.95) 0.93 (0.39-2.18) 1.29 (0.44-3.80) -e 0.29 0.75 
Prostate (C61) 1,636 0.88 (0.74-1.04) 1.00 0.98 (0.83-1.17) 0.98 (0.83-1.16) 1.06 (0.88-1.26) 1.03 (0.82-1.29) 0.37 0.49 
Kidney (C64) 118 1.31 (0.69-2.52) 1.00 1.41 (0.72-2.75) 1.30 (0.66-2.57) 1.16 (0.55-2.46) 1.33 (0.54-3.29) 0.95 0.94 
Bladder (C67) 92 0.76 (0.43-1.35) 1.00 0.33 (0.16-0.71) 0.61 (0.33-1.16) 0.32 (0.13-0.77) 0.52 (0.19-1.42) 0.03 0.15 
Brain (C71) 71 1.02 (0.48-2.17) 1.00 1.14 (0.54-2.42) 0.81 (0.37-1.81) 0.39 (0.13-1.15) 0.75 (0.23-2.43) 0.44 0.30 
Thyroid (C73) 79 1.01 (0.54-1.89) 1.00 1.08 (0.54-2.13) 0.66 (0.29-1.49) 0.26 (0.06-1.17) 0.42 (0.05-3.29) 0.38 0.09 
Non-Hodgkin lymphoma (C82-85) 198 0.84 (0.55-1.28) 1.00 0.73 (0.46-1.16) 0.96 (0.61-1.50) 0.63 (0.36-1.13) 0.48 (0.18-1.23) 0.36 0.09 
Multiple myeloma (C90.0) 64 2.07 (0.89-4.80) 1.00 1.03 (0.39-2.70) 0.74 (0.26-2.12) 1.47 (0.53-4.03) 1.83 (0.62-6.47) 0.14 0.19 
Leukaemia (C91-95) 104 1.03 (0.58-1.83) 1.00 0.75 (0.39-1.43) 0.65 (0.33-1.27) 0.53 (0.24-1.17) 0.66 (0.24-1.83) 0.43 0.33 
Other (Other C;D45-47) 377 1.16 (0.84-1.59) 1.00 0.72 (0.49-1.04) 1.06 (0.74-1.51) 1.04 (0.69-1.57) 0.84 (0.46-1.53) 0.09 0.71 
Non-alcohol-related (Other C;D45-47) 4,125 0.95 (0.86-1.05) 1.00 0.91 (0.82-1.01) 0.99 (0.89-1.11) 1.02 (0.91-1.15) 0.91 (0.78-1.07) 0.22 0.99 
All cancer (C00-97;D45-47) 5,883 0.98 (0.90-1.06) 1.00 0.92 (0.84-1.01) 1.02 (0.93-1.11) 1.07 (0.97-1.18) 1.03 (0.90-1.18) 0.06 0.06 
Models were adjusted for cancers-specific covariates as shown in article Supplementary Table 1. Cancer cases do not sum to totals as some participants were diagnosed 
with two primary cancers in the same month. a< 1 drink per week. bOverall. cLinear trend using median alcohol consumption of each category, excluding non-drinkers. 
dFemale breast cancer only. eZero cases in cell. ICD-10, International Classification of Diseases, version 10. 
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Table 8.2. Hazard ratios (HR) and 95% confidence intervals (CI) of cancer risk after excluding participants with physical functioning score < 50% by drinking-days per 
week among drinkers in the 45 and Up Study (2006-2010), New South Wales, Australia. 
 
n cases 
HR drinking-days per week in main analysis - adjusted for 
total alcohol consumption (95% CI) 
  HR drinking-days per week in sensitivity analysisa - adjusted 
for total alcohol consumption (95% CI) 
Cancer type (ICD-10 code) 1-2 3-5 6-7 pb ptrendc  n cases 1-2 3-5 6-7 pb ptrendc 
Mouth and pharynx (C00-14) 114 1.00 0.81 (0.50-1.32) 0.66 (0.38-1.14) 0.34 0.14  79 1.00 0.76 (0.42-1.38) 0.62 (0.32-1.21) 0.37 0.16 
Oesophagus (C15) 50 1.00 0.81 (0.35-1.88) 1.07 (0.48-2.40) 0.77 0.81  34 1.00 0.78 (0.30-2.01) 0.64 (0.24-1.70) 0.67 0.37 
- Adenocarcinoma (C15) 33 1.00 0.77 (0.27-2.19) 1.09 (0.40-2.99) 0.76 0.80  23 1.00 1.11 (0.35-3.47) 0.84 (0.24-2.96) 0.88 0.76 
- Squamous cell carcinoma (C15) 15 1.00 1.36 (0.29-6.42) 1.49 (0.32-6.98) 0.87 0.62  10 1.00 0.45 (0.07-2.81) 0.45 (0.08-2.63) 0.60 0.39 
Colorectum (C18-20) 630 1.00 0.87 (0.70-1.08) 0.84 (0.67-1.06) 0.31 0.16  480 1.00 0.94 (0.73-1.21) 0.92 (0.70-1.21) 0.83 0.58 
- Colon (C18-19) 414 1.00 0.91 (0.69-1.19) 0.77 (0.58-1.03) 0.19 0.07  302 1.00 0.94 (0.68-1.29) 0.78 (0.55-1.11) 0.32 0.15 
- Rectum (C20) 220 1.00 0.76 (0.52-1.11) 0.95 (0.64-1.40) 0.28 0.90  182 1.00 0.88 (0.57-1.35) 1.14 (0.73-1.78) 0.41 0.47 
Liver (C22) 31 1.00 0.78 (0.26-2.38) 1.54 (0.54-4.33) 0.39 0.34  25 1.00 0.41 (0.10-1.68) 1.42 (0.46-4.37) 0.17 0.38 
Larynx (C32) 29 1.00 1.37 (0.34-5.62) 2.01 (0.52-7.76) 0.53 0.26  20 1.00 0.58 (0.11-2.96) 1.25 (0.30-5.22) 0.53 0.54 
Breast (C50d) 630 1.00 1.16 (0.94-1.42) 0.95 (0.74-1.23) 0.12 0.73  528 1.00 1.18 (0.94-1.48) 0.95 (0.71-1.27) 0.11 0.76 
Alcohol-related (C00-15;18-20;22;32;50d) 1483 1.00 0.99 (0.86-1.13) 0.89 (0.76-1.04) 0.25 0.14  1166 1.00 1.00 (0.86-1.17) 0.89 (0.75-1.07) 0.28 0.20 
Stomach (C16) 66 1.00 0.80 (0.41-1.56) 0.71 (0.35-1.43) 0.62 0.34  49 1.00 0.76 (0.34-1.67) 0.80 (0.35-1.85) 0.78 0.64 
Pancreas (C25) 93 1.00 0.97 (0.56-1.68) 0.71 (0.38-1.32) 0.45 0.26  72 1.00 1.20 (0.62-2.29) 0.94 (0.45-1.93) 0.68 0.79 
Lung (C33-34) 348 1.00 0.78 (0.57-1.07) 0.94 (0.69-1.28) 0.27 0.82  240 1.00 0.82 (0.56-1.19) 0.97 (0.66-1.42) 0.49 1.00 
Melanoma (C43) 651 1.00 1.05 (0.85-1.31) 0.95 (0.75-1.21) 0.59 0.63  537 1.00 1.04 (0.82-1.31) 0.97 (0.74-1.27) 0.85 0.81 
Endometrium (C54.1) 52 1.00 0.91 (0.43-1.93) 1.30 (0.55-3.08) 0.64 0.55  42 1.00 0.93 (0.41-2.13) 1.33 (0.50-3.57) 0.69 0.57 
Ovary (C56) 39 1.00 0.75 (0.33-1.67) 0.55 (0.19-1.57) 0.53 0.26  32 1.00 0.95 (0.39-2.34) 0.73 (0.23-2.31) 0.83 0.59 
Prostate (C61) 1524 1.00 0.95 (0.82-1.09) 0.96 (0.82-1.12) 0.76 0.65  1302 1.00 0.93 (0.79-1.08) 0.94 (0.79-1.11) 0.61 0.49 
Kidney (C64) 105 1.00 0.83 (0.50-1.38) 0.63 (0.35-1.13) 0.30 0.12  85 1.00 1.08 (0.61-1.92) 0.79 (0.40-1.54) 0.52 0.45 
Bladder (C67) 78 1.00 0.61 (0.33-1.15) 0.57 (0.30-1.08) 0.17 0.10  59 1.00 0.54 (0.26-1.12) 0.57 (0.27-1.18) 0.19 0.15 
Brain (C71) 65 1.00 0.75 (0.40-1.41) 0.62 (0.29-1.33) 0.46 0.22  52 1.00 0.92 (0.46-1.84) 0.58 (0.24-1.42) 0.42 0.24 
Thyroid (C73) 55 1.00 0.84 (0.43-1.62) 0.52 (0.20-1.37) 0.41 0.21  47 1.00 0.77 (0.38-1.58) 0.50 (0.18-1.40) 0.42 0.19 
Non-Hodgkin lymphoma (C82-85) 174 1.00 1.15 (0.77-1.72) 0.97 (0.61-1.56) 0.61 0.88  140 1.00 0.98 (0.63-1.54) 0.90 (0.53-1.53) 0.91 0.70 
Multiple myeloma (C90.0) 51 1.00 1.14 (0.52-2.52) 1.11 (0.47-2.61) 0.95 0.84  37 1.00 0.79 (0.30-2.10) 1.11 (0.41-3.00) 0.73 0.75 
Leukaemia (C91-95) 91 1.00 0.67 (0.39-1.17) 0.61 (0.33-1.14) 0.24 0.12  68 1.00 0.63 (0.33-1.19) 0.59 (0.28-1.21) 0.26 0.15 
Other (Other C;D45-47) 339 1.00 0.96 (0.71-1.30) 1.14 (0.83-1.57) 0.49 0.39  238 1.00 0.99 (0.68-1.42) 1.35 (0.91-1.99) 0.14 0.11 
Non-alcohol-related (Other C;D45-47) 3738 1.00 0.92 (0.85-1.01) 0.92 (0.83-1.01) 0.15 0.09  3003 1.00 0.93 (0.84-1.03) 0.94 (0.84-1.05) 0.34 0.64 
All cancer (C00-97;D45-47) 5217 1.00 0.94 (0.87-1.02) 0.91 (0.84-0.99) 0.07 0.03  4166 1.00 0.95 (0.87-1.03) 0.93 (0.85-1.02) 0.30 0.14 
Non-drinkers were excluded. Models were adjusted for total alcohol consumption and cancer-specific covariates as listed in article Supplementary Table 1. Cancer cases do 
not sum to totals as some participants were diagnosed with two primary cancers in the same month. aParticipants with physical functioning score < 50% excluded. bOverall. 
cLinear trend using median number of drinking-days per week of each category. dFemale breast cancer only. ICD-10, International Classification of Diseases, version 10. 
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Table 8.3. Hazard ratios (HR) and 95% confidence intervals (CI) of cancer risk after excluding participants with physical functioning score < 50% by mean drinks per 
drinking-day among drinkers in the 45 and Up Study (2006-2010), New South Wales, Australia. 
 
n cases 
HR mean drinks per drinking-day in main analysis - adjusted 
for total alcohol consumption (95% CI) 
  HR mean drinks per drinking-day in sensitivity analysisa - 
adjusted for total alcohol consumption (95% CI) 
Cancer type (ICD-10 code) ≤ 2 > 2 and ≤ 4 > 4 pb ptrendc  n cases ≤ 2 > 2 and ≤ 4 > 4 pb ptrendc 
Mouth and pharynx (C00-14) 114 1.00 1.46 (0.90-2.37) 2.45 (1.22-4.92) 0.04 0.01  79 1.00 1.45 (0.80-2.60) 2.91 (1.26-6.74) 0.04 0.01 
Oesophagus (C15) 50 1.00 1.08 (0.50-2.35) 2.76 (1.01-7.53) 0.09 0.054  34 1.00 1.18 (0.45-3.10) 4.55 (1.36-15.2) 0.03 0.02 
- Adenocarcinoma (C15) 33 1.00 0.88 (0.35-2.23) 1.51 (0.40-5.71) 0.68 0.59  23 1.00 1.08 (0.34-3.45) 2.75 (0.55-13.7) 0.41 0.25 
- Squamous cell carcinoma (C15) 15 1.00 1.88 (0.42-8.53) 9.04 (1.71-47.7) 0.03 0.009  10 1.00 2.28 (0.33-15.6) 19.4 (2.52-148.9) 0.01 0.003 
Colorectum (C18-20) 630 1.00 0.81 (0.65-1.01) 1.15 (0.81-1.62) 0.03 0.74  480 1.00 0.85 (0.66-1.09) 1.36 (0.92-2.00) 0.02 0.25 
- Colon (C18-19) 414 1.00 0.75 (0.57-0.99) 1.26 (0.83-1.94) 0.01 0.57  302 1.00 0.82 (0.59-1.14) 1.76 (1.09-2.86) 0.003 0.06 
- Rectum (C20) 220 1.00 0.88 (0.62-1.26) 0.99 (0.56-1.75) 0.75 0.88  182 1.00 0.87 (0.59-1.28) 0.92 (0.49-1.72) 0.78 0.71 
Liver (C22) 31 1.00 0.84 (0.32-2.21) 1.56 (0.47-5.14) 0.56 0.48  25 1.00 0.83 (0.29-2.40) 1.46 (0.38-5.55) 0.67 0.59 
Larynx (C32) 29 1.00 1.23 (0.50-3.05) 0.48 (0.10-2.20) 0.33 0.37  20 1.00 1.20 (0.40-3.60) 0.39 (0.07-2.32) 0.33 0.30 
Breast (C50e) 630 1.00 1.26 (1.01-1.58) 1.24 (0.76-2.03) 0.13 0.11  528 1.00 1.25 (0.98-1.59) 1.08 (0.61-1.91) 0.19 0.29 
Alcohol-related (C00-15;18-20;22;32;50d) 1483 1.00 1.02 (0.89-1.17) 1.33 (1.04-1.69) 0.047 0.04  1166 1.00 1.04 (0.89-1.22) 1.42 (1.08-1.87) 0.03 0.02 
Stomach (C16) 66 1.00 1.15 (0.60-2.22) 1.55 (0.54-4.43) 0.72 0.42  49 1.00 1.09 (0.51-2.35) 2.13 (0.68-6.68) 0.38 0.22 
Pancreas (C25) 93 1.00 1.03 (0.59-1.81) 0.60 (0.19-1.87) 0.56 0.48  72 1.00 0.96 (0.51-1.81) 0.45 (0.12-1.77) 0.46 0.33 
Lung (C33-34) 348 1.00 1.40 (1.06-1.84) 1.46 (0.93-2.30) 0.051 0.06  240 1.00 1.66 (1.19-2.30) 1.51 (0.86-2.67) 0.01 0.07 
Melanoma (C43) 651 1.00 1.10 (0.89-1.35) 1.05 (0.72-1.52) 0.65 0.68  537 1.00 1.10 (0.88-1.38) 1.00 (0.66-1.52) 0.63 0.85 
Endometrium (C54.1) 52 1.00 1.04 (0.45-2.39) -e 1.00 0.27  42 1.00 0.92 (0.35-2.40) -e 0.98 0.33 
Ovary (C56) 39 1.00 3.54 (1.51-8.32) -e 0.02 0.16  32 1.00 2.84 (1.08-7.42) -e 0.11 0.41 
Prostate (C61) 1524 1.00 1.14 (1.00-1.30) 1.12 (0.90-1.39) 0.13 0.22  1302 1.00 1.14 (0.99-1.31) 1.13 (0.89-1.44) 0.18 0.23 
Kidney (C64) 105 1.00 1.13 (0.67-1.90) 2.61 (1.24-5.47) 0.03 0.02  85 1.00 0.97 (0.55-1.74) 2.15 (0.94-4.94) 0.10 0.09 
Bladder (C67) 78 1.00 0.64 (0.34-1.21) 0.46 (0.14-1.51) 0.30 0.15  59 1.00 0.56 (0.27-1.15) 0.32 (0.08-1.34) 0.19 0.08 
Brain (C71) 65 1.00 0.75 (0.38-1.49) 0.97 (0.31-3.02) 0.67 0.82  52 1.00 0.67 (0.30-1.48) 1.44 (0.43-4.79) 0.30 0.76 
Thyroid (C73) 55 1.00 1.04 (0.46-2.34) 2.52 (0.73-8.75) 0.31 0.23  47 1.00 1.11 (0.46-2.63) 3.34 (0.93-12.0) 0.16 0.11 
Non-Hodgkin lymphoma (C82-85) 174 1.00 0.90 (0.59-1.38) 0.58 (0.24-1.38) 0.46 0.25  140 1.00 0.86 (0.54-1.39) 0.66 (0.26-1.71) 0.68 0.38 
Multiple myeloma (C90.0) 51 1.00 1.22 (0.59-2.53) 1.15 (0.31-4.22) 0.87 0.76  37 1.00 1.45 (0.62-3.40) 1.61 (0.36-7.27) 0.69 0.48 
Leukaemia (C91-95) 91 1.00 0.81 (0.44-1.47) 1.71 (0.70-4.15) 0.19 0.36  68 1.00 0.69 (0.33-1.42) 2.04 (0.74-5.62) 0.07 0.30 
Other (Other C;D45-47) 339 1.00 1.08 (0.80-1.45) 1.50 (0.93-2.40) 0.23 0.11  238 1.00 0.84 (0.59-1.19) 0.93 (0.51-1.72) 0.60 0.67 
Non-alcohol-related (Other C;D45-47) 3738 1.00 1.12 (1.03-1.22) 1.14 (0.98-1.32) 0.03 0.04  3003 1.00 1.10 (1.00-1.21) 1.11 (0.94-1.31) 0.13 0.14 
All cancer (C00-97;D45-47) 5217 1.00 1.10 (1.02-1.18) 1.17 (1.04-1.33) 0.01 0.007  4166 1.00 1.09 (1.00-1.18) 1.17 (1.02-1.35) 0.052 0.02 
Non-drinkers were excluded. Models were adjusted for total alcohol consumption and cancer-specific covariates as listed in article Supplementary Table 1. Cancer cases do 
not sum to totals as some participants were diagnosed with two primary cancers in the same month. aParticipants with physical functioning score < 50% excluded. bOverall. 
cLinear trend using median number of drinks per drinking-day of each category. dFemale breast cancer only. eZero cases in cell. ICD-10, International Classification of 
Diseases, version 10.  
323 
 
Table 8.4. Hazard ratios (HR) and 95% confidence intervals (CI) of cancer risk after excluding participants with physical functioning score < 50% by drinking 
pattern among drinkers in the 45 and Up Study (2006-2010), New South Wales, Australia. 
Cancer type 
Drinking-days 
per week n cases 
HR mean drinks per drinking-day in main analysis 
(95% CI) 
  HR mean drinks per drinking-day in sensitivity 
analysisa (95% CI) 
≤ 2 > 2 and ≤ 4 > 4  n cases ≤ 2 > 2 and ≤ 4 > 4 
Colorectum 1-2 630 1.00 0.54 (0.32-0.91) 0.99 (0.58-1.67)  480 1.00 0.45 (0.23-0.87) 0.90 (0.47-1.75) 
3-5  0.91 (0.71-1.16) 0.69 (0.47-1.01) 1.04 (0.62-1.75)   0.87 (0.65-1.16) 0.81 (0.54-1.21) 1.35 (0.79-2.30) 
6-7  0.81 (0.64-1.04) 0.92 (0.69-1.23) 1.47 (1.06-2.02)   0.86 (0.64-1.14) 0.89 (0.64-1.25) 1.50 (1.04-2.17) 
Colon 1-2 414 1.00 0.50 (0.25-1.00) 0.97 (0.48-1.94)  302 1.00 0.40 (0.16-0.99) 1.17 (0.53-2.60) 
3-5  0.99 (0.74-1.34) 0.64 (0.39-1.05) 1.26 (0.66-2.40)   0.95 (0.66-1.35) 0.75 (0.44-1.28) 1.75 (0.90-3.41) 
6-7  0.77 (0.57-1.04) 0.89 (0.62-1.29) 1.82 (1.23-2.69)   0.76 (0.53-1.09) 0.86 (0.56-1.32) 1.85 (1.17-2.92) 
Kidney 1-2 105 1.00 1.64 (0.67-4.03) 3.55 (1.49-8.48)  85 1.00 1.75 (0.59-5.17) 4.06 (1.44-11.5) 
3-5  0.91 (0.45-1.83) 1.29 (0.59-2.83) 2.59 (1.03-6.49)   1.34 (0.60-2.98) 1.68 (0.69-4.11) 3.09 (1.08-8.81) 
6-7  1.26 (0.67-2.38) 0.58 (0.24-1.38) 0.70 (0.25-1.95)   1.73 (0.81-3.71) 0.65 (0.23-1.83) 1.02 (0.34-3.08) 
All cancer 1-2 5217 1.00 1.01 (0.88-1.17) 1.27 (1.07-1.52)  4166 1.00 0.98 (0.83-1.15) 1.21 (0.99-1.49) 
3-5  0.96 (0.88-1.05) 1.08 (0.97-1.21) 1.02 (0.85-1.23)   0.94 (0.85-1.04) 1.07 (0.94-1.21) 1.09 (0.89-1.33) 
6-7  0.95 (0.87-1.03) 1.06 (0.96-1.17) 1.11 (0.98-1.26)   0.95 (0.86-1.05) 1.04 (0.93-1.16) 1.07 (0.92-1.23) 
Non-drinkers were excluded. Models were adjusted for total alcohol consumption and cancer-specific covariates as listed in article Supplementary Table 1. 
aParticipants with physical functioning score < 50% excluded. 
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The sensitivity analyses for the continuous log-linear association between alcohol consumption and 
cancer risk for two exclusion scenarios (the exclusion of participants with a low physical functioning 
score and the exclusion of participants consuming < 7 drinks per week) are shown in Table 8.5. Both 
sensitivity analyses resulted in several risk estimates that differed from the main results. Specifically, 
the sensitivity analysis excluding participants with a low physical functioning score resulted in 
significant positive associations for mouth and pharynx and oesophageal cancer (squamous cell 
carcinoma), which were not observed in the main analysis. Associations for breast cancer, thyroid 
cancer and all cancers combined in men observed in the main analysis were non-significant, but 
there were no material differences in the hazard ratios compared to the main analysis. For the 
sensitivity analysis that excluded participants consuming < 7 drinks per week, the associations for 
breast and thyroid cancer observed in the main analysis were non-significant, and the hazard ratios 
moved closer toward the null in comparison to the main analysis. All cancers combined in men was 
also non-significant, but there was no material difference in hazard ratio compared to the main 
analysis. Risk estimates for cancer of the colorectum and colon were increased compared to the 
main analysis.
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Table 8.5. Hazard ratios (HR) and 95% confidence intervals (CI) of cancer risk per one drink increase in mean 
daily alcohol consumption after excluding participants with physical functioning score < 50% or those 
consuming < 7 drinks per week among drinkers in the 45 and Up Study (2006-2010), New South Wales, 
Australia. 
 Main analysis  Excluding MOS-PF < 50%  Excluding < 7 drinks/week 
Cancer type (ICD-10 code) n cases HR (95% CI)  n cases HR (95% CI)  n cases HR (95% CI) 
Mouth and pharynx (C00-14) 116 1.04 (0.94-1.15)  80 1.13 (1.00-1.27)  75 0.99 (0.87-1.13) 
Oesophagus (C15) 50 1.06 (0.91-1.23)  34 1.07 (0.89-1.30)  30 1.08 (0.92-1.27) 
- Adenocarcinoma (C15) 33 1.02 (0.84-1.24)  23 0.93 (0.69-1.25)  19 1.05 (0.85-1.29) 
- Squamous cell carcinoma (C15) 15 1.16 (0.91-1.46)  10 1.30 (1.02-1.67)  10 1.22 (0.92-1.60) 
Colorectum (C18-20) 641 1.07 (1.02-1.12)  488 1.06 (1.01-1.12)  376 1.10 (1.04-1.16) 
- Colon (C18-19) 422 1.10 (1.04-1.17)  308 1.09 (1.02-1.17)  242 1.15 (1.08-1.23) 
- Rectum (C20) 223 1.03 (0.96-1.12)  184 1.04 (0.95-1.13)  137 1.03 (0.94-1.13) 
Liver (C22) 33 1.09 (0.94-1.26)  26 1.12 (0.96-1.32)  24 1.05 (0.88-1.26) 
Larynx (C32) 29 1.18 (1.02-1.36)  20 1.19 (1.01-1.40)  24 1.18 (1.00-1.39) 
Breast (C50a) 643 1.09 (1.01-1.18)  538 1.07 (0.98-1.17)  332 1.03 (0.92-1.16) 
Alcohol-related (C00-15;18-20;22;32;50a) 1,511 1.07 (1.04-1.11)  1,186 1.08 (1.04-1.12)  860 1.08 (1.04-1.13) 
- Men 598 1.07 (1.03-1.12)  453 1.08 (1.03-1.13)  402 1.08 (1.03-1.13) 
- Women 913 1.07 (1.00-1.14)  733 1.07 (0.99-1.15)  458 1.05 (0.95-1.15) 
Stomach (C16) 67 1.08 (0.93-1.25)  50 1.08 (0.91-1.29)  39 1.07 (0.89-1.28) 
Pancreas (C25) 97 1.00 (0.86-1.16)  73 1.03 (0.88-1.21)  53 1.12 (0.94-1.33) 
Lung (C33-34) 357 0.98 (0.92-1.05)  243 0.97 (0.89-1.05)  230 0.97 (0.90-1.06) 
Melanoma (C43) 660 1.05 (0.99-1.10)  544 1.05 (0.99-1.11)  411 1.04 (0.98-1.11) 
Endometrium (C54.1) 52 1.11 (0.85-1.45)  42 1.07 (0.78-1.48)  25 1.24 (0.87-1.78) 
Ovary (C56) 39 0.97 (0.67-1.40)  32 1.05 (0.73-1.52)  16 1.21 (0.80-1.84) 
Prostate (C61) 1,539 1.02 (0.99-1.05)  1,315 1.01 (0.97-1.04)  1037 1.02 (0.98-1.06) 
Kidney (C64) 107 0.97 (0.86-1.11)  86 0.99 (0.86-1.14)  67 0.95 (0.81-1.13) 
Bladder (C67) 80 0.96 (0.82-1.12)  61 0.96 (0.81-1.15)  47 1.00 (0.83-1.19) 
Brain (C71) 65 0.95 (0.79-1.14)  52 0.89 (0.71-1.12)  35 0.97 (0.77-1.21) 
Thyroid (C73) 55 0.70 (0.50-0.98)  47 0.72 (0.51-1.04)  16 0.87 (0.54-1.39) 
Non-Hodgkin lymphoma (C82-85) 174 0.88 (0.77-1.00)  140 0.89 (0.77-1.03)  94 0.98 (0.75-1.06) 
Multiple myeloma (C90.0) 51 1.04 (0.87-1.24)  37 1.09 (0.89-1.34)  32 0.98 (0.77-1.25) 
Leukaemia (C91-95) 93 0.93 (0.79-1.09)  69 0.93 (0.77-1.11)  53 0.93 (0.75-1.14) 
Other (Other C;D45-47) 347 1.02 (0.95-1.10)  239 1.03 (0.94-1.12)  219 0.99 (0.90-1.08) 
Non-alcohol-related (Other C;D45-47) 3,790 1.01 (0.98-1.03)  3,033 1.00 (0.98-1.02)  2,375 1.00 (0.98-1.03) 
All cancer (C00-97;D45-47) 5,297 1.02 (1.00-1.04)  3,496 1.02 (1.00-1.05)  3,232 1.02 (1.00-1.05) 
- Men 3,578 1.02 (1.00-1.04)  2,859 1.02 (1.00-1.04)  2,393 1.02 (1.00-1.05) 
- Women 1,719 1.03 (0.98-1.08)  1,357 1.04 (0.98-1.10)  839 1.04 (0.97-1.12) 
Non-drinkers were excluded. Models were adjusted for cancer-specific covariates as listed in article 
Supplementary Table 1. Cancer cases do not sum to totals as some participants were diagnosed with two 
primary cancers in the same month. aFemale breast cancer only. ICD, International Classification of Diseases, 
version 10. MOS-PF, Medical Outcomes Study Physical Functioning score. 
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Conclusions. There was no material difference in the magnitude of the log-linear association 
between total alcohol consumption and risk of all cancers combined according to different exclusion 
scenarios aimed to assess the extent of bias from the ‘sick-quitter effect’. This suggests that the 
results for all cancers combined were robust and unlikely to be impacted importantly by bias from 
the ‘sick-quitter effect’. 
Nevertheless, important differences were found for individual cancer types in two of the sensitivity 
analyses examined. That is, when participants with a physical functioning score < 50% or consuming 
< 7 drinks per week were excluded. In the majority of cases where trends were significant in the 
main analysis and non-significant in the sensitivity analyses there was no material change in hazard 
ratios, with the exception of breast and thyroid cancer. 
The sensitivity test restricting the calculation to participants consuming ≥ 7 drinks per week 
suggested that the association between alcohol consumption and lower risk of thyroid cancer may 
be at least partially accounted for by bias from changes in drinking in response to ill-health. The 
finding that breast cancer risk may be overestimated was unexpected. For the sensitivity test 
restricting the calculation to participants consuming ≥ 7 drinks per week, this may be due to the fact 
that a non-linear relationship was found in the cubic spline analysis, with a plateauing of risk after 
approximately 7 drinks per week. The loss of significance may also reflect inadequate statistical 
power as the number of cases decreased by 48%. Therefore, further research is required to 
investigate the impact of confounding by the ‘sick-quitter effect’ on effect estimates for all cancer 
types, but for breast cancer risk in particular. 
There were few changes when examining drinking pattern, suggesting these results were robust and 
unlikely to be impacted importantly by bias from the ‘sick-quitter effect’. There was evidence of a 
positive association between with mean drinks per drinking-day and risk of cancer of the 
oesophagus (both subtypes combined). It should be noted however that the sensitivity test could 
not be expected to remove all bias, and so inverse associations for drinking frequency and all cancers 
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combined, and for colorectal and colon cancer in the overall drinking pattern analysis, are not 
necessarily causal. 
 
2. Population attributable fractions, cumulative absolute risk of cancer diagnosis and number of 
persons needed to quit or reduce drinking to prevent one cancer case. 
Rationale and methods. The population attributable fraction (PAF) for alcohol consumption and 
cancer in Australia has previously been estimated using internationally-derived relative risks[1]. It is 
possible that risk may differ between populations, and so it is of interest to investigate how the 
hazard ratios derived from the 45 and Up Study can be used to calculate estimates for population 
attributable fractions, as well as other outcomes which may have public health importance. Thus, 
the results of the continuous log-linear analysis in the main analysis were used to calculate three 
further results: PAF for cancer cases attributable to alcohol consumption in Australia in 2010, 
cumulative absolute risk of cancer diagnosis between the ages of 45 and 75 years by level of alcohol 
consumption, and number of persons needed to quit or reduce drinking by age 45 years to prevent 
one cancer case by age 75 years. Due to the significant interactions with sex for total alcohol 
consumption and risk of alcohol-related and all cancer observed in the main analysis, sex-specific 
hazard ratios were used in the calculations for these two cancer outcomes. 
The PAF calculations were performed using the same method as Pandeya et al., (2015), which relied 
on log-linear conversions of international relative risks to estimate PAFs for Australia in 2010[1]. The 
exact lag time between alcohol consumption and the occurrence of cancer is unknown, however 
Pandeya et al., (2015) assumed a lag time of nine years, attributing cancer incidence in 2010 to sex- 
and age-specific alcohol consumption in the 2001 National Health Survey (2001 alcohol consumption 
data shown in Supplementary Table 2[1]). A full description of the methods used to calculate PAFs, 
cumulative absolute risk of cancer diagnosis and number of persons needed to quit or reduce 
drinking to prevent one cancer case are presented in Appendix E.3. 
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Results. The population attributable fraction calculations for alcohol consumption and cancer in 
Australia in 2010 are shown in Table 8.6. At 2.5%, the estimated PAF for all cancers combined was 
similar to that obtained by Pandeya et al., (2015) with international relative risks, and did not 
materially differ when using hazard ratios derived from either of the two sensitivity tests. Regarding 
individual cancer types, the estimates for the main analysis were lower for cancers of the mouth and 
pharynx and rectum, similar for cancers of the oesophagus, liver and breast, and higher for cancers 
of the colon and larynx. The highest PAF was found for larynx cancer and the greatest number of 
attributable cases for colon cancer. The sensitivity test excluding participants with a low physical 
functioning score resulted in an increase in the majority of PAF estimates, while the sensitivity test 
restricting the hazard ratio calculation to participants consuming ≥ 7 drinks per week resulted in a 
decrease in the majority of PAF estimates. 
The estimated PAF for all cancers combined increased to 3.8% under the assumption that cancers of 
the stomach, pancreas and prostate and melanoma are causally related to alcohol consumption, and 
this estimate did not materially change in either of the two sensitivity tests. The highest PAF was 
found for stomach cancer and the greatest number of attributable cases for prostate cancer. The 
estimated PAF for all cancers combined decreased to net 1.6% under the assumption that cancers of 
the kidney and thyroid and NHL are causally related to alcohol consumption, with higher estimates 
obtained in the two sensitivity tests. The lowest PAF was found for thyroid cancer, with the estimate 
implying a 19% increase in thyroid cancer cases if the population consumed no alcohol. The 
estimated PAF for all cancers combined did not change materially under the assumption that both 
the positively and inversely associated cancers are causally related to alcohol consumption, except in 
the sensitivity test restricting the hazard ratio calculation to participants consuming ≥ 7 drinks per 
week, which resulted in a higher PAF for all cancers combined. 
The cumulative absolute risk of cancer between the ages of 45 and 75 years by level of alcohol 
consumption is shown in Figure 8.2. The absolute risk difference between drinking groups was larger 
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in men for all individual cancer types, but was larger in women for alcohol-related cancer combined. 
For all cancers combined, cumulative absolute risk to age 75 years in men was 34.0% in those 
consuming > 14 drinks per week (median 21 drinks per week) and 32.1% in non-drinkers, while in 
women these values were 25.6% (median 20 drinks per week) and 23.9% respectively. For alcohol-
related cancer risk by the age of 75 years, men and women consuming > 14 drinks per week ‘brought 
forward’ their risk of cancer by approximately 3.5 years, and those consuming > 0 and ≤ 14 drinks 
per week by approximately 1 year, compared to non-drinkers. 
The estimated number of persons needed to quit or decrease drinking by age 45 years to prevent 
one cancer case by age 75 years is shown in Table 8.7. One cancer case was estimated to be 
prevented for every 42 men or 37 women quitting (or never starting) drinking at > 14 drinks per 
week (median 20 drinks per week in women and 21 in men). The largest values were found for 
persons quitting (or never starting) drinking at > 0 and ≤ 14 drinks per week (median 5 drinks per 
week in women and 6 in men). The smallest values among the individual cancer types were for 
colorectal cancer in men and breast cancer in women. The sensitivity tests did not materially change 
estimates for alcohol-related cancers combined in men, while in women the sensitivity test 
restricting the hazard ratio calculation to participants consuming ≥ 7 drinks per week resulted in 
higher values. 
Conclusions. The PAF estimate for all cancers combined using log-linear hazard ratios from the 45 
and Up Study was similar to that of a previous study using internationally-derived relative risks.  
The estimates of cumulative absolute risk of cancer and number of persons needed to quit or reduce 
drinking to prevent one cancer case showed that colorectal and breast cancer contributed the most 
to the absolute cancer risk associated with alcohol consumption. 
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Table 8.6. Population attributable fractions for cancer caused by alcohol consumption in Australian persons in 2010 using international relative risks and hazard ratios 
from the 45 and Up Study (2006-2010), New South Wales, Australia. 
 
 
Pandeya et al., (2015)[1] 
 45 and Up Study: derived 
from main analysis 
 45 and Up Study: derived 
from sensitivity analysis 1a 
 45 and Up Study: derived 
from sensitivity analysis 2b 
Cancer type n cases n excess cases PAF (%)  n excess cases PAF (%)  n excess cases PAF (%)  n excess cases PAF (%) 
Alcohol-related             
Mouth and pharynxc 1,996 613 30.6  102 5.1  397 19.9  0d 0.0 
Oesophagus SCC 511 126 24.7  99 19.4  234 45.8  150 29.4 
Colone 10,865 868 8.0  1,258 11.6  1,105 10.2  1,996 18.4 
Rectume 3,967 470 11.8  165 4.2  175 4.4  150 3.8 
Liver 1,389 175 12.7  175 12.6  260 18.7  92 6.6 
Larynx 625 126 20.1  204 32.6  220 35.2  205 32.8 
Breast (female) 14,174 830 5.8  822 5.8  618 4.4  274 1.9 
All cancer 115,118 3,208 2.8  2,824 2.5  3,009 2.6  2,867 2.5 
Alcohol-related and positively associated             
Stomach 1,993 - -  184 9.3  198 9.9  160 8.0 
Pancreas 2,712 - -  0d 0.0  79 2.9  362 13.4 
Melanoma 11,370 - -  633 5.6  619 5.4  547 4.8 
Prostate 20,093 - -  710 3.5  221 1.1  544 2.7 
All cancer 115,118 - -  4,352 3.8  4,125 3.6  4,482 3.9 
Alcohol-related and inversely associated             
Kidney 2,722 - -  -86 -3.2  -32 -1.2  -138 -5.1 
Thyroid 2,209 - -  -419 -19.0  -390 -17.6  -215 -9.7 
Non-Hodgkin lymphoma 4,429 - -  -480 -10.8  -445 -10.0  -88 -2.0 
All cancer 115,118 - -  1,839 1.6  2,143 1.9  2,426 2.1 
Alcohol-related and all associated             
All cancer 115,118 - -  3,367 2.9  3,259 2.8  4,040 3.5 
Hazard ratios used in calculations for the 45 and Up Study were derived from total alcohol consumption as a log-linear variable among participants consuming ≥ 1 drink per 
week. For each age group used in the calculation, cancer incidence was attributed to alcohol consumption nine years earlier in the 2001 National Health Survey. Pandeya et 
al., (2015) used international log-linear relative risks. ‘n excess cases’ refers to cancer cases attributable to alcohol consumption out of the total number of cases, ‘n cases’. 
aParticipants with physical functioning score < 50% excluded. bAmong participants consuming ≥ 7 drinks per week. cICD-10: C01-06;09-14 in Pandeya et al. 2015 and C00-14 
for calculations in the 45 and Up Study. dHazard ratio less than 1 (0.994 for mouth and pharynx cancer and 0.997 for pancreatic cancer). eCancer of the Rectosigmoid 
junction (C19) was grouped with colon in Pandeya et al. 2015 and with rectum for calculations in the 45 and Up Study. PAF, Population Attributable Fraction. SCC, Squamous 
Cell Carcinoma. ICD-10: International Classification of Diseases, version 10. 
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Figure 8.2. Cumulative absolute risk of cancer diagnosis between the ages of 45 and 75 years in Australia in 
2013 using hazard ratios from the 45 and Up Study (2006-2010), New South Wales, Australia. Black line: 0 
drinks per week; Green line: 5 drinks per week in women and 6 drinks per week in men; Red line: 20 drinks 
per week in women and 21 drinks per week in men. Results derived from total alcohol consumption as a log-
linear variable among participants consuming ≥ 1 drink per week. International classification of diseases, 
version 10 codes for mouth and pharynx: C00-14;30-31 in incidence data and C00-14 as calculated in the 45 
and Up Study. 
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Figure 8.2. (Continued) 
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Table 8.7. Number of persons needed to quit or decrease drinking by age 45 years to prevent one cancer case by age 75 years in Australia in 
2013. 
 Men  Women 
Cancer type 
21 drinks/week 
→ Quit 
6 drinks/week 
→ Quit 
21 drinks/week 
→ 6 drinks/week 
 20 drinks/week 
→ Quit 
5 drinks/week 
→ Quit 
20 drinks/week 
→ 5 drinks/week 
Main analysis        
Mouth and pharynxa 567 2,063 782  1,622 6,744 2,133 
Oesophagus 977 3,630 1,337  3,629 15,414 4,745 
Colorectum 111 417 151  160 688 209 
Liver 508 1,949 687  1,635 7,172 2,118 
Larynx 591 2,490 775  4,287 20,632 5,412 
Breast - - -  44 193 57 
Alcohol-related 42 158 58  37 154 48 
Sensitivity analysis 1b        
Mouth and pharynxa 171 679 228  465 2,116 595 
Oesophagus 756 2,858 1,027  2,781 12,024 3,617 
Colorectum 127 472 173  184 783 240 
Liver 364 1,448 486  1,149 5,229 1,472 
Larynx 559 2,379 730  4,028 19,599 5,070 
Breast - - -  58 247 76 
Alcohol-related 40 149 54  38 161 50 
Sensitivity analysis 2c        
Mouth and pharynxa -d -d -d  -d -d -d 
Oesophagus 700 2,663 949  2,568 11,172 3,334 
Colorectum 80 309 108  114 504 148 
Liver 904 3,329 1,240  2,970 12,512 3,895 
Larynx 588 2,479 771  4,263 20,533 5,379 
Breast - - -  127 524 168 
Alcohol-related 40 150 55  54 222 70 
Results derived from total alcohol consumption as a log-linear variable among participants consuming ≥ 1 drink per week. aInternational 
classification of diseases, version 10: C00-14;30-31 in incidence data and C00-14 as calculated in the 45 and Up Study. bParticipants with physical 
functioning score < 50% excluded. cAmong participants consuming ≥ 7 drinks per week. dHazard ratio less than 1 (0.994 per drink per day). 
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8.3 – Discussion and Conclusions 
 
The main findings of this chapter were that total alcohol consumption was associated with increased 
risk of several types of cancer, including colorectum, colon, larynx, female breast, alcohol-related 
and all cancer, along with decreased risk of bladder and thyroid cancer and NHL. The results for total 
alcohol consumption were largely consistent with prior research, and a summary of the results in 
comparison with the IARC and WCRF conclusions are present in Table 8.8. While light alcohol 
consumption (up to 1 drink per day) has been found in a meta-analyses to increase risk of 
oesophageal SCC, mouth, pharynx and breast cancer[2-4], we found no significant associations for 
light drinking (up to 7 drinks per week). Nevertheless, the confidence intervals for the ≥ 3.5 to ≤ 7 
drinks per week category for most alcohol-related cancer types were consistent with a hazard ratio 
of at least 1.6, and so the analysis may have been underpowered to detect effects for light drinking. 
There was also evidence that the risk relationship between alcohol consumption and certain cancers 
may not be linear, including colorectum, colon and breast. This finding suggests that modelling 
cancer risk and estimating the burden of disease for these cancers may not be straightforward. 
In analyses examining the effects of drinking pattern, there was an independent association of mean 
drinks per drinking-day with increased risk of mouth and pharynx, oesophagus (squamous cell 
carcinoma), colorectum, colon, kidney, alcohol-related, non-alcohol-related and all cancer. Frequent 
drinking was associated with a lower risk of all cancer combined compared to less frequent drinking. 
Among participants consuming > 4 drinks per drinking-day, frequent drinking was also positively 
associated with colorectal and colon cancer risk and inversely associated with kidney cancer risk. A 
key implication of these results was that a reduction in the number of drinks consumed per drinking 
occasion is likely to be an effective approach to reduce cancer risk, independent of and in addition to 
limiting the total amount of alcohol consumed. Another implication was that there was no evidence 
that alcohol consumption is associated with increased risk of five cancer types (stomach, pancreas, 
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lung, melanoma and prostate) or decreased risk of kidney cancer, for which there is prior evidence 
of an association but the IARC has not declared causality. 
The additional analyses presented evidence that there was no material difference in the magnitude 
of the log-linear association between total alcohol consumption and risk of all cancers combined 
under a number of sensitivity tests aimed to test the extent of bias from the ‘sick-quitter effect’. 
Similarly, there was no material change in the inverse association between drinking frequency and 
risk of all cancers combined or in the results for overall drinking pattern. These results suggest that 
the results for all cancers combined were robust and unlikely to be impacted importantly by bias 
from the ‘sick-quitter effect’. 
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Table 8.8. Relationship between alcohol consumption and cancer according to the IARC[5, 6], the WCRF[7, 8] and the results for total alcohol consumption in the 45 and Up Study. 
Cancer type (ICD-10 code) IARC WCRF 45 and Up Study 
Mouth and pharynx (C00-14) Increased risk (RR 3 at 50 g/day); interaction with smoking Convincing increased risk No significant associationa 
Oesophagus (C15) Increased risk (RR 2 at 50 g/day); interaction with smokingb Convincing increased riskb No significant associationa 
Stomach (C16) Inconsistent evidence (increased risk in some studies) Probable increased riskc No significant association 
Colorectum (C18-20) Increased risk (only at > 30 g/day; RR 1.4 at 50 g/day) Convincing increased riskd Positive association (colorectum and colon) 
Liver (C22) Increased risk, interaction with smoking Convincing increased riskc Increased risk at > 28 drinks/weeka 
Gallbladder (C23-24) - Limited - no conclusion No significant association 
Pancreas (C25) Association with small increased risk (only at ≥ 30 g/day) Suggestive increased riske No significant association; interaction with smoking 
Larynx (C32) Increased risk (RR 2 at 50 g/day); interaction with smoking Convincing increased risk Positive association 
Lung (C33-34) Inconsistent evidence (increased risk in some studies) Limited - no conclusion No significant association 
Melanoma (C43) Inconsistent evidence Limited - no conclusionf No significant association 
Female breast (C50) Increased risk (RR 1.5 at 50 g/day) Convincing increased risk Positive associationg 
Male breast (C50) Inconsistent evidence - - 
Vulva and vagina (C51-52) Inconsistent evidence (increased risk in some studies) - - 
Cervix (C53) Inconsistent evidence (increased risk in some studies) Limited - no conclusionh - 
Endometrium (C54.1) Inconsistent evidence Limited - no conclusion No significant association 
Ovary (C56) Little evidence for association Limited - no conclusion No significant association 
Prostate (C61) Little evidence for association (increased risk in some studies) Limited - no conclusion No significant association 
Testis (C62) Inconsistent evidence - - 
Kidney (C64) No association (decreased risk in some studies) Probable decreased riski No significant association; interaction with smoking 
Bladder (C67) No association Limited - no conclusion No significant association 
Brain (C71) Inconsistent evidence - No significant association 
Thyroid (C73) Inconsistent evidence (decreased risk in some studies) - Inverse associationg 
Hodgkin lymphoma (C81) Inconsistent evidence (decreased risk in some studies) - - 
Non-Hodgkin lymphoma (C82-85) Inconsistent evidence (decreased risk in some studies) - Inverse association 
Multiple myeloma (C90.0) Inconsistent evidence - No significant association 
Leukaemia (C91-95)  Inconsistent evidence - No significant association 
aPositive association in sensitivity test aiming to mitigate bias from changes in drinking behaviours in response to ill-health. bSquamous cell carcinoma only; not enough evidence/no 
association for adenocarcinoma. cFor alcohol consumption > 30 g/day. dFor alcohol consumption > 45 g/day. eLimited-suggestive increased risk, for alcohol consumption > 3 drinks/day. 
fFor all skin cancer. gNo significant association and a material change in risk estimate in sensitivity test aiming to mitigate bias from changes in drinking behaviours in response to ill-
health. hFor alcoholism. iFor alcohol consumption ≤ 30 g/day. IARC relative risks are compared to non-drinkers. IARC, International Agency for Cancer Research. WCRF, World Cancer 
Research Fund. ICD-10, International Classification of Diseases version 10. RR, Relative Risk. 
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Nevertheless, for a number of individual cancer types, the risk relationship with alcohol varied from 
that observed in the main analysis when either participants with poor physical functioning, or those 
who consumed < 7 drinks per week, were excluded. Specifically, for mouth and pharynx, 
oesophageal (SCC) and liver cancers, the risks associated with alcohol may have been 
underestimated in the main analyses due to bias from the ‘sick-quitter effect’, including the 
association between mean drinks per drinking-day and oesophageal cancer. The inverse association 
for thyroid cancer may also have been overestimated in the main analysis. 
The PAF estimate for all cancers combined using log-linear hazard ratios from the 45 and Up Study 
was similar to that of a previous study using internationally-derived relative risks, while there was 
some variation by individual cancer type. The inclusion of cancers which have previously been 
associated with alcohol consumption made a material difference to the PAF estimate, increasing 
from 2.5% to 3.8% when including four positively associated cancers and decreasing to 1.6% when 
including three inversely associated cancers. This shows that determining whether the associations 
for the positively associated cancers are causal will make an important difference to burden of 
disease estimates for alcohol and cancer. It also follows that whether or not the associations for the 
inversely associated cancers are causal, the net impact of alcohol consumption on cancer PAFs will 
always be that of increased risk. 
The estimates of cumulative absolute risk of cancer and number of persons needed to quit or reduce 
drinking to prevent one cancer case showed that colorectal and breast cancer contributed the most 
to the absolute cancer risk associated with alcohol consumption. It was largely found that the 
number of persons needed to quit or reduce drinking to prevent one cancer case for all cancers 
combined were not materially affected by bias from the ‘sick-quitter effect’. One key finding was 
that the absolute risk difference between drinking groups was larger in men for all individual cancer 
types (excluding breast) due to the higher incidence of cancer in men. The absolute risk difference 
was larger in women for alcohol-related cancer combined due to the impact of breast cancer. It was 
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also shown that by age 75 years, persons consuming > 14 drinks per week ‘brought forward’ their 
risk of alcohol-related cancer by 3.5 years compared to non-drinkers. Other key findings included 
that one cancer case could be prevented by the age of 75 years for every 42 men or 37 women 
quitting (or never starting) drinking at > 14 drinks per week, and that targeting persons drinking > 14 
drinks per week to decrease their drinking to > 0 and ≤ 14 drinks per week is likely to be a more 
efficient strategy to reduce cancer incidence than targeting persons drinking > 0 and ≤ 14 drinks per 
week to decrease their drinking to zero. These results may be useful for planning preventative public 
health interventions to reduce the burden of cancer. 
The next chapter investigated the association between alcohol consumption, drinking pattern and 
risk of all-cause and cause-specific mortality. 
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Chapter 9 – Alcohol Consumption and All-Cause and Cause-Specific Mortality Risk 
 
Chapter summary 
This chapter contains an article prepared for publication, which investigated the association 
between alcohol consumption and risk of all-cause and cause-specific mortality, with a focus on the 
effect of pattern of drinking. This was achieved by using baseline data from the 45 and Up Study 
linked to the NSW Registry of Births, Deaths and Marriages to December 2014 and cause of death 
data to December 2012. The hazard of death was calculated for overall weekly alcohol intake 
assessed in three ways: as a categorical variable, a continuous log-linear variable and a continuous 
restricted cubic spline variable. After adjusting for total alcohol consumption, the independent effect 
on mortality of two measures of drinking pattern, drinking-days per week and drinks per drinking-
day, was examined, along with an analysis accounting for both measures simultaneously. Interaction 
tests were performed to test for effect modification by sex and smoking status. Causes of death for 
which there was evidence of an independent effect of drinking pattern were identified. The findings 
of the article were presented at the Australasian Epidemiological Association Annual Scientific 
Meeting 2017 (Sydney) and the 45 and Up Study Annual Forum 2017 (Sydney). 
In additional analyses, sensitivity analyses examined possible bias in risk estimates due to the sick-
quitter effect. Risk estimates were then used to calculate population attributable fractions, 
estimates of absolute risk and number of persons needed to quit or reduce drinking to prevent one 
death. 
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9.1 – Journal Article (Prepared for Publication) 
 
The following article is prepared for publication. The results of the proportional hazards assumption 
tests (Table F.1), the p-values for the interaction tests (Table F.2), and the Akaike information 
criterion results (Table F.3) are shown in Appendix F.1. Using the all-cause mortality model reported 
in the main analysis, a further investigation of the exclusion scenarios assessed in Chapter 7 aiming 
to mitigate bias from the ‘sick-quitter effect’ by their effect on the association between disease and 
all-cause mortality is shown in Appendix F.2. This investigation differs from the analyses reported in 
Chapter 7 because it examined whether the exclusion scenarios attenuate the association between 
the confounding factor (ill-health) and the outcome (all-cause mortality), rather than whether the 
exclusion scenarios reduce differences in health status between drinking groups. 
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Abstract 
Background: For many causes of death, the association of alcohol, and in particular pattern of 
drinking, with mortality remains unclear. We quantified these associations in the 45 and Up Study, a 
prospective cohort study in New South Wales (NSW). 
Methods: Cox proportional hazards were used to calculate hazard ratios (HR) and 95% confidence 
intervals (CI) of cause-specific mortality risk associated with alcohol consumption (drinks/week) and 
pattern of drinking among 253,935 participants aged ≥ 45 years (2006-2009). Deaths were 
ascertained by linkage to NSW mortality data to December 2012 for cause-specific mortality and 
December 2014 for all-cause mortality. To prevent bias from reverse causation, deaths occurring 
within three years of baseline were excluded. 
Results: In a median follow-up of 4.4 and 6.4 years, 6,254 and 13,988 deaths were captured to 
December 2012 and 2014, respectively. Increasing overall alcohol consumption increased risk of all-
cause mortality (HR/one drink increase in mean daily alcohol consumption: 1.03; 95% CI: 1.02-1.05), 
death from alcohol-related cancers combined (1.08; 1.01-1.16) including liver cancer (1.17; 1.01-
1.36), cardiovascular diseases other than ischaemic heart disease and stroke (1.13; 1.05-1.22), 
digestive system disease (1.15; 1.03-1.28) including liver disease (1.26; 1.11-1.43), and external 
causes (1.18; 1.07-1.31) including fall (1.34; 1.09-1.64) and other external causes (1.19; 1.00-1.41); J-
shaped associations were found for all-cause mortality and death from cardiovascular disease; an 
inverse association was found for death from non-Hodgkin lymphoma (0.61; 0.42-0.88). After 
adjusting for overall weekly intake, the average number of drinks consumed on drinking-days was 
independently associated with risk of all-cause mortality (1.21; 1.08-1.34 for > 4 drinks per drinking-
day) and death from cancer (1.38; 1.09-1.33) including oesophageal cancer (2.86; 1.08-7.56). More 
drinking-days per week was positively associated with risk of respiratory system disease mortality, 
and inversely associated with risk of all-cause mortality and death from all cancer combined, 
diabetes, cardiovascular disease and ischaemic heart disease after adjusting for overall intake. All-
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cause mortality risk was increased when more than 4 drinks were consumed per drinking-day on 
only one or two days in a week (i.e. heavy episodic drinking; 1.24; 1.07-1.43). 
Conclusions: Alcohol consumption increased the risk of death from many causes, although for some 
diseases, the relationship between quantity and risk was not linear. More drinks per drinking-day, 
including heavy episodic drinking, increased mortality risk independent of the additional risk 
associated with overall intake. Low-volume and more frequent drinking appeared to be protective 
but it is unclear whether these observations were causal or reflect methodological biases. 
Word count: 403
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Introduction 
Alcohol consumption increases the risk of a variety of diseases, and was attributed to 5.9% of deaths 
and 5.1% of the burden of disease and injury globally in 2012[1]. Meta-analyses have identified a J-
shaped relationship between alcohol and all-cause mortality, where low-volume ‘moderate’ drinking 
is associated with decreased risk and heavy drinking with increased risk[2-4]. It is unclear however 
whether the apparent protective relationship between low-volume drinking and all-cause mortality 
and diseases such as cardiovascular disease (CVD) is causal, or due to confounding by factors such as 
baseline health status, behavioural risk factors and/or socio-demographic characteristics[5, 6]. 
Indeed, meta-analyses that account for these study characteristics[7] and other factors including 
length of follow-up[7] and choice of reference group[7, 8] have failed to replicate the protective 
association between low-volume drinking and all-cause mortality. Thus, the evidence regarding the 
inverse relationship of low-volume drinking and mortality risk is inconsistent. 
Moreover, it has been reported that pattern of drinking influences risk of mortality independent of 
the overall amount of alcohol consumed. There have largely been two patterns of interest in relation 
to health outcomes: 1) low-volume frequent intake and 2) heavy infrequent intake, which is 
commonly referred to as either ‘binge drinking’ or ‘heavy episodic drinking’. Drinking frequency has 
been associated with differences in risk of all-cause mortality[9, 10], while a large number of drinks 
per drinking-day or heavy episodic ‘binge’ drinking have been found to increase risk[9, 11-14]. 
Relationships between drinking pattern and mortality are not straightforward, and there are several 
methodological issues which may cause spurious or biased associations. One is that higher drinking 
frequency is reported to be inversely related to both the number of drinks consumed per drinking-
day as well as the proportion of days with heavy episodic drinking[15]. For example, people who 
drink daily are less likely to engage in heavy episodic drinking. Consequently, failure to account for 
drinks per drinking-day when examining the effect of drinking frequency (and vice versa) could 
potentially result in confounding for either of the two individual measures of drinking pattern alone. 
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In addition, analyses are not always adjusted for the total amount of alcohol consumed, making it 
impossible to determine whether drinking pattern has an effect on risk that is independent of overall 
intake. Furthermore, confounding by unmeasured, or poorly measured, covariates that influence 
mortality risk may explain inverse relationships between drinking frequency and mortality, as a 
number of risk factors including lack of health insurance, being physically inactive and having fair or 
poor overall health have been associated with infrequent drinking[15]. 
Variation in the direction and strength of the relationship between alcohol consumption and 
mortality from specific causes has also been reported. Positive associations have been reported for 
death from cancers of the upper-aerodigestive tract[16], oesophagus (squamous cell carcinoma)[17], 
colorectum (women only)[18] and liver[19], tuberculosis[20], digestive system disease[21], liver 
cirrhosis[20], external causes[20-22]. Inverse associations have been reported for death from 
cancers of the stomach[18], lung[18] and kidney[18] and CVD including ischaemic heart disease (IHD) 
and stroke[23], and J-shaped associations for death from colorectal cancer[24], breast cancer[18] 
and all cancers combined[25]. Pattern of drinking has been less studied than total alcohol 
consumption for cause-specific mortality, and largely for CVD and cancer. Drinking frequency has 
been associated with both increased and decreased CVD mortality[9, 10, 14], and with increased 
mortality from oesophageal cancer and all cancers combined[10, 14]. A large number of drinks per 
drinking-day or heavy episodic ‘binge’ drinking have been reported to increase risk of CVD 
mortality[9, 14, 26], all cancer mortality[11, 14], and suicide[27]. Overall, large prospective studies of 
drinking pattern and mortality are scarce, especially those which have examined multiple causes of 
death and have included adjustment for total alcohol consumption. 
We used a large prospective Australian cohort study to quantify the risk of mortality in relation to 
total alcohol consumption and the independent effects of drinking frequency (number of alcohol 
drinking-days per week) and drinks per drinking-day. We directly compared the effects of low-
volume infrequent drinking with low-volume daily drinking and heavy infrequent (episodic) drinking. 
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Methods 
Study sample 
The Sax Institute’s 45 and Up Study is a prospective cohort study of 266,794 participants, with 
methods previously described[28]. In summary, men and women aged ≥ 45 years were randomly 
sampled from the general population of New South Wales (NSW) between 2006 and 2009 using the 
Department of Human Services enrolment database. The database includes all Australian citizens 
and permanents residents, and also some temporary residents and refugees. Oversampling by a 
factor of two was undertaken for persons living in rural and remote areas and those aged ≥ 80 years. 
Participants completed a health and lifestyle questionnaire, and the response rate was estimated to 
be 18%. Ethics approval for the 45 and Up Study was granted by the University of NSW Human 
Research Ethics Committee and the NSW Population Health Services Research Ethics Committee. 
Data linkage 
The 45 and Up Study questionnaire data were probabilistically linked to the NSW Registry of Births 
Deaths and Marriages (RBDM) and the Cause of Death Unit Record File (COD-URF) by the NSW 
Ministry of Health’s Centre for Health Record Linkage (CHeReL). In order to conduct sensitivity 
analyses, questionnaire data were also linked probabilistically to data from the NSW Cancer Registry 
(1994-2010). The CHeReL used a best practice approach in privacy preserving record linkage[29] 
along with the open source probabilistic record linkage software Choice Maker[30]. The probabilistic 
matching process is highly accurate (false-positive and false-negative rates < 0.4%), with a detailed 
explanation of the linkage process published elsewhere[31]. 
Mortality data 
Fact of death was derived from the NSW RBDM to December 2014 which captures deaths for all 
NSW residents. Cause of death from the COD-URF was available to December 2012 and was 
classified according to the International Classification of Diseases, version 10[32]. All causes of death 
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identified in a recent review of alcohol consumption and burden of disease[27], and two large 
analyses of alcohol consumption and cause-specific mortality[21, 22] were included. Relevant causes 
of death with less than 30 outcomes were combined with any other causes of death into an ‘other’ 
group, except for pancreatitis which was included in the other digestive system disease group. 
Cancer deaths were subdivided into ‘alcohol-related cancer’, as defined by the International Agency 
for Research on Cancer: mouth, pharynx, and larynx (combined), oesophagus, colorectum, liver, and 
female breast[33, 34] and ‘non-alcohol-related cancer’. Other cancer types of interest were those for 
which there is evidence of an association with alcohol and the number of deaths exceeded 30: 
stomach[35, 36], pancreas[36, 37], lung[36], melanoma[36], prostate[36, 38], kidney[36, 39], and 
non-Hodgkin lymphoma (NHL)[36, 40]. 
Death from CVD was subdivided into IHD, cerebrovascular disease and other. There is also evidence 
of increased risk of lower respiratory infection due to the immunosuppressive effects of alcohol 
consumption, so death from respiratory system disease was subdivided into lower respiratory 
infection and other[27]. Death from digestive system disease was subdivided into liver disease and 
other. Death from external causes was subdivided into transport accident, fall, suicide and other. 
Death from diabetes, dementia and cerebrovascular disease were not subdivided as for each of 
these outcomes 50% or more were missing subtype information. 
Alcohol consumption 
The question used to determine total alcohol consumption was “About how many alcoholic drinks do 
you have each week? One drink = a glass of wine, middy of beer or nip of spirits (put “0” if you do not 
drink, or have less than one drink each week)”. Responses were categorised into six values: ‘Non-
drinker (< 1 drink/week)’, ‘≥ 1 and ≤ 3.5 drinks/week’, ‘> 3.5 and ≤ 7 drinks/week’, ‘> 7 and ≤ 14 
drinks/week’, ‘> 14 and ≤ 28 drinks/week’ and ‘> 28 drinks/week’. The cut-points of 14 and 28 
drinks/week were chosen because they correspond with the Australian alcohol guidelines to 
minimise risk of long-term harm (≤ 2 drinks/day) and short-term harm (≤ 4 drinks/day)[41]. 
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An additional question, “On how many days each week do you usually drink alcohol?”, was used to 
make three categorical drinking pattern variables which applied to drinkers only. Firstly, drinking-
days per week (drinking frequency) was coded with three values: ‘1-2 days per week’, ‘3-5 days per 
week’ and ‘6-7 days per week’. Secondly, mean drinks per drinking-day (with drinking-day being any 
day in a week where at least one alcoholic drink was consumed) was calculated by dividing the 
number of drinks consumed per week by the number of days of alcohol consumption per week, 
giving the mean number of drinks per drinking-day. This variable was coded with three values: ‘≤ 2 
drinks per drinking-day’, ‘> 2 and ≤ 4 drinks per drinking-day’ and ‘> 4 drinks per drinking-day’. 
Finally, an ‘overall drinking pattern’ variable with nine categories was constructed by combining the 
drinking-days per week and drinks per drinking-day variables. This variable allowed for more specific 
drinking patterns to be examined, such as daily low-volume intake and heavy episodic drinking.  
Statistical analyses 
Participants with missing alcohol consumption data, a date of death less than three years after 
baseline (to prevent bias from reverse causation as done in previous analyses[20-22]) or a date of 
death earlier than their questionnaire completion date were excluded from the analysis. 
Hazard ratios (HR) and 95% confidence intervals (CI) of death were calculated using Cox proportional 
hazards regression models using age as the underlying time variable[42]. Censoring occurred if a 
participant died from a different cause to the cause being analysed or at the end of study period 
(December 2012 for cause-specific mortality and December 2014 for all-cause mortality). 
For each cause of death, three analyses of total weekly alcohol consumption were performed. 1) 
Categorical levels of alcohol consumption where light drinkers (≥ 1 and ≤ 3.5 drinks/week) were used 
as the reference group rather than non-drinkers to minimise bias from the ‘sick-quitter effect’. That 
is, ‘non-drinkers’ may have quit drinking due to ill-health and may be at higher risk of mortality[43]. 
Tests for linear trend excluding non-drinkers were conducted by replacing the categorical alcohol 
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consumption variable with a continuous variable where the median level of alcohol consumption 
was assigned to participants within each category (to limit the impact of outliers). Two-way 
statistical interaction tests between alcohol consumption and sex and smoking status (never-
smoking vs. ever-smoking) were conducted and the results stratified where relevant. 2) Total 
number of drinks/week was analysed as a continuous variable in log-linear Cox models with hazard 
ratios representing the change in risk per one drink increase in mean daily alcohol consumption, 
excluding non-drinkers. 3) To assess non-linearity, a restricted cubic spline was fitted with three 
knots at the 25th, 50th and 75th percentiles of alcohol consumption (excluding non-drinkers). The 
reference quantity of alcohol consumption was 1 drink per week. When graphed, the x-axis was 
truncated at 56 drinks per week for presentation purposes, but the model included participants up 
to the maximum quantity of drinking: 140 drinks per week. The Akaike Information Criterion (AIC) 
was used to compare the log-linear and cubic spline models for best fit. 
Three drinking patterns were assessed in separate models. To prevent bias from the ‘sick-quitter 
effect’ these analyses were restricted to drinkers. All three drinking patterns were analysed 
separately using categorical and continuous covariate counterparts (the continuous version was 
coded as the median number of drinks in each category): 1) Drinking frequency with 3 levels: those 
who reported consuming alcohol on ‘1-2 days per week’ (reference), ‘3-5 days’, ‘6-7 days’ per week. 
2) Mean drinks per drinking-day, where ‘≤ 2 drinks per drinking-day’ was the reference category, 
compared to ‘> 2 and ≤ 4 drinks per drinking-day’, and ‘> 4 drinks per drinking-day’. These models 
were calculated both without adjustment for total alcohol consumption and adjusted for total 
alcohol consumption (as a continuous log-linear variable). Statistical interaction tests for drinking 
pattern as a categorical variable (after adjusting for total alcohol consumption) and sex and smoking 
status were performed for each of the first two drinking patterns and the results stratified where 
appropriate. 3) An interaction test between the drinking frequency and drinks per drinking-day 
variables was performed for all causes of death. Where significant, drinking frequency stratified by 
levels of drinks per drinking-day and vice versa was examined, along with an overall drinking pattern. 
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The overall drinking pattern combined drinking frequency and mean drinks per drinking-day into a 
3x3 matrix resulting in 9 categories (‘overall drinking pattern’). The reference group was the 
category with the lowest total alcohol consumption: ‘≤ 2 drinks per drinking-day’ consumed on ‘1-2 
days per week’. The matrix captured low-volume episodic drinking, heavy episodic ‘binge’ drinking 
(defined here as > 4 drinks per drinking-day on 1-2 days per week), low-volume daily drinking and 
heavy daily drinking. Overall drinking pattern was also examined for all-cause mortality. 
Sensitivity analyses were conducted to examine the impact of self-reported history of disease at 
baseline on the main results. Specifically, participants who had ever been diagnosed with cancer 
(ascertained from both the baseline questionnaire and the NSW Cancer Registry) were excluded 
from analysis of cancer mortality. Likewise, a history of heart disease or stroke were excluded for 
CVD mortality, pre-existing diabetes for diabetes mortality, fair/poor memory for dementia-related 
mortality, asthma for death from respiratory system disease, depression for suicide, and had ever 
had cancer, heart disease, stroke or diabetes for all-cause mortality. These exclusions were made, 
where relevant, for all models except the log-linear trends and cubic spline models. 
All analyses were adjusted for covariates that are potentially related to mortality as self-reported in 
the baseline questionnaire, including sex, age, remoteness, education, household income, health 
insurance status, partner status, country of birth, smoking status and intensity, body mass index, 
physical activity, fruit consumption, vegetable consumption, fibre intake, red meat consumption, 
processed meat consumption, parity (women only), menopausal status (women only), hormone 
replacement therapy use (women only) and height. Remoteness categories were based on the 2006 
ARIA (Accessibility/Remoteness Index of Australia) index[44]. 
A test of the proportional hazards assumption was performed for all Cox models. If significant 
violations were detected then log-log survival curves stratified by the variables in violation were 
plotted. If the lines were considerably non-parallel upon visual inspection, the model was stratified 
by the variable in violation. 
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Analyses were performed using SAS 9.4. 
 
Results 
253,935 of 266,794 participants (95.2%) were included in the analysis after excluding 5041 (1.9%) 
participants with missing information on total alcohol consumption and a further 13 (0.005%) 
participants who died before their self-reported questionnaire date and 7805 (2.9%) participants 
who died within the first three years of follow-up. Of included participants, 6254 (2.5%) had died by 
December 2012 in a median follow-up of 4.4 years and 13,988 (5.5%) had died by December 2014 in 
a median follow-up of 6.4 years. 
Overall, 170,254 (67.0%) participants consumed at least one alcoholic drink per week, including 
36,472 (14.4%) who consumed > 14 drinks per week. Of drinkers, 2006 (1.2%) were excluded from 
the drinking pattern analyses due to missing information on number of drinking-days per week. Of 
the 168,248 drinkers included in the drinking pattern analyses, 62,027 (36.9%) consumed alcohol 6 
or 7 days per week and 17,643 (10.5%) reported an average of > 4 drinks per drinking-day. Overall, 
33,724 (19.8%) were low-volume daily drinkers, and 3988 (2.3%) reported infrequent (1-2 days) 
heavy (> 4 drinks) consumption and could be considered ‘binge’ drinkers. 
Participants consuming higher numbers of drinks per week were, on average, more likely to be men, 
Australian-born, consumed processed meat > 1 time per week and spent ≥ 2 hours outdoors per day 
(Table 1). Drinkers tended to be younger than non-drinkers. Among men, participants consuming 
higher numbers of drinks per week were more likely to be ≥ 180 cm tall. Among women, participants 
consuming higher numbers of drinks per week were more likely to be ≥ 165 cm tall, nulliparous and 
had ever used hormonal contraceptives. Non-drinkers were more likely to be current smokers and 
physically inactive compared to light drinkers, and less likely to have had a university degree, a 
household income ≥ $70,000 per year, private health insurance or be married or living with a 
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partner. For most baseline characteristics, there was greater variation by drinks per drinking-day 
than by drinking frequency. Participants consuming more than 4 drinks per drinking-day were more 
likely to be in lower socio-demographic categories and have unhealthy behavioural risk factors than 
those who consumed less than 4. Participants with higher drinking frequency were more likely to 
have private health insurance and less likely to be overweight or obese, while the reverse was true 
for participants with higher drinks per drinking-day. 
Among drinkers, a greater number of drinks per week was significantly associated with increased risk 
of death from digestive system disease, liver disease, external causes, falls and suicide and all-cause 
mortality, and decreased risk of death from prostate cancer and NHL (Table 2). There was significant 
variation in the risk of death from non-alcohol-related cancers combined by total weekly alcohol 
consumption, however there was no evidence of a linear trend. There were no significant 
interactions between total alcohol consumption and sex, while significant interactions with smoking 
status were detected for death from lung cancer (p = 0.02) and all-cause mortality (p = 0.01). When 
stratified by smoking status, risk was elevated in never-smokers compared to ever-smokers for > 14 
and ≤ 28 drinks per week for lung cancer mortality and for > 28 drinks per week for all-cause 
mortality (Supplementary Tables 1 and 2). 
When excluding participants with disease at baseline, the positive linear trends for suicide and all-
cause mortality remained significant, the inverse trend for prostate cancer was not significant, while 
the inverse trend for NHL was also not significant but the hazard ratios did not appear to differ 
materially. Furthermore, additional positive associations with drinking were detected for death from 
alcohol-related cancers combined, oesophageal cancer, kidney cancer, CVD and other CVD 
(Supplementary Table 3). 
Figure 1 shows the results of the log-linear models in which the risk associated with each additional 
drink per day was plotted for each cause of death. The direction and statistical significance of effect 
estimates were similar to the corresponding categorical models, but with no significant association 
355 
 
for suicide, and additional positive associations for death from alcohol-related cancers combined, 
liver cancer, other CVD and other external causes. 
Figure 2 shows the results of the restricted cubic spline models in which the risk associated with 
each additional drink per week was plotted by cause of death, accounting for a non-linear 
relationship with intake. The AIC was lower in the cubic spline model compared to the log-linear 
model for death from all cancers combined, liver cancer, breast cancer, non-alcohol-related cancers 
combined, CVD, IHD, respiratory system disease, fall, suicide, other external causes, other causes 
combined and all-cause mortality (results not shown), suggesting non-linear relationships between 
these causes of death and overall alcohol consumption among drinkers. 
After adjusting for total alcohol consumption, drinking frequency (drinking-days per week) was 
positively associated with risk of death from respiratory system disease (ptrend = 0.03; Table 3) and 
inversely associated with risk of death from all cancers combined (ptrend < 0.001), non-alcohol-related 
cancers combined (ptrend < 0.001), CVD (ptrend = 0.02), IHD (ptrend = 0.01), and all-cause mortality (ptrend 
< 0.001). Death from pancreatic cancer varied significantly by drinking frequency, however there was 
no evidence of a linear trend. A statistical interaction with sex was detected for non-alcohol-related 
cancers combined (p = 0.03), with lower HRs for 3-5 and 6-7 drinking-days per week in men 
(Supplementary Table 4). There were no significant interactions by smoking status.  
After excluding participants with disease at baseline in sensitivity analyses (see Supplementary Table 
5), the inverse linear trends observed for death from all cancers combined, non-alcohol-related 
cancers combined, IHD and all-cause mortality remained unchanged. The inverse linear trend for 
CVD mortality and drinking frequency observed in the main analysis was not significant in sensitivity 
analyses, however the HRs were not materially different. Likewise, the positive linear trend for 
respiratory system disease in the main analysis was not significant in sensitivity analyses, however 
the HRs were consistent with the main effects. After exclusion of baseline diabetes, there was an 
inverse association with drinking frequency and death from diabetes (ptrend = 0.04). After exclusion of 
356 
 
participants with prior cancer, lung cancer mortality risk varied by drinking frequency, with lower 
risk in those consuming alcohol 3-7 days compared to 1-2 drinking-days per week, but the linear 
trend was not significant. 
Table 4 shows mortality risk by mean drinks per drinking-day. After adjustment for total alcohol 
consumption, drinks per drinking-day was positively associated with risk of death from all cancers 
combined (ptrend = 0.006), oesophageal cancer (ptrend = 0.047), non-alcohol-related cancers combined 
(ptrend = 0.01), lung cancer (ptrend = 0.04), and all-cause mortality (ptrend = 0.001). A significant 
interaction with sex was detected for all-cause mortality (p = 0.02), with elevated HRs for ‘> 2 and ≤ 
4’ and ‘> 4’ drinks per drinking-day in women (Supplementary Table 6). There were no statistical 
interactions between smoking status and mean drinks per drinking-day. When excluding participants 
with disease at baseline and adjusting for total alcohol consumption all significant trends observed in 
the main analysis remained significant, and an additional positive association with mean drinks per 
drinking-day was detected for death from kidney cancer (ptrend = 0.03) (Supplementary Table 7). 
There were no significant interactions between drinking-days per week and drinks per drinking-day 
for any cause of death. Table 5 shows the results of the overall drinking pattern analysis for all-cause 
mortality. There were significantly elevated HRs in those consuming > 4 drinks on 6-7 days per week 
(i.e. heavy frequent drinkers), > 4 drinks on 1-2 days per week (i.e. heavy episodic ‘binge’ drinkers) 
and > 2 and ≤ 4 drinks on 1-2 days per week, compared to those in the lowest consumption group (≤ 
2 drinks on 1-2 days/week). There was also a significantly lowered HR in those consuming ≤ 2 drinks 
on 3-5 days per week. 
No violations of the proportional hazards assumption were detected. 
 
Discussion 
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We found that increasing numbers of alcoholic drinks per week was associated with increased risk of 
death from oesophageal cancer, liver cancer, kidney cancer, alcohol-related cancers combined, CVD, 
digestive system disease, liver disease, external causes, falls, suicide, all other causes combined and 
all-cause mortality. CVD and all-cause mortality had a J-shaped relationship with total weekly intake, 
however there was no significant decrease in risk, and for all-cause mortality, risk was significantly 
increased with heavier consumption. Decreased risk in relation to increasing numbers of drinks per 
week was found for death from NHL. Death from causes previously reported to have an association 
with alcohol consumption[27], including all cancers combined, mouth, pharynx and larynx cancer, 
colorectal cancer, breast cancer, diabetes, dementia, IHD, cerebrovascular disease, lower respiratory 
infection, other digestive system disease and transport accident, were not associated with alcohol 
consumption in our study, possibly due to limited power. Many causes of death were found to have 
a non-linear relationship with alcohol consumption, suggesting that the risks of drinking may be 
more complex than a simple dose-response relationship. This was the case for all cancers combined, 
liver cancer, breast cancer, non-alcohol-related cancers combined, CVD, IHD, respiratory system 
disease, fall, suicide, other external causes, other causes combined and all-cause mortality. Drinking 
pattern was independently related to mortality from a number of causes. Specifically, drinking 
frequency was positively associated with risk of death from respiratory system disease and inversely 
associated with risk of death from all cancers combined, non-alcohol-related cancers combined, 
diabetes, CVD, IHD and all-cause mortality. Mean number of drinks per drinking-day was positively 
associated with risk of death from all cancers combined, oesophageal cancer, non-alcohol-related 
cancers combined, lung cancer, kidney cancer and all-cause mortality. 
Our results for total weekly alcohol consumption are largely consistent with previous literature. As 
expected, we found that drinking was positively associated with a wide variety of mortality 
outcomes, including death from cancers, digestive system disease and external causes. For death 
from lower respiratory infection, diabetes, dementia and transport accident, we expected to find an 
association but did not. Most of these outcomes had a small number of deaths, especially in the 
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sensitivity analyses that excluded prior disease. It is possible these analyses were underpowered, as 
the confidence intervals for consuming > 28 drinks per week were often consistent with a substantial 
increased risk (e.g. greater than 5-fold increased risk for death from low respiratory infection) or 
decreased risk (e.g. approximately one tenth the risk for death from diabetes and dementia). 
The potential benefits of ‘moderate’ drinking for reducing the risk of death from CVD has received 
much attention. Proposed causal mechanisms for the benefits of drinking for CVD have included 
increased high density lipoprotein cholesterol, decreased low density lipoprotein cholesterol, 
increased insulin sensitivity, reduced atherosclerotic plaque formations and possible anti-coagulant 
effects including reduced fibrinogen levels[45-47]. However, methodological considerations have 
also been put forward as an explanation for the apparent protective effect[8], and we attempted to 
account for some of these factors in a number of ways. Specifically, we used light drinkers as the 
reference group rather than non-drinkers to account for the ‘sick-quitter effect’[43], we excluded 
participants who died within three years of baseline to mitigate the potential for reverse causation, 
and we excluded participants with prior CVD in a sensitivity analysis. Thus, even though we observed 
a J-shaped, non-linear association for risk of CVD mortality, we did not detect a significant decrease 
in risk for low levels of consumption. Indeed, it was noteworthy that the exclusion of participants 
with prior CVD resulted in a significant linear increase in risk for CVD mortality, indicating that 
reduction in alcohol consumption in response to CVD diagnosis is likely to have biased risk estimates 
for CVD mortality. That is, participants with pre-existing CVD may have reduced their level of 
drinking from higher levels down to low-volume drinking, and therefore may be included in the 
reference group. We also found non-linear relationships between alcohol consumption and all 
cancers combined, liver cancer, breast cancer, non-alcohol-related cancers combined, respiratory 
system disease, fall, suicide, other external causes, other causes combined and all-cause mortality, 
The reason for the non-linear relationships is unclear and requires further examination. 
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Of the seven cancer types known to be caused by alcohol[33, 34],we only observed a significant 
increased risk of death from oesophageal and liver cancer. In sensitivity analyses, the exclusion of 
participants with prior cancer tended to result in increased hazard ratios for heavy drinking (> 28 
drinks per week) for most of these cancer types, and for all cancers combined, indicating that 
estimates in the main analysis may have been biased by changes in alcohol consumption in response 
to pre-existing cancer diagnoses. It is likely that the length of follow-up was not sufficient to detect 
an increased risk of death from many of these cancer types, although the risks were in the right 
direction. 
We found that alcohol was related to a decreased risk of death from prostate cancer, which was not 
consistent with prior reports of increased risk[36, 38]. However, this effect disappeared when 
participants with prior cancer were excluded, indicating the main effect could be accounted for by 
reverse causation. We also observed a decreased risk of death from NHL, similar to other studies[36, 
40]). After excluding prior cancers the association was not significant, however there was no 
material change in the hazard ratios, and the confidence intervals were consistent with a large 
decrease in risk. Two alternate explanations have been proposed for the inverse relationship of NHL 
and alcohol. Either 1) that alcohol decreases risk of NHL by improved insulin sensitivity or an 
immunomodulatory effect[40], or 2) reverse causation, because the subtypes of NHL that 
characteristically produce symptoms before diagnosis (and may therefore cause a decrease in 
alcohol consumption prior to diagnosis) are inversely associated with drinking, while other subtypes 
without early symptoms do not[40]. However, our choice of reference group, the exclusion of prior 
cancer and deaths within three years of baseline would reduce the impact of any bias from reverse 
causation, suggesting that alcohol may indeed be protective for risk of NHL mortality. 
Our findings were suggestive of an increased risk of death from kidney cancer and were unexpected. 
Meta-analyses have reported a decreased risk with moderate drinking[18, 36] or an inverse 
association with drinking[39]. While the confidence intervals in our main analysis for the hazards of 
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kidney cancer mortality indicated the possibility for a protective association, the HRs were all greater 
than 1. We also observed a significant positive trend in risk after excluding prior cancer (although 
there were no deaths in the reference category so we were unable to report confidence intervals for 
individual categories of alcohol consumption). Our results indicate that the decreased risk of death 
from kidney cancer reported in meta-analyses may have been biased by methodological factors. 
Our results for the independent effect of drinking pattern on risk of mortality are only partially 
consistent with the few previous studies. Variation in study outcomes likely reflect the diversity of 
methods that have been used to assess drinking pattern. Specifically, the varied ways in which 
drinking patterns are defined, the strong relationship between patterns and overall consumption 
levels and the diversity in the methods used to assess drinking patterns[48, 49] makes comparisons 
between studies difficult. Indeed, almost every study to date has used a unique method to assess 
the impact of drinking pattern, including the decision to adjust for total alcohol consumption or not. 
We examined drinking patterns in three different ways, and observed different results for each. 
We found that more drinking-days per week was inversely associated with risk of all-cause mortality 
and several causes of death, including all cancers combined, non-alcohol-related cancers combined, 
CVD (including IHD) and diabetes. If causal, it is thought inverse associations for all-cause mortality 
are probably mediated through CVD mortality[8]. The suggested mechanism for reduced risk of 
diabetes with ‘moderate’ drinking is via decreased gluconeogenesis, decreased glycogenolysis and 
increased insulin sensitivity[26, 50]. Perhaps the mechanisms for reduced risk with ‘moderate’ 
drinking for CVD and diabetes also operate to lower risk with greater drinking frequency. The inverse 
associations between drinking frequency and death from all cancers combined and non-alcohol-
related cancers combined were unexpected, with a recent analysis reporting no relationship with 
incidence of these two cancer outcomes[51]. As there is no mechanistic basis for alcohol 
consumption to lower cancer risk, these two outcomes may serve as ‘negative controls’[52]. That is, 
the existence of inverse associations for cancer mortality may be evidence for residual reverse 
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causation, signifying that inverse associations with drinking frequency for other outcomes such as 
cardiovascular and all-cause mortality are overestimated. It is also possible that these inverse 
associations reflect bias from the potential methodological issues which can affect studies of 
drinking pattern, such as incomplete adjustment for confounding variables related to mortality risk.  
More drinking-days per week was positively related to respiratory system disease mortality. It has 
previously been reported that total alcohol consumption has no association with respiratory system 
disease mortality[20, 21], and no studies, to our knowledge, have examined the impact of drinking 
frequency. This novel finding could possibly be mediated by increased risk of lower respiratory 
infections which have been reported to be related to alcohol consumption[27]. 
More drinks per drinking-day was independently associated with risk of all-cause mortality and 
death from several cancers, with between 1.2 to 8.7 times increased risk observed among those 
reporting > 4 drinks per day. Our results were largely consistent with prior research, including 
previous studies which found a positive association between drinks per drinking-day or heavy 
episodic drinking and all-cause mortality[9, 11-14]. We did not however detect an effect for risk of 
death from CVD or its subtypes. Meta-analyses have reported relative risks of 1.75 (95% CI 1.36-
2.25) for heavy episodic drinking[53], and 1.10 (1.03-1.17) for ‘heavy irregular or binge’ drinking[54] 
for IHD incidence. The confidence intervals for an independent effect of CVD and its subtypes we 
observed were compatible with hazard ratios of up to 1.5 to 2, and therefore consistent with these 
findings. There is also evidence for an effect of heavy episodic drinking on risk of diabetes[27], but 
we did not detect an association with drinks per drinking-day. Our confidence intervals were 
compatible with a hazard ratio of up to 7 however, indicating that our analysis was likely 
underpowered for this outcome. There were no associations for death from digestive system disease 
and external causes, but the confidence intervals for > 4 drinks per drinking-day with these 
outcomes were consistent with hazard ratios of at least 2, so perhaps these analyses were also 
underpowered. 
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We found an increase in risk of mortality from all cancers combined with more drinks per drinking-
day. Evidence for a relationship between drinking pattern and cancer risk is sparse. Previous cohort 
studies have reported a positive association with heavy episodic drinking for cancer mortality[11], 
but no association with the highest number of drinks consumed in one day in a typical month for 
incidence (although there was a positive association for alcohol-related cancers combined in women 
alone)[51]. We did not detect an effect of drinks per drinking-day for death from alcohol-related 
cancers combined over and above the increased risk that was observed for overall consumption. The 
relative risks we observed for those reporting > 4 drinks per drinking-day were elevated but not 
significant. Similar to the analyses of overall alcohol consumption, our study may have been 
underpowered to detect an effect of drinks per drinking-day for some cancer types, and for breast 
cancer mortality in particular, due to few women with a high number of drinks per drinking-day. 
We did however observe an independent, increased risk of death from oesophageal and kidney 
cancer mortality (for kidney cancer, after excluding those with pre-existing cancer) in relation to 
drinks per drinking-day. We are the first, to our knowledge, to report these effects. For oesophageal 
cancer, the proposed causal mechanism is the carcinogenic effect of acetaldehyde[55]. This finding 
suggests that consumption of many drinks on one occasion may multiply the carcinogenic effect of 
acetaldehyde accumulation. It should be noted that while the > 28 drinks per week category of total 
alcohol consumption was not significant, the HR point estimate and 95% confidence interval were 
very similar to those of the > 4 drinks per drinking-day category (2.50, 0.92-6.77; 2.86, 1.08-7.56 
respectively). This may indicate that our analysis was only powered to detect a HR of approximately 
2.7 for this outcome, and also that the potential increased risk in those consuming > 28 drinks per 
week may be largely attributable to the independent increased risk associated with consuming many 
drinks on one day rather than the risk associated with total alcohol consumption, as all persons in 
this group consumed > 4 mean drinks per drinking-day. For kidney cancer mortality, our results 
suggest the apparent positive association for total alcohol consumption may be mediated through 
heavier drinkers consuming more drinks per drinking-day. 
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We also found increased risk of lung cancer mortality with more drinks per drinking-day, which is 
consistent with one cohort study reporting an effect for heavy episodic drinking on incidence[56]. 
That study found the effect was only present in smokers, but we did not detect an interaction with 
smoking status. As current smoking was positively associated with drinks per drinking-day in our 
study, residual confounding by smoking could be at least partially responsible for this result. 
There were no significant interactions between drinking-days per week and drinks per drinking-day 
for any cause of death including all-cause mortality. This is in contrast to a study reporting that 
drinks per drinking-day modified the relationship between drinking frequency and all-cause 
mortality, with a J-shaped association between drinking-days per week and mortality among persons 
consuming < 5 drinks per drinking-day and a linear dose-response association among persons 
consuming ≥ 5 drinks per drinking-day[57]. When we analysed drinking frequency and drinks per 
drinking-day simultaneously, for those who drank on only 1-2 days of the week, all-cause mortality 
risk was higher for those consuming more than 2 drinks on each of those days, compared to those 
who had less than 2. The risk for > 4 drinks per drinking-day was similar whether the drinks were 
consumed on 1-2 days or on 6-7 days. This shows that both heavy frequent drinking and heavy 
episodic ‘binge’ drinking independently increase risk of death. Indeed, the lack of significant 
interactions between drinking frequency and drinks per drinking-day means that for many causes of 
death, consuming a high number of drinks per drinking-day increases mortality risk regardless of 
whether it is 1 or 7 days per week. Further, even after rigorous attempts to prevent bias in relation 
to reverse causation, those who were frequent (3-5 days/week), low-volume (≤ 2 drinks) drinkers 
had a lower risk of death than infrequent (1-2 days/week) low-volume drinkers. In an analysis of an 
American population survey, it was reported that infrequent drinkers had a higher prevalence of 13 
of 15 measured risk factors compared to more frequent drinkers, including health insurance status, 
being physically inactive and having fair or poor overall health[15]. We adjusted for many of these 
factors in our analyses, however the possibility of residual confounding cannot be ruled out. 
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Our study has several strengths. It is a prospective cohort study with a large number of participants, 
and examined multiple causes of death using a consistent methodology. We directly compared 
drinking pattern measured in three different ways and comprehensively adjusted for a large number 
of potential confounders. We used age as the underlying time variable to minimise potential 
confounding by age. We used a reference group of very light drinkers as opposed to ‘non-drinkers’ 
to mitigate bias from the ‘sick-quitter effect’ and to ensure that any effect of drinking pattern is 
relative to other drinkers. The adjustment for total alcohol consumption allowed for investigation of 
the independent effect of drinking pattern as separate from overall consumption. Furthermore, 
adjusting for total alcohol consumption as a continuous (rather than a categorical variable, as in 
previous studies) should have minimised bias from residual confounding by total alcohol 
consumption between drinking pattern groups. 
Limitations of our study include the possibility of being underpowered for causes of death with a 
relatively low number of outcomes, which can be addressed by a longer period of follow-up. Due to 
the use of light drinkers as the reference group instead of lifetime abstainers, our hazard ratios for 
the true effects of alcohol consumption may be slightly underestimated (or overestimated, where 
hazard ratios were less than 1). Further, due to the questionnaire design our drinks per drinking-day 
variable was based on mean level of alcohol consumption. Some participants who were in fact heavy 
episodic drinkers will therefore have been grouped with less intense drinkers. For example, a 
participant consuming alcohol 2 days per week, with 5 drinks on one day and 1 on the other, would 
have been grouped with a participant consuming alcohol 2 days per week, with 3 drinks on both 
days. The risk profile of these two participants is possibly different but we were unable to 
differentiate between them. In addition, our drinking pattern analysis only included participants who 
usually consume at least one alcoholic drink per week, meaning those engaging in heavy episodic 
drinking less frequently than once per week were excluded. However, a possible advantage of using 
mean drinks per drinking-day may be that it is more representative of a person’s usual exposure to 
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alcohol than other measures such as highest number of drinks consumed in one day over a period of 
time. 
A potential issue in any observational study measuring alcohol consumption is the tendency for 
participants to underreport intake[58]. Risk estimates could therefore be biased if underreporting 
differs by drinking patterns and consumption levels. In both Australian and a Canadian studies, low-
risk and non-heavy episodic drinkers were found to underreport their alcohol consumption to a 
greater degree than higher-risk and heavy episodic drinkers[59, 60]. Conversely, an English study 
found underreporting was disproportionately associated with heavy drinking, frequent drinking and 
non-routine drinking compared to participants without these drinking behaviours[61]. If for example 
participants consuming alcohol 1-2 days per week underreported their total alcohol consumption to 
a greater degree than daily drinkers, this could result in conservative estimates of risk for total 
alcohol consumption. Additionally, despite our best efforts to control for covariates, confounding by 
unmeasured factors associated with both drinking pattern and risk of mortality could be responsible 
for at least part of our associations. For example, it was reported in a prospective study that 
declining health is associated with a reduction in drinking frequency[62], meaning estimates could 
be biased by poor baseline health. We attempted to account for this however by excluding 
outcomes within the first three years of follow-up. Perhaps this period was not long enough to 
capture potential changes in alcohol consumption in response to ill-health that may begin many 
years before death. Another limitation was that cause-specific mortality data was only available to 
2012 and all-cause mortality to 2014. A longer follow-up period works to mitigate selection bias[7], 
and it has been shown in meta-analyses that longer follow-up attenuates the association between 
moderate drinking and lowered risk of all-cause mortality[2, 3]. For this reason, inverse associations 
of moderate drinking, and perhaps drinking frequency, with mortality risk may be overestimated in 
our analysis, especially for cause-specific mortality. The issue of competing risks, whereby death 
from disease and injury associated with alcohol consumption earlier in life may confound 
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associations with risk of death from other causes later in life, may also result in an overestimation of 
decreased risk in analyses of both cause-specific and all-cause mortality[7, 63]. 
 
Conclusion 
In conclusion, we used a large prospective study to investigate the influence of total alcohol 
consumption on risk of all-cause and cause-specific mortality, finding mostly consistent results with 
previous research. Our robust examination of the influence of drinking pattern on mortality suggests 
that number of drinks per drinking-day is independently associated with risk of all-cause mortality 
and death from all cancers combined, oesophageal cancer, non-alcohol-related cancers combined, 
lung cancer and kidney cancer. More drinking-days per week was also positively associated with risk 
of respiratory system disease mortality and inversely associated with risk of all-cause mortality and 
death from all cancers combined, non-alcohol-related cancers combined, diabetes, CVD and IHD. 
There are however methodological limitations in this and prior studies which mean we cannot 
eliminate the possibility that the observed decreased mortality risk with both low-volume drinking 
and drinking frequency are overestimated. Both heavy frequent drinking and heavy episodic drinking 
were significantly related to all-cause mortality risk, and are likely to independently increase cancer 
mortality as well. 
These findings have a number of implications. Alcohol guidelines should emphasise that a high 
number of drinks per drinking-day, including heavy episodic drinking, is independently associated 
with mortality risk in addition to the total amount consumed. Drinks per drinking-day and drinking 
frequency should also be incorporated into calculations of the burden of disease and injury 
attributable to alcohol consumption, so that more accurate estimates reflecting the influence of 
pattern of drinking can be obtained. Finally, these results show that government policies and 
programs aiming to lessen alcohol-related harm should target persons consuming a high number of 
drinks per drinking-day and heavy episodic drinkers as a priority, to ensure that interventions have 
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maximal health impact. Mass media campaigns for heavy episodic drinking often target younger 
people and in relation to immediate harms, whereas these findings show that older age groups are 
also relevant targets, especially in relation to long-term harm. According to the 2016 National Drug 
Strategy Household Survey, 17% of Australians aged 60-69 years and 7% aged ≥ 70 years consumed > 
4 drinks per occasion at least monthly[64], meaning that a sizable portion of older Australians 
engage in heavy episodic drinking and are at increased mortality risk. 
In the absence of a randomised controlled trials, further investigation of the possible role of 
confounding by health status on drinking patterns and mortality is required to be confident that 
independent associations of drinking frequency and other drinking patterns with risk are truly 
causal. Nevertheless, our study has provided evidence that limiting drinks per drinking-day, including 
heavy episodic drinking, is an important approach to prevent mortality independent of and in 
addition to limiting total alcohol consumption. 
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Tables and figures 
 
Table 1. Socio-demographic and other characteristics by alcohol consumption in the 45 and Up Study (2006-2014), New South Wales, Australia. 
Characteristic at baseline 
Alcoholic drinks per week  Drinking frequency (days per week)  Drinks per drinking-day 
Non-drinkera ≥ 1 and ≤ 3.5 > 3.5 and ≤ 7 > 7 and ≤ 14 > 14 and ≤ 28 > 28  1-2 3-5 6-7  ≤ 2 > 2, ≤ 4 > 4 
n 83,681 39,464 49,226 45,092 26,553 9919  47,700 58,521 62,027  106,345 44,260 17,643 
Male (%) 32.5 41.0 43.9 53.4 72.3 89.6  46.8 50.0 60.0  42.8 64.2 84.5 
Mean age in years (SD) 63.6 (11.4) 61.1 (10.7) 62.3 (10.9) 61.5 (10.4) 61.3 (9.9) 60.4 (9.1)  59.8 (10.2) 59.7 (9.7) 64.4 (10.7)  63.6 (11.4) 60.1 (9.7) 59.3 (9.2) 
Major city resident (%) 52.9 54.0 52.0 51.2 49.0 44.8  53.5 52.1 48.9  52.3 50.9 46.4 
University degree (%) 17.6 26.2 26.6 28.1 27.0 19.3  24.5 29.0 26.0  27.7 27.4 18.3 
Household income ≥ $70,000b (%) 14.0 35.9 27.6 32.3 34.0 28.5  28.0 33.9 26.8  27.3 35.2 29.6 
Private health insurancec (%) 55.8 69.3 72.2 73.3 71.0 60.4  67.9 73.2 71.5  72.7 71.6 60.2 
Married or living with partner (%) 68.7 76.1 78.6 80.3 80.4 74.0  75.5 79.9 79.6  78.7 80.1 73.8 
Born in Australia (%) 73.0 72.8 75.8 77.4 78.8 82.0  75.0 77.3 76.7  74.8 78.7 81.0 
Current smoker (%) 7.4 5.6 5.1 6.6 9.6 17.7  7.5 5.9 7.8  4.8 8.4 17.0 
Overweight or obesed (%) 57.1 58.2 53.9 56.4 63.0 68.8  61.7 57.8 55.0  53.8 63.0 69.7 
Physically inactivee (%) 7.9 4.2 3.6 3.3 3.9 5.9  4.2 3.2 4.1  3.6 3.8 5.2 
< 2 fruit serves per dayf (%) 37.4 37.0 38.5 44.4 52.8 63.2  39.6 40.9 48.7  38.8 48.5 58.4 
< 5 vegetable serves per day (%) 64.3 66.1 65.1 66.7 70.0 73.2  67.1 66.3 67.6  65.3 69.2 72.0 
< 7 fibre serves per weekg (%) 14.6 13.2 10.9 13.2 16.7 26.7  14.5 12.9 14.3  11.5 15.6 23.8 
Red meat > 5 times per week (%) 9.9 8.6 9.3 10.8 14.5 21.7  9.0 9.5 14.1  9.5 12.1 18.1 
Processed meat > 1 time per week (%) 27.4 29.4 30.3 34.0 41.7 51.1  31.9 33.7 36.1  29.9 38.2 48.7 
Nulliparous (women) (%) 10.1 9.9 10.7 12.6 16.9 21.6  10.1 11.6 13.3  10.7 14.3 16.7 
Post-menopausal (women) (%) 66.3 63.2 65.3 63.5 61.6 54.3  60.5 61.1 70.0  65.7 57.7 53.5 
Ever used HRT (women) (%) 35.2 36.8 39.2 39.2 39.5 36.0  35.1 37.5 43.2  39.4 35.9 32.8 
Height ≥ 180 cm (men) (%) 26.7 30.9 32.0 33.8 34.8 35.9  32.6 34.8 32.5  31.5 34.9 35.7 
Height ≥ 165 cm (women) (%) 31.3 36.7 38.6 41.9 43.7 42.7  37.7 41.3 39.1  38.3 43.5 41.6 
Percentages include participants with missing or invalid responses. a< 1 alcoholic drink per week. bPre-tax annual household income from all sources in Australian dollars. cIncluding 
Department of Veterans’ Affairs white or gold card. dBody mass index ≥ 25 kgm-2. eWeekly physical activity time = 0 minutes. fExcludes fruit juice. gServes of breakfast cereal and brown or 
wholemeal bread. SD, Standard Deviation. HRT, Hormone Replacement Therapy. 
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Table 2. Hazard ratios and 95% confidence intervals of cause-specific mortality risk by alcohol consumption in the 45 and Up Study (2006-2014), New South Wales, Australia. 
  Drinks/week   
Cause of death (ICD-10 code) n deaths Non-drinkera ≥ 1 and ≤ 3.5 > 3.5 and ≤ 7 > 7 and ≤ 14 > 14 and ≤ 28 > 28 pb ptrendc 
Cancer (C00-97;D45-47) 2391 1.04 (0.92-1.19) 1.00 0.93 (0.81-1.08) 0.90 (0.78-1.05) 0.87 (0.74-1.03) 0.95 (0.76-1.18) 0.13 0.68 
- Alcohol-related (C00-15;18-20;22;32;50d) 524 0.91 (0.70-1.20) 1.00 0.82 (0.60-1.12) 0.99 (0.73-1.36) 0.90 (0.62-1.30) 1.33 (0.85-2.08) 0.37 0.07 
  - Mouth, pharynx and larynx (C00-14;32) 38 1.03 (0.36-2.95) 1.00 -e 1.50 (0.51-4.42) 0.99 (0.29-3.36) 0.80 (0.18-3.54) 0.92 0.70 
  - Oesophagus (C15) 78 1.33 (0.59-2.99) 1.00 1.30 (0.55-3.09) 1.44 (0.61-3.39) 0.59 (0.19-1.84) 2.50 (0.92-6.77) 0.19 0.27 
  - Colorectum (C18-20) 205 1.01 (0.64-1.58) 1.00 0.98 (0.60-1.62) 0.98 (0.58-1.65) 1.34 (0.77-2.32) 1.25 (0.59-2.65) 0.84 0.16 
  - Liver (C22) 62 2.04 (0.69-6.03) 1.00 2.14 (0.69-6.65) 2.56 (0.82-7.95) 2.10 (0.60-7.37) 4.04 (1.09-15.1) 0.46 0.06 
  - Breast (C50d) 141 0.62 (0.40-0.95) 1.00 0.55 (0.32-0.94) 0.60 (0.33-1.07) 0.47 (0.18-1.23) 0.78 (0.10-5.77) 0.20 0.19 
- Non-alcohol-related (Other C;D45-47) 1867 1.08 (0.94-1.25) 1.00 0.97 (0.82-1.14) 0.88 (0.74-1.05) 0.87 (0.72-1.05) 0.86 (0.67-1.12) 0.04 0.17 
  - Stomach (C16) 55 1.24 (0.57-3.17) 1.00 1.16 (0.45-2.99) 0.63 (0.21-1.89) 0.87 (0.29-2.66) 0.59 (0.12-2.94) 0.63 0.66 
  - Pancreas (C25) 154 1.15 (0.69-1.93) 1.00 1.10 (0.62-1.94) 1.13 (0.63-2.04) 1.11 (0.57-2.17) 0.68 (0.23-2.04) 0.94 0.58 
  - Lung (C33-34) 416 1.50 (1.05-2.13) 1.00 1.26 (0.86-1.86) 1.10 (0.74-1.64) 1.21 (0.80-1.84) 1.21 (0.72-2.01) 0.20 0.63 
  - Melanoma (C43) 98 0.77 (0.42-1.42) 1.00 0.72 (0.38-1.40) 0.62 (0.31-1.24) 0.86 (0.42-1.76) 0.47 (0.13-1.66) 0.73 0.37 
  - Prostate (C61) 243 0.72 (0.50-1.05) 1.00 0.72 (0.48-1.08) 0.56 (0.36-0.87) 0.59 (0.36-0.96) 0.56 (0.28-1.12) 0.13 0.049 
  - Kidney (C64) 47 1.43 (0.52-3.88) 1.00 1.31 (0.44-3.94) 1.15 (0.36-3.68) 1.05 (0.27-4.04) 2.28 (0.52-10.1) 0.89 0.33 
  - Non-Hodgkin lymphoma (C82-85) 75 1.01 (0.54-1.91) 1.00 0.65 (0.31-1.39) 0.50 (0.22-1.17) 0.42 (0.15-1.20) -e 0.29 0.02 
Diabetes (E10-14) 115 1.47 (0.81-2.66) 1.00 0.84 (0.40-1.77) 1.24 (0.61-2.54) 0.92 (0.38-2.23) 0.52 (0.11-2.32) 0.31 0.72 
Dementia (F00-03;G30) 218 0.90 (0.61-1.33) 1.00 0.79 (0.50-1.25) 0.80 (0.48-1.35) 0.62 (0.30-1.28) 0.39 (0.09-1.63) 0.64 0.29 
Cardiovascular disease (G45-46;I00-99) 1926 1.00 (0.87-1.15) 1.00 0.86 (0.73-1.01) 0.86 (0.72-1.03) 0.89 (0.72-1.09) 1.00 (0.75-1.33) 0.13 0.52 
- Ischaemic heart disease (I20-25) 915 1.02 (0.84-1.25) 1.00 0.90 (0.72-1.14) 0.80 (0.62-1.03) 0.90 (0.67-1.20) 0.80 (0.52-1.22) 0.29 0.46 
- Cerebrovascular disease (G45-46;I60-69) 468 0.96 (0.73-1.27) 1.00 0.82 (0.59-1.14) 0.83 (0.58-1.18) 0.91 (0.59-1.40) 0.95 (0.50-1.83) 0.79 0.67 
- Other cardiovascular disease (Other I) 543 1.00 (0.77-1.30) 1.00 0.82 (0.60-1.12) 1.00 (0.72-1.37) 0.82 (0.55-1.24) 1.45 (0.88-2.40) 0.22 0.08 
Respiratory system disease (J00-99) 517 1.26 (0.94-1.69) 1.00 1.13 (0.81-1.57) 1.19 (0.85-1.68) 1.22 (0.83-1.79) 0.99 (0.56-1.75) 0.69 0.76 
- Lower respiratory infection (J09-22) 87 1.27 (0.63-2.58) 1.00 0.96 (0.42-2.22) 1.41 (0.61-3.26) 1.75 (0.67-4.60) 0.73 (0.09-5.84) 0.75 0.63 
- Other respiratory system disease (Other J) 430 1.27 (0.91-1.75) 1.00 1.16 (0.81-1.67) 1.16 (0.80-1.69) 1.13 (0.74-1.73) 1.00 (0.55-1.81) 0.79 0.94 
Digestive system disease (K00-93) 175 1.33 (0.80-2.23) 1.00 1.20 (0.67-2.14) 1.13 (0.60-2.10) 1.40 (0.71-2.74) 2.41 (1.13-5.15) 0.30 0.04 
- Liver disease (K70-77) 40 1.66 (0.55-5.06) 1.00 0.66 (0.15-2.96) 1.14 (0.30-4.29) 0.91 (0.20-4.16) 4.54 (1.30-15.9) 0.03 0.002 
- Other digestive system disease (Other K) 135 1.24 (0.69-2.21) 1.00 1.32 (0.70-2.49) 1.11 (0.55-2.26) 1.59 (0.75-3.38) 1.01 (0.28-3.60) 0.86 0.80 
External (V01-Y98) 208 1.81 (1.11-2.95) 1.00 1.06 (0.59-1.88) 1.38 (0.79-2.45) 1.74 (0.93-3.23) 1.99 (0.90-4.36) 0.0500f 0.005 
- Transport accident (V00-99;Y85) 40 1.40 (0.49-3.96) 1.00 0.73 (0.21-2.55) 1.26 (0.40-3.93) 1.64 (0.50-5.40) 0.60 (0.07-5.35) 0.72 0.57 
- Fall (W00-19) 48 2.28 (0.68-7.72) 1.00 1.35 (0.33-5.44) 2.93 (0.78-11.1) 2.75 (0.59-12.8) 9.03 (1.86-43.7) 0.07 0.002 
- Suicide (X60-84;Y87.0) 39 8.72 (1.16-65.6) 1.00 2.40 (0.25-23.1) 5.98 (0.73-49.0) 7.55 (0.89-63.9) 5.49 (0.48-62.9) 0.15 0.04 
- Other external (W20-X59;Y86;Y87.1-98) 81 1.31 (0.66-2.59) 1.00 0.99 (0.45-2.19) 0.56 (0.20-1.52) 0.84 (0.28-2.47) 1.28 (0.34-4.80) 0.52 0.84 
Other (Other A00-R99) 704 1.11 (0.88-1.41) 1.00 1.08 (0.82-1.42) 0.95 (0.71-1.27) 0.86 (0.60-1.21) 1.29 (0.84-1.98) 0.37 0.67 
All-cause mortality (A00-Y98) 13,988 1.11 (1.05-1.17) 1.00 0.95 (0.89-1.01) 0.97 (0.91-1.04) 0.96 (0.89-1.03) 1.10 (1.00-1.21) < 0.001 0.02 
Models were adjusted for sex, age, remoteness, education, household income, health insurance status, partner status, country of birth, smoking status and dose, body mass index, physical 
activity, fruit consumption, vegetable consumption, fibre intake, red meat consumption, processed meat consumption, parity (women), menopausal status (women), hormone replacement 
therapy use (women) and height. a< 1 drink per week. bOverall. cLinear trend using median alcohol consumption of each category, excluding non-drinkers. dFemale breast cancer only. eZero 
deaths in cell. fp < 0.05. ICD-10, International Classification of Diseases, version 10. 
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Figure 1. Hazard ratios (HR) and 95% confidence intervals (CI) of cause-specific mortality risk per one drink 
increase in mean daily alcohol consumption among drinkers in the 45 and Up Study (2006-2014), New South 
Wales, Australia. Non-drinkers were excluded. Models were adjusted for sex, age, remoteness, education, 
household income, health insurance status, partner status, country of birth, smoking status and dose, body 
mass index, physical activity, fruit consumption, vegetable consumption, fibre intake, red meat 
consumption, processed meat consumption, parity (women), menopausal status (women), hormone 
replacement therapy use (women) and height. Breast cancer in women only. 
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Figure 2. Hazard ratios (HR) and 95% confidence intervals (CI) of cause-specific mortality risk by alcohol consumption using restricted cubic splines among drinkers in the 45 and Up Study 
(2006-2014), New South Wales, Australia. Non-drinkers were excluded. Models were adjusted for sex, age, remoteness, education, household income, health insurance status, partner 
status, country of birth, smoking status and dose, body mass index, physical activity, fruit consumption, vegetable consumption, fibre intake, red meat consumption, processed meat 
consumption, parity (women), menopausal status (women), hormone replacement therapy use (women) and height. Brackets show n cases. Breast cancer in women only. 
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Figure 2. (Continued) 
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Figure 2. (Continued) 
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Table 3. Hazard ratios (HR) and 95% confidence intervals (CI) of cause-specific mortality risk by drinking-days per week among drinkers in the 45 and Up Study (2006-2014), New South 
Wales, Australia. 
  HR drinking-days per week - unadjusted for total alcohol 
consumption (95% CI) 
 HR drinking-days per week - adjusted for total alcohol 
consumption (95% CI) 
Cause of death (ICD-10 code) n deaths 1-2 3-5 6-7 pa ptrendb  1-2 3-5 6-7 pa ptrendb 
Cancer (C00-97;D45-47) 1470 1.00 0.82 (0.71-0.94) 0.80 (0.70-0.91) 0.001 0.001  1.00 0.79 (0.68-0.91) 0.73 (0.63-0.85) < 0.001 < 0.001 
- Alcohol-related (C00-15;18-20;22;32;50c) 325 1.00 0.88 (0.65-1.19) 0.98 (0.75-1.29) 0.65 0.99  1.00 0.82 (0.60-1.12) 0.82 (0.60-1.12) 0.37 0.24 
  - Mouth, pharynx and larynx (C00-14;32) 25 1.00 3.00 (0.79-11.3) 2.49 (0.69-9.04) 0.27 0.25  1.00 3.23 (0.83-12.6) 2.97 (0.71-12.4) 0.23 0.19 
  - Oesophagus (C15) 53 1.00 0.89 (0.41-1.93) 0.85 (0.43-1.68) 0.90 0.65  1.00 0.77 (0.35-1.70) 0.58 (0.26-1.26) 0.38 0.16 
  - Colorectum (C18-20) 129 1.00 0.85 (0.52-1.40) 0.98 (0.63-1.50) 0.78 1.00  1.00 0.79 (0.48-1.31) 0.81 (0.49-1.36) 0.62 0.44 
  - Liver (C22) 41 1.00 1.05 (0.40-2.76) 1.81 (0.79-4.17) 0.23 0.12  1.00 0.94 (0.35-2.49) 1.36 (0.54-3.44) 0.65 0.45 
  - Breast (C50c) 77 1.00 0.68 (0.39-1.20) 0.70 (0.40-1.22) 0.31 0.20  1.00 0.79 (0.43-1.45) 0.97 (0.46-2.05) 0.69 0.90 
- Non-alcohol-related (Other C;D45-47) 1145 1.00 0.80 (0.68-0.94) 0.76 (0.65-0.87) < 0.001 < 0.001  1.00 0.78 (0.66-0.92) 0.71 (0.60-0.84) < 0.001 < 0.001 
  - Stomach (C16) 28 1.00 0.89 (0.31-2.56) 0.91 (0.36-2.33) 0.97 0.87  1.00 0.84 (0.28-2.47) 0.79 (0.27-2.35) 0.91 0.69 
  - Pancreas (C25) 91 1.00 1.35 (0.79-2.29) 0.75 (0.43-1.30) 0.06 0.21  1.00 1.27 (0.73-2.20) 0.65 (0.34-1.25) 0.048 0.15 
  - Lung (C33-34) 258 1.00 0.67 (0.46-0.96) 0.83 (0.62-1.13) 0.10 0.42  1.00 0.64 (0.44-0.93) 0.74 (0.52-1.06) 0.06 0.16 
  - Melanoma (C43) 68 1.00 0.75 (0.37-1.48) 0.87 (0.48-1.59) 0.70 0.76  1.00 0.79 (0.39-1.59) 1.00 (0.49-2.05) 0.71 0.93 
  - Prostate (C61) 166 1.00 0.56 (0.36-0.89) 0.71 (0.50-1.02) 0.04 0.13  1.00 0.61 (0.38-0.98) 0.90 (0.58-1.39) 0.10 0.75 
  - Kidney (C64) 26 1.00 0.69 (0.21-2.19) 1.06 (0.41-2.73) 0.70 0.79  1.00 0.64 (0.20-2.10) 0.91 (0.30-2.72) 0.73 0.95 
  - Non-Hodgkin lymphoma (C82-85) 41 1.00 1.05 (0.51-2.19) 0.34 (0.15-0.76) 0.009 0.006  1.00 1.30 (0.60-2.84) 0.56 (0.20-1.57) 0.15 0.30 
Diabetes (E10-14) 54 1.00 0.71 (0.34-1.49) 0.70 (0.37-1.33) 0.50 0.30  1.00 0.69 (0.33-1.47) 0.66 (0.31-1.40) 0.49 0.28 
Dementia (F00-03;G30) 104 1.00 1.05 (0.62-1.76) 0.76 (0.47-1.22) 0.34 0.22  1.00 1.08 (0.63-1.85) 0.84 (0.47-1.48) 0.62 0.52 
Cardiovascular disease (G45-46;I00-99) 1031 1.00 0.99 (0.83-1.18) 0.91 (0.78-1.06) 0.37 0.19  1.00 0.95 (0.79-1.13) 0.81 (0.68-0.97) 0.04 0.02 
- Ischaemic heart disease (I20-25) 501 1.00 0.90 (0.70-1.15) 0.78 (0.63-0.97) 0.08 0.02  1.00 0.88 (0.68-1.12) 0.72 (0.56-0.93) 0.04 0.01 
- Cerebrovascular disease (G45-46;I60-69) 240 1.00 0.99 (0.69-1.42) 0.89 (0.65-1.22) 0.69 0.42  1.00 0.95 (0.66-1.38) 0.81 (0.56-1.17) 0.47 0.24 
- Other cardiovascular disease (Other I) 290 1.00 1.21 (0.85-1.71) 1.23 (0.91-1.66) 0.40 0.22  1.00 1.13 (0.79-1.60) 1.02 (0.72-1.43) 0.74 0.97 
Respiratory system disease (J00-99) 291 1.00 1.25 (0.86-1.80) 1.43 (1.04-1.95) 0.08 0.03  1.00 1.26 (0.87-1.83) 1.47 (1.03-2.09) 0.11 0.03 
- Lower respiratory infection (J09-22) 44 1.00 1.32 (0.48-3.62) 1.86 (0.82-4.26) 0.29 0.12  1.00 1.27 (0.46-3.51) 1.67 (0.67-4.16) 0.53 0.26 
- Other respiratory system disease (Other J) 247 1.00 1.24 (0.83-1.85) 1.36 (0.83-1.85) 0.22 0.09  1.00 1.27 (0.85-1.89) 1.43 (0.97-2.11) 0.20 0.07 
Digestive system disease (K00-93) 100 1.00 1.12 (0.61-2.05) 1.39 (0.82-2.35) 0.42 0.20  1.00 1.02 (0.55-1.89) 1.07 (0.60-1.93) 0.97 0.81 
- Liver disease (K70-77) 24 1.00 0.54 (0.16-1.86) 1.40 (0.53-3.70) 0.25 0.40  1.00 0.40 (0.11-1.41) 0.62 (0.19-1.99) 0.36 0.49 
- Other digestive system disease (Other K) 76 1.00 1.46 (0.71-2.99) 1.43 (0.75-2.70) 0.51 0.33  1.00 1.50 (0.73-3.11) 1.56 (0.76-3.19) 0.44 0.26 
External (V01-Y98) 107 1.00 0.91 (0.51-1.61) 1.38 (0.85-2.25) 0.18 0.14  1.00 0.82 (0.46-1.46) 1.05 (0.60-1.82) 0.62 0.77 
- Transport accident (V00-99;Y85) 26 1.00 0.50 (0.14-1.75) 1.51 (0.57-3.96) 0.16 0.29  1.00 0.54 (0.15-1.93) 1.76 (0.57-5.49) 0.14 0.25 
- Fall (W00-19) 25 1.00 1.54 (0.33-7.26) 3.57 (0.99-12.9) 0.08 0.03  1.00 1.44 (0.30-6.83) 2.88 (0.73-11.4) 0.23 0.09 
- Suicide (X60-84;Y87.0) 18 1.00 1.93 (0.49-7.62) 1.27 (0.32-5.04) 0.58 0.89  1.00 1.57 (0.39-6.32) 0.71 (0.15-3.37) 0.40 0.52 
- Other external (W20-X59;Y86;Y87.1-98) 38 1.00 0.75 (0.30-1.88) 0.87 (0.40-1.89) 0.83 0.77  1.00 0.62 (0.24-1.59) 0.55 (0.23-1.32) 0.38 0.19 
Other (Other A00-R99) 392 1.00 1.07 (0.81-1.43) 1.05 (0.81-1.35) 0.88 0.76  1.00 1.02 (0.76-1.37) 0.92 (0.69-1.23) 0.71 0.52 
All-cause mortality (A00-Y98) 7965 1.00 0.91 (0.85-0.97) 0.93 (0.88-0.98) 0.006 0.03  1.00 0.88 (0.82-0.93) 0.85 (0.80-0.90) < 0.001 < 0.001 
Non-drinkers were excluded. Models were adjusted for sex, age, remoteness, education, household income, health insurance status, partner status, country of birth, smoking status and dose, 
body mass index, physical activity, fruit consumption, vegetable consumption, fibre intake, red meat consumption, processed meat consumption, parity (women), menopausal status (women), 
hormone replacement therapy use (women) and height. aOverall. bLinear trend using median number of drinking-days per week of each category. cFemale breast cancer only. ICD-10, 
International Classification of Diseases, version 10. 
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Table 4. Hazard ratios (HR) and 95% confidence intervals (CI) of cause-specific mortality risk by mean drinks per drinking-day among drinkers in the 45 and Up Study (2006-2014), New 
South Wales, Australia. 
  HR mean drinks per drinking-day - unadjusted for total alcohol 
consumption (95% CI) 
 HR mean drinks per drinking-day - adjusted for total alcohol 
consumption (95% CI) 
Cause of death (ICD-10 code) n deaths ≤ 2 > 2 and ≤ 4 > 4 pa ptrendb  ≤ 2 > 2 and ≤ 4 > 4 pa ptrendb 
Cancer (C00-97;D45-47) 1470 1.00 1.09 (0.96-1.24) 1.19 (1.00-1.42) 0.10 0.03  1.00 1.16 (1.00-1.33) 1.38 (1.09-1.33) 0.02 0.006 
- Alcohol-related (C00-15;18-20;22;32;50c) 325 1.00 0.94 (0.71-1.26) 1.58 (1.11-2.24) 0.02 0.03  1.00 0.91 (0.66-1.24) 1.42 (0.88-2.30) 0.13 0.24 
  - Mouth, pharynx and larynx (C00-14;32) 25 1.00 0.97 (0.38-2.47) 0.67 (0.20-2.28) 0.80 0.53  1.00 0.84 (0.31-2.29) 0.43 (0.31-2.29) 0.63 0.35 
  - Oesophagus (C15) 53 1.00 0.64 (0.29-1.44) 2.69 (1.33-5.46) 0.002 0.01  1.00 0.66 (0.28-1.53) 2.86 (1.08-7.56) 0.01 0.047 
  - Colorectum (C18-20) 129 1.00 1.09 (0.70-1.70) 1.67 (0.97-2.87) 0.18 0.08  1.00 1.07 (0.66-1.74) 1.60 (0.75-3.40) 0.44 0.25 
  - Liver (C22) 41 1.00 1.20 (0.54-2.66) 2.11 (0.89-5.03) 0.23 0.10  1.00 1.02 (0.44-2.34) 1.27 (0.38-4.27) 0.91 0.71 
  - Breast (C50c) 77 1.00 0.83 (0.43-1.61) -d 0.86 0.15  1.00 1.07 (0.50-2.29) -d 0.98 0.47 
- Non-alcohol-related (Other C;D45-47) 1145 1.00 1.13 (0.98-1.30) 1.10 (0.90-1.34) 0.21 0.20  1.00 1.24 (1.05-1.45) 1.37 (1.05-1.80) 0.02 0.01 
  - Stomach (C16) 28 1.00 1.26 (0.52-3.07) 1.02 (0.27-3.91) 0.87 0.87  1.00 1.16 (0.75-1.52) 0.81 (0.12-5.33) 0.88 0.90 
  - Pancreas (C25) 91 1.00 1.23 (0.74-2.03) 1.22 (0.60-2.45) 0.69 0.50  1.00 1.37 (0.78-2.40) 1.60 (0.63-4.06) 0.49 0.28 
  - Lung (C33-34) 258 1.00 1.42 (1.07-1.89) 1.40 (0.95-2.06) 0.04 0.047  1.00 1.51 (1.10-2.08) 1.66 (0.98-2.80) 0.03 0.04 
  - Melanoma (C43) 68 1.00 1.06 (0.61-1.84) 0.65 (0.25-1.72) 0.63 0.49  1.00 1.10 (0.57-2.12) 0.73 (0.20-2.73) 0.74 0.76 
  - Prostate (C61) 166 1.00 0.87 (0.60-1.26) 0.70 (0.39-1.91) 0.43 0.20  1.00 1.06 (0.69-1.62) 1.13 (0.53-2.40) 0.95 0.74 
  - Kidney (C64) 26 1.00 2.22 (0.89-5.54) 2.55 (0.75-8.62) 0.15 0.08  1.00 2.56 (0.94-6.98) 3.62 (0.76-17.2) 0.14 0.08 
  - Non-Hodgkin lymphoma (C82-85) 41 1.00 0.80 (0.37-1.73) 0.22 (0.03-1.63) 0.31 0.11  1.00 1.60 (0.65-3.94) 0.86 (0.10-7.31) 0.55 0.71 
Diabetes (E10-14) 54 1.00 1.26 (0.64-2.46) 1.62 (0.68-3.89) 0.52 0.25  1.00 1.56 (0.74-3.27) 2.60 (0.88-7.67) 0.20 0.08 
Dementia (F00-03;G30) 104 1.00 0.59 (0.31-1.13) 0.71 (0.28-1.80) 0.24 0.20  1.00 0.63 (0.31-1.29) 0.81 (0.27-2.45) 0.45 0.47 
Cardiovascular disease (G45-46;I00-99) 1031 1.00 0.94 (0.80-1.11) 1.26 (1.00-1.57) 0.07 0.13  1.00 0.92 (0.76-1.10) 1.17 (0.86-1.59) 0.18 0.51 
- Ischaemic heart disease (I20-25) 501 1.00 0.93 (0.74-1.18) 1.20 (0.87-1.63) 0.36 0.42  1.00 0.99 (0.76-1.29) 1.39 (0.92-2.10) 0.20 0.18 
- Cerebrovascular disease (G45-46;I60-69) 240 1.00 1.16 (0.82-1.62) 1.16 (0.69-1.94) 0.65 0.44  1.00 1.18 (0.80-1.74) 1.21 (0.62-2.38) 0.69 0.49 
- Other (Other I) 290 1.00 0.80 (0.57-1.12) 1.41 (0.93-2.15) 0.06 0.34  1.00 0.65 (0.45-0.94) 0.83 (0.46-1.50) 0.06 0.27 
Respiratory system disease (J00-99) 291 1.00 1.10 (0.83-1.47) 0.80 (0.50-1.27) 0.41 0.54  1.00 0.95 (0.69-1.32) 0.54 (0.28-1.03) 0.13 0.09 
- Lower respiratory infection (J09-22) 44 1.00 1.65 (0.80-3.38) 0.68 (0.15-3.02) 0.30 0.90  1.00 1.19 (0.52-2.72) 0.29 (0.04-2.17) 0.28 0.38 
- Other respiratory system disease (Other J) 247 1.00 1.01 (0.74-1.38) 0.80 (0.49-1.30) 0.64 0.45  1.00 0.90 (0.63-1.29) 0.59 (0.29-1.17) 0.31 0.15 
Digestive system disease (K00-93) 100 1.00 0.98 (0.58-1.66) 1.66 (0.90-3.06) 0.22 0.14  1.00 0.81 (0.46-1.42) 0.96 (0.40-2.32) 0.74 0.83 
- Liver disease (K70-77) 24 1.00 0.43 (0.09-2.00) 3.81 (1.39-10.4) 0.004 0.005  1.00 0.37 (0.08-1.74) 2.17 (0.62-7.65) 0.10 0.21 
- Other digestive system disease (Other K) 76 1.00 1.21 (0.69-2.13) 0.64 (0.22-1.87) 0.51 0.65  1.00 1.12 (0.57-2.20) 0.53 (0.13-2.21) 0.47 0.52 
External (V01-Y98) 107 1.00 1.83 (1.17-2.86) 1.49 (0.77-2.91) 0.03 0.08  1.00 1.47 (0.90-2.40) 0.81 (0.32-2.06) 0.12 0.98 
- Transport accident (V00-99;Y85) 26 1.00 1.58 (0.67-3.73) 0.35 (0.04-2.83) 0.27 0.59  1.00 1.24 (0.46-3.33) 0.16 (0.01-2.68) 0.22 0.37 
- Fall (W00-19) 25 1.00 2.10 (0.75-5.89) 4.66 (1.42-15.3) 0.04 0.009  1.00 1.94 (0.64-5.86) 3.85 (0.81-18.2) 0.22 0.08 
- Suicide (X60-84;Y87.0) 18 1.00 3.98 (1.33-11.9) 3.61 (0.80-16.4) 0.04 0.051  1.00 3.74 (1.13-12.4) 3.05 (0.39-23.7) 0.09 0.20 
- Other external (W20-X59;Y86;Y87.1-98) 38 1.00 1.19 (0.53-2.68) 0.89 (0.25-3.18) 0.87 0.98  1.00 0.80 (0.34-1.89) 0.24 (0.04-1.59) 0.33 0.15 
Other (Other A00-R99) 392 1.00 0.85 (0.65-1.11) 1.33 (0.96-1.86) 0.06 0.25  1.00 0.78 (0.58-1.05) 1.09 (0.68-1.74) 0.12 0.97 
All-cause mortality (A00-Y98) 7965 1.00 1.04 (0.99-1.10) 1.22 (1.13-1.32) < 0.001 < 0.001  1.00 1.04 (0.97-1.10) 1.21 (1.08-1.34) 0.002 0.001 
Non-drinkers were excluded. Models were adjusted for sex, age, remoteness, education, household income, health insurance status, partner status, country of birth, smoking status and dose, 
body mass index, physical activity, fruit consumption, vegetable consumption, fibre intake, red meat consumption, processed meat consumption, parity (women), menopausal status (women), 
hormone replacement therapy use (women) and height. aOverall. bLinear trend using median number of drinks per drinking-day of each category. cFemale breast cancer only. dZero deaths in 
cell. ICD-10, International Classification of Diseases, version 10.
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Table 5. Hazard ratios (HR) and 95% confidence intervals (CI) of all-
cause mortality risk by drinking pattern among drinkers in the 45 and 
Up Study (2006-2014), New South Wales, Australia. 
Drinking-days 
per week 
HR mean drinks per drinking-day (95% CI) 
≤ 2 > 2 and ≤ 4 > 4 
1-2 1.00 1.13 (1.00-1.28) 1.24 (1.07-1.43) 
3-5 0.92 (0.85-0.99) 0.96 (0.86-1.08) 1.18 (1.00-1.40) 
6-7 0.94 (0.88-1.01) 0.97 (0.90-1.05) 1.13 (1.02-1.26) 
Non-drinkers were excluded. n deaths = 7965. Model was adjusted for 
sex, age, remoteness, education, household income, health insurance 
status, partner status, country of birth, smoking status and dose, body 
mass index, physical activity, fruit consumption, vegetable consumption, 
fibre intake, red meat consumption, processed meat consumption, parity 
(women only), menopausal status (women only), hormone replacement 
therapy use (women only) and height.
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Supplementary data 
 
Supplementary Table 1. Hazard ratios and 95% confidence intervals of cause-specific mortality risk by alcohol consumption in never-smokers in the 45 and Up Study (2006-2014), New 
South Wales, Australia. 
  Drinks/week   
Cause of death (ICD-10 code) n deaths Non-drinkera ≥ 1 and ≤ 3.5 > 3.5 and ≤ 7 > 7 and ≤ 14 > 14 and ≤ 28 > 28 pb ptrendc 
Cancer (C00-97;D45-47) 1019 1.00 (0.83-1.20) 1.00 0.96 (0.78-1.19) 0.84 (0.66-1.07) 0.96 (0.70-1.30) 1.01 (0.60-1.69) 0.73 0.89 
- Alcohol-related (C00-15;18-20;22;32;50d) 247 0.76 (0.53-1.07) 1.00 0.77 (0.51-1.16) 0.83 (0.52-1.32) 0.77 (0.40-1.51) 1.13 (0.40-3.20) 0.69 0.98 
  - Mouth, pharynx and larynx (C00-14;32) 9 3.71 (0.14-99.0) 1.00 -e 12.4 (0.47-329.4) -e 14.1 (0.19-1061.6) 0.72 -f 
  - Oesophagus (C15) 25 1.52 (0.42-5.54) 1.00 1.33 (0.32-5.64) 1.49 (0.33-6.81) -e 2.61 (0.25-26.9) 0.98 0.86 
  - Colorectum (C18-20) 105 0.80 (0.46-1.39) 1.00 0.96 (0.51-1.81) 0.89 (0.43-1.83) 1.16 (0.47-2.86) -e 0.94 0.48 
  - Liver (C22) 24 1.45 (0.31-6.86) 1.00 1.74 (0.34-9.04) 2.85 (0.56-14.4) 1.11 (0.10-12.6) 5.32 (0.44-63.8) 0.63 0.30 
  - Breast (C50d) 84 0.55 (0.32-0.93) 1.00 0.50 (0.25-1.00) 0.28 (0.10-0.83) 0.93 (0.28-3.13) 3.69 (0.49-27.9) 0.03 0.68 
- Non-alcohol-related (Other C;D45-47) 772 1.10 (0.88-1.36) 1.00 1.04 (0.82-1.33) 0.86 (0.65-1.13) 1.03 (0.73-1.45) 1.00 (0.54-1.82) 0.52 0.86 
  - Stomach (C16) 23 0.77 (0.23-2.62) 1.00 1.41 (0.41-4.92) 0.47 (0.08-2.66) 0.43 (0.05-4.01) -e 0.71 0.12 
  - Pancreas (C25) 81 1.26 (0.62-2.57) 1.00 1.43 (0.66-3.10) 1.36 (0.58-3.17) 1.33 (0.44-4.00) 1.02 (0.13-8.21) 0.97 0.61 
  - Lung (C33-34) 66 1.08 (0.48-2.39) 1.00 1.37 (0.57-3.28) 0.81 (0.26-2.50) 3.52 (1.31-9.46) 1.33 (0.16-11.0) 0.06 0.02 
  - Melanoma (C43) 53 0.65 (0.31-1.37) 1.00 0.55 (0.23-1.32) 0.47 (0.17-1.26) 1.17 (0.45-3.06) 0.70 (0.09-5.52) 0.44 0.68 
  - Prostate (C61) 104 0.85 (0.48-1.49) 1.00 0.92 (0.50-1.70) 0.61 (0.29-1.28) 0.46 (0.17-1.26) 1.04 (0.30-3.59) 0.59 0.24 
  - Kidney (C64) 23 0.76 (0.23-2.51) 1.00 0.89 (0.22-3.63) 1.07 (0.23-4.94) 0.83 (0.09-7.85) 3.72 (0.37-37.2) 0.84 0.37 
  - Non-Hodgkin lymphoma (C82-85) 40 1.13 (0.47-2.71) 1.00 0.67 (0.22-2.00) 0.46 (0.12-1.79) 1.03 (0.26-4.14) -e 0.73 0.83 
Diabetes (E10-14) 52 1.84 (0.71-4.78) 1.00 1.25 (0.39-3.97) 1.51 (0.43-5.32) 0.74 (0.09-6.47) -e 0.77 0.62 
Dementia (F00-03;G30) 131 0.80 (0.48-1.32) 1.00 0.88 (0.48-1.60) 0.89 (0.43-1.84) 0.64 (0.19-2.18) -e 0.95 0.35 
Cardiovascular disease (G45-46;I00-99) 1011 0.95 (0.79-1.14) 1.00 0.90 (0.72-1.13) 0.88 (0.67-1.14) 0.77 (0.53-1.13) 1.16 (0.64-2.10) 0.71 0.74 
- Ischaemic heart disease (I20-25) 451 0.95 (0.72-1.25) 1.00 0.90 (0.65-1.25) 0.72 (0.48-1.09) 1.02 (0.62-1.68) 0.92 (0.37-2.32) 0.72 0.79 
- Cerebrovascular disease (G45-46;I60-69) 276 0.94 (0.66-1.34) 1.00 0.84 (0.55-1.30) 0.99 (0.60-1.63) 0.50 (0.20-1.28) 1.36 (0.41-4.45) 0.69 0.88 
- Other cardiovascular disease (Other I) 284 0.95 (0.66-1.35) 1.00 0.95 (0.63-1.46) 1.03 (0.64-1.68) 0.58 (0.25-1.30) 1.38 (0.49-3.94) 0.76 0.89 
Respiratory system disease (J00-99) 153 1.72 (0.97-3.04) 1.00 1.42 (0.74-2.76) 1.56 (0.74-3.31) 1.16 (0.38-3.59) 3.95 (1.11-14.1) 0.26 0.13 
- Lower respiratory infection (J09-22) 41 3.01 (0.70-12.9) 1.00 1.98 (0.38-10.4) 4.06 (0.73-22.7) 5.30 (0.69-40.7) 12.3 (1.02-148.6) 0.33 0.004 
- Other respiratory system disease (Other J) 112 1.47 (0.78-2.75) 1.00 1.28 (0.62-2.64) 1.18 (0.51-2.77) 0.62 (0.14-2.82) 2.74 (0.60-12.6) 0.58 0.63 
Digestive system disease (K00-93) 84 1.04 (0.54-2.01) 1.00 0.88 (0.40-1.94) 0.88 (0.34-2.26) 0.96 (0.26-3.48) 3.47 (0.92-12.1) 0.47 0.12 
- Liver disease (K70-77) 16 1.44 (0.30-7.03) 1.00 1.03 (0.14-7.48) 0.67 (0.06-7.66) 1.35 (0.11-16.1) 6.87 (0.82-57.3) 0.42 0.053 
- Other digestive system disease (Other K) 68 0.95 (0.46-1.95) 1.00 0.86 (0.36-2.04) 0.88 (0.31-2.47) 0.82 (0.17-3.85) 1.52 (0.18-13.1) 1.00 0.90 
External (V01-Y98) 109 1.24 (0.70-2.21) 1.00 0.69 (0.33-1.46) 0.77 (0.34-1.79) 1.52 (0.61-3.80) 4.35 (1.52-12.5) 0.02 0.002 
- Transport accident (V00-99;Y85) 21 1.13 (0.33-3.89) 1.00 0.77 (0.19-3.16) 0.25 (0.03-2.29) 1.56 (0.32-7.63) -e 0.72 0.84 
- Fall (W00-19) 27 1.73 (0.37-8.13) 1.00 1.66 (0.29-9.57) 3.71 (0.62-22.1) 4.70 (0.58-37.8) 37.5 (3.91-359.0) 0.02 0.001 
- Suicide (X60-84;Y87.0) 15 4.65 (0.58-37.5) 1.00 0.85 (0.05-13.7) 0.99 (0.06-16.0) 1.77 (0.11-29.2) 7.34 (0.43-125.8) 0.27 0.32 
- Other external (W20-X59;Y86;Y87.1-98) 46 1.01 (0.45-2.29) 1.00 0.43 (0.13-1.45) 0.60 (0.16-2.30) 0.47 (0.06-4.01) 4.19 (0.81-21.7) 0.17 0.16 
Other (Other A00-R99) 371 1.07 (0.78-1.47) 1.00 1.20 (0.84-1.72) 0.90 (0.58-1.39) 0.84 (0.46-1.53) 1.37 (0.61-3.08) 0.64 0.98 
All-cause mortality (A00-Y98) 6660 1.06 (0.99-1.15) 1.00 0.97 (0.89-1.06) 0.92 (0.84-1.02) 0.95 (0.83-1.09) 1.35 (1.10-1.65) < 0.001 0.09 
Models were adjusted for sex, age, remoteness, education, household income, health insurance status, partner status, country of birth, body mass index, physical activity, fruit consumption, 
vegetable consumption, fibre intake, red meat consumption, processed meat consumption, parity (women), menopausal status (women), hormone replacement therapy use (women) and 
height. a< 1 drink per week. bOverall. cLinear trend using median alcohol consumption of each category, excluding non-drinkers. dFemale breast cancer only. eZero deaths in cell. fModel failed 
to converge. ICD-10, International Classification of Diseases, version 10.
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Supplementary Table 2. Hazard ratios and 95% confidence intervals of cause-specific mortality risk by alcohol consumption in ever-smokers in the 45 and Up Study (2006-2014), New South 
Wales, Australia. 
  Drinks/week   
Cause of death (ICD-10 code) n deaths Non-drinkera ≥ 1 and ≤ 3.5 > 3.5 and ≤ 7 > 7 and ≤ 14 > 14 and ≤ 28 > 28 pb ptrendc 
Cancer (C00-97;D45-47) 1372 1.11 (0.92-1.32) 1.00 0.91 (0.74-1.10) 0.95 (0.78-1.15) 0.88 (0.71-1.08) 0.97 (0.74-1.25) 0.10 0.56 
- Alcohol-related (C00-15;18-20;22;32;50d) 277 1.19 (0.78-1.81) 1.00 0.93 (0.58-1.49) 1.25 (0.80-1.95) 1.11 (0.68-1.81) 1.60 (0.92-2.79) 0.37 0.051 
  - Mouth, pharynx and larynx (C00-14;32) 29 0.97 (0.29-3.24) 1.00 -e 1.18 (0.35-4.06) 0.98 (0.26-3.62) 0.46 (0.08-2.65) 0.93 0.84 
  - Oesophagus (C15) 53 1.30 (0.46-3.70) 1.00 1.30 (0.44-3.85) 1.43 (0.50-4.12) 0.71 (0.20-2.52) 2.58 (0.80-8.28) 0.34 0.31 
  - Colorectum (C18-20) 100 1.49 (0.70-3.19) 1.00 1.12 (0.49-2.56) 1.24 (0.55-2.79) 1.77 (0.79-3.97) 1.90 (0.75-4.82) 0.57 0.04 
  - Liver (C22) 38 2.56 (0.56-11.7) 1.00 2.47 (0.51-12.0) 2.49 (0.51-12.2) 2.85 (0.56-14.5) 4.57 (0.84-24.8) 0.67 0.11 
  - Breast (C50d) 57 0.78 (0.36-1.69) 1.00 0.70 (0.29-1.69) 1.04 (0.45-2.38) 0.34 (0.07-1.58) -e 0.70 0.24 
- Non-alcohol-related (Other C;D45-47) 1095 1.09 (0.89-1.33) 1.00 0.90 (0.73-1.12) 0.89 (0.71-1.10) 0.83 (0.66-1.05) 0.84 (0.63-1.14) 0.06 0.11 
  - Stomach (C16) 32 2.56 (0.72-9.11) 1.00 1.00 (0.22-4.50) 0.89 (0.20-4.03) 1.50 (0.34-6.50) 1.23 (0.19-7.77) 0.34 0.52 
  - Pancreas (C25) 73 1.06 (0.50-2.26) 1.00 0.77 (0.32-1.81) 0.95 (0.42-2.14) 0.95 (0.40-2.25) 0.52 (0.14-1.96) 0.88 0.24 
  - Lung (C33-34) 350 1.59 (1.08-2.36) 1.00 1.24 (0.81-1.91) 1.14 (0.74-1.74) 1.08 (0.69-1.71) 1.21 (0.70-2.07) 0.10 0.84 
  - Melanoma (C43) 45 1.19 (0.40-3.57) 1.00 1.20 (0.40-3.58) 1.00 (0.33-2.99) 0.91 (0.29-2.90) 0.52 (0.10-2.81) 0.93 0.16 
  - Prostate (C61) 139 0.62 (0.37-1.03) 1.00 0.58 (0.33-0.99) 0.54 (0.31-0.93) 0.60 (0.34-1.06) 0.43 (0.18-1.00) 0.18 0.14 
  - Kidney (C64) 24 4.84 (0.60-38.7) 1.00 3.18 (0.37-27.7) 2.20 (0.24-20.1) 2.18 (0.22-21.6) 4.31 (0.37-50.1) 0.58 0.57 
  - Non-Hodgkin lymphoma (C82-85) 25 0.95 (0.37-2.43) 1.00 0.65 (0.23-1.88) 0.54 (0.18-1.62) 0.23 (0.05-1.15) -e 0.48 0.01 
Diabetes (E10-14) 63 1.20 (0.55-2.61) 1.00 0.65 (0.24-1.75) 1.12 (0.46-2.69) 0.87 (0.31-2.39) 0.44 (0.09-2.08) 0.60 0.78 
Dementia (F00-03;G30) 87 1.03 (0.54-1.95) 1.00 0.67 (0.32-1.40) 0.71 (0.33-1.50) 0.62 (0.24-1.57) 0.49 (0.11-2.20) 0.57 0.56 
Cardiovascular disease (G45-46;I00-99) 915 1.07 (0.86-1.31) 1.00 0.81 (0.64-1.03) 0.85 (0.67-1.08) 0.90 (0.70-1.17) 0.95 (0.67-1.34) 0.09 0.55 
- Ischaemic heart disease (I20-25) 464 1.10 (0.81-1.47) 1.00 0.89 (0.64-1.24) 0.84 (0.60-1.17) 0.84 (0.58-1.21) 0.77 (0.47-1.28) 0.31 0.36 
- Cerebrovascular disease (G45-46;I60-69) 192 1.00 (0.64-1.58) 1.00 0.79 (0.48-1.30) 0.71 (0.42-1.20) 1.02 (0.59-1.74) 0.80 (0.36-1.79) 0.59 0.65 
- Other cardiovascular disease (Other I) 259 1.06 (0.72-1.57) 1.00 0.70 (0.44-1.10) 0.99 (0.64-1.53) 0.93 (0.56-1.53) 1.53 (0.84-2.78) 0.16 0.04 
Respiratory system disease (J00-99) 364 1.11 (0.78-1.58) 1.00 1.02 (0.70-1.50) 1.08 (0.74-1.59) 1.13 (0.74-1.72) 0.74 (0.39-1.39) 0.80 0.77 
- Lower respiratory infection (J09-22) 46 0.72 (0.29-1.77) 1.00 0.65 (0.24-1.75) 0.79 (0.30-2.13) 1.05 (0.35-3.17) -e 0.93 0.46 
- Other respiratory system disease (Other J) 318 1.20 (0.82-1.76) 1.00 1.11 (0.73-1.68) 1.14 (0.75-1.73) 1.16 (0.73-1.83) 0.86 (0.45-1.64) 0.87 0.90 
Digestive system disease (K00-93) 90 1.80 (0.77-4.20) 1.00 1.81 (0.74-4.44) 1.55 (0.62-3.86) 1.88 (0.74-4.79) 2.65 (0.95-7.45) 0.58 0.10 
- Liver disease (K70-77) 24 1.99 (0.40-9.91) 1.00 0.43 (0.04-4.87) 1.46 (0.26-8.20) 0.88 (0.12-6.56) 4.25 (0.81-22.4) 0.16 0.02 
- Other digestive system disease (Other K) 66 1.83 (0.67-5.00) 1.00 2.28 (0.81-6.38) 1.61 (0.55-4.76) 2.45 (0.83-7.23) 1.15 (0.21-6.17) 0.55 0.69 
External (V01-Y98) 99 3.55 (1.39-9.09) 1.00 2.10 (0.76-5.81) 2.91 (1.09-7.78) 2.91 (1.04-8.14) 2.11 (0.60-7.49) 0.11 0.21 
- Transport accident (V00-99;Y85) 19 2.46 (0.27-22.3) 1.00 0.80 (0.05-13.1) 4.99 (0.60-41.8) 3.30 (0.35-31.2) 1.81 (0.11-31.1) 0.41 0.48 
- Fall (W00-19) 21 4.54 (0.54-38.3) 1.00 1.68 (0.15-19.5) 4.15 (0.46-37.9) 2.85 (0.23-34.7) 8.02 (0.63-102.6) 0.50 0.15 
- Suicide (X60-84;Y87.0) 24 -f 1.00 -f -f -f -f 0.76 0.15 
- Other external (W20-X59;Y86;Y87.1-98) 35 2.09 (0.59-7.43) 1.00 2.19 (0.59-8.12) 0.67 (0.13-3.35) 1.21 (0.26-5.56) 0.52 (0.05-5.25) 0.28 0.46 
Other (Other A00-R99) 333 1.18 (0.82-1.69) 1.00 0.95 (0.64-1.42) 0.96 (0.64-1.43) 0.85 (0.54-1.34) 1.23 (0.73-2.09) 0.48 0.78 
All-cause mortality (A00-Y98) 7326 1.16 (1.08-1.26) 1.00 0.93 (0.85-1.01) 1.00 (0.92-1.09) 0.97 (0.88-1.06) 1.05 (0.93-1.18) < 0.001 0.19 
Models were adjusted for sex, age, remoteness, education, household income, health insurance status, partner status, country of birth, smoking status and dose, body mass index, physical 
activity, fruit consumption, vegetable consumption, fibre intake, red meat consumption, processed meat consumption, parity (women), menopausal status (women), hormone replacement 
therapy use (women) and height. a< 1 drink per week. bOverall. cLinear trend using median alcohol consumption of each category, excluding non-drinkers. dFemale breast cancer only. eZero 
deaths in cell. fNot possible to calculate due to zero deaths in reference group. ICD-10, International Classification of Diseases, version 10.
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Supplementary Table 3. Hazard ratios and 95% confidence intervals of cause-specific mortality risk by alcohol consumption after excluding participants with disease at baseline in the 45 
and Up Study (2006-2014), New South Wales, Australia. 
  Drinks/week   
Cause of death (ICD-10 code) n deaths Non-drinkera ≥ 1 and ≤ 3.5 > 3.5 and ≤ 7 > 7 and ≤ 14 > 14 and ≤ 28 > 28 pb ptrendc 
Cancer (C00-97;D45-47) 1313 1.18 (0.99-1.41) 1.00 1.08 (0.89-1.32) 0.96 (0.78-1.19) 1.02 (0.81-1.28) 1.22 (0.91-1.62) 0.14 0.26 
- Alcohol-related (C00-15;18-20;22;32;50d) 258 1.34 (0.87-2.06) 1.00 1.14 (0.70-1.86) 1.36 (0.84-2.22) 1.31 (0.76-2.25) 2.28 (1.26-4.12) 0.13 0.002 
  - Mouth, pharynx and larynx (C00-14;32) 20 1.04 (0.20-5.52) 1.00 -e 1.54 (0.29-8.20) 2.26 (0.43-11.8) 1.12 (0.15-8.54) 0.86 0.32 
  - Oesophagus (C15) 46 1.90 (0.54-6.71) 1.00 1.79 (0.46-6.98) 3.11 (0.86-11.3) 0.74 (0.12-4.55) 7.46 (1.89-29.4) 0.008 0.008 
  - Colorectum (C18-20) 118 1.15 (0.64-2.07) 1.00 1.08 (0.56-2.09) 0.86 (0.42-1.78) 1.12 (0.52-2.41) 1.02 (0.36-2.92) 0.97 0.42 
  - Liver (C22) 47 1.82 (0.52-6.41) 1.00 2.41 (0.66-8.84) 2.43 (0.65-9.12) 2.36 (0.57-9.76) 3.99 (0.90-17.7) 0.58 0.12 
  - Breast (C50d) 27 1.29 (0.42-3.98) 1.00 0.43 (0.08-2.38) 0.91 (0.20-4.19) 0.76 (0.08-7.10) 5.08 (0.52-50.2) 0.48 0.21 
- Non-alcohol-related (Other C;D45-47) 1055 1.15 (0.94-1.40) 1.00 1.07 (0.86-1.33) 0.89 (0.70-1.12) 0.96 (0.74-1.24) 1.02 (0.73-1.42) 0.17 0.76 
  - Stomach (C16) 40 1.49 (0.54-4.08) 1.00 1.35 (0.45-4.06) 0.44 (0.10-1.85) 0.75 (0.20-2.88) 0.32 (0.04-2.88) 0.30 0.41 
  - Pancreas (C25) 123 0.93 (0.52-1.66) 1.00 1.12 (0.61-2.09) 1.17 (0.62-2.22) 1.11 (0.53-2.31) 0.78 (0.26-2.41) 0.94 0.67 
  - Lung (C33-34) 291 1.44 (0.95-2.18) 1.00 1.27 (0.81-2.00) 0.94 (0.58-1.51) 1.08 (0.65-1.77) 1.26 (0.71-2.26) 0.22 0.98 
  - Melanoma (C43) 34 0.46 (0.17-1.24) 1.00 0.38 (0.12-1.16) 0.39 (0.13-1.23) 0.76 (0.26-2.22) 0.25 (0.03-2.09) 0.34 0.35 
  - Prostate (C61) 71 0.98 (0.49-1.98) 1.00 0.61 (0.27-1.40) 0.54 (0.22-1.29) 0.99 (0.43-2.30) 0.77 (0.21-2.81) 0.55 0.76 
  - Kidney (C64) 24 -f 1.00 -f -f -f -f 0.67 0.03 
  - Non-Hodgkin lymphoma (C82-85) 33 1.06 (0.41-2.77) 1.00 0.94 (0.32-2.75) 0.29 (0.06-1.47) 0.21 (0.03-1.79) -e 0.43 0.06 
Diabetes (E10-14) 20 0.88 (0.22-3.57) 1.00 1.11 (0.26-4.83) 0.52 (0.08-3.29) 0.88 (0.13-5.77) 1.15 (0.11-12.2) 0.97 0.58 
Dementia (F00-03;G30) 80 0.77 (0.40-1.48) 1.00 0.78 (0.40-1.48) 1.12 (0.51-2.46) 0.59 (0.16-2.14) -e 0.84 0.24 
Cardiovascular disease (G45-46;I00-99) 1018 0.99 (0.81-1.20) 1.00 0.88 (0.71-1.10) 0.93 (0.73-1.18) 0.99 (0.75-1.31) 1.34 (0.94-1.92) 0.29 0.047 
- Ischaemic heart disease (I20-25) 429 1.07 (0.79-1.45) 1.00 0.85 (0.60-1.21) 0.88 (0.61-1.28) 1.01 (0.66-1.54) 1.10 (0.63-1.93) 0.62 0.85 
- Cerebrovascular disease (G45-46;I60-69) 237 0.88 (0.61-1.27) 1.00 0.91 (0.60-1.38) 0.86 (0.54-1.37) 1.13 (0.66-1.92) 1.32 (0.63-2.80) 0.78 0.19 
- Other cardiovascular disease (Other I) 316 0.96 (0.68-1.37) 1.00 0.90 (0.60-1.34) 1.06 (0.70-1.61) 0.83 (0.49-1.42) 1.72 (0.94-3.13) 0.32 0.04 
Respiratory system disease (J00-99) 381 1.14 (0.81-1.59) 1.00 1.03 (0.70-1.50) 1.15 (0.78-1.69) 1.35 (0.88-2.08) 1.07 (0.57-2.02) 0.75 0.36 
- Lower respiratory infection (J09-22) 73 1.05 (0.51-2.18) 1.00 0.61 (0.24-1.57) 1.35 (0.57-3.20) 2.06 (0.78-5.47) 0.85 (0.11-6.91) 0.29 0.36 
- Other respiratory system disease (Other J) 308 1.17 (0.80-1.72) 1.00 1.15 (0.75-1.74) 1.12 (0.73-1.73) 1.25 (0.78-2.01) 1.08 (0.55-2.12) 0.96 0.60 
Suicide (X60-84;Y87.0) 18 -f 1.00 -f -f -f -f 0.81 0.04 
All-cause mortality (A00-Y98) 5435 1.10 (1.01-1.20) 1.00 0.94 (0.86-1.04) 1.04 (0.94-1.16) 1.03 (0.91-1.15) 1.21 (1.04-1.40) 0.001 0.01 
Participants who at baseline had ever had cancer were excluded from cancer analyses, ever had diabetes excluded from diabetes analysis, did not have good/very good/excellent memory 
excluded from dementia analysis, ever had heart disease or stroke excluded from cardiovascular disease analyses, ever had asthma excluded from respiratory system disease analyses, ever 
had depression excluded from suicide analysis and ever had cancer, heart disease, stroke or diabetes excluded from all-cause mortality analysis. Models were adjusted for sex, age, 
remoteness, education, household income, health insurance status, partner status, country of birth, smoking status and dose, body mass index, physical activity, fruit consumption, vegetable 
consumption, fibre intake, red meat consumption, processed meat consumption, parity (women), menopausal status (women), hormone replacement therapy use (women) and height. a< 1 
drink per week. bOverall. cLinear trend using median alcohol consumption of each category, excluding non-drinkers. dFemale breast cancer only. eZero deaths in cell. fNot possible to calculate 
due to zero deaths in reference group. ICD-10, International Classification of Diseases, version 10. 
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Supplementary Table 4. Hazard ratios (HR) and 95% confidence intervals (CI) of cause-specific mortality risk by drinking-days per week among drinkers by sex in the 45 and Up Study (2006-
2014), New South Wales, Australia. 
  HR drinking-days per week in men - adjusted for total alcohol 
consumption (95% CI) 
  HR drinking-days per week in women - adjusted for total alcohol 
consumption (95% CI) 
Cause of death (ICD-10 code) n deaths 1-2 3-5 6-7 pa ptrendb  n deaths 1-2 3-5 6-7 pa ptrendb 
Cancer (C00-97;D45-47) 1066 1.00 0.76 (0.64-0.91) 0.65 (0.55-0.78) < 0.001 < 0.001  404 1.00 0.85 (0.64-1.11) 0.96 (0.71-1.31) 0.42 0.85 
- Alcohol-related (C00-15;18-20;22;32) 196 1.00 0.86 (0.57-1.31) 0.84 (0.56-1.28) 0.69 0.01  129 1.00 0.79 (0.50-1.27) 0.84 (0.49-1.45) 0.63 0.53 
  - Mouth, pharynx and larynx (C00-14;32) -c 1.00 2.80 (0.71-11.1) 2.80 (0.66-11.9) 0.31 0.21  -c 1.00 -d -d -d -d 
  - Oesophagus (C15) 45 1.00 0.66 (0.28-1.53) 0.44 (0.19-1.02) 0.16 0.06  8 1.00 10.8 (0.13-918.1) 12.7 (0.14-1191.2) 0.52 0.31 
  - Colorectum (C18-20) 94 1.00 0.77 (0.42-1.42) 0.81 (0.45-1.47) 0.69 0.54  35 1.00 0.69 (0.28-1.71) 0.60 (0.23-1.58) 0.56 0.31 
  - Liver (C22) -c 1.00 0.86 (0.29-2.54) 1.25 (0.45-3.45) 0.73 0.60  -c 1.00 0.76 (0.04-13.7) 2.11 (0.11-38.8) 0.65 0.48 
- Non-alcohol-related (Other C;D45-47) 870 1.00 0.75 (0.62-0.90) 0.62 (0.51-0.75) < 0.001 < 0.001  275 1.00 0.88 (0.62-1.23) 1.04 (0.72-1.50) 0.56 0.81 
  - Stomach (C16) 22 1.00 0.86 (0.26-2.80) 0.60 (0.18-2.00) 0.68 0.39  6 1.00 3.21 (0.07-148.1) 13.3 (0.22-792.5) 0.43 0.20 
  - Pancreas (C25) 64 1.00 1.22 (0.62-2.41) 0.70 (0.32-1.51) 0.21 0.29  27 1.00 1.46 (0.55-3.85) 0.58 (0.15-2.20) 0.22 0.48 
  - Lung (C33-34) 183 1.00 0.64 (0.41-0.99) 0.55 (0.36-0.85) 0.02 0.008  75 1.00 0.64 (0.30-1.38) 1.55 (0.77-3.13) 0.04 0.13 
  - Melanoma (C43) 59 1.00 0.85 (0.39-1.85) 0.99 (0.45-2.16) 0.89 0.97  9 1.00 0.98 (0.13-7.66) 3.16 (0.21-47.4) 0.61 0.48 
  - Kidney (C64) 20 1.00 0.78 (0.20-3.05) 1.08 (0.30-3.90) 0.87 0.85  6 1.00 -d -d -d -d 
  - Non-Hodgkin lymphoma (C82-85) 32 1.00 1.68 (0.68-4.18) 0.62 (0.19-2.01) 0.08 0.41  9 1.00 0.85 (0.09-7.70) 1.83 (0.13-24.9) 0.83 0.70 
Diabetes (E10-14) 40 1.00 0.59 (0.25-1.38) 0.42 (0.17-1.02) 0.15 0.06  14 1.00 1.40 (0.24-8.10) 3.57 (0.55-23.1) 0.34 0.17 
Dementia (F00-03;G30) 70 1.00 1.31 (0.66-2.61) 1.12 (0.56-2.24) 0.73 0.79  34 1.00 0.96 (0.38-2.44) 0.59 (0.18-1.97) 0.62 0.41 
Cardiovascular disease (G45-46;I00-99) 740 1.00 1.01 (0.81-1.25) 0.87 (0.70-1.07) 0.23 0.14  291 1.00 0.82 (0.59-1.13) 0.65 (0.46-0.93) 0.06 0.02 
- Ischaemic heart disease (I20-25) 385 1.00 0.89 (0.66-1.20) 0.81 (0.60-1.08) 0.36 0.15  116 1.00 0.76 (0.47-1.25) 0.42 (0.24-0.74) 0.009 0.003 
- Cerebrovascular disease (G45-46;I60-69) 160 1.00 1.14 (0.73-1.78) 0.80 (0.51-1.27) 0.24 0.27  80 1.00 0.60 (0.31-1.18) 0.71 (0.37-1.34) 0.31 0.33 
- Other cardiovascular disease (Other I) 195 1.00 1.26 (0.80-2.00) 1.16 (0.75-1.80) 0.61 0.60  95 1.00 1.16 (0.65-2.07) 1.14 (0.59-2.20) 0.87 0.71 
Respiratory system disease (J00-99) 222 1.00 1.20 (0.78-1.85) 1.50 (1.00-2.24) 0.13 0.045  69 1.00 1.67 (0.78-3.60) 1.64 (0.75-3.63) 0.37 0.26 
- Lower respiratory infection (J09-22) 36 1.00 1.50 (0.46-4.93) 2.25 (0.78-6.44) 0.30 0.12  8 1.00 -d -d -d -d 
- Other respiratory system disease (Other J) 186 1.00 1.17 (0.73-1.87) 1.39 (0.89-2.17) 0.32 0.13  61 1.00 1.75 (0.76-4.00) 1.77 (0.75-4.14) 0.36 0.23 
Digestive system disease (K00-93) 73 1.00 1.12 (0.53-2.37) 1.13 (0.55-2.31) 0.94 0.76  27 1.00 0.83 (0.26-2.65) 0.83 (0.26-2.68) 0.94 0.77 
- Liver disease (K70-77) 18 1.00 0.87 (0.19-4.09) 1.02 (0.22-4.75) 0.97 0.93  6 1.00 -e 0.71 (0.02-21.7) 0.98 0.59 
- Other digestive system disease (Other K) 55 1.00 1.38 (0.58-3.26) 1.54 (0.67-3.57) 0.60 0.32  21 1.00 1.74 (0.38-8.02) 1.23 (0.25-6.01) 0.74 0.90 
External (V01-Y98) 79 1.00 0.88 (0.44-1.76) 1.11 (0.58-2.14) 0.75 0.67  28 1.00 0.70 (0.23-2.15) 0.95 (0.31-2.90) 0.79 0.96 
- Transport accident (V00-99;Y85) 18 1.00 0.70 (0.15-3.38) 2.55 (0.62-10.5) 0.15 0.14  8 1.00 0.20 (0.02-2.60) 0.35 (0.03-4.07) 0.45 0.42 
- Fall (W00-19) 16 1.00 1.52 (0.23-10.2) 2.91 (0.51-16.5) 0.41 0.19  9 1.00 1.13 (0.04-30.9) 2.02 (0.09-44.3) 0.87 0.62 
- Suicide (X60-84;Y87.0) -c 1.00 1.32 (0.23-7.49) 0.97 (0.16-5.84) 0.90 0.90  -c 1.00 -d -d -d -d 
- Other external (W20-X59;Y86;Y87.1-98) -c 1.00 0.72 (0.25-2.01) 0.55 (0.20-1.49) 0.50 0.24  -c 1.00 -d -d -d -d 
Other (Other A00-R99) 297 1.00 1.03 (0.73-1.45) 0.87 (0.62-1.22) 0.49 0.34  95 1.00 1.13 (0.62-2.03) 1.34 (0.71-2.55) 0.66 0.37 
All-cause mortality (A00-Y98) 5725 1.00 0.87 (0.81-0.95) 0.85 (0.78-0.91) < 0.001 < 0.001  2240 1.00 0.87 (0.77-0.98) 0.83 (0.73-0.94) 0.01 0.005 
Non-drinkers were excluded. Models were adjusted for age, remoteness, education, household income, health insurance status, partner status, country of birth, smoking status and dose, body 
mass index, physical activity, fruit consumption, vegetable consumption, fibre intake, red meat consumption, processed meat consumption, parity (women), menopausal status (women), 
hormone replacement therapy use (women) and height. aOverall. bLinear trend using median number of drinking-days per week of each category. cCensored due to < 5 deaths in women, or if 
this value would enable calculation of value for another cell for which there is < 5 deaths in women. dModel failed to converge. eZero deaths in cell. ICD-10, International Classification of 
Diseases, version 10. 
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Supplementary Table 5. Hazard ratios (HR) and 95% confidence intervals (CI) of cause-specific mortality risk by drinking-days per week among drinkers after excluding participants with 
disease at baseline in the 45 and Up Study (2006-2014), New South Wales, Australia. 
  HR drinking-days per week in main analysis - adjusted for total 
alcohol consumption (95% CI) 
  HR drinking-days per week after disease exclusiona - adjusted 
for total alcohol consumption (95% CI) 
Cause of death (ICD-10 code) n deaths 1-2 3-5 6-7 pb ptrendc  n deaths 1-2 3-5 6-7 pb ptrendc 
Cancer (C00-97;D45-47) 1470 1.00 0.79 (0.68-0.91) 0.73 (0.63-0.85) < 0.001 < 0.001  795 1.00 0.79 (0.64-0.96) 0.69 (0.56-0.84) 0.001 < 0.001 
- Alcohol-related (C00-15;18-20;22;32;50d) 325 1.00 0.82 (0.60-1.12) 0.82 (0.60-1.12) 0.37 0.24  157 1.00 0.98 (0.62-1.55) 0.90 (0.57-1.44) 0.89 0.64 
  - Mouth, pharynx and larynx (C00-14;32) 25 1.00 3.23 (0.83-12.6) 2.97 (0.71-12.4) 0.23 0.19  15 1.00 7.11 (0.82-61.3) 3.60 (0.37-34.9) 0.15 0.49 
  - Oesophagus (C15) 53 1.00 0.77 (0.35-1.70) 0.58 (0.26-1.26) 0.38 0.16  32 1.00 0.33 (0.10-1.10) 0.55 (0.21-1.41) 0.17 0.30 
  - Colorectum (C18-20) 129 1.00 0.79 (0.48-1.31) 0.81 (0.49-1.36) 0.62 0.44  69 1.00 1.04 (0.52-2.06) 0.95 (0.47-1.92) 0.96 0.86 
  - Liver (C22) 41 1.00 0.94 (0.35-2.49) 1.36 (0.54-3.44) 0.65 0.45  32 1.00 1.45 (0.47-4.46) 1.68 (0.54-5.23) 0.67 0.38 
  - Breast (C50d) 77 1.00 0.79 (0.43-1.45) 0.97 (0.46-2.05) 0.69 0.90  9 1.00 0.53 (0.09-3.03) 0.13 (0.01-1.76) 0.31 0.13 
- Non-alcohol-related (Other C;D45-47) 1145 1.00 0.78 (0.66-0.92) 0.71 (0.60-0.84) < 0.001 < 0.001  638 1.00 0.75 (0.60-0.94) 0.65 (0.52-0.82) 0.001 < 0.001 
  - Stomach (C16) 28 1.00 0.84 (0.28-2.47) 0.79 (0.27-2.35) 0.91 0.69  18 1.00 0.87 (0.23-3.23) 0.68 (0.18-2.62) 0.85 0.57 
  - Pancreas (C25) 91 1.00 1.27 (0.73-2.20) 0.65 (0.34-1.25) 0.048 0.15  78 1.00 1.04 (0.58-1.86) 0.57 (0.28-1.13) 0.11 0.09 
  - Lung (C33-34) 258 1.00 0.64 (0.44-0.93) 0.74 (0.52-1.06) 0.06 0.16  181 1.00 0.51 (0.32-0.80) 0.65 (0.43-0.99) 0.01 0.08 
  - Melanoma (C43) 68 1.00 0.79 (0.39-1.59) 1.00 (0.49-2.05) 0.71 0.93  25 1.00 0.63 (0.19-2.07) 0.86 (0.27-2.78) 0.73 0.86 
  - Prostate (C61) 166 1.00 0.61 (0.38-0.98) 0.90 (0.58-1.39) 0.10 0.75  44 1.00 0.54 (0.21-1.40) 0.81 (0.34-1.90) 0.44 0.73 
  - Kidney (C64) 26 1.00 0.64 (0.20-2.10) 0.91 (0.30-2.72) 0.73 0.95  15 1.00 1.31 (0.23-7.60) 1.30 (0.22-7.59) 0.95 0.81 
  - Non-Hodgkin lymphoma (C82-85) 41 1.00 1.30 (0.60-2.84) 0.56 (0.20-1.57) 0.15 0.30  17 1.00 2.78 (0.76-10.2) 1.01 (0.16-6.26) 0.16 0.85 
Diabetes (E10-14) 54 1.00 0.69 (0.33-1.47) 0.66 (0.31-1.40) 0.49 0.28  12 1.00 0.27 (0.04-1.67) 0.16 (0.03-0.87) 0.09 0.04 
Dementia (F00-03;G30) 104 1.00 1.08 (0.63-1.85) 0.84 (0.47-1.48) 0.62 0.52  41 1.00 1.05 (0.44-2.50) 0.85 (0.33-2.21) 0.90 0.74 
Cardiovascular disease (G45-46;I00-99) 1031 1.00 0.95 (0.79-1.13) 0.81 (0.68-0.97) 0.04 0.02  559 1.00 0.76 (0.60-0.98) 0.80 (0.63-1.01) 0.08 0.10 
- Ischaemic heart disease (I20-25) 501 1.00 0.88 (0.68-1.12) 0.72 (0.56-0.93) 0.04 0.01  229 1.00 0.68 (0.46-0.99) 0.68 (0.47-0.98) 0.06 0.047 
- Cerebrovascular disease (G45-46;I60-69) 240 1.00 0.95 (0.66-1.38) 0.81 (0.56-1.17) 0.47 0.24  153 1.00 0.62 (0.38-1.02) 0.76 (0.49-1.18) 0.16 0.29 
- Other cardiovascular disease (Other I) 290 1.00 1.13 (0.79-1.60) 1.02 (0.72-1.43) 0.74 0.97  177 1.00 1.13 (0.72-1.79) 1.10 (0.71-1.72) 0.86 0.71 
Respiratory system disease (J00-99) 291 1.00 1.26 (0.87-1.83) 1.47 (1.03-2.09) 0.11 0.03  224 1.00 1.48 (0.97-2.26) 1.42 (0.94-2.15) 0.16 0.14 
- Lower respiratory infection (J09-22) 44 1.00 1.27 (0.46-3.51) 1.67 (0.67-4.16) 0.53 0.26  39 1.00 1.35 (0.47-3.91) 1.36 (0.51-3.60) 0.81 0.57 
- Other respiratory system disease (Other J) 247 1.00 1.27 (0.85-1.89) 1.43 (0.97-2.11) 0.20 0.07  185 1.00 1.51 (0.95-2.40) 1.43 (0.91-2.26) 0.20 0.18 
Suicide (X60-84;Y87.0) 18 1.00 1.57 (0.39-6.32) 0.71 (0.15-3.37) 0.40 0.52  10 1.00 2.34 (0.19-28.2) 1.62 (0.13-20.3) 0.78 0.87 
All-cause mortality (A00-Y98) 7965 1.00 0.88 (0.82-0.93) 0.85 (0.80-0.90) < 0.001 < 0.001  3172 1.00 0.87 (0.78-0.96) 0.88 (0.80-0.98) 0.01 0.03 
Non-drinkers were excluded. Models were adjusted for sex, age, remoteness, education, household income, health insurance status, partner status, country of birth, smoking status and dose, 
body mass index, physical activity, fruit consumption, vegetable consumption, fibre intake, red meat consumption, processed meat consumption, parity (women), menopausal status (women), 
hormone replacement therapy use (women) and height. aParticipants who at baseline had ever had cancer were excluded from cancer analyses, ever had diabetes excluded from diabetes 
analysis, did not have good/very good/excellent memory excluded from dementia analysis, ever had heart disease or stroke excluded from cardiovascular disease analyses, ever had asthma 
excluded from respiratory system disease analyses, ever had depression excluded from suicide analysis and ever had cancer, heart disease, stroke or diabetes excluded from all-cause mortality 
analysis. bOverall. cLinear trend using median number of drinking-days per week of each category. dFemale breast cancer only. ICD-10, International Classification of Diseases, version 10. 
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Supplementary Table 6. Hazard ratios (HR) and 95% confidence intervals (CI) of cause-specific mortality risk by mean drinks per drinking-day among drinkers by sex in the 45 and Up 
Study (2006-2014), New South Wales, Australia. 
  HR mean drinks per drinking-day in men - adjusted for total 
alcohol consumption (95% CI) 
  HR mean drinks per drinking-day in women - adjusted for total 
alcohol consumption (95% CI) 
Cause of death (ICD-10 code) n deaths ≤ 2 > 2 and ≤ 4 > 4 pa ptrendb  n deaths ≤ 2 > 2 and ≤ 4 > 4 pa ptrendb 
Cancer (C00-97;D45-47) 1066 1.00 1.17 (0.99-1.37) 1.52 (1.17-1.96) 0.006 0.001  404 1.00 1.13 (0.82-1.54) 0.85 (0.42-1.70) 0.57 0.99 
- Alcohol-related (C00-15;18-20;22;32) 196 1.00 0.92 (0.62-1.34) 1.52 (0.88-2.61) 0.13 0.17  129 1.00 1.03 (0.58-1.83) 1.18 (0.38-3.68) 0.96 0.79 
  - Mouth, pharynx and larynx (C00-14;32) -c 1.00 0.88 (0.31-2.48) 0.53 (0.09-3.09) 0.77 0.49  -c 1.00 -d -d -d -d 
  - Oesophagus (C15) 45 1.00 0.50 (0.19-1.28) 2.58 (0.91-7.26) 0.01 0.10  8 1.00 3.86 (0.12-126.9) 82.3 (0.33-20716.9) 0.29 0.12 
  - Colorectum (C18-20) 94 1.00 1.07 (0.62-1.84) 1.47 (0.63-3.43) 0.65 0.39  35 1.00 0.95 (0.32-2.86) 2.75 (0.56-13.4) 0.38 0.31 
  - Liver (C22) -c 1.00 0.91 (0.36-2.28) 1.30 (0.38-4.44) 0.82 0.69  -c 1.00 0.53 (0.03-9.41) -e 0.91 0.33 
- Non-alcohol-related (Other C;D45-47) 870 1.00 1.24 (1.04-1.48) 1.53 (1.14-2.04) 0.009 0.003  275 1.00 1.16 (0.80-1.70) 0.72 (0.30-1.73) 0.42 0.84 
  - Stomach (C16) 22 1.00 1.17 (0.39-3.46) 0.81 (0.11-5.81) 0.88 0.89  6 1.00 2.83 (0.08-107.5) -e 0.85 0.77 
  - Pancreas (C25) 64 1.00 1.16 (0.60-2.21) 1.49 (0.54-4.10) 0.75 0.45  27 1.00 2.86 (0.86-9.51) -e 0.23 0.67 
  - Lung (C33-34) 183 1.00 1.58 (1.09-2.29) 1.90 (1.07-3.39) 0.04 0.02  75 1.00 1.31 (0.68-2.51) 0.80 (0.19-3.37) 0.56 0.95 
  - Melanoma (C43) 59 1.00 1.15 (0.58-2.28) 0.79 (0.20-3.08) 0.75 0.86  9 1.00 1.04 (0.06-17.4) -e 1.00 0.63 
  - Kidney (C64) 20 1.00 2.88 (0.94-8.79) 4.21 (0.83-21.2) 0.13 0.07  6 1.00 -d -d -d -d 
  - Non-Hodgkin lymphoma (C82-85) 32 1.00 1.39 (0.52-3.71) 0.78 (0.09-7.21) 0.73 0.92  9 1.00 6.14 (0.31-121.7) -e 0.49 0.62 
Diabetes (E10-14) 40 1.00 1.77 (0.77-4.06) 3.31 (1.04-10.5) 0.12 0.17  14 1.00 1.55 (0.22-11.0) -e 0.91 0.92 
Dementia (F00-03;G30) 70 1.00 0.54 (0.25-1.17) 0.51 (0.13-1.96) 0.27 0.19  34 1.00 0.61 (0.07-5.34) 2.60 (0.32-21.1) 0.59 0.59 
Cardiovascular disease (G45-46;I00-99) 740 1.00 0.86 (0.70-1.06) 1.13 (0.81-1.58) 0.10 0.72  291 1.00 1.32 (0.85-2.05) 1.08 (0.45-2.56) 0.46 0.48 
- Ischaemic heart disease (I20-25) 385 1.00 0.88 (0.66-1.17) 1.27 (0.81-1.99) 0.18 0.46  116 1.00 1.91 (1.02-3.59) 2.08 (0.70-6.14) 0.09 0.06 
- Cerebrovascular disease (G45-46;I60-69) 160 1.00 1.33 (0.86-2.06) 1.43 (0.69-2.98) 0.41 0.26  80 1.00 0.88 (0.37-2.10) 0.75 (0.14-4.01) 0.93 0.70 
- Other (Other I) 195 1.00 0.61 (0.41-0.92) 0.83 (0.44-1.57) 0.055 0.31  95 1.00 1.19 (0.49-2.84) -e 0.93 0.48 
Respiratory system disease (J00-99) 222 1.00 0.94 (0.66-1.34) 0.50 (0.25-1.00) 0.11 0.07  69 1.00 1.08 (0.47-2.48) 0.53 (0.06-4.35) 0.80 0.71 
- Lower respiratory infection (J09-22) 36 1.00 0.94 (0.38-2.34) 0.05 (0.00-1.10) 0.11 0.09  8 1.00 -d -d -d -d 
- Other respiratory system disease (Other J) 186 1.00 0.89 (0.60-1.32) 0.62 (0.30-1.29) 0.44 0.21  61 1.00 1.07 (0.45-2.57) -e 0.99 0.36 
Digestive system disease (K00-93) 73 1.00 0.76 (0.40-1.42) 0.84 (0.32-2.22) 0.69 0.65  27 1.00 1.08 (0.30-3.93) 2.67 (0.37-19.6) 0.59 0.40 
- Liver disease (K70-77) 18 1.00 0.19 (0.02-1.64) 1.68 (0.42-6.82) 0.15 0.35  6 1.00 1.51 (0.05-48.7) 21.9 (0.47-1015.8) 0.28 0.14 
- Other digestive system disease (Other K) 55 1.00 1.28 (0.59-2.75) 0.65 (0.14-3.07) 0.52 0.77  21 1.00 0.60 (0.10-3.59) 0.79 (0.03-24.8) 0.84 0.76 
External (V01-Y98) 79 1.00 1.49 (0.86-2.58) 0.79 (0.30-2.13) 0.15 0.88  28 1.00 1.44 (0.45-4.58) 1.16 (0.09-15.6) 0.82 0.72 
- Transport accident (V00-99;Y85) 18 1.00 1.01 (0.31-3.23) 0.15 (0.01-2.71) 0.33 0.25  8 1.00 2.38 (0.27-20.8) -e 0.74 0.76 
- Fall (W00-19) 16 1.00 2.04 (0.51-8.14) 4.33 (0.74-25.3) 0.26 0.10  9 1.00 2.14 (0.16-29.0) 4.51 (0.06-346.7) 0.74 0.44 
- Suicide (X60-84;Y87.0) -c 1.00 5.99 (1.38-26.1) 4.51 (0.48-42.3) 0.055 0.16  -c 1.00 -d -d -d -d 
- Other external (W20-X59;Y86;Y87.1-98) -c 1.00 0.87 (0.35-2.16) 0.22 (0.03-1.64) 0.31 0.17  -c 1.00 -d -d -d -d 
Other (Other A00-R99) 297 1.00 0.66 (0.48-0.92) 0.97 (0.58-1.61) 0.03 0.56  95 1.00 1.51 (0.76-2.99) 1.48 (0.42-5.29) 0.48 0.33 
All-cause mortality (A00-Y98) 5725 1.00 1.00 (0.93-1.07) 1.17 (1.04-1.31) 0.006 0.02  2240 1.00 1.22 (1.06-1.41) 1.34 (1.03-1.75) 0.009 0.004 
Non-drinkers were excluded. Models were adjusted for age, remoteness, education, household income, health insurance status, partner status, country of birth, smoking status and dose, body 
mass index, physical activity, fruit consumption, vegetable consumption, fibre intake, red meat consumption, processed meat consumption, parity (women), menopausal status (women), 
hormone replacement therapy use (women) and height. aOverall. bLinear trend using median number of drinks per drinking-day of each category. cCensored due to < 5 deaths in women, or if 
this value would enable calculation of value for another cell for which there is < 5 deaths in women. dModel failed to converge. eZero deaths in cell. ICD-10, International Classification of 
Diseases, version 10.
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Supplementary Table 7. Hazard ratios (HR) and 95% confidence intervals (CI) of cause-specific mortality risk by mean drinks per drinking-day among drinkers after excluding participants 
with disease at baseline in the 45 and Up Study (2006-2014), New South Wales, Australia. 
  HR mean drinks per drinking-day in main analysis - adjusted for 
total alcohol consumption (95% CI) 
  HR mean drinks per drinking-day after disease exclusiona - 
adjusted for total alcohol consumption (95% CI) 
Cause of death (ICD-10 code) n deaths ≤ 2 > 2 and ≤ 4 > 4 pb ptrendc  n deaths ≤ 2 > 2 and ≤ 4 > 4 pb ptrendc 
Cancer (C00-97;D45-47) 1470 1.00 1.16 (1.00-1.33) 1.38 (1.09-1.33) 0.02 0.006  795 1.00 1.21 (1.00-1.47) 1.52 (1.12-2.06) 0.02 0.006 
- Alcohol-related (C00-15;18-20;22;32;50d) 325 1.00 0.91 (0.66-1.24) 1.42 (0.88-2.30) 0.13 0.24  157 1.00 0.87 (0.56-1.34) 1.43 (0.76-2.66) 0.23 0.34 
  - Mouth, pharynx and larynx (C00-14;32) 25 1.00 0.84 (0.31-2.29) 0.43 (0.31-2.29) 0.63 0.35  15 1.00 2.06 (0.57-7.50) 0.87 (0.11-6.88) 0.37 0.94 
  - Oesophagus (C15) 53 1.00 0.66 (0.28-1.53) 2.86 (1.08-7.56) 0.01 0.047  32 1.00 0.69 (0.22-2.24) 4.50 (1.49-13.6) 0.004 0.006 
  - Colorectum (C18-20) 129 1.00 1.07 (0.66-1.74) 1.60 (0.75-3.40) 0.44 0.25  69 1.00 0.73 (0.36-1.48) 1.03 (0.35-3.10) 0.60 0.90 
  - Liver (C22) 41 1.00 1.02 (0.44-2.34) 1.27 (0.38-4.27) 0.91 0.71  32 1.00 0.97 (0.38-2.49) 0.93 (0.23-3.82) 0.99 0.92 
  - Breast (C50d) 77 1.00 1.07 (0.50-2.29) -e 0.98 0.47  9 1.00 0.44 (0.03-6.46) -e 0.83 0.42 
- Non-alcohol-related (Other C;D45-47) 1145 1.00 1.24 (1.05-1.45) 1.37 (1.05-1.80) 0.02 0.01  638 1.00 1.34 (1.08-1.65) 1.57 (1.11-2.23) 0.01 0.006 
  - Stomach (C16) 28 1.00 1.16 (0.75-1.52) 0.81 (0.12-5.33) 0.88 0.90  18 1.00 1.13 (0.33-3.93) 0.77 (0.08-7.41) 0.92 0.88 
  - Pancreas (C25) 91 1.00 1.37 (0.78-2.40) 1.60 (0.63-4.06) 0.49 0.28  78 1.00 1.26 (0.68-2.34) 1.54 (0.57-4.15) 0.66 0.37 
  - Lung (C33-34) 258 1.00 1.51 (1.10-2.08) 1.66 (0.98-2.80) 0.03 0.04  181 1.00 1.47 (1.01-2.16) 1.99 (1.09-3.64) 0.054 0.02 
  - Melanoma (C43) 68 1.00 1.10 (0.57-2.12) 0.73 (0.20-2.73) 0.74 0.76  25 1.00 0.68 (0.22-2.12) 0.42 (0.04-4.05) 0.71 0.42 
  - Prostate (C61) 166 1.00 1.06 (0.69-1.62) 1.13 (0.53-2.40) 0.95 0.74  44 1.00 1.62 (0.74-3.55) 0.85 (0.17-4.42) 0.31 0.85 
  - Kidney (C64) 26 1.00 2.56 (0.94-6.98) 3.62 (0.76-17.2) 0.14 0.08  15 1.00 5.85 (1.41-24.2) 8.68 (1.24-61.0) 0.04 0.03 
  - Non-Hodgkin lymphoma (C82-85) 41 1.00 1.60 (0.65-3.94) 0.86 (0.10-7.31) 0.55 0.71  17 1.00 1.82 (0.38-8.81) 2.17 (0.22-21.0) 0.67 0.41 
Diabetes (E10-14) 54 1.00 1.56 (0.74-3.27) 2.60 (0.88-7.67) 0.20 0.08  12 1.00 1.58 (0.29-8.71) 0.67 (0.02-30.4) 0.71 0.99 
Dementia (F00-03;G30) 104 1.00 0.63 (0.31-1.29) 0.81 (0.27-2.45) 0.45 0.47  41 1.00 0.88 (0.29-2.66) 0.55 (0.06-5.39) 0.87 0.61 
Cardiovascular disease (G45-46;I00-99) 1031 1.00 0.92 (0.76-1.10) 1.17 (0.86-1.59) 0.18 0.51  559 1.00 0.97 (0.76-1.24) 1.11 (0.74-1.66) 0.77 0.70 
- Ischaemic heart disease (I20-25) 501 1.00 0.99 (0.76-1.29) 1.39 (0.92-2.10) 0.20 0.18  229 1.00 1.01 (0.69-1.46) 1.20 (0.65-2.20) 0.82 0.60 
- Cerebrovascular disease (G45-46;I60-69) 240 1.00 1.18 (0.80-1.74) 1.21 (0.62-2.38) 0.69 0.49  153 1.00 1.31 (0.83-2.08) 1.18 (0.52-2.67) 0.51 0.53 
- Other (Other I) 290 1.00 0.65 (0.45-0.94) 0.83 (0.46-1.50) 0.06 0.27  177 1.00 0.69 (0.43-1.10) 0.93 (0.45-1.92) 0.25 0.60 
Respiratory system disease (J00-99) 291 1.00 0.95 (0.69-1.32) 0.54 (0.28-1.03) 0.13 0.09  224 1.00 0.95 (0.66-1.37) 0.48 (0.22-1.01) 0.11 0.08 
- Lower respiratory infection (J09-22) 44 1.00 1.19 (0.52-2.72) 0.29 (0.04-2.17) 0.28 0.38  39 1.00 1.32 (0.55-3.17) 0.30 (0.04-2.46) 0.24 0.46 
- Other respiratory system disease (Other J) 247 1.00 0.90 (0.63-1.29) 0.59 (0.29-1.17) 0.31 0.15  185 1.00 0.88 (0.58-1.32) 0.51 (0.23-1.14) 0.25 0.12 
Suicide (X60-84;Y87.0) 18 1.00 3.74 (1.13-12.4) 3.05 (0.39-23.7) 0.09 0.20  10 1.00 7.92 (1.12-56.0) 5.60 (0.29-109) 0.11 0.25 
All-cause mortality (A00-Y98) 7965 1.00 1.04 (0.97-1.10) 1.21 (1.08-1.34) 0.002 0.001  3172 1.00 1.01 (0.92-1.12) 1.03 (0.87-1.22) 0.93 0.71 
Non-drinkers were excluded. Models were adjusted for sex, age, remoteness, education, household income, health insurance status, partner status, country of birth, smoking status and dose, 
body mass index, physical activity, fruit consumption, vegetable consumption, fibre intake, red meat consumption, processed meat consumption, parity (women), menopausal status (women), 
hormone replacement therapy use (women) and height. aParticipants who at baseline had ever had cancer were excluded from cancer analyses, ever had diabetes excluded from diabetes 
analysis, did not have good/very good/excellent memory excluded from dementia analysis, ever had heart disease or stroke excluded from cardiovascular disease analyses, ever had asthma 
excluded from respiratory system disease analyses, ever had depression excluded from suicide analysis and ever had cancer, heart disease, stroke or diabetes excluded from all-cause mortality 
analysis. bOverall. cLinear trend using median number of drinks per drinking-day of each category. dFemale breast cancer only. eZero deaths in cell. ICD-10, International Classification of 
Diseases, version 10. 
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9.2 – Additional Analyses 
 
Additional research questions regarding the relationship between alcohol consumption and 
mortality reported in the main analysis are reported here. The first set of analyses addressed the 
potential impact of the ‘sick-quitter effect’ and other biases on the main results. The second set used 
the mortality-specific risk estimates to calculate the population attributable fraction (PAF) of alcohol 
for the Australia, cumulative absolute risk of mortality, and the number of persons needed to quit or 
reduce drinking to prevent one death. 
1. The impact of the ‘sick-quitter effect’ and other changes in drinking behaviours in response to 
ill-health on risk estimates. 
Rationale and methods. A number of promising methods for mitigating bias from the ‘sick-quitter 
effect’ (and other changes in drinking behaviour) were identified in Chapter 7. Based on these 
findings, there are several exclusion scenarios that would be expected to decrease bias from the 
‘sick-quitter effect’ in the mortality main analysis: exclusion of participants with a physical 
functioning score < 50%, exclusion of participants that consumed < 7 drinks per week, exclusion of 
deaths within five years of baseline (rather than three years as in the main analysis), exclusion of 
participants with prior disease (as this was performed in the article) and exclusion of participants 
aged ≥ 65 years at baseline. For analyses aimed at identifying a linear trend between alcohol and 
risk, methods that would be expected to increase bias from the ‘sick-quitter effect’ would be the 
inclusion of non-drinkers in the calculation and the inclusion of deaths within three years of baseline. 
As some of these exclusion scenarios include a large proportion of cases, these analyses were only 
investigated for all-cause mortality. 
Fully adjusted HRs and 95% CIs for risk of all-cause mortality were estimated from Cox Proportional 
Hazards models (as per the main results) under each ‘exclusion scenario’ noted above, and directly 
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compared with the main results. These models were conducted for total alcohol consumption as a 
log-linear variable. 
Mortality-specific HRs and 95% CIs were then calculated for total alcohol consumption, drinking 
frequency, and drinks per drinking-day after exclusion of participants with a physical functioning 
score < 50%. Overall drinking pattern, incorporating both number of drinking-days and number of 
drinks per drinking-day was assessed for all-cause mortality. The low physical functioning score 
exclusion scenario was selected for these more detailed analyses based on the conclusion in Chapter 
7 that it was likely the most effective exclusion scenario examined to assess bias from the ‘sick-
quitter effect’. 
For the continuous log-linear analysis estimating the increase in risk per additional drink/day, 
sensitivity tests excluding participants with prior disease (as this exclusion was performed for most 
results in the article), excluding participants with a physical functioning score < 50% and restricting 
the calculation to participants consuming ≥ 7 drinks per week (as this exclusion was intended to be 
applied to the log-linear analysis specifically) were performed. 
Results. The log-linear association between alcohol consumption and risk of all-cause mortality was 
slightly altered under each exclusion scenario (Figure 9.1). Specifically, when non-drinkers were 
included in the calculation, the association between alcohol and mortality was not significant, and 
the HR was significantly lower than the main analysis (the confidence intervals did not overlap). 
Further, lower mortality HRs were observed when deaths within the first three years of follow-up 
were included in the calculation and separately, when participants aged ≥ 65 years were excluded.  
The remaining exclusion scenarios resulted in slightly higher risk estimates, however the confidence 
intervals overlapped with the main analysis. 
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Figure 9.1. Hazard ratios (HR) and 95% confidence intervals (CI) of all-cause mortality risk per one 
drink increase in mean daily alcohol consumption among drinkers by different exclusion scenarios 
in the 45 and Up Study (2006-2014), New South Wales, Australia. Non-drinkers were excluded. 
Models were adjusted for sex, age, remoteness, education, household income, health insurance 
status, partner status, country of birth, smoking status and dose, body mass index, physical 
activity, fruit consumption, vegetable consumption, fibre intake, red meat consumption, processed 
meat consumption, parity (women), menopausal status (women), hormone replacement therapy 
use (women) and height. Prior disease refers to cancer, cardiovascular disease and diabetes. 
 
The sensitivity analyses excluding participants with a low physical functioning score resulted in 
several risk estimates that differed from the main results and are presented in Tables 9.1-9.4. For 
categorical total alcohol consumption, there were significant trends of increased risk for death from 
liver cancer and other causes combined, and of decreased risk for death from breast cancer and 
dementia (Table 9.1). The trends for death from prostate cancer, non-Hodgkin lymphoma, external 
causes and suicide were non-significant, however there were no clear differences in hazard ratios 
compared to the main analysis. For drinking-days per week, the inverse associations of drinking 
frequency with death from cardiovascular disease and ischaemic heart disease were non-significant 
however the hazard ratios were not materially different compared to the main analysis (Table 9.2). 
There was also an inverse association for death from oesophageal cancer. There were no other 
changes in results.  
For mean drinks per drinking-day, significant trends of increased risk of death from cardiovascular 
disease and fall were detected (Table 9.3). The associations for death from cancer, non-alcohol-
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related cancer and lung cancer were non-significant, however there were no clear differences in 
hazard ratios compared to the main analysis. There was also evidence of higher risk in those 
consuming > 4 compared to > 2 and ≤ 4 drinks per drinking-day for death from cardiovascular 
disease. For the overall drinking pattern sensitivity analysis, the results were similar to the main 
analysis (Table 9.4). 
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Table 9.1. Hazard ratios and 95% confidence intervals of cause-specific mortality risk by alcohol consumption after excluding participants with physical functioning score < 50% at baseline 
in the 45 and Up Study (2006-2014), New South Wales, Australia. 
  Drinks/week   
Cause of death (ICD-10 code) n deaths Non-drinkera ≥ 1 and ≤ 3.5 > 3.5 and ≤ 7 > 7 and ≤ 14 > 14 and ≤ 28 > 28 pb ptrendc 
Cancer (C00-97;D45-47) 1556 0.99 (0.84-1.16) 1.00 0.83 (0.70-0.99) 0.85 (0.71-1.01) 0.90 (0.74-1.10) 0.95 (0.73-1.24) 0.13 0.73 
- Alcohol-related (C00-15;18-20;22;32;50d) 355 0.83 (0.60-1.13) 1.00 0.64 (0.45-0.93) 0.77 (0.53-1.10) 0.79 (0.52-1.21) 1.31 (0.79-2.17) 0.06 0.08 
  - Mouth, pharynx and larynx (C00-14;32) 28 0.84 (0.24-2.87) 1.00 -e 1.19 (0.34-4.17) 1.21 (0.33-4.44) 1.02 (0.21-4.89) 0.99 0.35 
  - Oesophagus (C15) 52 1.45 (0.56-3.74) 1.00 1.15 (0.41-3.19) 0.99 (0.35-2.82) 0.55 (0.15-2.00) 2.01 (0.61-6.55) 0.42 0.44 
  - Colorectum (C18-20) 139 0.93 (0.54-1.58) 1.00 0.75 (0.41-1.37) 0.86 (0.47-1.58) 1.14 (0.59-2.19) 1.40 (0.62-3.19) 0.66 0.12 
  - Liver (C22) 38 1.41 (0.39-5.18) 1.00 1.34 (0.33-5.39) 2.27 (0.60-8.50) 1.59 (0.34-7.36) 4.87 (1.08-21.8) 0.27 0.04 
  - Breast (C50d) 98 0.58 (0.35-0.96) 1.00 0.50 (0.27-0.91) 0.41 (0.20-0.83) 0.45 (0.16-1.32) -e 0.10 0.04 
- Non-alcohol-related (Other C;D45-47) 1201 1.05 (0.87-1.26) 1.00 0.90 (0.73-1.10) 0.88 (0.71-1.08) 0.94 (0.75-1.18) 0.86 (0.63-1.18) 0.30 0.62 
  - Stomach (C16) 32 1.14 (0.35-3.70) 1.00 1.41 (0.42-4.71) 0.67 (0.16-2.70) 0.89 (0.21-3.70) 0.91 (0.16-5.34) 0.90 0.94 
  - Pancreas (C25) 109 1.35 (0.69-2.64) 1.00 1.27 (0.63-2.58) 1.47 (0.73-2.97) 1.32 (0.59-2.91) 1.03 (0.32-3.30) 0.92 0.91 
  - Lung (C33-34) 266 1.44 (0.92-2.24) 1.00 1.11 (0.69-1.81) 1.08 (0.67-1.75) 1.38 (0.84-2.27) 1.03 (0.54-1.98) 0.37 0.59 
  - Melanoma (C43) 76 0.62 (0.31-1.22) 1.00 0.50 (0.24-1.03) 0.41 (0.19-0.90) 0.80 (0.38-1.67) 0.28 (0.06-1.27) 0.15 0.34 
  - Prostate (C61) 146 0.55 (0.33-0.92) 1.00 0.68 (0.41-1.12) 0.50 (0.29-0.87) 0.59 (0.33-1.06) 0.61 (0.27-1.37) 0.16 0.20 
  - Kidney (C64) 28 2.47 (0.54-11.3) 1.00 1.65 (0.32-8.54) 2.16 (0.43-10.9) 1.01 (0.14-7.44) 3.22 (0.43-24.4) 0.71 0.68 
  - Non-Hodgkin lymphoma (C82-85) 51 0.93 (0.42-2.09) 1.00 0.66 (0.26-1.66) 0.74 (0.29-1.88) 0.65 (0.21-2.01) -e 0.93 0.19 
Diabetes (E10-14) 35 1.79 (0.57-5.64) 1.00 1.42 (0.40-4.97) 1.63 (0.46-5.74) 0.75 (0.13-4.24) 0.79 (0.08-7.43) 0.80 0.74 
Dementia (F00-03;G30) 90 0.96 (0.51-1.81) 1.00 0.93 (0.47-1.84) 0.89 (0.42-1.87) 0.25 (0.06-1.10) -e 0.62 0.04 
Cardiovascular disease (G45-46;I00-99) 815 1.05 (0.84-1.30) 1.00 0.92 (0.72-1.18) 0.94 (0.73-1.21) 0.90 (0.66-1.21) 1.08 (0.72-1.61) 0.75 0.85 
- Ischaemic heart disease (I20-25) 405 1.10 (0.80-1.51) 1.00 1.02 (0.72-1.43) 0.92 (0.64-1.32) 0.84 (0.55-1.29) 1.04 (0.61-1.79) 0.76 0.51 
- Cerebrovascular disease (G45-46;I60-69) 196 1.00 (0.64-1.56) 1.00 0.86 (0.52-1.42) 0.92 (0.54-1.57) 1.22 (0.68-2.19) 0.85 (0.32-2.25) 0.87 0.43 
- Other cardiovascular disease (Other I) 214 0.98 (0.65-1.50) 1.00 0.82 (0.51-1.31) 0.98 (0.61-1.59) 0.76 (0.41-1.40) 1.28 (0.60-2.77) 0.75 0.64 
Respiratory system disease (J00-99) 186 1.62 (0.96-2.73) 1.00 1.27 (0.72-2.25) 1.27 (0.70-2.29) 1.53 (0.81-2.91) 1.49 (0.63-3.51) 0.53 0.24 
- Lower respiratory infection (J09-22) 28 0.81 (0.27-2.45) 1.00 0.38 (0.09-1.63) 0.93 (0.26-3.33) 0.89 (0.19-4.12) 0.72 (0.07-7.57) 0.84 0.84 
- Other respiratory system disease (Other J) 158 1.93 (1.05-3.55) 1.00 1.62 (0.85-3.09) 1.43 (0.72-2.82) 1.73 (0.84-3.55) 1.69 (0.66-4.35) 0.41 0.33 
Digestive system disease (K00-93) 90 1.89 (0.87-4.12) 1.00 1.40 (0.59-3.30) 1.14 (0.45-2.87) 1.68 (0.64-4.37) 3.34 (1.19-9.35) 0.15 0.04 
- Liver disease (K70-77) 24 1.95 (0.41-9.38) 1.00 0.80 (0.11-5.72) 0.79 (0.11-5.67) 1.70 (0.27-10.6) 7.65 (1.46-40.2) 0.02 < 0.001 
- Other digestive system disease (Other K) 66 1.84 (0.75-4.52) 1.00 1.52 (0.57-4.04) 1.21 (0.42-3.47) 1.56 (0.51-4.80) 0.70 (0.08-5.98) 0.72 0.82 
External (V01-Y98) 109 1.74 (0.89-3.42) 1.00 1.01 (0.47-2.19) 1.35 (0.64-2.85) 1.74 (0.78-3.86) 1.69 (0.60-4.73) 0.35 0.15 
- Transport accident (V00-99;Y85) 32 0.80 (0.25-2.52) 1.00 0.45 (0.11-1.88) 1.29 (0.41-4.02) 1.66 (0.50-5.53) 0.63 (0.07-5.72) 0.49 0.47 
- Fall (W00-19) 16 2.79 (0.32-24.3) 1.00 1.02 (0.09-11.9) 1.81 (0.17-18.9) 1.25 (0.07-21.4) 11.1 (0.87-140.8) 0.26 0.04 
- Suicide (X60-84;Y87.0) 23 -f 1.00 -f -f -f -f 0.55 0.18 
- Other external (W20-X59;Y86;Y87.1-98) 38 1.16 (0.41-3.26) 1.00 1.29 (0.43-3.89) 0.49 (0.12-2.08) 1.18 (0.31-4.59) 1.42 (0.25-7.88) 0.79 0.89 
Other (Other A00-R99) 305 1.08 (0.74-1.59) 1.00 1.09 (0.72-1.64) 1.20 (0.79-1.82) 1.04 (0.64-1.70) 1.98 (1.14-3.43) 0.20 0.04 
All-cause mortality (A00-Y98) 7401 1.12 (1.04-1.21) 1.00 0.96 (0.89-1.05) 0.99 (0.91-1.08) 0.98 (0.89-1.08) 1.19 (1.05-1.34) < 0.001 0.008 
Models were adjusted for sex, age, remoteness, education, household income, health insurance status, partner status, country of birth, smoking status and dose, body mass index, physical 
activity, fruit consumption, vegetable consumption, fibre intake, red meat consumption, processed meat consumption, parity (women), menopausal status (women), hormone replacement 
therapy use (women) and height. a< 1 drink per week. bOverall. cLinear trend using median alcohol consumption of each category, excluding non-drinkers. dFemale breast cancer only. eZero 
deaths in cell. fNot possible to calculate due to zero deaths in reference group. ICD-10, International Classification of Diseases, version 10. 
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Table 9.2. Hazard ratios (HR) and 95% confidence intervals (CI) of cause-specific mortality risk after excluding participants with physical functioning score < 50% by drinking-days per week 
among drinkers in the 45 and Up Study (2006-2014), New South Wales, Australia. 
  HR drinking-days per week in main analysis - adjusted for total 
alcohol consumption (95% CI) 
  HR drinking-days per week in sensitivity analysisa - adjusted for 
total alcohol consumption (95% CI) 
Cause of death (ICD-10 code) n deaths 1-2 3-5 6-7 pb ptrendc  n deaths 1-2 3-5 6-7 pb ptrendc 
Cancer (C00-97;D45-47) 1470 1.00 0.79 (0.68-0.91) 0.73 (0.63-0.85) < 0.001 < 0.001  1032 1.00 0.77 (0.64-0.91) 0.71 (0.59-0.86) < 0.001 < 0.001 
- Alcohol-related (C00-15;18-20;22;32;50d) 325 1.00 0.82 (0.60-1.12) 0.82 (0.60-1.12) 0.37 0.24  232 1.00 0.70 (0.49-1.01) 0.69 (0.48-1.01) 0.10 0.07 
  - Mouth, pharynx and larynx (C00-14;32) 25 1.00 3.23 (0.83-12.6) 2.97 (0.71-12.4) 0.23 0.19  20 1.00 3.64 (0.72-18.5) 2.62 (0.47-14.7) 0.29 0.42 
  - Oesophagus (C15) 53 1.00 0.77 (0.35-1.70) 0.58 (0.26-1.26) 0.38 0.16  35 1.00 0.42 (0.16-1.14) 0.37 (0.14-0.95) 0.09 0.049 
  - Colorectum (C18-20) 129 1.00 0.79 (0.48-1.31) 0.81 (0.49-1.36) 0.62 0.44  92 1.00 0.78 (0.42-1.43) 0.83 (0.45-1.53) 0.71 0.61 
  - Liver (C22) 41 1.00 0.94 (0.35-2.49) 1.36 (0.54-3.44) 0.65 0.45  26 1.00 0.78 (0.22-2.76) 1.29 (0.40-4.11) 0.65 0.56 
  - Breast (C50d) 77 1.00 0.79 (0.43-1.45) 0.97 (0.46-2.05) 0.69 0.90  59 1.00 0.71 (0.36-1.40) 0.77 (0.32-1.89) 0.61 0.52 
- Non-alcohol-related (Other C;D45-47) 1145 1.00 0.78 (0.66-0.92) 0.71 (0.60-0.84) < 0.001 < 0.001  800 1.00 0.79 (0.65-0.96) 0.72 (0.59-0.89) 0.007 0.003 
  - Stomach (C16) 28 1.00 0.84 (0.28-2.47) 0.79 (0.27-2.35) 0.91 0.69  19 1.00 1.06 (0.28-4.02) 0.65 (0.16-2.71) 0.69 0.49 
  - Pancreas (C25) 91 1.00 1.27 (0.73-2.20) 0.65 (0.34-1.25) 0.048 0.15  74 1.00 1.30 (0.69-2.45) 0.76 (0.36-1.57) 0.18 0.35 
  - Lung (C33-34) 258 1.00 0.64 (0.44-0.93) 0.74 (0.52-1.06) 0.06 0.16  176 1.00 0.58 (0.36-0.92) 0.79 (0.51-1.22) 0.07 0.45 
  - Melanoma (C43) 68 1.00 0.79 (0.39-1.59) 1.00 (0.49-2.05) 0.71 0.93  57 1.00 0.71 (0.34-1.50) 0.79 (0.36-1.73) 0.67 0.58 
  - Prostate (C61) 166 1.00 0.61 (0.38-0.98) 0.90 (0.58-1.39) 0.10 0.75  110 1.00 0.52 (0.29-0.92) 0.72 (0.42-1.24) 0.08 0.31 
  - Kidney (C64) 26 1.00 0.64 (0.20-2.10) 0.91 (0.30-2.72) 0.73 0.95  16 1.00 1.02 (0.25-4.13) 0.65 (0.14-3.08) 0.78 0.56 
  - Non-Hodgkin lymphoma (C82-85) 41 1.00 1.30 (0.60-2.84) 0.56 (0.20-1.57) 0.15 0.30  32 1.00 1.36 (0.55-3.37) 0.58 (0.18-1.84) 0.20 0.35 
Diabetes (E10-14) 54 1.00 0.69 (0.33-1.47) 0.66 (0.31-1.40) 0.49 0.28  21 1.00 0.75 (0.23-2.37) 0.57 (0.15-2.08) 0.69 0.39 
Dementia (F00-03;G30) 104 1.00 1.08 (0.63-1.85) 0.84 (0.47-1.48) 0.62 0.52  48 1.00 0.82 (0.35-1.90) 0.96 (0.41-2.26) 0.88 0.94 
Cardiovascular disease (G45-46;I00-99) 1031 1.00 0.95 (0.79-1.13) 0.81 (0.68-0.97) 0.04 0.02  506 1.00 1.05 (0.81-1.35) 0.82 (0.63-1.06) 0.08 0.09 
- Ischaemic heart disease (I20-25) 501 1.00 0.88 (0.68-1.12) 0.72 (0.56-0.93) 0.04 0.01  256 1.00 1.02 (0.72-1.45) 0.75 (0.52-1.09) 0.15 0.11 
- Cerebrovascular disease (G45-46;I60-69) 240 1.00 0.95 (0.66-1.38) 0.81 (0.56-1.17) 0.47 0.24  117 1.00 0.89 (0.51-1.53) 0.90 (0.52-1.56) 0.90 0.74 
- Other cardiovascular disease (Other I) 290 1.00 1.13 (0.79-1.60) 1.02 (0.72-1.43) 0.74 0.97  133 1.00 1.27 (0.77-2.12) 0.88 (0.51-1.49) 0.23 0.46 
Respiratory system disease (J00-99) 291 1.00 1.26 (0.87-1.83) 1.47 (1.03-2.09) 0.11 0.03  112 1.00 1.39 (0.71-2.70) 1.85 (0.99-3.46) 0.71 0.047 
- Lower respiratory infection (J09-22) 44 1.00 1.27 (0.46-3.51) 1.67 (0.67-4.16) 0.53 0.26  17 1.00 1.94 (0.26-14.4) 1.89 (0.30-11.7) 0.77 0.55 
- Other respiratory system disease (Other J) 247 1.00 1.27 (0.85-1.89) 1.43 (0.97-2.11) 0.20 0.07  95 1.00 1.39 (0.68-2.84) 1.83 (0.93-3.60) 0.20 0.07 
Digestive system disease (K00-93) 100 1.00 1.02 (0.55-1.89) 1.07 (0.60-1.93) 0.97 0.81  53 1.00 0.63 (0.26-1.52) 0.85 (0.39-1.90) 0.57 0.84 
- Liver disease (K70-77) 24 1.00 0.40 (0.11-1.41) 0.62 (0.19-1.99) 0.36 0.49  16 1.00 0.19 (0.04-1.03) 0.30 (0.07-1.28) 0.11 0.14 
- Other digestive system disease (Other K) 76 1.00 1.50 (0.73-3.11) 1.56 (0.76-3.19) 0.44 0.26  37 1.00 1.22 (0.41-3.65) 1.94 (0.68-5.55) 0.39 0.18 
External (V01-Y98) 107 1.00 0.82 (0.46-1.46) 1.05 (0.60-1.82) 0.62 0.77  65 1.00 0.73 (0.35-1.50) 0.98 (0.48-2.03) 0.59 0.95 
- Transport accident (V00-99;Y85) 26 1.00 0.54 (0.15-1.93) 1.76 (0.57-5.49) 0.14 0.25  24 1.00 0.49 (0.14-1.76) 1.34 (0.42-4.30) 0.26 0.55 
- Fall (W00-19) 25 1.00 1.44 (0.30-6.83) 2.88 (0.73-11.4) 0.23 0.09  8 1.00 -e -e 0.94 0.17 
- Suicide (X60-84;Y87.0) 18 1.00 1.57 (0.39-6.32) 0.71 (0.15-3.37) 0.40 0.52  10 1.00 1.26 (0.21-7.51) 0.50 (0.06-4.04) 0.54 0.45 
- Other external (W20-X59;Y86;Y87.1-98) 38 1.00 0.62 (0.24-1.59) 0.55 (0.23-1.32) 0.38 0.19  23 1.00 0.56 (0.17-1.86) 0.51 (0.15-1.69) 0.50 0.28 
Other (Other A00-R99) 392 1.00 1.02 (0.76-1.37) 0.92 (0.69-1.23) 0.71 0.52  205 1.00 1.42 (0.92-2.19) 1.13 (0.72-1.76) 0.21 0.86 
All-cause mortality (A00-Y98) 7965 1.00 0.88 (0.82-0.93) 0.85 (0.80-0.90) < 0.001 < 0.001  4760 1.00 0.85 (0.78-0.93) 0.84 (0.77-0.91) < 0.001 < 0.001 
Non-drinkers were excluded. Models were adjusted for sex, age, remoteness, education, household income, health insurance status, partner status, country of birth, smoking status and dose, 
body mass index, physical activity, fruit consumption, vegetable consumption, fibre intake, red meat consumption, processed meat consumption, parity (women), menopausal status (women), 
hormone replacement therapy use (women) and height. aParticipants with physical functioning score < 50% excluded. bOverall. cLinear trend using median number of drinking-days per week of 
each category. dFemale breast cancer only. eNot possible to calculate due to zero deaths in reference group. ICD-10, International Classification of Diseases, version 10. 
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Table 9.3. Hazard ratios (HR) and 95% confidence intervals (CI) of cause-specific mortality risk after excluding participants with physical functioning score < 50% by mean drinks per 
drinking-day among drinkers in the 45 and Up Study (2006-2014), New South Wales, Australia. 
  HR mean drinks per drinking-day in main analysis - adjusted for 
total alcohol consumption (95% CI) 
  HR mean drinks per drinking-day in sensitivity analysisa - adjusted 
for total alcohol consumption (95% CI) 
Cause of death (ICD-10 code) n deaths ≤ 2 > 2 and ≤ 4 > 4 pb ptrendc  n deaths ≤ 2 > 2 and ≤ 4 > 4 pb ptrendc 
Cancer (C00-97;D45-47) 1470 1.00 1.16 (1.00-1.33) 1.38 (1.09-1.33) 0.02 0.006  1032 1.00 1.16 (0.98-1.37) 1.28 (0.96-1.71) 0.16 0.07 
- Alcohol-related (C00-15;18-20;22;32;50d) 325 1.00 0.91 (0.66-1.24) 1.42 (0.88-2.30) 0.13 0.24  232 1.00 0.84 (0.58-1.22) 1.49 (0.85-2.64) 0.08 0.29 
  - Mouth, pharynx and larynx (C00-14;32) 25 1.00 0.84 (0.31-2.29) 0.43 (0.31-2.29) 0.63 0.35  20 1.00 1.42 (0.48-4.24) 0.86 (0.14-5.15) 0.69 0.92 
  - Oesophagus (C15) 53 1.00 0.66 (0.28-1.53) 2.86 (1.08-7.56) 0.01 0.047  35 1.00 0.49 (0.15-1.53) 3.89 (1.20-12.6) 0.005 0.03 
  - Colorectum (C18-20) 129 1.00 1.07 (0.66-1.74) 1.60 (0.75-3.40) 0.44 0.25  92 1.00 0.80 (0.45-1.44) 1.07 (0.42-2.74) 0.65 0.98 
  - Liver (C22) 41 1.00 1.02 (0.44-2.34) 1.27 (0.38-4.27) 0.91 0.71  26 1.00 1.03 (0.35-2.99) 1.66 (0.41-6.81) 0.74 0.49 
  - Breast (C50d) 77 1.00 1.07 (0.50-2.29) -e 0.98 0.47  59 1.00 1.20 (0.52-2.77) -e 0.91 0.77 
- Non-alcohol-related (Other C;D45-47) 1145 1.00 1.24 (1.05-1.45) 1.37 (1.05-1.80) 0.02 0.01  800 1.00 1.26 (1.04-1.52) 1.23 (0.88-1.72) 0.06 0.12 
  - Stomach (C16) 28 1.00 1.16 (0.75-1.52) 0.81 (0.12-5.33) 0.88 0.90  19 1.00 1.36 (0.41-4.51) 1.32 (0.17-10.6) 0.88 0.75 
  - Pancreas (C25) 91 1.00 1.37 (0.78-2.40) 1.60 (0.63-4.06) 0.49 0.28  74 1.00 1.08 (0.58-2.01) 1.11 (0.38-3.28) 0.97 0.83 
  - Lung (C33-34) 258 1.00 1.51 (1.10-2.08) 1.66 (0.98-2.80) 0.03 0.04  176 1.00 1.59 (1.08-2.34) 1.38 (0.70-2.72) 0.055 0.22 
  - Melanoma (C43) 68 1.00 1.10 (0.57-2.12) 0.73 (0.20-2.73) 0.74 0.76  57 1.00 1.37 (0.68-2.74) 0.86 (0.21-3.59) 0.50 0.93 
  - Prostate (C61) 166 1.00 1.06 (0.69-1.62) 1.13 (0.53-2.40) 0.95 0.74  110 1.00 1.45 (0.88-2.38) 1.44 (0.59-3.51) 0.34 0.29 
  - Kidney (C64) 26 1.00 2.56 (0.94-6.98) 3.62 (0.76-17.2) 0.14 0.08  16 1.00 3.27 (0.90-11.9) 4.05 (0.48-34.3) 0.19 0.15 
  - Non-Hodgkin lymphoma (C82-85) 41 1.00 1.60 (0.65-3.94) 0.86 (0.10-7.31) 0.55 0.71  32 1.00 1.99 (0.76-5.22) 1.17 (0.12-11.1) 0.36 0.47 
Diabetes (E10-14) 54 1.00 1.56 (0.74-3.27) 2.60 (0.88-7.67) 0.20 0.08  21 1.00 1.22 (0.38-3.91) 1.11 (0.13-9.77) 0.94 0.86 
Dementia (F00-03;G30) 104 1.00 0.63 (0.31-1.29) 0.81 (0.27-2.45) 0.45 0.47  48 1.00 0.64 (0.21-1.93) 0.46 (0.05-4.55) 0.66 0.39 
Cardiovascular disease (G45-46;I00-99) 1031 1.00 0.92 (0.76-1.10) 1.17 (0.86-1.59) 0.18 0.51  506 1.00 0.90 (0.70-1.18) 1.69 (1.12-2.54) 0.004 0.04 
- Ischaemic heart disease (I20-25) 501 1.00 0.99 (0.76-1.29) 1.39 (0.92-2.10) 0.20 0.18  256 1.00 0.80 (0.55-1.15) 1.71 (0.99-2.95) 0.01 0.15 
- Cerebrovascular disease (G45-46;I60-69) 240 1.00 1.18 (0.80-1.74) 1.21 (0.62-2.38) 0.69 0.49  117 1.00 1.24 (0.73-2.12) 1.12 (0.40-3.09) 0.72 0.69 
- Other (Other I) 290 1.00 0.65 (0.45-0.94) 0.83 (0.46-1.50) 0.06 0.27  133 1.00 0.82 (0.48-1.41) 2.04 (0.93-4.48) 0.0497 0.16 
Respiratory system disease (J00-99) 291 1.00 0.95 (0.69-1.32) 0.54 (0.28-1.03) 0.13 0.09  112 1.00 0.95 (0.57-1.60) 0.55 (0.19-1.57) 0.48 0.32 
- Lower respiratory infection (J09-22) 44 1.00 1.19 (0.52-2.72) 0.29 (0.04-2.17) 0.28 0.38  17 1.00 0.69 (0.14-3.50) 0.08 (0.00-4.33) 0.45 0.24 
- Other respiratory system disease (Other J) 247 1.00 0.90 (0.63-1.29) 0.59 (0.29-1.17) 0.31 0.15  95 1.00 0.96 (0.55-1.69) 0.63 (0.21-1.88) 0.67 0.46 
Digestive system disease (K00-93) 100 1.00 0.81 (0.46-1.42) 0.96 (0.40-2.32) 0.74 0.83  53 1.00 0.73 (0.34-1.54) 0.96 (0.31-2.95) 0.67 0.83 
- Liver disease (K70-77) 24 1.00 0.37 (0.08-1.74) 2.17 (0.62-7.65) 0.10 0.21  16 1.00 0.33 (0.04-2.94) 3.58 (0.79-16.4) 0.06 0.07 
- Other digestive system disease (Other K) 76 1.00 1.12 (0.57-2.20) 0.53 (0.13-2.21) 0.47 0.52  37 1.00 1.03 (0.39-2.72) 0.22 (0.02-3.02) 0.41 0.39 
External (V01-Y98) 107 1.00 1.47 (0.90-2.40) 0.81 (0.32-2.06) 0.12 0.98  65 1.00 1.76 (0.95-3.27) 0.76 (0.21-2.73) 0.052 0.93 
- Transport accident (V00-99;Y85) 26 1.00 1.24 (0.46-3.33) 0.16 (0.01-2.68) 0.22 0.37  24 1.00 1.38 (0.51-3.73) 0.20 (0.01-3.28) 0.22 0.49 
- Fall (W00-19) 25 1.00 1.94 (0.64-5.86) 3.85 (0.81-18.2) 0.22 0.08  8 1.00 14.7 (1.76-127.4) 49.6 (1.34-1834.6) 0.04 0.02 
- Suicide (X60-84;Y87.0) 18 1.00 3.74 (1.13-12.4) 3.05 (0.39-23.7) 0.09 0.20  10 1.00 1.86 (0.37-9.32) 2.14 (0.15-30.5) 0.74 0.54 
- Other external (W20-X59;Y86;Y87.1-98) 38 1.00 0.80 (0.34-1.89) 0.24 (0.04-1.59) 0.33 0.15  23 1.00 1.31 (0.44-3.92) 0.51 (0.05-4.81) 0.53 0.69 
Other (Other A00-R99) 392 1.00 0.78 (0.58-1.05) 1.09 (0.68-1.74) 0.12 0.97  205 1.00 0.80 (0.54-1.17) 0.95 (0.50-1.80) 0.47 0.70 
All-cause mortality (A00-Y98) 7965 1.00 1.04 (0.97-1.10) 1.21 (1.08-1.34) 0.002 0.001  4760 1.00 1.03 (0.95-1.11) 1.24 (1.08-1.42) 0.006 0.005 
Non-drinkers were excluded. Models were adjusted for sex, age, remoteness, education, household income, health insurance status, partner status, country of birth, smoking status and dose, 
body mass index, physical activity, fruit consumption, vegetable consumption, fibre intake, red meat consumption, processed meat consumption, parity (women), menopausal status (women), 
hormone replacement therapy use (women) and height. aParticipants with physical functioning score < 50% excluded. bOverall. cLinear trend using median number of drinks per drinking-day of 
each category. dFemale breast cancer only. eZero deaths in cell. ICD-10, International Classification of Diseases, version 10.
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Table 9.4. Hazard ratios (HR) and 95% confidence intervals (CI) of all-cause mortality risk after excluding participants with physical functioning score < 50% by 
drinking pattern among drinkers in the 45 and Up Study (2006-2014), New South Wales, Australia. 
Drinking-days 
per week n deaths 
HR mean drinks per drinking-day in main analysis 
(95% CI) 
  HR mean drinks per drinking-day of in sensitivity 
analysisa (95% CI) 
≤ 2 > 2 and ≤ 4 > 4  n deaths ≤ 2 > 2 and ≤ 4 > 4 
1-2 7965 1.00 1.13 (1.00-1.28) 1.24 (1.07-1.43)  4760 1.00 1.16 (0.99-1.35) 1.27 (1.05-1.54) 
3-5  0.92 (0.85-0.99) 0.96 (0.86-1.08) 1.18 (1.00-1.40)   0.90 (0.82-0.99) 0.93 (0.81-1.07) 1.25 (1.01-1.55) 
6-7  0.94 (0.88-1.01) 0.97 (0.90-1.05) 1.13 (1.02-1.26)   0.95 (0.87-1.04) 0.96 (0.86-1.07) 1.16 (1.02-1.33) 
Non-drinkers were excluded. Model was adjusted for sex, age, remoteness, education, household income, health insurance status, partner status, country of 
birth, smoking status and dose, body mass index, physical activity, fruit consumption, vegetable consumption, fibre intake, red meat consumption, processed 
meat consumption, parity (women only), menopausal status (women only), hormone replacement therapy use (women only) and height. aParticipants with 
physical functioning score < 50% excluded.
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The sensitivity analyses for the continuous log-linear association between alcohol consumption and 
mortality for three exclusion scenarios (the exclusion of participants with prior disease, the exclusion 
of participants with a low physical functioning score, and the exclusion of participants consuming < 7 
drinks per week) are shown in Table 9.5. All three sensitivity analyses resulted in several risk 
estimates that differed from the main results. Specifically, the sensitivity analysis excluding 
participants with prior disease resulted in significant positive associations for death from 
oesophageal cancer, breast cancer and cardiovascular disease, which were not observed in the main 
analysis. The positive association with death from liver cancer and inverse association with death 
from prostate cancer observed in the main analysis were non-significant, with the hazard ratio for 
death from prostate cancer appearing to change the most compared to the main analysis. The 
sensitivity analysis excluding participants with a low physical functioning score resulted in significant 
positive associations for death from oesophageal cancer and other causes combined. The positive 
associations for death from other cardiovascular disease, external causes, fall and other external 
causes, and the inverse associations for death from prostate cancer and non-Hodgkin lymphoma 
(NHL), were non-significant, with the hazard ratio for death from NHL appearing to change the most 
compared to the main analysis. The sensitivity analysis that excluded participants consuming < 7 
drinks per week resulted in significant positive associations for death from cardiovascular disease 
and other causes combined. The positive associations for death from liver cancer, digestive system 
disease, external causes and fall, and the inverse associations for death from prostate cancer and 
NHL observed in the main analysis, were non-significant, with the hazard ratios for death from fall 
and NHL appearing to change the most compared to the main analysis. 
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Table 9.5. Hazard ratios (HR) and 95% confidence intervals (CI) of cause-specific mortality risk per one drink increase in mean daily alcohol consumption after excluding participants 
with prior disease, a physical functioning score < 50% or those consuming < 7 drinks per week among drinkers in the 45 and Up Study (2006-2014), New South Wales, Australia. 
 Main analysis  Excluding prior diseasea  Excluding MOS-PF < 50%  Excluding < 7 drinks/week 
Cause of death (ICD-10 code) n deaths HR (95% CI)  n deaths HR (95% CI)  n deaths HR (95% CI)  n deaths HR (95% CI) 
Cancer (C00-97;D45-47) 1,509 1.01 (0.97-1.04)  824 1.04 (1.00-1.09)  1,052 1.02 (0.98-1.06)  909 1.03 (0.99-1.08) 
- Alcohol-related (C00-15;18-20;22;32;50b) 331 1.08 (1.01-1.16)  161 1.16 (1.07-1.25)  235 1.10 (1.02-1.20)  202 1.09 (1.00-1.18) 
  - Mouth, pharynx and larynx (C00-14;32) 25 1.01 (0.83-1.24)  15 1.06 (0.85-1.32)  20 1.07 (0.87-1.32)  20 0.93 (0.70-1.22) 
  - Oesophagus (C15) 53 1.13 (0.98-1.30)  32 1.25 (1.09-1.43)  35 1.18 (1.01-1.39)  38 1.14 (0.96-1.35) 
  - Colorectum (C18-20) 131 1.08 (0.96-1.20)  70 1.08 (0.92-1.26)  93 1.10 (0.97-1.25)  79 1.12 (0.99-1.28) 
  - Liver (C22) 42 1.17 (1.01-1.36)  33 1.15 (0.98-1.36)  27 1.22 (1.03-1.45)  33 1.08 (0.89-1.28) 
  - Breast (C50b) 80 0.94 (0.72-1.24)  11 1.59 (1.10-2.29)  60 0.69 (0.47-1.02)  32 1.17 (0.86-1.59) 
- Non-alcohol-related (Other C;D45-47) 1,178 0.98 (0.95-1.03)  663 1.01 (0.96-1.06)  817 1.00 (0.95-1.05)  707 1.02 (0.97-1.07) 
  - Stomach (C16) 32 1.00 (0.79-1.27)  22 0.98 (0.73-1.30)  22 1.08 (0.83-1.42)  18 1.09 (0.83-1.43) 
  - Pancreas (C25) 97 0.97 (0.83-1.13)  83 0.97 (0.82-1.14)  76 1.01 (0.86-1.18)  58 0.93 (0.76-1.13) 
  - Lung (C33-34) 264 1.03 (0.95-1.10)  185 1.02 (0.93-1.11)  179 1.02 (0.93-1.12)  179 1.01 (0.93-1.11) 
  - Melanoma (C43) 70 0.93 (0.77-1.12)  26 0.87 (0.65-1.17)  57 0.91 (0.74-1.11)  42 0.94 (0.74-1.20) 
  - Prostate (C61) 169 0.88 (0.78-1.00)  46 1.01 (0.82-1.25)  113 0.90 (0.77-1.04)  99 0.92 (0.79-1.08) 
  - Kidney (C64) 28 1.08 (0.85-1.37)  16 1.22 (0.96-1.56)  17 1.02 (0.74-1.41)  21 0.98 (0.65-1.32) 
  - Non-Hodgkin lymphoma (C82-85) 41 0.61 (0.42-0.88)  17 0.43 (0.20-0.92)  32 0.75 (0.52-1.09)  16 0.77 (0.45-1.29) 
Diabetes (E10-14) 55 0.96 (0.78-1.18)  13 1.36 (0.96-1.93)  21 1.00 (0.73-1.37)  31 0.96 (0.74-1.26) 
Dementia (F00-03;G30) 111 0.89 (0.73-1.08)  43 0.79 (0.55-1.13)  52 0.73 (0.52-1.03)  56 0.89 (0.68-1.17) 
Cardiovascular disease (G45-46;I00-99) 1,059 1.04 (0.99-1.09)  577 1.09 (1.03-1.15)  511 1.01 (0.95-1.08)  603 1.08 (1.03-1.14) 
- Ischaemic heart disease (I20-25) 514 0.99 (0.93-1.06)  237 1.03 (0.95-1.13)  258 0.98 (0.89-1.07)  286 1.05 (0.97-1.13) 
- Cerebrovascular disease (G45-46;I60-69) 247 1.02 (0.92-1.13)  157 1.09 (0.97-1.22)  119 1.03 (0.89-1.19)  142 1.03 (0.90-1.17) 
- Other (Other I) 298 1.13 (1.05-1.22)  183 1.15 (1.05-1.27)  134 1.06 (0.93-1.21)  175 1.17 (1.07-1.28) 
Respiratory system disease (J00-99) 300 1.03 (0.95-1.12)  230 1.06 (0.98-1.16)  114 1.10 (0.97-1.23)  198 0.99 (0.90-1.10) 
- Lower respiratory infection (J09-22) 45 1.14 (0.94-1.38)  39 1.19 (0.98-1.45)  17 1.27 (0.93-1.73)  30 1.10 (0.84-1.42) 
- Other respiratory system disease (Other J) 255 1.01 (0.93-1.11)  191 1.04 (0.94-1.14)  97 1.07 (0.94-1.22)  168 0.98 (0.87-1.10) 
Digestive system disease (K00-93) 100 1.15 (1.03-1.28)  - -  53 1.22 (1.08-1.39)  64 1.13 (1.00-1.28) 
- Liver disease (K70-77) 24 1.26 (1.11-1.43)  - -  16 1.38 (1.20-1.59)  18 1.25 (1.08-1.45) 
- Other digestive system disease (Other K) 76 1.00 (0.84-1.20)  - -  37 0.94 (0.72-1.24)  46 0.94 (0.73-1.20) 
External (V01-Y98) 110 1.18 (1.07-1.33)  - -  67 1.10 (0.96-1.27)  76 1.12 (0.99-1.27) 
- Transport accident (V00-99;Y85) 26 1.03 (0.79-1.33)  - -  24 1.04 (0.81-1.34)  18 0.87 (0.59-1.29) 
- Fall (W00-19) 26 1.34 (1.09-1.64)  - -  9 1.29 (0.88-1.90)  21 1.14 (0.87-1.48) 
- Suicide (X60-84;Y87.0) 19 1.21 (0.96-1.52)  10 1.31 (0.95-1.80)  11 1.22 (0.88-1.69)  16 1.07 (0.77-1.49) 
- Other external (W20-X59;Y86;Y87.1-98) 39 1.19 (1.00-1.41)  - -  23 1.07 (0.82-1.40)  21 1.21 (1.00-1.46) 
Other (Other A00-R99) 402 1.05 (0.99-1.13)  - -  210 1.12 (1.04-1.22)  238 1.10 (1.02-1.19) 
All-cause mortality (A00-Y98) 8,153 1.03 (1.02-1.05)  3,267 1.05 (1.03-1.07)  4,830 1.04 (1.02-1.06)  4,914 1.05 (1.03-1.07) 
Non-drinkers were excluded. Models were adjusted for sex, age, remoteness, education, household income, health insurance status, partner status, country of birth, smoking status 
and dose, body mass index, physical activity, fruit consumption, vegetable consumption, fibre intake, red meat consumption, processed meat consumption, parity (women only), 
menopausal status (women only), hormone replacement therapy use (women only) and height. aParticipants who at baseline had ever had cancer were excluded from cancer analyses, 
ever had diabetes excluded from diabetes analysis, did not have good/very good/excellent memory excluded from dementia analysis, ever had heart disease or stroke excluded from 
cardiovascular disease analyses, ever had asthma excluded from respiratory system disease analyses, ever had depression excluded from suicide analysis and ever had cancer, heart 
disease, stroke or diabetes excluded from all-cause mortality analysis. bFemale breast cancer only. ICD, International Classification of Diseases, version 10. MOS-PF, Medical Outcomes 
Study Physical Functioning score.  
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Conclusions. The magnitude of the log-linear association between total alcohol consumption and all-
cause mortality risk appeared to vary according to different exclusion scenarios aimed to assess the 
extent of bias from the ‘sick-quitter effect’. The sensitivity analyses that would be expected to 
increase bias from the ‘sick-quitter effect’ (including non-drinkers in the calculation, including deaths 
within the first three years of follow-up) both resulted in lower effect estimates, while four of the 
five the sensitivity analyses that would be expected to reduce bias from the ‘sick-quitter effect’ 
(restricting the calculation to participants consuming ≥ 7 drinks per week, the exclusion of deaths 
occurring within the first five years of follow-up, the exclusion of participants with a physical 
functioning score of < 50% and the exclusion of participants ever diagnosed with cancer or 
cardiovascular disease, but not restriction to participants aged < 65 years at baseline) resulted in 
higher effect estimates. The restriction to participants aged < 65 years at baseline resulted in the 
exclusion of the majority of deaths, and so this sensitivity test was likely underpowered. The results 
suggest that while the methods used to limit bias in the main analysis (excluding non-drinkers and 
excluding deaths that occurred within the first three years of follow-up) were effective, it is probable 
that bias from the ‘sick-quitter effect’ has not been eliminated entirely. 
Some important differences were found for individual causes of death in three of the sensitivity 
analyses examined. That is, when participants with a physical functioning score < 50%, consuming < 
7 drinks per week or with prior disease were excluded. In the majority of cases where trends were 
significant in the main analysis and non-significant in the sensitivity analyses there was no material 
change in hazard ratios, with the exception of death from prostate cancer, NHL and fall. 
The results suggest that the main analysis may have underestimated the association between 
alcohol consumption and risk of all-cause and cause-specific mortality due to participants decreasing 
their drinking in response to ill-health, in addition to quitting entirely. For death from prostate 
cancer and NHL, the loss of significance and increase in effect estimates suggests that the 
association between alcohol consumption and lower risk of these outcomes may be at least partially 
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accounted for by this bias. The risk of death from fall may also have been overestimated, but this 
may be due to the fact that a non-linear relationship was found in the cubic spline analysis, with a 
lower risk gradient associated with heavier drinking. In the categorical analysis, the finding that the 
exclusion of participants with a low physical functioning score resulted in a new association with 
decreased risk of death from dementia adds to the evidence that this association may be causal, 
however this was not found in all sensitivity analyses. In addition, the finding of an association with 
decreased risk of death from breast cancer for this sensitivity analysis was unexpected, and 
inconsistent with the analysis excluding participants with prior cancer which found a new association 
with increased risk. Therefore, further research involving a greater number of dementia and breast 
cancer deaths is required to investigate these alcohol-mortality relationships and the impact of 
confounding by the ‘sick-quitter effect’ on effect estimates. 
Regarding drinking patterns, the lack of material change in associations for drinking frequency, 
drinks per drinking-day and overall drinking pattern suggests that these effect estimates are robust 
to changes in drinking pattern in response to ill-health. There was largely no evidence that these 
estimates were be biased. However, the inverse association between drinking frequency and death 
from oesophageal cancer was unexpected. Considering that there was a positive association with 
drinks per drinking-day for this outcome, this perhaps implies that infrequent heavy drinking (heavy 
episodic drinking) raises risk of death from oesophageal cancer more so than other drinking 
patterns. It should be noted however that the sensitivity test could not be expected to remove all 
bias, and so inverse associations for drinking frequency and all-cause and cause-specific mortality 
are not necessarily causal. 
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2. Population attributable fractions, cumulative absolute risk of mortality and number of 
persons needed to quit or reduce drinking to prevent one death. 
Rationale and methods. As for alcohol consumption and cancer incidence, it is of interest to 
investigate how the hazard ratios derived from the 45 and Up Study can be used to calculate 
estimates for population attributable fractions, as well as other outcomes which may have public 
health importance. Thus, the results of the continuous log-linear analysis in the main analysis were 
used to calculate three further results: PAF for deaths attributable to alcohol consumption in 
Australia in 2010, cumulative absolute risk of mortality between the ages of 45 and 75 years by level 
of alcohol consumption, and number of persons needed to quit or reduce drinking by age 45 years to 
prevent one death by age 75 years. Due to finding no significant interactions with sex for total 
alcohol consumption and risk of any mortality outcome, sex-specific hazard ratios were not used 
The PAF calculations were performed using the same method as Pandeya et al., (2015), which relied 
on log-linear conversions of international relative risks to estimate PAFs for cancer in Australia in 
2010[1]. So that lag time would be consistent for each cause of death and to be consistent with the 
analyses for cancer incidence, a lag time of nine years was used, attributing mortality in 2010 to sex- 
and age-specific alcohol consumption in the 2001 National Health Survey (2001 alcohol consumption 
data shown in Supplementary Table 2[1]). A full description of the methods used to calculate PAFs, 
cumulative absolute risk of mortality and number of persons needed to quit or reduce drinking to 
prevent one death are presented in Appendix E.3. 
Results. The population attributable fraction calculations for alcohol consumption and mortality in 
Australia in 2010 are shown in Table 9.6. In the calculation derived from the log-linear analysis 
hazard ratios, the PAF for all-cause mortality was 2.2% and 4.4% when calculated without and with 
the exclusion of participants with prior disease (cancer for the cancer mortality hazard ratio and 
cardiovascular disease for the cardiovascular disease mortality hazard ratio) at baseline respectively. 
The highest PAF was found for death from external causes. The sensitivity test excluding participants 
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with a low physical functioning score resulted in a decrease in the majority of PAF estimates, while 
the sensitivity test restricting the hazard ratio calculation to participants consuming ≥ 7 drinks per 
week resulted in an increase in the majority of PAF estimates. In the calculation derived from the 
restricted cubic spline hazard ratios, the net PAF for all-cause mortality was lower, at 0.3% and 1.8% 
when calculated without and with the exclusion of participants with prior disease at baseline 
respectively. The highest PAF remained death from external causes. The sensitivity test excluding 
participants with a low physical functioning score resulted in a decrease in the majority of PAF 
estimates, with the net PAF for all-cause mortality remaining above 0. 
The cumulative absolute risk of mortality between the ages of 45 and 75 years by level of alcohol 
consumption is shown in Figure 9.2. The absolute risk difference between drinking groups was larger 
in men for all mortality outcomes. For all-cause mortality calculated from hazard ratios which 
excluded participants with prior disease at baseline, cumulative absolute risk to age 75 years in men 
was 23.5% in those consuming > 14 drinks per week (median 21 drinks per week) and 20.7% in non-
drinkers, while in women these values were 15.2% (median 20 drinks per week) and 13.4% 
respectively. By the age of 75 years, men and women consuming > 14 drinks per week ‘brought 
forward’ their risk of all-cause mortality by approximately 2 years, and those consuming > 0 and ≤ 14 
drinks per week by approximately 0.5 years, compared to non-drinkers. 
The estimated number of persons needed to quit or decrease drinking by age 45 years to prevent 
one death by age 75 years is shown in Table 9.7. For all-cause mortality calculated from hazard ratios 
which excluded participants with prior disease at baseline, one death was estimated to be prevented 
for every 36 men or 56 women quitting (or never starting) drinking at > 14 drinks per week (median 
20 drinks per week in women and 21 in men). The largest values were found for persons quitting (or 
never starting) drinking at > 0 and ≤ 14 drinks per week (median 5 drinks per week in women and 6 
in men). The smallest values among the specific causes of death were for death from cancer and 
cardiovascular disease. The sensitivity test excluding participants with a low physical functioning 
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score did not materially change the values for all-cause mortality, while the sensitivity test restricting 
the hazard ratio calculation to participants consuming ≥ 7 drinks per week resulted in smaller values.  
Regarding participants consuming ≤ 14 drinks per week, the cumulative absolute risk difference of 
all-cause mortality obtained from the analysis excluding participants with prior disease was 0.77% 
for men (for those consuming a median of 6 drinks per week compared to non-drinkers) and 0.43% 
for women (for those consuming a median of 5 drinks per week compared to non-drinkers) (Figure 
9.2). Higher values of 0.94% and 0.53% respectively were obtained in the sensitivity analysis derived 
from hazard ratios when restricting to participants consuming ≥ 7 drinks per week (data not shown). 
Conclusions. The PAF estimate for all-cause mortality using log-linear hazard ratios from the 45 and 
Up Study varied substantially depending on the assumptions made about whether linear or non-
linear relationships should be modelled, whether the association of lower risk of some diseases with 
drinking is causal and whether participants with prior disease should be excluded from calculations, 
and also in the sensitivity tests aiming to detect bias from the ‘sick-quitter effect’.  
The estimates of cumulative absolute risk of mortality and number of persons needed to quit or 
reduce drinking to prevent one death showed that cancer and cardiovascular disease (when 
excluding participants with prior disease) were the largest contributing causes of death to the 
absolute cancer risk associated with alcohol consumption. 
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Table 9.6. Population attributable fractions for deaths caused and prevented by alcohol consumption in Australian persons aged ≥ 45 
years in 2010 using hazard ratios from the 45 and Up Study (2006-2012), New South Wales, Australia. 
 
 Derived from main 
analysis 
 Derived from sensitivity 
analysis 1a 
 Derived from sensitivity 
analysis 2b 
Cause of death n deaths n excess deaths PAF (%)  n excess deaths PAF (%)  n excess deaths PAF (%) 
Log-linear-derived calculation          
Cancer 41,979 229 0.5  779 1.9  1,267 3.0 
Cancer (excluding prior cancer) 41,979 1,730 4.1  2,119 5.0  3,113 7.4 
CVD 44,706 1,011 2.3  274 0.6  2,292 5.1 
CVD (excluding prior CVD) 44,706 2,448 5.5  427 1.0  3,126 7.0 
Digestive system disease 4,899 644 13.2  1,028 22.1  552 11.3 
External causes 5,481 1,158 21.1  573 10.4  701 12.8 
All-cause mortality method 1c 135,214 3,042 2.2  2,708 2.0  4,812 3.6 
All-cause mortality method 2d 135,214 5,980 4.4  4,201 3.1  7,492 5.5 
Cubic spline-derived calculation          
Cancer 41,979 -1,231 -2.9  -1,344 -3.2  - - 
Cancer (excluding prior cancer) 41,979 -495 -1.2  420 1.0  - - 
CVD 44,706 -577 -1.3  -542 -1.2  - - 
CVD (excluding prior CVD) 44,706 633 1.4  -1,251 -2.8  - - 
Digestive system disease 4,899 651 13.3  993 20.3  - - 
External causes 5,481 1,621 29.6  1,010 18.4  - - 
All-cause mortality method 1c 135,214 465 0.3  116 0.1  - - 
All-cause mortality method 2d 135,214 2,411 1.8  1,172 0.9  - - 
Hazard ratios used in calculations for the 45 and Up Study were derived from total alcohol consumption in linear and restricted cubic 
spline models among participants consuming ≥ 1 drink per week. For each age group used in the calculation, mortality was attributed to 
alcohol consumption nine years earlier in the 2001 National Health Survey. ‘n excess deaths’ refers to deaths attributable to alcohol 
consumption out of the total number of deaths, ‘n deaths’. aParticipants with physical functioning score < 50% excluded. bAmong 
participants consuming ≥ 7 drinks per week. cSummation of the cancer, CVD, digestive system disease and external mortality. dSummation 
of cancer (excluding prior cancer), CVD (excluding prior CVD), digestive system disease and external mortality. PAF, Population 
Attributable Fraction. CVD, Cardiovascular Disease.
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Figure 9.2. Cumulative absolute risk of mortality between the ages of 45 and 75 years in Australia in 2013 
using hazard ratios from the 45 and Up Study (2006-2014), New South Wales, Australia. Black line: 0 drinks 
per week; Green line: 5 drinks per week in women and 6 drinks per week in men; Red line: 20 drinks per 
week in women and 21 drinks per week in men. Results derived from total alcohol consumption in a linear 
model among participants consuming ≥ 1 drink per week. The prior diseases excluded from the second all-
cause mortality analysis were cancer, CVD and diabetes. CVD, Cardiovascular disease. 
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Figure 9.2. (Continued) 
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Table 9.7. Number of persons needed to quit or decrease drinking by age 45 years to prevent one death by age 75 years in Australia in 2013. 
 Men  Women 
Cause of death 
21 drinks/week 
→ Quit 
6 drinks/week 
→ Quit 
21 drinks/week 
→ 6 drinks/week 
 20 drinks/week 
→ Quit 
5 drinks/week 
→ Quit 
20 drinks/week 
→ 5 drinks/week 
Main analysis        
Cancer 558 1,965 780  823 3,308 1,094 
Cancer (excluding prior cancer) 79 287 109  114 475 150 
CVD 159 579 220  382 1,590 503 
CVD (excluding prior CVD) 72 273 97  167 731 217 
Digestive system disease 216 877 285  397 1,849 505 
External causes 121 509 159  291 1,397 367 
All-cause mortality method 1a 57 203 79  89 363 117 
All-cause mortality method 2b 36 131 50  56 233 74 
Sensitivity analysis 1c        
Cancer 168 599 234  246 1,003 326 
Cancer (excluding prior cancer) 66 240 90  94 395 123 
CVD 561 1,983 781  1,365 5,521 1,813 
CVD (excluding prior CVD) 363 1,293 505  882 3,588 1,169 
Digestive system disease 146 639 188  258 1,293 322 
External causes 213 827 287  534 2,369 689 
All-cause mortality method 1a 48 171 66  74 305 98 
All-cause mortality method 2b 36 128 49  55 228 72 
Sensitivity analysis 2d        
Cancer 106 380 146  154 632 203 
Cancer (excluding prior cancer) 46 173 63  66 282 86 
CVD 76 287 103  178 772 230 
CVD (excluding prior CVD) 58 226 78  134 599 173 
Digestive system disease 244 976 325  454 2,076 581 
External causes 180 712 241  446 2,019 573 
All-cause mortality method 1a 35 126 48  54 224 71 
All-cause mortality method 2b 29 107 40  45 189 59 
Results were derived from total alcohol consumption in a linear model among participants consuming ≥ 1 drink per week. aMain analysis. bParticipants with 
a prior diagnosis of cancer, CVD or diabetes excluded. cParticipants with physical functioning score < 50% excluded. dAmong participants consuming ≥ 7 
drinks per week. CVD, Cardiovascular Disease. 
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9.3 – Discussion and Conclusions 
 
The main findings of this chapter were that total alcohol consumption was associated with increased 
risk of all-cause mortality and many causes of death, including alcohol-related cancer, oesophageal 
cancer, liver cancer, kidney cancer, cardiovascular disease, digestive system disease, liver disease, 
external causes, fall, suicide, other external causes, other causes combined. There was an inverse 
association with death from NHL. The results for total alcohol consumption were largely consistent 
with prior research. There was also evidence that the inclusion or exclusion of participants with prior 
disease at baseline made a material difference to risk estimates for several causes of death. This was 
particularly important for cardiovascular disease mortality. Despite finding a J-shaped non-linear 
association between alcohol consumption and cardiovascular disease mortality in the main analyses, 
there was no significant protective effect. The evidence suggested that reduction in alcohol 
consumption in response to cardiovascular disease diagnosis is likely to have biased risk estimates 
for cardiovascular disease mortality, due to the appearance of the new significant linear trend of 
increased risk when excluding participants with prior cardiovascular disease. 
In analyses examining the effects of drinking pattern, there was an independent association of mean 
drinks per drinking-day with increased risk of death from cancer, oesophageal cancer, non-alcohol-
related cancer, lung cancer, kidney cancer and all-cause mortality. Frequent drinking was associated 
with higher risk of respiratory system disease mortality and lower risk of death from cancer, non-
alcohol-related cancer, diabetes, cardiovascular disease, ischaemic heart disease and all-cause 
mortality compared to less frequent drinking. There is no mechanistic basis for alcohol consumption 
to lower cancer risk, and yet strong inverse associations with drinking frequency were observed for 
all cancers combined and non-alcohol-related cancers combined. These two outcomes may serve as 
‘negative controls’[2], indicating that inverse associations with drinking frequency for other 
outcomes including all-cause mortality and cardiovascular disease mortality may be attributable to 
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bias from reverse causation or incomplete adjustment from confounding. A key implication of these 
results was that a reduction in the number of drinks consumed per drinking occasion is likely to be 
an effective approach to prevent cancer and all-cause mortality, independent of and in addition to 
limiting the total amount of alcohol consumed. Increasing drinking frequency without changing total 
alcohol consumption may also be an effective approach, although it cannot be ruled out that the 
association with protection may be attributable to bias. Another important finding was that both 
heavy frequent drinking and heavy episodic drinking were significantly related to all-cause mortality 
risk. Altogether, these findings have implications for risk modelling, burden of disease estimates, 
alcohol health guidelines and government policies and programs aiming to lessen alcohol-related 
harm. 
The additional analyses revealed several important findings. Firstly, there was evidence that bias 
from the ‘sick-quitter effect’ and decreased drinking in response to ill-health may have biased 
estimates between alcohol-consumption and all-cause mortality in the main analysis, resulting in an 
underestimation of the association. For a number of individual causes of death, the risk relationship 
with alcohol varied from that observed in the main analysis when either participants with poor 
physical functioning, those who consumed < 7 drinks per week, or those with prior disease, were 
excluded. Specifically, for death from oesophageal cancer, liver cancer, breast cancer, cardiovascular 
disease and other causes combined, the risks associated with alcohol may have been 
underestimated in the main analyses due to bias from the ‘sick-quitter effect’. The inverse 
association for death from dementia may also have been underestimated. In addition, the inverse 
associations for death from prostate cancer and NHL may also have been overestimated in the main 
analysis, while the inverse association for death from dementia may have been underestimated. On 
the other hand, the drinking pattern results were largely unaffected by the sensitivity tests, 
providing evidence that these findings were robust to bias from changes in drinking patterns in 
response to ill-health. 
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The PAF estimate for all-cause mortality varied substantially depending on the assumptions made 
about whether linear or non-linear relationships should be modelled, whether the association of 
lower risk of some diseases with drinking is causal and whether participants with prior disease 
should be excluded from calculations. There were also material changes in the estimate in sensitivity 
tests aiming to detect bias from the ‘sick-quitter effect’. The World Health Organisation estimated 
that 3.2% of deaths in Australia in 2012 were attributable to alcohol consumption[3], which is 
comparable to the range of estimates derived from the 45 and Up Study. In all cases the 45 and Up 
Study-derived PAF estimates were greater than zero, indicating that under all scenarios tested 
alcohol consumption caused more deaths than it prevented. It is possible that the value of 2.2% 
derived using continuous log-linear hazard ratios in the main analysis could be greatly 
underestimated, with the PAF doubling to 4.4% if participants with prior cancer and cardiovascular 
disease are excluded from the calculations, with a higher PAF still of up to 5.5% when taking into 
account the sensitivity analysis designed to reduce bias from the ‘sick-quitter effect’. If a variable 
were available to exclude participants with prior digestive system disease, then the estimate for this 
outcome and all-cause mortality may have been higher still. On the other hand, if the relationship 
between alcohol consumption and reduced risk of cardiovascular disease and cancer mortality is 
assumed to be causal, then PAF estimates for all-cause mortality decrease by approximately 2% 
compared to their corresponding estimates derived from continuous log-linear hazard ratios. It 
should be noted that these PAF estimates applied to deaths in Australia among persons aged ≥ 45 
years (94% of all deaths in 2010). If the proportion of alcohol-attributable deaths is higher in persons 
aged < 45 years than persons aged ≥ 45 years, these estimates may have been slightly higher if 
persons of all ages were included in the calculations. A limitation of this analysis was that lag time 
between alcohol consumption and mortality may differ for each cause of death, and for death from 
external causes current drinking is likely to be more relevant than past drinking. 
The estimates of cumulative absolute risk of mortality and number of persons needed to quit or 
reduce drinking to prevent one death showed that cancer and cardiovascular disease (when 
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excluding participants with prior disease) contributed the most to the absolute cancer risk 
associated with alcohol consumption. One key finding was that when excluding participants with 
prior disease, by age 75 years, persons consuming > 14 drinks per week ‘brought forward’ their risk 
of all-cause mortality by 2 years compared to non-drinkers. Another key finding included that (when 
excluding participants with prior disease) one death could be prevented by the age of 75 years for 
every 36 men or 56 women quitting (or never starting) drinking at > 14 drinks per week, with even 
lower numbers in the sensitivity test designed to reduce bias from the ‘sick-quitter effect’. As for 
cancer incidence, it was also found that targeting persons drinking > 14 drinks per week to decrease 
their drinking to > 0 and ≤ 14 drinks per week is likely to be a more efficient strategy to reduce 
alcohol-attributable mortality than targeting persons drinking > 0 and ≤ 14 drinks per week to 
decrease their drinking to zero. These results may be useful for planning preventative public health 
interventions to reduce the burden of alcohol-related mortality. 
The results also have implications for the Australian alcohol guidelines. The guidelines recommend a 
cut-point value of ≤ 2 drinks per day (allowing for consumption up to 14 drinks per week) to reduce 
the risk of long-term harm. The cut-point was chosen to limit the risk of death to the arbitrary value 
of 1 in 100[4]. The cumulative absolute risk difference obtained from the analysis excluding 
participants with prior disease was 0.77% for men (for those consuming a median of 6 drinks per 
week compared to non-drinkers) and 0.43% for women (for those consuming a median of 5 drinks 
per week compared to non-drinkers). As the same hazard ratios were used in the calculation for men 
and women, the reason for the larger absolute risk difference in men is largely due to the higher 
underlying absolute mortality risk at any point in time for men compared to women. Extrapolating 
these values, the results imply that men and women could consume up to 7 and 11 drinks per week 
respectively and have an absolute risk of alcohol-attributable mortality less than 1%. As there was no 
interaction between sex and total alcohol consumption for all-cause mortality risk, it would be 
conservative to select the male value in the development of alcohol guidelines. Therefore, based on 
the results of the 45 and Up Study accounting for the ‘sick-quitter effect’, a conservative drinking 
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guideline could recommend an upper limit of 7 drinks per week to ensure that lifetime risk of 
alcohol-attributable mortality is less than 1%. This is before taking into account that the calculated 
values underestimate the true lifetime absolute mortality risk attributable to alcohol consumption 
due to only capturing the age period of 45 to 75 years, and so the guideline may need to be even 
lower. Further, the absolute risk difference estimate derived from the sensitivity test restricting to 
participants consuming ≥ 7 drinks per week suggested that values of the main analysis may be 
underestimated, meaning that a guideline of 7 drinks per week may still be too high. In summary, 
using the hazard ratios derived from the 45 and Up Study, there is evidence that the Australian 
alcohol guideline to limit the risk of long term harm could be lowered to 7 drinks per week, to limit 
lifetime risk of alcohol-attributable mortality to 1%. 
The final chapter of this thesis is the discussion. This chapter summarises the findings of the first 
nine chapters and the strengths and weaknesses of the analyses, explores implications for 
government policy and outlines areas for further research. 
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Chapter 10 – Discussion and Conclusions 
 
Chapter summary 
This chapter summarises the key findings of each chapter, as well as the strengths and limitations of 
the analyses. The implications of the results for policy are examined, including recommendations for 
potential strategies to reduce alcohol-related harm in Australia, messaging concerning the harms of 
heavy episodic drinking, and modifications to the national alcohol guidelines. Finally, gaps in the 
research base regarding alcohol consumption and heavy episodic drinking are identified and 
recommendations for future research made. 
 
10.1 – Discussion 
 
Summary of findings 
This thesis investigated several important topics related to alcohol consumption and its impact on 
burden of disease and injury in Australia. Alcohol consumption is commonplace in Australia, as is 
drinking at levels above health guidelines. Chapter 1 presented an introduction to alcohol and the 
Australian context. It was described how alcohol consumption affects the human body; the role of 
alcohol in Australian society, including the nature of the alcohol industry, how alcoholic beverages 
are classified, Australian alcohol health guidelines, the prevalence of drinking behaviours, and public 
health efforts to reduce alcohol-related harm. 
Alcohol consumption is commonplace in Australia and is associated with substantial social and 
economic harm. Of adults, 81% are current consumers of alcohol, and 19% of adults (28% of men; 
10% of women) consume greater than two standard drinks per day on average, exceeding the 2009 
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NHMRC guideline for risk of long-term harm. There is little variation by age, with 19% to 23% of 
persons exceeding this guideline in all adult age groups less than 70 years. Persons born in non-
English speaking countries have a lower prevalence of exceeding the long-term risk guideline than 
persons born in English-speaking countries and in Australia. Population sub-groups with a higher 
prevalence of consuming alcohol at levels that put them at risk of long-term harm include Aboriginal 
and Torres Strait Islanders, persons living in regional and remote areas, those with higher socio-
economic status, and those who are employed, and/or homosexual or bisexual. In addition, 27% of 
adults (36% of men and 17% of women) exceed the guideline for risk of short-term harm by 
consuming greater than four standard drinks on a single occasion at least monthly. The burden of 
disease and injury due to alcohol consumption may worsen over time, as adult per capita alcohol 
consumption in Australia is projected to increase by 11% between 2010 and 2025[1]. 
The chapter then discussed potential methodological issues for observational studies of alcohol 
consumption. One of the key issues identified was the ‘sick-quitter effect’, whereby former drinkers 
may have health conditions which caused them to quit drinking, and which may be related to 
increased morbidity and mortality when compared to lifetime abstainers. A reference group of non-
drinkers may therefore result in an underestimate of the health risks associated with drinking, and 
therefore a reference group of ‘light drinkers’ might be more appropriate.  
Finally, the aims of the thesis were specified: 
1. Review of the association between alcohol consumption and disease and injury, with a 
focus on cancer. 
2. Systematically review previous systematic reviews and meta-analyses of the association 
between alcohol consumption and all-cause mortality. 
3. Investigate the clustering of alcohol consumption with other behavioural risk factors and 
assess potential variation by country of birth. 
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4. Quantify the relationship between a variety of incident health conditions and drinking 
cessation. 
5. Quantify the relationship between alcohol consumption and cancer risk. 
6. Quantify the relationship between alcohol consumption and risk of all-cause and cause-
specific mortality. 
Chapter 2 presented a narrative review of the relationship between alcohol consumption and risk 
of disease and injury. The burden of disease and injury attributable to alcohol consumption in 
Australia in 2011 was 5.1%[2]. Of all risk factors, alcohol contributed third-most to the burden of 
disease and injury, behind smoking (9.0%) and overweight and obesity (5.5%)[2]. Drinking is 
associated with increased risk of many conditions, including at least seven types of cancer (mouth, 
pharynx, oesophagus, colorectum, liver, larynx and female breast). The incidence of two alcohol-
related cancers, breast and liver, has been increasing over time in Australia[3], although how much 
of this increase is attributable to alcohol consumption is unclear. Other diseases positively 
associated with alcohol consumption include certain infections, nutritional deficiencies, overweight 
and obesity, vascular dementia, alcohol-related dementia, Wernicke-Korsakoff syndrome, alcohol 
use disorder, epilepsy, neurodegeneration, liver disease, acute pancreatitis in men and chronic 
pancreatitis in both sexes, and other digestive system diseases such as alcoholic gastritis and 
intestinal malabsorption. Several external causes of morbidity and mortality are also related to 
alcohol, including injury, poisoning, drowning, self-harm and interpersonal violence. There is 
evidence of a J-shaped association, where lower volume drinking is associated with decreased risk 
and higher volume drinking with increased risk, for type 2 diabetes and certain types of 
cardiovascular disease (CVD) such as ischaemic heart disease and ischaemic stroke. 
A key finding of Chapter 2 was that for 23 types of cancer, the evidence for a causal relationship with 
alcohol consumption remains inconsistent or unclear. For some cancer types there is evidence from 
meta-analyses of an association with alcohol intake, but the evidence is not sufficient for the IARC 
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and WCRF to declare these associations as causal. Another key finding was that there is a need for 
observational research to explore the impact of potential biases, such as the ‘sick-quitter effect’, on 
risk estimates for disease, especially those for which an inverse association was found. Finally, it was 
found that for many health outcomes, including cancer, the influence of pattern of drinking of 
drinking on risk has not been quantified. 
Chapter 3 presented a systematic review of systematic reviews that investigated the association 
between alcohol and all-cause mortality, with a focus on methodological quality and risk of bias. 
The majority of the 18 included reviews reported a J- or U-shaped relationship with risk, with some 
finding only a positive association and some no association. The majority of reviews were considered 
to be at high risk of bias, or used a reference group of non-drinkers, which possibly biased results 
due to the ‘sick-quitter effect’. Only one review both used a reference group of lifetime abstainers 
and was considered at low risk of bias[4], and this review reported only a positive association, with a 
42% increased risk of all-cause mortality for > 6 drinks/day or ≥ 65 g/day. 
The reviews examined the influence of many factors on the shape of the alcohol-mortality risk curve, 
but in most cases, the evidence was limited or inconsistent. The factors for which this applied 
included sex, age, population (region or ethnicity), current smoking, the exclusion of participants 
with pre-existing CVD, average cohort alcohol consumption, variability in cohort alcohol 
consumption, the proportion of non-drinkers in the cohort, per capita alcohol consumption in the 
population, length of follow-up, primary study year of publication, level of adjustment for 
confounders, modelling method, primary study methodological quality and choice of reference 
group. There was also limited evidence that the risk relationship was not influenced by primary 
study sample size or by evidence of industry funding. There was however good evidence that the 
alcohol-mortality relationship differs by choice of reference group and by adjustment for primary 
study characteristics (such as adjustment for smoking, adequacy of drinking measure and follow-up 
time) at the meta-analysis level. There was also good evidence that inverse relationships between 
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alcohol and mortality could be accounted for by adjustment for primary study characteristics at the 
meta-analysis level. Additionally, that observed decreases in mortality risk is attenuated when using 
a reference group of lifetime abstainers (instead of non-drinkers) and is eliminated when using a 
reference group of occasional drinkers. Evidence was lacking for whether certain populations (e.g. 
Africa, the Middle East, Latin America), ex-smoking, pattern of drinking (including drinking frequency 
and heavy episodic drinking, independent of total alcohol consumption), change in alcohol 
consumption over time, measurement of alcohol consumption at single or multiple time points, and 
beverage type affected mortality. Evidence was also lacking regarding whether risk is cumulative 
over the lifetime or if exposure during certain periods of life are more critical for risk. 
The key findings of the systematic review were 1) potential factors that impact the relationship 
between alcohol and mortality remain unclear due to the low methodological quality of previous 
systematic reviews and meta-analyses, and 2) there is evidence that the apparent protective effect 
of moderate drinking on mortality may be accounted for by biases in primary study design including 
choice of reference choice of group, inadequate measures of alcohol consumption and differences in 
adjustment for confounding and inclusion criteria. These same factors may also be responsible for 
underestimating the harms of higher levels of drinking. It was concluded that there is a need for 
well-designed reviews and meta-analyses to examine the shape of the alcohol-mortality risk curve 
and how population subgroups, the distribution of alcohol consumption in the cohort or population, 
measures of alcohol exposure and primary study methodology may influence the relationship. The 
influence of drinking pattern on mortality risk was identified as a key evidence gap. Furthermore, 
given that the risk relationship may vary by population around the world, there is a need for local 
Australian data. 
Chapters 4 and 5 described the cohort, the 45 and Up Study, and the methods used to address the 
aims of this thesis. This included the description of three drinking patterns and a comprehensive list 
of potential cancer and mortality-specific covariates. It was shown that the 45 and Up Study is 
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comparable to other contemporaneous population surveys in NSW and Australia, although there is a 
possibility that the cohort may have better health status and healthier behaviours than the general 
population. A higher proportion of participants in the 45 and Up Study consumed alcohol at least 
weekly compared to three population surveys. Overall, 32.7% of the cohort were non-drinkers at 
baseline and 3.8% had more than 28 drinks per week. The median number of drinks per week was 4. 
Of drinkers, 37.2% consumed alcohol 6-7 days per week, and 10.5% consumed > 4 drinks per 
drinking-day. The large number of participants in the study, the use of multiple measures of alcohol 
consumption and drinking pattern and the consideration of a large number of important covariates 
were identified as strengths of the study, and overall it was concluded that the 45 and Up Study was 
well-suited to investigate the influence of alcohol consumption on risk of cancer and mortality while 
ensuring that bias from confounding was minimised. 
Chapter 6 considered the co-occurrence of alcohol consumption with other modifiable risk factors 
by combining them into a weighted chronic disease risk index (CDRI). Alcohol consumption 
contributed the most to CDRI scores among Australian-born participants and participants born in 
English-speaking countries. Participants born in Australia and English-speaking countries had higher 
odds of consuming > 14 drinks per week, having 6-7 drinking-days per week, and consuming > 4 
drinks per drinking-day compared to participants born elsewhere, even when restricted to drinkers. 
For almost all regions of birth, the odds of consuming > 14 drinks per week increased with greater 
years lived in Australia, particularly for participants born in non-English speaking countries. Using the 
CDRI, the regions of birth with the highest potential risk of chronic disease due the combination of 
risk factors were the Middle East and North Africa, and Eastern and Central Europe, while the 
regions of birth with the lowest risk were East Asia, Southeast Asia and Central and South Asia. There 
was evidence that the differences in CDRI score between Australian-born participants and 
immigrants were largely attenuated with greater number of years since migration. Specifically, the 
risk profile of immigrants approximated that of the Australian-born participants the longer they had 
lived in Australia. Overall, a key finding was that lifestyle behaviours acculturate to those of the host 
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population over time. This particularly applied to alcohol consumption for participants born in non-
English speaking countries. It was concluded that health interventions should be targeted not only at 
groups with the highest CDRI scores overall, but also at groups with low CDRI scores that may be at 
risk of worsening risk factors over time, including increased alcohol consumption. 
Chapter 7 investigated the relationship between a variety of incident health conditions and 
drinking cessation using the 45 and Up Study baseline and follow-up questionnaires. A key finding 
was that many health conditions are associated with drinking cessation and therefore have the 
potential to bias risk estimates for alcohol consumption and outcomes such as mortality. Indicators 
of general health, such as self-rated overall health and physical functioning score were associated 
with the highest hazards of quitting, with those who reported a decline in self-rated health to poor 
2.9 times more likely to quit drinking than those who maintained better health. Further, the 
persistence of associations between the general health indicator variables and drinking cessation 
after adjustment for all other health conditions suggested that there are other health conditions not 
diagnosed or not examined in the analysis that also lead to quitting. It was concluded that the 
exclusion of participants with specific health conditions (such as cancer and CVD as in some previous 
studies) is unlikely to be an adequate method of addressing the ‘sick-quitter effect’, and that 
accounting for indicators of general health, which capture most conditions associated with 
cessation, is preferable. It should be noted however that when the analysis was restricted to 
participants with good overall health or good general health indicators at follow-up, although the 
associations between quitting and health conditions were attenuated, many of the health conditions 
remained significant predictors of quitting. Thus, although preferable to excluding specific health 
conditions, accounting for general health indicators is not a completely adequate method of 
addressing the ‘sick-quitter effect’. Alternative methods of addressing the ‘sick-quitter effect’ were 
suggested, including using lifetime abstainers or light drinkers (or both) as the reference group, 
calculating a log-linear trend in risk for drinkers only, and/or excluding outcomes that occur early in 
the period of follow-up. 
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Additional analyses examined the association between incident health conditions and other changes 
in drinking behaviour, and found that the occurrence of disease and a decline in indicators of general 
health were also observed in relation to 1) a reduction in alcohol consumption to very light drinking 
(i.e. from > 3.5 drinks per week to ≥ 1 and ≤ 3.5 drinks per week), 2) a reduction in drinking 
frequency to 1-2 days per week, and 3) an increase in number of drinks consumed per drinking-day 
to > 4 drinks per drinking-day. Thus, just as using non-drinkers as a reference group in studies of 
alcohol consumption and health outcomes may bias risk estimates, so too may the use of very light 
drinkers as the reference group (i.e. a ‘sick-decreaser effect’). The results also suggested that 
frequent drinkers may have better health status than infrequent drinkers. In sensitivity analyses, the 
exclusion of participants with a low physical functioning score was shown to be the most effective 
method of addressing bias from persons changing drinking behaviours in response to ill-health, 
however studies would require that sufficient numbers of cases are retained for reliable estimates of 
risk. This method was used in sensitivity analyses in the analyses of cancer and mortality. As 
participants who consumed about 7 drinks per week appeared to have the best health status, a 
sensitivity test for the continuous linear analyses in later chapters limited to participants that 
consumed ≥ 7 drinks per week was performed to examine risk relationships under the assumption 
that the association between moderate drinking and better health status at baseline is entirely 
attributable to bias. Other methods used in later chapters to address bias from the ‘sick-quitter 
effect’ and other changes in drinking behaviours in response to ill-health included a restriction to 
participants aged less than 65 years and the exclusion of participants that died within 3 years of 
baseline. 
Chapter 8 quantified the relationship between alcohol consumption and cancer risk using Cox 
proportional hazard models and 45 and Up Study baseline data linked to the NSW Cancer Registry. In 
a median follow-up of 2.4 years, 7,733 participants had at least one diagnosis of cancer. Analyses 
included total alcohol consumption, drinking frequency and drinks per drinking-day. The results for 
total alcohol consumption were largely consistent with prior research, with increasing numbers of 
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alcoholic drinks per week associated with increased risk of cancers of the colorectum, colon, larynx 
and female breast, alcohol-related cancers combined and all cancers combined. Consuming > 28 
drinks per week was also associated with increased risk of liver cancer. For thyroid cancer and non-
Hodgkin lymphoma (NHL), where alcohol is reported to be associated with decreased risk, inverse 
associations were found. 
Of note was the independent association of drinking pattern on a number of cancer types. 
Specifically, drinks per day drinking-day and risk of cancers of the mouth and pharynx, oesophagus 
(squamous cell carcinoma), colorectum, colon, kidney, alcohol-related cancers combined and all 
cancer. There was also evidence of increased risk associated with heavy episodic drinking (> 4 drinks 
per drinking-day, 1-2 days per week) for kidney and all cancer, and with heavy frequent drinking (> 4 
drinks, 6-7 days per week) for colorectal and colon cancer, when examining drinking frequency in 
conjunction with drinks per drinking-day. 
The additional analyses in Chapter 8 examined the impact of strategies to mitigate potential bias 
from the ‘sick-quitter effect’ and changes in alcohol consumption related to ill-health on risk 
estimates for cancer. This included a restriction to participants with a physical functioning score ≥ 
50% and separately, to participants consuming ≥ 7 drinks per week. Among those with ≥ 50% 
physical functioning, linear positive trends with total alcohol consumption for cancers of the mouth 
and pharynx, oesophagus (squamous cell carcinoma). When limited to participants who consumed ≥ 
7 drinks per week, risk estimates were increased for colorectal and colon cancer, and were non-
significant and materially increased for thyroid cancer and materially decreased for breast cancer 
compared to the main analysis. Taken together, this suggests that the ‘sick-quitter effect’ may result 
in an underestimation of risk for certain cancer types due to participants decreasing their drinking in 
response to ill-health, in addition to quitting entirely. The sensitivity tests also suggested that the 
inverse association between alcohol and risk of thyroid cancer may be attributable to this same bias. 
It is possible that the loss of significance for breast cancer in sensitivity analyses may reflect 
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inadequate statistical power because the number of cases decreased by 48%. While differences 
were found for individual cancer types, there was little difference across the results of sensitivity 
tests for the continuous log-linear analysis for all cancers combined. Specifically, the hazard ratio for 
all cancers combined was 1.02 (1.00-1.04) per additional drink per day in the main analysis (broadly 
similar to the findings in all sensitivity analyses). This provided evidence that the association 
between total alcohol consumption and all cancer was not materially biased due to changes in 
alcohol consumption in response to ill-health. 
Restriction to participants with a physical functioning score ≥ 50% was also performed for the 
drinking pattern analyses. There was no material change to the inverse association between drinking 
frequency and risk of all cancers combined, however it should be noted it was shown in Chapter 7 
that this sensitivity test was likely to be less effective at mitigating potential bias when examining 
drinking frequency compared to both total alcohol consumption and drinks per drinking-day. There 
was evidence however that changes in drinking behaviour in response to ill-health may be 
responsible for bias resulting in an underestimate of the association between mean drinks per 
drinking-day and oesophageal cancer. 
Chapter 8 also reported estimates of population attributable fractions (PAF) for cancer and alcohol. 
The PAF estimate for Australia of 2.5% for all cancers combined was similar to a previous estimate of 
2.8% that used internationally-derived relative risks[5], although there was some variation by 
individual cancer types. The sensitivity test that included cancers for which there is evidence of an 
association with alcohol consumption (but for which IARC has not declared a causal association) 
made a material difference to the PAF estimate, increasing from 2.5% to 3.8% (i.e. stomach, 
pancreas, melanoma, prostate), and decreasing to 1.6% when three inversely associated cancers 
(kidney, thyroid, NHL) were included. The variation in PAF estimates demonstrates that determining 
whether the associations for the positively associated cancers are causal will make an important 
difference to burden of disease estimates for alcohol and cancer. The overall PAF estimate did not 
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change materially in sensitivity analyses, indicating that the results are not likely to be substantially 
biased by the ‘sick-quitter effect’. 
Estimates of absolute risk and number of persons needed to quit or reduce drinking to prevent one 
cancer case were also calculated. One cancer case could be prevented by the age of 75 years for 
every 42 men or 37 women who consume > 14 drinks per week quitting (or never starting) drinking. 
Persons consuming > 14 drinks per week ‘brought forward’ their risk of alcohol-related cancer by 3.5 
years compared to non-drinkers. The results for all cancer risk were in most cases not materially 
altered by the sensitivity analyses aiming to reduce bias from the ‘sick-quitter effect’, indicating little 
evidence that the results were biased due to confounding by baseline health status.  
Chapter 9 quantified the relationship of alcohol consumption and mortality using Cox proportional 
hazard models and 45 and Up Study baseline data linked to the NSW Registry of Births, Deaths and 
Marriages. In 6.4 years follow-up, 13,988 deaths occurred that were included for analysis. The 
results for total alcohol consumption were largely consistent with prior research, with increasing 
numbers of alcoholic drinks per week associated with increased risk of all-cause mortality and death 
from alcohol-related cancer including oesophageal, liver and kidney cancer, CVD, digestive system 
disease including liver disease, external causes including fall and suicide, and other causes combined. 
There was an inverse association with death from NHL. J-shaped associations were found for all-
cause mortality and death from CVD. Mortality estimates were affected by inclusion or exclusion of 
participants with prior disease at baseline, with the positive associations with risk for death from 
alcohol-related cancer, oesophageal cancer, kidney cancer, and CVD only significant when these 
participants were excluded. 
There was an independent positive association between drinks per drinking-day and risk of death 
from all cancer, oesophageal cancer, non-alcohol-related cancer, lung cancer, kidney cancer and all-
cause mortality. Frequent drinking was independently associated with higher risk of respiratory 
system disease mortality and lower risk of death from all cancer, non-alcohol-related cancer, 
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diabetes, CVD, ischaemic heart disease and all-cause mortality compared to less frequent drinking, 
although it is possible that these associations at least partially reflect residual confounding by 
baseline health status. There was evidence of increased risk associated with heavy episodic drinking 
(> 4 drinks per drinking-day, 1-2 days/week), heavy frequent drinking (> 4 drinks, 6-7 days/week), 
and decreased risk of frequent low-volume drinking (≤ 2 drinks on 3-5 days/week), for all-cause 
mortality risk. 
There were some important conclusions regarding bias. Despite finding a J-shaped non-linear 
association between alcohol consumption and CVD mortality, there was no significant protective 
effect. The evidence suggested that reduction in alcohol consumption in response to CVD diagnosis 
is likely to have biased risk estimates for CVD mortality, due to a significant linear trend of increased 
risk when participants with prior CVD were excluded. This interpretation was supported by the 
empirical evidence from Chapter 7 that heart disease and stroke are both associated with drinking 
cessation and reduction. Another conclusion concerning the possibility of bias was for drinking 
frequency. Specifically, there is no mechanistic basis for alcohol consumption to lower cancer risk, 
and yet strong inverse associations with drinking frequency were observed for all cancers combined 
and non-alcohol-related cancers combined. These two outcomes may serve as ‘negative controls’[6], 
indicating that inverse associations with drinking frequency for other outcomes including CVD and 
all-cause mortality may be attributable to bias from reverse causation or incomplete adjustment 
from confounding. 
Additional analyses in Chapter 9 examined the impact of sensitivity analyses aimed to mitigate 
potential bias from the ‘sick-quitter effect’ and other changes in alcohol consumption related to ill-
health. These sensitivity tests included restriction to participants with a physical functioning score ≥ 
50% and to participants consuming ≥ 7 drinks per week. Many differences in risk estimates were 
found for individual causes of death when employing these sensitivity tests. There were trends of 
increased risk with total alcohol consumption for death from oesophageal cancer, liver cancer, CVD 
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and other causes combined, while there were trends of decreased risk for death from breast cancer 
and dementia. The trend of increased risk was non-significant and materially decreased for death 
from fall compared to the main analysis, while the trend of decreased risk was non-significant and 
materially increased for death from NHL, suggesting that these associations may be at least partially 
accounted for by changes in drinking behaviours in response to ill-health, in addition to quitting 
entirely. The finding that the exclusion of participants with a low physical functioning score resulted 
in an inverse association for dementia mortality also adds to the evidence that this association may 
be causal, however this was not found in all sensitivity analyses. 
Furthermore, in a sensitivity test excluding participants with prior disease for the log-linear analysis, 
were significant positive associations for risk of death from oesophageal cancer, breast cancer, and 
CVD. The inverse association for death from prostate cancer was non-significant and materially 
increased compared to the main analysis. The results suggest that risk estimates for several cancer 
mortality outcomes in the main analysis may be underestimated due to participants decreasing their 
alcohol intake in response to ill-health. For breast cancer mortality, the results were inconsistent 
overall, with the sensitivity test restricting to participants consuming ≥ 7 drinks per week resulting in 
a significant positive association and the test restricting to participants with a physical functioning 
score ≥ 50% resulting in an inverse association. This suggests further research involving greater 
numbers of breast cancer deaths is required to investigate the role of bias from changes in drinking 
behaviours in response to ill-health on this association. 
The possibility that mortality risk may be underestimated was supported by the sensitivity tests for 
the continuous log-linear analysis for all-cause mortality. Two sensitivity tests that would be 
expected to increase bias from the ‘sick-quitter effect’ (including non-drinkers and deaths occurring 
within three years of baseline) both resulted in lower effect estimates, while four sensitivity analyses 
that would be expected to reduce bias from the ‘sick-quitter effect’ (restricting to participants with a 
physical functioning score ≥ 50%, restricting to participants consuming ≥ 7 drinks per week, 
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excluding deaths occurring within 5 years of baseline, and excluding participants who had ever been 
diagnosed with cancer or CVD) resulted in higher effect estimates. This suggests that while the steps 
taken of restricting to drinkers only and excluding deaths occurring within the first three years of 
follow-up were effective in reducing bias from the ‘sick-quitter effect’ and decreased drinking in 
response to ill-health, it is probable that these biases was not eliminated entirely, meaning that the 
effect estimates in the main analysis are likely to be underestimated. Overall, there was evidence 
that bias induced by changes in drinking behaviours in response to ill-health is important to account 
for when interpreting the results. 
Restriction to participants with a physical functioning score ≥ 50% was also performed for the 
drinking pattern analyses, and there was largely no evidence that these risk estimates may be biased 
due to changes in drinking behaviours in response to ill-health. It should again be noted however 
that this sensitivity test may not have been effective at mitigating potential bias when examining 
drinking frequency. 
Chapter 9 also contained estimates of PAF for all-cause mortality, which varied appreciably 
depending on the assumptions made about whether linear or non-linear relationships were 
modelled, whether the association for some diseases of reduced risk with low-volume drinking is 
causal and whether participants with prior disease or a physical functioning score < 50% should be 
excluded from calculations. In all cases, the 45 and Up Study-derived PAF estimates were greater 
than zero, indicating that under all scenarios tested, alcohol consumption caused more deaths than 
it prevented. A PAF of 2.2% was derived using continuous log-linear hazard ratios in the main 
analysis, but this doubled to 4.4% if participants with prior cancer and CVD were excluded from the 
calculations, with a PAF of up to 5.5% when using the log-linear hazard ratios derived from the 
sensitivity analysis restricting to participants consuming ≥ 7 drinks per week. Thus, the main analysis 
may have substantially underestimated the association between alcohol consumption and mortality 
due to confounding by baseline health status. 
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Estimates of absolute risk and number of persons needed to quit or reduce drinking to prevent one 
death were calculated. One death could be prevented by the age of 75 years for every 36 men or 56 
women who consume > 14 drinks per week quitting (or never starting) drinking. Persons consuming 
> 14 drinks per week ‘brought forward’ their risk of all-cause mortality by 2 years compared to non-
drinkers. There was evidence that these values may be underestimated due to confounding by 
baseline health status. Finally, if the conservative assumption is made that the inverse association 
between alcohol consumption and risk of mortality is entirely attributable to bias, there was 
evidence that the Australian alcohol guideline to limit the risk of long-term harm should be lowered 
from ≤ 2 drinks per day (allowing up to 14 drinks per week) to ≤ 7 drinks per week to ensure that 
lifetime risk of alcohol-attributable mortality for all persons remains less than 1%.
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Strengths and limitations of the thesis 
One major strength of this thesis is the large sample size of the 45 and Up Study, which allowed for 
detailed analyses of drinking patterns on various health outcomes. Specifically, risk factor clustering 
for a dozen regions of birth including those which make up a relatively small proportion of the 
Australian population; the relation of 32 health conditions and indicators of general health to 
drinking cessation and other changes in drinking behaviour; and risk of a large range of cancer types 
and causes of death. Indeed, the analysis of factors related to drinking cessation is substantially 
larger than any previous study on the topic, with approximately 6.5 times more participants than the 
next largest study[7]. 
Another important strength of the thesis was the use of data linkage to obtain cancer incidence and 
mortality outcomes. As all cancer cases diagnosed and deaths occurring in NSW are recorded in the 
NSW Central Cancer Registry and NSW Registry of Births, Deaths and Marriages respectively, it is 
expected that almost all outcomes were captured. This eliminated bias from loss to follow-up, which 
if differential by level of alcohol consumption or drinking pattern may have resulted in an 
underestimate of cancer or mortality risk in certain drinking groups. This also avoided potential bias 
from alternative methods of outcome ascertainment, such as self-report which is less reliable. 
The large number of key covariates available for adjustment was another strength of the thesis. 
Chapter 4 demonstrated the variation in alcohol consumption by each covariate, revealing that 
failure to adjust for these covariates may have biased risk estimates in prior studies. It has also been 
shown in prior research that a large number and variety of covariates are associated with alcohol 
consumption and patterns of drinking[8, 9]. The quantity and breadth of covariates adjusted for was 
comparable to other large previous studies of alcohol consumption and cancer and mortality risk[10-
12]. 
The measures of alcohol consumption and drinking pattern used in the analyses were also a 
strength. When total alcohol consumption was examined categorically, a reference group of very 
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light drinkers was used rather than non-drinkers to mitigate bias from the ‘sick-quitter effect’. Total 
alcohol consumption was also modelled as a continuous log-linear variable and a restricted cubic 
spline excluding non-drinkers, to limit the impact of this bias. Unlike the majority of prior studies 
investigating the effect of pattern of drinking, drinking frequency and drinks per drinking-day were 
adjusted for total alcohol consumption enabling the independent effect of these measures of 
drinking pattern to be evaluated. This was an important strength, as it is otherwise not possible to 
determine whether effects are due to drinking pattern itself or are simply attributable to total 
alcohol consumption. The test for interaction between drinking frequency and drinks per drinking-
day and stratification into an overall drinking pattern variable enabled the impact of these measures 
of drinking pattern on risk to be explored concurrently, something few previous studies have 
examined. 
A further strength of the thesis was the use of sensitivity tests aimed to systematically and 
comprehensively examine the impact of bias due to the ‘sick-quitter effect’ and other changes in 
drinking behaviours in response to ill-health (decreased drinking and changes in drinking frequency 
and drinks per drinking-day). In particular, the empirically-derived sensitivity test of restricting to 
participants with a physical functioning score of ≥ 50%, to test the robustness of the cancer and 
mortality risk estimates to these biases. This provided evidence that the effect estimates for all-
cause mortality were likely to be higher than those reported in the main analysis due to the inclusion 
of those with impaired health status at baseline, who were more likely to have quit or decreased 
drinking. The observed estimates for all cancer risk however, appeared to be robust and not 
materially impacted by the ‘sick-quitter effect’. 
There were also several limitations. While the number of participants in the study was large, the 
length of follow-up and number of outcomes was limited. This was especially true for the cancer 
incidence data, which was only available for analysis to December 2010 at the time of thesis 
submission. This reduced the statistical power of the analyses.  
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Another limitation was the measure of alcohol consumption. In particular, the questionnaire item for 
number of drinks consumed per week had the instruction: “Put “0” if you do not drink, or have less 
than once drink each week”. This meant the ‘non-drinking’ group was an amalgam of three distinct 
drinking groups – lifetime abstainers, former drinkers and occasional drinkers, which likely have 
different risk profiles. While it has been suggested that lifetime abstainers should be used as a 
reference group, there is evidence that lifetime abstainers have poorer health status in comparison 
to drinkers, and therefore using lifetime abstainers as the reference group may result in conservative 
estimates of the effects of drinking on health, which has been termed the ‘sick non-starter 
effect’[13, 14]. Risks in relation to drinking cessation were also unable to be investigated, including 
the length of time following cessation that risk of alcohol-related cancer and mortality return to 
baseline, and whether there is a particular age by which one can cease heavy episodic drinking to 
obtain maximal health benefits. 
Some prior studies have also recorded alcohol consumption at multiple time points (either 
retrospectively or prospectively from baseline)[12, 15] to enable estimates of lifetime alcohol 
consumption rather than consumption at a single time point. This also has the advantage of 
mitigating bias from regression dilution, which can occur in studies measuring alcohol consumption 
at a single time point[16]. While prospective alcohol consumption data was available with the first 
follow-up questionnaire, retrospective data would be required to investigate questions relating to 
drinking over the life course. One of these questions is whether cancer and mortality risk related to 
alcohol consumption and pattern of drinking is cumulative, or whether exposure at particular stages 
of life is important, such as during young adulthood. For example, there is evidence that ultraviolet 
light exposure during childhood and adolescence is associated with greater risk of skin cancer 
compared to exposure during adulthood[17]. 
A further questionnaire item which would have enabled comparison to some previous studies was 
the maximum number of drinks consumed on one occasion over a longer time period, such as one 
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month[18, 19]. This would have enabled heavy episodic drinking that occurs less frequently than 
once per week to be examined. As a result, future follow-up questionnaires may contain a question 
to identify lifetime abstainers, former drinkers and occasional drinkers, along with the question: “In 
a typical month, what is the largest number of drinks you have in one day?”. Beverage type was also 
missing from the questionnaire, meaning that it was not possible to compare potential differences in 
risk relationships by this factor. For example, there is some evidence that beverage type may be 
important for CVD[20] and alcoholic liver disease risk[21], with lower risk associated with wine 
consumption compared to beer and spirit consumption. 
Alcohol exposure was ascertained by self-report, which may be unreliable. Respondents may have 
had difficulty estimating (often underestimating) the quantity of alcohol they consume[22, 23], and 
may also under-report consumption due to concern that their drinking does not match societal 
norms[22, 24]. These issues typically result in an underestimate of consumption overall, which if 
differential could bias associations between total alcohol consumption and health outcomes towards 
or away from the null. Reports are inconsistent on whether underreporting differs by drinking 
pattern. Australian and Canadian studies found that low-risk and non-heavy episodic drinkers 
underreported their alcohol consumption to a greater degree than higher-risk and heavy episodic 
drinkers[25, 26], while an English study found underreporting was disproportionately associated 
with heavy drinking, frequent drinking and non-routine drinking[27]. Therefore, the risk estimates 
for drinking patterns may also be susceptible to bias from measurement error. Overall, if alcohol 
consumption is underreported in the 45 and Up Study, the extent of risk associated with each level 
of drinking would be an overestimate, as the risk ascribed to a specific level of consumption may 
actually represent the risk associated with higher levels of consumption. This means that extra 
caution should be applied when inferring thresholds of risk for alcohol consumption guidelines.  
It was also shown in Chapter 5 (and has previously been reported[28]) that the participants of the 45 
and Up Study are not representative of the general population of NSW. Participants generally had 
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more favourable socio-demographic, self-rated overall health and lifestyle risk factors than in 
population surveys, as well as a greater prevalence of weekly alcohol consumption. Further, those 
with more extreme drinking behaviours, such as those with mental illness and those who are 
institutionalised, are not likely to participate in surveys of this kind. This may have led to a ‘healthy 
volunteer effect’[29, 30], causing the observed incidence of cancer, CVD and mortality to be lower 
than expected. A detailed comparison of the 45 and Up Study with the NSW Population Survey 
found consistent exposure-outcome relationships between the two studies however, meaning that 
the 45 and Up Study will most likely provide generalisable results when analyses are based on 
internal comparisons within the cohort[28]. 
Further, as the 45 and Up Study was based on middle-aged and older participants, survival bias 
cannot be ruled out[31]. Given those with a history of heavy drinking and heavy episodic drinking are 
at a higher risk of mortality and morbidity, they are less likely to be sampled. Thus heavy drinkers 
may be underrepresented in the 45 and Up Study, particularly those in older age groups. Indeed, 
there were few heavy drinkers among women, which reduced the reliability of risk estimates for 
heavy drinking and drinks per drinking-day for some female-specific outcomes, including risk of 
breast, endometrial and cervical cancer. The exclusion of persons aged < 45 years also meant that 
the harms of drinking in younger persons and interactions with age could not be examined. For 
example, the risk relationship between alcohol consumption and outcomes such as all-cause 
mortality and death from external causes may have differed if younger participants were included. 
Lastly, despite efforts to use sensitivity tests to remove bias from the ‘sick-quitter effect’ and other 
changes in drinking behaviour caused by ill-health, these attempts could not be expected to remove 
all of the bias, as shown in Chapter 7. Therefore, the effect estimates for cancer and mortality risk 
may still be biased due to differing health status between groups of different consumption levels. 
Moreover, this bias makes interpretations about the association between low-volume drinking and 
frequent drinking with reduced mortality risk difficult, because sensitivity tests suggested that 
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excluding those with ill-health reduced inverse associations, but it was not possible to infer whether 
the effect could be wholly accounted for by bias. The use of a younger cohort with alcohol 
consumption ascertained at multiple time points may help to reduce the impact of this bias. A 
randomised controlled trial of low-volume drinking and drinking frequency would provide more 
conclusive evidence[32]. 
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Research gaps and implications for future research 
The relationship between alcohol consumption and health outcomes 
For many health conditions, despite the work in this thesis, the precise relationship between alcohol 
consumption, drinking pattern, and risk of incidence and mortality remains to be determined. For 
outcomes which have been inversely associated with alcohol consumption in particular, such as type 
2 diabetes, dementia and CVD, further studies are required with careful examination of bias from 
changes in drinking behaviours in response to ill-health to investigate whether these inverse 
associations are truly causal, and whether the risk of harm associated with heavy drinking and heavy 
episodic drinking is underestimated. This may also involve the use of measures of drinking pattern 
which were not available in this study but have been previously used in research, such as beverage 
type and maximum number of drinks consumed in one day in one month (to capture heavy episodic 
drinking that occurs less frequently than once per week). Additional research is also required for 
some female-specific outcomes such as drinking pattern and risk of breast, endometrial and ovarian 
cancer due to the small number of women with a high number of drinks per drinking-day in this 
study. Furthermore, as risk relationships may vary among populations around the world, it would be 
of interest to examine the association between alcohol consumption and health outcomes among 
immigrant groups in Australia as well as Indigenous Australians. There were not yet enough cancer 
cases and deaths to answer this question using the 45 and Up Study for the former, while Indigenous 
status data was not available and was outside the scope of this thesis for the latter. Indigenous 
Australians experience substantial burden from alcohol-related harm, and so epidemiological 
research in this group should be a priority. 
In addition, for diseases other than cancer, associations were only able to be examined for mortality, 
rather than incidence. As well as potential bias from confounding due to differences in health status 
between drinking groups, there may be true underlying differences in the risk relationship for 
certain diseases for incidence compared to mortality. For example, it has been reported in a meta-
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analysis that the relationship between alcohol consumption and liver cirrhosis differs whether the 
outcome is incidence or mortality, as alcohol consumption negatively influences the course of 
existing liver cirrhosis and accelerates liver cirrhosis mortality[33]. Risk relationships with alcohol 
consumption and drinking pattern for other diseases may similarly differ by choice of outcome, and 
so the impact of bias from changes in drinking behaviour in response to ill-health should be 
investigated for the incidence of disease as well as mortality. The use of incidence as an outcome for 
diseases such as type 2 diabetes and dementia may also have the advantage of providing greater 
statistical power, which may have been lacking in this study. 
Furthermore, studies investigating the independent effect of drinking pattern on risk of disease 
incidence and mortality must include adjustment for total alcohol consumption, to determine 
whether drinking pattern has an independent effect on risk or whether the effect is primarily 
mediated through total alcohol consumption. 
Recommendation: Further research is required to understand the relationship between alcohol 
consumption, drinking pattern and risk of disease incidence and mortality. Variation in the risk 
relationship by population subgroups such as immigrants and Indigenous Australians could be 
investigated. It is especially important that the role of bias from changes in drinking behaviours in 
response to ill-health be investigated for all associations, along with adjustment for total alcohol 
consumption when examining the influence of patterns of drinking on risk. 
 
The systematic review of previous systematic reviews and meta-analyses also highlighted several 
opportunities to improve the evidence base regarding the association between alcohol consumption 
and all-cause mortality. As most prior systematic reviews were found to be at high risk of bias, the 
evidence was inconsistent for differences in the risk relationship by sex and age, and there was only 
limited evidence for differences by smoking status and duration of follow-up. Furthermore, there 
were some topics for which systematic review evidence was lacking entirely. These included 
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whether the risk relationship differed by certain populations (e.g. Africa, the Middle East, Latin 
America), smoking status when including an ex-smoking category, pattern of drinking (including 
drinking frequency and heavy episodic drinking), changes in alcohol consumption over time, and 
beverage type. One of the most important topics of research is whether the association between 
low-volume drinking and decreased risk may be accounted for by biases in primary study design, 
including choice of reference choice of group, inadequate measures of alcohol consumption, 
differences in adjustment for confounding and differences in inclusion criteria. Further carefully 
designed systematic reviews and meta-analyses with high methodological quality (such as the review 
by Stockwell et al., (2016)[4]) that capture primary studies that have been published since 2016 are 
required to investigate the influence of these factors, particularly pattern of drinking, on the 
association between drinking and all-cause mortality. 
Recommendation: Systematic reviews and meta-analyses with high methodological quality are 
required to investigate factors influencing the association between alcohol consumption and all-
cause mortality, including patterns of drinking such as drinking frequency and heavy episodic 
drinking. A research priority should be to continue to investigate whether the inverse association 
between low-volume drinking and mortality can be accounted for by bias. 
 
One area of research relating to drinking pattern and alcohol consumption more broadly is the 
timing between exposure and outcome for risk of cancer, other disease and mortality. Firstly, it 
should be investigated whether the lag-time between drinking patterns (such as heavy episodic 
drinking) and cancer risk is the same as that for total alcohol consumption. That is, the length of time 
between exposure and outcome. Previous estimates for the lag-time between alcohol consumption 
and cancer mortality have ranged from 8 to 25 years[34, 35]. Another research gap is whether the 
risk associated with heavy episodic drinking while young persists throughout life, and whether risk is 
greater during certain age periods, such as in young adulthood. Does the cessation of heavy episodic 
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drinking cause a reduction in cancer and mortality over time and a return to the baseline level of 
risk, or only prevent further increased risk? Is there a particular age by which one can cease heavy 
episodic drinking to obtain maximal benefit to cancer and mortality risk? For example, there is 
evidence that increased risk of breast cancer with drinking begins in young adulthood[36], and in the 
Nurses’ Health Study it was found that alcohol consumption in earlier and later life both 
independently increase risk[37]. Understanding risk lag-time and the relationship between changes 
in heavy episodic drinking behaviour (and more broadly, for total alcohol consumption) and health 
outcomes would enable population attributable fractions and burden of disease estimates for 
drinking, as well as individual risk assessments, to be modelled more accurately. The incorporation 
of heavy episodic drinking and possibly other patterns of drinking into these estimates would ensure 
that individual and population interventions involving alcohol consumption can be planned and 
targeted to achieve maximal health benefit. 
Recommendation: Further research is required to understand the exact lag-time between exposure 
and outcomes, differences in risk by age and period of life, and the effect of changes in drinking 
behaviours on associations between total alcohol consumption and patterns of drinking (including 
heavy episodic drinking) on risk of cancer, other disease and mortality. 
 
It was shown in Chapter 1 that there are no consistent definitions for terms such as ‘occasional’, 
‘light’, ‘low-volume’, ‘moderate’ and ‘heavy’ drinking, as well as the term ‘heavy episodic drinking’. 
These terms should be globally standardised so that the findings of studies can be more easily 
compared and translated into practice. For heavy episodic drinking, the occasional consumption of > 
4 drinks per drinking-day could be adopted as a standardised definition, or alternatively the 
definition recommended in a review adapted from the United States National Institute on Alcohol 
Abuse and Alcoholism definition: “A pattern of drinking alcohol that brings BAC to 0.08 gram percent 
or above (≥5/4 for men/women in 2 hr) on more than one occasion within the past 6 months”[38]. 
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Recommendation: Terms such as ‘occasional’, ‘light’, ‘low-volume’, ‘moderate’ and ‘heavy’ drinking, 
as well as the term ‘heavy episodic drinking’, could be globally standardised to enable the results of 
future studies to be more easily compared and translated into practice. 
 
Causal mechanisms for differences in risk by pattern of drinking 
It is also of importance to investigate evidence for causal mechanisms regarding the independent 
effect of drinks per drinking-day and heavy episodic drinking on cancer, other disease and mortality 
risk. For example, it was found there was an independent positive association between drinks per 
drinking-day and risk of mouth, pharynx and oesophageal cancer, but not breast cancer. Perhaps this 
implies that the accumulation of acetaldehyde in the upper aerodigestive tract on single drinking 
occasions has an exponential effect on cancer risk at this site, while the drinking-induced increase in 
levels of hormones associated with breast cancer risk depends only on total alcohol consumption. It 
may also be necessary to investigate causal mechanisms for drinking frequency if the association 
with decreased risk of cancer, other disease and mortality is truly causal. 
Recommendation: Further research is required to understand the mechanistic evidence underlying 
the independent relationship between drinking patterns (especially drinks per drinking-day and 
heavy episodic drinking) and cancer, other disease and mortality risk. 
 
Mitigating bias from the ‘sick-quitter effect’ and other changes in drinking behaviours in response to 
ill-health 
This thesis also identified a number of methodological considerations for future studies of alcohol 
and its impact on health outcomes. It was shown in Chapter 7 that the exclusion of participants with 
health conditions or poor indicators of general health at baseline is likely to be an inadequate 
method of addressing bias from the ‘sick-quitter effect’ and other changes in drinking behaviours in 
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response to ill-health. Future studies should instead use a reference group of lifetime abstainers or 
light drinkers (or both), calculate a log-linear trend in risk for drinkers only, assign ex-drinkers to 
their former levels of drinking at analysis (if available), ascertain alcohol consumption at multiple 
time points (either retrospectively or prospectively from baseline), exclude outcomes that occur 
early in the period of follow-up, or restrict the study to younger participants. Ideally more than one 
of these methods would be performed, along with a sensitivity test to at least examine the 
possibility that changes in drinking behaviours in response to ill-health may have biased risk 
estimates. It would also be of interest for future studies to quantify the magnitude of potential bias 
from the ‘sick non-starter effect’[13, 14] on risk estimates for cancer, other diseases and mortality.  
Recommendation: Future studies using alcohol consumption as an exposure should use methods 
other than the exclusion of participants with health conditions or poor indicators of general health 
to address bias from the ‘sick-quitter effect’. A sensitivity test examining the possibility of bias due to 
changes in drinking behaviours in response to ill-health should also be performed. The possibility of 
bias due to the ‘sick non-starter effect’ should also be investigated. 
 
While it was shown that the exclusion of participants with a low physical functioning score (i.e. score 
< 50) was likely to be useful as a sensitivity test to assess whether the ‘sick-quitter effect’ and other 
changes in drinking behaviours in response to ill-health have biased risk estimates, this test did not 
eliminate all bias. In particular, this test was shown to be less effective at mitigating potential bias 
when examining drinking frequency compared to both total alcohol consumption and drinks per 
drinking-day. This sensitivity test could be refined by examining alternative cut-points for restriction. 
This comparison could be performed empirically using the same methods as in Chapter 7. 
Furthermore, only four indicators of general health were examined in this thesis. There are many 
other indicators of general health and health status in the literature, including the Medical 
Outcomes Study Short Form surveys (a portion of which appeared in the 45 and Up Study as the 
443 
 
physical functioning score), Nottingham Health Profile, Sickness Impact Profile, Health Utilities Index, 
the Quality of Well-being Scale, Assessment of Quality of Life, and the Charlson Comorbidity 
Index[39, 40]. It is possible that these may be better predictors of drinking cessation than the 
indicators of general health examined in this thesis, and therefore may be used to create a more 
effective sensitivity test. 
Recommendation: Further research is required to refine the sensitivity test involving the exclusion 
of participants with low physical functioning score to examine possible bias due to changes in 
drinking behaviours in response to ill-health. The use of alternative indicators of general health as a 
sensitivity test should also be investigated. 
 
Ill-health and changes in other behavioural risk factors 
As it was shown that the development of a variety of health conditions is associated with changes in 
alcohol consumption, it would also be of interest to investigate how this may apply to other risk 
factors, including the co-occurrence of multiple risk factors. For example, one area of research may 
be to examine whether ill-health is associated with changes in CDRI score as well as changes in 
individual risk factors, to ascertain a more complete picture of how ill-health is associated with 
behaviour change, and how this may influence future chronic disease risk. Whether any changes 
persist in the long-term is also an area for further research. Furthermore, perhaps changes in other 
risk factors in response to ill-health may cause biased associations with health outcomes in the same 
way as the ‘sick-quitter effect’ for alcohol consumption. 
Recommendation: The association between the development of health conditions and changes in 
behavioural risk factors other than alcohol consumption should be investigated, including changes in 
the co-occurrence of multiple risk factors. 
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Evidence for implementation of the findings for heavy episodic drinking to achieve public health 
benefit 
Due to the finding of independent associations with risk, there is also a need for implementation 
research around interventions, both individual and population, targeting heavy episodic drinking for 
the prevention of cancer, other disease and mortality. One question which should be investigated is 
whether behaviour change can be facilitated by increasing awareness that heavy episodic drinking 
raises risk of cancer and other chronic disease in addition to acute events such as accidents and 
injuries. It is particularly important for this research to be performed in middle-aged and older 
persons, due to the ageing of the population and the higher risk of cancer in this group, and as anti-
heavy episodic drinking campaigns have typically been targeted at younger persons in the past. As 
consuming > 4 drinks per drinking-day is more prevalent in men than women[41], targeting middle-
aged and older men in particular could be a worthwhile strategy, especially if it can be determined 
whether cessation of heavy episodic drinking results in decreased cancer risk over time. There is also 
a need for further research on the effectiveness of primary healthcare brief alcohol interventions in 
ethnic minority groups[42], and it was found in this thesis that immigrants born in non-English 
speaking countries in particular were at potential risk of worsening alcohol consumption behaviours 
over time. Therefore research could also be performed in immigrants and Indigenous Australians. 
Recommendation: There is a need for implementation research on individual and population 
interventions targeting heavy episodic drinking for the prevention of cancer, other disease and 
mortality. A research priority should be to investigate interventions for middle-aged and older 
persons, particularly men, immigrant groups and Indigenous Australians. 
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Implications for policy and action 
The outcomes of this thesis have a number of implications for policy and actions aimed at reducing 
the burden of disease and injury from alcohol consumption in Australia, and in particular for 
informing future reviews and health guidelines. The NHMRC guidelines recommend: 
1. “For healthy men and women, drinking no more than two standard drinks on any day reduces 
the lifetime risk of harm from alcohol-related disease or injury.” 
2. “For healthy men and women, drinking no more than four standard drinks on a single occasion 
reduces the risk of alcohol-related injury arising from that occasion.”[43] 
 
The current NHMRC guideline to reduce the lifetime risk harm was designed to limit lifetime risk of 
alcohol-related mortality to 1%[43]. It should be noted however that the guidelines are based on 
international relative risks, and risk may differ between populations. The findings for alcohol and 
mortality observed in this thesis suggest that 2 drinks per day may be too many. Specifically, the 
association between alcohol consumption and all-cause mortality appeared to be substantially 
underestimated due to methodological factors such as changes in drinking behaviour caused by ill-
health. In the main analysis, the risk of all-cause mortality per additional drink per day was 1.03 (95% 
confidence interval: 1.02-1.05) but up to 1.05 (1.03-1.07) in sensitivity analyses, while the PAF value 
for drinking and all-cause mortality was 2.2% in the main analysis and as high as 5.5% in sensitivity 
analyses. There was evidence presented that the NHMRC guideline to reduce the lifetime risk of 
harm could be lowered to 7 drinks per week, to ensure that lifetime risk of alcohol-attributable 
mortality remains less than 1%. The limitation should be noted that if alcohol consumption was 
underreported in the 45 and Up Study then the level of risk associated with 7 drinks per week may 
be an overestimate. Furthermore, it may be prudent for future guidelines to reassess whether a 1% 
lifetime risk of mortality is an appropriate cut-point, as this level of risk is higher than society accepts 
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for most other voluntary (such as driving) and involuntary exposures (such as contaminants in 
drinking water)[44]. 
It was also found that drinks per drinking-day, including heavy episodic drinking, is an independent 
risk factor for cancer incidence and all-cause mortality. A significant increased risk was detected for > 
2 drinks per drinking-day for cancer incidence and > 4 drinks per drinking-day for all-cause mortality, 
however the exact threshold for harm is unknown. The guidelines could therefore emphasise that 
consuming many drinks in one occasion increases risk of long-term harm including cancer and all-
cause mortality (not just injury as captured by the current guideline to limit risk of short-term harm), 
to a greater degree than the same quantity of alcohol consumed over several occasions. That is, in 
addition to a guideline of 7 drinks per week, risk of long-term harm will be lower if individuals limit 
their consumption on any one day as much as possible. If one were to consume 7 drinks per week, 
the safest drinking pattern would be one drink per day. As the threshold for increased risk associated 
with drinks per drinking-day is unknown but increased cancer risk was detected at > 2 drinks per 
drinking-day, the current recommendation of no more than 2 drinks on any day could be retained as 
a guideline for drinks per drinking-day. 
The existence of two guidelines and two cut-points, one to limit risk of long-term harm and one to 
limit risk of short-term harm, is potentially confusing to individuals and sends mixed messages. The 
results support one clear guideline to limit risk of both long-term and short-term harm, addressing 
both a maximum number of drinks per week and a maximum number of drinks per day. Therefore, a 
potential future drinking guideline could recommend: 
For healthy men and women, drinking no more than seven standard drinks per week and 
no more than two standard drinks on any day reduces the lifetime risk of harm from both 
alcohol-related disease and injury. 
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The results also have implications for other aspects of the alcohol guidelines. There was formerly a 
recommendation to have one or two alcohol-free days per week, in the 2001 guidelines[45]. The 
rationale for this was that although the evidence for effect on health was limited, it may help people 
control their drinking habits and avoid alcohol dependency. This recommendation did not appear in 
the 2009 guidelines, although it is mentioned in the explanatory document that alcohol-free days 
can further reduce the lifetime risk of disease and injury[43]. The results of this thesis imply however 
that heavy episodic drinking, even 1-2 days per week, can cause a substantial increased risk of 
cancer incidence and all-cause mortality, similar to that of heavy frequent drinking. This suggests 
that a recommendation of 1-2 alcohol-free days per week (or even 5-6) would not importantly 
reduce alcohol-related harm. 
Furthermore, it was shown in the alcohol and mortality analysis that despite observing a J-shaped 
non-linear association between alcohol consumption and CVD mortality, there was no significant 
protective effect. The use of light drinkers as the reference group rather than non-drinkers, the 
exclusion of participants who died within three years of baseline, and the exclusion of participants 
with prior CVD as a sensitivity analysis were used to account for potential methodological 
considerations which may have caused a spurious protective association in previous studies. 
Importantly, the exclusion of participants with prior CVD resulted in a significant positive linear trend 
of alcohol and risk for CVD mortality. It was also shown empirically in Chapter 7 that heart disease 
and stroke are associated with drinking consumption cessation and reduction. Therefore, this thesis 
provides evidence that alcohol guidelines should not regard the apparent protective association 
between ‘moderate’ drinking and CVD mortality as causal. 
Finally, as it was shown that drinking pattern influences cancer and mortality risk, population health 
surveys designed to measure the prevalence of drinking behaviours could record frequency of 
alcohol consumption as well as total amount. This will enable the drinks per drinking-day and more 
complex patterns of drinking such as heavy episodic drinking and heavy frequent drinking to be 
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captured, so that the prevalence of drinking patterns in Australia can be monitored and linked to 
health outcomes. These estimates may also be used to calculate more accurate disease burden and 
population attributable fractions for alcohol consumption. 
Recommendation: To develop guidelines that reduce the burden of alcohol-related harm in 
Australia, the national alcohol guidelines revision could consider the evidence presented in this 
thesis along with all previous evidence. Specifically, that the alcohol-mortality relationship may be 
underestimated due to bias from changes in alcohol consumption in response to ill-health and that a 
limit of 7 drinks per week may be required to ensure that lifetime risk of alcohol-attributable 
mortality remains below 1%, that individuals limit their consumption on any one day as much as 
possible, and that the apparent protective association between ‘moderate’ drinking and 
cardiovascular disease mortality should not be regarded as causal. A potential future drinking 
guideline could recommend: For healthy men and women, drinking no more than seven standard 
drinks per week and no more than two standard drinks on any day reduces the lifetime risk of harm 
from both alcohol-related disease and injury. Population health surveys could also be designed to 
capture drinking pattern so that the prevalence of harmful patterns of drinking can be estimated.  
 
As well as alcohol guidelines, the findings of this thesis can also be considered in the alcohol policy 
debate. In Chapter 1, current public health efforts to reduce alcohol-related harm in Australia were 
discussed. The seven policy areas which can be used to reduce the burden of alcohol consumption 
were pricing and taxation, regulating physical availability, modifying the drinking environment, drink-
driving countermeasures, education and persuasion, restrictions on marketing and treatment and 
early intervention[46]. Support for change to alcohol policy in Australia is high, with a 2017 
Foundation for Alcohol Research and Education survey found that 81% of Australians wanted further 
action taken to reduce alcohol-related harm[47]. Ideally, all seven policy areas will continue to be 
researched, developed and expanded, but the findings of this thesis relate most directly to the policy 
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area of ‘education and persuasion’. That is, programs aiming to educate and inform Australians of 
the harms associated with alcohol consumption. 
There is evidence that government alcohol harm reduction campaigns that focus on the long-term 
harms of alcohol (particularly cancer and stroke risk) and include drinking guidelines, promote 
behaviour change to a greater degree than campaigns without these features[48]. Of 83 English-
language television advertisements evaluated in 2015 by over 2000 Australian participants who 
consumed alcohol at least weekly, an Australian advertisement focusing on cancer risk was the most 
effective in motivating a reduction in drinking[48]. In general, advertisements with a focus on long-
term harms were more effective than those focusing on short-term harms including injury and 
violence. It was also reported in a Western Australian study that a 2010 mass media education 
campaign on alcohol and cancer risk was effective in increasing women’s knowledge of alcohol as a 
risk factor for cancer, knowledge of drinking guidelines, and intention to decrease alcohol 
consumption[49]. 
Altogether, this means the findings of this thesis that consuming more than 4 drinks per day on only 
1 or 2 days per week increases risk of cancer by 27% and all-cause mortality by 24%, could be used 
as evidence for future mass media campaigns and other elements of ‘education and persuasion’ 
policy such as school-based education campaigns and on drink labelling. Namely, messaging 
surrounding alcohol consumption, particularly heavy episodic drinking, could be changed to promote 
greater awareness of the link between drinking and cancer risk and other long-term harms. 
At present, mass media campaigns funded by state and federal governments often focus on themes 
relating to acute consequences of alcohol consumption, such as violence, injury and drink-
driving[46]. Alcohol harm reduction is typically viewed by the government and public through the 
prism of policing and public safety rather than that of long-term harms such as cancer, liver disease 
and CVD. This is despite recent evidence that of all deaths in Australia caused by alcohol 
consumption, cancer deaths comprised 36% – more than any other disease or injury[50]. There is 
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great opportunity for an increase in public awareness regarding alcohol and cancer risk as a 2017 
Foundation for Alcohol Research and Education national survey reported that only 15% and 25% of 
respondents were aware of the link between drinking and breast and mouth/throat cancer 
respectively[47]. This compares to 78% of respondents who were aware of the link with liver 
cirrhosis. In addition, in 2013 it was found that 56% of men and 42% of women believed there is a 
level of drinking which does not increase risk of lifetime harm[41]. The lack of existing public 
knowledge of the link between drinking and cancer, combined with the evidence that raising 
awareness of cancer risk is one of the most effective methods in motivating a reduction in drinking 
suggests there is a substantial public health opportunity to be gained in reframing the focus of 
government alcohol harm reduction campaigns, particularly those focusing on heavy episodic 
drinking, to cancer risk and other long-term harms. 
A shift in focus to chronic disease prevention may also increase the relevance of anti-heavy episodic 
drinking campaigns to older Australians. In 2016, 17% of Australians aged 60-69 years and 7% aged ≥ 
70 years consumed > 4 drinks per occasion at least monthly[51], meaning that a sizable portion of 
older Australians engage in heavy episodic drinking and are at increased risk of cancer and all-cause 
mortality. Harm reduction campaigns focusing on heavy episodic drinking could therefore consider 
middle-aged and older Australians as a key target constituent group.  
Finally, in addition to media campaigns, there are also implications for alcoholic beverage labelling. 
Warning labels were voluntarily introduced by the alcohol industry in Australia in 2011, but are not 
mandatory[46]. The findings of this thesis suggest that mandatory warning labels could be 
introduced in Australia similar to tobacco products, with messaging focused on the harms of heavy 
episodic drinking for cancer risk and other long-term harms, and targeted at middle-aged and older 
drinkers. As only 38% of Australians are aware of the national guideline of 2 standard drinks per day 
to minimise risk of long-term harm[47], and that guideline promotion was found to be a component 
of advertisements which effectively motivate reductions in drinking behaviour[48], perhaps a 
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greater emphasis on standard drinks and the national guidelines could also feature on alcohol 
labelling. Another potential change for alcohol labelling could be to introduce plain packaging, which 
has been successfully implemented for tobacco products in Australia and has been associated with 
an increased rate of smoking cessation attempts[52]. Finally, although there is no precedent, 
standardised serving sizes for alcoholic beverages to ensure that all products contain a maximum of 
one standard drink per serve could also assist individuals to monitor their alcohol consumption more 
accurately, and if implemented globally would facilitate cancer control strategies by enabling 
comparisons between populations and the standardising of risk. 
Recommendation: To reduce the burden of alcohol-related harm in Australia, mass media 
campaigns, education programs and alcoholic beverage labelling could emphasise the long-term 
harms of alcohol consumption and the national alcohol guidelines, especially regarding heavy 
episodic drinking and cancer and mortality risk. These campaigns could consider middle-aged and 
older Australians who are particularly at risk of these harms.  
 
The findings in this thesis around illness as determinants for drinking cessation have implications for 
guidelines relating to ‘treatment and early intervention’. That is, recommendations relating to 
screening patients for alcohol use in a medical setting and brief interventions. In Chapter 7, it was 
found that many health conditions were associated with drinking cessation. For these conditions, 
the occurrence of illness may have been a “teachable moment” for some participants to improve 
their health behaviours[53], including the reduction or cessation of alcohol consumption. While it 
was not possible to examine in this thesis, it would be informative to investigate whether 
participants were quitting drinking spontaneously or if they were informed to do so by their medical 
practitioners. For diseases which are caused by drinking (e.g. cancer, CVD, liver disease and bone 
fractures), diseases which are exacerbated by alcohol or where alcohol may interfere with treatment 
(e.g. cancer, osteoporosis, diabetes, depression and anxiety) and diseases for which alcohol 
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increases risk of recurrence (e.g. cancer), the clinical guidelines for the prevention and management 
of each disease could recommend the reduction or cessation of alcohol consumption. For example, 
the Royal Australian College of General Practitioners Guidelines for preventive activities in general 
practice recommends that practitioners advise patients with pancreatitis, diabetes, liver disease, 
sleep disorders, sexual dysfunction, other major organ disease and mental health problems that 
“non-drinking is the safest option”[54]. Patients with hypertension are advised to “limit alcohol 
intake to no more than two (for men) or one (for women) standard drinks per day”. Based on the 
findings of the narrative review and the cancer and mortality analyses, diseases which could be 
added to this list include cancer, other CVD, infectious diseases, nutritional deficiencies, overweight 
and obesity, epilepsy and certain types of dementia, as drinking increases risk or exacerbates the 
condition, along with osteoporosis and Parkinson’s disease as drinking increases fall risk. Patients 
who have been injured as a result of external causes would also be an appropriate target for drinking 
assessment and intervention if alcohol was a contributing factor. 
These changes should improve health outcomes for patients, as there is consistent evidence in 
systematic reviews that primary healthcare brief alcohol interventions are effective in addressing 
‘hazardous and harmful’ alcohol consumption[42]. As well as in general practice, screening and brief 
interventions could be considered by specialists and allied health practitioners such as dietitians who 
are in contact with patients for the management of their specific health conditions. There is also 
evidence that Australian oncologists could do more to provide cancer survivors with guidelines for 
healthy eating, including the reduction of alcohol consumption[55]. Unfortunately, some Australian 
general practitioners do not routinely assess the alcohol consumption of their patients or provide 
recommendations for their drinking[56, 57], with barriers including a lack of confidence in managing 
alcohol issues and a desire to avoid an adversarial patient-doctor relationship[57, 58].  
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Recommendation: To reduce the burden of alcohol-related harm in Australia, the occurrence of ill-
health could be considered as an opportunity to screen the drinking behaviours of patients, educate 
them on the long-terms harms of alcohol consumption, and offer brief alcohol interventions in the 
primary care setting. 
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10.2 – Conclusions 
 
In conclusion, this thesis has made several important contributions to the evidence base for the 
impact of alcohol on disease and mortality. The narrative review investigated the relationship 
between alcohol consumption and numerous health outcomes, identifying important gaps in the 
evidence such as the uncertain relationship for many types of cancer, lack of evidence for the effect 
of pattern of drinking for many outcomes, and the possibility that risk estimates may be biased due 
to the ‘sick-quitter effect’ and other biases. It was then shown that previous systematic reviews of 
the association between alcohol consumption and all-cause mortality were largely at high risk of 
bias, and that there is little evidence concerning the factors that may influence this relationship, and 
for some factors such as pattern of drinking no evidence at all. It was also concluded that the 
apparent protective effect of moderate drinking on mortality may be accounted for by biases in 
primary study design. The investigation of risk factor co-occurrence revealed that lifestyle 
behaviours, including drinking behaviours, acculturate to those of the host population over time. It 
was shown that immigrants to Australia from non-English-speaking countries in particular appeared 
to be at risk of worsening alcohol consumption behaviours over time. Investigation of the ‘sick-
quitter effect’ resulted in the identification of a sensitivity test, restriction to participants with a 
physical functioning score ≥ 50%, to examine the potential for bias in associations between alcohol 
consumption and health outcomes. A systematic investigation of the effect of total alcohol 
consumption on cancer and mortality risk was performed, finding results that were largely 
consistent with prior research. There was also evidence for scepticism of the protective association 
between ‘moderate’ alcohol consumption and drinking frequency on risk of CVD and all-cause 
mortality, as these may be attributable to reverse causation or confounding. When the sensitivity 
test restricting to participants with a physical functioning score ≥ 50% was applied to mortality risk 
estimates, the risk of all-cause mortality in relation to alcohol consumption appeared to be 
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substantially underestimated when not accounted for. Finally, another important contribution to the 
evidence base was the systematic investigation of the independent effect of drinking pattern on 
cancer and mortality risk (with adjustment for total alcohol intake), with the key finding that drinks 
per drinking-day and heavy episodic drinking are independently associated with risk of cancers of 
the mouth, pharynx, oesophagus and kidney, and all-cause mortality. 
Many areas for future research have been identified that will further understanding of the 
relationship between alcohol consumption to health, such as the risk relationship between alcohol 
consumption, pattern of drinking and health outcomes in key population subgroups such as 
immigrants and Indigenous Australians, mechanistic evidence for the effect of pattern of drinking on 
risk of cancer and other diseases, and further investigation into the nature of bias due to changes in 
drinking behaviours in response to ill-health. 
While progress has been made in recent decades in enacting policy aiming to reduce the burden of 
alcohol-related harm in Australia, there is still great public health opportunity to be gained from 
actions that could yet be implemented. In particular, it was shown that national alcohol guidelines 
could be revised to decrease the recommended level of drinking to reduce the lifetime risk of harm 
from disease and injury, and to address the independent harms of drinks per drinking-day and heavy 
episodic drinking, such as cancer risk. Further, the occurrence of ill-health could be used as an 
opportunity to screen the drinking behaviours of patients and offer brief alcohol interventions in the 
primary care setting. Finally, mass media campaigns, education programs and alcoholic beverage 
labelling could emphasise the long-term harms of alcohol consumption and the national alcohol 
guidelines, especially regarding heavy episodic drinking and cancer and mortality risk. There is 
evidence that a focus on cancer risk especially is likely to be effective in motivating behaviour 
change. These campaigns could also consider middle-aged and older Australians who are at greater 
risk of these harms, but who are not the usual subject of anti-heavy episodic drinking campaigns.  
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There must be continued communication of research findings to the public, government and non-
government organisations, along with sustained advocacy from public health stakeholders for 
policies and action to reduce the burden of alcohol-related harm, to create a healthier drinking 
culture for all Australians. 
 
 
 
 
 
“Three cups do I mix for the temperate; one to health, which they empty first, the second 
to love and pleasure, the third to sleep. When this bowl is drunk up, wise guests go home. 
The fourth bowl is ours no longer, but belongs to violence; the fifth to uproar, the sixth to 
drunken revel, the seventh to black eyes, the eighth is the policeman’s, the ninth belongs 
to biliousness, and the tenth to insanity and the hurling of furniture.” 
- Eubulus, 375 BC[59] 
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Appendices 
 
Appendix A – Narrative Review of Alcohol Consumption and Risk of Disease and Injury: Outcomes 
Other than Cancer 
 
Scope 
The diseases and injuries captured were those stated to be caused (or in some cases, prevented) by 
alcohol consumption in the 2009 Australian alcohol guidelines, the World Health Organisation Global 
Status Report on Alcohol and Health 2014, and a 2017 review of alcohol consumption and burden of 
disease[1-3]; namely, cancer, various infectious diseases, diabetes, nutritional deficiencies, 
overweight and obesity, dementia, neuropsychiatric conditions, cardiovascular disease, liver disease, 
pancreatitis, other digestive system diseases and external causes of morbidity and mortality. 
Psoriasis and pregnancy and birth complications such as foetal alcohol spectrum disorders which do 
not directly cause death in adults (and therefore could not be investigated using the 45 and Up Study 
with linkage to mortality data) were not considered.
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Infections (ICD-10: A15-19; B20-24; J09-22) 
Burden in Australia 
Of all deaths in Australia in 2015, lower respiratory tract infections, tuberculosis and human 
immunodeficiency virus (HIV) were a contributing cause towards 20,403 (13%) deaths, including 
3532 (2.2%) deaths where these infections were the underlying cause[4]. Alcohol consumption was 
attributed to 246 deaths from infection in 2010, including 232 (9%) lower respiratory infection 
deaths, 12 (23%) tuberculosis deaths and 3 (4%) HIV deaths[5, 6]. The most recent estimate of the 
disease burden from influenza and lower respiratory infections attributable to alcohol consumption 
in Australia was 6%[7]. 
Epidemiology 
A systematic review and meta-analysis found that people who consume 60 g/day of alcohol had a 
33% higher risk of community acquired pneumonia compared to abstainers, while those with alcohol 
use disorders had 8 times the risk[8]. A linear dose-response relationship was found with total 
alcohol consumption. 
For tuberculosis, a systematic review and meta-analysis found that those consuming ≥ 40 g/day 
alcohol and/or with an alcohol use disorder had an odds ratio of 2.94 (95% confidence interval: 1.89-
4.59) compared to non-drinkers/those without an alcohol use disorder[9]. However, there was 
significant heterogeneity between studies. Another systematic review found a threshold effect, 
where risk was significant at intakes > 60 g/day[10]. Heavy alcohol consumption also increases the 
risk of mortality in those diagnosed with tuberculosis[11]. 
In a recent meta-analysis, those consuming alcohol had double the risk of incident HIV infection 
compared to non-drinkers, while heavy episodic drinkers had 2.2 times the risk compared to non-
heavy episodic drinkers[12]. There were no differences across developing and developed countries.  
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Causal mechanisms 
Heavy drinking increases the risk of lower respiratory tract infections (in particular, pneumonia) and 
tuberculosis by inhibiting the action of the immune system, thereby increasing susceptibility to 
infection[2, 13]. The mechanisms by which alcohol consumption increases susceptibility to infectious 
disease include lessened innate immunity through decreased production of lysozyme and 
complement, and the damaging of gastrointestinal and respiratory tract immune barriers. Acquired 
immunity is also affected, through decreased ability to produce antibodies in response to antigens 
and a reduced lymphocyte proliferative response (via inhibition of the activities of dendritic cells, 
CD4+ and CD8+ T-lymphocytes). Various other mechanisms are involved, including inhibition of the 
activities of alveolar macrophages, polymorphonuclear leukocytes and bone marrow granulopoietic 
function[8, 14]. Nutritional deficiencies induced by heavy alcohol consumption may also play a 
role[8, 9]. 
There are two explanations for the association between drinking and HIV infection which are not 
necessarily mutually exclusive. Firstly, that alcohol consumption through its effects on judgement 
and disinhibition increases the likelihood of unsafe sex, or that people who take more risks in 
general are more likely to both consume more alcohol and partake in risky behaviours including 
unsafe sex and drug injection[15]. Another mechanism is the harmful effect of alcohol on the 
immune system increasing susceptibility to infection. Alcohol consumption has also been shown to 
negatively impact disease progression in those already infected with HIV, by interacting with 
antiretroviral therapies and other medications[14-16]. Heavy drinking is also associated with 
reduced treatment adherence[16]. 
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Diabetes (ICD-10: E10-14) 
Burden in Australia 
Diabetes was responsible for 2.3% of the total burden of disease in Australia in 2011[7]. In 2011-12 it 
was estimated that 917,000 Australian adults (5.4%) were living with diabetes, of which 849,000 
were cases of type 2 diabetes[17]. The prevalence of diabetes approximately tripled between 1989-
90 and 2011-12. Diabetes was an underlying or associated cause of death in a total of 16,420 (10.3%) 
deaths in 2015[4]. It was estimated that 2.1% of the burden of diabetes in Australia in 2011 was 
attributable to alcohol consumption[7]. On the other hand, it was estimated that a net 208 deaths 
from diabetes were prevented due to alcohol consumption in Australia in 2010[5]. 
Epidemiology 
Alcohol consumption has been associated with an approximate 30-40% reduced risk of incident type 
2 diabetes in moderate drinkers[5, 18-20]. The relationship is either J-shaped or U-shaped, with 
heavy episodic drinking associated with increased risk[19]. Compared to lifetime abstainers, the 
maximum protective effect has been reported at approximately 25 g/day, while the relative risk is 
significantly increased above 1 at intakes ≥ 50 g/day in women and 60 g/day in men[20]. Women 
may gain greater benefit from moderate drinking than men[20].  
A systematic review and meta-analysis found that in patients with type 2 diabetes, moderate alcohol 
consumption was associated with protection against coronary heart disease incidence, coronary 
heart disease mortality and all-cause mortality[21]. The reference group in that study was non-
drinkers however, meaning that the point estimate for protection was possibly overestimated due to 
the presence of former drinkers in the reference group. 
Other potential biases in cohort studies examining the relationship between alcohol consumption 
and diabetes include misclassification of alcohol consumption and the potential for incomplete 
control of confounding[19, 22]. For example, one study accounted for a variety of socio-
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demographic and health-related variables which were found to cluster with heavy drinking, including 
employment status, marijuana use and depression, finding that accounting for these factors 
attenuated the apparent lowered odds of diabetes in moderate drinkers compared to lifetime 
abstainers[22]. There is also heterogeneity in relative risks in studies of both men and women, and it 
has been suggested that this may be due to confounding by patterns of alcohol consumption (e.g. 
heavy episodic drinking, drinking with meals)[20]. 
Causal mechanisms 
The proposed mechanism for the protective effect on type 2 diabetes incidence is through 
decreased gluconeogenesis, decreased glycogenolysis and increased insulin sensitivity[19]. Insulin 
sensitivity is increased by inhibiting adipose tissue from releasing fatty acids, which in skeletal 
muscles are substrate competitors in the Krebs cycle[19]. This assists the rate of glucose 
metabolism. In non-diabetics, regular moderate alcohol consumption also decreases fasting and 
post-prandial insulin levels[19]. Alcohol may also play a role in prevention through altered lipid 
metabolism, lowered blood pressure or an anti-inflammatory effect[5, 13]. The mechanism for 
greater risk with heavy drinking may be through the association of heavy drinking with poor diet, 
contribution to excess bodyweight or a direct toxic effect on pancreatic islet cells[5, 23]. Alcohol 
consumption does not have a role in the aetiology of type 1 diabetes, which is primarily caused by 
genetic and epigenetic factors[24]. 
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Nutritional deficiencies (ICD-10: E40-64) 
Burden in Australia 
Heavy alcohol consumption was found to be associated with a number of nutritional deficiencies, 
including vitamin A, vitamin B1 (e.g. Wernicke-Korsakoff syndrome), vitamin B2 (pellagra), folate, 
vitamin D, vitamin E, calcium, iron, zinc and magnesium deficiency[1, 25]. Nutritional deficiencies 
were an underlying or associated cause of death in a total of 942 (0.6%) deaths in Australia in 
2015[4]. The most common causes were protein-energy malnutrition, vitamin B deficiency and 
vitamin D deficiency. In the 1980’s Australia had the highest prevalence of Wernicke-Korsakoff 
syndrome in the world at 2.8%, however this decreased to approximately 1% following the 
fortification of bread with vitamin B1 in 1991[26, 27]. 
Epidemiology 
A study of alcoholics in Portugal found that over half had low folate and vitamin B6 status, but none 
had low vitamin B12 status[28], however more moderate levels of alcohol consumption may also 
produce changes in vitamin status. For example, a randomised cross-over study found that 24 g/day 
of ethanol is enough to cause significant reductions in serum folate and vitamin B12[29]. 
Causal mechanisms 
The reason nutritional deficiencies are associated with alcohol consumption is two-fold. Specifically, 
alcohol displaces the consumption of other nutrient-rich foods while also altering the absorption and 
metabolism of nutrients[30]. The mechanisms by which heavy alcohol consumption can alter the 
absorption and metabolism of nutrients include the inhibition of pancreatic enzyme release, 
reducing the absorptive capacity of cells in the stomach and intestines, inhibiting fat absorption and 
therefore the absorption of fat-soluble vitamins A, D, E and K as well as calcium, impaired utilisation 
of vitamin B1 due to impairment of the enzymes that process it, decreased storage of vitamin A in 
the liver with alcohol-induced liver damage, increased urinary excretion of magnesium and zinc, 
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nutrient loss with vomiting and diarrhoea, zinc malabsorption secondary to other nutrient deficiency 
diseases and gastrointestinal bleeding causing iron loss[25, 31]. 
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Overweight and obesity (ICD-10: E66) 
Burden in Australia 
High body mass was responsible for 5.5% of the total burden of disease in Australia in 2011[7]. In 
2014-15, 63% of Australian adults were overweight or obese, increasing from 56% in 1995[32]. The 
proportion overweight or obese in 2014-15 was 71% for men and 56% for women. Overweight and 
obesity are risk factors for many conditions, including hypertension, cardiovascular disease, stroke, 
diabetes, cancer (oesophagus, stomach, colorectum, liver, gallbladder, pancreas, breast, 
endometrium, ovary, prostate and kidney), osteoarthritis, sleep apnoea and infertility[33, 34]. 
Alcohol comprised 5.1% and 3.5% of total energy intake for adult men and women respectively in 
Australia in 2011-12[35]. 
Epidemiology 
Studies examining the relationship between alcohol consumption and obesity often produce 
inconsistent results[36]. For moderate drinking, the majority of longitudinal and experimental 
studies find no association with weight gain over time, although both positive and negative 
associations have been reported. Heavy alcohol consumption and heavy episodic drinking are both 
associated with weight gain. In addition, those who increase their level of alcohol consumption over 
time are more likely to gain weight than those who consume alcohol at a constant level. The 
association between drinking and body weight is usually more apparent in studies of men than of 
women[36]. 
Causal mechanisms 
The mechanism by which alcohol consumption causes overweight and obesity is by contribution to 
total energy intake. This occurs if there is no compensation of energy intake by a reduction in the 
consumption of other foods[36]. The ethanol in alcoholic beverages contains 29 kJ of energy per 
gram, or 290 kJ in an Australian standard drink[37]. The approximate energy requirements for 
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moderately active 76 kg men and 61 kg women aged 51-70 years are 12,100 kJ and 9600 kJ 
respectively[38]. Different types of alcoholic beverage contain various amounts of carbohydrates 
that also contribute to the total energy content of the beverage. The estimated average energy 
content of various alcoholic beverages consumed in Australia in 2011-13 is shown below in Table 
A.1. The energy content of alcoholic beverage varies by type, with a ‘middy’ of light beer and ‘nip’ of 
spirits having the lowest energy content and a ready-to-drink beverage, the highest. 
In addition to the energy content of the drinks themselves, a majority of studies in a review found 
that alcohol consumption can promote appetite, increasing the consumption of food during a 
meal[39]. Further, alcohol may inhibit the action of hormones that control satiety including leptin 
and glucagon-like peptide-1, and also by effecting the regulation of neurotransmitters such as 
opioids, serotonin and gamma-aminobutyric acid within the appetite pathways in the brain[36]. 
Alcohol consumption may also impact fat storage in the body via its effect on inhibiting fat oxidation 
(the breakdown of fat as a source of energy), thereby leading to the long-term accumulation of body 
fat. Finally, there is evidence that genetic factors such as ADH1B polymorphism may modify the 
relationship between alcohol consumption and bodyweight among alcoholics, possibly by altering 
the utilisation of ethanol as a source of energy[36]. 
 
Table A.1. Estimated average energy content in alcoholic 
beverages consumed in Australia in 2011-13[37]. 
Beverage Serving size (mL) Energy per serve (kJ) 
Full strength beer 285-425a 408-608 
Light beer 285-425a 294-438 
Red wine 150 486 
White wine 150 444 
Spirits 30 274 
Cider 285-425a 530-791 
Ready-to-drinkb 375 923 
aCommon serving sizes for beer and cider range from a 285 mL 
‘middy’ to a 425 mL ‘schooner’. bMean of commercial ‘gin and 
tonic’, ‘rum and cola’, ‘vodka and soft drink’ and ‘whisky or 
scotch and cola’ ready-to-drink beverages. 
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The finding that moderate alcohol consumption does not increase bodyweight has been attributed 
to increased energy expenditure caused by an inefficiency in ethanol metabolism by the liver 
microsomal ethanol oxidising system, but also to possible confounding by health and lifestyle factors 
such as physical activity which promote weight control and are associated with moderate 
drinking[30, 36]. 
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Dementia (ICD-10: F00-03; G30) 
Burden in Australia 
Dementia is a disease associated with brain damage and causes a decline in memory and cognitive 
function. An estimated 354,000 people in Australia were living with dementia in 2016, comprising 
9% of the population aged ≥ 65 years and approximately 30% of the population aged ≥ 85 years[40]. 
Of all deaths in Australia in 2015, dementia, of which Alzheimer’s disease is the most common[41], 
was a contributing cause towards 25,921 (16%) deaths, including 12,625 (7.9%) deaths where 
dementia was the underlying cause[4]. 
Epidemiology 
Moderate alcohol consumption has been reported to be associated with a lower risk of Alzheimer’s 
disease[1, 18]. One systematic review and meta-analysis reported that drinkers had a lower risk of 
both dementia of any type (risk ratio: 0.63; 95% confidence interval: 0.53-0.75) and Alzheimer’s 
disease (0.57; 0.44-0.74) when compared to non-drinkers, although there was significant 
heterogeneity between studies[42]. Few studies used lifetime abstainers as the reference group or 
accounted for the level of cognitive function at baseline. Another more recent systematic review of 
19 cohort and case-control studies found 7 studies where alcohol consumption was protective, 9 
studies where there was no association, and 3 studies where drinking was associated with increased 
risk, concluding that the evidence is inconsistent[43]. Some studies reported that heavy drinking was 
associated with increased risk, but the evidence overall was inconsistent. The authors of the review 
noted several methodological limitations in the literature. These included the possibility of bias in 
self-reported alcohol consumption, the use of caregivers to collect data from participants rather 
than the participants themselves, that drinking is only measured at baseline and may change, 
variation between studies in how alcohol consumption is quantified (e.g. drinks per week, grams of 
ethanol per day, drink type), the possibility of confounding by biological and behavioural factors that 
influence Alzheimer’s disease risk, and variation in the quality of methods used to ascertain an 
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Alzheimer’s disease diagnosis[43]. There is insufficient evidence to determine whether risk of 
Alzheimer’s disease is modified by drinking pattern and beverage type[41].  
Due to the hypothesis that low-volume drinking decreases risk of cardiovascular disease the 
possibility that drinking may reduce risk of vascular dementia has also been investigated. One 
systematic review and meta-analysis found no significant association of alcohol with risk of vascular 
dementia compared to non-drinkers (0.82; 0.50-1.35)[42], however a cohort study found that 
alcohol use disorders were associated with approximately triple the risk (along with increased risk of 
Alzheimer’s disease and total dementia)[44]. Further research is needed to understand how alcohol 
consumption is associated with risk of dementia (including Alzheimer’s disease and vascular 
dementia), whether risk is altered by drinking pattern or beverage type, and whether associations 
may be accounted for by confounding due to baseline level of cognitive function. 
Heavy levels of alcohol consumption also cause dementia through two other diseases: alcohol-
related dementia and Wernicke-Korsakoff syndrome[45]. The distinction between these conditions 
is not fully elucidated, and so they are sometimes grouped as ‘alcohol-related brain damage’. An 
Australian autopsy study estimated a prevalence of Wernicke-Korsakoff syndrome of 1.1%, and most 
cases were in people with a history of alcoholism[26]. Only 16% of cases were diagnosed while the 
person was alive. Compared to dementia caused by Alzheimer’s disease, patients with these 
conditions are more likely to be male and younger[46]. The level of alcohol consumption required to 
cause either condition remains unclear, but approximately 70-84 grams of ethanol per day or above 
over an extended period has been shown to be sufficient to cause cognitive deficits[45]. There is 
evidence that abstinence from alcohol halts or even partially reverses cognitive decline for both 
conditions[45]. Further areas for research include how risk is influenced by different patterns of 
drinking such as heavy episodic drinking, duration of alcohol abuse and withdrawal periods. 
 
 
475 
 
Causal mechanisms 
The antioxidant action of flavonoids such as polyphenols and resveratrol present in red wine have 
been proposed to contribute to the potential protective mechanism of alcohol and dementia by 
inhibiting the aggregation of amyloid-β plaque in the brain and therefore preventing 
neurodegeneration[41]. Additionally, alcoholic beverages contain fulvic acid which may prevent τ 
protein aggregation, which is seen in Alzheimer’s disease pathology[41]. Proposed mechanisms for 
the harmful effects of heavy alcohol consumption on Alzheimer’s disease are via damage to 
cholinergic neurons, vascular changes or nutritional deficiencies which affect cognitive function[41]. 
The suggested mechanism for the association of heavy drinking with increased risk of vascular 
dementia is through an effect on cardiovascular disease, including increased risk of hypertension and 
haemorrhagic stroke[44]. Alcohol-related dementia is caused by the neurotoxic effects of heavy 
alcohol consumption while Wernicke-Korsakoff syndrome is caused by vitamin B1 deficiency that 
often accompanies heavy alcohol consumption[45].  
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Neuropsychiatric conditions (ICD-10: F10; 32-33; 34.1; G31.2; 40-41) 
Burden in Australia 
A variety of neuropsychiatric conditions are associated with alcohol consumption, including mental 
and behavioural disorders, depression, degeneration of the nervous system and epilepsy[3, 13]. The 
prevalence of alcohol use disorders (comprising alcohol dependence and harmful use of alcohol) in 
Australia was estimated to be 5.0% for men and 2.1% for women in 2010[2]. It was estimated that 
380 deaths from neuropsychiatric conditions in Australia in 2010 were caused by alcohol 
consumption, including 310 deaths due to mental and behavioural disorders due to use of alcohol 
and 66 (22%) of the 294 epilepsy deaths[5, 6]. It was estimated that 13% of the burden of epilepsy in 
Australia in 2011 was attributable to alcohol consumption[7]. 
Epidemiology 
Alcohol use disorders occur when an individual displays characteristics of alcohol dependence such 
as withdrawal symptoms, or characteristics of alcohol abuse including interference with work, 
interference with interpersonal relationships, and engagement in risky activities such as drink driving 
or unsafe sex[47]. Prior to 2013, alcohol dependence and alcohol abuse were considered separate 
disorders. Alcohol use disorders are associated with many other mental health conditions, including 
substance abuse, depression, anxiety, phobias, panic disorder and lower social and emotional 
functioning[48]. There are also socio-demographic risk factors for alcohol use disorder, including 
younger age, being male, having lower household income and not being married or living with a 
partner[48]. In particular, heavy alcohol consumption is associated with major depressive disorder, 
however it remains unknown whether this is due to causation, reverse-causation and/or other 
factors such as genetic vulnerability[3, 49, 50]. When alcohol use disorder and major depressive 
disorder co-occur in an individual, there is a higher risk of low global functioning, alcohol 
dependence and suicide attempt than for either condition alone[51]. 
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Heavy alcohol consumption has been shown to cause neurodegeneration at multiple sites in the 
brain, particularly the frontal lobes (responsible for memory, temporal ordering, attention and 
judgement), and in both grey and white matter[52]. A 30-year longitudinal study found that both 
moderate (≥ 7 and < 14 drinks per week) and heavier drinking were associated with decline in lexical 
fluency, a measure of cognitive ability[53]. This study also reported a significantly higher risk of 
hippocampal atrophy in those consuming ≥ 14 drinks per week. Further, a dose-response 
relationship has been demonstrated for alcohol consumption and risk of epilepsy, with an estimated 
lag time between exposure and outcome of ten years[3]. Importantly, abstinence from alcohol 
consumption can partially reverse neurodegeneration and improve cognitive deficits[52], and 
withdrawal from alcohol consumption is associated with non-epileptic seizures[49]. 
Causal mechanisms 
Potential mechanisms by which heavy alcohol consumption causes depression include its adverse 
effects on interpersonal relationships and employment, genetic susceptibility for both alcohol use 
disorders and depression, and alcohol-induced biochemical changes, such as a disruption to folate 
metabolism which can lead to depression[50]. The mechanism by which alcohol consumption causes 
neurodegeneration is through cellular atrophy and death, and through inhibition of new cell 
generation caused primarily by oxidative stress in the brain associated with acute alcohol 
intoxication[52]. Finally, the proposed mechanisms by which alcohol consumption causes epilepsy 
are via a ‘kindling’ effect where repeated bouts of heavy drinking lower the threshold for epileptic 
seizures, as well as an increase in head trauma associated with drinking, cerebral atrophy, 
neurotransmitter changes, ionic balance disturbances, lesions and cerebrovascular infarctions[3, 49]. 
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Cardiovascular disease (ICD-10: G45-46; I00-99) 
Burden in Australia 
Cardiovascular disease (CVD) was responsible for 15% of the total burden of disease in Australia in 
2011[7], 5% of which was attributable to alcohol consumption in 2011[7]. Of all deaths in Australia in 
2015, CVD was a contributing cause towards 87,385 (55%) deaths, including 45,446 (29%) deaths 
where CVD was the underlying cause[4] (including 19,777 ischaemic heart disease, 10,869 
cerebrovascular disease, 14,800 other). It has been estimated that a net 356 (0.8%) of the 45,576 
CVD deaths in 2010 were caused by alcohol consumption[5, 6]. 
Epidemiology 
Alcohol consumption has a J-shaped association with prevalence of a range of cardiovascular risk 
factors (including hypertension, coronary calcification and triglyceride levels) and with outcomes, 
such as peripheral artery disease, ischaemic heart disease, myocardial infarction, congestive heart 
failure, Raynaud’s phenomenon and ischaemic stroke[18, 54, 55]. This means that low-volume 
drinking is associated with lower risk and heavy drinking with higher risk compared to non-drinking. 
Relative risks from a systematic review and meta-analysis for drinking 2.5 to 14.9 grams of ethanol 
per day compared to non-drinking were 0.75 (0.65-0.88) for coronary heart disease and 0.80 (0.74-
0.87) for stroke[54]. Heavy drinking (greater than 60 grams per day) was associated with relative 
risks of 0.76 (0.52-1.09) and 1.62 (1.32-1.98) for coronary heart disease and stroke respectively. The 
association of moderate drinking with dysrhythmia and haemorrhagic stroke is inconclusive, 
however heavier drinking is associated with increased risk[13, 56]. It has been reported that the 
protective effects of moderate drinking on CVD persist whether or not ex-drinkers are included in 
the reference group[13, 54]. The apparent cardiovascular benefits of moderate alcohol consumption 
are greater in those with existing coronary heart disease and/or diabetes, however there is still some 
evidence of protection for persons without these conditions[18]. 
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Comparable findings have been observed regarding cardiovascular mortality. A systematic review 
and meta-analysis found that alcohol consumption reduced the risk of death from CVD (> 0 and ≤ 60 
grams per day), coronary heart disease (≥ 2.5 grams per day) and stroke (≥ 2.5 and < 15 grams per 
day), when compared to non-drinkers[54]. When the analysis examined all drinkers combined 
compared to lifetime abstainers, the reduced risk for CVD and coronary heart disease remained, 
while an increased risk was found for stroke mortality. Systematic reviews and meta-analyses have 
also examined the effect of moderate alcohol consumption on all-cause mortality in patients with 
existing CVD, coronary artery disease and hypertension, finding reduced risk in each of these 
cases[57-59]. In all three reviews former drinkers were included in the control group, and so these 
estimates could be biased by the ‘sick-quitter effect’. 
Pattern of drinking (e.g. number of drinks per occasion) appears to have independent effects on CVD 
over and above the total amount of alcohol consumed. Specifically, regular daily alcohol 
consumption is associated with greater cardiovascular benefits compared to more occasional 
consumption, and consuming alcohol before or during a meal may increase the protective effects of 
moderate drinking[18]. Heavy episodic drinking (i.e. consuming many drinks on one occasion) is 
associated with increased risk of ischaemic heart disease, myocardial infarction, ischaemic stroke 
and haemorrhagic stroke compared to non-drinkers or to those who consume the same quantity of 
alcohol spread over a greater number of occasions[13, 18, 55]. A systematic review and meta-
analysis found that among drinkers with an average daily alcohol consumption of less than 30 grams 
per day, heavy episodic drinkers had a relative risk of ischemic heart disease of 1.75 (1.36-2.25) 
compared to persons who did not engage in heavy episodic drinking[55]. 
The relationship between temporal changes in alcohol consumption and risk of CVD has also been 
investigated. A recent cohort study examined change in alcohol consumption over time and risk of 
coronary heart disease[60]. It found that postmenopausal women who increased their alcohol 
consumption over a five year period had a lower risk of coronary heart disease after adjusting for 
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total alcohol consumption at baseline, while those who decreased their alcohol consumption had no 
significant difference in risk. 
However, there is controversy regarding the quantification of cardiovascular benefits related to low-
volume alcohol consumption, and to what extent these apparent benefits may be explained by 
poorly selected control groups, misclassification of alcohol consumption, confounding or other 
factors[18, 19]. Of particular concern is the ‘sick-quitter effect’ and confounding by illness present at 
baseline, as illnesses can be strongly associated with both drinking habits and cardiovascular 
outcomes[61]. A large American study provided evidence that confounding by socio-demographic 
factors and health status may bias risk estimates for CVD, because low-volume drinkers were less 
likely to have a low household income, be unemployed, obese, have hypertension or poor general 
health status compared to non-drinkers[62]. As a result, studies that have used a reference group of 
non-drinkers may have overestimated the protective effects between low-volume drinking and CVD. 
An analysis of the same study accounted for a variety of socio-demographic and health-related 
variables, such as employment status, marijuana use, depression and distress, reported that 
accounting for these factors eliminated the protective association of low-volume drinking on “heart 
problems” and hypertension, when compared to lifetime abstainers[22].  
Another factor which could explain protective associations for CVD is the exclusion of participants 
with health conditions at baseline. This may induce selection bias in studies of CVD (and other health 
outcomes), which can potentially create spurious J-shaped associations where the underlying 
relationship is linear[63, 64]. This is because the participants who remain in the cohort may have an 
uneven distribution of CVD risk factors other than alcohol consumption, which has the potential to 
cause confounding. 
There is also evidence that measuring alcohol consumption over multiple time points results in 
higher estimates of the risk of arterial stiffness in relation to heavy drinking, compared to measuring 
only recent alcohol consumption[65]. In addition to mitigating bias from the ‘sick-quitter effect’, the 
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measurement of alcohol consumption over multiple time points prevents bias from regression 
dilution which can occur in studies measuring alcohol consumption at a single time point[65]. 
Regression dilution bias refers to a situation where measurement error in an exposure can cause a 
widened distribution of exposure values, resulting in a fitted regression line with a lower gradient 
and thereby biasing estimates of effect towards the null[66]. Averaging measurements of exposure 
at multiple time points reduces measurement error and therefore mitigates this bias. 
Finally, the possibility that alcohol industry funding may have influenced estimates of effect for 
drinking and CVD has also been examined. A systematic review and meta-analysis found that studies 
with evidence of industry funding are more likely to report a protective effect of drinking on stroke 
incidence compared to studies without evidence of industry funding, but not for other types of 
CVD[67]. 
It is possible that bias may also influence risk estimates for pattern of drinking, particularly the 
apparent inverse association of frequent low-volume drinking with CVD. In the aforementioned large 
American study, among low-volume drinkers, infrequent drinkers were more likely to have 13 socio-
demographic and health-related risk factors compared to frequent drinkers, including low household 
income, no health insurance, smoking, obesity and physical inactivity. This indicates that 
confounding may account for the apparent protective associations observed between frequent 
drinking and CVD, rather than alcohol consumption itself[68]. 
Overall, the Australian alcohol guidelines consider the evidence for a protective effect with low-
volume drinking too uncertain to make specific claims about potential cardiovascular health 
benefits, and state that few persons below the age of 40 years would benefit[1]. There is a clear 
need for further research to clarify whether low-volume drinking and greater drinking frequency 
causally lower CVD risk, and whether past findings in prospective cohort studies are biased. A 
randomised controlled trial of low-volume drinking and risk of chronic disease could address this 
issue conclusively[69]. 
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Causal mechanisms 
If causal, the protective association with low-volume drinking is proposed to be primarily 
attributable to mechanisms known to reduce risk of heart disease such as, increased high density 
lipoprotein (HDL) cholesterol, decreased low density lipoprotein (LDL) cholesterol, increased insulin 
sensitivity, reduced atherosclerotic plaque formations and possible anti-coagulant effects including 
reduced fibrinogen levels[1, 18, 70, 71], while decreased inflammation perhaps has a minor role[18]. 
A systematic review and meta-analysis of randomised controlled trials examined the effect of 
moderate drinking on 13 biomarkers associated with CVD risk[71]. It found that alcohol consumption 
significantly raised HDL cholesterol, apolipoprotein A1 and adiponectin and lowered fibrinogen 
levels – all factors associated with lower risk of CVD. There was no significant association with LDL 
cholesterol or eight other cardiovascular risk markers[71]. Overall, for 9 of 13 cardiovascular risk 
markers examined there was no association, and there was significant heterogeneity in the HDL 
cholesterol and apolipoprotein A1 meta-analyses. Moderate alcohol consumption has also been 
associated with lowered homocysteine, a risk factor for CVD[72]. The potential cardiovascular 
benefits of alcohol are believed to be conferred by ethanol itself rather than other components 
within alcoholic beverages[18]. Red wine should theoretically offer additional cardiovascular benefit 
due to its relatively high levels of bioflavonoids (molecules with antioxidant, antiplatelet and other 
effects which protect against CVD) compared to other beverage types, however overall quantity and 
frequency of alcohol consumption appear to have a greater association with risk than type of 
beverage[18]. Increased clotting, hypertension, ventricular fibrillation and elevated homocysteine 
levels as well as cardiomyopathy caused by a direct toxic effect of alcohol on heart muscle are 
proposed as means for the harmful effects of heavy drinking[13, 72-74]. 
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Liver disease (ICD-10: K70-77) 
Burden in Australia 
Of all deaths in Australia in 2015, liver disease was a contributing cause towards 4945 (3.1%) deaths, 
including 1857 (1.2%) deaths where liver disease was the underlying cause[4] (891 from alcoholic 
liver disease, 455 from fibrosis and cirrhosis of the liver, and 511 from other causes). This does not 
include the 1820 deaths due to liver cancer for which liver disease is a risk factor[75]. It was 
estimated that 24% of the burden of chronic liver disease in 2011 was attributable to alcohol 
consumption[7], while 746 (47%) of the 1592 liver disease deaths in 2010 were attributable to 
alcohol consumption[5, 6]. It is notable that there is a large difference in burden from liver disease 
by Indigenous status, as Indigenous Australians have a liver disease mortality rate approximately 
four times that of non-Indigenous Australians[75]. 
Epidemiology 
Alcoholic liver disease is a spectrum of conditions progressing from alcoholic fatty liver to alcoholic 
hepatitis, liver fibrosis and ultimately liver cirrhosis[76, 77]. More than one condition may be present 
at once. Elevated risk is seen at levels of alcohol consumption greater than 60 g/day in men and 
greater than 20 g/day in women, however the precise threshold at which risk increases is unknown. 
It has been reported in a meta-analysis that the association between drinking and liver cirrhosis is 
stronger when the outcome is mortality rather than morbidity[78]. Beer and spirit consumption may 
promote alcoholic liver disease to a greater extent than wine[76]. Pattern of drinking is also 
important, as drinking outside of meal times as opposed to with meals, and heavy episodic drinking 
of at least five drinks in one occasion for men and four drinks for women also increase risk. A cohort 
study found that after adjusting for total alcohol consumption, a higher drinking frequency in days 
per week was associated with increased risk of alcoholic liver cirrhosis in men but not in women[79]. 
Continued alcohol consumption worsens already existing liver disease and reduces survival[13]. 
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Although alcohol consumption is a necessary cause of alcoholic liver disease, the dose-response 
relationship is complex and is influenced by a number of confounding factors[76]. In the presence of 
alcohol consumption, other factors that increase risk include fat intake, excess body weight, 
smoking, genetic factors, haemochromatosis, HIV and viral hepatitis from hepatitis B and C viruses 
(HBV, HCV)[76, 77]. There appears to be a multiplicative effect on risk between alcohol consumption 
and HCV-induced hepatitis, and the threshold at which alcohol consumption begins to increase risk 
may be lower in those with HCV-induced hepatitis. There are also multiplicative effects on risk 
between alcohol consumption and obesity, HBV, HIV, haemochromatosis and non-alcoholic fatty 
liver disease[77]. More research is needed to better understand the interaction between alcohol 
consumption and these risk factors[77]. 
Causal mechanisms 
There are several mechanisms by which alcohol consumption causes liver disease, acting at multiple 
stages along the spectrum from alcoholic fatty liver to liver cirrhosis. Drinking contributes to 
alcoholic fatty liver by increasing lipogenesis and decreasing fatty acid oxidation, through inhibiting 
enzyme activity and modifying transcription factors associated with lipid metabolism in the liver[77]. 
Regarding alcoholic hepatitis, alcohol contributes by increases the permeability of the intestines to 
lipopolysaccharides which promote inflammation in the liver, the infiltration of immune cells into 
the liver, and the metabolism of ethanol forms acetaldehyde and reactive oxygen species that injure 
hepatocytes[77]. The presence of inflammation stimulates hepatic stellate cells to produce excess 
extracellular matrix proteins, which cause fibrosis. Drinking also contributes to fibrosis directly by 
inhibiting anti-fibrotic factors. Over time fibrosis can develop into cirrhosis and ultimately 
hepatocellular carcinoma, and the continued consumption of alcohol after fibrosis has occurred, 
accelerates this process. Finally, alcohol consumption also prevents liver regeneration through the 
inhibition of hepatocyte proliferation.  
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Pancreatitis (ICD-10: K85-86.1) 
Burden in Australia 
Pancreatitis refers to inflammation of the pancreas. In 2015, acute pancreatitis was a contributing 
cause towards 369 (0.2%) Australian deaths, including 181 (0.1%) as an underlying cause of death[4]. 
The exact number of deaths due to chronic pancreatitis (ICD-10: 86.0-86.1) is not reported as 
Australian cause of death data is only available for integer ICD codes. Chronic pancreatic was 
therefore a contributing cause for up to 176 deaths, and an underlying cause for up to 35 deaths. It 
was estimated that 24% of the pancreatitis burden in 2011 was attributable to alcohol 
consumption[7], while 39 pancreatitis deaths in 2010 were attributable to alcohol consumption[5]. 
Epidemiology 
Like liver disease, pancreatitis is considered to be a spectrum of conditions, with recurrent acute 
pancreatitis being a risk factor for chronic pancreatitis[80]. Chronic pancreatitis is in turn a risk factor 
for pancreatic cancer. A recent systematic review found that alcohol consumption is associated with 
risk of both acute and chronic pancreatitis, however the dose-response curves for acute pancreatitis 
differed by sex[81]. Alcohol consumption produced a linear increase in risk of acute pancreatitis in 
men with a relative risk of 1.89 (95% confidence interval: 1.25-2.86) at 50 g/day, but in women a J-
shaped relationship was found with an association with decreased risk at levels of consumption 
below 40 g/day. There was a linear relationship for chronic pancreatitis for both sexes combined 
with a relative risk of 2.51 (1.74-3.61) at 50 g/day. For any pancreatitis, the relationship was linear 
increasing in men and J-shaped in women. There was low to moderate inter-study heterogeneity for 
acute pancreatitis in women, but moderate to high heterogeneity for chronic pancreatitis and acute 
pancreatitis in men. There is a possible interaction between alcohol consumption and 
choledocholithiasis (the presence of gallstones in the biliary tract) on risk of pancreatitis[81]. A 
smaller systematic review and meta-analysis found no effect for alcohol drinking overall vs non-
drinking for either acute or chronic pancreatitis, but the one included primary study which examined 
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different levels of alcohol consumption found that heavy drinking was associated with a relative risk 
of 1.75 (1.11-2.75) for acute pancreatitis and 2.18 (1.19-3.98) for chronic pancreatitis[82]. Further 
research is needed to compare lifetime abstainers and ex-drinkers, and whether risk relationships 
differ by patterns of drinking[81]. 
Causal mechanisms 
The hypothesised mechanism by which alcohol consumption causes acute pancreatitis is through 
oxidant stress, increased digestive and lysosomal enzyme synthesis, and the accumulation of 
cholesteryl esters and fatty acid ethyl esters (alcohol metabolites) in pancreatic acinar cells[83]. 
These materials destabilise lysosomes and zymogen granules, causing a decrease in digestive 
enzyme secretion and an increase in concentration of lysosomes and digestive enzymes in the cell. In 
this state the acinar cells are more susceptible to alcoholic acute pancreatitis however the specific 
trigger for this remains unknown, and may be related to genetic polymorphisms in enzymes that 
metabolise ethanol[83, 84]. During acute pancreatitis, acinar cells undergo necrosis and release 
cytokines that stimulate pancreatic stellate cells to overproduce extracellular matrix proteins, which 
cause pancreatic fibrosis[83]. Separate to this process, acetaldehyde from the metabolism of ethanol 
also stimulates the stellate cells directly through oxidant stress. The accumulation of pancreatic 
fibrosis with repeated episodes of acute pancreatitis then increases risk of chronic pancreatitis. 
Factors that may promote progression to chronic pancreatitis include continued alcohol 
consumption, smoking, number and severity of acute pancreatitis episodes, the hereditary 
pancreatitis gene PRSS1 and other genetic polymorphisms[84]. 
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Other digestive system diseases (ICD-10: K00-69; 80-83; 86.2-93) 
Burden in Australia 
Apart from liver disease and pancreatitis, a range of other diseases of the digestive system are 
associated with alcohol consumption. Other digestive system diseases accounted for 3594 to 3629 
(2.3%) deaths in Australia in 2015[4]. The exact number of deaths is not reported as Australian cause 
of death data is only available for integer ICD codes. The most common causes of death in this group 
were paralytic ileus/intestinal obstruction, vascular disorders of the intestine and diseases of the 
gallbladder/biliary tract. 
Epidemiology 
A diverse group of conditions is associated with alcohol consumption, comprising diseases of the 
oesophagus including gastro-oesophageal reflux disease, diseases of the stomach including 
ulceration and alcoholic gastritis, diseases of the appendix, diseases of the intestines including 
diverticular disease and irritable bowel syndrome, diseases of the anus and rectum including 
haemorrhoids, diseases of the peritoneum, and intestinal malabsorption[3, 85]. For most conditions 
alcohol is associated with increased risk, however there is a possible inverse association between 
alcohol consumption and gallbladder and biliary tract disease[3]. Despite previous reports of an 
inverse association between alcohol consumption and risk of gallstone formation, a recent meta-
analysis found no significant association[86, 87]. 
Causal mechanisms 
Some of the mechanisms by which alcohol consumption harms the digestive system (aside from 
harming the liver and pancreas) include ethanol and acetaldehyde causing mucosal inflammation 
and erosion in the oesophagus, stomach and intestines; reduced oesophageal motility; decreased 
lower oesophageal sphincter pressure resulting in reflux, changed gastric acid secretion; altered gut 
microflora and impaired gut mucosal immune system; and altered proliferation of epithelial cells in 
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the rectum and interference with the absorption of certain vitamins, monosaccharides, amino acids 
and lipids in the intestines[85]. A proposed mechanism for the protective effect of alcohol 
consumption on gallstone formation is via increased serum high-density lipoprotein cholesterol 
which is associated with lower risk[86]. 
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External causes of morbidity and mortality (ICD10: V01-Y98) 
Burden in Australia 
A range of injuries and other external causes of morbidity and mortality are attributable to alcohol, 
including interpersonal violence, falls, motor vehicle accidents, self-harm and suicide, poisoning, 
suffocation, drownings and fires[1, 2]. Injuries were responsible for 9% of the total burden of disease 
in Australia in 2011[7]. Of all deaths in Australia in 2015, external causes were a contributing cause 
of 17,301 (11%) deaths, including 10,573 (6.6%) deaths where external causes were the underlying 
cause[4]. The most common causes were intentional self-harm (most common cause in men), 
accidental fall (most common cause in women), transport accident and accidental poisoning. It was 
estimated that 1495 injury deaths in 2010 were caused by alcohol consumption[5]. 
Alcohol contributed an estimated 21% of the burden from injury including 23% of the burden from 
suicide and self-inflicted injury in 2011[7]. Alcohol consumption has been attributed to 33% of male, 
and 11% of female, motor vehicle deaths in Australia, while the corresponding figures for male and 
female pedestrian deaths were 40% and 17% respectively[1]. Alcohol has also been attributed to 
44% of fire deaths, 34% of drowning deaths and 27% of violence-related deaths in Australia[88]. 
There is also a significant burden in the form of hospitalisation for alcohol-related injury and assault. 
In Australia in 2013, 10% of men and 5% of women reported being hospitalised as a result of an 
alcohol-related injury during their lifetime[89]. 
Epidemiology 
Men are at higher risk of alcohol-related injuries than women at all levels of alcohol consumption[1]. 
For both motor vehicle accident injuries (24% increase in odds per 10 grams) and non-motor vehicle 
injuries (30% increase in odds per 10 grams), there is an exponential dose-response relationship 
between acute alcohol consumption and risk of injury[90]. Alcohol is unique as a lifestyle risk factor 
in that it can impact the health of the user’s family and friends[1]. It is known that alcohol 
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consumption increases the risk of domestic violence in men already predisposed to this behaviour. 
There is also serious harm to children who witness or experience alcohol-related domestic violence. 
Alcohol consumption can also injure persons other than the drinker through its effect on risk of non-
domestic violence and motor vehicle accidents[13].  
Methodological issues regarding alcohol consumption and injury have been reported in the 
literature. There is potential for the relationship between drinking and injury to be under- or 
overestimated due to study methodologies relying on self-reported alcohol consumption[1]. Further, 
unlike for the diseases discussed in the other sections of this chapter, studies that measure acute 
alcohol consumption provide better estimates of injury risk than studies measuring usual alcohol 
consumption[90]. 
Causal mechanisms 
The mechanism by which alcohol consumption increases the risk of injury is through its depressant 
effect on the central nervous system, inhibiting coordination, balance, reaction time and the ability 
to resolve conflicts while promoting drowsiness, disinhibition, risk-taking and aggressive 
behaviour[1]. Engaging in risky activities while drinking is not uncommon in Australia. In 2013 12% of 
people reported driving a vehicle while under the influence of alcohol in the previous 12 months, 8% 
went swimming, and 2% operated a boat or heavy machinery[89]. Heavy alcohol consumption also 
decreases bone density which increases the likelihood of fractures when falls occur[91]. 
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Appendix B – Additional Tables for Chapter 4 
 
Table B.1. Socio-demographic characteristics at baseline by alcohol consumption in the 45 and Up Study 
(2006-2009), New South Wales, Australia. 
  Alcoholic drinks per week 
Variable  n Mean (SD) Median (Q1-Q3) Non-drinkera (%) ≥ 1, ≤ 14 (%) > 14 (%) 
Sex       
Men 123,769 9.9 (11.9) 6 (1-14) 23.3 51.8 23.4 
Women 143,025 4.4 (6.2) 2 (0-7) 40.8 51.0 6.0 
Age (years)       
≥ 45, < 55 77,852 7.1 (9.8) 4 (0-10) 29.5 54.9 14.4 
≥ 55, < 65 85,822 7.6 (10.2) 4 (0-10) 30.0 52.8 15.8 
≥ 65, < 75 58,018 7.1 (9.7) 4 (0-10) 34.3 49.0 14.6 
≥ 75, < 85 36,853 5.8 (8.3) 2 (0-8) 39.7 46.7 10.2 
≥ 85 8,249 4.0 (6.4) 0 (0-7) 48.7 41.1 5.2 
Remoteness       
Major city 139,090 6.6 (9.2) 3 (0-10) 33.3 51.7 12.9 
Inner regional 92,735 7.3 (9.9) 4 (0-10) 31.6 51.7 15.2 
Outer regional 27,295 7.4 (10.7) 4 (0-10) 34.4 48.4 15.5 
Remote 2,539 8.0 (11.4) 4 (0-10) 32.4 48.1 16.9 
Missing 5,135 7.4 (9.9) 5 (0-10) 28.2 56.1 14.6 
Annual household incomeb       
< $30,000 78,021 5.9 (9.9) 2 (0-8) 43.2 42.7 11.6 
≥ $30,000, < $70,000 68,184 7.7 (10.0) 5 (0-10) 28.2 54.7 16.1 
≥ $70,000 62,780 8.7 (9.7) 6 (2-12) 18.8 61.6 19.0 
Missing 57,809 5.6 (8.5) 2 (0-8) 38.8 48.2 9.6 
Highest level of education       
No school certificate 31,367 5.6 (9.9) 1 (0-7) 46.9 38.4 11.1 
School certificate 58,700 6.2 (9.3) 3 (0-10) 38.1 48.1 11.9 
Higher school certificate 26,059 7.4 (10.1) 4 (0-10) 31.4 51.3 15.3 
Trade or apprenticeship 29,594 9.2 (12.0) 5 (0-14) 27.8 49.6 20.9 
Certificate or diploma 55,188 6.7 (8.9) 4 (0-10) 30.9 55.0 13.0 
University degree or higher 61,521 7.4 (8.8) 5 (1-10) 24.5 59.6 15.0 
Missing 4,465 5.9 (10.1) 2 (0-7) 38.8 40.7 10.0 
Health insurance status       
None 40,211 7.2 (10.9) 3 (0-10) 36.1 46.8 15.1 
Health care concession card 47,654 5.8 (10.3) 1 (0-7) 46.7 38.5 11.4 
DVA white or gold card 4,802 7.1 (10.6) 3 (0-10) 35.8 46.8 14.1 
Private, no extras 130,810 7.3 (9.1) 5 (0-10) 26.8 57.2 14.8 
Private, with extras 38,233 7.1 (9.1) 4 (0-10) 30.1 54.5 14.0 
Missing 5,084 6.1 (10.7) 2 (0-8) 41.8 39.9 11.4 
Married/living with partner       
No 66,548 6.1 (10.3) 2 (0-8) 41.2 44.1 11.8 
Yes 198,625 7.2 (9.4) 4 (0-10) 29.9 53.9 14.8 
Missing 1,621 8.2 (10.5) 5 (0-12) 28.2 47.8 17.9 
a< 1 alcoholic drink per week. bPre-tax annual household income from all sources in Australian dollars. cCell 
contains < 5 participants. Missing alcohol data not shown. SD, Standard Deviation. Q1, 25th percentile. Q3, 75th 
percentile. DVA, Department of Veterans’ Affairs. NZ, New Zealand. UK, United Kingdom. USA, United States of 
America. 
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Table B.1. (Continued) 
  Alcoholic drinks per week 
Variable  n Mean (SD) Median (Q1-Q3) Non-drinkera (%) ≥ 1, ≤ 14 (%) > 14 (%) 
Country of birth       
Australia 199,875 7.3 (9.9) 4 (0-10) 31.9 51.7 14.9 
Canada/Ireland/NZ/UK/USA 33,149 7.8 (9.7) 5 (0-10) 26.2 56.6 15.8 
Other country 31,427 4.2 (7.3) 1 (0-6) 44.5 44.4 6.8 
Missing 2,343 6.5 (9.8) 3 (0-10) 34.9 43.8 12.0 
Years lived in Australia       
< 10 3,063 4.8 (7.2) 2 (0-7) 41.9 46.5 8.8 
≥ 10 and < 20 6,362 4.2 (7.3) 1 (0-6) 46.2 42.7 7.4 
≥ 20 and < 30 10,029 5.5 (8.5) 2 (0-8) 38.6 48.4 10.2 
≥ 30 and < 40 13,254 6.7 (9.3) 4 (0-10) 32.1 52.1 13.3 
≥ 40 28,771 6.6 (9.1) 4 (0-10) 32.0 53.5 12.3 
Born in Australia 199,875 7.3 (9.9) 4 (0-10) 31.9 51.7 14.9 
Missing 5,440 6.0 (9.1) 2 (0-8) 35.5 45.4 10.7 
Language spoken at home       
English only 241,352 7.3 (9.8) 4 (0-10) 31.2 52.3 14.9 
Other language 25,439 3.9 (7.3) 1 (0-5) 46.8 42.4 6.1 
Missing < 5 -c -c -c -c -c 
Total 266,794 7.0 (9.7) 4 (0-10) 32.7 51.4 14.0 
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Table B.2. Alcohol consumption by key behavioural and physical covariates at baseline in the 45 and Up 
Study (2006-2009), New South Wales, Australia. 
  Alcoholic drinks per week 
Variable  n Mean (SD) Median (Q1-Q3) Non-drinkera (%) ≥ 1, ≤ 14 (%) > 14 (%) 
Smoking status and dose 
(cigarettes/day) 
      
Never smoker 152,066 5.0 (7.4) 2 (0-7) 38.1 51.8 7.9 
Ex-smoker; ≤ 15 46,046 8.3 (9.2) 6 (1-12) 23.1 58.2 17.6 
Ex-smoker; > 15 46,813 10.7 (12.5) 7 (1-15) 24.6 47.8 26.5 
Ex-smoker; Missing 1,707 8.7 (10.2) 6 (1-14) 23.4 52.1 18.5 
Current smoker; ≤ 15 9,273 8.1 (10.9) 4 (0-12) 32.9 46.3 18.8 
Current smoker; > 15 9,612 11.6 (16.3) 5 (0-18) 34.0 36.1 27.6 
Current smoker; Missing 419 8.3 (12.5) 4 (0-10) 32.9 40.8 16.2 
Missing 858 7.5 (10.4) 4 (0-10) 32.3 47.0 16.6 
Height (cm)       
Male; < 175 46,796 9.0 (11.5) 5 (0-14) 27.5 50.1 20.6 
Male; ≥ 175, < 180 33,348 10.3 (11.9) 7 (1-15) 21.3 52.7 24.8 
Male; ≥ 180 38,732 10.7 (12.3) 7 (2-15) 19.7 53.2 26.1 
Female; < 160 45,606 3.8 (5.9) 1 (0-6) 46.8 45.6 4.7 
Female; ≥ 160, < 165 38,797 4.5 (6.2) 2 (0-7) 39.8 52.4 6.0 
Female; ≥ 165 50,927 5.1 (6.5) 2 (0-8) 35.5 55.6 7.3 
Missing 12,588 5.8 (8.5) 2 (0-8) 37.5 47.8 10.4 
Body mass index (kgm-2)       
Underweight (< 18.5) 3,406 5.4 (9.0) 4 (0-10) 31.5 54.7 12.0 
Normal range (≥ 18.5, < 25.0) 90,787 6.6 (8.8) 2 (0-7) 43.8 44.3 9.0 
Overweight (≥ 25.0, < 30.0) 97,404 7.8 (10.0) 5 (0-11) 28.8 52.9 16.7 
Obese (≥ 30.0) 55,056 6.7 (10.6) 2 (0-10) 38.7 45.3 14.2 
Missing 20,141 5.9 (9.0) 2 (0-8) 38.5 46.8 10.8 
Physical activity (min/weekb)       
Inactive (0) 15,201 5.6 (10.5) 0 (0-7) 50.1 35.6 11.5 
Insufficient (> 0, < 150) 43,843 6.1 (9.6) 2 (0-8) 38.2 47.4 11.8 
Sufficient (≥ 150, < 300) 40,840 6.8 (9.5) 4 (0-10) 32.1 52.8 13.5 
High (≥ 300) 160,024 7.4 (9.6) 5 (0-10) 29.4 54.1 15.2 
Missing 6886 6.0 (9.6) 2 (0-8) 37.7 39.7 10.2 
Total 266,794 7.0 (9.7) 4 (0-10) 32.7 51.4 14.0 
a< 1 alcoholic drink per week. bTime spent in vigorous physical activity was given twice the weighting of lower 
intensity physical activity. Missing alcohol data not shown. SD, Standard Deviation. Q1, 25th percentile. Q3, 75th 
percentile. 
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Table B.3. Alcohol consumption by sun exposure covariates at baseline in the 45 and Up Study (2006-2009), 
New South Wales, Australia. 
  Alcoholic drinks per week 
Variable  n Mean (SD) Median (Q1-Q3) Non-drinkera (%) ≥ 1, ≤ 14 (%) > 14 (%) 
Time outdoors (hours/day)       
< 2 70,154 5.5 (8.1) 2 (0-8) 38.1 50.5 9.7 
≥ 2, < 4 98,123 6.7 (9.1) 4 (0-10) 32.1 53.2 13.1 
≥ 4, < 6 46,526 7.9 (10.1) 5 (0-12) 29.2 52.4 16.9 
≥ 6 40,587 9.3 (12.0) 6 (0-14) 27.1 49.9 21.2 
Missing 11,404 6.5 (10.3) 2 (0-10) 38.7 42.2 12.7 
Skin tone       
Fair 187,290 7.0 (9.7) 4 (0-10) 32.6 51.5 14.3 
Olive 70,764 7.0 (9.6) 4 (0-10) 31.5 52.6 14.0 
Brown or black 5,252 4.8 (9.5) 0 (0-6) 48.0 36.3 9.4 
Missing 3,488 6.3 (10.3) 2 (0-9) 37.4 45.1 11.2 
Total 266,794 7.0 (9.7) 4 (0-10) 32.7 51.4 14.0 
a< 1 alcoholic drink per week. Missing alcohol data not shown. SD, Standard Deviation. Q1, 25th percentile. Q3, 
75th percentile. 
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Table B.4. Alcohol consumption by dietary factors at baseline in the 45 and Up Study (2006-2009), New South 
Wales, Australia. 
  Alcoholic drinks per week 
Variable  n Mean (SD) Median (Q1-Q3) Non-drinkera (%) ≥ 1, ≤ 14 (%) > 14 (%) 
Fruit consumptionb       
< 1 serve/day 25,200 10.2 (13.6) 6 (0-14) 31.2 42.4 24.3 
≥ 1, < 2 serves/day 85,431 8.0 (10.3) 5 (0-12) 29.2 51.9 17.3 
≥ 2 serves/day 149,468 5.8 (8.2) 3 (0-8) 34.9 52.9 10.5 
Missing 6,695 7.2 (10.5) 3 (0-10) 33.9 45.5 14.3 
Vegetable consumptionc       
< 3 serves/day 95,126 7.6 (10.6) 4 (0-10) 32.4 49.3 16.4 
≥ 3, < 5 serves/day 81,074 6.8 (9.2) 4 (0-10) 31.2 53.7 13.5 
≥ 5 serves/day 83,871 6.4 (9.0) 3 (0-10) 34.1 52.0 12.0 
Missing 6,723 6.6 (10.0) 3 (0-10) 36.0 45.3 12.5 
Fibre intaked       
< 7 serves/week 37,215 8.6 (12.4) 4 (0-12) 33.8 45.2 19.5 
≥ 7, < 14 serves/week 74,569 6.7 (8.9) 4 (0-10) 31.4 54.3 12.9 
≥ 14, < 21 serves/week 63,067 6.8 (8.8) 4 (0-10) 30.1 55.4 13.0 
≥ 21 serves/week 66,427 6.6 (9.2) 3 (0-10) 34.8 50.3 13.4 
Missing 25,516 6.8 (10.2) 3 (0-10) 35.5 45.1 13.6 
Red meat consumption       
0 times/week 14,516 3.9 (7.5) 0 (0-6) 51.6 38.7 6.3 
> 0, ≤ 2 times/week 80,151 5.9 (8.4) 3 (0-8) 34.7 52.6 10.7 
> 2, ≤ 5 times/week 137,955 7.4 (9.7) 4 (0-10) 29.9 53.3 15.3 
> 5 times/week 28,619 9.3 (12.5) 5 (0-14) 30.5 46.3 21.6 
Missing 5,553 6.3 (9.4) 3 (0-10) 36.5 45.7 11.8 
Processed meat consumption       
0 times/week 88,879 5.4 (8.1) 2 (0-7) 39.2 49.2 9.1 
> 0, ≤ 1 times/week 87,548 7.0 (9.2) 4 (0-10) 30.1 54.7 13.9 
> 1, ≤ 2 times/week 43,270 8.0 (10.4) 5 (0-12) 28.9 52.1 17.5 
> 2 times/week 41,525 9.3 (12.1) 6 (0-14) 27.6 49.2 21.7 
Missing 5,572 6.2 (9.3) 3 (0-10) 36.6 45.5 11.4 
Total 266,794 7.0 (9.7) 4 (0-10) 32.7 51.4 14.0 
a< 1 alcoholic drink per week. bServe = one medium piece, two small pieces or one cup of diced or canned fruit, 
excluding fruit juice. cServe = half cup of cooked vegetables or one cup of raw vegetables. dServe = slice or piece 
of brown/wholemeal bread or bowl of breakfast cereal per week. Missing alcohol data not shown. SD, Standard 
Deviation. Q1, 25th percentile. Q3, 75th percentile. 
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Table B.5. Alcohol consumption by female reproductive characteristics at baseline among women in the 45 
and Up Study (2006-2009), New South Wales, Australia. 
  Alcoholic drinks per week 
Variable  n Mean (SD) Median (Q1-Q3) Non-drinkera (%) ≥ 1, ≤ 14 (%) > 14 (%) 
Parity and age at first birth       
No children 15,632 5.5 (7.3) 3 (0-8) 37.5 51.4 9.5 
1 child, < 25 years 3,414 4.6 (6.9) 1 (0-7) 44.5 45.5 7.5 
1 child, ≥ 25 years 8,498 4.8 (6.8) 2 (0-7) 39.8 50.7 7.5 
2 children, < 25 years 19,787 4.5 (6.4) 2 (0-7) 41.2 50.6 6.1 
2 children, ≥ 25 years 27,087 4.9 (6.1) 3 (0-7) 34.4 57.8 6.4 
≥ 3 children, < 25 years 40,105 3.7 (5.8) 1 (0-6) 47.1 45.9 4.5 
≥ 3 children, ≥ 25 years 21,966 4.4 (5.8) 2 (0-7) 37.0 55.9 5.2 
Missing 6,536 3.7 (5.9) 0.5 (0-6) 46.7 42.3 4.4 
Breastfeeding time (months)       
Never breastfed 31,763 4.6 (6.8) 1.5 (0-7) 44.6 46.2 7.4 
> 0, ≤ 12 59,404 4.5 (6.2) 2 (0-7) 40.4 51.3 6.0 
> 12, ≤ 24 27,997 4.5 (6.0) 2 (0-7) 37.6 55.3 5.6 
> 24 20,954 4.1 (5.6) 2 (0-6) 40.4 53.2 4.7 
Missing 2,907 3.8 (6.0) 1 (0-6) 40.6 41.7 4.0 
Menopausal status       
Pre-menopausal 17,936 4.9 (6.5) 3 (0-7) 34.9 56.5 7.0 
Irregular periods 8,153 5.2 (6.8) 3 (0-8) 33.7 57.3 8.0 
Post-menopausal 93,140 4.4 (6.1) 2 (0-7) 41.7 50.4 5.6 
Missing 23,796 4.3 (6.4) 1 (0-7) 43.8 47.3 5.9 
Hormonal contraceptive use       
Never user 29,673 2.9 (5.2) 0 (0-4) 55.2 37.7 3.0 
Ever user 110,745 4.9 (6.4) 3 (0-7) 36.7 54.9 6.8 
Missing 2,607 3.4 (5.9) 0 (0-5) 49.3 37.2 3.7 
HRT use       
Never used 86,852 4.3 (6.2) 2 (0-7) 41.7 50.2 5.9 
Formerly used 38,254 4.6 (6.2) 2 (0-7) 39.9 52.2 6.1 
Current user 14,257 5.1 (6.5) 3 (0-7) 35.2 56.1 7.1 
Missing 3,662 3.4 (5.7) 0 (0-5) 48.0 38.8 3.4 
Total 143,025 4.4 (6.2) 2 (0-7) 40.8 51.0 6.0 
a< 1 alcoholic drink per week. Missing alcohol data not shown. SD, Standard Deviation. Q1, 25th percentile. Q3, 
75th percentile. HRT, Hormone Replacement Therapy.   
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Table B.6. Alcohol consumption by medical and health-related factors at baseline in the 45 and Up Study 
(2006-2009), New South Wales, Australia. 
  Alcoholic drinks per week 
Variable  n Mean (SD) Median (Q1-Q3) Non-drinkera (%) ≥ 1, ≤ 14 (%) > 14 (%) 
Bowel screening historyb       
Not in last 10 years 135,599 6.7 (9.8) 3 (0-10) 34.6 50.1 13.3 
Yes; ≥ 2, ≤ 10 years ago 56,529 7.2 (9.5) 4 (0-10) 31.2 52.8 14.6 
Yes; < 2 years ago 62,351 7.5 (9.6) 5 (0-10) 29.1 54.1 15.6 
Missing 12,315 6.5 (9.7) 3 (0-10) 36.7 46.0 12.3 
Breast screening historyc       
Not in last 10 years 18,545 4.1 (6.7) 1 (0-6) 46.4 44.7 6.2 
Yes; ≥ 2, ≤ 10 years ago 47,659 4.3 (6.1) 2 (0-7) 42.8 49.4 5.5 
Yes; < 2 years ago 68,665 4.7 (6.2) 2 (0-7) 37.2 54.9 6.4 
Missing 8,156 3.8 (6.1) 1 (0-6) 46.5 42.3 4.8 
Prostate screening historyd       
Never 34,570 10.0 (12.9) 6 (0-14) 25.2 49.6 23.6 
Yes; ≥ 1, ≤ 3 times 41,874 10.0 (11.7) 7 (1-14) 21.5 53.3 24.1 
Yes; > 3 times 32,244 9.9 (11.0) 7 (1-14) 21.5 53.8 23.7 
Yes; times missing 4,868 8.6 (11.3) 5 (0-14) 29.2 48.2 19.6 
Missing 10,213 9.1 (11.9) 5 (0-14) 27.6 48.3 20.6 
Aspirin usee       
No 208,806 7.0 (9.7) 4 (0-10) 32.1 52.0 14.0 
Yes 57,962 6.9 (9.7) 4 (0-10) 34.6 49.1 14.1 
Missing 26 2.9 (5.2) 0 (0-5) 57.7 30.8 -f 
Self-rated overall health       
Excellent 38,887 7.1 (8.3) 5 (0-10) 24.9 61.0 13.0 
Very good 95,001 7.3 (9.1) 5 (0-10) 28.0 56.1 14.7 
Good 86,936 7.1 (10.2) 3 (0-10) 34.9 48.4 14.8 
Fair 30,893 6.2 (11.0) 1 (0-8) 44.7 39.5 12.9 
Poor 5,656 5.2 (11.4) 0 (0-6) 54.7 30.6 10.2 
Missing 9,421 5.8 (9.6) 2 (0-8) 39.0 43.5 10.6 
Physical functioning score       
≥ 75% 181,837 7.5 (9.6) 0 (0-5) 27.9 55.6 15.4 
≥ 50%, < 75% 23,571 6.2 (10.2) 1 (0-7) 41.5 44.5 12.4 
≥ 25%, < 50% 12,867 5.5 (9.9) 2 (0-8) 47.7 38.9 11.1 
< 25% 8,450 4.5 (9.7) 5 (0-10) 56.6 31.7 8.5 
Missing 31,170 6.0 (9.2) 2 (0-8) 38.3 45.3 11.1 
Total 266,794 7.0 (9.7) 4 (0-10) 32.7 51.4 14.0 
a< 1 alcoholic drink per week. bFaecal occult blood test, sigmoidoscopy or colonoscopy. cBreast screening 
mammogram; women only. dProstate specific antigen blood test; men only. eUse in most of the previous 4 
weeks. fCell contains < 5 participants. Missing alcohol data not shown. SD, Standard Deviation. Q1, 25th 
percentile. Q3, 75th percentile. 
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Appendix C – Additional Tables for Chapter 6 
 
Table C.1. Number of participants included in the Chapter 6 analyses by country and region of birth. 
Region of birth Country of birth n % of region % of total 
Australia   199 908  100.0 75.7 
 
Australia 199 900 100.0 75.7 
 
Norfolk Island 8 0.0 0.0 
     New Zealand 
 
5 069 100.0 1.9 
 
New Zealand 5 069 100.0 1.9 
     Oceania 
 
887 100.0 0.3 
 
Cook Islands 19 2.1 0.0 
 
Fiji 503 56.7 0.2 
 
French Polynesia 5 0.6 0.0 
 
Kiribati 6 0.7 0.0 
 
Nauru -a -a -a 
 
New Caledonia 17 1.9 0.0 
 
Niue 5 0.6 0.0 
 
Papua New Guinea 205 23.1 0.1 
 
Samoa 51 5.7 0.0 
 
Solomon Islands 6 0.7 0.0 
 
Tonga 53 6.0 0.0 
 
Vanuatu 14 1.6 0.0 
 
Wallis and Futuna -a -a -a 
     East Asia 
 
3 231 100.0 1.2 
 
China 1 868 57.8 0.7 
 
Hong Kong 707 21.9 0.3 
 
Japan 221 6.8 0.1 
 
Macau 20 0.6 0.0 
 
South Korea 315 9.7 0.1 
 
Taiwan 100 3.1 0.0 
     Southeast Asia 
 
4 487 100.0 1.7 
 
Brunei Darussalam 7 0.2 0.0 
 
Burma (Myanmar) 109 2.4 0.0 
 
Cambodia 94 2.1 0.0 
 
East Timor 31 0.7 0.0 
 
Indonesia 495 11.0 0.2 
 
Laos 83 1.8 0.0 
 
Malaysia 669 14.9 0.3 
 
Philippines 1 253 27.9 0.5 
 
Singapore 254 5.7 0.1 
 
Sri Lanka 530 11.8 0.2 
 
Thailand 130 2.9 0.0 
 
Viet Nam 832 18.5 0.3 
aCensored due to < 5 participants, or if this value would enable calculation of value for another cell with < 5 
participants. 
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Table C.1. (Continued) 
Region of birth Country of birth n % of region % of total 
Central & South Asia  1 357 100.0 0.5 
 Afghanistan 46 3.4 0.0 
 Armenia 13 1.0 0.0 
 Bangladesh 70 5.2 0.0 
 Georgia -a -a -a 
 India 1 130 83.3 0.4 
 Kyrgyz Republic -a -a -a 
 Mongolia -a -a -a 
 Nepal 12 0.9 0.0 
 Pakistan 81 6.0 0.0 
     United Kingdom & Ireland  26 282 100.0 10.0 
 Channel Islands 18 0.1 0.0 
 Ireland 1 148 4.4 0.4 
 Isle of Man 6 0.0 0.0 
 Northern Ireland 24 0.1 0.0 
 Scotland 319 1.2 0.1 
 United Kingdom 24 669 93.9 9.3 
 Wales 98 0.4 0.0 
     
Western Europe 
 
11 534 100.0 4.4 
 
Austria 552 4.8 0.2 
 
Belgium 94 0.8 0.0 
 
Cyprus 146 1.3 0.1 
 
Denmark 207 1.8 0.1 
 
Finland 190 1.6 0.1 
 
France 362 3.1 0.1 
 
Germany 2 786 24.2 1.1 
 
Gibraltar 8 0.1 0.0 
 
Greece 838 7.3 0.3 
 
Iceland 8 0.1 0.0 
 
Israel 52 0.5 0.0 
 
Italy 2 121 18.4 0.8 
 
Luxembourg 6 0.1 0.0 
 
Malta 656 5.7 0.2 
 
Netherlands 2 642 22.9 1.0 
 
Norway 60 0.5 0.0 
 
Portugal 161 1.4 0.1 
 
Spain 211 1.8 0.1 
 
Sweden 128 1.1 0.0 
 
Switzerland 306 2.7 0.1 
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Table C.1. (Continued) 
Region of birth Country of birth n % of region % of total 
Eastern & Central Europe  3 940 100.0 1.5 
 Albania 5 0.1 0.0 
 Belarus -a -a -a 
 Bosnia Herzegovina 80 2.0 0.0 
 Bulgaria 27 0.7 0.0 
 Croatia 442 11.2 0.2 
 Czech Republic 308 7.8 0.1 
 Estonia 106 2.7 0.0 
 Hungary 574 14.6 0.2 
 Latvia 165 4.2 0.1 
 Lithuania 61 1.5 0.0 
 Moldova 5 0.1 0.0 
 Montenegro -a -a -a 
 Poland 925 23.5 0.4 
 Republic of Macedonia 208 5.3 0.1 
 Romania 138 3.5 0.1 
 Russian Federation 147 3.7 0.1 
 Serbia 115 2.9 0.0 
 Slovakia 58 1.5 0.0 
 Slovenia 114 2.9 0.0 
 Ukraine 147 3.7 0.1 
 Union of Soviet Socialist Republics 31 0.8 0.0 
 Yugoslavia 279 7.1 0.1 
     
Middle East & North Africa  2 125 100.0 0.8 
 Algeria 10 0.5 0.0 
 Bahrain 11 0.5 0.0 
 Egypt 649 30.5 0.2 
 Gaza Strip & West Bank 64 3.0 0.0 
 Iran 189 8.9 0.1 
 Iraq 220 10.4 0.1 
 Jordan 45 2.1 0.0 
 Lebanon 693 32.6 0.3 
 Libya 5 0.2 0.0 
 Morocco 10 0.5 0.0 
 Syria 43 2.0 0.0 
 Tunisia -a -a -a 
 Turkey 179 8.4 0.1 
 Yemen -a -a -a 
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Table C.1. (Continued) 
Region of birth Country of birth n % of region % of total 
Sub-Saharan Africa  2 247 100.0 0.9 
 Africa Unspecified 32 1.4 0.0 
 Botswana -a -a -a 
 Congo -a -a -a 
 East Africa 20 0.9 0.0 
 Ethiopia 7 0.3 0.0 
 Ghana 21 0.9 0.0 
 Kenya 99 4.4 0.0 
 
Lesotho -a -a -a 
 Madagascar 5 0.2 0.0 
 Malawi 11 0.5 0.0 
 Mauritius 211 9.4 0.1 
 Mozambique -a -a -a 
 Namibia 8 0.4 0.0 
 Nigeria 18 0.8 0.0 
 Senegal -a -a -a 
 Seychelles 6 0.3 0.0 
 South Africa 1 444 64.3 0.5 
 St Helena -a -a -a 
 Sudan 67 3.0 0.0 
 Tanzania 32 1.4 0.0 
 Uganda 27 1.2 0.0 
 Zambia 53 2.4 0.0 
 Zimbabwe 174 7.7 0.1 
     
North America  1 768 100.0 0.7 
 Bermuda 13 0.7 0.0 
 Canada 576 32.6 0.2 
 United States of America 1 179 66.7 0.4 
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Table C.1. (Continued) 
Region of birth Country of birth n % of region % of total 
Central & South America 
 
1 267 100.0 0.5 
 
Argentina 179 14.1 0.1 
 
Bolivia 9 0.7 0.0 
 
Brazil 68 5.4 0.0 
 
Chile 386 30.5 0.1 
 
Colombia 69 5.4 0.0 
 
Costa Rica 5 0.4 0.0 
 
Cuba 6 0.5 0.0 
 
Dominican Republic -a -a -a 
 
Dutch West Indies 10 0.8 0.0 
 
Ecuador 34 2.7 0.0 
 
El Salvador 30 2.4 0.0 
 
Falkland Islands -a -a -a 
 
Guatemala -a -a -a 
 
Guyana 5 0.4 0.0 
 
Jamaica 9 0.7 0.0 
 
Mexico 19 1.5 0.0 
 
Netherlands Antilles -a -a -a 
 
Nicaragua 10 0.8 0.0 
 
Panama -a -a -a 
 
Paraguay 6 0.5 0.0 
 
Peru 123 9.7 0.0 
 
South America Unspecified 7 0.6 0.0 
 
St Vincent and the Grenadines -a -a -a 
 
Suriname -a -a -a 
 
Trinidad and Tobago 21 1.7 0.0 
 
Uruguay 241 19.0 0.1 
 
Venezuela 17 1.3 0.0 
     Total born overseas 
 
64 194 
 
24.3 
     Total 
 
264 102 
 
100.0 
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Table C.2: Decade first migrated to Australia for at least one year by place of birth. 
  Decade first migrated to Australia for at least one year (n [row %]) 
Place of birth n 1910s 1920s 1930s 1940s 1950s 1960s 1970s 1980s 1990s 2000s Unspecified 
New Zealand 5,069 5 [0.1] 57 [1.1] 78 [1.5] 102 [2.0] 334 [6.6] 923 [18.2] 1,454 [28.7] 1,147 [22.6] 469 [9.3] 300 [5.9] 200 [4.0] 
Oceania 887 0 [0.0] 6 [0.7] 29 [3.3] 50 [5.6] 67 [7.6] 127 [14.3] 156 [17.6] 235 [26.5] 125 [14.1] 59 [6.7] 33 [3.7] 
East Asia 3,231 -a -a 20 [0.6] 83 [2.6] 154 [4.8] 192 [5.9] 356 [11.0] 1,024 [31.7] 1,032 [31.9] 280 [8.7] 86 [2.7] 
Southeast Asia 4,487 -a -a 8 [0.2] 48 [1.1] 201 [4.5] 304 [6.8] 892 [19.9] 1,758 [39.2] 871 [19.4] 256 [5.7] 146 [3.3] 
Central & South Asia 1,357 -a -a 6 [0.4] 63 [4.6] 71 [5.2] 192 [14.1] 266 [19.6] 250 [18.4] 330 [24.3] 139 [10.2] 38 [2.8] 
UK & Ireland 26,282 20 [0.1] 387 [1.5] 138 [0.5] 1,426 [5.4] 5,017 [19.1] 8,755 [33.3] 4,828 [18.4] 2,927 [11.1] 1,095 [4.2] 660 [2.5] 1,029 [3.9] 
Western Europe 11,534 0 [0.0] 26 [0.2] 159 [1.4] 535 [4.6] 4,753 [41.2] 2,805 [24.3] 1,147 [9.9] 984 [8.5] 314 [2.7] 140 [1.2] 671 [5.8] 
Eastern & Central Europe 3,940 0 [0.0] 5 [0.1] 27 [0.7] 572 [14.5] 1,086 [27.6] 827 [21.0] 450 [11.4] 306 [7.8] 277 [7.0] 75 [1.9] 315 [8.0] 
Middle East & North Africa 2,125 -a -a 6 [0.3] 87 [4.1] 236 [11.1] 385 [18.1] 581 [27.3] 341 [16.0] 247 [11.6] 99 [4.7] 138 [6.5] 
Sub-Saharan Africa 2,247 0 [0.0] -a 6 [0.3] -a 50 [2.2] 397 [17.7] 429 [19.1] 604 [26.9] 346 [15.4] 330 [14.7] 66 [2.9] 
North America 1,768 0 [0.0] 8 [0.5] 10 [0.6] 47 [2.7] 71 [4.0] 338 [19.1] 573 [32.4] 375 [21.2] 211 [11.9] 96 [5.4] 39 [2.2] 
Central & South America 1,267 0 [0.0] -a 0 [0.0] -a 13 [1.0] 92 [7.3] 611 [48.2] 280 [22.1] 136 [10.7] 43 [3.4] 88 [7.0] 
Total born overseas 64,194 26 [0.0] 505 [0.8] 487 [0.8] 3,033 [4.7] 12,053 [18.8] 15,337 [23.9] 11,743 [18.3] 10,231 [15.9] 5,453 [8.5] 2,477 [3.9] 2,849 [4.4] 
aCensored due to < 5 participants, or if this value would enable calculation of value for another cell with < 5 participants. 
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Appendix D – Additional Figure for Chapter 7 Journal Article 
 
Figure D.1. Odds ratios (OR; 95% confidence intervals, CI) of quitting drinking at follow-up by 
health conditions newly acquired between baseline and follow-up in the 45 and Up Study (2006-
2016), New South Wales, Australia. Adjusted for sex, age, remoteness, education, household 
income, health insurance status, partner status and country of birth. 
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Appendix E.1 – Additional Tables for Chapter 8 Journal Article 
Table E.1. Proportional hazards assumption tests by cancer type in the 45 and Up Study (2006-2010), New South Wales, Australia. 
 Total alcohol consumption model  Drinking-days per week model  Drinks per drinking-day model  Drinking pattern model 
Cancer type p Variables in violation  p Variables in violation  p Variables in violation  p Variables in violation 
Mouth and pharynx 0.73 -  0.81 -  0.80 -  - - 
Oesophagus 0.94 -  0.90 -  0.74 -  - - 
- Adenocarcinoma 0.45 -  0.30 -  0.19 -  - - 
- Squamous cell carcinoma 0.57 -  0.80 -  0.88 -  - - 
Colorectum 0.02 Partner status, fruit  0.02 Partner status, BMI  0.02 Partner status, BMI  0.01 Partner status, BMI 
- Colon 0.26 -  0.12 -  0.11 -  0.13 - 
- Rectum 0.10 -  0.10 -  0.33 -  - - 
Liver 0.72 -  0.81 -  0.94 -  - - 
Larynx 0.36 -  0.31 -  0.42 -  - - 
Breast 0.87 -  0.71 -  0.65 -  - - 
Alcohol-related 0.04 Partner status, PA, fruit  0.08 -  0.07 -  - - 
Stomach 0.54 -  0.66 -  0.65 -  - - 
Pancreas 0.09 -  0.26 -  0.32 -  - - 
Lung 0.39 -  0.27 -  0.27 -  - - 
Melanoma 0.43 -  0.09 -  0.11 -  - - 
Endometrium 0.76 -  0.69 -  0.72 -  - - 
Ovary 0.47 -  0.44 -  0.48 -  - - 
Prostate 0.49 -  0.61 -  0.73 -  - - 
Kidney 0.74 -  0.23 -  0.30 -  0.28 - 
Bladder 0.74 -  0.44 -  0.43 -  - - 
Brain 0.34 -  0.11 -  0.29 -  - - 
Thyroid 0.03 Health insurance  0.08 -  0.048 Health insurance  - - 
Non-Hodgkin lymphoma 0.58 -  0.49 -  0.31 -  - - 
Multiple myeloma 0.01 Income, health insurance  0.59 -  0.49 -  - - 
Leukaemia 0.38 -  0.15 -  0.15 -  - - 
Other 0.15 -  0.18 -  0.14 -  - - 
Non-alcohol-related 0.23 -  0.12 -  0.10 -  - - 
All cancer 0.13 -  0.11 -  0.09 -  0.09 - 
BMI, Body Mass Index. PA, physical activity. 
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Table E.2. Interaction tests by cancer type in the 45 and Up Study (2006-2010), New South Wales, Australia. 
 Total alcohol consumption  Drinking-days per week  Mean drinks per drinking-day  
Cancer type Sex Smokinga BMIb HRTc  Sex Smokinga BMIb HRTc  Sex Smokinga BMIb HRTc  Drinking patternd 
Mouth and pharynx 0.64 0.34 - -  0.14 0.95 - -  0.06 0.95 - -  0.22 
Oesophagus 0.79 0.70 - -  0.46 0.94 - -  0.48 0.55 - -  0.97 
- Adenocarcinoma 0.99 0.71 - -  0.70 0.72 - -  1.00 0.74 - -  0.99 
- Squamous cell carcinoma 1.00 0.82 - -  0.40 0.79 - -  0.70 0.90 - -  0.53 
Colorectum 0.87 0.40 0.31 -  0.62 0.18 0.32 -  0.43 0.80 0.80 -  0.04 
- Colon 0.31 0.84 0.36 -  0.95 0.12 0.27 -  0.25 0.36 0.87 -  0.03 
- Rectum 0.39 0.10 0.01 -  0.41 0.96 0.32 -  0.71 0.51 0.81 -  0.74 
Liver 0.58 0.85 - -  0.95 0.90 - -  0.60 0.90 - -  0.88 
Larynx 0.83 1.00 - -  1.00 1.00 - -  1.00 1.00 - -  1.00 
Breast - 0.22 - 0.45  - 0.04 - 0.64  - 0.17 - 0.19  0.38 
Alcohol-related 0.01 0.25 - -  0.004 0.32 - -  0.02 0.07 - -  0.33 
Stomach 0.69 0.09 - -  0.86 0.37 - -  1.00 0.30 - -  0.78 
Pancreas 0.07 0.04 0.97 -  0.86 0.27 0.96 -  0.35 0.52 0.80 -  0.97 
Lung 0.64 0.97 - -  0.50 0.88 - -  0.055 0.52 - -  0.98 
Melanoma 0.77 0.50 - -  0.71 0.71 - -  0.07 0.67 - -  0.10 
Endometrium - 0.46 - -  - 0.14 - -  - 1.00 - -  0.82 
Ovary - 0.87 - -  - 0.95 - -  - 0.99 - -  0.78 
Prostate - 0.89 - -  - 0.88 - -  - 0.52 - -  0.73 
Kidney 0.89 0.02 - -  0.47 0.19 - -  0.60 0.02 - -  0.02 
Bladder 0.29 0.44 - -  0.80 0.06 - -  0.20 0.79 - -  0.34 
Brain 0.31 0.58 - -  0.91 0.93 - -  0.59 0.97 - -  0.59 
Thyroid 0.56 0.23 - -  0.63 0.08 - -  0.45 0.60 - -  0.97 
Non-Hodgkin lymphoma 0.83 0.52 - -  0.70 0.50 - -  0.53 0.37 - -  0.82 
Multiple myeloma 0.88 0.45 - -  0.14 0.33 - -  0.62 0.03 - -  0.83 
Leukaemia 0.99 0.57 - -  0.86 0.28 - -  0.78 0.68 - -  0.47 
Other 0.95 0.31 - -  0.70 0.74 - -  0.88 0.30 - -  0.35 
Non-alcohol-related 0.15 0.005 - -  0.77 0.70 - -  0.37 0.09 - -  0.40 
All cancer 0.04 0.004 - -  0.10 0.31 - -  0.09 0.53 - -  0.37 
aNever-smokers vs. ever-smokers. bBMI ≥ 18.5 and < 25.0 kgm-2 vs. BMI ≥ 25.0 kgm-2. cNever used vs ever used HRT. dBetween drinking-days per week and mean drinks 
per drinking-day variables. BMI, Body Mass Index. HRT, Hormone Replacement Therapy. 
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Table E.3. Akaike information criterion of log-linear and restricted cubic spline 
models by cancer type in the 45 and Up Study (2006-2010), New South Wales, 
Australia. 
 Akaike Information Criterion 
Cancer type 
Log-linear 
model 
Restricted cubic 
spline model 
Restricted cubic 
spline model lower? 
Mouth and pharynx 2,091.834 2093.365 No 
Oesophagus 891.472 893.260 No 
- Adenocarcinoma 602.395 603.760 No 
- Squamous cell carcinoma 274.295 275.949 No 
Colorectum 10,554.976 10,554.680 Yes 
- Colon 7,484.087 7,482.533 Yes 
- Rectum 3,975.444 3,977.341 No 
Liver 591.859 592.262 No 
Larynx 512.810 514.808 No 
Breast 10,978.683 10,977.439 Yes 
Alcohol-related 27,232.786 27,234.777 No 
Stomach 1,170.473 1,172.437 No 
Pancreas 1,712.732 1,714.724 No 
Lung 5,858.493 5,860.479 No 
Melanoma 11,812.321 11,813.465 No 
Endometrium 892.079 894.053 No 
Ovary 701.075 699.782 Yes 
Prostate 26,018.802 26,020.101 No 
Kidney 1,936.148 1,937.349 No 
Bladder 1,342.390 1,338.259 Yes 
Brain 1,233.330 1234.842 No 
Thyroid 1,045.393 1047.214 No 
Non-Hodgkin lymphoma 3,175.487 3,177.486 No 
Multiple myeloma 931.169 933.144 No 
Leukaemia 1,668.044 1670.009 No 
Other 6,152.303 6,153.470 No 
Non-alcohol-related 67,152.487 67,154.356 No 
All cancer 94,977.104 94,978.883 No 
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Appendix E.2 – Additional Interaction Tests for Chapter 8 
 
Rationale and Methods. It was identified in Chapter 2 that an area for further research is whether 
body mass index (BMI) modifies the relationship between alcohol consumption and risk of colorectal 
and pancreatic cancer, and whether hormone replacement therapy (HRT) use modifies the 
relationship between alcohol consumption and risk of breast cancer. Statistical interactions between 
these variables (BMI: ≥ 18.5 and < 25.0 kgm-2 vs. ≥ 25.0 kgm-2 for colorectal and pancreatic cancer; 
HRT use: never vs. ever for breast cancer) were examined for total alcohol consumption, drinking 
frequency and drinks per drinking-day. 
 
Results. A significant interaction was found between total alcohol consumption and BMI for risk of 
cancer of the rectum, but not for any other measures of alcohol consumption or for other cancer 
types (Table E.2). Stratification of the relationship between total alcohol consumption and risk of 
cancer of the rectum by BMI is shown in Table E.4. In no stratum was the overall p-value or test for 
trend significant. The > 7 and ≤ 14 drinks per week category was associated with significantly lower 
risk in participants with a BMI ≥ 18.5 and < 25 kgm-2 and with significantly higher risk in participants 
with a BMI ≥ 25 kgm-2. There were no significant interactions found between alcohol consumption 
and hormone replacement therapy for breast cancer risk. 
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Table E.4. Hazard ratios and 95% confidence intervals of rectum cancer risk by alcohol consumption and BMI status in the 45 and Up Study (2006-2010), New South 
Wales, Australia. 
  Drinks/week (95% CI)   
Rectum cancer analysis n cases Non-drinkera ≥ 1 and ≤ 3.5 > 3.5 and ≤ 7 > 7 and ≤ 14 > 14 and ≤ 28 > 28 Pb ptrendc 
Main analysis 315 0.92 (0.64-1.32) 1.00 0.90 (0.61-1.33) 1.00 (0.68-1.48) 0.90 (0.58-1.40) 1.09 (0.65-1.85) 0.96 0.73 
 - BMI ≥ 18.5 and < 25 kgm-2 123 0.78 (0.46-1.33) 1.00 0.67 (0.37-1.22) 0.41 (0.21-0.82) 0.85 (0.44-1.63) 1.41 (0.65-3.03) 0.06 0.20 
 - BMI ≥ 25 kgm-2 168 1.18 (0.69-2.03) 1.00 1.05 (0.58-1.91) 1.78 (1.03-3.08) 0.97 (0.51-1.87) 1.12 (0.53-2.36) 0.12 0.71 
Models were adjusted for sex, age, remoteness, education, household income, health insurance status, partner status, country of birth, smoking status and dose, body mass 
index, physical activity, fruit consumption, vegetable consumption, fibre intake, red meat consumption, processed meat consumption, hormone replacement therapy use 
(women), aspirin use and bowel screening history. a< 1 drink per week. bOverall. cLinear trend using median alcohol consumption of each category, excluding non-drinkers. 
BMI, Body Mass Index. 
 
Conclusion. The results showed that the relationship between drinking and risk of rectum cancer was modified by bodyweight. When stratified, it appeared 
that participants with a BMI ≥ 18.5 and < 25 kgm-2 who consumed between > 7 and ≤ 14 drinks per week had a lower risk of rectal cancer than light 
drinkers, whereas those with a BMI ≥ 25 kgm-2 had increased risk. There were no significant trends overall however in either stratum, nor were there any 
interactions detected with drinking patterns or for colon or colorectal cancer. Therefore more research is required to determine whether persons with 
greater bodyweight have a higher risk of colorectum cancer associated with alcohol consumption compared to those with lesser bodyweight. In addition, 
the lack of significant interaction between drinking and bodyweight for pancreas cancer risk and between drinking and hormone replacement therapy for 
breast cancer risk adds to the evidence that the risk factors act independently for these cancer types. 
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Appendix E.3 – Detailed Description of Methods Used to Calculate Additional Results in Chapters 8 
and 9 
 
Population attributable fractions 
Cancer 
The survey data was categorised into 12 drinking groups by average alcohol consumption per day: 
None; > 0 to < 1 g; ≥ 1 to < 2 g; ≥ 2 to < 5; ≥ 5 to < 10 g; ≥ 10 to < 15 g; ≥ 15 to < 20 g; ≥ 20 to < 30 g; ≥ 
30 to < 40 g; ≥ 40 to < 50 g; ≥ 50 to < 60 g; ≥ 60 g. The hazard ratio for each drinking group was 
calculated using the median level of intake within each category. For this analysis, like Pandeya et al., 
(2015), the sex-specific PAFs for cancer incidence in 2010 were attributed to alcohol consumption in 
2001, but the log-linear hazard ratios obtained from the 45 and Up Study were used instead. Cancer 
cases in 2010 were ascertained from the Australian Cancer Incidence and Mortality books[1]. Cancer 
cases in each age group were attributed to the alcohol consumption of the age group ten years 
younger. For each sex, age and level of drinking group, the PAF was given by: 
𝑃𝐴𝐹 =  
𝐹(𝐻𝑅 − 1)
𝐹(𝐻𝑅 − 1) + 1
 
Where F = the proportion of the sex and age group in the drinking group and HR = the hazard ratio of 
the median alcohol consumption in grams per day of the drinking group. For this calculation it was 
assumed that each drink per week in the 45 and Up Study was equivalent to 10 grams of alcohol. 
After summing the PAFs for all drinking groups in a sex and age group, the summed PAF was 
multiplied by the number of cancer cases for the cancer type in question. This gave the number of 
excess cases due to alcohol. The excess cases were then summed for all sex and age groups to obtain 
the overall PAF. This was performed for cancers of the mouth and pharynx, oesophagus (squamous 
cell carcinoma), colorectum, liver, larynx, female breast, alcohol-related cancers combined. 
Hypothetical PAFs were also calculated for cancers of the stomach, pancreas, prostate, kidney and 
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thyroid, and melanoma and Non-Hodgkin lymphoma, under the assumption that the associations of 
these cancers with alcohol are causal. In addition to using the hazard ratios from the main analysis, 
the effect on PAF estimates of using the hazard ratios derived from the sensitivity tests excluding 
participants with a physical functioning score < 50% and restricting the calculation to participants 
consuming ≥ 7 drinks per week was also examined. A hypothetical PAF was not calculated for lung 
cancer due to the finding of a hazard ratio point estimate less than one in the main analysis and both 
sensitivity tests. The results were compared to the findings of Pandeya et al., (2015). As the 
distribution of drinks consumed per drinking-day by sex, age and total alcohol consumption was not 
available in the 2001 National Health Survey data, it was not possible to model an independent 
association of mean drinks per drinking-day on cancer risk for the PAF calculations. 
 
Mortality 
For the mortality PAF calculations, sex- and age-specific deaths in 2010 were ascertained from the 
General Record of Incidence of Mortality books[2]. It has previously been reported that the 
relationship between alcohol consumption and mortality may differ for persons aged < 40 or 45 
years[3, 4], while the 45 and Up Study contains participants aged ≥ 45 years only. The PAFs were 
therefore calculated only for deaths in Australians aged ≥ 45 years (94% of all deaths in 2010), and 
using alcohol consumption in persons aged ≥ 35 years in 2001. PAFs were calculated for cancer, 
cardiovascular disease, digestive system disease, external and all-cause mortality. A sensitivity 
analysis was performed excluding participants with a prior diagnosis of cancer or cardiovascular 
disease from the calculation of the hazard ratio used to derive the cancer and cardiovascular disease 
mortality PAFs respectively. In addition to using the hazard ratios from the main analysis, the effect 
on PAF estimates of using the hazard ratios derived from the sensitivity tests excluding participants 
with a physical functioning score < 50% and restricting the calculation to participants consuming ≥ 7 
drinks per week was also examined. Finally, as the relationship between alcohol consumption and 
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mortality may be non-linear, another sensitivity analysis was performed using hazard ratios derived 
from the restricted cubic spline analysis rather than the continuous log-linear analysis. As the 
restricted cubic splines used a reference group of 1 drink per week, it was assumed that the hazard 
ratio associated with non-drinking was also 1.00. The sensitivity analyses excluding participants with 
prior cancer, cardiovascular disease and a low physical functioning score were repeated for the 
restricted cubic spline derived analysis. 
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Cumulative absolute risk and number of persons needed to quit or reduce drinking to prevent one 
cancer case or death 
Cancer 
The hazard ratios obtained from the continuous log-linear analysis, the 2014-15 National Health 
Survey sex- and age-specific alcohol consumption prevalence data[5] and sex- and age-specific 2013 
national cancer incidence data[1] were used to calculate the cumulative absolute risk of cancer in 
Australians between the ages of 45 and 75 years in 2013 by alcohol consumption status. This 
method was used in a previous study examining smoking status and cumulative risk of mortality in 
the 45 and Up Study[6]. Cancer incidence data was available in five-year increments while drinking 
data was available only in ten-year increments, so sex- and age-specific ten-year increments for 
cancer incidence were calculated using a mean weighted by the population in each sex and five-year 
age group in 2013[7]. Cumulative risk was calculated by sex for three drinking groups: Non-drinkers, 
drinkers consuming > 0 and ≤ 14 drinks per week, and drinkers consuming > 14 drinks per week. 
Three age groups were used: 45-54 years, 55-64 years and 65-74 years. In each sex and age group, 
the absolute rates of a specific cancer in drinkers consuming > 14 drinks per week (A>14), non-
drinkers (A0) and drinkers consuming ≤ 14 drinks per week (A≤14) were given by: 
A>14 = A / (P>14 + P≤14 x HR≤14 / HR>14 + P0 / HR>14) 
A0 = A / (P>14 x HR>14 + P≤14 x HR≤14 + P0) 
A≤14 = A0 x HR≤14 
Where A = the Australian incidence rate for this cancer type in this sex and age group, P0 = the 
national prevalence of non-drinkers for this sex and age group, P≤14 = the national prevalence of 
drinkers consuming > 0 and ≤ 14 drinks per week for this sex and age group, P>14 = the national 
prevalence of drinkers consuming > 14 drinks per week for this sex and age group, HR≤14 = the sex-
specific hazard ratio for this cancer type in persons consuming 1-14 drinks per week compared to 
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non-drinkers derived from the log-linear analysis of total alcohol consumption (calculated for the 
median drinker within this group from the 45 and Up Study: 6 drinks per week for men and 5 drinks 
per week for women), and HR>14 = the sex-specific hazard ratio for this cancer type in persons 
consuming > 14 drinks per week compared to non-drinkers derived from the log-linear analysis of 
total alcohol consumption (calculated for the median drinker within this group from the 45 and Up 
Study: 21 drinks per week for men and 20 drinks per week for women). Absolute incidence for this 
cancer type was then calculated for each sex and ten-year age group (𝑖), by: 
1 - exp(-10 ∑ 𝐴𝑖
𝑥
𝑖=(45−54) ) 
Where x = age 55, 65 or 75 years, and Ai = A0, A≤14 or A>14 for each ten-year age group. These were 
then summed to calculate the sex-specific cumulative absolute risk of cancer between the ages of 45 
and x by drinking status. This was performed for cancers of the mouth and pharynx, oesophagus, 
colorectum, liver, larynx, female breast, alcohol-related cancers combined and all cancers combined. 
The results were graphed. 
The absolute difference in risk of cancer by drinking group between the ages of 45 and 75 years was 
used to calculate sex-specific numbers of persons needed to quit or reduce drinking by age 45 years 
to prevent one cancer case by age 75 years, by: 
𝑛 = 
1
𝐴𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝑟𝑖𝑠𝑘 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒
 
Three scenarios were calculated: a person consuming > 14 drinks per week becoming a non-drinker 
(or never starting drinking) by age 45, a person consuming > 0 and ≤ 14 drinks per week becoming a 
non-drinker (or never starting drinking) by age 45, and a person consuming > 14 drinks per week 
becoming a person consuming > 0 and ≤ 14 drinks per week by age 45. Again, for each of the 
drinking groups, the median drinker within this group from the 45 and Up Study was used (5 drinks 
for women and 6 drinks for men for persons consuming > 0 and ≤ 14 drinks per week; 20 drinks for 
women and 21 drinks for men for persons consuming > 14 drinks per week). It should be noted that 
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a limitation of this analysis is the lag time between alcohol consumption and the occurrence of 
cancer. If for example the lag time is 10 years, this would imply a person would need to quit or 
decrease drinking by age 35 years to obtain the complete reduction in risk presented here. The 
impact of using the hazard ratios derived from the sensitivity tests excluding participants with a 
physical functioning score < 50% and restricting the calculation to participants consuming ≥ 7 drinks 
per week was also examined. 
 
Mortality 
The hazard ratios obtained from the continuous log-linear analysis, the 2014-15 National Health 
Survey sex- and age-specific alcohol consumption prevalence data[5] and sex- and age-specific 2013 
national mortality incidence data[2] were used to calculate the cumulative absolute risk of mortality 
in Australians between the ages of 45 and 75 years in 2013 by alcohol consumption status. 
Calculations were performed for cancer mortality (both with and without the exclusion of prior 
cancer), cardiovascular disease mortality (both with and without the exclusion of prior 
cardiovascular disease), digestive system disease mortality, external cause mortality and all-cause 
mortality (both with and without the exclusion of prior cancer, cardiovascular disease and diabetes). 
The results were graphed. As only two non-zero categories of alcohol consumption were available, a 
sensitivity analysis using the hazard ratios obtained from the restricted cubic spline analysis was not 
performed. 
The absolute difference in risk of mortality by drinking group between the ages of 45 and 75 years 
was used to calculate sex-specific numbers of persons needed to quit or reduce drinking by age 45 
years to prevent one death by age 75 years using the same method as in Chapter 8. It should be 
noted that a limitation of this analysis is the lag time between alcohol consumption and mortality. If 
for example the lag time is 10 years, this would imply a person would need to quit or decrease 
drinking by age 35 years to obtain the complete reduction in risk presented here. The impact of 
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using the hazard ratios derived from the sensitivity tests excluding participants with a physical 
functioning score < 50% and restricting the calculation to participants consuming ≥ 7 drinks per week 
was also examined. 
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Appendix F.1 – Additional Tables for Chapter 9 Journal Article 
Table F.1. Proportional hazards assumption tests by cause of death in the 45 and Up Study (2006-2014), New South Wales, Australia. 
 Total alcohol consumption model  Drinking-days per week model  Drinks per drinking-day model  Drinking pattern model 
Cause of death p Variables in violation  p Variables in violation  p Variables in violation  p Variables in violation 
Cancer 0.89 -  0.81 -  0.78 -  - - 
- Alcohol-related 0.63 -  0.77 -  0.91 -  - - 
  - Mouth, pharynx and larynx 0.52 -  0.62 -  0.64 -  - - 
  - Oesophagus 0.41 -  0.81 -  0.81 -  - - 
  - Colorectum 0.42 -  0.07 -  0.06 -  - - 
  - Liver 0.53 -  0.87 -  0.89 -  - - 
  - Breast 0.29 -  0.32 -  0.36 -  - - 
- Non-alcohol-related 0.90 -  0.77 -  0.75 -  - - 
  - Stomach 0.74 -  0.43 -  0.52 -  - - 
  - Pancreas 0.25 -  0.80 -  0.81 -  - - 
  - Lung 0.72 -  0.60 -  0.58 -  - - 
  - Melanoma 0.33 -  0.82 -  0.71 -  - - 
  - Prostate 0.52 -  0.92 -  0.93 -  - - 
  - Kidney 0.47 -  0.60 -  0.56 -  - - 
  - Non-Hodgkin lymphoma 0.71 -  0.33 -  0.32 -  - - 
Diabetes 0.89 -  0.70 -  0.69 -  - - 
Dementia 0.71 -  0.57 -  0.47 -  - - 
Cardiovascular disease 0.71 -  0.86 -  0.86 -  - - 
- Ischaemic heart disease 0.20 -  0.86 -  0.84 -  - - 
- Cerebrovascular disease 0.65 -  0.43 -  0.26 -  - - 
- Other cardiovascular disease 0.48 -  0.43 -  0.42 -  - - 
Respiratory system disease 0.55 -  0.58 -  0.56 -  - - 
- Lower respiratory infection 0.64 -  0.72 -  0.86 -  - - 
- Other respiratory system disease 0.44 -  0.26 -  0.21 -  - - 
Digestive system disease 0.53 -  0.88 -  0.93 -  - - 
- Liver disease 0.21 -  0.43 -  0.48 -  - - 
- Other digestive system disease 0.70 -  0.67 -  0.68 -  - - 
External 0.54 -  0.88 -  0.93 -  - - 
- Transport accident 0.37 -  0.56 -  0.57 -  - - 
- Fall 0.79 -  0.85 -  0.86 -  - - 
- Suicide 0.50 -  0.47 -  0.46 -  - - 
- Other external 0.72 -  0.64 -  0.60 -  - - 
Other 0.051 -  0.53 -  0.52 -  - - 
All-cause mortality 0.26 -  0.68 -  0.79 -  0.82 - 
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Table F.2. Interaction tests by cause of death in the 45 and Up Study (2006-2014), New South Wales, Australia. 
 Total alcohol consumption  Drinking-days per week  Mean drinks per drinking-day   
Cause of death Sex Smokinga  Sex Smokinga  Sex Smokinga  Drinking patternb 
Cancer 0.35 0.30  0.13 0.34  0.31 0.34  0.16 
- Alcohol-related 0.91 0.58  0.86 0.84  0.63 0.36  0.60 
  - Mouth, pharynx and larynx 1.00 0.86  1.00 0.41  1.00 0.67  0.62 
  - Oesophagus 0.82 1.00  0.43 0.38  0.21 0.42  0.40 
  - Colorectum 0.66 0.82  0.93 0.26  0.32 0.08  0.47 
  - Liver 0.85 0.81  0.61 0.32  0.69 0.58  0.32 
  - Breast - 0.33  - 0.48  - 0.40  0.89 
- Non-alcohol-related 0.36 0.39  0.03 0.16  0.36 0.11  0.10 
  - Stomach 0.43 0.57  0.42 0.48  1.00 0.87  0.99 
  - Pancreas 0.86 0.89  0.86 0.15  0.77 0.89  0.16 
  - Lung 1.00 0.02  0.06 0.18  0.78 0.13  0.71 
  - Melanoma 0.85 0.65  0.68 0.61  0.88 0.53  0.08 
  - Prostate - 0.59  - 0.80  - 0.58  0.91 
  - Kidney 0.78 0.71  0.96 0.87  0.96 0.86  0.39 
  - Non-Hodgkin lymphoma 0.78 0.73  0.37 0.34  1.00 0.26  0.82 
Diabetes 0.69 0.93  0.18 0.88  0.99 0.92  0.63 
Dementia 0.98 0.75  0.44 0.82  0.73 0.55  0.42 
Cardiovascular disease 0.11 0.56  0.59 0.59  0.24 0.20  0.11 
- Ischaemic heart disease 0.43 0.85  0.62 0.84  0.10 0.95  0.13 
- Cerebrovascular disease 0.33 0.46  0.13 0.49  0.98 0.053  0.79 
- Other cardiovascular disease 0.56 0.54  0.28 0.82  0.97 0.30  0.69 
Respiratory system disease 0.29 0.47  0.78 0.22  0.97 0.43  0.96 
- Lower respiratory infection 0.60 0.73  0.79 0.28  0.13 0.41  0.96 
- Other respiratory system disease 0.63 0.76  0.72 0.55  0.91 0.33  0.92 
Digestive system disease 0.92 0.81  0.87 0.69  0.63 0.39  0.99 
- Liver disease 0.36 0.94  0.67 0.60  0.68 0.53  0.95 
- Other digestive system disease 0.38 0.69  0.81 0.80  0.38 0.91  0.98 
External 0.65 0.06  0.76 0.07  0.97 0.14  0.71 
- Transport accident 0.80 0.44  0.87 0.43  0.74 0.97  0.95 
- Fall 0.77 0.52  0.64 0.96  0.80 0.46  1.00 
- Suicide 0.84 0.73  0.92 1.00  0.50 0.36  0.62 
- Other external 0.71 0.16  0.65 0.91  1.00 0.17  0.98 
Other 0.49 0.78  0.83 0.51  0.14 0.97  0.79 
All-cause mortality 0.13c 0.01c  0.88 0.10  0.02 0.54  0.68 
aNever-smokers vs. ever-smokers. bBetween drinking-days per week and mean drinks per drinking-day variables. cDerived without using age as 
the underlying time variable due to insufficient computing power. dBetween drinking-days per week and mean drinks per drinking-day variables. 
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Table F.3. Akaike information criterion of log-linear and restricted cubic spline models by 
cause of death in the 45 and Up Study (2006-2014), New South Wales, Australia. 
 Akaike Information Criterion 
Cause of death 
Log-linear 
model 
Restricted cubic 
spline model 
Restricted cubic 
spline model lower? 
Cancer 27,686.821 27,685.452 Yes 
- Alcohol-related 6,266.332 6,267.992 No 
  - Mouth, pharynx and larynx 506.702 507.520 No 
  - Oesophagus 1,025.705 1,027.698 No 
  - Colorectum 2,480.816 2,482.685 No 
  - Liver 821.884 820.264 Yes 
  - Breast 1,479.842 1,477.222 Yes 
- Non-alcohol-related 21,456.564 21,455.663 Yes 
  - Stomach 645.681 647.378 No 
  - Pancreas 1,871.418 1,873.019 No 
  - Lung 4,709.746 4,711.634 No 
  - Melanoma 1,347.316 1,349.248 No 
  - Prostate 2,887.887 2,888.079 No 
  - Kidney 600.845 602.269 No 
  - Non-Hodgkin lymphoma 809.176 810.454 No 
Diabetes 1,023.986 1,025.972 No 
Dementia 1,817.869 1,819.865 No 
Cardiovascular disease 17,872.181 17,867.379 Yes 
- Ischaemic heart disease 8,745.425 8,743.522 Yes 
- Cerebrovascular disease 4,177.548 4,178.791 No 
- Other cardiovascular disease 5,081.479 5,081.601 No 
Respiratory system disease 5,008.045 5,007.990 Yes 
- Lower respiratory infection 761.654 763.220 No 
- Other respiratory system disease 4,315.388 4,315.977 No 
Digestive system disease 1,753.005 1,754.991 No 
- Liver disease 531.124 533.122 No 
- Other digestive system disease 1,299.644 1,300.534 No 
External 2,003.013 2,004.321 No 
- Transport accident 547.898 548.638 No 
- Fall 510.690 509.738 Yes 
- Suicide 427.543 426.857 Yes 
- Other external 710.052 709.780 Yes 
Other 6,955.119 6,954.727 Yes 
All-cause mortality 149,183.27 149,175.88 Yes 
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Appendix F.2 – Further Investigation of the Exclusion Scenarios Assessed in Chapter 7 Aiming to 
Mitigate Bias from the ‘Sick-Quitter Effect’ by Effect on the Association between Disease and All-
Cause Mortality 
 
Using the all-cause mortality model reported in the main analysis of Chapter 9, it was possible to 
investigate the effect of the exclusion scenarios used in the additional analyses of Chapter 7 on the 
association between disease and all-cause mortality, to further assess their use as potential 
sensitivity tests to mitigate bias from the ‘sick-quitter effect’. The following question was 
investigated: 
1. Whether the exclusion of participants with different types of health characteristics at 
baseline attenuates the association between prevalent disease and all-cause mortality for 
participants who remain in the cohort. 
Rationale and methods. If the exclusion of participants with poor health status can attenuate 
associations between disease and all-cause mortality for those who remain in the cohort, this may 
reduce bias from the ‘sick-quitter effect’. This is because one of the criteria for confounding is that 
the potential confounder must be associated with risk of the outcome[1]. To examine the effect of 
the methods of restriction on the association between disease and all-cause mortality, the six 
diseases examined using the exclusion scenarios in Chapter 7 were added to the all-cause mortality 
model reported in the main analysis in Chapter 9. The ‘no restriction’ scenario included non-drinkers 
and deaths within the first three years of follow-up. The hazard ratio of all-cause mortality 
associated with the presence of each of the six diseases at baseline was examined by exclusion 
scenario. 
Results. The fully adjusted hazard ratios of all-cause mortality by disease status at baseline and 
method of restriction is shown in Table E.4. For most exclusion scenarios there were no obvious 
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changes in the association between baseline disease and mortality. Exceptions were restriction to 
participants aged < 65 years, which resulted in non-significance for Parkinson’s disease and poor 
memory (and material changes in the hazard ratio point estimates), and stronger associations for the 
remaining four diseases, and restriction to participants never diagnosed with cancer or 
cardiovascular disease, which resulted in higher effect estimates for the four remaining diseases. The 
exclusion of participants who died within three years of baseline also resulted in the largest 
attenuation of the association between mortality and baseline cancer diagnosis and hip fracture. 
Conclusions. It was shown that most exclusion scenarios did not consistently change associations 
between baseline disease and mortality. The exclusion of participants with a baseline cancer or 
cardiovascular disease diagnosis resulted in stronger associations for the remaining diseases, 
suggesting that confounding from these diseases on the association between alcohol consumption 
and all-cause mortality may become stronger if this is performed. Restriction to participants aged 
less than 65 years resulted in non-significance for two diseases, but resulted in stronger associations 
for other diseases. Overall, this analysis showed that the exclusion of participants with poor health 
status is unlikely to mitigate bias from the ‘sick-quitter effect’ through attenuating the association 
between disease and all-cause mortality for participants remaining in the cohort. Rather, the 
mitigation of bias operates primarily through the reduction of differences in health status between 
drinking groups.  
 
531 
 
Table F.4. Hazard ratio of all-cause mortality by disease status at baseline by exclusion scenario in the 45 and Up Study (2006-2014), New South 
Wales, Australia. 
 HR of all-cause mortality for presence of disease at baseline (95% CI) 
Exclusion scenario 
Ever had cancer Ever had CVD Ever had 
diabetes 
Ever had 
Parkinson’s disease 
Hip fracture in 
past 5 years 
Poor memory 
No exclusion 1.70 (1.65-1.75) 1.41 (1.37-1.45) 1.37 (1.32-1.42) 1.49 (1.36-1.63) 1.48 (1.35-1.62) 1.50 (1.42-1.59) 
Poor overall health 1.68 (1.63-1.73) 1.38 (1.34-1.43) 1.36 (1.30-1.41) 1.52 (1.38-1.68) 1.45 (1.31-1.61) 1.45 (1.36-1.55) 
Poor quality of life 1.71 (1.66-1.77) 1.41 (1.37-1.46) 1.38 (1.33-1.44) 1.50 (1.36-1.66) 1.43 (1.29-1.59) 1.48 (1.39-1.58) 
Need help with daily tasks 1.74 (1.69-1.80) 1.38 (1.33-1.43) 1.37 (1.31-1.44) 1.27 (1.11-1.45) 1.47 (1.27-1.70) 1.34 (1.24-1.46) 
Physical functioning score < 50% 1.92 (1.84-2.00) 1.32 (1.27-1.38) 1.38 (1.31-1.46) 1.47 (1.26-1.71) 1.37 (1.10-1.70) 1.47 (1.33-1.62) 
Ever had cancer or CVD - - 1.51 (1.42-1.60) 2.49 (2.15-2.88) 1.62 (1.41-1.87) 1.60 (1.46-1.75) 
Death within 3 years of baseline 1.44 (1.39-1.49) 1.39 (1.34-1.44) 1.39 (1.33-1.46) 1.70 (1.52-1.90) 1.32 (1.16-1.51) 1.51 (1.41-1.63) 
Age ≥ 65 years 3.35 (3.12-3.59) 1.63 (1.49-1.79) 1.64 (1.49-1.81) 1.19 (0.84-1.69) 1.70 (1.12-2.56) 1.12 (0.96-1.32) 
Models adjusted for total alcohol consumption (categorical), sex, age, remoteness, education, household income, health insurance status, partner 
status, country of birth, smoking status and dose, body mass index, physical activity, fruit consumption, vegetable consumption, fibre intake, red meat 
consumption, processed meat consumption, parity (women), menopausal status (women), hormone replacement therapy use (women), height and 
other five illnesses. Calculations derived without using age as the underlying time variable due to insufficient computing power. HR, Hazard Ratio. CI, 
Confidence Interval. CVD, Cardiovascular Disease. 
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